ID,TEXT,TAGS
0,Consequences of mutant huntington (mhtt) gene transcription are not well known.,"[{'end': 22, 'start': 16, 'tag': 'CellOrMolecularDysfunction'}, {'end': 59, 'start': 41, 'tag': 'CellFunction'}, {'end': 39, 'start': 35, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 39, 'start': 35, 'tag': 'GeneOrGenome'}]"
1,This includes genetic testing and both primary and secondary symptoms.,"[{'end': 69, 'start': 39, 'tag': 'SignOrSymptom'}, {'end': 29, 'start': 14, 'tag': 'HealthCareActivity'}]"
2,Parkinson's and Huntington's diseases are two of the most common neurodegenerative disorders.,"[{'end': 11, 'start': 0, 'tag': 'DiseaseOrSyndrome'}, {'end': 37, 'start': 16, 'tag': 'DiseaseOrSyndrome'}, {'end': 92, 'start': 65, 'tag': 'DiseaseOrSyndrome'}]"
3,"In this paper, a new discrete chaotic system is introduced, which can mimic the brain's behavior for neurodegenerative diseases such as Parkinson, Huntington, and Hypokinesia.","[{'end': 145, 'start': 136, 'tag': 'DiseaseOrSyndrome'}, {'end': 157, 'start': 147, 'tag': 'DiseaseOrSyndrome'}, {'end': 174, 'start': 163, 'tag': 'SignOrSymptom'}, {'end': 174, 'start': 163, 'tag': 'DiseaseOrSyndrome'}, {'end': 96, 'start': 80, 'tag': 'BiologicFunction'}, {'end': 127, 'start': 101, 'tag': 'DiseaseOrSyndrome'}, {'end': 44, 'start': 21, 'tag': 'ResearchActivity'}]"
4,This system is described based on the similarity between the brain's behavior in normal and abnormal conditions and the chaotic systems.,"[{'end': 111, 'start': 92, 'tag': 'PathologicFunction'}, {'end': 77, 'start': 61, 'tag': 'BiologicFunction'}, {'end': 135, 'start': 120, 'tag': 'ResearchActivity'}, {'end': 48, 'start': 38, 'tag': 'Finding'}]"
5,Mitophagy is a metabolic process that removes dysfunctional or redundant mitochondria.,"[{'end': 9, 'start': 0, 'tag': 'CellFunction'}, {'end': 32, 'start': 15, 'tag': 'CellFunction'}, {'end': 85, 'start': 73, 'tag': 'CellComponent'}, {'end': 85, 'start': 73, 'tag': 'CellOrMolecularDysfunction'}, {'end': 59, 'start': 46, 'tag': 'CellOrMolecularDysfunction'}]"
6,"Furthermore, we focus on the recent advances in understanding the potential role of mitophagy in the pathogenesis of major neurodegenerative diseases (Parkinson's, Alzheimer's, Huntington's, etc.) and aging.","[{'end': 162, 'start': 151, 'tag': 'DiseaseOrSyndrome'}, {'end': 149, 'start': 123, 'tag': 'DiseaseOrSyndrome'}, {'end': 35, 'start': 29, 'tag': 'TemporalConcept'}, {'end': 206, 'start': 201, 'tag': 'BiologicFunction'}, {'end': 206, 'start': 201, 'tag': 'CellFunction'}, {'end': 189, 'start': 177, 'tag': 'DiseaseOrSyndrome'}, {'end': 175, 'start': 164, 'tag': 'DiseaseOrSyndrome'}, {'end': 113, 'start': 101, 'tag': 'PathologicFunction'}, {'end': 93, 'start': 84, 'tag': 'CellFunction'}, {'end': 44, 'start': 36, 'tag': 'Finding'}]"
7,Understanding its pathophysiology is important in establishing a preventive and therapeutic plan.,"[{'end': 33, 'start': 18, 'tag': 'PathologicFunction'}, {'end': 33, 'start': 18, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 96, 'start': 65, 'tag': 'HealthCareActivity'}]"
8,"In this literature review, we cover the physiology of olfaction, its role in neurodegeneration, and its characteristics in patients with HD.","[{'end': 63, 'start': 40, 'tag': 'BiologicFunction'}, {'end': 25, 'start': 19, 'tag': 'ResearchActivity'}, {'end': 25, 'start': 19, 'tag': 'HealthCareActivity'}, {'end': 94, 'start': 77, 'tag': 'CellOrMolecularDysfunction'}, {'end': 139, 'start': 123, 'tag': 'PatientOrDisabledGroup'}, {'end': 18, 'start': 8, 'tag': 'ResearchActivity'}]"
9,"In the general population, olfactory dysfunction is present in 3.8-5.8% and the prevalence increases significantly in those older than 80 years.","[{'end': 25, 'start': 7, 'tag': 'PopulationGroup'}, {'end': 143, 'start': 118, 'tag': 'PopulationGroup'}, {'end': 48, 'start': 27, 'tag': 'DiseaseOrSyndrome'}, {'end': 48, 'start': 27, 'tag': 'PathologicFunction'}]"
10,"No specific treatment for olfactory impairment in HD has been proposed; identifying and avoiding potential medications that cause olfactory dysfunction, as well as general safety recommendations remain the basis of the therapeutic strategy.","[{'end': 46, 'start': 26, 'tag': 'PathologicFunction'}, {'end': 151, 'start': 130, 'tag': 'PathologicFunction'}, {'end': 52, 'start': 50, 'tag': 'DiseaseOrSyndrome'}, {'end': 21, 'start': 12, 'tag': 'HealthCareActivity'}, {'end': 21, 'start': 12, 'tag': 'ResearchActivity'}, {'end': 118, 'start': 107, 'tag': 'PharmacologicSubstance'}, {'end': 239, 'start': 219, 'tag': 'HealthCareActivity'}, {'end': 194, 'start': 172, 'tag': 'HealthCareActivity'}, {'end': 151, 'start': 130, 'tag': 'DiseaseOrSyndrome'}]"
11,"There are several treatment strategies for the neurodegenerative diseases, but most of them fail to cross the Blood-Brain Barrier (BBB).","[{'end': 134, 'start': 131, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 129, 'start': 110, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 73, 'start': 47, 'tag': 'DiseaseOrSyndrome'}, {'end': 27, 'start': 18, 'tag': 'HealthCareActivity'}, {'end': 27, 'start': 18, 'tag': 'ResearchActivity'}]"
12,"Potential targets for therapy that may prove beneficial across many of these diseases are also identified, defining nodes in the ataxia telangiectasia-mutated (ATM) complex, mismatch repair, and poly ADP-ribose polymerases (PARPs).","[{'end': 172, 'start': 129, 'tag': 'GeneOrGenome'}, {'end': 189, 'start': 174, 'tag': 'CellFunction'}, {'end': 222, 'start': 195, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 222, 'start': 195, 'tag': 'BiologicallyActiveSubstance'}, {'end': 229, 'start': 224, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 229, 'start': 224, 'tag': 'GeneOrGenome'}, {'end': 229, 'start': 224, 'tag': 'BiologicallyActiveSubstance'}, {'end': 105, 'start': 95, 'tag': 'Finding'}, {'end': 121, 'start': 116, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 29, 'start': 22, 'tag': 'HealthCareActivity'}, {'end': 172, 'start': 129, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 172, 'start': 129, 'tag': 'BiologicallyActiveSubstance'}]"
13,"However, there are multiple challenges along the translational pipeline, many of which are common across diseases and pertinent to multiple donor cell types.","[{'end': 145, 'start': 140, 'tag': 'PopulationGroup'}, {'end': 71, 'start': 49, 'tag': 'ResearchActivity'}, {'end': 156, 'start': 146, 'tag': 'Cell'}]"
14,"They suggest strategies to address these challenges, based on the consensus view emerging from international workshops and discussion within the platform 'Stem Cells for Huntington's Disease'.","[{'end': 118, 'start': 95, 'tag': 'ResearchActivity'}, {'end': 133, 'start': 123, 'tag': 'ResearchActivity'}, {'end': 191, 'start': 154, 'tag': 'HealthCareRelatedOrganization'}, {'end': 80, 'start': 66, 'tag': 'ResearchActivity'}, {'end': 190, 'start': 170, 'tag': 'DiseaseOrSyndrome'}]"
15,Background Retinal biomarkers in neurodegenerative disorders have attracted much attention in recent years.,"[{'end': 29, 'start': 11, 'tag': 'ClinicalAttribute'}, {'end': 90, 'start': 81, 'tag': 'BiologicFunction'}, {'end': 106, 'start': 94, 'tag': 'TemporalConcept'}, {'end': 60, 'start': 33, 'tag': 'DiseaseOrSyndrome'}]"
16,"Methods A total of 50 subjects, including 25 motor-manifest HD patients and 25 gender- and age-matched controls, were enrolled.","[{'end': 30, 'start': 22, 'tag': 'PopulationGroup'}, {'end': 71, 'start': 60, 'tag': 'PatientOrDisabledGroup'}, {'end': 111, 'start': 103, 'tag': 'PopulationGroup'}, {'end': 85, 'start': 79, 'tag': 'OrganismAttribute'}, {'end': 59, 'start': 45, 'tag': 'ClinicalAttribute'}, {'end': 94, 'start': 91, 'tag': 'OrganismAttribute'}]"
17,"Melatonin, a pineal hormone, has various physiological functions in the brain, including regulating circadian rhythms, clearing free radicals, inhibiting biomolecular oxidation, and suppressing neuroinflammation.","[{'end': 64, 'start': 41, 'tag': 'BiologicFunction'}, {'end': 117, 'start': 89, 'tag': 'BiologicFunction'}, {'end': 117, 'start': 100, 'tag': 'BiologicFunction'}, {'end': 141, 'start': 128, 'tag': 'Chemical'}, {'end': 211, 'start': 182, 'tag': 'CellFunction'}, {'end': 176, 'start': 154, 'tag': 'CellFunction'}, {'end': 27, 'start': 13, 'tag': 'BiologicallyActiveSubstance'}, {'end': 141, 'start': 119, 'tag': 'CellFunction'}, {'end': 176, 'start': 143, 'tag': 'CellFunction'}, {'end': 77, 'start': 72, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 9, 'start': 0, 'tag': 'Chemical'}, {'end': 9, 'start': 0, 'tag': 'BiologicallyActiveSubstance'}, {'end': 9, 'start': 0, 'tag': 'PharmacologicSubstance'}, {'end': 211, 'start': 194, 'tag': 'PathologicFunction'}]"
18,Objectives (1) To train HD team members to facilitate goals of care and ACP conversations at all stages of HD; (2) To create materials for care planning in HD focused on patient-centered goals of care and health-related quality of life; and (3) To modify clinic workflow to include goals of care and ACP discussions.,"[{'end': 39, 'start': 27, 'tag': 'PopulationGroup'}, {'end': 67, 'start': 54, 'tag': 'HealthCareActivity'}, {'end': 75, 'start': 72, 'tag': 'HealthCareActivity'}, {'end': 134, 'start': 125, 'tag': 'Substance'}, {'end': 152, 'start': 139, 'tag': 'HealthCareActivity'}, {'end': 261, 'start': 255, 'tag': 'HealthCareRelatedOrganization'}, {'end': 303, 'start': 300, 'tag': 'HealthCareActivity'}, {'end': 315, 'start': 304, 'tag': 'HealthCareActivity'}, {'end': 103, 'start': 97, 'tag': 'TemporalConcept'}, {'end': 200, 'start': 170, 'tag': 'HealthCareActivity'}, {'end': 295, 'start': 282, 'tag': 'HealthCareActivity'}, {'end': 235, 'start': 220, 'tag': 'Finding'}, {'end': 211, 'start': 205, 'tag': 'HealthCareActivity'}, {'end': 235, 'start': 231, 'tag': 'TemporalConcept'}, {'end': 26, 'start': 24, 'tag': 'DiseaseOrSyndrome'}, {'end': 109, 'start': 107, 'tag': 'DiseaseOrSyndrome'}, {'end': 158, 'start': 156, 'tag': 'DiseaseOrSyndrome'}, {'end': 270, 'start': 255, 'tag': 'HealthCareActivity'}]"
19,"Mast cells also exert profound effects on their microenvironment and neighboring cells including behavior and/or activation of astrocytes, microglia, and neurons, which, in turn, are implicated in neuroinflammation, neurogenesis and neurodegeneration.","[{'end': 10, 'start': 0, 'tag': 'Cell'}, {'end': 64, 'start': 48, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 64, 'start': 48, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 123, 'start': 113, 'tag': 'CellFunction'}, {'end': 105, 'start': 97, 'tag': 'BiologicFunction'}, {'end': 105, 'start': 97, 'tag': 'IndividualBehavior'}, {'end': 105, 'start': 97, 'tag': 'ResearchActivity'}, {'end': 228, 'start': 216, 'tag': 'BiologicFunction'}, {'end': 214, 'start': 197, 'tag': 'PathologicFunction'}, {'end': 148, 'start': 139, 'tag': 'Cell'}, {'end': 250, 'start': 233, 'tag': 'CellOrMolecularDysfunction'}, {'end': 86, 'start': 81, 'tag': 'Cell'}, {'end': 161, 'start': 154, 'tag': 'Cell'}, {'end': 137, 'start': 127, 'tag': 'Cell'}]"
20,Mast cells also affect disruption/permeability of the blood brain barrier enabling toxin and immune cell entry exacerbating an inflammatory microenvironment.,"[{'end': 10, 'start': 0, 'tag': 'Cell'}, {'end': 73, 'start': 54, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 88, 'start': 83, 'tag': 'BiologicallyActiveSubstance'}, {'end': 88, 'start': 83, 'tag': 'InjuryOrPoisoning'}, {'end': 104, 'start': 93, 'tag': 'Cell'}, {'end': 139, 'start': 127, 'tag': 'PathologicFunction'}, {'end': 156, 'start': 140, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 156, 'start': 140, 'tag': 'BodyPartOrganOrOrganComponent'}]"
21,"However, additional research is required in order to understand the most effective exercise therapy for these indications; the best way to monitor the response to interventions; the influence of exercise on sleep dysfunction in Huntington's disease and amyotrophic lateral sclerosis; and the mechanisms underlying exercise-induced sleep modifications.","[{'end': 99, 'start': 83, 'tag': 'HealthCareActivity'}, {'end': 146, 'start': 139, 'tag': 'HealthCareActivity'}, {'end': 224, 'start': 207, 'tag': 'PathologicFunction'}, {'end': 203, 'start': 195, 'tag': 'HealthCareActivity'}, {'end': 322, 'start': 314, 'tag': 'HealthCareActivity'}, {'end': 212, 'start': 207, 'tag': 'BiologicFunction'}, {'end': 336, 'start': 331, 'tag': 'BiologicFunction'}, {'end': 176, 'start': 163, 'tag': 'HealthCareActivity'}, {'end': 176, 'start': 163, 'tag': 'ResearchActivity'}, {'end': 224, 'start': 213, 'tag': 'PathologicFunction'}, {'end': 248, 'start': 228, 'tag': 'DiseaseOrSyndrome'}, {'end': 282, 'start': 253, 'tag': 'DiseaseOrSyndrome'}, {'end': 28, 'start': 20, 'tag': 'ResearchActivity'}, {'end': 146, 'start': 139, 'tag': 'ManufacturedObject'}]"
22,Aptamers can be used to detect these neurodegenerative disease biomarkers.,"[{'end': 8, 'start': 0, 'tag': 'NucleicAcidNucleosideOrNucleotide'}, {'end': 62, 'start': 37, 'tag': 'DiseaseOrSyndrome'}, {'end': 73, 'start': 63, 'tag': 'ClinicalAttribute'}]"
23,"Aptamer, a small oligonucleotide sequence, is screened in vitro, which can bind to corresponding protein markers with high affinity and specificity.","[{'end': 7, 'start': 0, 'tag': 'NucleicAcidNucleosideOrNucleotide'}, {'end': 32, 'start': 17, 'tag': 'NucleicAcidNucleosideOrNucleotide'}, {'end': 41, 'start': 17, 'tag': 'MolecularSequence'}, {'end': 112, 'start': 97, 'tag': 'ClinicalAttribute'}, {'end': 131, 'start': 123, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 54, 'start': 46, 'tag': 'HealthCareActivity'}, {'end': 54, 'start': 46, 'tag': 'ResearchActivity'}, {'end': 63, 'start': 55, 'tag': 'ResearchActivity'}, {'end': 147, 'start': 136, 'tag': 'Finding'}]"
24,"Since mammalian PRDXs were identified 30 years ago, their significance was long overshadowed by the other well-studied ROS/RNS defense systems.","[{'end': 15, 'start': 6, 'tag': 'Eukaryote'}, {'end': 21, 'start': 16, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 21, 'start': 16, 'tag': 'GeneOrGenome'}, {'end': 46, 'start': 41, 'tag': 'TemporalConcept'}, {'end': 142, 'start': 119, 'tag': 'CellFunction'}, {'end': 21, 'start': 16, 'tag': 'BiologicallyActiveSubstance'}]"
25,"The microbiota-gut-brain axis provides a potential pathway through which changes in the gut could modulate brain function, including cognition.","[{'end': 91, 'start': 88, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 29, 'start': 15, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 58, 'start': 51, 'tag': 'CellFunction'}, {'end': 142, 'start': 133, 'tag': 'BiologicFunction'}, {'end': 121, 'start': 107, 'tag': 'BiologicFunction'}, {'end': 14, 'start': 4, 'tag': 'Organism'}]"
26,Several pre-clinical studies have used stem cells in animal models of HD.,"[{'end': 28, 'start': 8, 'tag': 'ResearchActivity'}, {'end': 49, 'start': 39, 'tag': 'Cell'}, {'end': 66, 'start': 53, 'tag': 'ResearchActivity'}, {'end': 72, 'start': 70, 'tag': 'DiseaseOrSyndrome'}, {'end': 72, 'start': 53, 'tag': 'ExperimentalModelOfDisease'}]"
27,"However, cerebral venous thrombosis (CVT), iron-deficiency anemia and neutropenia have not been reported as its presentations to date.","[{'end': 35, 'start': 9, 'tag': 'DiseaseOrSyndrome'}, {'end': 35, 'start': 9, 'tag': 'PathologicFunction'}, {'end': 40, 'start': 37, 'tag': 'DiseaseOrSyndrome'}, {'end': 40, 'start': 37, 'tag': 'PathologicFunction'}, {'end': 65, 'start': 43, 'tag': 'DiseaseOrSyndrome'}, {'end': 125, 'start': 112, 'tag': 'SignOrSymptom'}, {'end': 133, 'start': 126, 'tag': 'TemporalConcept'}, {'end': 81, 'start': 70, 'tag': 'DiseaseOrSyndrome'}, {'end': 81, 'start': 70, 'tag': 'AnatomicalAbnormality'}]"
28,"Within the Huntington's disease gene expansion carrier group, we also discovered associations among gut bacteria, cognitive performance and clinical outcomes.","[{'end': 135, 'start': 114, 'tag': 'ClinicalAttribute'}, {'end': 157, 'start': 140, 'tag': 'ClinicalAttribute'}, {'end': 60, 'start': 47, 'tag': 'PopulationGroup'}, {'end': 31, 'start': 11, 'tag': 'DiseaseOrSyndrome'}, {'end': 46, 'start': 32, 'tag': 'CellOrMolecularDysfunction'}, {'end': 103, 'start': 100, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 112, 'start': 104, 'tag': 'Bacterium'}]"
29,"We examined the effect of NDDs such as ALS, HD, and PD on gait and developed a convolutional long short-term memory (ConvLSTM) and threedimensional convolutional learning network (3D CNN)-based approach to detecting neurodegenerative conditions and predicting disease severity.","[{'end': 46, 'start': 44, 'tag': 'DiseaseOrSyndrome'}, {'end': 54, 'start': 52, 'tag': 'DiseaseOrSyndrome'}, {'end': 42, 'start': 39, 'tag': 'DiseaseOrSyndrome'}, {'end': 276, 'start': 260, 'tag': 'ClinicalAttribute'}, {'end': 30, 'start': 26, 'tag': 'DiseaseOrSyndrome'}, {'end': 202, 'start': 187, 'tag': 'MachineActivity'}, {'end': 178, 'start': 131, 'tag': 'MachineActivity'}, {'end': 244, 'start': 216, 'tag': 'DiseaseOrSyndrome'}, {'end': 62, 'start': 58, 'tag': 'OrganismAttribute'}, {'end': 115, 'start': 79, 'tag': 'MachineActivity'}, {'end': 125, 'start': 117, 'tag': 'MachineActivity'}, {'end': 186, 'start': 180, 'tag': 'MachineActivity'}]"
30,"Background Huntington's disease is a rare, severe, inherited neurodegenerative disease in which we assessed the safety and efficacy of grafting human fetal ganglionic eminence intrastriatally.","[{'end': 143, 'start': 135, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 143, 'start': 135, 'tag': 'HealthCareActivity'}, {'end': 175, 'start': 144, 'tag': 'EmbryonicStructure'}, {'end': 191, 'start': 176, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 86, 'start': 51, 'tag': 'DiseaseOrSyndrome'}, {'end': 118, 'start': 112, 'tag': 'HealthCareActivity'}, {'end': 49, 'start': 43, 'tag': 'Finding'}, {'end': 31, 'start': 11, 'tag': 'DiseaseOrSyndrome'}, {'end': 86, 'start': 61, 'tag': 'DiseaseOrSyndrome'}, {'end': 41, 'start': 37, 'tag': 'TemporalConcept'}]"
31,"In the hippocampal administration of A beta 40 induced young AD model mice, the intramedullary injection of Rab27a-shRNA adenovirus inhibits OCYYoung-EVs secretion from bone and aggravates cognitive impairment.","[{'end': 104, 'start': 80, 'tag': 'HealthCareActivity'}, {'end': 173, 'start': 169, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 209, 'start': 189, 'tag': 'DiseaseOrSyndrome'}, {'end': 43, 'start': 37, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 74, 'start': 47, 'tag': 'ExperimentalModelOfDisease'}, {'end': 33, 'start': 7, 'tag': 'ResearchActivity'}, {'end': 131, 'start': 108, 'tag': 'Virus'}, {'end': 149, 'start': 141, 'tag': 'Cell'}, {'end': 153, 'start': 150, 'tag': 'CellComponent'}]"
32,A relationship between environmental exposure to air pollution and cognitive impairment and neurological disorders has been described.,"[{'end': 62, 'start': 49, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 114, 'start': 92, 'tag': 'DiseaseOrSyndrome'}, {'end': 14, 'start': 2, 'tag': 'Finding'}, {'end': 87, 'start': 67, 'tag': 'DiseaseOrSyndrome'}, {'end': 62, 'start': 23, 'tag': 'InjuryOrPoisoning'}]"
33,Background: Alzheimer's disease (AD) is associated with EEG changes across the sleep-wake cycle.,"[{'end': 59, 'start': 56, 'tag': 'HealthCareActivity'}, {'end': 95, 'start': 79, 'tag': 'BiologicFunction'}, {'end': 31, 'start': 12, 'tag': 'DiseaseOrSyndrome'}, {'end': 35, 'start': 33, 'tag': 'DiseaseOrSyndrome'}]"
34,"As the brain is a non-linear system, non-linear EEG features across behavioral states may provide an informative physiologic biomarker of AD.","[{'end': 51, 'start': 48, 'tag': 'HealthCareActivity'}, {'end': 85, 'start': 79, 'tag': 'TemporalConcept'}, {'end': 140, 'start': 138, 'tag': 'DiseaseOrSyndrome'}, {'end': 134, 'start': 113, 'tag': 'ClinicalAttribute'}, {'end': 12, 'start': 7, 'tag': 'BodyPartOrganOrOrganComponent'}]"
35,Multiscale fluctuation dispersion entropy (MFDE) provides a sensitive non-linear measure of EEG information content across a range of biologically relevant time-scales.,"[{'end': 95, 'start': 92, 'tag': 'HealthCareActivity'}, {'end': 160, 'start': 156, 'tag': 'TemporalConcept'}, {'end': 41, 'start': 0, 'tag': 'ClinicalAttribute'}, {'end': 47, 'start': 43, 'tag': 'HealthCareActivity'}, {'end': 88, 'start': 60, 'tag': 'ResearchActivity'}]"
36,Objective: To evaluate MFDE in awake and sleep EEGs as a potential biomarker for AD.,"[{'end': 36, 'start': 31, 'tag': 'Finding'}, {'end': 46, 'start': 41, 'tag': 'BiologicFunction'}, {'end': 76, 'start': 57, 'tag': 'ClinicalAttribute'}, {'end': 83, 'start': 81, 'tag': 'DiseaseOrSyndrome'}, {'end': 51, 'start': 47, 'tag': 'HealthCareActivity'}, {'end': 27, 'start': 23, 'tag': 'ClinicalAttribute'}]"
37,"Methods: We analyzed overnight scalp EEGs from 35 cognitively normal healthy controls, 23 participants with mild cognitive impairment (MCI), and 19 participants with mild dementia due to AD.","[{'end': 36, 'start': 31, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 85, 'start': 69, 'tag': 'PopulationGroup'}, {'end': 189, 'start': 187, 'tag': 'DiseaseOrSyndrome'}, {'end': 179, 'start': 171, 'tag': 'DiseaseOrSyndrome'}, {'end': 102, 'start': 90, 'tag': 'PopulationGroup'}, {'end': 160, 'start': 148, 'tag': 'PopulationGroup'}, {'end': 68, 'start': 50, 'tag': 'Finding'}, {'end': 138, 'start': 135, 'tag': 'DiseaseOrSyndrome'}, {'end': 133, 'start': 108, 'tag': 'DiseaseOrSyndrome'}, {'end': 170, 'start': 166, 'tag': 'Finding'}, {'end': 20, 'start': 12, 'tag': 'ResearchActivity'}, {'end': 41, 'start': 37, 'tag': 'HealthCareActivity'}, {'end': 30, 'start': 21, 'tag': 'TemporalConcept'}]"
38,"We examined measures of entropy in wake and sleep states, including a slow-to-fast-activity ratio of entropy (SFAR-entropy).","[{'end': 39, 'start': 35, 'tag': 'BiologicFunction'}, {'end': 39, 'start': 35, 'tag': 'TemporalConcept'}, {'end': 56, 'start': 50, 'tag': 'TemporalConcept'}, {'end': 49, 'start': 44, 'tag': 'BiologicFunction'}, {'end': 31, 'start': 24, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 108, 'start': 70, 'tag': 'ClinicalAttribute'}, {'end': 122, 'start': 110, 'tag': 'ClinicalAttribute'}]"
39,"We compared SFAR-entropy to linear EEG measures including a slow-to-fast-activity ratio of power spectral density (SFAR-PSD) and relative alpha power, as well as to cognitive function.","[{'end': 38, 'start': 35, 'tag': 'HealthCareActivity'}, {'end': 183, 'start': 165, 'tag': 'BiologicFunction'}, {'end': 113, 'start': 60, 'tag': 'ClinicalAttribute'}, {'end': 149, 'start': 129, 'tag': 'ClinicalAttribute'}, {'end': 123, 'start': 115, 'tag': 'ClinicalAttribute'}, {'end': 24, 'start': 12, 'tag': 'ClinicalAttribute'}]"
40,Results: SFAR-entropy differentiated dementia from MCI and controls.,"[{'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 45, 'start': 37, 'tag': 'DiseaseOrSyndrome'}, {'end': 67, 'start': 59, 'tag': 'PopulationGroup'}, {'end': 54, 'start': 51, 'tag': 'DiseaseOrSyndrome'}, {'end': 21, 'start': 9, 'tag': 'ClinicalAttribute'}]"
41,"This effect was greatest in REM sleep, a state associated with high cholinergic activity.","[{'end': 37, 'start': 28, 'tag': 'BiologicFunction'}, {'end': 88, 'start': 68, 'tag': 'BiologicFunction'}]"
42,Differentiation was evident in the whole brain EEG and was most prominent in temporal and occipital regions.,"[{'end': 50, 'start': 47, 'tag': 'HealthCareActivity'}, {'end': 107, 'start': 100, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 85, 'start': 77, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 107, 'start': 90, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 15, 'start': 0, 'tag': 'CellFunction'}, {'end': 46, 'start': 41, 'tag': 'BodyPartOrganOrOrganComponent'}]"
43,Five minutes of REM sleep was sufficient to distinguish dementia from MCI and controls.,"[{'end': 25, 'start': 16, 'tag': 'BiologicFunction'}, {'end': 64, 'start': 56, 'tag': 'DiseaseOrSyndrome'}, {'end': 86, 'start': 78, 'tag': 'PopulationGroup'}, {'end': 73, 'start': 70, 'tag': 'DiseaseOrSyndrome'}]"
44,Higher SFAR-entropy during REM sleep was associated with worse performance on the Montreal Cognitive Assessment.,"[{'end': 36, 'start': 27, 'tag': 'BiologicFunction'}, {'end': 62, 'start': 57, 'tag': 'Finding'}, {'end': 111, 'start': 82, 'tag': 'HealthCareActivity'}, {'end': 74, 'start': 63, 'tag': 'Finding'}, {'end': 19, 'start': 7, 'tag': 'ClinicalAttribute'}]"
45,"Classifiers based on REM sleep SFAR-entropy distinguished dementia from MCI and controls with high accuracy, and outperformed classifiers based on SFAR-PSD and relative alpha power.","[{'end': 30, 'start': 21, 'tag': 'BiologicFunction'}, {'end': 66, 'start': 58, 'tag': 'DiseaseOrSyndrome'}, {'end': 88, 'start': 80, 'tag': 'PopulationGroup'}, {'end': 107, 'start': 99, 'tag': 'Finding'}, {'end': 75, 'start': 72, 'tag': 'DiseaseOrSyndrome'}, {'end': 43, 'start': 31, 'tag': 'ClinicalAttribute'}, {'end': 155, 'start': 147, 'tag': 'ClinicalAttribute'}, {'end': 180, 'start': 160, 'tag': 'ClinicalAttribute'}]"
46,Conclusion: SFAR-entropy measured in REM sleep robustly discriminates dementia in AD from MCI and healthy controls.,"[{'end': 46, 'start': 37, 'tag': 'BiologicFunction'}, {'end': 114, 'start': 98, 'tag': 'PopulationGroup'}, {'end': 84, 'start': 82, 'tag': 'DiseaseOrSyndrome'}, {'end': 78, 'start': 70, 'tag': 'DiseaseOrSyndrome'}, {'end': 93, 'start': 90, 'tag': 'DiseaseOrSyndrome'}, {'end': 33, 'start': 25, 'tag': 'HealthCareActivity'}, {'end': 24, 'start': 12, 'tag': 'ClinicalAttribute'}]"
47,"Microglia, the major immune cells in the brain, mediate neuroinflammation, increased oxidative stress, and impaired neurotransmission in Alzheimer's disease (AD), in which most AD risk genes are highly expressed.","[{'end': 133, 'start': 116, 'tag': 'CellFunction'}, {'end': 33, 'start': 21, 'tag': 'Cell'}, {'end': 9, 'start': 0, 'tag': 'Cell'}, {'end': 211, 'start': 202, 'tag': 'CellFunction'}, {'end': 156, 'start': 137, 'tag': 'DiseaseOrSyndrome'}, {'end': 160, 'start': 158, 'tag': 'DiseaseOrSyndrome'}, {'end': 179, 'start': 177, 'tag': 'DiseaseOrSyndrome'}, {'end': 46, 'start': 41, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 73, 'start': 56, 'tag': 'PathologicFunction'}, {'end': 101, 'start': 85, 'tag': 'CellOrMolecularDysfunction'}, {'end': 190, 'start': 180, 'tag': 'GeneOrGenome'}]"
48,"In microglia, due to the limitations of current single-omics data analysis, risk genes, the regulatory mechanisms, the mechanisms of action of immune responses and the exploration of drug targets for AD immunotherapy are still unclear.","[{'end': 102, 'start': 92, 'tag': 'GeneOrGenome'}, {'end': 179, 'start': 168, 'tag': 'HealthCareActivity'}, {'end': 216, 'start': 203, 'tag': 'PharmacologicSubstance'}, {'end': 216, 'start': 203, 'tag': 'HealthCareActivity'}, {'end': 159, 'start': 143, 'tag': 'BiologicFunction'}, {'end': 187, 'start': 183, 'tag': 'PharmacologicSubstance'}, {'end': 202, 'start': 200, 'tag': 'DiseaseOrSyndrome'}, {'end': 12, 'start': 3, 'tag': 'Cell'}, {'end': 74, 'start': 48, 'tag': 'ResearchActivity'}, {'end': 47, 'start': 40, 'tag': 'TemporalConcept'}, {'end': 86, 'start': 76, 'tag': 'GeneOrGenome'}]"
49,"Therefore, we proposed a method to integrate multi-omics data based on the construction of gene regulatory networks (GRN), by combining weighted gene co-expression network analysis (WGCNA) with single-cell regulatory network inference and clustering (SCENIC).","[{'end': 115, 'start': 91, 'tag': 'ResearchActivity'}, {'end': 120, 'start': 117, 'tag': 'ResearchActivity'}, {'end': 249, 'start': 194, 'tag': 'ResearchActivity'}, {'end': 61, 'start': 45, 'tag': 'ResearchActivity'}, {'end': 61, 'start': 57, 'tag': 'ResearchActivity'}, {'end': 180, 'start': 136, 'tag': 'ResearchActivity'}, {'end': 31, 'start': 25, 'tag': 'ResearchActivity'}, {'end': 31, 'start': 25, 'tag': 'HealthCareActivity'}, {'end': 187, 'start': 182, 'tag': 'ResearchActivity'}, {'end': 257, 'start': 251, 'tag': 'ResearchActivity'}]"
50,"This enables snRNA-seq data and bulkRNA-seq data to obtain data on the deeper intermolecular regulatory relationships, related genes, and the molecular mechanisms of immune-cell action.","[{'end': 132, 'start': 127, 'tag': 'GeneOrGenome'}, {'end': 162, 'start': 142, 'tag': 'CellFunction'}, {'end': 27, 'start': 13, 'tag': 'ResearchActivity'}, {'end': 48, 'start': 32, 'tag': 'ResearchActivity'}, {'end': 63, 'start': 59, 'tag': 'ResearchActivity'}, {'end': 177, 'start': 166, 'tag': 'Cell'}, {'end': 117, 'start': 104, 'tag': 'Finding'}]"
51,"In our approach, not only were central transcription factors (TF) STAT3, CEBPB, SPI1, and regulatory mechanisms identified more accurately than with single-omics but also immunotherapy targeting central TFs to drugs was found to be significantly different between patients.","[{'end': 64, 'start': 62, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 64, 'start': 62, 'tag': 'BiologicallyActiveSubstance'}, {'end': 78, 'start': 73, 'tag': 'GeneOrGenome'}, {'end': 84, 'start': 80, 'tag': 'GeneOrGenome'}, {'end': 84, 'start': 80, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 184, 'start': 171, 'tag': 'HealthCareActivity'}, {'end': 215, 'start': 210, 'tag': 'PharmacologicSubstance'}, {'end': 60, 'start': 39, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 60, 'start': 39, 'tag': 'BiologicallyActiveSubstance'}, {'end': 71, 'start': 66, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 71, 'start': 66, 'tag': 'GeneOrGenome'}, {'end': 71, 'start': 66, 'tag': 'BiologicallyActiveSubstance'}, {'end': 272, 'start': 264, 'tag': 'PatientOrDisabledGroup'}, {'end': 161, 'start': 149, 'tag': 'ResearchActivity'}, {'end': 78, 'start': 73, 'tag': 'BiologicallyActiveSubstance'}, {'end': 78, 'start': 73, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 84, 'start': 80, 'tag': 'BiologicallyActiveSubstance'}, {'end': 206, 'start': 203, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 206, 'start': 203, 'tag': 'BiologicallyActiveSubstance'}]"
52,"Thus, in addition to providing new insights into the potential regulatory mechanisms and pathogenic genes of AD microglia, this approach can assist clinicians in making the most rational treatment plans for patients with different risks; it also has significant implications for identifying AD immunotherapy targets and targeting microglia-associated immune drugs.","[{'end': 307, 'start': 294, 'tag': 'HealthCareActivity'}, {'end': 99, 'start': 89, 'tag': 'PathologicFunction'}, {'end': 363, 'start': 351, 'tag': 'PharmacologicSubstance'}, {'end': 111, 'start': 109, 'tag': 'DiseaseOrSyndrome'}, {'end': 293, 'start': 291, 'tag': 'DiseaseOrSyndrome'}, {'end': 215, 'start': 207, 'tag': 'PatientOrDisabledGroup'}, {'end': 121, 'start': 112, 'tag': 'Cell'}, {'end': 339, 'start': 330, 'tag': 'Cell'}, {'end': 196, 'start': 187, 'tag': 'HealthCareActivity'}, {'end': 196, 'start': 187, 'tag': 'ResearchActivity'}, {'end': 158, 'start': 148, 'tag': 'HealthCareActivity'}, {'end': 105, 'start': 100, 'tag': 'GeneOrGenome'}]"
53,"Objective: Increased life expectancy and exponential growth of adults suffering from Alzheimer's disease (AD) worldwide, has led to biomarkers incorporation for diagnosis in early stages.","[{'end': 25, 'start': 21, 'tag': 'TemporalConcept'}, {'end': 186, 'start': 180, 'tag': 'TemporalConcept'}, {'end': 59, 'start': 53, 'tag': 'BiologicFunction'}, {'end': 186, 'start': 174, 'tag': 'TemporalConcept'}, {'end': 36, 'start': 21, 'tag': 'TemporalConcept'}, {'end': 104, 'start': 85, 'tag': 'DiseaseOrSyndrome'}, {'end': 108, 'start': 106, 'tag': 'DiseaseOrSyndrome'}, {'end': 170, 'start': 161, 'tag': 'HealthCareActivity'}, {'end': 142, 'start': 132, 'tag': 'ClinicalAttribute'}, {'end': 179, 'start': 174, 'tag': 'TemporalConcept'}, {'end': 69, 'start': 63, 'tag': 'PopulationGroup'}]"
54,Use of neuropsychological testing remains limited.,"[{'end': 33, 'start': 7, 'tag': 'HealthCareActivity'}]"
55,This study aimed to identify which neuropsychological tests best indicated underlying AD pathophysiology.,"[{'end': 59, 'start': 35, 'tag': 'HealthCareActivity'}, {'end': 88, 'start': 86, 'tag': 'DiseaseOrSyndrome'}, {'end': 10, 'start': 5, 'tag': 'ResearchActivity'}, {'end': 104, 'start': 89, 'tag': 'PathologicFunction'}, {'end': 104, 'start': 89, 'tag': 'BiomedicalOccupationOrDiscipline'}]"
56,Methods: One hundred and forty-one patients with MCI (Mild Cognitive Impairment) were studied.,"[{'end': 79, 'start': 54, 'tag': 'DiseaseOrSyndrome'}, {'end': 43, 'start': 35, 'tag': 'PatientOrDisabledGroup'}, {'end': 52, 'start': 49, 'tag': 'DiseaseOrSyndrome'}]"
57,"A neuropsychological test battery based on the Uniform Data Set (UDS) from the Alzheimer's Disease Centers program of the National Institute on Aging (NIA) was performed and amyloid markers recorded; according to presence or absence of amyloid identified by positive PIB-PET findings, or low CSF A beta 42 levels, patients were separated into MCI amyloid-(n:58) and MCI amyloid + (n = 83) cases.","[{'end': 33, 'start': 2, 'tag': 'HealthCareActivity'}, {'end': 149, 'start': 122, 'tag': 'HealthCareRelatedOrganization'}, {'end': 154, 'start': 151, 'tag': 'HealthCareRelatedOrganization'}, {'end': 305, 'start': 296, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 305, 'start': 296, 'tag': 'BiologicallyActiveSubstance'}, {'end': 25, 'start': 2, 'tag': 'HealthCareActivity'}, {'end': 291, 'start': 288, 'tag': 'Finding'}, {'end': 295, 'start': 292, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 322, 'start': 314, 'tag': 'PatientOrDisabledGroup'}, {'end': 181, 'start': 174, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 243, 'start': 236, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 354, 'start': 347, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 377, 'start': 370, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 181, 'start': 174, 'tag': 'BiologicallyActiveSubstance'}, {'end': 243, 'start': 236, 'tag': 'BiologicallyActiveSubstance'}, {'end': 354, 'start': 347, 'tag': 'BiologicallyActiveSubstance'}, {'end': 377, 'start': 370, 'tag': 'BiologicallyActiveSubstance'}, {'end': 98, 'start': 79, 'tag': 'DiseaseOrSyndrome'}, {'end': 346, 'start': 343, 'tag': 'DiseaseOrSyndrome'}, {'end': 369, 'start': 366, 'tag': 'DiseaseOrSyndrome'}, {'end': 221, 'start': 213, 'tag': 'Finding'}, {'end': 274, 'start': 267, 'tag': 'HealthCareActivity'}, {'end': 302, 'start': 296, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 63, 'start': 47, 'tag': 'ResearchActivity'}, {'end': 20, 'start': 2, 'tag': 'HealthCareActivity'}, {'end': 25, 'start': 21, 'tag': 'ResearchActivity'}, {'end': 25, 'start': 21, 'tag': 'HealthCareActivity'}, {'end': 189, 'start': 182, 'tag': 'ClinicalAttribute'}, {'end': 114, 'start': 79, 'tag': 'ResearchActivity'}, {'end': 232, 'start': 225, 'tag': 'Finding'}, {'end': 312, 'start': 292, 'tag': 'ClinicalAttribute'}, {'end': 68, 'start': 65, 'tag': 'ResearchActivity'}]"
58,Results: Statistical differences were found in all memory tests between groups.,"[{'end': 32, 'start': 9, 'tag': 'Finding'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 78, 'start': 72, 'tag': 'PopulationGroup'}, {'end': 63, 'start': 51, 'tag': 'ResearchActivity'}, {'end': 63, 'start': 51, 'tag': 'HealthCareActivity'}, {'end': 57, 'start': 51, 'tag': 'BiologicFunction'}]"
59,"Delayed recall score at thirty minutes on the Rey Auditory Verbal Learning Test (AVLT) was the best predictor of amyloid pathology presence (AUC 0.68), followed by AVLT total learning (AUC 0.66) and AVLT Recognition (AUC 0.59) scores, providing useful cut off values in the clinical setting.","[{'end': 38, 'start': 31, 'tag': 'TemporalConcept'}, {'end': 14, 'start': 8, 'tag': 'BiologicFunction'}, {'end': 130, 'start': 113, 'tag': 'PathologicFunction'}, {'end': 290, 'start': 274, 'tag': 'HealthCareActivity'}, {'end': 183, 'start': 175, 'tag': 'BiologicFunction'}, {'end': 215, 'start': 204, 'tag': 'BiologicFunction'}, {'end': 79, 'start': 46, 'tag': 'HealthCareActivity'}, {'end': 233, 'start': 227, 'tag': 'Finding'}, {'end': 20, 'start': 15, 'tag': 'Finding'}, {'end': 120, 'start': 113, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 120, 'start': 113, 'tag': 'BiologicallyActiveSubstance'}, {'end': 139, 'start': 131, 'tag': 'Finding'}, {'end': 144, 'start': 141, 'tag': 'ResearchActivity'}, {'end': 188, 'start': 185, 'tag': 'ResearchActivity'}, {'end': 220, 'start': 217, 'tag': 'ResearchActivity'}, {'end': 85, 'start': 81, 'tag': 'HealthCareActivity'}, {'end': 168, 'start': 164, 'tag': 'HealthCareActivity'}, {'end': 203, 'start': 199, 'tag': 'HealthCareActivity'}, {'end': 266, 'start': 252, 'tag': 'ResearchActivity'}]"
60,"Conclusions: Use of neuropsychological testing, specifically AVLT scores with cutoff values, contributed to the correct diagnosis of MCI due to AD in this SouthAmerican cohort.","[{'end': 91, 'start': 78, 'tag': 'ResearchActivity'}, {'end': 46, 'start': 20, 'tag': 'HealthCareActivity'}, {'end': 72, 'start': 66, 'tag': 'Finding'}, {'end': 146, 'start': 144, 'tag': 'DiseaseOrSyndrome'}, {'end': 129, 'start': 120, 'tag': 'HealthCareActivity'}, {'end': 136, 'start': 133, 'tag': 'DiseaseOrSyndrome'}, {'end': 175, 'start': 169, 'tag': 'PopulationGroup'}, {'end': 65, 'start': 61, 'tag': 'ResearchActivity'}, {'end': 168, 'start': 155, 'tag': 'PopulationGroup'}]"
61,Objectives: Cognitive impairment and apathy are well-documented features of idiopathic normal pressure hydrocephalus (iNPH).,"[{'end': 43, 'start': 37, 'tag': 'DiseaseOrSyndrome'}, {'end': 116, 'start': 76, 'tag': 'DiseaseOrSyndrome'}, {'end': 32, 'start': 12, 'tag': 'DiseaseOrSyndrome'}, {'end': 122, 'start': 118, 'tag': 'DiseaseOrSyndrome'}]"
62,"However, research examining other neuropsychiatric manifestations of iNPH is scant, and it is unknown whether the neuropsychiatric presentation differs for iNPH patients with comorbid Alzheimer's disease (AD)versusiNPH without AD.","[{'end': 143, 'start': 131, 'tag': 'Finding'}, {'end': 65, 'start': 34, 'tag': 'SignOrSymptom'}, {'end': 203, 'start': 184, 'tag': 'DiseaseOrSyndrome'}, {'end': 207, 'start': 205, 'tag': 'DiseaseOrSyndrome'}, {'end': 229, 'start': 227, 'tag': 'DiseaseOrSyndrome'}, {'end': 169, 'start': 161, 'tag': 'PatientOrDisabledGroup'}, {'end': 17, 'start': 9, 'tag': 'ResearchActivity'}, {'end': 73, 'start': 69, 'tag': 'DiseaseOrSyndrome'}, {'end': 160, 'start': 156, 'tag': 'DiseaseOrSyndrome'}, {'end': 218, 'start': 214, 'tag': 'DiseaseOrSyndrome'}]"
63,This study aims to advance our understanding of neuropsychiatric syndromes associated with iNPH.,"[{'end': 10, 'start': 5, 'tag': 'ResearchActivity'}, {'end': 44, 'start': 31, 'tag': 'BiologicFunction'}, {'end': 74, 'start': 48, 'tag': 'DiseaseOrSyndrome'}, {'end': 95, 'start': 91, 'tag': 'DiseaseOrSyndrome'}]"
64,Methods: Fifty patients from Butler Hospital's Normal Pressure Hydrocephalus Clinic met inclusion criteria.,"[{'end': 76, 'start': 47, 'tag': 'DiseaseOrSyndrome'}, {'end': 23, 'start': 15, 'tag': 'PatientOrDisabledGroup'}, {'end': 46, 'start': 29, 'tag': 'HealthCareRelatedOrganization'}, {'end': 83, 'start': 47, 'tag': 'HealthCareRelatedOrganization'}, {'end': 106, 'start': 88, 'tag': 'HealthCareActivity'}]"
65,"Caregiver ratings on the Frontal Systems Behavior Scale (FrSBe) were examined to appraise changes in apathy, executive dysfunction, and disinhibition.","[{'end': 149, 'start': 136, 'tag': 'BiologicFunction'}, {'end': 149, 'start': 136, 'tag': 'DiseaseOrSyndrome'}, {'end': 9, 'start': 0, 'tag': 'HealthCareActivity'}, {'end': 62, 'start': 57, 'tag': 'HealthCareActivity'}, {'end': 130, 'start': 109, 'tag': 'DiseaseOrSyndrome'}, {'end': 107, 'start': 101, 'tag': 'DiseaseOrSyndrome'}, {'end': 130, 'start': 119, 'tag': 'PathologicFunction'}, {'end': 55, 'start': 25, 'tag': 'HealthCareActivity'}]"
66,"Patients also completed cognitive tests of global cognition, psychomotor speed, and executive functioning.","[{'end': 105, 'start': 84, 'tag': 'BiologicFunction'}, {'end': 59, 'start': 50, 'tag': 'BiologicFunction'}, {'end': 39, 'start': 24, 'tag': 'HealthCareActivity'}, {'end': 39, 'start': 24, 'tag': 'ResearchActivity'}, {'end': 8, 'start': 0, 'tag': 'PatientOrDisabledGroup'}, {'end': 78, 'start': 61, 'tag': 'BiologicFunction'}]"
67,AD biomarker status was determined by either amyloid-beta (A beta) positron emission tomography (PET) imaging or cerebrospinal fluid (CSF) total tau to A beta-42 ratio.,"[{'end': 109, 'start': 102, 'tag': 'HealthCareActivity'}, {'end': 148, 'start': 145, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 137, 'start': 134, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 148, 'start': 145, 'tag': 'BiologicallyActiveSubstance'}, {'end': 2, 'start': 0, 'tag': 'DiseaseOrSyndrome'}, {'end': 12, 'start': 3, 'tag': 'ClinicalAttribute'}, {'end': 132, 'start': 113, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 148, 'start': 139, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 148, 'start': 139, 'tag': 'BiologicallyActiveSubstance'}, {'end': 52, 'start': 45, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 52, 'start': 45, 'tag': 'BiologicallyActiveSubstance'}, {'end': 57, 'start': 45, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 100, 'start': 97, 'tag': 'HealthCareActivity'}, {'end': 19, 'start': 13, 'tag': 'Finding'}, {'end': 65, 'start': 59, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 158, 'start': 152, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 95, 'start': 67, 'tag': 'HealthCareActivity'}, {'end': 167, 'start': 139, 'tag': 'ClinicalAttribute'}, {'end': 132, 'start': 113, 'tag': 'ClinicalAttribute'}]"
68,Results: Results revealed clinically significant elevations on the FrSBe's apathy and executive dysfunction scales and modest correlations among these scales and cognitive measures.,"[{'end': 48, 'start': 26, 'tag': 'Finding'}, {'end': 59, 'start': 49, 'tag': 'Finding'}, {'end': 72, 'start': 67, 'tag': 'HealthCareActivity'}, {'end': 107, 'start': 86, 'tag': 'DiseaseOrSyndrome'}, {'end': 81, 'start': 75, 'tag': 'DiseaseOrSyndrome'}, {'end': 180, 'start': 162, 'tag': 'ClinicalAttribute'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 16, 'start': 9, 'tag': 'ResearchActivity'}, {'end': 138, 'start': 126, 'tag': 'ResearchActivity'}]"
69,"Of the 44 patients with available neuroimaging or CSF draw data, 14 presented with comorbid AD.","[{'end': 46, 'start': 34, 'tag': 'HealthCareActivity'}, {'end': 53, 'start': 50, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 94, 'start': 92, 'tag': 'DiseaseOrSyndrome'}, {'end': 18, 'start': 10, 'tag': 'PatientOrDisabledGroup'}, {'end': 63, 'start': 59, 'tag': 'ResearchActivity'}]"
70,"Relative to the iNPH-only group, the iNPH + AD group showed a larger increase from pre-illness to current informant ratings on the executive dysfunction scale, but not the apathy or disinhibition scales.","[{'end': 152, 'start': 131, 'tag': 'DiseaseOrSyndrome'}, {'end': 178, 'start': 172, 'tag': 'DiseaseOrSyndrome'}, {'end': 46, 'start': 44, 'tag': 'DiseaseOrSyndrome'}, {'end': 105, 'start': 98, 'tag': 'TemporalConcept'}, {'end': 31, 'start': 26, 'tag': 'PopulationGroup'}, {'end': 52, 'start': 47, 'tag': 'PopulationGroup'}, {'end': 20, 'start': 16, 'tag': 'DiseaseOrSyndrome'}, {'end': 41, 'start': 37, 'tag': 'DiseaseOrSyndrome'}, {'end': 94, 'start': 87, 'tag': 'DiseaseOrSyndrome'}, {'end': 94, 'start': 83, 'tag': 'TemporalConcept'}]"
71,Conclusions: These results replicate and extend prior research by identifying apathy and executive dysfunction as prominent neuropsychiatric symptoms of iNPH and suggest comorbid AD exacerbates dysexecutive behaviors.,"[{'end': 149, 'start': 124, 'tag': 'SignOrSymptom'}, {'end': 110, 'start': 89, 'tag': 'DiseaseOrSyndrome'}, {'end': 84, 'start': 78, 'tag': 'DiseaseOrSyndrome'}, {'end': 181, 'start': 179, 'tag': 'DiseaseOrSyndrome'}, {'end': 62, 'start': 54, 'tag': 'ResearchActivity'}, {'end': 157, 'start': 153, 'tag': 'DiseaseOrSyndrome'}, {'end': 216, 'start': 194, 'tag': 'DiseaseOrSyndrome'}]"
72,"Future research is warranted to examine the effects of comorbid AD pathology in response to shunt surgery for iNPH, neuropsychiatric symptom changes, and resultant caregiver burden.","[{'end': 180, 'start': 164, 'tag': 'BiologicFunction'}, {'end': 66, 'start': 64, 'tag': 'DiseaseOrSyndrome'}, {'end': 15, 'start': 7, 'tag': 'ResearchActivity'}, {'end': 76, 'start': 67, 'tag': 'PathologicFunction'}, {'end': 76, 'start': 67, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 51, 'start': 44, 'tag': 'Finding'}, {'end': 88, 'start': 80, 'tag': 'OrganismAttribute'}, {'end': 140, 'start': 116, 'tag': 'SignOrSymptom'}, {'end': 6, 'start': 0, 'tag': 'TemporalConcept'}, {'end': 113, 'start': 112, 'tag': 'DiseaseOrSyndrome'}]"
73,Background: Wide-ranging functional defects in eye movements have been reported in Alzheimer's disease (AD) dementia.,"[{'end': 60, 'start': 47, 'tag': 'BiologicFunction'}, {'end': 102, 'start': 83, 'tag': 'DiseaseOrSyndrome'}, {'end': 106, 'start': 104, 'tag': 'DiseaseOrSyndrome'}, {'end': 116, 'start': 108, 'tag': 'DiseaseOrSyndrome'}, {'end': 43, 'start': 12, 'tag': 'PathologicFunction'}]"
74,The detection of abnormal eye movements and reading problems may identify persons at risk of AD when clear clinical symptoms are lacking.,"[{'end': 60, 'start': 44, 'tag': 'DiseaseOrSyndrome'}, {'end': 39, 'start': 17, 'tag': 'PathologicFunction'}, {'end': 81, 'start': 74, 'tag': 'PopulationGroup'}, {'end': 25, 'start': 17, 'tag': 'Finding'}, {'end': 124, 'start': 107, 'tag': 'SignOrSymptom'}, {'end': 95, 'start': 93, 'tag': 'DiseaseOrSyndrome'}, {'end': 13, 'start': 4, 'tag': 'HealthCareActivity'}, {'end': 89, 'start': 85, 'tag': 'Finding'}]"
75,Objective: To examine whether computer-based eye-tracking (ET) analysis of King-Devick (KD) test results differentiates cognitively healthy persons from persons with minor problems in cognitive testing or diagnosed mild AD.,"[{'end': 147, 'start': 140, 'tag': 'PopulationGroup'}, {'end': 160, 'start': 153, 'tag': 'PopulationGroup'}, {'end': 222, 'start': 220, 'tag': 'DiseaseOrSyndrome'}, {'end': 139, 'start': 132, 'tag': 'OrganismAttribute'}, {'end': 214, 'start': 205, 'tag': 'HealthCareActivity'}, {'end': 201, 'start': 194, 'tag': 'HealthCareActivity'}, {'end': 201, 'start': 184, 'tag': 'HealthCareActivity'}, {'end': 71, 'start': 63, 'tag': 'HealthCareActivity'}, {'end': 57, 'start': 30, 'tag': 'HealthCareActivity'}, {'end': 139, 'start': 120, 'tag': 'OrganismAttribute'}, {'end': 219, 'start': 215, 'tag': 'Finding'}, {'end': 96, 'start': 92, 'tag': 'ResearchActivity'}, {'end': 96, 'start': 92, 'tag': 'HealthCareActivity'}, {'end': 86, 'start': 75, 'tag': 'HealthCareActivity'}]"
76,"Methods: We recruited 78 participants (57 non-demented, 21 with mild AD) who underwent neurological examination, the Consortium to Establish a Registry for Alzheimer's Disease neuropsychological test battery (CERAD-NB), and a Clinical Dementia Rating (CDR) interview.","[{'end': 111, 'start': 87, 'tag': 'HealthCareActivity'}, {'end': 54, 'start': 46, 'tag': 'DiseaseOrSyndrome'}, {'end': 199, 'start': 176, 'tag': 'HealthCareActivity'}, {'end': 217, 'start': 209, 'tag': 'HealthCareActivity'}, {'end': 71, 'start': 69, 'tag': 'DiseaseOrSyndrome'}, {'end': 37, 'start': 25, 'tag': 'PopulationGroup'}, {'end': 175, 'start': 156, 'tag': 'DiseaseOrSyndrome'}, {'end': 250, 'start': 226, 'tag': 'HealthCareActivity'}, {'end': 255, 'start': 252, 'tag': 'HealthCareActivity'}, {'end': 68, 'start': 64, 'tag': 'Finding'}, {'end': 199, 'start': 195, 'tag': 'ResearchActivity'}, {'end': 199, 'start': 195, 'tag': 'HealthCareActivity'}, {'end': 207, 'start': 117, 'tag': 'HealthCareActivity'}]"
77,"The non-demented participants were further divided into control (normal CERAD subtests, mean MMSE= 28) and objective mild cognitive impairment (MCI; decline in at least one CERAD memory score, mean MMSE= 27) groups.","[{'end': 71, 'start': 65, 'tag': 'Finding'}, {'end': 16, 'start': 8, 'tag': 'DiseaseOrSyndrome'}, {'end': 97, 'start': 93, 'tag': 'HealthCareActivity'}, {'end': 202, 'start': 198, 'tag': 'HealthCareActivity'}, {'end': 77, 'start': 72, 'tag': 'HealthCareActivity'}, {'end': 178, 'start': 173, 'tag': 'HealthCareActivity'}, {'end': 191, 'start': 186, 'tag': 'Finding'}, {'end': 29, 'start': 17, 'tag': 'PopulationGroup'}, {'end': 142, 'start': 122, 'tag': 'DiseaseOrSyndrome'}, {'end': 147, 'start': 144, 'tag': 'DiseaseOrSyndrome'}, {'end': 63, 'start': 56, 'tag': 'PopulationGroup'}, {'end': 214, 'start': 208, 'tag': 'PopulationGroup'}, {'end': 142, 'start': 117, 'tag': 'DiseaseOrSyndrome'}, {'end': 121, 'start': 117, 'tag': 'Finding'}, {'end': 185, 'start': 179, 'tag': 'BiologicFunction'}]"
78,The KD reading test was performed using computer-based ET.,"[{'end': 19, 'start': 4, 'tag': 'HealthCareActivity'}, {'end': 57, 'start': 40, 'tag': 'HealthCareActivity'}]"
79,"The total time used for the reading test, errors made, fixation and saccade durations, and saccade amplitudes were analyzed.","[{'end': 48, 'start': 42, 'tag': 'Finding'}, {'end': 63, 'start': 55, 'tag': 'HealthCareActivity'}, {'end': 63, 'start': 55, 'tag': 'BiologicFunction'}, {'end': 63, 'start': 55, 'tag': 'ResearchActivity'}, {'end': 75, 'start': 68, 'tag': 'Finding'}, {'end': 98, 'start': 91, 'tag': 'Finding'}, {'end': 14, 'start': 10, 'tag': 'TemporalConcept'}, {'end': 123, 'start': 115, 'tag': 'ResearchActivity'}, {'end': 40, 'start': 28, 'tag': 'HealthCareActivity'}, {'end': 85, 'start': 76, 'tag': 'TemporalConcept'}]"
80,"Results: We found significant differences between the control, objective MCI, and AD groups in regard to the mean saccade amplitude (3.58, 3.33, and 3.21 ms, respectively, p < 0.03) and duration (27.1, 25.3, and 24.8 ms, respectively, p < 0.05).","[{'end': 194, 'start': 186, 'tag': 'TemporalConcept'}, {'end': 84, 'start': 82, 'tag': 'DiseaseOrSyndrome'}, {'end': 76, 'start': 73, 'tag': 'DiseaseOrSyndrome'}, {'end': 61, 'start': 54, 'tag': 'PopulationGroup'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 91, 'start': 85, 'tag': 'PopulationGroup'}, {'end': 41, 'start': 18, 'tag': 'Finding'}, {'end': 121, 'start': 114, 'tag': 'Finding'}]"
81,The KD error scores in the AD group differed significantly (p < 0.01) from the other groups.,"[{'end': 19, 'start': 7, 'tag': 'Finding'}, {'end': 29, 'start': 27, 'tag': 'DiseaseOrSyndrome'}, {'end': 91, 'start': 85, 'tag': 'PopulationGroup'}, {'end': 35, 'start': 30, 'tag': 'PopulationGroup'}, {'end': 6, 'start': 4, 'tag': 'HealthCareActivity'}]"
82,Conclusion: Computed ET analysis of the KD test may help detect persons with objective MCI early when clear clinical symptoms are lacking.,"[{'end': 71, 'start': 64, 'tag': 'PopulationGroup'}, {'end': 125, 'start': 108, 'tag': 'SignOrSymptom'}, {'end': 90, 'start': 87, 'tag': 'DiseaseOrSyndrome'}, {'end': 96, 'start': 91, 'tag': 'TemporalConcept'}, {'end': 32, 'start': 24, 'tag': 'ResearchActivity'}, {'end': 47, 'start': 43, 'tag': 'ResearchActivity'}, {'end': 47, 'start': 43, 'tag': 'HealthCareActivity'}, {'end': 23, 'start': 12, 'tag': 'HealthCareActivity'}, {'end': 42, 'start': 40, 'tag': 'HealthCareActivity'}]"
83,The portable device for ET is easy to use in primary health care memory clinics.,"[{'end': 26, 'start': 24, 'tag': 'HealthCareActivity'}, {'end': 79, 'start': 45, 'tag': 'HealthCareRelatedOrganization'}]"
84,Introduction: Machine learning (ML) may harbor the potential to capture the metabolic complexity in Alzheimer Disease (AD).,"[{'end': 30, 'start': 14, 'tag': 'MachineActivity'}, {'end': 85, 'start': 76, 'tag': 'CellFunction'}, {'end': 117, 'start': 100, 'tag': 'DiseaseOrSyndrome'}, {'end': 121, 'start': 119, 'tag': 'DiseaseOrSyndrome'}, {'end': 34, 'start': 32, 'tag': 'MachineActivity'}]"
85,Here we set out to test the performance of metabolites in blood to categorize AD when compared to CSF biomarkers.,"[{'end': 101, 'start': 98, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 80, 'start': 78, 'tag': 'DiseaseOrSyndrome'}, {'end': 112, 'start': 102, 'tag': 'ClinicalAttribute'}, {'end': 63, 'start': 58, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 39, 'start': 28, 'tag': 'Finding'}, {'end': 54, 'start': 43, 'tag': 'BiologicallyActiveSubstance'}, {'end': 23, 'start': 19, 'tag': 'ResearchActivity'}, {'end': 23, 'start': 19, 'tag': 'HealthCareActivity'}]"
86,Methods: This study analyzed samples from 242 cognitively normal (CN) people and 115 with AD-type dementia utilizing plasma metabolites (n=883).,"[{'end': 68, 'start': 66, 'tag': 'Finding'}, {'end': 92, 'start': 90, 'tag': 'DiseaseOrSyndrome'}, {'end': 106, 'start': 98, 'tag': 'DiseaseOrSyndrome'}, {'end': 19, 'start': 14, 'tag': 'ResearchActivity'}, {'end': 123, 'start': 117, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 64, 'start': 46, 'tag': 'Finding'}, {'end': 76, 'start': 70, 'tag': 'PopulationGroup'}, {'end': 135, 'start': 124, 'tag': 'BiologicallyActiveSubstance'}, {'end': 106, 'start': 90, 'tag': 'DiseaseOrSyndrome'}, {'end': 36, 'start': 29, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 36, 'start': 29, 'tag': 'Substance'}]"
87,"Deep Learning (DL), Extreme Gradient Boosting (XGBoost) and Random Forest (RF) were used to differentiate AD from CN.","[{'end': 13, 'start': 0, 'tag': 'MachineActivity'}, {'end': 17, 'start': 15, 'tag': 'MachineActivity'}, {'end': 105, 'start': 92, 'tag': 'CellFunction'}, {'end': 116, 'start': 114, 'tag': 'Finding'}, {'end': 73, 'start': 60, 'tag': 'MachineActivity'}, {'end': 77, 'start': 75, 'tag': 'MachineActivity'}, {'end': 108, 'start': 106, 'tag': 'DiseaseOrSyndrome'}, {'end': 45, 'start': 20, 'tag': 'MachineActivity'}, {'end': 54, 'start': 47, 'tag': 'MachineActivity'}]"
88,These models were internally validated using Nested Cross Validation (NCV).,"[{'end': 68, 'start': 45, 'tag': 'ResearchActivity'}, {'end': 73, 'start': 70, 'tag': 'ResearchActivity'}, {'end': 12, 'start': 6, 'tag': 'ResearchActivity'}]"
89,"Results: On the test data, DL produced the AUC of 0.85 (0.80-0.89), XGBoost produced 0.88 (0.86-0.89) and RF produced 0.85 (0.83-0.87).","[{'end': 29, 'start': 27, 'tag': 'MachineActivity'}, {'end': 108, 'start': 106, 'tag': 'MachineActivity'}, {'end': 25, 'start': 21, 'tag': 'ResearchActivity'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 46, 'start': 43, 'tag': 'ResearchActivity'}, {'end': 20, 'start': 16, 'tag': 'ResearchActivity'}, {'end': 20, 'start': 16, 'tag': 'HealthCareActivity'}, {'end': 75, 'start': 68, 'tag': 'MachineActivity'}]"
90,"By comparison, CSF measures of amyloid, p-tau and t-tau (together with age and gender) produced with XGBoost the AUC values of 0.78, 0.83 and 0.87, respectively.","[{'end': 13, 'start': 3, 'tag': 'ResearchActivity'}, {'end': 45, 'start': 42, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 55, 'start': 52, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 18, 'start': 15, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 45, 'start': 42, 'tag': 'BiologicallyActiveSubstance'}, {'end': 55, 'start': 52, 'tag': 'BiologicallyActiveSubstance'}, {'end': 38, 'start': 31, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 38, 'start': 31, 'tag': 'BiologicallyActiveSubstance'}, {'end': 55, 'start': 50, 'tag': 'BiologicallyActiveSubstance'}, {'end': 55, 'start': 50, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 74, 'start': 71, 'tag': 'OrganismAttribute'}, {'end': 45, 'start': 40, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 45, 'start': 40, 'tag': 'BiologicallyActiveSubstance'}, {'end': 116, 'start': 113, 'tag': 'ResearchActivity'}, {'end': 85, 'start': 79, 'tag': 'OrganismAttribute'}, {'end': 108, 'start': 101, 'tag': 'MachineActivity'}]"
91,Discussion: This study showed that plasma metabolites have the potential to match the AUC of well-established AD CSF biomarkers in a relatively small cohort.,"[{'end': 81, 'start': 76, 'tag': 'ResearchActivity'}, {'end': 116, 'start': 113, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 112, 'start': 110, 'tag': 'DiseaseOrSyndrome'}, {'end': 127, 'start': 117, 'tag': 'ClinicalAttribute'}, {'end': 22, 'start': 17, 'tag': 'ResearchActivity'}, {'end': 41, 'start': 35, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 156, 'start': 150, 'tag': 'PopulationGroup'}, {'end': 89, 'start': 86, 'tag': 'ResearchActivity'}, {'end': 53, 'start': 42, 'tag': 'BiologicallyActiveSubstance'}]"
92,"Further studies in independent cohorts are needed to validate whether this specific panel of blood metabolites can separate AD from controls, and how specific it is for AD as compared with other neurodegenerative disorders.","[{'end': 222, 'start': 195, 'tag': 'DiseaseOrSyndrome'}, {'end': 126, 'start': 124, 'tag': 'DiseaseOrSyndrome'}, {'end': 171, 'start': 169, 'tag': 'DiseaseOrSyndrome'}, {'end': 140, 'start': 132, 'tag': 'PopulationGroup'}, {'end': 38, 'start': 31, 'tag': 'PopulationGroup'}, {'end': 15, 'start': 8, 'tag': 'ResearchActivity'}, {'end': 98, 'start': 93, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 110, 'start': 99, 'tag': 'BiologicallyActiveSubstance'}]"
93,(C) 2019 The Authors.,[]
94,Published by Elsevier Inc.,[]
95,on behalf of the Alzheimer's Association.,"[{'end': 40, 'start': 17, 'tag': 'HealthCareRelatedOrganization'}]"
96,Background: Growing evidence suggests that there may be a sex-specific biological risk for Alzheimer's disease (AD).,"[{'end': 110, 'start': 91, 'tag': 'DiseaseOrSyndrome'}, {'end': 114, 'start': 112, 'tag': 'DiseaseOrSyndrome'}, {'end': 61, 'start': 58, 'tag': 'OrganismAttribute'}, {'end': 28, 'start': 20, 'tag': 'Finding'}]"
97,"Individuals with autosomal dominant AD due to a mutation (E280A) in Presenilin-1 (PSEN1) are genetically determined to develop early-onset dementia and thus, have few age-related risk factors for AD that are known to vary by sex (i.e., cardiovascular disease, menopause, life expectancy).","[{'end': 11, 'start': 0, 'tag': 'PopulationGroup'}, {'end': 258, 'start': 236, 'tag': 'DiseaseOrSyndrome'}, {'end': 258, 'start': 236, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 269, 'start': 260, 'tag': 'BiologicFunction'}, {'end': 191, 'start': 179, 'tag': 'Finding'}, {'end': 286, 'start': 271, 'tag': 'TemporalConcept'}, {'end': 80, 'start': 68, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 80, 'start': 68, 'tag': 'GeneOrGenome'}, {'end': 80, 'start': 68, 'tag': 'BiologicallyActiveSubstance'}, {'end': 38, 'start': 17, 'tag': 'DiseaseOrSyndrome'}, {'end': 87, 'start': 82, 'tag': 'GeneOrGenome'}, {'end': 87, 'start': 82, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 87, 'start': 82, 'tag': 'BiologicallyActiveSubstance'}, {'end': 138, 'start': 133, 'tag': 'TemporalConcept'}, {'end': 56, 'start': 48, 'tag': 'CellOrMolecularDysfunction'}, {'end': 170, 'start': 167, 'tag': 'OrganismAttribute'}, {'end': 198, 'start': 196, 'tag': 'DiseaseOrSyndrome'}, {'end': 147, 'start': 139, 'tag': 'DiseaseOrSyndrome'}, {'end': 228, 'start': 225, 'tag': 'OrganismAttribute'}, {'end': 63, 'start': 58, 'tag': 'AminoAcidPeptideOrProtein'}]"
98,Objective: Investigate sex differences in markers of cognition and neurodegeneration in autosomal dominant AD.,"[{'end': 38, 'start': 27, 'tag': 'Finding'}, {'end': 109, 'start': 88, 'tag': 'DiseaseOrSyndrome'}, {'end': 84, 'start': 67, 'tag': 'CellOrMolecularDysfunction'}, {'end': 62, 'start': 53, 'tag': 'BiologicFunction'}, {'end': 26, 'start': 23, 'tag': 'OrganismAttribute'}]"
99,"Methods: We conducted a retrospective study in 19 cognitively-unimpaired PSEN1 mutation carriers (age range 20-44; 11 females), 11 symptomatic carriers (age range 42-56; 8 females), and 23 matched non-carriers family members (age range 20-50; 13 females).","[{'end': 43, 'start': 24, 'tag': 'ResearchActivity'}, {'end': 125, 'start': 118, 'tag': 'OrganismAttribute'}, {'end': 179, 'start': 172, 'tag': 'OrganismAttribute'}, {'end': 224, 'start': 210, 'tag': 'PopulationGroup'}, {'end': 224, 'start': 210, 'tag': 'Finding'}, {'end': 253, 'start': 246, 'tag': 'OrganismAttribute'}, {'end': 142, 'start': 131, 'tag': 'SignOrSymptom'}, {'end': 96, 'start': 88, 'tag': 'PopulationGroup'}, {'end': 151, 'start': 143, 'tag': 'PopulationGroup'}, {'end': 209, 'start': 201, 'tag': 'PopulationGroup'}, {'end': 78, 'start': 73, 'tag': 'GeneOrGenome'}, {'end': 78, 'start': 73, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 78, 'start': 73, 'tag': 'BiologicallyActiveSubstance'}, {'end': 87, 'start': 79, 'tag': 'CellOrMolecularDysfunction'}, {'end': 209, 'start': 197, 'tag': 'PopulationGroup'}, {'end': 101, 'start': 98, 'tag': 'OrganismAttribute'}, {'end': 156, 'start': 153, 'tag': 'OrganismAttribute'}, {'end': 229, 'start': 226, 'tag': 'OrganismAttribute'}, {'end': 96, 'start': 79, 'tag': 'PopulationGroup'}]"
100,"We examined hippocampal volume ratio, CERAD Total Score, and CERAD Word List (i.e., Learning, Delayed Recall, and Recognition).","[{'end': 92, 'start': 84, 'tag': 'BiologicFunction'}, {'end': 125, 'start': 114, 'tag': 'BiologicFunction'}, {'end': 30, 'start': 12, 'tag': 'ClinicalAttribute'}, {'end': 55, 'start': 38, 'tag': 'HealthCareActivity'}, {'end': 76, 'start': 61, 'tag': 'HealthCareActivity'}, {'end': 108, 'start': 94, 'tag': 'BiologicFunction'}]"
101,"Mann-Whitney U tests, Spearman correlations and regression models were conducted.","[{'end': 65, 'start': 48, 'tag': 'ResearchActivity'}, {'end': 43, 'start': 22, 'tag': 'ResearchActivity'}, {'end': 20, 'start': 0, 'tag': 'ResearchActivity'}]"
102,"Results: There were no differential associations between age, CERAD Total Score, CERAD Word List-Learning, Delayed Recall, Recognition, and hippocampal volume ratio in male and female carriers and non-carriers.","[{'end': 134, 'start': 123, 'tag': 'BiologicFunction'}, {'end': 183, 'start': 177, 'tag': 'OrganismAttribute'}, {'end': 172, 'start': 168, 'tag': 'OrganismAttribute'}, {'end': 192, 'start': 184, 'tag': 'PopulationGroup'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 209, 'start': 197, 'tag': 'PopulationGroup'}, {'end': 60, 'start': 57, 'tag': 'OrganismAttribute'}, {'end': 158, 'start': 140, 'tag': 'ClinicalAttribute'}, {'end': 67, 'start': 62, 'tag': 'HealthCareActivity'}, {'end': 105, 'start': 81, 'tag': 'HealthCareActivity'}, {'end': 121, 'start': 107, 'tag': 'BiologicFunction'}, {'end': 121, 'start': 107, 'tag': 'HealthCareActivity'}, {'end': 79, 'start': 68, 'tag': 'Finding'}]"
103,"Cognitively-unimpaired female carriers showed better CERAD Total scores and CERAD Word List-Learning than cognitively-unimpaired male carriers, despite having similar hippocampal volume ratios.","[{'end': 71, 'start': 59, 'tag': 'Finding'}, {'end': 29, 'start': 23, 'tag': 'OrganismAttribute'}, {'end': 133, 'start': 129, 'tag': 'OrganismAttribute'}, {'end': 38, 'start': 30, 'tag': 'PopulationGroup'}, {'end': 142, 'start': 134, 'tag': 'PopulationGroup'}, {'end': 185, 'start': 167, 'tag': 'ClinicalAttribute'}, {'end': 22, 'start': 0, 'tag': 'Finding'}, {'end': 58, 'start': 53, 'tag': 'HealthCareActivity'}, {'end': 100, 'start': 76, 'tag': 'HealthCareActivity'}, {'end': 128, 'start': 106, 'tag': 'Finding'}]"
104,The interaction of sex and hippocampal volume ratio did not predict cognitive performance across groups.,"[{'end': 89, 'start': 78, 'tag': 'Finding'}, {'end': 22, 'start': 19, 'tag': 'OrganismAttribute'}, {'end': 103, 'start': 97, 'tag': 'PopulationGroup'}, {'end': 45, 'start': 27, 'tag': 'ClinicalAttribute'}]"
105,"Conclusion: Our preliminary findings suggest that cognitively-unimpaired female carriers showed a verbal memory reserve, and as disease progresses, female carriers did not exhibit a cognitive susceptibility to AD-related neurodegeneration.","[{'end': 27, 'start': 16, 'tag': 'TemporalConcept'}, {'end': 79, 'start': 73, 'tag': 'OrganismAttribute'}, {'end': 154, 'start': 148, 'tag': 'OrganismAttribute'}, {'end': 88, 'start': 80, 'tag': 'PopulationGroup'}, {'end': 163, 'start': 155, 'tag': 'PopulationGroup'}, {'end': 238, 'start': 221, 'tag': 'CellOrMolecularDysfunction'}, {'end': 212, 'start': 210, 'tag': 'DiseaseOrSyndrome'}, {'end': 111, 'start': 98, 'tag': 'BiologicFunction'}, {'end': 72, 'start': 50, 'tag': 'Finding'}]"
106,Future studies with larger samples of autosomal dominant AD are warranted to further understand sex differences in AD-related clinical and pathological markers.,"[{'end': 111, 'start': 100, 'tag': 'Finding'}, {'end': 14, 'start': 7, 'tag': 'ResearchActivity'}, {'end': 59, 'start': 38, 'tag': 'DiseaseOrSyndrome'}, {'end': 117, 'start': 115, 'tag': 'DiseaseOrSyndrome'}, {'end': 99, 'start': 96, 'tag': 'OrganismAttribute'}]"
107,The biological definition of Alzheimer's disease using CSF biomarkers requires abnormal levels of both amyloid (A) and tau (T).,"[{'end': 87, 'start': 79, 'tag': 'Finding'}, {'end': 94, 'start': 79, 'tag': 'Finding'}, {'end': 122, 'start': 119, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 48, 'start': 29, 'tag': 'DiseaseOrSyndrome'}, {'end': 58, 'start': 55, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 122, 'start': 119, 'tag': 'BiologicallyActiveSubstance'}, {'end': 110, 'start': 103, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 110, 'start': 103, 'tag': 'BiologicallyActiveSubstance'}, {'end': 69, 'start': 59, 'tag': 'ClinicalAttribute'}]"
108,"However, biomarkers and corresponding cutoffs may not always reflect the presence or absence of pathology.","[{'end': 45, 'start': 38, 'tag': 'ResearchActivity'}, {'end': 19, 'start': 9, 'tag': 'ClinicalAttribute'}, {'end': 105, 'start': 96, 'tag': 'PathologicFunction'}, {'end': 105, 'start': 96, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 81, 'start': 73, 'tag': 'Finding'}, {'end': 92, 'start': 85, 'tag': 'Finding'}]"
109,"Previous studies suggest that up to 32% of individuals with autopsy-confirmed Alzheimer's disease show normal CSF p-tau levels in vivo, but these studies are sparse and had small sample sizes.","[{'end': 109, 'start': 103, 'tag': 'Finding'}, {'end': 8, 'start': 0, 'tag': 'TemporalConcept'}, {'end': 119, 'start': 116, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 97, 'start': 78, 'tag': 'DiseaseOrSyndrome'}, {'end': 113, 'start': 110, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 119, 'start': 116, 'tag': 'BiologicallyActiveSubstance'}, {'end': 54, 'start': 43, 'tag': 'PopulationGroup'}, {'end': 16, 'start': 9, 'tag': 'ResearchActivity'}, {'end': 153, 'start': 146, 'tag': 'ResearchActivity'}, {'end': 119, 'start': 114, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 119, 'start': 114, 'tag': 'BiologicallyActiveSubstance'}, {'end': 134, 'start': 127, 'tag': 'ResearchActivity'}, {'end': 185, 'start': 179, 'tag': 'Substance'}, {'end': 185, 'start': 179, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 126, 'start': 110, 'tag': 'ClinicalAttribute'}, {'end': 67, 'start': 60, 'tag': 'HealthCareActivity'}]"
110,"Therefore, in three independent autopsy cohorts, we studied whether or not CSF A+T- excluded Alzheimer's disease based on autopsy.","[{'end': 39, 'start': 32, 'tag': 'HealthCareActivity'}, {'end': 129, 'start': 122, 'tag': 'HealthCareActivity'}, {'end': 112, 'start': 93, 'tag': 'DiseaseOrSyndrome'}, {'end': 78, 'start': 75, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 47, 'start': 40, 'tag': 'PopulationGroup'}]"
111,"We included 215 individuals, for whom ante-mortem CSF collection and autopsy had been performed, from three cohorts: (i) the Amsterdam Dementia Cohort (ADC) [n = 80, 37 (46%) Alzheimer's disease at autopsy, time between CSF collection and death 4.5 +/- 2.9 years]; (ii) the Antwerp Dementia Cohort (DEM) [n = 92, 84 (91%) Alzheimer's disease at autopsy, time CSF collection to death 1.7 +/- 2.3 years]; and (iii) the Alzheimer's Disease Neuroimaging Initiative (ADNI) [n = 43, 31 (72%) Alzheimer's disease at autopsy, time CSF collection to death 5.1 +/- 2.5 years].","[{'end': 64, 'start': 54, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 76, 'start': 69, 'tag': 'HealthCareActivity'}, {'end': 205, 'start': 198, 'tag': 'HealthCareActivity'}, {'end': 352, 'start': 345, 'tag': 'HealthCareActivity'}, {'end': 373, 'start': 363, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 516, 'start': 509, 'tag': 'HealthCareActivity'}, {'end': 460, 'start': 417, 'tag': 'ResearchActivity'}, {'end': 460, 'start': 417, 'tag': 'HealthCareRelatedOrganization'}, {'end': 143, 'start': 135, 'tag': 'DiseaseOrSyndrome'}, {'end': 290, 'start': 282, 'tag': 'DiseaseOrSyndrome'}, {'end': 466, 'start': 462, 'tag': 'HealthCareRelatedOrganization'}, {'end': 466, 'start': 462, 'tag': 'ResearchActivity'}, {'end': 244, 'start': 239, 'tag': 'BiologicFunction'}, {'end': 382, 'start': 377, 'tag': 'BiologicFunction'}, {'end': 546, 'start': 541, 'tag': 'BiologicFunction'}, {'end': 244, 'start': 239, 'tag': 'PathologicFunction'}, {'end': 382, 'start': 377, 'tag': 'PathologicFunction'}, {'end': 546, 'start': 541, 'tag': 'PathologicFunction'}, {'end': 244, 'start': 239, 'tag': 'CellFunction'}, {'end': 382, 'start': 377, 'tag': 'CellFunction'}, {'end': 546, 'start': 541, 'tag': 'CellFunction'}, {'end': 194, 'start': 175, 'tag': 'DiseaseOrSyndrome'}, {'end': 341, 'start': 322, 'tag': 'DiseaseOrSyndrome'}, {'end': 505, 'start': 486, 'tag': 'DiseaseOrSyndrome'}, {'end': 53, 'start': 50, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 223, 'start': 220, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 362, 'start': 359, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 526, 'start': 523, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 115, 'start': 108, 'tag': 'PopulationGroup'}, {'end': 27, 'start': 16, 'tag': 'PopulationGroup'}, {'end': 436, 'start': 417, 'tag': 'DiseaseOrSyndrome'}, {'end': 211, 'start': 207, 'tag': 'TemporalConcept'}, {'end': 358, 'start': 354, 'tag': 'TemporalConcept'}, {'end': 522, 'start': 518, 'tag': 'TemporalConcept'}, {'end': 262, 'start': 257, 'tag': 'TemporalConcept'}, {'end': 400, 'start': 395, 'tag': 'TemporalConcept'}, {'end': 564, 'start': 559, 'tag': 'TemporalConcept'}, {'end': 150, 'start': 125, 'tag': 'PatientOrDisabledGroup'}, {'end': 297, 'start': 274, 'tag': 'PatientOrDisabledGroup'}]"
112,Biomarker profiles were based on dichotomized CSF A beta(1-42) and p-tau levels.,"[{'end': 72, 'start': 69, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 49, 'start': 46, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 72, 'start': 69, 'tag': 'BiologicallyActiveSubstance'}, {'end': 72, 'start': 67, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 72, 'start': 67, 'tag': 'BiologicallyActiveSubstance'}, {'end': 56, 'start': 50, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 18, 'start': 10, 'tag': 'ResearchActivity'}, {'end': 9, 'start': 0, 'tag': 'ClinicalAttribute'}, {'end': 79, 'start': 69, 'tag': 'ClinicalAttribute'}]"
113,The accuracy of CSF AT profiles to detect autopsy-confirmed Alzheimer's disease was assessed.,"[{'end': 79, 'start': 60, 'tag': 'DiseaseOrSyndrome'}, {'end': 19, 'start': 16, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 12, 'start': 4, 'tag': 'Finding'}, {'end': 31, 'start': 23, 'tag': 'ResearchActivity'}, {'end': 49, 'start': 42, 'tag': 'HealthCareActivity'}]"
114,"Lastly, we investigated whether the concordance of AT profiles with autopsy diagnosis improved when CSF was collected closer to death in 9 (10%) DEM and 30 (70%) ADNI individuals with repeated CSF measurements available.","[{'end': 75, 'start': 68, 'tag': 'HealthCareActivity'}, {'end': 6, 'start': 0, 'tag': 'TemporalConcept'}, {'end': 166, 'start': 162, 'tag': 'HealthCareRelatedOrganization'}, {'end': 166, 'start': 162, 'tag': 'ResearchActivity'}, {'end': 133, 'start': 128, 'tag': 'BiologicFunction'}, {'end': 133, 'start': 128, 'tag': 'PathologicFunction'}, {'end': 133, 'start': 128, 'tag': 'CellFunction'}, {'end': 103, 'start': 100, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 196, 'start': 193, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 178, 'start': 167, 'tag': 'PopulationGroup'}, {'end': 85, 'start': 76, 'tag': 'HealthCareActivity'}, {'end': 209, 'start': 197, 'tag': 'HealthCareActivity'}, {'end': 62, 'start': 54, 'tag': 'ResearchActivity'}, {'end': 209, 'start': 197, 'tag': 'ResearchActivity'}]"
115,"In total, 50-73% of A+T- individuals and 100% of A+T+ individuals had Alzheimer's disease at autopsy.","[{'end': 100, 'start': 93, 'tag': 'HealthCareActivity'}, {'end': 89, 'start': 70, 'tag': 'DiseaseOrSyndrome'}, {'end': 36, 'start': 25, 'tag': 'PopulationGroup'}, {'end': 65, 'start': 54, 'tag': 'PopulationGroup'}]"
116,"Amyloid status showed the highest accuracy to detect autopsy-confirmed Alzheimer's disease (accuracy, sensitivity and specificity in the ADC: 88%, 92% and 84%; in the DEM: 87%, 94% and 12%; and in the ADNI cohort: 86%, 90% and 75%, respectively).","[{'end': 205, 'start': 201, 'tag': 'HealthCareRelatedOrganization'}, {'end': 205, 'start': 201, 'tag': 'ResearchActivity'}, {'end': 90, 'start': 71, 'tag': 'DiseaseOrSyndrome'}, {'end': 113, 'start': 102, 'tag': 'Finding'}, {'end': 129, 'start': 118, 'tag': 'Finding'}, {'end': 42, 'start': 34, 'tag': 'Finding'}, {'end': 100, 'start': 92, 'tag': 'Finding'}, {'end': 14, 'start': 8, 'tag': 'Finding'}, {'end': 212, 'start': 206, 'tag': 'PopulationGroup'}, {'end': 7, 'start': 0, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 60, 'start': 53, 'tag': 'HealthCareActivity'}]"
117,The addition of CSF p-tau did not further improve these estimates.,"[{'end': 25, 'start': 22, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 19, 'start': 16, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 25, 'start': 22, 'tag': 'BiologicallyActiveSubstance'}, {'end': 25, 'start': 20, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 25, 'start': 20, 'tag': 'BiologicallyActiveSubstance'}, {'end': 25, 'start': 16, 'tag': 'ClinicalAttribute'}]"
118,We observed no differences in demographics or degree of Alzheimer's disease neuropathology between A+T- and A+T+ individuals with autopsy-confirmed Alzheimer's disease.,"[{'end': 26, 'start': 12, 'tag': 'Finding'}, {'end': 75, 'start': 56, 'tag': 'DiseaseOrSyndrome'}, {'end': 167, 'start': 148, 'tag': 'DiseaseOrSyndrome'}, {'end': 90, 'start': 76, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 90, 'start': 76, 'tag': 'PathologicFunction'}, {'end': 124, 'start': 113, 'tag': 'PopulationGroup'}, {'end': 137, 'start': 130, 'tag': 'HealthCareActivity'}]"
119,All individuals with repeated CSF measurements remained stable in A beta(1-42) status during follow-up.,"[{'end': 33, 'start': 30, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 15, 'start': 4, 'tag': 'PopulationGroup'}, {'end': 102, 'start': 93, 'tag': 'HealthCareActivity'}, {'end': 102, 'start': 93, 'tag': 'TemporalConcept'}, {'end': 46, 'start': 34, 'tag': 'HealthCareActivity'}, {'end': 85, 'start': 79, 'tag': 'Finding'}, {'end': 78, 'start': 66, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 46, 'start': 34, 'tag': 'ResearchActivity'}, {'end': 78, 'start': 66, 'tag': 'BiologicallyActiveSubstance'}]"
120,"None of the Alzheimer's disease individuals with a normal p-tau status changed to abnormal; however, four (44%) DEM individuals and two (7%) ADNI individuals changed from abnormal to normal p-tau status over time, and all had Alzheimer's disease at autopsy.","[{'end': 256, 'start': 249, 'tag': 'HealthCareActivity'}, {'end': 57, 'start': 51, 'tag': 'Finding'}, {'end': 189, 'start': 183, 'tag': 'Finding'}, {'end': 90, 'start': 82, 'tag': 'Finding'}, {'end': 179, 'start': 171, 'tag': 'Finding'}, {'end': 145, 'start': 141, 'tag': 'HealthCareRelatedOrganization'}, {'end': 145, 'start': 141, 'tag': 'ResearchActivity'}, {'end': 63, 'start': 60, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 195, 'start': 192, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 31, 'start': 12, 'tag': 'DiseaseOrSyndrome'}, {'end': 245, 'start': 226, 'tag': 'DiseaseOrSyndrome'}, {'end': 63, 'start': 60, 'tag': 'BiologicallyActiveSubstance'}, {'end': 195, 'start': 192, 'tag': 'BiologicallyActiveSubstance'}, {'end': 43, 'start': 32, 'tag': 'PopulationGroup'}, {'end': 127, 'start': 116, 'tag': 'PopulationGroup'}, {'end': 157, 'start': 146, 'tag': 'PopulationGroup'}, {'end': 212, 'start': 208, 'tag': 'TemporalConcept'}, {'end': 63, 'start': 58, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 195, 'start': 190, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 63, 'start': 58, 'tag': 'BiologicallyActiveSubstance'}, {'end': 195, 'start': 190, 'tag': 'BiologicallyActiveSubstance'}, {'end': 70, 'start': 64, 'tag': 'Finding'}, {'end': 202, 'start': 196, 'tag': 'Finding'}]"
121,"In summary, we found that up to 73% of A+T- individuals had Alzheimer's disease at autopsy.","[{'end': 90, 'start': 83, 'tag': 'HealthCareActivity'}, {'end': 79, 'start': 60, 'tag': 'DiseaseOrSyndrome'}, {'end': 55, 'start': 44, 'tag': 'PopulationGroup'}]"
122,This should be taken into account in both research and clinical settings.,"[{'end': 72, 'start': 55, 'tag': 'ResearchActivity'}, {'end': 50, 'start': 42, 'tag': 'ResearchActivity'}]"
123,The biological definition of Alzheimer's disease using CSF biomarkers requires both abnormal amyloid (A) and tau (T) levels.,"[{'end': 92, 'start': 84, 'tag': 'Finding'}, {'end': 112, 'start': 109, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 48, 'start': 29, 'tag': 'DiseaseOrSyndrome'}, {'end': 58, 'start': 55, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 112, 'start': 109, 'tag': 'BiologicallyActiveSubstance'}, {'end': 100, 'start': 93, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 100, 'start': 93, 'tag': 'BiologicallyActiveSubstance'}, {'end': 69, 'start': 59, 'tag': 'ClinicalAttribute'}]"
124,"However, in a large multicentre cohort, Vromen et al.","[{'end': 38, 'start': 32, 'tag': 'PopulationGroup'}]"
125,"found that up to 73% of A+T- individuals had Alzheimer's disease at autopsy, with implications for both research and clinical settings.","[{'end': 75, 'start': 68, 'tag': 'HealthCareActivity'}, {'end': 134, 'start': 117, 'tag': 'ResearchActivity'}, {'end': 64, 'start': 45, 'tag': 'DiseaseOrSyndrome'}, {'end': 40, 'start': 29, 'tag': 'PopulationGroup'}, {'end': 112, 'start': 104, 'tag': 'ResearchActivity'}]"
126,"Background: Obesity is related to quantitative neuroimaging abnormalities including reduced gray matter volumes and impaired white matter microstructural integrity, although the underlying mechanisms are not well understood.","[{'end': 19, 'start': 12, 'tag': 'DiseaseOrSyndrome'}, {'end': 163, 'start': 154, 'tag': 'IndividualBehavior'}, {'end': 59, 'start': 47, 'tag': 'HealthCareActivity'}, {'end': 103, 'start': 92, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 137, 'start': 125, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 73, 'start': 34, 'tag': 'Finding'}, {'end': 163, 'start': 125, 'tag': 'ClinicalAttribute'}, {'end': 111, 'start': 92, 'tag': 'ClinicalAttribute'}]"
127,Objective: We assessed influence of obesity on neuroinflammation imaging that may mediate brain morphometric changes.,"[{'end': 43, 'start': 36, 'tag': 'DiseaseOrSyndrome'}, {'end': 72, 'start': 65, 'tag': 'HealthCareActivity'}, {'end': 95, 'start': 90, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 64, 'start': 47, 'tag': 'PathologicFunction'}]"
128,Establishing the role of neuroinflammation in obesity will enhance understanding of this modifiable disorder as a risk factor for Alzheimer's disease (AD) dementia.,"[{'end': 53, 'start': 46, 'tag': 'DiseaseOrSyndrome'}, {'end': 108, 'start': 100, 'tag': 'DiseaseOrSyndrome'}, {'end': 125, 'start': 114, 'tag': 'Finding'}, {'end': 149, 'start': 130, 'tag': 'DiseaseOrSyndrome'}, {'end': 153, 'start': 151, 'tag': 'DiseaseOrSyndrome'}, {'end': 42, 'start': 25, 'tag': 'PathologicFunction'}, {'end': 163, 'start': 155, 'tag': 'DiseaseOrSyndrome'}, {'end': 80, 'start': 67, 'tag': 'BiologicFunction'}]"
129,Methods: We analyzed brain MRIs from 104 cognitively normal participants (CDR = 0) and biomarker negativity for CSF amyloid or tau.,"[{'end': 31, 'start': 27, 'tag': 'HealthCareActivity'}, {'end': 123, 'start': 112, 'tag': 'ClinicalAttribute'}, {'end': 130, 'start': 127, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 115, 'start': 112, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 130, 'start': 127, 'tag': 'BiologicallyActiveSubstance'}, {'end': 96, 'start': 87, 'tag': 'ClinicalAttribute'}, {'end': 26, 'start': 21, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 72, 'start': 60, 'tag': 'PopulationGroup'}, {'end': 123, 'start': 116, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 123, 'start': 116, 'tag': 'BiologicallyActiveSubstance'}, {'end': 59, 'start': 41, 'tag': 'Finding'}, {'end': 20, 'start': 12, 'tag': 'ResearchActivity'}, {'end': 130, 'start': 127, 'tag': 'ClinicalAttribute'}, {'end': 115, 'start': 112, 'tag': 'ClinicalAttribute'}]"
130,"We classified body mass index (BMI) as normal (BMI <25, N = 62) or overweight and obese (BMI = 25, N = 42).","[{'end': 77, 'start': 67, 'tag': 'Finding'}, {'end': 87, 'start': 82, 'tag': 'Finding'}, {'end': 45, 'start': 39, 'tag': 'Finding'}, {'end': 34, 'start': 31, 'tag': 'ClinicalAttribute'}, {'end': 50, 'start': 47, 'tag': 'ClinicalAttribute'}, {'end': 92, 'start': 89, 'tag': 'ClinicalAttribute'}, {'end': 29, 'start': 14, 'tag': 'ClinicalAttribute'}, {'end': 18, 'start': 14, 'tag': 'BodyPartOrganOrOrganComponent'}]"
131,Blood pressure was measured.,"[{'end': 5, 'start': 0, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 14, 'start': 0, 'tag': 'BiologicFunction'}]"
132,BMI and blood pressure classifications were related to neuroinflammation imaging (NII) derived edema fraction in 17 white matter tracts.,"[{'end': 100, 'start': 95, 'tag': 'PathologicFunction'}, {'end': 135, 'start': 116, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 80, 'start': 73, 'tag': 'HealthCareActivity'}, {'end': 22, 'start': 8, 'tag': 'BiologicFunction'}, {'end': 3, 'start': 0, 'tag': 'ClinicalAttribute'}, {'end': 72, 'start': 55, 'tag': 'PathologicFunction'}, {'end': 109, 'start': 95, 'tag': 'ClinicalAttribute'}]"
133,"This metric was also correlated to hippocampal volumes and CSF biomarkers of inflammation and neurodegeneration: YKL-40, SNAP25, VILIP, tau, and NFL.","[{'end': 127, 'start': 121, 'tag': 'GeneOrGenome'}, {'end': 127, 'start': 121, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 134, 'start': 129, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 148, 'start': 145, 'tag': 'BiologicallyActiveSubstance'}, {'end': 148, 'start': 145, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 119, 'start': 113, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 119, 'start': 113, 'tag': 'BiologicallyActiveSubstance'}, {'end': 89, 'start': 77, 'tag': 'PathologicFunction'}, {'end': 139, 'start': 136, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 62, 'start': 59, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 139, 'start': 136, 'tag': 'BiologicallyActiveSubstance'}, {'end': 73, 'start': 63, 'tag': 'ClinicalAttribute'}, {'end': 111, 'start': 94, 'tag': 'CellOrMolecularDysfunction'}, {'end': 54, 'start': 35, 'tag': 'ClinicalAttribute'}, {'end': 127, 'start': 121, 'tag': 'BiologicallyActiveSubstance'}, {'end': 134, 'start': 129, 'tag': 'BiologicallyActiveSubstance'}]"
134,"Results: Participants with BMI <25 had lower NII-derived edema fraction, with protective effects of normal blood pressure.","[{'end': 62, 'start': 57, 'tag': 'PathologicFunction'}, {'end': 106, 'start': 100, 'tag': 'Finding'}, {'end': 121, 'start': 107, 'tag': 'BiologicFunction'}, {'end': 30, 'start': 27, 'tag': 'ClinicalAttribute'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 21, 'start': 9, 'tag': 'PopulationGroup'}, {'end': 96, 'start': 78, 'tag': 'Finding'}, {'end': 71, 'start': 57, 'tag': 'ClinicalAttribute'}]"
135,"Statistically significant white matter tracts included the internal capsule, external capsule, and corona radiata, FDR corrected for multiple comparisons to alpha = 0.05.","[{'end': 75, 'start': 59, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 93, 'start': 77, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 113, 'start': 99, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 45, 'start': 26, 'tag': 'BodyPartOrganOrOrganComponent'}]"
136,"Higher NII-derived edema fractions in the internal capsule, corpus callosum, gyrus, and superior fronto-occipital fasciculus were related with smaller hippocampal volumes only in individuals with BMI >= 25.","[{'end': 24, 'start': 19, 'tag': 'PathologicFunction'}, {'end': 58, 'start': 42, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 75, 'start': 60, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 199, 'start': 196, 'tag': 'ClinicalAttribute'}, {'end': 190, 'start': 179, 'tag': 'PopulationGroup'}, {'end': 82, 'start': 77, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 124, 'start': 88, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 170, 'start': 151, 'tag': 'ClinicalAttribute'}]"
137,There were no statistically significant correlations between NII-derived edema fraction and CSF biomarkers.,"[{'end': 78, 'start': 73, 'tag': 'PathologicFunction'}, {'end': 52, 'start': 28, 'tag': 'Finding'}, {'end': 95, 'start': 92, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 106, 'start': 96, 'tag': 'ClinicalAttribute'}, {'end': 87, 'start': 73, 'tag': 'ClinicalAttribute'}]"
138,"Conclusion: We demonstrate statistically significant relationships between neuroinflammation, elevated BMI, and hippocampal volume, raising implications for neuroinflammation mechanisms of obesity-related brain dysfunction in cognitively normal elderly.","[{'end': 66, 'start': 41, 'tag': 'Finding'}, {'end': 222, 'start': 211, 'tag': 'PathologicFunction'}, {'end': 106, 'start': 103, 'tag': 'ClinicalAttribute'}, {'end': 210, 'start': 205, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 92, 'start': 75, 'tag': 'PathologicFunction'}, {'end': 174, 'start': 157, 'tag': 'PathologicFunction'}, {'end': 244, 'start': 226, 'tag': 'Finding'}, {'end': 252, 'start': 245, 'tag': 'PopulationGroup'}, {'end': 130, 'start': 112, 'tag': 'ClinicalAttribute'}, {'end': 196, 'start': 189, 'tag': 'DiseaseOrSyndrome'}]"
139,Background: Psychotic symptoms are common in Alzheimer's disease (AD) and related neurodegenerative disorders and are associated with more rapid disease progression and increased mortality.,"[{'end': 30, 'start': 12, 'tag': 'SignOrSymptom'}, {'end': 188, 'start': 179, 'tag': 'Finding'}, {'end': 109, 'start': 82, 'tag': 'DiseaseOrSyndrome'}, {'end': 64, 'start': 45, 'tag': 'DiseaseOrSyndrome'}, {'end': 68, 'start': 66, 'tag': 'DiseaseOrSyndrome'}, {'end': 164, 'start': 153, 'tag': 'PathologicFunction'}, {'end': 164, 'start': 153, 'tag': 'TemporalConcept'}, {'end': 164, 'start': 145, 'tag': 'PathologicFunction'}]"
140,It is unclear to what degree existing criteria are utilized in clinical research and practice.,"[{'end': 80, 'start': 63, 'tag': 'ResearchActivity'}, {'end': 93, 'start': 85, 'tag': 'BiologicFunction'}, {'end': 93, 'start': 85, 'tag': 'HealthCareActivity'}, {'end': 71, 'start': 63, 'tag': 'HealthCareActivity'}]"
141,Objective: To establish research criteria for the diagnosis of psychosis in AD.,"[{'end': 72, 'start': 63, 'tag': 'DiseaseOrSyndrome'}, {'end': 78, 'start': 76, 'tag': 'DiseaseOrSyndrome'}, {'end': 32, 'start': 24, 'tag': 'ResearchActivity'}, {'end': 59, 'start': 50, 'tag': 'HealthCareActivity'}]"
142,Methods: The International Society to Advance Alzheimer's Research and Treatment (ISTAART) Neuropsychiatric Symptoms (NPS) Professional Interest Area (PIA) psychosis subgroup reviewed existing criteria for psychosis in AD and related dementias.,"[{'end': 121, 'start': 118, 'tag': 'SignOrSymptom'}, {'end': 165, 'start': 156, 'tag': 'DiseaseOrSyndrome'}, {'end': 215, 'start': 206, 'tag': 'DiseaseOrSyndrome'}, {'end': 243, 'start': 234, 'tag': 'DiseaseOrSyndrome'}, {'end': 221, 'start': 219, 'tag': 'DiseaseOrSyndrome'}, {'end': 80, 'start': 13, 'tag': 'HealthCareRelatedOrganization'}, {'end': 89, 'start': 82, 'tag': 'HealthCareRelatedOrganization'}, {'end': 116, 'start': 91, 'tag': 'SignOrSymptom'}]"
143,"Through a series of in person and on-line meetings, a priority checklist was devised to capture features necessary for current research and clinical needs.","[{'end': 29, 'start': 23, 'tag': 'PopulationGroup'}, {'end': 50, 'start': 34, 'tag': 'ResearchActivity'}, {'end': 126, 'start': 119, 'tag': 'TemporalConcept'}, {'end': 135, 'start': 127, 'tag': 'ResearchActivity'}, {'end': 62, 'start': 54, 'tag': 'Finding'}]"
144,"PubMed, Medline and other relevant databases were searched for relevant criteria.","[{'end': 44, 'start': 35, 'tag': 'ResearchActivity'}, {'end': 6, 'start': 0, 'tag': 'HealthCareRelatedOrganization'}, {'end': 15, 'start': 8, 'tag': 'HealthCareRelatedOrganization'}]"
145,"Results: Consensus identified three sets of criteria suitable for review including those of Jeste and Finkel, Lyketsos, and the Diagnostic and Statistical Manual for Mental Disorders, 5th edition.","[{'end': 72, 'start': 66, 'tag': 'ResearchActivity'}, {'end': 72, 'start': 66, 'tag': 'HealthCareActivity'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 182, 'start': 128, 'tag': 'HealthCareActivity'}]"
146,"It was concluded that existing criteria could be augmented by including a more specific differentiation between delusions and hallucinations, address overlap with related conditions (agitation in particular), adding the possibility of symptoms emerging in the preclinical and prodromal phases, and building on developing research in disease biomarkers.","[{'end': 121, 'start': 112, 'tag': 'DiseaseOrSyndrome'}, {'end': 140, 'start': 126, 'tag': 'DiseaseOrSyndrome'}, {'end': 192, 'start': 183, 'tag': 'SignOrSymptom'}, {'end': 103, 'start': 88, 'tag': 'CellFunction'}, {'end': 157, 'start': 150, 'tag': 'TemporalConcept'}, {'end': 243, 'start': 235, 'tag': 'SignOrSymptom'}, {'end': 181, 'start': 171, 'tag': 'DiseaseOrSyndrome'}, {'end': 329, 'start': 321, 'tag': 'ResearchActivity'}, {'end': 351, 'start': 341, 'tag': 'ClinicalAttribute'}, {'end': 292, 'start': 286, 'tag': 'TemporalConcept'}, {'end': 271, 'start': 260, 'tag': 'TemporalConcept'}, {'end': 292, 'start': 276, 'tag': 'TemporalConcept'}]"
147,"Conclusion: We propose criteria, developed to improve phenotypic classification of psychosis in AD, and advance the research agenda in the field to improve epidemiological, biomarker, and genetics research in the field.","[{'end': 131, 'start': 116, 'tag': 'ResearchActivity'}, {'end': 171, 'start': 156, 'tag': 'ResearchActivity'}, {'end': 196, 'start': 188, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 196, 'start': 188, 'tag': 'CellFunction'}, {'end': 92, 'start': 83, 'tag': 'DiseaseOrSyndrome'}, {'end': 98, 'start': 96, 'tag': 'DiseaseOrSyndrome'}, {'end': 182, 'start': 173, 'tag': 'ClinicalAttribute'}, {'end': 205, 'start': 197, 'tag': 'ResearchActivity'}, {'end': 64, 'start': 54, 'tag': 'OrganismAttribute'}, {'end': 79, 'start': 65, 'tag': 'ResearchActivity'}]"
148,These criteria serve as a complement to the International Psychogeriatric Association criteria for psychosis in neurocognitive disorders.,"[{'end': 136, 'start': 112, 'tag': 'DiseaseOrSyndrome'}, {'end': 108, 'start': 99, 'tag': 'DiseaseOrSyndrome'}, {'end': 85, 'start': 44, 'tag': 'HealthCareRelatedOrganization'}]"
149,The identification of reliable biomarkers in biological fluids is paramount to optimizing the diagnosis of Alzheimer's disease (AD).,"[{'end': 126, 'start': 107, 'tag': 'DiseaseOrSyndrome'}, {'end': 130, 'start': 128, 'tag': 'DiseaseOrSyndrome'}, {'end': 103, 'start': 94, 'tag': 'HealthCareActivity'}, {'end': 41, 'start': 31, 'tag': 'ClinicalAttribute'}, {'end': 62, 'start': 45, 'tag': 'Substance'}]"
150,"Measurement of A beta 42, t-tau, and p-tau in cerebrospinal fluid (CSF) is the most accepted method to support the diagnosis of AD.","[{'end': 11, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 11, 'start': 0, 'tag': 'HealthCareActivity'}, {'end': 24, 'start': 15, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 24, 'start': 15, 'tag': 'BiologicallyActiveSubstance'}, {'end': 31, 'start': 28, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 42, 'start': 39, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 70, 'start': 67, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 31, 'start': 28, 'tag': 'BiologicallyActiveSubstance'}, {'end': 42, 'start': 39, 'tag': 'BiologicallyActiveSubstance'}, {'end': 130, 'start': 128, 'tag': 'DiseaseOrSyndrome'}, {'end': 65, 'start': 46, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 99, 'start': 93, 'tag': 'ResearchActivity'}, {'end': 99, 'start': 93, 'tag': 'HealthCareActivity'}, {'end': 124, 'start': 115, 'tag': 'HealthCareActivity'}, {'end': 31, 'start': 26, 'tag': 'BiologicallyActiveSubstance'}, {'end': 31, 'start': 26, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 42, 'start': 37, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 42, 'start': 37, 'tag': 'BiologicallyActiveSubstance'}, {'end': 21, 'start': 15, 'tag': 'AminoAcidPeptideOrProtein'}]"
151,"However, lumbar puncture represents an invasive investigation, whereas saliva is one of the most accessible body fluids.","[{'end': 119, 'start': 108, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 119, 'start': 108, 'tag': 'Substance'}, {'end': 47, 'start': 39, 'tag': 'Finding'}, {'end': 61, 'start': 48, 'tag': 'ResearchActivity'}, {'end': 24, 'start': 9, 'tag': 'HealthCareActivity'}, {'end': 77, 'start': 71, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 112, 'start': 108, 'tag': 'BodyPartOrganOrOrganComponent'}]"
152,"The aim of our study was to investigate salivary concentrations in AD and evaluate the correlation between salivary and CSF A beta 42 concentrations in AD patients, patients with non-AD dementias, and controls.","[{'end': 63, 'start': 49, 'tag': 'BiologicFunction'}, {'end': 148, 'start': 120, 'tag': 'ClinicalAttribute'}, {'end': 133, 'start': 124, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 133, 'start': 124, 'tag': 'BiologicallyActiveSubstance'}, {'end': 195, 'start': 186, 'tag': 'DiseaseOrSyndrome'}, {'end': 48, 'start': 40, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 115, 'start': 107, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 123, 'start': 120, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 69, 'start': 67, 'tag': 'DiseaseOrSyndrome'}, {'end': 154, 'start': 152, 'tag': 'DiseaseOrSyndrome'}, {'end': 185, 'start': 183, 'tag': 'DiseaseOrSyndrome'}, {'end': 209, 'start': 201, 'tag': 'PopulationGroup'}, {'end': 163, 'start': 155, 'tag': 'PatientOrDisabledGroup'}, {'end': 173, 'start': 165, 'tag': 'PatientOrDisabledGroup'}, {'end': 20, 'start': 15, 'tag': 'ResearchActivity'}, {'end': 130, 'start': 124, 'tag': 'AminoAcidPeptideOrProtein'}]"
153,"We recruited 100 subjects: 18 AD patients, 64 patients with non-AD dementias, and 18 controls.","[{'end': 76, 'start': 67, 'tag': 'DiseaseOrSyndrome'}, {'end': 32, 'start': 30, 'tag': 'DiseaseOrSyndrome'}, {'end': 66, 'start': 64, 'tag': 'DiseaseOrSyndrome'}, {'end': 93, 'start': 85, 'tag': 'PopulationGroup'}, {'end': 41, 'start': 33, 'tag': 'PatientOrDisabledGroup'}, {'end': 54, 'start': 46, 'tag': 'PatientOrDisabledGroup'}, {'end': 25, 'start': 17, 'tag': 'PopulationGroup'}]"
154,"The mean saliva A beta 42 concentrations in AD patients were higher than in controls (p < 0.001), and to patients with non-AD dementias (p = 0.001).","[{'end': 40, 'start': 9, 'tag': 'ClinicalAttribute'}, {'end': 25, 'start': 16, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 25, 'start': 16, 'tag': 'BiologicallyActiveSubstance'}, {'end': 135, 'start': 126, 'tag': 'DiseaseOrSyndrome'}, {'end': 15, 'start': 9, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 46, 'start': 44, 'tag': 'DiseaseOrSyndrome'}, {'end': 125, 'start': 123, 'tag': 'DiseaseOrSyndrome'}, {'end': 84, 'start': 76, 'tag': 'PopulationGroup'}, {'end': 55, 'start': 47, 'tag': 'PatientOrDisabledGroup'}, {'end': 113, 'start': 105, 'tag': 'PatientOrDisabledGroup'}, {'end': 22, 'start': 16, 'tag': 'AminoAcidPeptideOrProtein'}]"
155,"A significant negative correlation between salivary and CSF A beta 42 concentrations was found in the overall group (r = -0.562, p < 0.001) and in non-AD patients (r = -0.443, p < 0.001).","[{'end': 84, 'start': 56, 'tag': 'ClinicalAttribute'}, {'end': 69, 'start': 60, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 69, 'start': 60, 'tag': 'BiologicallyActiveSubstance'}, {'end': 51, 'start': 43, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 59, 'start': 56, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 153, 'start': 151, 'tag': 'DiseaseOrSyndrome'}, {'end': 162, 'start': 154, 'tag': 'PatientOrDisabledGroup'}, {'end': 115, 'start': 110, 'tag': 'PopulationGroup'}, {'end': 66, 'start': 60, 'tag': 'AminoAcidPeptideOrProtein'}]"
156,"Salivary A beta 42 concentrations positively correlated with CSF t-tau (r = 0.321, p = 0.001) and p-tau (r = 0.297, p = 0.001).","[{'end': 33, 'start': 0, 'tag': 'ClinicalAttribute'}, {'end': 18, 'start': 9, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 18, 'start': 9, 'tag': 'BiologicallyActiveSubstance'}, {'end': 70, 'start': 67, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 103, 'start': 100, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 64, 'start': 61, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 70, 'start': 67, 'tag': 'BiologicallyActiveSubstance'}, {'end': 103, 'start': 100, 'tag': 'BiologicallyActiveSubstance'}, {'end': 70, 'start': 65, 'tag': 'BiologicallyActiveSubstance'}, {'end': 70, 'start': 65, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 103, 'start': 98, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 103, 'start': 98, 'tag': 'BiologicallyActiveSubstance'}, {'end': 15, 'start': 9, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 70, 'start': 61, 'tag': 'ClinicalAttribute'}, {'end': 103, 'start': 98, 'tag': 'ClinicalAttribute'}, {'end': 64, 'start': 61, 'tag': 'ClinicalAttribute'}]"
157,"Our study showed that in AD patients' saliva, A beta 42 concentrations are specifically increased, and we found an interesting negative correlation between CSF and salivary A beta 42 concentrations that warrants further investigation.","[{'end': 70, 'start': 56, 'tag': 'BiologicFunction'}, {'end': 197, 'start': 164, 'tag': 'ClinicalAttribute'}, {'end': 233, 'start': 220, 'tag': 'ResearchActivity'}, {'end': 55, 'start': 46, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 182, 'start': 173, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 55, 'start': 46, 'tag': 'BiologicallyActiveSubstance'}, {'end': 182, 'start': 173, 'tag': 'BiologicallyActiveSubstance'}, {'end': 172, 'start': 164, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 44, 'start': 38, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 159, 'start': 156, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 27, 'start': 25, 'tag': 'DiseaseOrSyndrome'}, {'end': 36, 'start': 28, 'tag': 'PatientOrDisabledGroup'}, {'end': 9, 'start': 4, 'tag': 'ResearchActivity'}, {'end': 52, 'start': 46, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 179, 'start': 173, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 147, 'start': 127, 'tag': 'ResearchActivity'}]"
158,Author Summary Functional network disruption is a well-established finding in Alzheimer's disease.,"[{'end': 74, 'start': 67, 'tag': 'Finding'}, {'end': 97, 'start': 78, 'tag': 'DiseaseOrSyndrome'}, {'end': 44, 'start': 15, 'tag': 'PathologicFunction'}]"
159,Sensitive network-based biomarkers are however not available.,"[{'end': 9, 'start': 0, 'tag': 'PathologicFunction'}, {'end': 34, 'start': 24, 'tag': 'ClinicalAttribute'}, {'end': 17, 'start': 10, 'tag': 'PopulationGroup'}, {'end': 17, 'start': 10, 'tag': 'CellFunction'}]"
160,"We aimed to detect neuronal dysfunction at a predementia (mild cognitive impairment, MCI) stage of Alzheimer's disease, by applying a network-level neural variability measure to magnetoencephalography data: the inverted joint permutation entropy (JPE(inv)).","[{'end': 18, 'start': 12, 'tag': 'Finding'}, {'end': 39, 'start': 19, 'tag': 'CellOrMolecularDysfunction'}, {'end': 200, 'start': 178, 'tag': 'HealthCareActivity'}, {'end': 118, 'start': 99, 'tag': 'DiseaseOrSyndrome'}, {'end': 205, 'start': 201, 'tag': 'ResearchActivity'}, {'end': 83, 'start': 63, 'tag': 'DiseaseOrSyndrome'}, {'end': 88, 'start': 85, 'tag': 'DiseaseOrSyndrome'}, {'end': 166, 'start': 155, 'tag': 'Finding'}, {'end': 141, 'start': 134, 'tag': 'PopulationGroup'}, {'end': 141, 'start': 134, 'tag': 'CellFunction'}, {'end': 83, 'start': 58, 'tag': 'DiseaseOrSyndrome'}, {'end': 62, 'start': 58, 'tag': 'Finding'}, {'end': 95, 'start': 90, 'tag': 'TemporalConcept'}, {'end': 95, 'start': 90, 'tag': 'ClinicalAttribute'}, {'end': 245, 'start': 211, 'tag': 'ClinicalAttribute'}, {'end': 56, 'start': 45, 'tag': 'TemporalConcept'}, {'end': 174, 'start': 167, 'tag': 'ResearchActivity'}, {'end': 174, 'start': 167, 'tag': 'HealthCareActivity'}, {'end': 255, 'start': 247, 'tag': 'ClinicalAttribute'}]"
161,This measure integrates information on local signal variability/complexity and nonlinear coupling.,"[{'end': 97, 'start': 89, 'tag': 'Finding'}, {'end': 63, 'start': 52, 'tag': 'Finding'}]"
162,"We found significant differences in JPE(inv) between subjects with subjective cognitive decline and MCI, primarily in the theta band.","[{'end': 132, 'start': 122, 'tag': 'ResearchActivity'}, {'end': 95, 'start': 67, 'tag': 'DiseaseOrSyndrome'}, {'end': 103, 'start': 100, 'tag': 'DiseaseOrSyndrome'}, {'end': 32, 'start': 9, 'tag': 'Finding'}, {'end': 95, 'start': 78, 'tag': 'DiseaseOrSyndrome'}, {'end': 61, 'start': 53, 'tag': 'PopulationGroup'}, {'end': 44, 'start': 36, 'tag': 'ClinicalAttribute'}]"
163,"The diagnostic ability of the JPE(inv) was reported to be similar to that of relative theta power, the most potent neurophysiological biomarker of predementia Alzheimer's disease to date.","[{'end': 186, 'start': 179, 'tag': 'TemporalConcept'}, {'end': 186, 'start': 182, 'tag': 'TemporalConcept'}, {'end': 22, 'start': 15, 'tag': 'OrganismAttribute'}, {'end': 178, 'start': 159, 'tag': 'DiseaseOrSyndrome'}, {'end': 143, 'start': 115, 'tag': 'ClinicalAttribute'}, {'end': 14, 'start': 4, 'tag': 'HealthCareActivity'}, {'end': 38, 'start': 30, 'tag': 'ClinicalAttribute'}, {'end': 97, 'start': 86, 'tag': 'ClinicalAttribute'}, {'end': 158, 'start': 147, 'tag': 'TemporalConcept'}]"
164,Increasing evidence suggests that measures of signal variability and complexity could present promising biomarkers for Alzheimer's disease (AD).,"[{'end': 138, 'start': 119, 'tag': 'DiseaseOrSyndrome'}, {'end': 142, 'start': 140, 'tag': 'DiseaseOrSyndrome'}, {'end': 114, 'start': 94, 'tag': 'ClinicalAttribute'}, {'end': 64, 'start': 46, 'tag': 'Finding'}, {'end': 19, 'start': 11, 'tag': 'Finding'}]"
165,Earlier studies have however been limited to the characterization of local activity.,"[{'end': 65, 'start': 49, 'tag': 'ResearchActivity'}, {'end': 15, 'start': 8, 'tag': 'ResearchActivity'}, {'end': 7, 'start': 0, 'tag': 'TemporalConcept'}]"
166,"Here, we investigate whether a network version of permutation entropy could serve as a novel biomarker for early-stage AD.","[{'end': 102, 'start': 87, 'tag': 'ClinicalAttribute'}, {'end': 69, 'start': 62, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 121, 'start': 119, 'tag': 'DiseaseOrSyndrome'}, {'end': 102, 'start': 93, 'tag': 'ClinicalAttribute'}, {'end': 112, 'start': 107, 'tag': 'TemporalConcept'}, {'end': 38, 'start': 31, 'tag': 'PopulationGroup'}, {'end': 38, 'start': 31, 'tag': 'CellFunction'}, {'end': 118, 'start': 113, 'tag': 'TemporalConcept'}, {'end': 118, 'start': 113, 'tag': 'ClinicalAttribute'}, {'end': 69, 'start': 31, 'tag': 'ClinicalAttribute'}]"
167,Resting-state source-space magnetoencephalography was recorded in 18 subjects with subjective cognitive decline (SCD) and 18 subjects with mild cognitive impairment (MCI).,"[{'end': 49, 'start': 0, 'tag': 'HealthCareActivity'}, {'end': 111, 'start': 83, 'tag': 'DiseaseOrSyndrome'}, {'end': 116, 'start': 113, 'tag': 'DiseaseOrSyndrome'}, {'end': 164, 'start': 144, 'tag': 'DiseaseOrSyndrome'}, {'end': 169, 'start': 166, 'tag': 'DiseaseOrSyndrome'}, {'end': 111, 'start': 94, 'tag': 'DiseaseOrSyndrome'}, {'end': 164, 'start': 139, 'tag': 'DiseaseOrSyndrome'}, {'end': 77, 'start': 69, 'tag': 'PopulationGroup'}, {'end': 133, 'start': 125, 'tag': 'PopulationGroup'}, {'end': 143, 'start': 139, 'tag': 'Finding'}]"
168,Local activity was characterized by permutation entropy (PE).,"[{'end': 55, 'start': 48, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 55, 'start': 36, 'tag': 'ResearchActivity'}]"
169,"Network-level interactions were studied using the inverted joint permutation entropy (JPE(inv)), corrected for volume conduction.","[{'end': 128, 'start': 118, 'tag': 'BiologicFunction'}, {'end': 128, 'start': 118, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 84, 'start': 77, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 64, 'start': 59, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 26, 'start': 14, 'tag': 'Finding'}, {'end': 84, 'start': 50, 'tag': 'ClinicalAttribute'}, {'end': 94, 'start': 86, 'tag': 'ClinicalAttribute'}]"
170,The JPE(inv) showed a reduction of nonlinear connectivity in MCI subjects in the theta and alpha band.,"[{'end': 31, 'start': 22, 'tag': 'Finding'}, {'end': 31, 'start': 22, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 64, 'start': 61, 'tag': 'DiseaseOrSyndrome'}, {'end': 73, 'start': 65, 'tag': 'PopulationGroup'}, {'end': 57, 'start': 45, 'tag': 'BiologicFunction'}, {'end': 12, 'start': 4, 'tag': 'ClinicalAttribute'}, {'end': 101, 'start': 81, 'tag': 'ResearchActivity'}]"
171,Local PE showed increased theta band entropy.,"[{'end': 36, 'start': 26, 'tag': 'ResearchActivity'}, {'end': 44, 'start': 37, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 8, 'start': 0, 'tag': 'ResearchActivity'}]"
172,Between-group differences were widespread across brain regions.,"[{'end': 25, 'start': 8, 'tag': 'Finding'}, {'end': 62, 'start': 49, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 25, 'start': 14, 'tag': 'Finding'}, {'end': 13, 'start': 8, 'tag': 'PopulationGroup'}]"
173,Receiver operating characteristic (ROC) analysis of classification of MCI versus SCD subjects revealed that a logistic regression model trained on JPE(inv) features (78.4% [62.5-93.3%]) slightly outperformed PE (76.9% [60.3-93.4%]) and relative theta power-based models (76.9% [60.4-93.3%]).,"[{'end': 135, 'start': 110, 'tag': 'ResearchActivity'}, {'end': 38, 'start': 35, 'tag': 'ResearchActivity'}, {'end': 84, 'start': 81, 'tag': 'DiseaseOrSyndrome'}, {'end': 73, 'start': 70, 'tag': 'DiseaseOrSyndrome'}, {'end': 48, 'start': 40, 'tag': 'ResearchActivity'}, {'end': 33, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 269, 'start': 263, 'tag': 'ResearchActivity'}, {'end': 93, 'start': 85, 'tag': 'PopulationGroup'}, {'end': 155, 'start': 147, 'tag': 'ClinicalAttribute'}, {'end': 256, 'start': 245, 'tag': 'ClinicalAttribute'}]"
174,Classification performance of theta JPE(inv) was at least as good as the relative theta power benchmark.,"[{'end': 26, 'start': 15, 'tag': 'Finding'}, {'end': 93, 'start': 82, 'tag': 'ClinicalAttribute'}, {'end': 44, 'start': 30, 'tag': 'ClinicalAttribute'}]"
175,The JPE(inv) is therefore a potential biomarker for early-stage AD that should be explored in larger studies.,"[{'end': 66, 'start': 64, 'tag': 'DiseaseOrSyndrome'}, {'end': 47, 'start': 38, 'tag': 'ClinicalAttribute'}, {'end': 108, 'start': 101, 'tag': 'ResearchActivity'}, {'end': 57, 'start': 52, 'tag': 'TemporalConcept'}, {'end': 47, 'start': 28, 'tag': 'ClinicalAttribute'}, {'end': 63, 'start': 58, 'tag': 'TemporalConcept'}, {'end': 63, 'start': 58, 'tag': 'ClinicalAttribute'}, {'end': 12, 'start': 4, 'tag': 'ClinicalAttribute'}]"
176,The coronavirus disease 2019 (COVID-19) pandemic led to an abrupt halt of many Alzheimer's disease (AD) research studies at sites spanning the world.,"[{'end': 120, 'start': 104, 'tag': 'ResearchActivity'}, {'end': 148, 'start': 143, 'tag': 'PopulationGroup'}, {'end': 98, 'start': 79, 'tag': 'DiseaseOrSyndrome'}, {'end': 102, 'start': 100, 'tag': 'DiseaseOrSyndrome'}, {'end': 15, 'start': 4, 'tag': 'Virus'}, {'end': 28, 'start': 4, 'tag': 'DiseaseOrSyndrome'}, {'end': 38, 'start': 30, 'tag': 'DiseaseOrSyndrome'}]"
177,"This is especially true for studies requiring in-person contact, such as studies collecting biofluids.","[{'end': 35, 'start': 28, 'tag': 'ResearchActivity'}, {'end': 80, 'start': 73, 'tag': 'ResearchActivity'}, {'end': 101, 'start': 92, 'tag': 'Substance'}]"
178,"Since COVID-19 is likely to remain a threat for an extended period, the resumption of fluid biomarker studies requires the development and implementation of procedures that minimize the risk of in-person visits to participants, staff, and individuals handling the biofluid samples.","[{'end': 167, 'start': 157, 'tag': 'HealthCareActivity'}, {'end': 233, 'start': 228, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 101, 'start': 92, 'tag': 'ClinicalAttribute'}, {'end': 226, 'start': 214, 'tag': 'PopulationGroup'}, {'end': 250, 'start': 239, 'tag': 'PopulationGroup'}, {'end': 91, 'start': 86, 'tag': 'Substance'}, {'end': 134, 'start': 123, 'tag': 'BiologicFunction'}, {'end': 134, 'start': 123, 'tag': 'CellFunction'}, {'end': 109, 'start': 102, 'tag': 'ResearchActivity'}, {'end': 66, 'start': 60, 'tag': 'TemporalConcept'}, {'end': 14, 'start': 6, 'tag': 'DiseaseOrSyndrome'}, {'end': 210, 'start': 194, 'tag': 'HealthCareActivity'}, {'end': 280, 'start': 264, 'tag': 'Substance'}]"
179,"Some issues to consider include structuring the visit workflow to minimize contacts and promote social distancing; screening and/or testing participants and staff for COVID-19; wearing masks and performing hand hygiene; and precautions for handling, storing, and analyzing biofluids.","[{'end': 124, 'start': 115, 'tag': 'HealthCareActivity'}, {'end': 124, 'start': 115, 'tag': 'ResearchActivity'}, {'end': 162, 'start': 157, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 218, 'start': 206, 'tag': 'IndividualBehavior'}, {'end': 218, 'start': 206, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 53, 'start': 48, 'tag': 'HealthCareActivity'}, {'end': 152, 'start': 140, 'tag': 'PopulationGroup'}, {'end': 139, 'start': 132, 'tag': 'HealthCareActivity'}, {'end': 282, 'start': 273, 'tag': 'Substance'}, {'end': 113, 'start': 96, 'tag': 'Finding'}, {'end': 175, 'start': 167, 'tag': 'DiseaseOrSyndrome'}, {'end': 190, 'start': 177, 'tag': 'Finding'}]"
180,AD fluid biomarker research remains a vitally important public health priority and resuming studies requires appropriate safety procedures to protect research participants and staff.,"[{'end': 138, 'start': 121, 'tag': 'HealthCareActivity'}, {'end': 181, 'start': 176, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 69, 'start': 56, 'tag': 'HealthCareActivity'}, {'end': 2, 'start': 0, 'tag': 'DiseaseOrSyndrome'}, {'end': 18, 'start': 9, 'tag': 'ClinicalAttribute'}, {'end': 171, 'start': 159, 'tag': 'PopulationGroup'}, {'end': 8, 'start': 3, 'tag': 'Substance'}, {'end': 27, 'start': 19, 'tag': 'ResearchActivity'}, {'end': 158, 'start': 150, 'tag': 'ResearchActivity'}, {'end': 99, 'start': 92, 'tag': 'ResearchActivity'}, {'end': 78, 'start': 70, 'tag': 'Finding'}]"
181,Cerebrospinal fluid neurofilament light and plasma neurofilament light concentrations are elevated in patients with mild cognitive im-pairment and Alzheimer's disease.,"[{'end': 142, 'start': 116, 'tag': 'DiseaseOrSyndrome'}, {'end': 39, 'start': 20, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 70, 'start': 51, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 39, 'start': 20, 'tag': 'BiologicallyActiveSubstance'}, {'end': 70, 'start': 51, 'tag': 'BiologicallyActiveSubstance'}, {'end': 19, 'start': 0, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 166, 'start': 147, 'tag': 'DiseaseOrSyndrome'}, {'end': 110, 'start': 102, 'tag': 'PatientOrDisabledGroup'}, {'end': 50, 'start': 44, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 85, 'start': 44, 'tag': 'ClinicalAttribute'}]"
182,We investigated the clinical rele-vance of increased neurofilament light concentrations in mild cog-nitive impairment and Alzheimer's disease patients.,"[{'end': 117, 'start': 107, 'tag': 'DiseaseOrSyndrome'}, {'end': 72, 'start': 53, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 72, 'start': 53, 'tag': 'BiologicallyActiveSubstance'}, {'end': 87, 'start': 73, 'tag': 'BiologicFunction'}, {'end': 141, 'start': 122, 'tag': 'DiseaseOrSyndrome'}, {'end': 150, 'start': 142, 'tag': 'PatientOrDisabledGroup'}, {'end': 15, 'start': 3, 'tag': 'ResearchActivity'}, {'end': 95, 'start': 91, 'tag': 'Finding'}]"
183,"In this study, 244 subjects were divided into cognitively normal control (n = 67), stable mild cognitive impairment (n = 52), progressive mild cogni-tive impairment (n = 68), and Alzheimer's disease (n = 57).","[{'end': 198, 'start': 179, 'tag': 'DiseaseOrSyndrome'}, {'end': 137, 'start': 126, 'tag': 'TemporalConcept'}, {'end': 13, 'start': 8, 'tag': 'ResearchActivity'}, {'end': 72, 'start': 65, 'tag': 'PopulationGroup'}, {'end': 64, 'start': 46, 'tag': 'Finding'}, {'end': 115, 'start': 90, 'tag': 'DiseaseOrSyndrome'}, {'end': 27, 'start': 19, 'tag': 'PopulationGroup'}, {'end': 142, 'start': 138, 'tag': 'Finding'}]"
184,Linear regression examined the relationships between neurofilament light levels in cerebrospinal fluid or plasma and the diagnostic group.,"[{'end': 72, 'start': 53, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 72, 'start': 53, 'tag': 'BiologicallyActiveSubstance'}, {'end': 17, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 102, 'start': 83, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 44, 'start': 31, 'tag': 'Finding'}, {'end': 112, 'start': 106, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 137, 'start': 121, 'tag': 'PopulationGroup'}]"
185,The relationships between neurofilament light and other biomark-ers were assessed by Spearman correlation.,"[{'end': 45, 'start': 26, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 45, 'start': 26, 'tag': 'BiologicallyActiveSubstance'}, {'end': 17, 'start': 4, 'tag': 'Finding'}, {'end': 105, 'start': 85, 'tag': 'ResearchActivity'}]"
186,"Linear mixed-effects models were used to test cerebrospinal fluid and plasma neurofil-ament light as predictors of Alzheimer's disease characteristics, in-cluding cognition, cortical glucose metabolism, and brain structure.","[{'end': 222, 'start': 207, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 201, 'start': 183, 'tag': 'CellFunction'}, {'end': 150, 'start': 127, 'tag': 'ClinicalAttribute'}, {'end': 182, 'start': 174, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 111, 'start': 101, 'tag': 'Finding'}, {'end': 150, 'start': 135, 'tag': 'OrganismAttribute'}, {'end': 201, 'start': 191, 'tag': 'BiologicFunction'}, {'end': 201, 'start': 191, 'tag': 'CellFunction'}, {'end': 134, 'start': 115, 'tag': 'DiseaseOrSyndrome'}, {'end': 65, 'start': 46, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 190, 'start': 183, 'tag': 'Chemical'}, {'end': 190, 'start': 183, 'tag': 'PharmacologicSubstance'}, {'end': 190, 'start': 183, 'tag': 'BiologicallyActiveSubstance'}, {'end': 76, 'start': 70, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 172, 'start': 163, 'tag': 'BiologicFunction'}, {'end': 27, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 45, 'start': 41, 'tag': 'ResearchActivity'}, {'end': 45, 'start': 41, 'tag': 'HealthCareActivity'}, {'end': 97, 'start': 70, 'tag': 'ClinicalAttribute'}]"
187,Cerebrospinal fluid and plasma neurofilament light levels were sig-nificantly elevated in Alzheimer's disease.,"[{'end': 50, 'start': 31, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 50, 'start': 31, 'tag': 'BiologicallyActiveSubstance'}, {'end': 19, 'start': 0, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 109, 'start': 90, 'tag': 'DiseaseOrSyndrome'}, {'end': 30, 'start': 24, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 57, 'start': 24, 'tag': 'ClinicalAttribute'}]"
188,"Still, the correlations be-tween neurofilament light and other cerebrospinal fluid biomark-ers within the diagnostic groups were often not statistically signif-icant.","[{'end': 52, 'start': 33, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 52, 'start': 33, 'tag': 'BiologicallyActiveSubstance'}, {'end': 82, 'start': 63, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 123, 'start': 117, 'tag': 'PopulationGroup'}, {'end': 116, 'start': 106, 'tag': 'HealthCareActivity'}, {'end': 23, 'start': 11, 'tag': 'ResearchActivity'}, {'end': 94, 'start': 83, 'tag': 'ClinicalAttribute'}]"
189,"In addition, the diagnostic accuracy of cerebrospinal fluid and plasma neurofilament light for progressive mild cognitive im-pairment and Alzheimer's disease was almost the same as that of cerebrospinal fluid total tau (T-tau).","[{'end': 90, 'start': 71, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 90, 'start': 71, 'tag': 'BiologicallyActiveSubstance'}, {'end': 225, 'start': 220, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 225, 'start': 220, 'tag': 'BiologicallyActiveSubstance'}, {'end': 36, 'start': 17, 'tag': 'Finding'}, {'end': 218, 'start': 215, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 225, 'start': 222, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 157, 'start': 138, 'tag': 'DiseaseOrSyndrome'}, {'end': 218, 'start': 215, 'tag': 'BiologicallyActiveSubstance'}, {'end': 225, 'start': 222, 'tag': 'BiologicallyActiveSubstance'}, {'end': 59, 'start': 40, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 208, 'start': 189, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 106, 'start': 95, 'tag': 'TemporalConcept'}, {'end': 218, 'start': 209, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 218, 'start': 209, 'tag': 'BiologicallyActiveSubstance'}, {'end': 70, 'start': 64, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 111, 'start': 107, 'tag': 'Finding'}, {'end': 218, 'start': 189, 'tag': 'ClinicalAttribute'}, {'end': 90, 'start': 64, 'tag': 'ClinicalAttribute'}]"
190,It is phosphorylated tau (P-tau) and high cerebrospinal fluid.,"[{'end': 20, 'start': 6, 'tag': 'CellFunction'}, {'end': 31, 'start': 26, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 31, 'start': 26, 'tag': 'BiologicallyActiveSubstance'}, {'end': 24, 'start': 21, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 31, 'start': 28, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 24, 'start': 21, 'tag': 'BiologicallyActiveSubstance'}, {'end': 31, 'start': 28, 'tag': 'BiologicallyActiveSubstance'}, {'end': 61, 'start': 42, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 24, 'start': 6, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 24, 'start': 6, 'tag': 'BiologicallyActiveSubstance'}, {'end': 41, 'start': 37, 'tag': 'Finding'}]"
191,Neurofilament light predicted conversion from mild cognitive impairment to Alzheimer's disease.,"[{'end': 19, 'start': 0, 'tag': 'BiologicallyActiveSubstance'}, {'end': 19, 'start': 0, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 94, 'start': 75, 'tag': 'DiseaseOrSyndrome'}, {'end': 71, 'start': 51, 'tag': 'DiseaseOrSyndrome'}, {'end': 71, 'start': 46, 'tag': 'DiseaseOrSyndrome'}, {'end': 50, 'start': 46, 'tag': 'Finding'}, {'end': 40, 'start': 30, 'tag': 'Finding'}]"
192,"A high neurofilament light is related to poor cognition, low cere-bral metabolism, hippocampal atrophy, and ventricular enlarge-ment caused by Alzheimer's disease.","[{'end': 55, 'start': 41, 'tag': 'Finding'}, {'end': 102, 'start': 83, 'tag': 'DiseaseOrSyndrome'}, {'end': 119, 'start': 108, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 26, 'start': 7, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 26, 'start': 7, 'tag': 'BiologicallyActiveSubstance'}, {'end': 81, 'start': 71, 'tag': 'BiologicFunction'}, {'end': 81, 'start': 71, 'tag': 'CellFunction'}, {'end': 60, 'start': 57, 'tag': 'Finding'}, {'end': 162, 'start': 143, 'tag': 'DiseaseOrSyndrome'}, {'end': 55, 'start': 46, 'tag': 'BiologicFunction'}, {'end': 94, 'start': 83, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 94, 'start': 83, 'tag': 'Cell'}, {'end': 6, 'start': 2, 'tag': 'Finding'}]"
193,Our work further identifies cerebrospinal fluid neurofilament light and plasma neurofilament light as biomarkers of axonal degeneration in patients with mild cog-nitive impairment and Alzheimer's disease.,"[{'end': 135, 'start': 116, 'tag': 'CellOrMolecularDysfunction'}, {'end': 67, 'start': 48, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 98, 'start': 79, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 67, 'start': 48, 'tag': 'BiologicallyActiveSubstance'}, {'end': 98, 'start': 79, 'tag': 'BiologicallyActiveSubstance'}, {'end': 135, 'start': 123, 'tag': 'PathologicFunction'}, {'end': 203, 'start': 184, 'tag': 'DiseaseOrSyndrome'}, {'end': 47, 'start': 28, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 147, 'start': 139, 'tag': 'PatientOrDisabledGroup'}, {'end': 112, 'start': 102, 'tag': 'ClinicalAttribute'}, {'end': 78, 'start': 72, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 122, 'start': 116, 'tag': 'CellComponent'}, {'end': 179, 'start': 153, 'tag': 'DiseaseOrSyndrome'}, {'end': 67, 'start': 28, 'tag': 'ClinicalAttribute'}, {'end': 98, 'start': 72, 'tag': 'ClinicalAttribute'}]"
194,Introduction: Retinal thickness measured with optical coherence tomography has been proposed as a noninvasive biomarker for Alzheimer's disease (AD).,"[{'end': 21, 'start': 14, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 74, 'start': 46, 'tag': 'HealthCareActivity'}, {'end': 143, 'start': 124, 'tag': 'DiseaseOrSyndrome'}, {'end': 147, 'start': 145, 'tag': 'DiseaseOrSyndrome'}, {'end': 119, 'start': 98, 'tag': 'ClinicalAttribute'}, {'end': 31, 'start': 14, 'tag': 'ClinicalAttribute'}]"
195,"We therefore measured retinal thickness in well-characterized AD and control participants, considering ophthalmological confounders.","[{'end': 64, 'start': 62, 'tag': 'DiseaseOrSyndrome'}, {'end': 89, 'start': 77, 'tag': 'PopulationGroup'}, {'end': 131, 'start': 103, 'tag': 'Finding'}, {'end': 39, 'start': 22, 'tag': 'ClinicalAttribute'}]"
196,"Methods: We included 57 amyloid-proven AD cases and 85 cognitively normal, amyloid-negative controls.","[{'end': 31, 'start': 24, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 82, 'start': 75, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 31, 'start': 24, 'tag': 'BiologicallyActiveSubstance'}, {'end': 82, 'start': 75, 'tag': 'BiologicallyActiveSubstance'}, {'end': 41, 'start': 39, 'tag': 'DiseaseOrSyndrome'}, {'end': 100, 'start': 92, 'tag': 'PopulationGroup'}, {'end': 73, 'start': 55, 'tag': 'Finding'}, {'end': 47, 'start': 39, 'tag': 'PatientOrDisabledGroup'}]"
197,All subjects underwent retinal thickness measurements with spectral domain optical coherence tomography and an ophthalmological assessment to exclude ocular disease.,"[{'end': 103, 'start': 59, 'tag': 'HealthCareActivity'}, {'end': 12, 'start': 4, 'tag': 'PopulationGroup'}, {'end': 164, 'start': 150, 'tag': 'DiseaseOrSyndrome'}, {'end': 138, 'start': 111, 'tag': 'HealthCareActivity'}, {'end': 40, 'start': 23, 'tag': 'ClinicalAttribute'}]"
198,"Results: Retinal thickness did not discriminate cases from controls, including stratified analyses for early- versus late-onset AD.","[{'end': 127, 'start': 117, 'tag': 'TemporalConcept'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 130, 'start': 128, 'tag': 'DiseaseOrSyndrome'}, {'end': 67, 'start': 59, 'tag': 'PopulationGroup'}, {'end': 98, 'start': 90, 'tag': 'ResearchActivity'}, {'end': 26, 'start': 9, 'tag': 'ClinicalAttribute'}, {'end': 108, 'start': 103, 'tag': 'TemporalConcept'}]"
199,We found significant associations between macular thickness and global cortical atrophy [beta -0.358; P = .01] and parietal cortical atrophy on magnetic resonance imaging [beta -0.371; P < .01] in AD cases.,"[{'end': 140, 'start': 115, 'tag': 'AnatomicalAbnormality'}, {'end': 59, 'start': 42, 'tag': 'ClinicalAttribute'}, {'end': 199, 'start': 197, 'tag': 'DiseaseOrSyndrome'}, {'end': 205, 'start': 197, 'tag': 'PatientOrDisabledGroup'}, {'end': 87, 'start': 80, 'tag': 'PathologicFunction'}, {'end': 87, 'start': 80, 'tag': 'DiseaseOrSyndrome'}, {'end': 170, 'start': 144, 'tag': 'HealthCareActivity'}, {'end': 79, 'start': 71, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 132, 'start': 124, 'tag': 'BodyPartOrganOrOrganComponent'}]"
200,"Discussion: In this study, representing the largest optical coherence tomography cohort with amyloid-proven AD cases, we show that retinal thickness does not discriminate AD from controls, despite evident changes on clinical, neuroimaging, and CSF measures, querying the use of retinal thickness measurements as an AD biomarker.","[{'end': 80, 'start': 52, 'tag': 'HealthCareActivity'}, {'end': 247, 'start': 244, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 87, 'start': 81, 'tag': 'PopulationGroup'}, {'end': 100, 'start': 93, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 100, 'start': 93, 'tag': 'BiologicallyActiveSubstance'}, {'end': 110, 'start': 108, 'tag': 'DiseaseOrSyndrome'}, {'end': 173, 'start': 171, 'tag': 'DiseaseOrSyndrome'}, {'end': 317, 'start': 315, 'tag': 'DiseaseOrSyndrome'}, {'end': 327, 'start': 318, 'tag': 'ClinicalAttribute'}, {'end': 25, 'start': 20, 'tag': 'ResearchActivity'}, {'end': 187, 'start': 179, 'tag': 'PopulationGroup'}, {'end': 238, 'start': 226, 'tag': 'HealthCareActivity'}, {'end': 116, 'start': 108, 'tag': 'PatientOrDisabledGroup'}, {'end': 308, 'start': 296, 'tag': 'HealthCareActivity'}, {'end': 148, 'start': 131, 'tag': 'ClinicalAttribute'}, {'end': 295, 'start': 278, 'tag': 'ClinicalAttribute'}]"
201,Introduction Blood proteins are emerging as candidate biomarkers for Alzheimer's disease (AD).,"[{'end': 18, 'start': 13, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 88, 'start': 69, 'tag': 'DiseaseOrSyndrome'}, {'end': 92, 'start': 90, 'tag': 'DiseaseOrSyndrome'}, {'end': 64, 'start': 54, 'tag': 'ClinicalAttribute'}, {'end': 27, 'start': 19, 'tag': 'AminoAcidPeptideOrProtein'}]"
202,"We systematically profiled the plasma proteome to identify novel AD blood biomarkers and develop a high-performance, blood-based test for AD.","[{'end': 46, 'start': 38, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 46, 'start': 38, 'tag': 'BiologicallyActiveSubstance'}, {'end': 67, 'start': 65, 'tag': 'DiseaseOrSyndrome'}, {'end': 140, 'start': 138, 'tag': 'DiseaseOrSyndrome'}, {'end': 84, 'start': 74, 'tag': 'ClinicalAttribute'}, {'end': 37, 'start': 31, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 73, 'start': 68, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 122, 'start': 117, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 115, 'start': 104, 'tag': 'Finding'}, {'end': 133, 'start': 129, 'tag': 'ResearchActivity'}, {'end': 133, 'start': 129, 'tag': 'HealthCareActivity'}, {'end': 103, 'start': 99, 'tag': 'Finding'}]"
203,Methods We quantified 1160 plasma proteins in a Hong Kong Chinese cohort by high-throughput proximity extension assay and validated the results in an independent cohort.,"[{'end': 161, 'start': 150, 'tag': 'Finding'}, {'end': 65, 'start': 48, 'tag': 'PopulationGroup'}, {'end': 33, 'start': 27, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 42, 'start': 34, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 72, 'start': 66, 'tag': 'PopulationGroup'}, {'end': 168, 'start': 162, 'tag': 'PopulationGroup'}, {'end': 117, 'start': 76, 'tag': 'ResearchActivity'}]"
204,"In subgroup analyses, plasma biomarkers for amyloid, tau, phosphorylated tau, and neurodegeneration were used as endophenotypes of AD.","[{'end': 72, 'start': 58, 'tag': 'CellFunction'}, {'end': 56, 'start': 53, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 76, 'start': 73, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 56, 'start': 53, 'tag': 'BiologicallyActiveSubstance'}, {'end': 76, 'start': 73, 'tag': 'BiologicallyActiveSubstance'}, {'end': 133, 'start': 131, 'tag': 'DiseaseOrSyndrome'}, {'end': 76, 'start': 58, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 76, 'start': 58, 'tag': 'BiologicallyActiveSubstance'}, {'end': 51, 'start': 44, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 51, 'start': 44, 'tag': 'BiologicallyActiveSubstance'}, {'end': 39, 'start': 29, 'tag': 'ClinicalAttribute'}, {'end': 28, 'start': 22, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 20, 'start': 12, 'tag': 'ResearchActivity'}, {'end': 99, 'start': 82, 'tag': 'CellOrMolecularDysfunction'}, {'end': 127, 'start': 113, 'tag': 'ClinicalAttribute'}]"
205,Results We identified 429 proteins that were dysregulated in AD plasma.,"[{'end': 57, 'start': 45, 'tag': 'PathologicFunction'}, {'end': 63, 'start': 61, 'tag': 'DiseaseOrSyndrome'}, {'end': 70, 'start': 64, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 34, 'start': 26, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}]"
206,"We selected 19 hub proteins representative of the AD plasma protein profile, which formed the basis of a scoring system that accurately classified clinical AD (area under the curve = 0.9690-0.9816) and associated endophenotypes.","[{'end': 27, 'start': 15, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 52, 'start': 50, 'tag': 'DiseaseOrSyndrome'}, {'end': 158, 'start': 147, 'tag': 'DiseaseOrSyndrome'}, {'end': 180, 'start': 160, 'tag': 'ResearchActivity'}, {'end': 59, 'start': 53, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 75, 'start': 60, 'tag': 'ResearchActivity'}, {'end': 227, 'start': 213, 'tag': 'ClinicalAttribute'}]"
207,"Moreover, specific hub proteins exhibit disease stage-dependent dysregulation, which can delineate AD stages.","[{'end': 31, 'start': 19, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 53, 'start': 40, 'tag': 'ClinicalAttribute'}, {'end': 53, 'start': 40, 'tag': 'TemporalConcept'}, {'end': 108, 'start': 102, 'tag': 'TemporalConcept'}, {'end': 77, 'start': 64, 'tag': 'Finding'}, {'end': 101, 'start': 99, 'tag': 'DiseaseOrSyndrome'}]"
208,"Discussion This study comprehensively profiled the AD plasma proteome and serves as a foundation for a high-performance, blood-based test for clinical AD screening and staging.","[{'end': 69, 'start': 61, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 69, 'start': 61, 'tag': 'BiologicallyActiveSubstance'}, {'end': 175, 'start': 168, 'tag': 'TemporalConcept'}, {'end': 53, 'start': 51, 'tag': 'DiseaseOrSyndrome'}, {'end': 163, 'start': 142, 'tag': 'HealthCareActivity'}, {'end': 21, 'start': 16, 'tag': 'ResearchActivity'}, {'end': 60, 'start': 54, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 126, 'start': 121, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 119, 'start': 108, 'tag': 'Finding'}, {'end': 137, 'start': 133, 'tag': 'ResearchActivity'}, {'end': 137, 'start': 133, 'tag': 'HealthCareActivity'}, {'end': 107, 'start': 103, 'tag': 'Finding'}]"
209,"Background CSF biomarkers are well-established for routine clinical use, yet a paucity of comparative assessment exists regarding CSF extraction methods during lumbar puncture.","[{'end': 58, 'start': 51, 'tag': 'TemporalConcept'}, {'end': 175, 'start': 160, 'tag': 'HealthCareActivity'}, {'end': 14, 'start': 11, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 133, 'start': 130, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 25, 'start': 15, 'tag': 'ClinicalAttribute'}, {'end': 112, 'start': 102, 'tag': 'HealthCareActivity'}, {'end': 112, 'start': 102, 'tag': 'ResearchActivity'}, {'end': 71, 'start': 59, 'tag': 'Finding'}, {'end': 152, 'start': 130, 'tag': 'ResearchActivity'}]"
210,"Here, we compare in detail biomarker profiles in CSF extracted using either gravity drip or aspiration.","[{'end': 102, 'start': 92, 'tag': 'ResearchActivity'}, {'end': 52, 'start': 49, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 36, 'start': 27, 'tag': 'ClinicalAttribute'}, {'end': 45, 'start': 37, 'tag': 'ResearchActivity'}, {'end': 88, 'start': 76, 'tag': 'ResearchActivity'}]"
211,"Methods Biomarkers for beta-amyloidopathy (A beta 1-42, A beta 1-40), tauopathy (total tau), or synapse pathology (BACE1, Neurogranin Trunc-p75, alpha-synuclein) were assessed between gravity or aspiration extraction methods in a sub-population of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study (cognitively normal, N = 36; mild cognitive impairment, N = 8; Alzheimer's disease, N = 6).","[{'end': 79, 'start': 70, 'tag': 'DiseaseOrSyndrome'}, {'end': 143, 'start': 122, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 143, 'start': 122, 'tag': 'BiologicallyActiveSubstance'}, {'end': 191, 'start': 184, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 224, 'start': 195, 'tag': 'ResearchActivity'}, {'end': 120, 'start': 115, 'tag': 'GeneOrGenome'}, {'end': 120, 'start': 115, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 120, 'start': 115, 'tag': 'BiologicallyActiveSubstance'}, {'end': 103, 'start': 96, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 41, 'start': 23, 'tag': 'PathologicFunction'}, {'end': 160, 'start': 145, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 160, 'start': 145, 'tag': 'BiologicallyActiveSubstance'}, {'end': 160, 'start': 151, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 160, 'start': 151, 'tag': 'BiologicallyActiveSubstance'}, {'end': 244, 'start': 234, 'tag': 'PopulationGroup'}, {'end': 18, 'start': 8, 'tag': 'ClinicalAttribute'}, {'end': 54, 'start': 43, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 67, 'start': 56, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 54, 'start': 43, 'tag': 'BiologicallyActiveSubstance'}, {'end': 67, 'start': 56, 'tag': 'BiologicallyActiveSubstance'}, {'end': 90, 'start': 87, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 392, 'start': 373, 'tag': 'DiseaseOrSyndrome'}, {'end': 90, 'start': 87, 'tag': 'BiologicallyActiveSubstance'}, {'end': 90, 'start': 81, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 90, 'start': 81, 'tag': 'BiologicallyActiveSubstance'}, {'end': 309, 'start': 304, 'tag': 'ResearchActivity'}, {'end': 113, 'start': 104, 'tag': 'PathologicFunction'}, {'end': 113, 'start': 104, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 329, 'start': 311, 'tag': 'Finding'}, {'end': 364, 'start': 339, 'tag': 'DiseaseOrSyndrome'}, {'end': 49, 'start': 43, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 62, 'start': 56, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 296, 'start': 252, 'tag': 'ResearchActivity'}, {'end': 302, 'start': 298, 'tag': 'ResearchActivity'}]"
212,Results High biomarker concordance between extraction methods was seen (concordance correlation > 0.85).,"[{'end': 22, 'start': 13, 'tag': 'ClinicalAttribute'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 61, 'start': 43, 'tag': 'ResearchActivity'}, {'end': 95, 'start': 72, 'tag': 'ResearchActivity'}]"
213,Passing Bablock regression defined low beta coefficients indicating high scalability.,"[{'end': 38, 'start': 35, 'tag': 'Finding'}, {'end': 72, 'start': 68, 'tag': 'Finding'}, {'end': 56, 'start': 39, 'tag': 'ResearchActivity'}, {'end': 26, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 84, 'start': 73, 'tag': 'ResearchActivity'}]"
214,Conclusions Levels of these commonly assessed CSF biomarkers are not influenced by extraction method.,"[{'end': 49, 'start': 46, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 100, 'start': 83, 'tag': 'ResearchActivity'}, {'end': 60, 'start': 50, 'tag': 'ClinicalAttribute'}]"
215,"Results of this study should be incorporated into new consensus guidelines for CSF collection, storage, and analysis of biomarkers.","[{'end': 93, 'start': 83, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 102, 'start': 95, 'tag': 'CellComponent'}, {'end': 102, 'start': 95, 'tag': 'BiologicFunction'}, {'end': 82, 'start': 79, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 130, 'start': 120, 'tag': 'ClinicalAttribute'}, {'end': 21, 'start': 16, 'tag': 'ResearchActivity'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 116, 'start': 108, 'tag': 'ResearchActivity'}]"
216,"Alzheimer's disease (AD) is the most frequent neurodegenerative disease with an increasing prevalence in industrialized, aging populations.","[{'end': 101, 'start': 80, 'tag': 'Finding'}, {'end': 133, 'start': 132, 'tag': 'PopulationGroup'}, {'end': 119, 'start': 105, 'tag': 'PopulationGroup'}, {'end': 126, 'start': 121, 'tag': 'BiologicFunction'}, {'end': 126, 'start': 121, 'tag': 'CellFunction'}, {'end': 71, 'start': 46, 'tag': 'DiseaseOrSyndrome'}, {'end': 19, 'start': 0, 'tag': 'DiseaseOrSyndrome'}, {'end': 23, 'start': 21, 'tag': 'DiseaseOrSyndrome'}, {'end': 45, 'start': 37, 'tag': 'TemporalConcept'}, {'end': 138, 'start': 121, 'tag': 'PopulationGroup'}]"
217,AD susceptibility has an established genetic basis which has been the focus of a large number of genome-wide association studies (GWAS) published over the last decade.,"[{'end': 17, 'start': 3, 'tag': 'Finding'}, {'end': 44, 'start': 37, 'tag': 'HealthCareActivity'}, {'end': 166, 'start': 155, 'tag': 'TemporalConcept'}, {'end': 50, 'start': 37, 'tag': 'CellFunction'}, {'end': 128, 'start': 97, 'tag': 'ResearchActivity'}, {'end': 134, 'start': 130, 'tag': 'ResearchActivity'}, {'end': 2, 'start': 0, 'tag': 'DiseaseOrSyndrome'}]"
218,"Most of these GWAS used dichotomized clinical diagnostic status, i.e., case vs.","[{'end': 18, 'start': 14, 'tag': 'ResearchActivity'}, {'end': 63, 'start': 24, 'tag': 'ResearchActivity'}]"
219,"control classification, as outcome phenotypes, without the use of biomarkers.","[{'end': 34, 'start': 27, 'tag': 'Finding'}, {'end': 45, 'start': 35, 'tag': 'OrganismAttribute'}, {'end': 76, 'start': 66, 'tag': 'ClinicalAttribute'}]"
220,"An alternative and potentially more powerful study design is afforded by using quantitative AD-related phenotypes as GWAS outcome traits, an analysis paradigm that we followed in this work.","[{'end': 129, 'start': 122, 'tag': 'Finding'}, {'end': 158, 'start': 150, 'tag': 'ResearchActivity'}, {'end': 121, 'start': 117, 'tag': 'ResearchActivity'}, {'end': 94, 'start': 92, 'tag': 'DiseaseOrSyndrome'}, {'end': 113, 'start': 103, 'tag': 'OrganismAttribute'}, {'end': 50, 'start': 45, 'tag': 'ResearchActivity'}, {'end': 149, 'start': 141, 'tag': 'ResearchActivity'}, {'end': 57, 'start': 51, 'tag': 'ResearchActivity'}, {'end': 57, 'start': 51, 'tag': 'HealthCareActivity'}]"
221,"Specifically, we utilized genotype and phenotype data from n = 931 individuals collected under the auspices of the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery (EMIF-AD MBD) study to perform a total of 19 separate GWAS analyses.","[{'end': 267, 'start': 263, 'tag': 'ResearchActivity'}, {'end': 48, 'start': 39, 'tag': 'OrganismAttribute'}, {'end': 217, 'start': 215, 'tag': 'DiseaseOrSyndrome'}, {'end': 53, 'start': 49, 'tag': 'ResearchActivity'}, {'end': 78, 'start': 67, 'tag': 'PopulationGroup'}, {'end': 177, 'start': 158, 'tag': 'DiseaseOrSyndrome'}, {'end': 228, 'start': 223, 'tag': 'ResearchActivity'}, {'end': 208, 'start': 115, 'tag': 'ResearchActivity'}, {'end': 276, 'start': 268, 'tag': 'ResearchActivity'}, {'end': 34, 'start': 26, 'tag': 'OrganismAttribute'}, {'end': 198, 'start': 189, 'tag': 'ClinicalAttribute'}, {'end': 123, 'start': 115, 'tag': 'PopulationGroup'}, {'end': 153, 'start': 115, 'tag': 'HealthCareRelatedOrganization'}, {'end': 221, 'start': 210, 'tag': 'ResearchActivity'}]"
222,As outcomes we used five magnetic resonance imaging (MRI) traits and seven cognitive performance traits.,"[{'end': 64, 'start': 58, 'tag': 'OrganismAttribute'}, {'end': 103, 'start': 97, 'tag': 'OrganismAttribute'}, {'end': 11, 'start': 3, 'tag': 'Finding'}, {'end': 56, 'start': 53, 'tag': 'HealthCareActivity'}, {'end': 96, 'start': 75, 'tag': 'Finding'}, {'end': 51, 'start': 25, 'tag': 'HealthCareActivity'}]"
223,"For the latter, longitudinal data from at least two timepoints were available in addition to cross-sectional assessments at baseline.","[{'end': 62, 'start': 52, 'tag': 'TemporalConcept'}, {'end': 33, 'start': 16, 'tag': 'ResearchActivity'}, {'end': 120, 'start': 93, 'tag': 'ResearchActivity'}]"
224,"Our GWAS analyses revealed several genome-wide significant associations for the neuropsychological performance measures, in particular those assayed longitudinally.","[{'end': 8, 'start': 4, 'tag': 'ResearchActivity'}, {'end': 110, 'start': 99, 'tag': 'Finding'}, {'end': 17, 'start': 9, 'tag': 'ResearchActivity'}, {'end': 98, 'start': 80, 'tag': 'HealthCareActivity'}, {'end': 71, 'start': 35, 'tag': 'Finding'}]"
225,Among the most noteworthy signals were associations in or near EHBP1 (EH domain binding protein 1; on chromosome 2p15) and CEP112 (centrosomal protein 112; 17q24.1) with delayed recall as well as SMOC2 (SPARC related modular calcium binding 2; 6p27) with immediate recall in a memory performance test.,"[{'end': 68, 'start': 63, 'tag': 'GeneOrGenome'}, {'end': 97, 'start': 70, 'tag': 'BiologicallyActiveSubstance'}, {'end': 97, 'start': 70, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 154, 'start': 131, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 242, 'start': 203, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 184, 'start': 178, 'tag': 'BiologicFunction'}, {'end': 271, 'start': 265, 'tag': 'BiologicFunction'}, {'end': 264, 'start': 255, 'tag': 'TemporalConcept'}, {'end': 177, 'start': 170, 'tag': 'TemporalConcept'}, {'end': 295, 'start': 284, 'tag': 'Finding'}, {'end': 283, 'start': 277, 'tag': 'BiologicFunction'}, {'end': 300, 'start': 296, 'tag': 'ResearchActivity'}, {'end': 300, 'start': 296, 'tag': 'HealthCareActivity'}, {'end': 33, 'start': 26, 'tag': 'CellFunction'}, {'end': 68, 'start': 63, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 68, 'start': 63, 'tag': 'BiologicallyActiveSubstance'}, {'end': 117, 'start': 102, 'tag': 'CellComponent'}, {'end': 129, 'start': 123, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 129, 'start': 123, 'tag': 'BiologicallyActiveSubstance'}, {'end': 154, 'start': 131, 'tag': 'BiologicallyActiveSubstance'}, {'end': 242, 'start': 203, 'tag': 'BiologicallyActiveSubstance'}, {'end': 201, 'start': 196, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 201, 'start': 196, 'tag': 'GeneOrGenome'}]"
226,"On the X chromosome, which is often excluded in other GWAS, we identified a genome-wide significant signal near IL1RAPL1 (interleukin 1 receptor accessory protein like 1; Xp21.3).","[{'end': 19, 'start': 7, 'tag': 'CellComponent'}, {'end': 19, 'start': 7, 'tag': 'GeneOrGenome'}, {'end': 58, 'start': 54, 'tag': 'ResearchActivity'}, {'end': 82, 'start': 76, 'tag': 'GeneOrGenome'}, {'end': 120, 'start': 112, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 169, 'start': 122, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 120, 'start': 112, 'tag': 'BiologicallyActiveSubstance'}, {'end': 120, 'start': 112, 'tag': 'GeneOrGenome'}]"
227,"While polygenic score (PGS) analyses showed the expected strong associations with SNPs highlighted in relevant previous GWAS on hippocampal volume and cognitive function, they did not show noteworthy associations with recent AD risk GWAS findings.","[{'end': 86, 'start': 82, 'tag': 'MolecularSequence'}, {'end': 124, 'start': 120, 'tag': 'ResearchActivity'}, {'end': 237, 'start': 233, 'tag': 'ResearchActivity'}, {'end': 224, 'start': 218, 'tag': 'TemporalConcept'}, {'end': 227, 'start': 225, 'tag': 'DiseaseOrSyndrome'}, {'end': 36, 'start': 6, 'tag': 'ResearchActivity'}, {'end': 169, 'start': 151, 'tag': 'BiologicFunction'}, {'end': 146, 'start': 128, 'tag': 'ClinicalAttribute'}, {'end': 232, 'start': 228, 'tag': 'Finding'}]"
228,"In summary, our study highlights the power of using quantitative endophenotypes as outcome traits in AD-related GWAS analyses and nominates several new loci not previously implicated in cognitive decline.","[{'end': 90, 'start': 83, 'tag': 'PathologicFunction'}, {'end': 97, 'start': 91, 'tag': 'OrganismAttribute'}, {'end': 116, 'start': 112, 'tag': 'ResearchActivity'}, {'end': 103, 'start': 101, 'tag': 'DiseaseOrSyndrome'}, {'end': 21, 'start': 16, 'tag': 'ResearchActivity'}, {'end': 203, 'start': 186, 'tag': 'DiseaseOrSyndrome'}, {'end': 125, 'start': 117, 'tag': 'ResearchActivity'}, {'end': 79, 'start': 52, 'tag': 'ClinicalAttribute'}, {'end': 156, 'start': 152, 'tag': 'GeneOrGenome'}]"
229,BACKGROUND: Preclinical Alzheimer's disease clinical trials test candidate treatments in individuals with biomarker evidence but no cognitive impairment.,"[{'end': 85, 'start': 75, 'tag': 'HealthCareActivity'}, {'end': 85, 'start': 75, 'tag': 'ResearchActivity'}, {'end': 59, 'start': 44, 'tag': 'ResearchActivity'}, {'end': 43, 'start': 24, 'tag': 'DiseaseOrSyndrome'}, {'end': 115, 'start': 106, 'tag': 'ClinicalAttribute'}, {'end': 100, 'start': 89, 'tag': 'PopulationGroup'}, {'end': 152, 'start': 132, 'tag': 'DiseaseOrSyndrome'}, {'end': 124, 'start': 116, 'tag': 'Finding'}, {'end': 64, 'start': 60, 'tag': 'ResearchActivity'}, {'end': 64, 'start': 60, 'tag': 'HealthCareActivity'}, {'end': 23, 'start': 12, 'tag': 'TemporalConcept'}]"
230,"Participants are required to co-enroll with a knowledgeable study partner, to whom biomarker information is disclosed.","[{'end': 92, 'start': 83, 'tag': 'ClinicalAttribute'}, {'end': 65, 'start': 60, 'tag': 'ResearchActivity'}, {'end': 12, 'start': 0, 'tag': 'PopulationGroup'}, {'end': 73, 'start': 66, 'tag': 'PopulationGroup'}]"
231,OBJECTIVE: We investigated whether reluctance to share biomarker results is associated with viewing the study partner requirement as a barrier to preclinical trial enrollment.,"[{'end': 45, 'start': 35, 'tag': 'BiologicFunction'}, {'end': 142, 'start': 135, 'tag': 'ManufacturedObject'}, {'end': 163, 'start': 146, 'tag': 'ResearchActivity'}, {'end': 64, 'start': 55, 'tag': 'ClinicalAttribute'}, {'end': 109, 'start': 104, 'tag': 'ResearchActivity'}, {'end': 174, 'start': 164, 'tag': 'HealthCareActivity'}, {'end': 117, 'start': 110, 'tag': 'PopulationGroup'}]"
232,DESIGN: We developed a nine-item assessment on views toward the study partner requirement and performed in-person interviews based on a hypothetical clinical trial requiring biomarker testing and disclosure.,"[{'end': 206, 'start': 196, 'tag': 'IndividualBehavior'}, {'end': 163, 'start': 149, 'tag': 'ResearchActivity'}, {'end': 183, 'start': 174, 'tag': 'ClinicalAttribute'}, {'end': 191, 'start': 184, 'tag': 'HealthCareActivity'}, {'end': 69, 'start': 64, 'tag': 'ResearchActivity'}, {'end': 43, 'start': 33, 'tag': 'HealthCareActivity'}, {'end': 43, 'start': 33, 'tag': 'ResearchActivity'}, {'end': 77, 'start': 70, 'tag': 'PopulationGroup'}, {'end': 89, 'start': 78, 'tag': 'Finding'}, {'end': 124, 'start': 104, 'tag': 'HealthCareActivity'}]"
233,"SETTING: We conducted interviews on campus at the University of California, Irvine.","[{'end': 7, 'start': 0, 'tag': 'BiologicFunction'}, {'end': 82, 'start': 50, 'tag': 'HealthCareRelatedOrganization'}, {'end': 32, 'start': 22, 'tag': 'HealthCareActivity'}]"
234,"PARTICIPANTS: Two hundred cognitively unimpaired older adults recruited from the University of California, Irvine Consent-to-Contact Registry participated in the study.","[{'end': 48, 'start': 26, 'tag': 'Finding'}, {'end': 54, 'start': 49, 'tag': 'TemporalConcept'}, {'end': 61, 'start': 49, 'tag': 'PopulationGroup'}, {'end': 167, 'start': 162, 'tag': 'ResearchActivity'}, {'end': 113, 'start': 81, 'tag': 'HealthCareRelatedOrganization'}, {'end': 61, 'start': 55, 'tag': 'PopulationGroup'}]"
235,"MEASUREMENTS: We used logistic regression models, adjusting for potential confounders, to examine potential associations with viewing the study partner requirement as a barrier to preclinical trial enrollment.","[{'end': 176, 'start': 169, 'tag': 'ManufacturedObject'}, {'end': 197, 'start': 180, 'tag': 'ResearchActivity'}, {'end': 85, 'start': 74, 'tag': 'Finding'}, {'end': 48, 'start': 22, 'tag': 'ResearchActivity'}, {'end': 143, 'start': 138, 'tag': 'ResearchActivity'}, {'end': 208, 'start': 198, 'tag': 'HealthCareActivity'}, {'end': 151, 'start': 144, 'tag': 'PopulationGroup'}, {'end': 163, 'start': 152, 'tag': 'Finding'}]"
236,RESULTS: Eighteen percent of participants reported strong agreement that the study partner requirement was a barrier to enrollment.,"[{'end': 116, 'start': 109, 'tag': 'ManufacturedObject'}, {'end': 41, 'start': 29, 'tag': 'PopulationGroup'}, {'end': 82, 'start': 77, 'tag': 'ResearchActivity'}, {'end': 130, 'start': 120, 'tag': 'HealthCareActivity'}, {'end': 90, 'start': 83, 'tag': 'PopulationGroup'}, {'end': 102, 'start': 91, 'tag': 'Finding'}]"
237,Ten participants (5%) agreed at any level that they would be reluctant to share their biomarker result with a study partner.,"[{'end': 95, 'start': 86, 'tag': 'ClinicalAttribute'}, {'end': 16, 'start': 4, 'tag': 'PopulationGroup'}, {'end': 115, 'start': 110, 'tag': 'ResearchActivity'}, {'end': 102, 'start': 96, 'tag': 'Finding'}, {'end': 123, 'start': 116, 'tag': 'PopulationGroup'}]"
238,"The estimated odds of viewing the study partner requirement as a barrier to enrollment were 26 times higher for these participants (OR=26.3, 95% CI 4.0, 172.3), compared to those who strongly disagreed that they would be reluctant to share their biomarker result.","[{'end': 72, 'start': 65, 'tag': 'ManufacturedObject'}, {'end': 255, 'start': 246, 'tag': 'ClinicalAttribute'}, {'end': 130, 'start': 118, 'tag': 'PopulationGroup'}, {'end': 39, 'start': 34, 'tag': 'ResearchActivity'}, {'end': 262, 'start': 256, 'tag': 'Finding'}, {'end': 147, 'start': 145, 'tag': 'ResearchActivity'}, {'end': 86, 'start': 76, 'tag': 'HealthCareActivity'}, {'end': 47, 'start': 40, 'tag': 'PopulationGroup'}, {'end': 59, 'start': 48, 'tag': 'Finding'}]"
239,"Overall, participants more frequently agreed with positive statements than negative statements about the study partner requirement, including 76% indicating they would want their study partner with them when they learned biomarker results.","[{'end': 37, 'start': 27, 'tag': 'TemporalConcept'}, {'end': 230, 'start': 221, 'tag': 'ClinicalAttribute'}, {'end': 21, 'start': 9, 'tag': 'PopulationGroup'}, {'end': 110, 'start': 105, 'tag': 'ResearchActivity'}, {'end': 184, 'start': 179, 'tag': 'ResearchActivity'}, {'end': 192, 'start': 185, 'tag': 'PopulationGroup'}, {'end': 118, 'start': 111, 'tag': 'PopulationGroup'}]"
240,CONCLUSIONS: This is one of the first studies to explore how potential preclinical Alzheimer's disease trial participants feel about sharing their personal biomarker information with a study partner.,"[{'end': 37, 'start': 32, 'tag': 'TemporalConcept'}, {'end': 155, 'start': 147, 'tag': 'OrganismAttribute'}, {'end': 102, 'start': 83, 'tag': 'DiseaseOrSyndrome'}, {'end': 165, 'start': 156, 'tag': 'ClinicalAttribute'}, {'end': 121, 'start': 109, 'tag': 'PopulationGroup'}, {'end': 45, 'start': 38, 'tag': 'ResearchActivity'}, {'end': 190, 'start': 185, 'tag': 'ResearchActivity'}, {'end': 108, 'start': 103, 'tag': 'ResearchActivity'}, {'end': 82, 'start': 71, 'tag': 'TemporalConcept'}, {'end': 198, 'start': 191, 'tag': 'PopulationGroup'}]"
241,"Most participants viewed the study partner as an asset to trial enrollment, including having a partner present during biomarker disclosure.","[{'end': 138, 'start': 128, 'tag': 'IndividualBehavior'}, {'end': 127, 'start': 118, 'tag': 'ClinicalAttribute'}, {'end': 17, 'start': 5, 'tag': 'PopulationGroup'}, {'end': 34, 'start': 29, 'tag': 'ResearchActivity'}, {'end': 63, 'start': 58, 'tag': 'ResearchActivity'}, {'end': 74, 'start': 64, 'tag': 'HealthCareActivity'}, {'end': 42, 'start': 35, 'tag': 'PopulationGroup'}, {'end': 102, 'start': 95, 'tag': 'PopulationGroup'}]"
242,Background: Neuroimaging studies of autosomal dominant Alzheimer's disease (ADAD) enable characterization of the trajectories of cerebral amyloid-beta (A beta) and tau accumulation in the decades prior to clinical symptom onset.,"[{'end': 105, 'start': 89, 'tag': 'ResearchActivity'}, {'end': 195, 'start': 188, 'tag': 'TemporalConcept'}, {'end': 74, 'start': 36, 'tag': 'DiseaseOrSyndrome'}, {'end': 167, 'start': 164, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 167, 'start': 164, 'tag': 'BiologicallyActiveSubstance'}, {'end': 32, 'start': 25, 'tag': 'ResearchActivity'}, {'end': 145, 'start': 138, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 145, 'start': 138, 'tag': 'BiologicallyActiveSubstance'}, {'end': 150, 'start': 138, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 158, 'start': 152, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 180, 'start': 168, 'tag': 'Finding'}, {'end': 227, 'start': 214, 'tag': 'TemporalConcept'}, {'end': 221, 'start': 214, 'tag': 'SignOrSymptom'}, {'end': 80, 'start': 76, 'tag': 'DiseaseOrSyndrome'}, {'end': 24, 'start': 12, 'tag': 'HealthCareActivity'}]"
243,Longitudinal rates of regional tau accumulation measured with positron emission tomography (PET) and their relationship with other biomarker and cognitive changes remain to be fully characterized in ADAD.,"[{'end': 162, 'start': 145, 'tag': 'Finding'}, {'end': 34, 'start': 31, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 34, 'start': 31, 'tag': 'BiologicallyActiveSubstance'}, {'end': 140, 'start': 131, 'tag': 'ClinicalAttribute'}, {'end': 119, 'start': 107, 'tag': 'Finding'}, {'end': 95, 'start': 92, 'tag': 'HealthCareActivity'}, {'end': 47, 'start': 35, 'tag': 'Finding'}, {'end': 90, 'start': 62, 'tag': 'HealthCareActivity'}, {'end': 203, 'start': 199, 'tag': 'DiseaseOrSyndrome'}]"
244,"Methods: Fourteen ADAD mutation carriers (Presenilin-1 E280A) and 15 age-matched non-carriers from the Colombian kindred underwent 2-3 sessions of A beta (11C-Pittsburgh compound B) and tau (18F-flortaucipir) PET, structural magnetic resonance imaging, and neuropsychological evaluation over a 2-4-year follow-up period.","[{'end': 112, 'start': 103, 'tag': 'PopulationGroup'}, {'end': 180, 'start': 155, 'tag': 'Chemical'}, {'end': 251, 'start': 214, 'tag': 'HealthCareActivity'}, {'end': 207, 'start': 191, 'tag': 'Chemical'}, {'end': 302, 'start': 298, 'tag': 'TemporalConcept'}, {'end': 54, 'start': 42, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 54, 'start': 42, 'tag': 'GeneOrGenome'}, {'end': 54, 'start': 42, 'tag': 'BiologicallyActiveSubstance'}, {'end': 31, 'start': 23, 'tag': 'CellOrMolecularDysfunction'}, {'end': 93, 'start': 81, 'tag': 'PopulationGroup'}, {'end': 60, 'start': 55, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 189, 'start': 186, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 189, 'start': 186, 'tag': 'BiologicallyActiveSubstance'}, {'end': 319, 'start': 313, 'tag': 'TemporalConcept'}, {'end': 72, 'start': 69, 'tag': 'OrganismAttribute'}, {'end': 312, 'start': 303, 'tag': 'HealthCareActivity'}, {'end': 312, 'start': 303, 'tag': 'TemporalConcept'}, {'end': 212, 'start': 209, 'tag': 'HealthCareActivity'}, {'end': 40, 'start': 32, 'tag': 'PopulationGroup'}, {'end': 153, 'start': 147, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 286, 'start': 257, 'tag': 'HealthCareActivity'}, {'end': 22, 'start': 18, 'tag': 'DiseaseOrSyndrome'}]"
245,"Annualized rates of change for imaging and cognitive variables were compared between carriers and non-carriers, and relationships among baseline measurements and rates of change were assessed within carriers.","[{'end': 38, 'start': 31, 'tag': 'HealthCareActivity'}, {'end': 110, 'start': 98, 'tag': 'PopulationGroup'}, {'end': 129, 'start': 116, 'tag': 'Finding'}, {'end': 157, 'start': 145, 'tag': 'HealthCareActivity'}, {'end': 93, 'start': 85, 'tag': 'PopulationGroup'}, {'end': 207, 'start': 199, 'tag': 'PopulationGroup'}, {'end': 16, 'start': 11, 'tag': 'TemporalConcept'}, {'end': 167, 'start': 162, 'tag': 'TemporalConcept'}]"
246,"Results: Longitudinal measurements were consistent with a sequence of ADAD-related changes beginning with A beta accumulation (16 years prior to expected symptom onset, EYO), followed by entorhinal cortex (EC) tau (9 EYO), neocortical tau (6 EYO), hippocampal atrophy (6 EYO), and cognitive decline (4 EYO).","[{'end': 267, 'start': 248, 'tag': 'DiseaseOrSyndrome'}, {'end': 204, 'start': 187, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 172, 'start': 169, 'tag': 'TemporalConcept'}, {'end': 220, 'start': 217, 'tag': 'TemporalConcept'}, {'end': 245, 'start': 242, 'tag': 'TemporalConcept'}, {'end': 274, 'start': 271, 'tag': 'TemporalConcept'}, {'end': 305, 'start': 302, 'tag': 'TemporalConcept'}, {'end': 208, 'start': 206, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 213, 'start': 210, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 238, 'start': 235, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 213, 'start': 210, 'tag': 'BiologicallyActiveSubstance'}, {'end': 238, 'start': 235, 'tag': 'BiologicallyActiveSubstance'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 298, 'start': 281, 'tag': 'DiseaseOrSyndrome'}, {'end': 135, 'start': 130, 'tag': 'TemporalConcept'}, {'end': 34, 'start': 9, 'tag': 'HealthCareActivity'}, {'end': 112, 'start': 106, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 125, 'start': 113, 'tag': 'Finding'}, {'end': 167, 'start': 145, 'tag': 'TemporalConcept'}, {'end': 74, 'start': 70, 'tag': 'DiseaseOrSyndrome'}, {'end': 90, 'start': 83, 'tag': 'Finding'}, {'end': 234, 'start': 223, 'tag': 'BodyPartOrganOrOrganComponent'}]"
247,Rates of tau accumulation among carriers were most rapid in parietal neocortex (similar to 9%/year).,"[{'end': 98, 'start': 94, 'tag': 'TemporalConcept'}, {'end': 12, 'start': 9, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 12, 'start': 9, 'tag': 'BiologicallyActiveSubstance'}, {'end': 40, 'start': 32, 'tag': 'PopulationGroup'}, {'end': 25, 'start': 13, 'tag': 'Finding'}, {'end': 78, 'start': 60, 'tag': 'BodyPartOrganOrOrganComponent'}]"
248,EC tau PET signal at baseline was a significant predictor of subsequent neocortical tau accumulation and cognitive decline within carriers.,"[{'end': 2, 'start': 0, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 6, 'start': 3, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 87, 'start': 84, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 6, 'start': 3, 'tag': 'BiologicallyActiveSubstance'}, {'end': 87, 'start': 84, 'tag': 'BiologicallyActiveSubstance'}, {'end': 122, 'start': 105, 'tag': 'DiseaseOrSyndrome'}, {'end': 10, 'start': 7, 'tag': 'HealthCareActivity'}, {'end': 138, 'start': 130, 'tag': 'PopulationGroup'}, {'end': 100, 'start': 88, 'tag': 'Finding'}, {'end': 83, 'start': 72, 'tag': 'BodyPartOrganOrOrganComponent'}]"
249,Conclusions: Our results are consistent with the sequence of biological changes in ADAD implied by cross-sectional studies and highlight the importance of EC tau as an early biomarker and a potential link between A beta burden and neocortical tau accumulation in ADAD.,"[{'end': 122, 'start': 99, 'tag': 'ResearchActivity'}, {'end': 157, 'start': 155, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 161, 'start': 158, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 246, 'start': 243, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 161, 'start': 158, 'tag': 'BiologicallyActiveSubstance'}, {'end': 246, 'start': 243, 'tag': 'BiologicallyActiveSubstance'}, {'end': 183, 'start': 174, 'tag': 'ClinicalAttribute'}, {'end': 173, 'start': 168, 'tag': 'TemporalConcept'}, {'end': 219, 'start': 213, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 259, 'start': 247, 'tag': 'Finding'}, {'end': 226, 'start': 220, 'tag': 'ResearchActivity'}, {'end': 87, 'start': 83, 'tag': 'DiseaseOrSyndrome'}, {'end': 267, 'start': 263, 'tag': 'DiseaseOrSyndrome'}, {'end': 242, 'start': 231, 'tag': 'BodyPartOrganOrOrganComponent'}]"
250,"Background: Assessment of human brain atrophy in temporal regions using magnetic resonance imaging (MRI), resting state functional MRI connectivity in the left parietal cortex, and limbic electroencephalographic (rsEEG) rhythms as well as plasma amyloid peptide 42 (A beta(42)) has shown that each is a promising biomarker of disease progression in amnestic mild cognitive impairment (aMCI) patients with prodromal Alzheimer's disease (AD).","[{'end': 22, 'start': 12, 'tag': 'HealthCareActivity'}, {'end': 22, 'start': 12, 'tag': 'ResearchActivity'}, {'end': 175, 'start': 155, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 211, 'start': 188, 'tag': 'HealthCareActivity'}, {'end': 227, 'start': 220, 'tag': 'Finding'}, {'end': 227, 'start': 220, 'tag': 'BiologicFunction'}, {'end': 434, 'start': 405, 'tag': 'DiseaseOrSyndrome'}, {'end': 45, 'start': 32, 'tag': 'DiseaseOrSyndrome'}, {'end': 389, 'start': 385, 'tag': 'DiseaseOrSyndrome'}, {'end': 438, 'start': 436, 'tag': 'DiseaseOrSyndrome'}, {'end': 322, 'start': 313, 'tag': 'ClinicalAttribute'}, {'end': 399, 'start': 391, 'tag': 'PatientOrDisabledGroup'}, {'end': 345, 'start': 326, 'tag': 'PathologicFunction'}, {'end': 103, 'start': 100, 'tag': 'HealthCareActivity'}, {'end': 134, 'start': 106, 'tag': 'HealthCareActivity'}, {'end': 383, 'start': 349, 'tag': 'DiseaseOrSyndrome'}, {'end': 65, 'start': 49, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 31, 'start': 26, 'tag': 'Eukaryote'}, {'end': 147, 'start': 135, 'tag': 'BiologicFunction'}, {'end': 98, 'start': 72, 'tag': 'HealthCareActivity'}, {'end': 187, 'start': 181, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 264, 'start': 239, 'tag': 'ClinicalAttribute'}]"
251,"However, the value of their combined use is unknown.",[]
252,Objective: To evaluate the association with cognitive decline and the effect on sample size calculation when using a biomarker composite matrix in prodromal AD clinical trials.,"[{'end': 175, 'start': 160, 'tag': 'ResearchActivity'}, {'end': 159, 'start': 147, 'tag': 'DiseaseOrSyndrome'}, {'end': 126, 'start': 117, 'tag': 'ClinicalAttribute'}, {'end': 91, 'start': 87, 'tag': 'OrganismAttribute'}, {'end': 61, 'start': 44, 'tag': 'DiseaseOrSyndrome'}, {'end': 86, 'start': 80, 'tag': 'Substance'}, {'end': 86, 'start': 80, 'tag': 'BodyPartOrganOrOrganComponent'}]"
253,Methods: Multicenter longitudinal study with follow-up of 2 years or until development of incident dementia.,"[{'end': 39, 'start': 9, 'tag': 'ResearchActivity'}, {'end': 86, 'start': 75, 'tag': 'BiologicFunction'}, {'end': 86, 'start': 75, 'tag': 'CellFunction'}, {'end': 107, 'start': 99, 'tag': 'DiseaseOrSyndrome'}, {'end': 54, 'start': 45, 'tag': 'HealthCareActivity'}, {'end': 54, 'start': 45, 'tag': 'TemporalConcept'}, {'end': 65, 'start': 60, 'tag': 'TemporalConcept'}]"
254,APOE epsilon 4-specific cerebrospinal fluid (CSF) A beta(42)/P-tau cut-offs were used to identify aMCI with prodromal AD.,"[{'end': 120, 'start': 108, 'tag': 'DiseaseOrSyndrome'}, {'end': 102, 'start': 98, 'tag': 'DiseaseOrSyndrome'}, {'end': 14, 'start': 0, 'tag': 'GeneOrGenome'}, {'end': 75, 'start': 67, 'tag': 'ResearchActivity'}, {'end': 66, 'start': 24, 'tag': 'ClinicalAttribute'}]"
255,"Linear mixed models were performed 1) with repeated matrix values and time as factors to explain the longitudinal changes in ADAS-cog13, 2) with CSF A beta(42)/P-tau status, time, and CSF A beta(42)/P-tau status x time interaction as factors to explain the longitudinal changes in matrix measures, and 3) to compute sample size estimation for a trial implemented with the selected matrices.","[{'end': 338, 'start': 328, 'tag': 'BiologicFunction'}, {'end': 121, 'start': 101, 'tag': 'ResearchActivity'}, {'end': 277, 'start': 257, 'tag': 'ResearchActivity'}, {'end': 74, 'start': 70, 'tag': 'TemporalConcept'}, {'end': 178, 'start': 174, 'tag': 'TemporalConcept'}, {'end': 218, 'start': 214, 'tag': 'TemporalConcept'}, {'end': 327, 'start': 323, 'tag': 'OrganismAttribute'}, {'end': 350, 'start': 345, 'tag': 'ResearchActivity'}, {'end': 19, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 172, 'start': 166, 'tag': 'Finding'}, {'end': 211, 'start': 205, 'tag': 'Finding'}, {'end': 322, 'start': 316, 'tag': 'Substance'}, {'end': 322, 'start': 316, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 138, 'start': 125, 'tag': 'HealthCareActivity'}, {'end': 165, 'start': 145, 'tag': 'ClinicalAttribute'}, {'end': 204, 'start': 184, 'tag': 'ClinicalAttribute'}, {'end': 65, 'start': 43, 'tag': 'ResearchActivity'}, {'end': 296, 'start': 281, 'tag': 'ResearchActivity'}]"
256,Results: The best composite matrix included the MRI volumes of hippocampal dentate gyrus and lateral ventricle.,"[{'end': 110, 'start': 93, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 88, 'start': 63, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 51, 'start': 48, 'tag': 'HealthCareActivity'}, {'end': 88, 'start': 52, 'tag': 'ClinicalAttribute'}, {'end': 34, 'start': 18, 'tag': 'ResearchActivity'}]"
257,"This matrix showed the best sensitivity to track disease progression and required a sample size 31% lower than that of the best individual biomarker (i.e., volume of hippocampal dentate gyrus).","[{'end': 191, 'start': 166, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 148, 'start': 139, 'tag': 'ClinicalAttribute'}, {'end': 39, 'start': 28, 'tag': 'Finding'}, {'end': 68, 'start': 49, 'tag': 'PathologicFunction'}, {'end': 138, 'start': 128, 'tag': 'PopulationGroup'}, {'end': 138, 'start': 128, 'tag': 'OrganismAttribute'}, {'end': 95, 'start': 91, 'tag': 'OrganismAttribute'}, {'end': 90, 'start': 84, 'tag': 'Substance'}, {'end': 90, 'start': 84, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 191, 'start': 156, 'tag': 'ClinicalAttribute'}]"
258,Conclusion: Optimal matrices improved the statistical power to track disease development and to measure clinical progression in the short-term period.,"[{'end': 59, 'start': 42, 'tag': 'ResearchActivity'}, {'end': 88, 'start': 69, 'tag': 'PathologicFunction'}, {'end': 37, 'start': 29, 'tag': 'Finding'}, {'end': 124, 'start': 104, 'tag': 'TemporalConcept'}, {'end': 149, 'start': 143, 'tag': 'TemporalConcept'}, {'end': 142, 'start': 132, 'tag': 'TemporalConcept'}]"
259,This might contribute to optimize the design of future clinical trials in MCI.,"[{'end': 70, 'start': 55, 'tag': 'ResearchActivity'}, {'end': 77, 'start': 74, 'tag': 'DiseaseOrSyndrome'}, {'end': 54, 'start': 48, 'tag': 'TemporalConcept'}, {'end': 44, 'start': 38, 'tag': 'ResearchActivity'}, {'end': 44, 'start': 38, 'tag': 'HealthCareActivity'}]"
260,Neuroimaging-based brain-age estimation via machine learning has emerged as an important new approach for studying brain aging.,"[{'end': 39, 'start': 29, 'tag': 'BiologicFunction'}, {'end': 126, 'start': 121, 'tag': 'BiologicFunction'}, {'end': 126, 'start': 121, 'tag': 'CellFunction'}, {'end': 60, 'start': 44, 'tag': 'MachineActivity'}, {'end': 24, 'start': 19, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 120, 'start': 115, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 28, 'start': 25, 'tag': 'OrganismAttribute'}]"
261,"The difference between one's estimated brain age and chronological age, the brain age gap (BAG), has been proposed as an Alzheimer's Disease (AD) biomarker.","[{'end': 144, 'start': 142, 'tag': 'DiseaseOrSyndrome'}, {'end': 155, 'start': 146, 'tag': 'ClinicalAttribute'}, {'end': 44, 'start': 39, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 81, 'start': 76, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 140, 'start': 121, 'tag': 'DiseaseOrSyndrome'}, {'end': 48, 'start': 45, 'tag': 'OrganismAttribute'}, {'end': 85, 'start': 82, 'tag': 'OrganismAttribute'}, {'end': 70, 'start': 53, 'tag': 'OrganismAttribute'}, {'end': 89, 'start': 76, 'tag': 'ClinicalAttribute'}, {'end': 94, 'start': 91, 'tag': 'ClinicalAttribute'}]"
262,"However, most past studies on the BAG have been cross-sectional.","[{'end': 63, 'start': 48, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 18, 'start': 14, 'tag': 'TemporalConcept'}, {'end': 26, 'start': 19, 'tag': 'ResearchActivity'}, {'end': 37, 'start': 34, 'tag': 'ClinicalAttribute'}]"
263,Quantifying longitudinal changes in an individual's BAG temporal pattern would likely improve prediction of AD progression and clinical outcome based on neurophysiological changes.,"[{'end': 32, 'start': 12, 'tag': 'ResearchActivity'}, {'end': 143, 'start': 127, 'tag': 'ClinicalAttribute'}, {'end': 110, 'start': 108, 'tag': 'DiseaseOrSyndrome'}, {'end': 122, 'start': 111, 'tag': 'PathologicFunction'}, {'end': 122, 'start': 111, 'tag': 'TemporalConcept'}, {'end': 49, 'start': 39, 'tag': 'PopulationGroup'}, {'end': 49, 'start': 39, 'tag': 'OrganismAttribute'}, {'end': 64, 'start': 56, 'tag': 'TemporalConcept'}, {'end': 104, 'start': 94, 'tag': 'Finding'}, {'end': 24, 'start': 12, 'tag': 'ResearchActivity'}, {'end': 179, 'start': 153, 'tag': 'Finding'}, {'end': 55, 'start': 52, 'tag': 'ClinicalAttribute'}]"
264,"To fill this gap, our study conducted predictive modeling using a large neuroimaging dataset with up to 8 years of follow-up to examine the temporal patterns of the BAG's trajectory and how it varies by subject-level characteristics (sex, APOE e 4 carriership) and disease status.","[{'end': 57, 'start': 49, 'tag': 'ResearchActivity'}, {'end': 279, 'start': 265, 'tag': 'ClinicalAttribute'}, {'end': 237, 'start': 234, 'tag': 'OrganismAttribute'}, {'end': 84, 'start': 72, 'tag': 'HealthCareActivity'}, {'end': 232, 'start': 217, 'tag': 'OrganismAttribute'}, {'end': 27, 'start': 22, 'tag': 'ResearchActivity'}, {'end': 124, 'start': 115, 'tag': 'HealthCareActivity'}, {'end': 124, 'start': 115, 'tag': 'TemporalConcept'}, {'end': 111, 'start': 106, 'tag': 'TemporalConcept'}, {'end': 92, 'start': 85, 'tag': 'ResearchActivity'}, {'end': 148, 'start': 140, 'tag': 'TemporalConcept'}, {'end': 243, 'start': 239, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 243, 'start': 239, 'tag': 'BiologicallyActiveSubstance'}, {'end': 157, 'start': 149, 'tag': 'ResearchActivity'}, {'end': 247, 'start': 239, 'tag': 'GeneOrGenome'}, {'end': 259, 'start': 248, 'tag': 'Finding'}, {'end': 168, 'start': 165, 'tag': 'ClinicalAttribute'}]"
265,"Specifically, we explored the pattern and rate of change in BAG over time in individuals who remain stable with normal cognition or mild cognitive impairment (MCI), as well as individuals who progress to clinical AD.","[{'end': 200, 'start': 192, 'tag': 'TemporalConcept'}, {'end': 118, 'start': 112, 'tag': 'Finding'}, {'end': 46, 'start': 42, 'tag': 'TemporalConcept'}, {'end': 215, 'start': 213, 'tag': 'DiseaseOrSyndrome'}, {'end': 88, 'start': 77, 'tag': 'PopulationGroup'}, {'end': 187, 'start': 176, 'tag': 'PopulationGroup'}, {'end': 162, 'start': 159, 'tag': 'DiseaseOrSyndrome'}, {'end': 73, 'start': 69, 'tag': 'TemporalConcept'}, {'end': 128, 'start': 119, 'tag': 'BiologicFunction'}, {'end': 157, 'start': 132, 'tag': 'DiseaseOrSyndrome'}, {'end': 56, 'start': 50, 'tag': 'Finding'}, {'end': 63, 'start': 60, 'tag': 'ClinicalAttribute'}]"
266,Combining multimodal imaging data in a support vector regression model to estimate brain age yielded improved performance over single modality.,"[{'end': 28, 'start': 10, 'tag': 'HealthCareActivity'}, {'end': 142, 'start': 134, 'tag': 'HealthCareActivity'}, {'end': 70, 'start': 39, 'tag': 'ResearchActivity'}, {'end': 88, 'start': 83, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 33, 'start': 29, 'tag': 'ResearchActivity'}, {'end': 121, 'start': 110, 'tag': 'Finding'}, {'end': 92, 'start': 89, 'tag': 'OrganismAttribute'}]"
267,Multilevel modeling results showed the BAG followed a linear increasing trajectory with a significantly faster rate in individuals with MCI who progressed to AD compared to cognitively normal or MCI individuals who did not progress.,"[{'end': 19, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 231, 'start': 223, 'tag': 'TemporalConcept'}, {'end': 115, 'start': 111, 'tag': 'TemporalConcept'}, {'end': 71, 'start': 61, 'tag': 'Finding'}, {'end': 160, 'start': 158, 'tag': 'DiseaseOrSyndrome'}, {'end': 130, 'start': 119, 'tag': 'PopulationGroup'}, {'end': 210, 'start': 199, 'tag': 'PopulationGroup'}, {'end': 139, 'start': 136, 'tag': 'DiseaseOrSyndrome'}, {'end': 198, 'start': 195, 'tag': 'DiseaseOrSyndrome'}, {'end': 191, 'start': 173, 'tag': 'Finding'}, {'end': 42, 'start': 39, 'tag': 'ClinicalAttribute'}]"
268,The dynamic changes in the BAG during AD progression were further moderated by sex and APOE e 4 carriership.,"[{'end': 82, 'start': 79, 'tag': 'OrganismAttribute'}, {'end': 40, 'start': 38, 'tag': 'DiseaseOrSyndrome'}, {'end': 52, 'start': 41, 'tag': 'PathologicFunction'}, {'end': 52, 'start': 41, 'tag': 'TemporalConcept'}, {'end': 91, 'start': 87, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 91, 'start': 87, 'tag': 'BiologicallyActiveSubstance'}, {'end': 19, 'start': 4, 'tag': 'Finding'}, {'end': 95, 'start': 87, 'tag': 'GeneOrGenome'}, {'end': 107, 'start': 96, 'tag': 'Finding'}, {'end': 30, 'start': 27, 'tag': 'ClinicalAttribute'}]"
269,Our findings demonstrate the BAG as a potential biomarker for understanding individual specific temporal patterns related to AD progression.,"[{'end': 127, 'start': 125, 'tag': 'DiseaseOrSyndrome'}, {'end': 139, 'start': 128, 'tag': 'PathologicFunction'}, {'end': 139, 'start': 128, 'tag': 'TemporalConcept'}, {'end': 86, 'start': 76, 'tag': 'PopulationGroup'}, {'end': 86, 'start': 76, 'tag': 'OrganismAttribute'}, {'end': 104, 'start': 96, 'tag': 'TemporalConcept'}, {'end': 75, 'start': 62, 'tag': 'BiologicFunction'}, {'end': 57, 'start': 38, 'tag': 'ClinicalAttribute'}, {'end': 113, 'start': 105, 'tag': 'ResearchActivity'}, {'end': 32, 'start': 29, 'tag': 'ClinicalAttribute'}]"
270,Background: The REFLECT trials were conducted to examine the treatment of mild-to-moderate Alzheimer's disease utilizing a peroxisome proliferator-activated receptor gamma agonist.,"[{'end': 171, 'start': 123, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 179, 'start': 172, 'tag': 'BiologicallyActiveSubstance'}, {'end': 90, 'start': 82, 'tag': 'Finding'}, {'end': 171, 'start': 123, 'tag': 'BiologicallyActiveSubstance'}, {'end': 110, 'start': 91, 'tag': 'DiseaseOrSyndrome'}, {'end': 70, 'start': 61, 'tag': 'HealthCareActivity'}, {'end': 70, 'start': 61, 'tag': 'ResearchActivity'}, {'end': 78, 'start': 74, 'tag': 'Finding'}, {'end': 30, 'start': 16, 'tag': 'ResearchActivity'}]"
271,Objective: To generate a predictive biomarker indicative of positive treatment response using samples from the previously conducted REFLECT trials.,"[{'end': 146, 'start': 132, 'tag': 'ResearchActivity'}, {'end': 87, 'start': 69, 'tag': 'ClinicalAttribute'}, {'end': 45, 'start': 25, 'tag': 'ClinicalAttribute'}]"
272,"Methods: Data were analyzed on 360 participants spanning multiple negative REFLECT trials, which included treatment with rosiglitazone and rosiglitazone XR.","[{'end': 134, 'start': 121, 'tag': 'Chemical'}, {'end': 155, 'start': 139, 'tag': 'Chemical'}, {'end': 115, 'start': 106, 'tag': 'HealthCareActivity'}, {'end': 115, 'start': 106, 'tag': 'ResearchActivity'}, {'end': 47, 'start': 35, 'tag': 'PopulationGroup'}, {'end': 13, 'start': 9, 'tag': 'ResearchActivity'}, {'end': 134, 'start': 121, 'tag': 'PharmacologicSubstance'}, {'end': 155, 'start': 139, 'tag': 'PharmacologicSubstance'}, {'end': 89, 'start': 75, 'tag': 'ResearchActivity'}]"
273,Support vector machine analyses were conducted to generate a predictive biomarker profile.,"[{'end': 81, 'start': 61, 'tag': 'ClinicalAttribute'}, {'end': 22, 'start': 0, 'tag': 'MachineActivity'}, {'end': 31, 'start': 23, 'tag': 'ResearchActivity'}]"
274,"Results: A pre-defined 6-protein predictive biomarker (IL6, IL10, CRP, TNF alpha, FABP-3, and PPY) correctly classified treatment response with 100%accuracy across study arms for REFLECT Phase II trial (AVA100193) and multiple Phase III trials (AVA105640, AV102672, and AVA102670).","[{'end': 58, 'start': 55, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 58, 'start': 55, 'tag': 'GeneOrGenome'}, {'end': 69, 'start': 66, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 69, 'start': 66, 'tag': 'GeneOrGenome'}, {'end': 69, 'start': 66, 'tag': 'BiologicallyActiveSubstance'}, {'end': 80, 'start': 71, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 97, 'start': 94, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 97, 'start': 94, 'tag': 'GeneOrGenome'}, {'end': 201, 'start': 187, 'tag': 'ResearchActivity'}, {'end': 138, 'start': 120, 'tag': 'ClinicalAttribute'}, {'end': 53, 'start': 33, 'tag': 'ClinicalAttribute'}, {'end': 169, 'start': 164, 'tag': 'ResearchActivity'}, {'end': 156, 'start': 148, 'tag': 'Finding'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 201, 'start': 179, 'tag': 'ResearchActivity'}, {'end': 64, 'start': 60, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 64, 'start': 60, 'tag': 'BiologicallyActiveSubstance'}, {'end': 58, 'start': 55, 'tag': 'BiologicallyActiveSubstance'}, {'end': 64, 'start': 60, 'tag': 'GeneOrGenome'}, {'end': 80, 'start': 71, 'tag': 'BiologicallyActiveSubstance'}, {'end': 88, 'start': 82, 'tag': 'BiologicallyActiveSubstance'}, {'end': 88, 'start': 82, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 88, 'start': 82, 'tag': 'GeneOrGenome'}, {'end': 97, 'start': 94, 'tag': 'BiologicallyActiveSubstance'}, {'end': 243, 'start': 227, 'tag': 'ResearchActivity'}, {'end': 254, 'start': 245, 'tag': 'ResearchActivity'}, {'end': 264, 'start': 256, 'tag': 'ResearchActivity'}, {'end': 279, 'start': 270, 'tag': 'ResearchActivity'}, {'end': 212, 'start': 203, 'tag': 'ResearchActivity'}]"
275,"When the data was combined across all rosiglitazone trial arms, a global RSG-predictive biomarker with the same 6-protein predictive biomarker was able to accurately classify 98%of treatment responders.","[{'end': 51, 'start': 38, 'tag': 'Chemical'}, {'end': 97, 'start': 77, 'tag': 'ClinicalAttribute'}, {'end': 142, 'start': 122, 'tag': 'ClinicalAttribute'}, {'end': 13, 'start': 9, 'tag': 'ResearchActivity'}, {'end': 190, 'start': 181, 'tag': 'HealthCareActivity'}, {'end': 190, 'start': 181, 'tag': 'ResearchActivity'}, {'end': 57, 'start': 52, 'tag': 'ResearchActivity'}, {'end': 51, 'start': 38, 'tag': 'PharmacologicSubstance'}, {'end': 201, 'start': 191, 'tag': 'PopulationGroup'}]"
276,Conclusion: A predictive biomarker comprising of metabolic and inflammatory markers was highly accurate in identifying those patients most likely to experience positive treatment response across the REFLECT trials.,"[{'end': 58, 'start': 49, 'tag': 'CellFunction'}, {'end': 187, 'start': 169, 'tag': 'ClinicalAttribute'}, {'end': 34, 'start': 14, 'tag': 'ClinicalAttribute'}, {'end': 159, 'start': 149, 'tag': 'BiologicFunction'}, {'end': 133, 'start': 125, 'tag': 'PatientOrDisabledGroup'}, {'end': 83, 'start': 63, 'tag': 'ClinicalAttribute'}, {'end': 213, 'start': 199, 'tag': 'ResearchActivity'}]"
277,"This study provides additional proof-of-concept that a predictive biomarker can be utilized to help with screening and predicting treatment response, which holds tremendous benefit for clinical trials.","[{'end': 148, 'start': 130, 'tag': 'ClinicalAttribute'}, {'end': 75, 'start': 55, 'tag': 'ClinicalAttribute'}, {'end': 200, 'start': 185, 'tag': 'ResearchActivity'}, {'end': 114, 'start': 105, 'tag': 'HealthCareActivity'}, {'end': 114, 'start': 105, 'tag': 'ResearchActivity'}, {'end': 10, 'start': 5, 'tag': 'ResearchActivity'}, {'end': 175, 'start': 174, 'tag': 'Finding'}]"
278,The apolipoprotein E epsilon 4 allele (APOE4) is the major genetic risk factor for sporadic Alzheimer's disease (AD).,"[{'end': 78, 'start': 59, 'tag': 'Finding'}, {'end': 111, 'start': 92, 'tag': 'DiseaseOrSyndrome'}, {'end': 115, 'start': 113, 'tag': 'DiseaseOrSyndrome'}, {'end': 91, 'start': 83, 'tag': 'TemporalConcept'}, {'end': 111, 'start': 83, 'tag': 'DiseaseOrSyndrome'}, {'end': 37, 'start': 31, 'tag': 'GeneOrGenome'}, {'end': 37, 'start': 4, 'tag': 'GeneOrGenome'}, {'end': 44, 'start': 39, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 44, 'start': 39, 'tag': 'BiologicallyActiveSubstance'}]"
279,APOE4 may have effects on cognition and brain atrophy years before the onset of symptomatic AD.,"[{'end': 53, 'start': 40, 'tag': 'DiseaseOrSyndrome'}, {'end': 94, 'start': 92, 'tag': 'DiseaseOrSyndrome'}, {'end': 66, 'start': 60, 'tag': 'TemporalConcept'}, {'end': 59, 'start': 54, 'tag': 'TemporalConcept'}, {'end': 35, 'start': 26, 'tag': 'BiologicFunction'}, {'end': 22, 'start': 15, 'tag': 'Finding'}, {'end': 76, 'start': 71, 'tag': 'TemporalConcept'}, {'end': 5, 'start': 0, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 5, 'start': 0, 'tag': 'BiologicallyActiveSubstance'}, {'end': 91, 'start': 80, 'tag': 'SignOrSymptom'}]"
280,"We analyzed the effects of APOE4 in a unique cohort of young adults who had undergone comprehensive assessments as part of the Dominantly Inherited Alzheimer Network (DIAN), an international longitudinal study of individuals from families with autosomal dominant AD.","[{'end': 67, 'start': 55, 'tag': 'PopulationGroup'}, {'end': 111, 'start': 100, 'tag': 'HealthCareActivity'}, {'end': 238, 'start': 230, 'tag': 'PopulationGroup'}, {'end': 265, 'start': 244, 'tag': 'DiseaseOrSyndrome'}, {'end': 209, 'start': 191, 'tag': 'ResearchActivity'}, {'end': 224, 'start': 213, 'tag': 'PopulationGroup'}, {'end': 23, 'start': 16, 'tag': 'Finding'}, {'end': 32, 'start': 27, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 32, 'start': 27, 'tag': 'BiologicallyActiveSubstance'}, {'end': 51, 'start': 45, 'tag': 'PopulationGroup'}, {'end': 11, 'start': 3, 'tag': 'ResearchActivity'}, {'end': 165, 'start': 127, 'tag': 'HealthCareRelatedOrganization'}, {'end': 171, 'start': 167, 'tag': 'HealthCareRelatedOrganization'}]"
281,"We analyzed the effect of an APOE4 allele on cognitive measures, volumetric MRI, amyloid deposition, glucose metabolism, and on cerebrospinal fluid levels of AD biomarkers in 162 participants that did not carry the mutant gene (noncarriers).","[{'end': 226, 'start': 215, 'tag': 'GeneOrGenome'}, {'end': 221, 'start': 215, 'tag': 'CellOrMolecularDysfunction'}, {'end': 119, 'start': 101, 'tag': 'CellFunction'}, {'end': 63, 'start': 45, 'tag': 'ClinicalAttribute'}, {'end': 79, 'start': 65, 'tag': 'HealthCareActivity'}, {'end': 239, 'start': 228, 'tag': 'PopulationGroup'}, {'end': 160, 'start': 158, 'tag': 'DiseaseOrSyndrome'}, {'end': 147, 'start': 128, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 191, 'start': 179, 'tag': 'PopulationGroup'}, {'end': 88, 'start': 81, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 88, 'start': 81, 'tag': 'BiologicallyActiveSubstance'}, {'end': 171, 'start': 161, 'tag': 'ClinicalAttribute'}, {'end': 41, 'start': 35, 'tag': 'GeneOrGenome'}, {'end': 34, 'start': 29, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 34, 'start': 29, 'tag': 'BiologicallyActiveSubstance'}, {'end': 11, 'start': 3, 'tag': 'ResearchActivity'}, {'end': 99, 'start': 81, 'tag': 'PathologicFunction'}]"
282,APOE4+ and APOE4- mutation noncarriers had similar performance on cognitive measures.,"[{'end': 84, 'start': 66, 'tag': 'ClinicalAttribute'}, {'end': 26, 'start': 18, 'tag': 'CellOrMolecularDysfunction'}, {'end': 38, 'start': 27, 'tag': 'PopulationGroup'}, {'end': 62, 'start': 51, 'tag': 'Finding'}, {'end': 5, 'start': 0, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 16, 'start': 11, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 5, 'start': 0, 'tag': 'BiologicallyActiveSubstance'}, {'end': 16, 'start': 11, 'tag': 'BiologicallyActiveSubstance'}]"
283,"Amyloid deposition began at an earlier age in APOE4+ participants, whereas hippocampal volume was similar between the groups.","[{'end': 38, 'start': 31, 'tag': 'TemporalConcept'}, {'end': 65, 'start': 53, 'tag': 'PopulationGroup'}, {'end': 124, 'start': 118, 'tag': 'PopulationGroup'}, {'end': 42, 'start': 39, 'tag': 'OrganismAttribute'}, {'end': 51, 'start': 46, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 51, 'start': 46, 'tag': 'BiologicallyActiveSubstance'}, {'end': 93, 'start': 75, 'tag': 'ClinicalAttribute'}, {'end': 18, 'start': 0, 'tag': 'PathologicFunction'}]"
284,"These preliminary findings are consistent with growing evidence that the APOE4 allele may exert effects in midlife years before symptom onset, promoting amyloid deposition before altering cognitive performance or brain structure.","[{'end': 228, 'start': 213, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 114, 'start': 107, 'tag': 'TemporalConcept'}, {'end': 63, 'start': 47, 'tag': 'Finding'}, {'end': 17, 'start': 6, 'tag': 'TemporalConcept'}, {'end': 160, 'start': 153, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 160, 'start': 153, 'tag': 'BiologicallyActiveSubstance'}, {'end': 127, 'start': 121, 'tag': 'TemporalConcept'}, {'end': 178, 'start': 172, 'tag': 'TemporalConcept'}, {'end': 120, 'start': 115, 'tag': 'TemporalConcept'}, {'end': 103, 'start': 96, 'tag': 'Finding'}, {'end': 209, 'start': 188, 'tag': 'Finding'}, {'end': 85, 'start': 79, 'tag': 'GeneOrGenome'}, {'end': 78, 'start': 73, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 78, 'start': 73, 'tag': 'BiologicallyActiveSubstance'}, {'end': 141, 'start': 136, 'tag': 'TemporalConcept'}, {'end': 135, 'start': 128, 'tag': 'SignOrSymptom'}, {'end': 171, 'start': 153, 'tag': 'PathologicFunction'}]"
285,(C) 2019 Elsevier Inc.,[]
286,All rights reserved.,[]
287,"Introduction Neurofilament light chain (NfL) is becoming increasingly notable in neurological diseases including AD, and it has been suggested as a new peripherical biomarker of neurodegeneration.","[{'end': 102, 'start': 81, 'tag': 'DiseaseOrSyndrome'}, {'end': 195, 'start': 178, 'tag': 'CellOrMolecularDysfunction'}, {'end': 43, 'start': 40, 'tag': 'BiologicallyActiveSubstance'}, {'end': 43, 'start': 40, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 115, 'start': 113, 'tag': 'DiseaseOrSyndrome'}, {'end': 174, 'start': 152, 'tag': 'ClinicalAttribute'}, {'end': 38, 'start': 13, 'tag': 'BiologicallyActiveSubstance'}, {'end': 38, 'start': 13, 'tag': 'AminoAcidPeptideOrProtein'}]"
288,"We aimed to compare plasma NfL levels among Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI), and AD patients and to evaluate relationships between NfL and CSF biomarkers and neuropsychological scores.","[{'end': 105, 'start': 80, 'tag': 'DiseaseOrSyndrome'}, {'end': 189, 'start': 179, 'tag': 'ClinicalAttribute'}, {'end': 26, 'start': 20, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 128, 'start': 120, 'tag': 'PatientOrDisabledGroup'}, {'end': 178, 'start': 175, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 30, 'start': 27, 'tag': 'BiologicallyActiveSubstance'}, {'end': 170, 'start': 167, 'tag': 'BiologicallyActiveSubstance'}, {'end': 30, 'start': 27, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 170, 'start': 167, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 119, 'start': 117, 'tag': 'DiseaseOrSyndrome'}, {'end': 110, 'start': 107, 'tag': 'DiseaseOrSyndrome'}, {'end': 158, 'start': 145, 'tag': 'Finding'}, {'end': 219, 'start': 194, 'tag': 'HealthCareActivity'}, {'end': 37, 'start': 20, 'tag': 'ClinicalAttribute'}, {'end': 72, 'start': 44, 'tag': 'DiseaseOrSyndrome'}, {'end': 77, 'start': 74, 'tag': 'DiseaseOrSyndrome'}]"
289,"Materials and methods We enrolled 110 patients (34 SCD, 53 MCI, and 23 AD), who underwent clinical and neuropsychological evaluation, APOE genotyping, and plasma NfL analysis.","[{'end': 149, 'start': 139, 'tag': 'ResearchActivity'}, {'end': 161, 'start': 155, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 46, 'start': 38, 'tag': 'PatientOrDisabledGroup'}, {'end': 165, 'start': 162, 'tag': 'BiologicallyActiveSubstance'}, {'end': 165, 'start': 162, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 73, 'start': 71, 'tag': 'DiseaseOrSyndrome'}, {'end': 62, 'start': 59, 'tag': 'DiseaseOrSyndrome'}, {'end': 138, 'start': 134, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 138, 'start': 134, 'tag': 'BiologicallyActiveSubstance'}, {'end': 132, 'start': 90, 'tag': 'HealthCareActivity'}, {'end': 174, 'start': 166, 'tag': 'ResearchActivity'}, {'end': 21, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 54, 'start': 51, 'tag': 'DiseaseOrSyndrome'}]"
290,Ninety-one patients underwent at least one amyloid burden biomarker (CSF and/or amyloid PET); 86 patients also underwent CSF phosphorylated-tau (p-tau) and total-tau (t-tau) measurement.,"[{'end': 57, 'start': 51, 'tag': 'ResearchActivity'}, {'end': 139, 'start': 125, 'tag': 'CellFunction'}, {'end': 143, 'start': 140, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 150, 'start': 147, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 165, 'start': 156, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 172, 'start': 167, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 19, 'start': 11, 'tag': 'PatientOrDisabledGroup'}, {'end': 105, 'start': 97, 'tag': 'PatientOrDisabledGroup'}, {'end': 72, 'start': 69, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 124, 'start': 121, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 50, 'start': 43, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 87, 'start': 80, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 50, 'start': 43, 'tag': 'BiologicallyActiveSubstance'}, {'end': 87, 'start': 80, 'tag': 'BiologicallyActiveSubstance'}, {'end': 143, 'start': 140, 'tag': 'BiologicallyActiveSubstance'}, {'end': 150, 'start': 147, 'tag': 'BiologicallyActiveSubstance'}, {'end': 165, 'start': 156, 'tag': 'BiologicallyActiveSubstance'}, {'end': 172, 'start': 167, 'tag': 'BiologicallyActiveSubstance'}, {'end': 185, 'start': 174, 'tag': 'ResearchActivity'}, {'end': 185, 'start': 174, 'tag': 'HealthCareActivity'}, {'end': 67, 'start': 58, 'tag': 'ClinicalAttribute'}, {'end': 91, 'start': 88, 'tag': 'HealthCareActivity'}, {'end': 150, 'start': 145, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 150, 'start': 145, 'tag': 'BiologicallyActiveSubstance'}]"
291,Patients were classified as A + if they presented at least one positive amyloid biomarker or A- if not.,"[{'end': 8, 'start': 0, 'tag': 'PatientOrDisabledGroup'}, {'end': 79, 'start': 72, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 79, 'start': 72, 'tag': 'BiologicallyActiveSubstance'}, {'end': 89, 'start': 80, 'tag': 'ClinicalAttribute'}]"
292,Results NfL levels were significantly increased in AD and MCI compared to SCD patients.,"[{'end': 47, 'start': 24, 'tag': 'Finding'}, {'end': 86, 'start': 78, 'tag': 'PatientOrDisabledGroup'}, {'end': 11, 'start': 8, 'tag': 'BiologicallyActiveSubstance'}, {'end': 11, 'start': 8, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 53, 'start': 51, 'tag': 'DiseaseOrSyndrome'}, {'end': 61, 'start': 58, 'tag': 'DiseaseOrSyndrome'}, {'end': 18, 'start': 8, 'tag': 'ClinicalAttribute'}, {'end': 77, 'start': 74, 'tag': 'DiseaseOrSyndrome'}]"
293,"These differences depend on A status, e.g., SCD A + had lower NfLs than MCI A + but comparable with MCI A-.","[{'end': 66, 'start': 62, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 66, 'start': 62, 'tag': 'BiologicallyActiveSubstance'}, {'end': 17, 'start': 6, 'tag': 'Finding'}, {'end': 36, 'start': 30, 'tag': 'Finding'}, {'end': 75, 'start': 72, 'tag': 'DiseaseOrSyndrome'}, {'end': 103, 'start': 100, 'tag': 'DiseaseOrSyndrome'}, {'end': 47, 'start': 44, 'tag': 'DiseaseOrSyndrome'}]"
294,"Similarly, MCI A + had higher NfL levels than MCI A-, but comparable with AD.","[{'end': 33, 'start': 30, 'tag': 'BiologicallyActiveSubstance'}, {'end': 33, 'start': 30, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 76, 'start': 74, 'tag': 'DiseaseOrSyndrome'}, {'end': 14, 'start': 11, 'tag': 'DiseaseOrSyndrome'}, {'end': 49, 'start': 46, 'tag': 'DiseaseOrSyndrome'}, {'end': 40, 'start': 30, 'tag': 'ClinicalAttribute'}]"
295,"NfL levels correlated with p-tau in SCD, with all CSF biomarkers in MCI patients.","[{'end': 32, 'start': 29, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 64, 'start': 54, 'tag': 'ClinicalAttribute'}, {'end': 80, 'start': 72, 'tag': 'PatientOrDisabledGroup'}, {'end': 53, 'start': 50, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 3, 'start': 0, 'tag': 'BiologicallyActiveSubstance'}, {'end': 3, 'start': 0, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 32, 'start': 29, 'tag': 'BiologicallyActiveSubstance'}, {'end': 71, 'start': 68, 'tag': 'DiseaseOrSyndrome'}, {'end': 32, 'start': 27, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 32, 'start': 27, 'tag': 'BiologicallyActiveSubstance'}, {'end': 10, 'start': 0, 'tag': 'ClinicalAttribute'}, {'end': 39, 'start': 36, 'tag': 'DiseaseOrSyndrome'}]"
296,No correlations were found in AD subgroup.,"[{'end': 32, 'start': 30, 'tag': 'DiseaseOrSyndrome'}, {'end': 15, 'start': 3, 'tag': 'ResearchActivity'}]"
297,"In SCD, NfL levels were negatively correlated with memory test scores.","[{'end': 11, 'start': 8, 'tag': 'BiologicallyActiveSubstance'}, {'end': 11, 'start': 8, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 57, 'start': 51, 'tag': 'BiologicFunction'}, {'end': 6, 'start': 3, 'tag': 'DiseaseOrSyndrome'}, {'end': 18, 'start': 8, 'tag': 'ClinicalAttribute'}, {'end': 69, 'start': 51, 'tag': 'HealthCareActivity'}]"
298,Conclusions Plasma NfL levels might be a promising biomarker for neurodegeneration to discriminate cognitive decline due to AD from other conditions causing cognitive impairment in prodromal stages.,"[{'end': 148, 'start': 138, 'tag': 'DiseaseOrSyndrome'}, {'end': 197, 'start': 181, 'tag': 'SignOrSymptom'}, {'end': 18, 'start': 12, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 82, 'start': 65, 'tag': 'CellOrMolecularDysfunction'}, {'end': 22, 'start': 19, 'tag': 'BiologicallyActiveSubstance'}, {'end': 22, 'start': 19, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 126, 'start': 124, 'tag': 'DiseaseOrSyndrome'}, {'end': 60, 'start': 51, 'tag': 'ClinicalAttribute'}, {'end': 197, 'start': 191, 'tag': 'TemporalConcept'}, {'end': 116, 'start': 99, 'tag': 'DiseaseOrSyndrome'}, {'end': 177, 'start': 157, 'tag': 'DiseaseOrSyndrome'}, {'end': 29, 'start': 12, 'tag': 'ClinicalAttribute'}]"
299,"Considering correlations with CSF p-tau and memory tests in SCD, NfL might be a useful peripheral biomarker also in preclinical phases of AD.","[{'end': 39, 'start': 36, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 33, 'start': 30, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 68, 'start': 65, 'tag': 'BiologicallyActiveSubstance'}, {'end': 68, 'start': 65, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 39, 'start': 36, 'tag': 'BiologicallyActiveSubstance'}, {'end': 140, 'start': 138, 'tag': 'DiseaseOrSyndrome'}, {'end': 107, 'start': 98, 'tag': 'ClinicalAttribute'}, {'end': 97, 'start': 87, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 24, 'start': 12, 'tag': 'ResearchActivity'}, {'end': 56, 'start': 51, 'tag': 'ResearchActivity'}, {'end': 56, 'start': 51, 'tag': 'HealthCareActivity'}, {'end': 39, 'start': 34, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 39, 'start': 34, 'tag': 'BiologicallyActiveSubstance'}, {'end': 50, 'start': 44, 'tag': 'BiologicFunction'}, {'end': 63, 'start': 60, 'tag': 'DiseaseOrSyndrome'}]"
300,Background: Alzheimer's disease (AD)-related tauopathy can be measured with CSF phosphorylated tau (pTau) and tau PET.,"[{'end': 54, 'start': 45, 'tag': 'DiseaseOrSyndrome'}, {'end': 104, 'start': 100, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 104, 'start': 100, 'tag': 'BiologicallyActiveSubstance'}, {'end': 113, 'start': 110, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 31, 'start': 12, 'tag': 'DiseaseOrSyndrome'}, {'end': 79, 'start': 76, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 113, 'start': 110, 'tag': 'BiologicallyActiveSubstance'}, {'end': 35, 'start': 33, 'tag': 'DiseaseOrSyndrome'}, {'end': 98, 'start': 80, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 98, 'start': 80, 'tag': 'BiologicallyActiveSubstance'}, {'end': 117, 'start': 114, 'tag': 'HealthCareActivity'}]"
301,We aim to investigate the associations between these measurements and their relative ability to predict subsequent disease progression.,"[{'end': 92, 'start': 85, 'tag': 'OrganismAttribute'}, {'end': 134, 'start': 115, 'tag': 'PathologicFunction'}, {'end': 65, 'start': 53, 'tag': 'HealthCareActivity'}]"
302,"Methods: In 219 cognitively unimpaired and 122 impaired Alzheimer's Disease Neuroimaging Initiative participants with concurrent amyloid-beta (A beta) PET (F-18-florbetapir or(18)F-florbetaben),F-18-flortaucipir (FTP) PET, CSF measurements, structural MRI, and cognition, we examined inter-relationships between these biomarkers and their predictions of subsequent FTP and cognition changes.","[{'end': 390, 'start': 373, 'tag': 'Finding'}, {'end': 128, 'start': 118, 'tag': 'TemporalConcept'}, {'end': 99, 'start': 56, 'tag': 'ResearchActivity'}, {'end': 99, 'start': 56, 'tag': 'HealthCareRelatedOrganization'}, {'end': 211, 'start': 199, 'tag': 'Chemical'}, {'end': 38, 'start': 16, 'tag': 'Finding'}, {'end': 211, 'start': 194, 'tag': 'Chemical'}, {'end': 255, 'start': 241, 'tag': 'HealthCareActivity'}, {'end': 226, 'start': 223, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 303, 'start': 290, 'tag': 'Finding'}, {'end': 112, 'start': 100, 'tag': 'PopulationGroup'}, {'end': 75, 'start': 56, 'tag': 'DiseaseOrSyndrome'}, {'end': 328, 'start': 318, 'tag': 'ClinicalAttribute'}, {'end': 141, 'start': 129, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 270, 'start': 261, 'tag': 'BiologicFunction'}, {'end': 239, 'start': 227, 'tag': 'HealthCareActivity'}, {'end': 154, 'start': 151, 'tag': 'HealthCareActivity'}, {'end': 221, 'start': 218, 'tag': 'HealthCareActivity'}, {'end': 149, 'start': 143, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 172, 'start': 156, 'tag': 'Chemical'}, {'end': 192, 'start': 175, 'tag': 'Chemical'}]"
303,Results: The use of a CSF pTau/A beta(40) ratio eliminated positive associations we observed between CSF pTau alone and CSF A beta(42) in the normal A beta range likely reflecting individual differences in CSF production rather than pathology.,"[{'end': 148, 'start': 142, 'tag': 'Finding'}, {'end': 109, 'start': 105, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 109, 'start': 105, 'tag': 'BiologicallyActiveSubstance'}, {'end': 104, 'start': 101, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 123, 'start': 120, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 209, 'start': 206, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 242, 'start': 233, 'tag': 'PathologicFunction'}, {'end': 242, 'start': 233, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 202, 'start': 191, 'tag': 'Finding'}, {'end': 190, 'start': 180, 'tag': 'PopulationGroup'}, {'end': 190, 'start': 180, 'tag': 'OrganismAttribute'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 134, 'start': 124, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 155, 'start': 149, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 47, 'start': 22, 'tag': 'ClinicalAttribute'}, {'end': 134, 'start': 124, 'tag': 'BiologicallyActiveSubstance'}]"
304,"Use of the CSF pTau/A beta(40) ratio also increased expected associations with A beta PET, FTP PET, hippocampal volume, and cognitive decline compared to pTau alone.","[{'end': 158, 'start': 154, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 158, 'start': 154, 'tag': 'BiologicallyActiveSubstance'}, {'end': 141, 'start': 124, 'tag': 'DiseaseOrSyndrome'}, {'end': 89, 'start': 86, 'tag': 'HealthCareActivity'}, {'end': 98, 'start': 95, 'tag': 'HealthCareActivity'}, {'end': 85, 'start': 79, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 118, 'start': 100, 'tag': 'ClinicalAttribute'}, {'end': 36, 'start': 11, 'tag': 'ClinicalAttribute'}, {'end': 94, 'start': 91, 'tag': 'Chemical'}]"
305,"In A beta+ individuals, abnormal CSF pTau/A beta(40) only individuals (26.7%) were 4 times more prevalent (p < 0.001) than abnormal FTP only individuals (6.8%).","[{'end': 32, 'start': 24, 'tag': 'Finding'}, {'end': 131, 'start': 123, 'tag': 'Finding'}, {'end': 22, 'start': 11, 'tag': 'PopulationGroup'}, {'end': 69, 'start': 58, 'tag': 'PopulationGroup'}, {'end': 152, 'start': 141, 'tag': 'PopulationGroup'}, {'end': 9, 'start': 3, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 52, 'start': 33, 'tag': 'ClinicalAttribute'}, {'end': 135, 'start': 132, 'tag': 'Chemical'}]"
306,"Furthermore, among individuals on the AD pathway, CSF pTau/A beta(40) mediates the association between A beta PET and FTP PET accumulation, but FTP PET is more closely linked to subsequent cognitive decline than CSF pTau/A beta(40).","[{'end': 40, 'start': 38, 'tag': 'DiseaseOrSyndrome'}, {'end': 30, 'start': 19, 'tag': 'PopulationGroup'}, {'end': 206, 'start': 189, 'tag': 'DiseaseOrSyndrome'}, {'end': 48, 'start': 41, 'tag': 'CellFunction'}, {'end': 113, 'start': 110, 'tag': 'HealthCareActivity'}, {'end': 125, 'start': 122, 'tag': 'HealthCareActivity'}, {'end': 151, 'start': 148, 'tag': 'HealthCareActivity'}, {'end': 109, 'start': 103, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 138, 'start': 126, 'tag': 'Finding'}, {'end': 69, 'start': 50, 'tag': 'ClinicalAttribute'}, {'end': 121, 'start': 118, 'tag': 'Chemical'}, {'end': 147, 'start': 144, 'tag': 'Chemical'}, {'end': 231, 'start': 212, 'tag': 'ClinicalAttribute'}]"
307,"Conclusions: Together, these findings suggest that CSF pTau/A beta(40) may be a superior measure of tauopathy compared to CSF pTau alone, and CSF pTau/A beta(40) enables detection of tau accumulation at an earlier stage than FTP among A beta+ individuals.","[{'end': 109, 'start': 100, 'tag': 'DiseaseOrSyndrome'}, {'end': 130, 'start': 126, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 130, 'start': 126, 'tag': 'BiologicallyActiveSubstance'}, {'end': 213, 'start': 206, 'tag': 'TemporalConcept'}, {'end': 186, 'start': 183, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 125, 'start': 122, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 186, 'start': 183, 'tag': 'BiologicallyActiveSubstance'}, {'end': 254, 'start': 243, 'tag': 'PopulationGroup'}, {'end': 179, 'start': 170, 'tag': 'HealthCareActivity'}, {'end': 241, 'start': 235, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 199, 'start': 187, 'tag': 'Finding'}, {'end': 219, 'start': 214, 'tag': 'TemporalConcept'}, {'end': 219, 'start': 214, 'tag': 'ClinicalAttribute'}, {'end': 70, 'start': 51, 'tag': 'ClinicalAttribute'}, {'end': 161, 'start': 142, 'tag': 'ClinicalAttribute'}, {'end': 228, 'start': 225, 'tag': 'Chemical'}]"
308,Background Previous models of Alzheimer's disease (AD) progression were primarily hypothetical or based on data originating from single cohort studies.,"[{'end': 19, 'start': 11, 'tag': 'TemporalConcept'}, {'end': 49, 'start': 30, 'tag': 'DiseaseOrSyndrome'}, {'end': 53, 'start': 51, 'tag': 'DiseaseOrSyndrome'}, {'end': 111, 'start': 107, 'tag': 'ResearchActivity'}, {'end': 150, 'start': 129, 'tag': 'ResearchActivity'}, {'end': 66, 'start': 55, 'tag': 'PathologicFunction'}, {'end': 66, 'start': 55, 'tag': 'TemporalConcept'}, {'end': 26, 'start': 20, 'tag': 'ResearchActivity'}, {'end': 142, 'start': 136, 'tag': 'PopulationGroup'}]"
309,"However, cohort datasets are subject to specific inclusion and exclusion criteria that influence the signals observed in their collected data.","[{'end': 141, 'start': 137, 'tag': 'ResearchActivity'}, {'end': 15, 'start': 9, 'tag': 'PopulationGroup'}, {'end': 24, 'start': 16, 'tag': 'ResearchActivity'}, {'end': 108, 'start': 101, 'tag': 'CellFunction'}, {'end': 81, 'start': 63, 'tag': 'ResearchActivity'}, {'end': 81, 'start': 73, 'tag': 'ResearchActivity'}, {'end': 58, 'start': 49, 'tag': 'ResearchActivity'}]"
310,"Furthermore, each study measures only a subset of AD-relevant variables.","[{'end': 52, 'start': 50, 'tag': 'DiseaseOrSyndrome'}, {'end': 23, 'start': 18, 'tag': 'ResearchActivity'}]"
311,"To gain a comprehensive understanding of AD progression, the heterogeneity and robustness of estimated progression patterns must be understood, and complementary information contained in cohort datasets be leveraged.","[{'end': 37, 'start': 10, 'tag': 'ResearchActivity'}, {'end': 74, 'start': 61, 'tag': 'Finding'}, {'end': 43, 'start': 41, 'tag': 'DiseaseOrSyndrome'}, {'end': 55, 'start': 44, 'tag': 'PathologicFunction'}, {'end': 114, 'start': 103, 'tag': 'PathologicFunction'}, {'end': 55, 'start': 44, 'tag': 'TemporalConcept'}, {'end': 114, 'start': 103, 'tag': 'TemporalConcept'}, {'end': 193, 'start': 187, 'tag': 'PopulationGroup'}, {'end': 123, 'start': 115, 'tag': 'ResearchActivity'}, {'end': 202, 'start': 194, 'tag': 'ResearchActivity'}, {'end': 89, 'start': 79, 'tag': 'ResearchActivity'}]"
312,Methods We compared ten event-based models that we fit to ten independent AD cohort datasets.,"[{'end': 76, 'start': 74, 'tag': 'DiseaseOrSyndrome'}, {'end': 42, 'start': 36, 'tag': 'ResearchActivity'}, {'end': 83, 'start': 77, 'tag': 'PopulationGroup'}, {'end': 92, 'start': 84, 'tag': 'ResearchActivity'}]"
313,"Additionally, we designed and applied a novel rank aggregation algorithm that combines partially overlapping, individual event sequences into a meta-sequence containing the complementary information from each cohort.","[{'end': 72, 'start': 40, 'tag': 'MachineActivity'}, {'end': 120, 'start': 110, 'tag': 'PopulationGroup'}, {'end': 120, 'start': 110, 'tag': 'OrganismAttribute'}, {'end': 215, 'start': 209, 'tag': 'PopulationGroup'}, {'end': 157, 'start': 144, 'tag': 'MachineActivity'}]"
314,"Results We observed overall consistency across the ten event-based model sequences (average pairwise Kendall's tau correlation coefficient of 0.69 +/- 0.28), despite variance in the positioning of mainly imaging variables.","[{'end': 193, 'start': 182, 'tag': 'HealthCareActivity'}, {'end': 211, 'start': 204, 'tag': 'HealthCareActivity'}, {'end': 114, 'start': 111, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 114, 'start': 111, 'tag': 'BiologicallyActiveSubstance'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 72, 'start': 55, 'tag': 'ResearchActivity'}, {'end': 138, 'start': 101, 'tag': 'ResearchActivity'}]"
315,"The changes described in the aggregated meta-sequence are broadly consistent with the current understanding of AD progression, starting with cerebrospinal fluid amyloid beta, followed by tauopathy, memory impairment, FDG-PET, and ultimately brain deterioration and impairment of visual memory.","[{'end': 196, 'start': 187, 'tag': 'DiseaseOrSyndrome'}, {'end': 275, 'start': 265, 'tag': 'Finding'}, {'end': 292, 'start': 279, 'tag': 'BiologicFunction'}, {'end': 215, 'start': 198, 'tag': 'DiseaseOrSyndrome'}, {'end': 113, 'start': 111, 'tag': 'DiseaseOrSyndrome'}, {'end': 160, 'start': 141, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 246, 'start': 241, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 93, 'start': 86, 'tag': 'TemporalConcept'}, {'end': 224, 'start': 217, 'tag': 'HealthCareActivity'}, {'end': 125, 'start': 114, 'tag': 'PathologicFunction'}, {'end': 125, 'start': 114, 'tag': 'TemporalConcept'}, {'end': 107, 'start': 94, 'tag': 'BiologicFunction'}, {'end': 173, 'start': 161, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 11, 'start': 4, 'tag': 'Finding'}, {'end': 260, 'start': 247, 'tag': 'Finding'}, {'end': 53, 'start': 40, 'tag': 'MachineActivity'}]"
316,"Conclusion Overall, the event-based models demonstrated similar and robust disease cascades across independent AD cohorts.","[{'end': 113, 'start': 111, 'tag': 'DiseaseOrSyndrome'}, {'end': 121, 'start': 114, 'tag': 'PopulationGroup'}, {'end': 42, 'start': 24, 'tag': 'ResearchActivity'}]"
317,Aggregation of data-driven results can combine complementary strengths and information of patient-level datasets.,"[{'end': 11, 'start': 0, 'tag': 'CellFunction'}, {'end': 11, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 97, 'start': 90, 'tag': 'PatientOrDisabledGroup'}, {'end': 34, 'start': 15, 'tag': 'ResearchActivity'}, {'end': 112, 'start': 104, 'tag': 'ResearchActivity'}]"
318,"Accordingly, the derived meta-sequence draws a more complete picture of AD pathology compared to models relying on single cohorts.","[{'end': 74, 'start': 72, 'tag': 'DiseaseOrSyndrome'}, {'end': 129, 'start': 122, 'tag': 'PopulationGroup'}, {'end': 84, 'start': 75, 'tag': 'PathologicFunction'}, {'end': 84, 'start': 75, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 103, 'start': 97, 'tag': 'ResearchActivity'}, {'end': 38, 'start': 25, 'tag': 'MachineActivity'}]"
319,IntroductionPreviously generated serum and plasma proteomic profiles were examined among adults with Down syndrome (DS) to determine whether these profiles could discriminate those with mild cognitive impairment (MCI-DS) and Alzheimer's disease (DS-AD) from those cognitively stable (CS).,"[{'end': 68, 'start': 50, 'tag': 'ResearchActivity'}, {'end': 38, 'start': 33, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 244, 'start': 225, 'tag': 'DiseaseOrSyndrome'}, {'end': 251, 'start': 249, 'tag': 'DiseaseOrSyndrome'}, {'end': 216, 'start': 213, 'tag': 'DiseaseOrSyndrome'}, {'end': 49, 'start': 43, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 211, 'start': 186, 'tag': 'DiseaseOrSyndrome'}, {'end': 114, 'start': 101, 'tag': 'DiseaseOrSyndrome'}, {'end': 118, 'start': 116, 'tag': 'DiseaseOrSyndrome'}, {'end': 219, 'start': 217, 'tag': 'DiseaseOrSyndrome'}, {'end': 248, 'start': 246, 'tag': 'DiseaseOrSyndrome'}, {'end': 95, 'start': 89, 'tag': 'PopulationGroup'}, {'end': 155, 'start': 147, 'tag': 'ResearchActivity'}, {'end': 282, 'start': 264, 'tag': 'Finding'}]"
320,MethodsData were analyzed on n = 305 (n = 225 CS; n = 44 MCI-DS; n = 36 DS-AD) enrolled in the Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS).,"[{'end': 149, 'start': 143, 'tag': 'HealthCareRelatedOrganization'}, {'end': 77, 'start': 75, 'tag': 'DiseaseOrSyndrome'}, {'end': 60, 'start': 57, 'tag': 'DiseaseOrSyndrome'}, {'end': 63, 'start': 61, 'tag': 'DiseaseOrSyndrome'}, {'end': 74, 'start': 72, 'tag': 'DiseaseOrSyndrome'}, {'end': 141, 'start': 95, 'tag': 'HealthCareRelatedOrganization'}]"
321,"ResultsDistinguishing MCI-DS from CS, the serum profile produced an area under the curve (AUC) = 0.95 (sensitivity [SN] = 0.91; specificity [SP] = 0.99) and an AUC = 0.98 (SN = 0.96; SP = 0.97) for plasma when using an optimized cut-off score.","[{'end': 47, 'start': 42, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 236, 'start': 229, 'tag': 'ResearchActivity'}, {'end': 88, 'start': 68, 'tag': 'ResearchActivity'}, {'end': 242, 'start': 237, 'tag': 'Finding'}, {'end': 25, 'start': 22, 'tag': 'DiseaseOrSyndrome'}, {'end': 114, 'start': 103, 'tag': 'Finding'}, {'end': 139, 'start': 128, 'tag': 'Finding'}, {'end': 204, 'start': 198, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 28, 'start': 26, 'tag': 'DiseaseOrSyndrome'}, {'end': 93, 'start': 90, 'tag': 'ResearchActivity'}, {'end': 163, 'start': 160, 'tag': 'ResearchActivity'}, {'end': 55, 'start': 48, 'tag': 'ResearchActivity'}]"
322,"Distinguishing DS-AD from CS, the serum profile produced an AUC = 0.93 (SN = 0.81; SP = 0.99) and an AUC = 0.95 (SN = 0.86; SP = 1.0) for plasma when using an optimized cut-off score.","[{'end': 39, 'start': 34, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 176, 'start': 169, 'tag': 'ResearchActivity'}, {'end': 20, 'start': 18, 'tag': 'DiseaseOrSyndrome'}, {'end': 182, 'start': 177, 'tag': 'Finding'}, {'end': 144, 'start': 138, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 17, 'start': 15, 'tag': 'DiseaseOrSyndrome'}, {'end': 63, 'start': 60, 'tag': 'ResearchActivity'}, {'end': 104, 'start': 101, 'tag': 'ResearchActivity'}]"
323,AUC remained unchanged to slightly improved when age and sex were included.,"[{'end': 60, 'start': 57, 'tag': 'OrganismAttribute'}, {'end': 52, 'start': 49, 'tag': 'OrganismAttribute'}, {'end': 3, 'start': 0, 'tag': 'ResearchActivity'}]"
324,"Eotaxin3, interleukin (IL)-10, C-reactive protein, IL-18, serum amyloid A , and FABP3 correlated fractions at r(2) > = 0.90.","[{'end': 8, 'start': 0, 'tag': 'BiologicallyActiveSubstance'}, {'end': 49, 'start': 31, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 49, 'start': 31, 'tag': 'BiologicallyActiveSubstance'}, {'end': 56, 'start': 51, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 56, 'start': 51, 'tag': 'BiologicallyActiveSubstance'}, {'end': 56, 'start': 51, 'tag': 'GeneOrGenome'}, {'end': 73, 'start': 58, 'tag': 'ClinicalAttribute'}, {'end': 85, 'start': 80, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 85, 'start': 80, 'tag': 'GeneOrGenome'}, {'end': 85, 'start': 80, 'tag': 'BiologicallyActiveSubstance'}, {'end': 29, 'start': 10, 'tag': 'BiologicallyActiveSubstance'}, {'end': 29, 'start': 10, 'tag': 'BiologicallyActiveSubstance'}, {'end': 8, 'start': 0, 'tag': 'AminoAcidPeptideOrProtein'}]"
325,DiscussionProteomic profiles showed excellent detection accuracy for MCI-DS and DS-AD.,"[{'end': 85, 'start': 83, 'tag': 'DiseaseOrSyndrome'}, {'end': 72, 'start': 69, 'tag': 'DiseaseOrSyndrome'}, {'end': 64, 'start': 56, 'tag': 'Finding'}, {'end': 55, 'start': 46, 'tag': 'HealthCareActivity'}, {'end': 75, 'start': 73, 'tag': 'DiseaseOrSyndrome'}, {'end': 82, 'start': 80, 'tag': 'DiseaseOrSyndrome'}, {'end': 28, 'start': 10, 'tag': 'ResearchActivity'}]"
326,"We have previously investigated, discovered, and replicated plasma protein biomarkers for use to triage potential trials participants for PET or cerebrospinal fluid measures of Alzheimer's disease (AD) pathology.","[{'end': 103, 'start': 97, 'tag': 'HealthCareActivity'}, {'end': 85, 'start': 67, 'tag': 'ClinicalAttribute'}, {'end': 196, 'start': 177, 'tag': 'DiseaseOrSyndrome'}, {'end': 200, 'start': 198, 'tag': 'DiseaseOrSyndrome'}, {'end': 164, 'start': 145, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 133, 'start': 121, 'tag': 'PopulationGroup'}, {'end': 66, 'start': 60, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 211, 'start': 202, 'tag': 'PathologicFunction'}, {'end': 211, 'start': 202, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 141, 'start': 138, 'tag': 'HealthCareActivity'}, {'end': 120, 'start': 114, 'tag': 'ResearchActivity'}]"
327,"This study sought to undertake validation of these candidate plasma biomarkers in a large, multi-center sample collection.","[{'end': 41, 'start': 31, 'tag': 'ResearchActivity'}, {'end': 78, 'start': 68, 'tag': 'ClinicalAttribute'}, {'end': 10, 'start': 5, 'tag': 'ResearchActivity'}, {'end': 67, 'start': 61, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 121, 'start': 104, 'tag': 'HealthCareActivity'}]"
328,"Targeted plasma analyses of 34 proteins with prior evidence for prediction of in vivo pathology were conducted in up to 1,000 samples from cognitively healthy elderly individuals, people with mild cognitive impairment, and in patients with AD-type dementia, selected from the EMIF-AD catalogue.","[{'end': 242, 'start': 240, 'tag': 'DiseaseOrSyndrome'}, {'end': 283, 'start': 281, 'tag': 'DiseaseOrSyndrome'}, {'end': 234, 'start': 226, 'tag': 'PatientOrDisabledGroup'}, {'end': 178, 'start': 167, 'tag': 'PopulationGroup'}, {'end': 256, 'start': 248, 'tag': 'DiseaseOrSyndrome'}, {'end': 15, 'start': 9, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 95, 'start': 86, 'tag': 'PathologicFunction'}, {'end': 95, 'start': 86, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 39, 'start': 31, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 59, 'start': 51, 'tag': 'Finding'}, {'end': 24, 'start': 16, 'tag': 'ResearchActivity'}, {'end': 166, 'start': 159, 'tag': 'PopulationGroup'}, {'end': 74, 'start': 64, 'tag': 'Finding'}, {'end': 217, 'start': 192, 'tag': 'DiseaseOrSyndrome'}, {'end': 158, 'start': 139, 'tag': 'OrganismAttribute'}, {'end': 85, 'start': 78, 'tag': 'ResearchActivity'}, {'end': 186, 'start': 180, 'tag': 'PopulationGroup'}, {'end': 256, 'start': 240, 'tag': 'DiseaseOrSyndrome'}, {'end': 133, 'start': 126, 'tag': 'Substance'}, {'end': 133, 'start': 126, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 293, 'start': 276, 'tag': 'ResearchActivity'}]"
329,"Proteins were measured using Luminex xMAP, ELISA, and Meso Scale Discovery assays.","[{'end': 8, 'start': 0, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 41, 'start': 29, 'tag': 'ResearchActivity'}, {'end': 48, 'start': 43, 'tag': 'ResearchActivity'}, {'end': 81, 'start': 54, 'tag': 'ResearchActivity'}]"
330,Seven proteins replicated in their ability to predict in vivo amyloid pathology.,"[{'end': 79, 'start': 62, 'tag': 'PathologicFunction'}, {'end': 42, 'start': 35, 'tag': 'OrganismAttribute'}, {'end': 14, 'start': 6, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 61, 'start': 54, 'tag': 'ResearchActivity'}]"
331,"These proteins form a biomarker panel that, along with age, could significantly discriminate between individuals with high and low amyloid pathology with an area under the curve of 0.74.","[{'end': 148, 'start': 131, 'tag': 'PathologicFunction'}, {'end': 130, 'start': 127, 'tag': 'Finding'}, {'end': 31, 'start': 22, 'tag': 'ClinicalAttribute'}, {'end': 177, 'start': 157, 'tag': 'ResearchActivity'}, {'end': 112, 'start': 101, 'tag': 'PopulationGroup'}, {'end': 14, 'start': 6, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 58, 'start': 55, 'tag': 'OrganismAttribute'}, {'end': 122, 'start': 118, 'tag': 'Finding'}, {'end': 37, 'start': 22, 'tag': 'ResearchActivity'}]"
332,The performance of this biomarker panel remained consistent when tested in apolipoprotein E epsilon 4 non-carrier individuals only.,"[{'end': 33, 'start': 24, 'tag': 'ClinicalAttribute'}, {'end': 125, 'start': 114, 'tag': 'PopulationGroup'}, {'end': 15, 'start': 4, 'tag': 'Finding'}, {'end': 39, 'start': 24, 'tag': 'ResearchActivity'}, {'end': 101, 'start': 75, 'tag': 'GeneOrGenome'}, {'end': 113, 'start': 102, 'tag': 'PopulationGroup'}]"
333,"This blood-based panel is biologically relevant, measurable using practical immunocapture arrays, and could significantly reduce the cost incurred to clinical trials through screen failure.","[{'end': 188, 'start': 181, 'tag': 'IndividualBehavior'}, {'end': 188, 'start': 181, 'tag': 'DiseaseOrSyndrome'}, {'end': 165, 'start': 150, 'tag': 'ResearchActivity'}, {'end': 10, 'start': 5, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 180, 'start': 174, 'tag': 'HealthCareActivity'}, {'end': 180, 'start': 174, 'tag': 'ResearchActivity'}, {'end': 96, 'start': 76, 'tag': 'ResearchActivity'}]"
334,Background: Aberrant amyloid-beta (A beta) deposition in the brain occurs two decades prior to the manifestation of Alzheimer's disease (AD) clinical symptoms and therefore brain A beta load measured using PET serves as a gold standard biomarker for the early diagnosis of AD.,"[{'end': 112, 'start': 99, 'tag': 'SignOrSymptom'}, {'end': 85, 'start': 78, 'tag': 'TemporalConcept'}, {'end': 158, 'start': 141, 'tag': 'SignOrSymptom'}, {'end': 135, 'start': 116, 'tag': 'DiseaseOrSyndrome'}, {'end': 139, 'start': 137, 'tag': 'DiseaseOrSyndrome'}, {'end': 275, 'start': 273, 'tag': 'DiseaseOrSyndrome'}, {'end': 245, 'start': 236, 'tag': 'ClinicalAttribute'}, {'end': 66, 'start': 61, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 178, 'start': 173, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 28, 'start': 21, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 28, 'start': 21, 'tag': 'BiologicallyActiveSubstance'}, {'end': 269, 'start': 260, 'tag': 'HealthCareActivity'}, {'end': 33, 'start': 21, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 259, 'start': 254, 'tag': 'TemporalConcept'}, {'end': 209, 'start': 206, 'tag': 'HealthCareActivity'}, {'end': 41, 'start': 35, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 185, 'start': 179, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 269, 'start': 254, 'tag': 'HealthCareActivity'}, {'end': 53, 'start': 43, 'tag': 'PathologicFunction'}, {'end': 33, 'start': 12, 'tag': 'PathologicFunction'}, {'end': 190, 'start': 173, 'tag': 'ClinicalAttribute'}]"
335,"However, the uneconomical nature of PET makes blood markers, that reflect brain A beta deposition, attractive candidates for investigation as surrogate markers.","[{'end': 138, 'start': 125, 'tag': 'ResearchActivity'}, {'end': 79, 'start': 74, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 51, 'start': 46, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 39, 'start': 36, 'tag': 'HealthCareActivity'}, {'end': 86, 'start': 80, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 59, 'start': 52, 'tag': 'ClinicalAttribute'}, {'end': 159, 'start': 142, 'tag': 'ClinicalAttribute'}, {'end': 97, 'start': 80, 'tag': 'PathologicFunction'}]"
336,Objective: Investigation of plasma A beta as a surrogate marker for brain A beta deposition in cognitively normal elderly individuals.,"[{'end': 24, 'start': 11, 'tag': 'ResearchActivity'}, {'end': 63, 'start': 47, 'tag': 'ClinicalAttribute'}, {'end': 73, 'start': 68, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 133, 'start': 122, 'tag': 'PopulationGroup'}, {'end': 34, 'start': 28, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 113, 'start': 95, 'tag': 'Finding'}, {'end': 121, 'start': 114, 'tag': 'PopulationGroup'}, {'end': 41, 'start': 35, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 80, 'start': 74, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 91, 'start': 74, 'tag': 'PathologicFunction'}]"
337,"Methods: Plasma A beta(40) and A beta(42) concentrations were measured using the ultrasensitive Single Molecule Array (Simoa) assay in 95 cognitively normal elderly individuals, who have all undergone PET to assess brain A beta deposition.","[{'end': 131, 'start': 126, 'tag': 'ResearchActivity'}, {'end': 222, 'start': 215, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 56, 'start': 42, 'tag': 'BiologicFunction'}, {'end': 15, 'start': 9, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 176, 'start': 165, 'tag': 'PopulationGroup'}, {'end': 156, 'start': 138, 'tag': 'Finding'}, {'end': 164, 'start': 157, 'tag': 'PopulationGroup'}, {'end': 204, 'start': 201, 'tag': 'HealthCareActivity'}, {'end': 26, 'start': 16, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 41, 'start': 31, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 227, 'start': 221, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 26, 'start': 16, 'tag': 'BiologicallyActiveSubstance'}, {'end': 41, 'start': 31, 'tag': 'BiologicallyActiveSubstance'}, {'end': 117, 'start': 96, 'tag': 'ResearchActivity'}, {'end': 124, 'start': 119, 'tag': 'ResearchActivity'}, {'end': 238, 'start': 221, 'tag': 'PathologicFunction'}]"
338,"Based on the standard uptake value ratios (SUVR) obtained from PET imaging, using the tracer F-18-Florbetaben, plasma A beta was compared between 32 participants assessed to have low brain A beta load (A beta-, SUVR <1.35) and 63 assessed to have high brain A beta load (A beta+, SUVR >= 1.35).","[{'end': 92, 'start': 86, 'tag': 'Chemical'}, {'end': 74, 'start': 63, 'tag': 'HealthCareActivity'}, {'end': 182, 'start': 179, 'tag': 'Finding'}, {'end': 161, 'start': 149, 'tag': 'PopulationGroup'}, {'end': 117, 'start': 111, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 124, 'start': 118, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 208, 'start': 202, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 277, 'start': 271, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 251, 'start': 247, 'tag': 'Finding'}, {'end': 109, 'start': 93, 'tag': 'Chemical'}, {'end': 41, 'start': 13, 'tag': 'ResearchActivity'}, {'end': 47, 'start': 43, 'tag': 'ResearchActivity'}, {'end': 200, 'start': 183, 'tag': 'ClinicalAttribute'}, {'end': 269, 'start': 252, 'tag': 'ClinicalAttribute'}, {'end': 215, 'start': 211, 'tag': 'ResearchActivity'}, {'end': 284, 'start': 280, 'tag': 'ResearchActivity'}]"
339,Results: Plasma A beta(42)/A beta(40) ratios were lower in the A beta+ group compared to the A beta- group.,"[{'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 76, 'start': 71, 'tag': 'PopulationGroup'}, {'end': 106, 'start': 101, 'tag': 'PopulationGroup'}, {'end': 69, 'start': 63, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 99, 'start': 93, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 44, 'start': 9, 'tag': 'ClinicalAttribute'}]"
340,"Plasma A beta(40) and A beta(42) levels were not significantly different between A beta- and A beta+ groups, although a trend of higher plasma A beta(40) was observed in the A beta+ group.","[{'end': 6, 'start': 0, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 142, 'start': 136, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 107, 'start': 101, 'tag': 'PopulationGroup'}, {'end': 187, 'start': 182, 'tag': 'PopulationGroup'}, {'end': 17, 'start': 7, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 32, 'start': 22, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 87, 'start': 81, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 99, 'start': 93, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 153, 'start': 143, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 180, 'start': 174, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 153, 'start': 143, 'tag': 'BiologicallyActiveSubstance'}, {'end': 17, 'start': 7, 'tag': 'BiologicallyActiveSubstance'}, {'end': 32, 'start': 22, 'tag': 'BiologicallyActiveSubstance'}]"
341,"Additionally, plasma A beta(42)/A beta(40) ratios along with the known AD risk factors, age and APOE epsilon 4 status, resulted in A beta+ participants being distinguished from A beta- participants based on an area under the receiver operating characteristic curve shown to be 78%.","[{'end': 264, 'start': 210, 'tag': 'ResearchActivity'}, {'end': 73, 'start': 71, 'tag': 'DiseaseOrSyndrome'}, {'end': 151, 'start': 139, 'tag': 'PopulationGroup'}, {'end': 197, 'start': 185, 'tag': 'PopulationGroup'}, {'end': 91, 'start': 88, 'tag': 'OrganismAttribute'}, {'end': 117, 'start': 111, 'tag': 'Finding'}, {'end': 137, 'start': 131, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 183, 'start': 177, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 86, 'start': 74, 'tag': 'Finding'}, {'end': 110, 'start': 96, 'tag': 'GeneOrGenome'}, {'end': 49, 'start': 14, 'tag': 'ClinicalAttribute'}]"
342,"Conclusion: Plasma A beta ratios in this study are a potential biomarker for brain A beta deposition and therefore, for preclinical AD.","[{'end': 18, 'start': 12, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 134, 'start': 132, 'tag': 'DiseaseOrSyndrome'}, {'end': 82, 'start': 77, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 46, 'start': 41, 'tag': 'ResearchActivity'}, {'end': 134, 'start': 120, 'tag': 'DiseaseOrSyndrome'}, {'end': 25, 'start': 19, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 72, 'start': 53, 'tag': 'ClinicalAttribute'}, {'end': 100, 'start': 83, 'tag': 'PathologicFunction'}]"
343,"However, this method to measure plasma A beta needs further development to increase the accuracy of this promising AD blood biomarker.","[{'end': 117, 'start': 115, 'tag': 'DiseaseOrSyndrome'}, {'end': 133, 'start': 124, 'tag': 'ClinicalAttribute'}, {'end': 20, 'start': 14, 'tag': 'ResearchActivity'}, {'end': 20, 'start': 14, 'tag': 'HealthCareActivity'}, {'end': 71, 'start': 60, 'tag': 'BiologicFunction'}, {'end': 71, 'start': 60, 'tag': 'CellFunction'}, {'end': 96, 'start': 88, 'tag': 'Finding'}, {'end': 38, 'start': 32, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 123, 'start': 118, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 45, 'start': 39, 'tag': 'AminoAcidPeptideOrProtein'}]"
344,"Introduction: Plasma markers have been reported to be associated with brain amyloid burden, tau pathology, or neurodegeneration.","[{'end': 20, 'start': 14, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 95, 'start': 92, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 95, 'start': 92, 'tag': 'BiologicallyActiveSubstance'}, {'end': 105, 'start': 92, 'tag': 'PathologicFunction'}, {'end': 75, 'start': 70, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 83, 'start': 76, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 83, 'start': 76, 'tag': 'BiologicallyActiveSubstance'}, {'end': 127, 'start': 110, 'tag': 'CellOrMolecularDysfunction'}, {'end': 90, 'start': 84, 'tag': 'ResearchActivity'}, {'end': 28, 'start': 21, 'tag': 'ClinicalAttribute'}]"
345,We aimed to evaluate whether plasma biomarker profiles could predict Alzheimer's disease (AD) pathology and clinical progression in older adults without dementia.,"[{'end': 128, 'start': 108, 'tag': 'TemporalConcept'}, {'end': 144, 'start': 132, 'tag': 'PopulationGroup'}, {'end': 88, 'start': 69, 'tag': 'DiseaseOrSyndrome'}, {'end': 92, 'start': 90, 'tag': 'DiseaseOrSyndrome'}, {'end': 45, 'start': 36, 'tag': 'ClinicalAttribute'}, {'end': 161, 'start': 153, 'tag': 'DiseaseOrSyndrome'}, {'end': 35, 'start': 29, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 103, 'start': 94, 'tag': 'PathologicFunction'}, {'end': 103, 'start': 94, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 128, 'start': 117, 'tag': 'PathologicFunction'}, {'end': 128, 'start': 117, 'tag': 'TemporalConcept'}, {'end': 54, 'start': 46, 'tag': 'ResearchActivity'}]"
346,Methods: Cross-sectional and longitudinal data of participants enrolled in this study were from the Alzheimer's Disease Neuroimaging Initiative (ADNI).,"[{'end': 46, 'start': 42, 'tag': 'ResearchActivity'}, {'end': 24, 'start': 9, 'tag': 'ResearchActivity'}, {'end': 143, 'start': 100, 'tag': 'ResearchActivity'}, {'end': 143, 'start': 100, 'tag': 'HealthCareRelatedOrganization'}, {'end': 46, 'start': 29, 'tag': 'ResearchActivity'}, {'end': 149, 'start': 145, 'tag': 'HealthCareRelatedOrganization'}, {'end': 149, 'start': 145, 'tag': 'ResearchActivity'}, {'end': 46, 'start': 42, 'tag': 'ResearchActivity'}, {'end': 62, 'start': 50, 'tag': 'PopulationGroup'}, {'end': 119, 'start': 100, 'tag': 'DiseaseOrSyndrome'}, {'end': 85, 'start': 80, 'tag': 'ResearchActivity'}]"
347,"Plasma amyloid beta (A beta)(1-42)/A beta(1-40) ratio was selected as the marker for amyloid pathology, p-tau181 for tau pathology, and neurofilament light for neurodegeneration.","[{'end': 102, 'start': 85, 'tag': 'PathologicFunction'}, {'end': 155, 'start': 136, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 155, 'start': 136, 'tag': 'BiologicallyActiveSubstance'}, {'end': 6, 'start': 0, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 130, 'start': 117, 'tag': 'PathologicFunction'}, {'end': 14, 'start': 7, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 14, 'start': 7, 'tag': 'BiologicallyActiveSubstance'}, {'end': 80, 'start': 74, 'tag': 'ClinicalAttribute'}, {'end': 112, 'start': 104, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 112, 'start': 104, 'tag': 'BiologicallyActiveSubstance'}, {'end': 27, 'start': 21, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 41, 'start': 35, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 177, 'start': 160, 'tag': 'CellOrMolecularDysfunction'}, {'end': 19, 'start': 7, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 53, 'start': 20, 'tag': 'ClinicalAttribute'}, {'end': 6, 'start': 0, 'tag': 'ClinicalAttribute'}]"
348,Cut-offs for these plasma markers were calculated with well-established positron emission tomography and structural imaging biomarkers as reference.,"[{'end': 123, 'start': 105, 'tag': 'HealthCareActivity'}, {'end': 134, 'start': 124, 'tag': 'ClinicalAttribute'}, {'end': 25, 'start': 19, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 100, 'start': 72, 'tag': 'HealthCareActivity'}, {'end': 33, 'start': 26, 'tag': 'ClinicalAttribute'}, {'end': 8, 'start': 0, 'tag': 'ResearchActivity'}]"
349,Older adults without dementia were categorized into eight groups at baseline by plasma amyloid/tau/neurodegeneration (A/T/N) cut-offs.,"[{'end': 12, 'start': 0, 'tag': 'PopulationGroup'}, {'end': 98, 'start': 95, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 98, 'start': 95, 'tag': 'BiologicallyActiveSubstance'}, {'end': 94, 'start': 87, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 94, 'start': 87, 'tag': 'BiologicallyActiveSubstance'}, {'end': 29, 'start': 21, 'tag': 'DiseaseOrSyndrome'}, {'end': 86, 'start': 80, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 64, 'start': 58, 'tag': 'PopulationGroup'}, {'end': 116, 'start': 99, 'tag': 'CellOrMolecularDysfunction'}, {'end': 133, 'start': 125, 'tag': 'ResearchActivity'}]"
350,Clinical progression was analyzed using linear mixed-effects models and Cox proportional hazard models.,"[{'end': 67, 'start': 40, 'tag': 'ResearchActivity'}, {'end': 20, 'start': 0, 'tag': 'TemporalConcept'}, {'end': 102, 'start': 72, 'tag': 'ResearchActivity'}]"
351,"Results: A total of 183 participants (97 cognitively normal [CN] subjects and 86 patients with mild cognitive impairment [MCI]; mean age 72.6 years, and 48.1% men) were included.","[{'end': 63, 'start': 61, 'tag': 'Finding'}, {'end': 89, 'start': 81, 'tag': 'PatientOrDisabledGroup'}, {'end': 36, 'start': 24, 'tag': 'PopulationGroup'}, {'end': 125, 'start': 122, 'tag': 'DiseaseOrSyndrome'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 136, 'start': 133, 'tag': 'OrganismAttribute'}, {'end': 147, 'start': 142, 'tag': 'TemporalConcept'}, {'end': 59, 'start': 41, 'tag': 'Finding'}, {'end': 120, 'start': 95, 'tag': 'DiseaseOrSyndrome'}, {'end': 73, 'start': 65, 'tag': 'PopulationGroup'}, {'end': 162, 'start': 159, 'tag': 'PopulationGroup'}]"
352,Participants with A+ had significantly higher proportions of apolipoprotein E (APOE) gene 4 carriers than those with A-.,"[{'end': 91, 'start': 85, 'tag': 'GeneOrGenome'}, {'end': 77, 'start': 61, 'tag': 'GeneOrGenome'}, {'end': 12, 'start': 0, 'tag': 'PopulationGroup'}, {'end': 83, 'start': 79, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 83, 'start': 79, 'tag': 'BiologicallyActiveSubstance'}, {'end': 100, 'start': 92, 'tag': 'PopulationGroup'}]"
353,"Brain atrophy was observed in all groups of CN, whereas cognition decline was obvious in the A+T+N+ group.","[{'end': 13, 'start': 0, 'tag': 'DiseaseOrSyndrome'}, {'end': 46, 'start': 44, 'tag': 'Finding'}, {'end': 40, 'start': 34, 'tag': 'PopulationGroup'}, {'end': 65, 'start': 56, 'tag': 'BiologicFunction'}, {'end': 105, 'start': 100, 'tag': 'PopulationGroup'}, {'end': 73, 'start': 66, 'tag': 'Finding'}]"
354,"Compared to A-T-N-, MCI patients with A+T+N+ had faster cognition worsening and faster brain atrophy.","[{'end': 75, 'start': 66, 'tag': 'Finding'}, {'end': 100, 'start': 87, 'tag': 'DiseaseOrSyndrome'}, {'end': 32, 'start': 24, 'tag': 'PatientOrDisabledGroup'}, {'end': 23, 'start': 20, 'tag': 'DiseaseOrSyndrome'}, {'end': 65, 'start': 56, 'tag': 'BiologicFunction'}]"
355,"In the whole cohort, A+T+N+ and A+T+N- participants were at higher risk of clinical progression.","[{'end': 95, 'start': 75, 'tag': 'TemporalConcept'}, {'end': 51, 'start': 39, 'tag': 'PopulationGroup'}, {'end': 19, 'start': 13, 'tag': 'PopulationGroup'}, {'end': 71, 'start': 67, 'tag': 'Finding'}]"
356,"Discussion: Plasma A/T/N biomarker profiles may predict AD pathology and clinical progression, indicating a potential role for plasma biomarkers in clinical trials.","[{'end': 93, 'start': 73, 'tag': 'TemporalConcept'}, {'end': 18, 'start': 12, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 163, 'start': 148, 'tag': 'ResearchActivity'}, {'end': 58, 'start': 56, 'tag': 'DiseaseOrSyndrome'}, {'end': 34, 'start': 12, 'tag': 'ClinicalAttribute'}, {'end': 144, 'start': 134, 'tag': 'ClinicalAttribute'}, {'end': 133, 'start': 127, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 68, 'start': 59, 'tag': 'PathologicFunction'}, {'end': 68, 'start': 59, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 43, 'start': 35, 'tag': 'ResearchActivity'}]"
357,More research is warranted to develop a robust plasma AD framework.,"[{'end': 56, 'start': 54, 'tag': 'DiseaseOrSyndrome'}, {'end': 13, 'start': 5, 'tag': 'ResearchActivity'}, {'end': 53, 'start': 47, 'tag': 'BodyPartOrganOrOrganComponent'}]"
358,Background: Biomarkers may soon be used to predict decline in older individuals.,"[{'end': 67, 'start': 62, 'tag': 'TemporalConcept'}, {'end': 79, 'start': 68, 'tag': 'PopulationGroup'}, {'end': 22, 'start': 12, 'tag': 'ClinicalAttribute'}]"
359,Extended follow-up studies are needed to determine the stability of such biomarker-based predictions.,"[{'end': 26, 'start': 9, 'tag': 'ResearchActivity'}, {'end': 82, 'start': 73, 'tag': 'ClinicalAttribute'}]"
360,"Objective: To examine the long-term performance of baseline cognitive, neuroimaging, and cerebrospinal fluid (CSF) biomarker-assisted prognosis in patients with mild cognitive impairment.","[{'end': 143, 'start': 134, 'tag': 'HealthCareActivity'}, {'end': 35, 'start': 26, 'tag': 'TemporalConcept'}, {'end': 47, 'start': 36, 'tag': 'Finding'}, {'end': 155, 'start': 147, 'tag': 'PatientOrDisabledGroup'}, {'end': 113, 'start': 110, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 124, 'start': 115, 'tag': 'ClinicalAttribute'}, {'end': 108, 'start': 89, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 83, 'start': 71, 'tag': 'HealthCareActivity'}, {'end': 186, 'start': 166, 'tag': 'DiseaseOrSyndrome'}, {'end': 186, 'start': 161, 'tag': 'DiseaseOrSyndrome'}, {'end': 165, 'start': 161, 'tag': 'Finding'}]"
361,"Methods: Established, biomarker-defined, cohorts of subjects with mild cognitive impairment were examined for progression to dementia.","[{'end': 31, 'start': 22, 'tag': 'ClinicalAttribute'}, {'end': 133, 'start': 125, 'tag': 'DiseaseOrSyndrome'}, {'end': 121, 'start': 110, 'tag': 'PathologicFunction'}, {'end': 121, 'start': 110, 'tag': 'TemporalConcept'}, {'end': 60, 'start': 52, 'tag': 'PopulationGroup'}, {'end': 91, 'start': 71, 'tag': 'DiseaseOrSyndrome'}, {'end': 91, 'start': 66, 'tag': 'DiseaseOrSyndrome'}, {'end': 48, 'start': 41, 'tag': 'PopulationGroup'}, {'end': 70, 'start': 66, 'tag': 'Finding'}]"
362,"Subjects with a baseline volumetric MRI, lumbar puncture, and Rey Auditory Verbal Learning Test were included.","[{'end': 56, 'start': 41, 'tag': 'HealthCareActivity'}, {'end': 39, 'start': 25, 'tag': 'HealthCareActivity'}, {'end': 95, 'start': 62, 'tag': 'HealthCareActivity'}]"
363,Dementia-free survival time in each biomarker-defined risk group was determined with Kaplan-Meier survival curves.,"[{'end': 45, 'start': 36, 'tag': 'ClinicalAttribute'}, {'end': 22, 'start': 14, 'tag': 'CellFunction'}, {'end': 106, 'start': 98, 'tag': 'CellFunction'}, {'end': 64, 'start': 59, 'tag': 'PopulationGroup'}, {'end': 27, 'start': 23, 'tag': 'TemporalConcept'}, {'end': 8, 'start': 0, 'tag': 'DiseaseOrSyndrome'}, {'end': 113, 'start': 85, 'tag': 'ResearchActivity'}]"
364,The influence of each risk factor or combination of factors on dementia-free survival was examined with Cox proportional hazard analyses.,"[{'end': 33, 'start': 22, 'tag': 'Finding'}, {'end': 71, 'start': 63, 'tag': 'DiseaseOrSyndrome'}, {'end': 85, 'start': 77, 'tag': 'CellFunction'}, {'end': 136, 'start': 104, 'tag': 'ResearchActivity'}]"
365,Results: 185 subjects were followed longitudinally for a mean (SD) 4.3 (2.8) years.,"[{'end': 82, 'start': 77, 'tag': 'TemporalConcept'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 21, 'start': 13, 'tag': 'PopulationGroup'}]"
366,59% of participants converted within the follow-up period and the median dementia-free survival time was 2.8 years.,"[{'end': 72, 'start': 66, 'tag': 'ResearchActivity'}, {'end': 114, 'start': 109, 'tag': 'TemporalConcept'}, {'end': 81, 'start': 73, 'tag': 'DiseaseOrSyndrome'}, {'end': 19, 'start': 7, 'tag': 'PopulationGroup'}, {'end': 57, 'start': 51, 'tag': 'TemporalConcept'}, {'end': 95, 'start': 87, 'tag': 'CellFunction'}, {'end': 50, 'start': 41, 'tag': 'HealthCareActivity'}, {'end': 50, 'start': 41, 'tag': 'TemporalConcept'}, {'end': 100, 'start': 96, 'tag': 'TemporalConcept'}]"
367,Each individual risk factor predicted conversion to dementia (HR 1.9-3.7).,"[{'end': 15, 'start': 5, 'tag': 'PopulationGroup'}, {'end': 15, 'start': 5, 'tag': 'OrganismAttribute'}, {'end': 48, 'start': 38, 'tag': 'Finding'}, {'end': 27, 'start': 16, 'tag': 'Finding'}, {'end': 60, 'start': 52, 'tag': 'DiseaseOrSyndrome'}]"
368,"The joint presence of any two risk factors increased risk for conversion (HR 7.1-11.0), with the presence of medial temporal atrophy and memory impairment showing the greatest risk for decline.","[{'end': 9, 'start': 4, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 18, 'start': 10, 'tag': 'Finding'}, {'end': 72, 'start': 62, 'tag': 'CellFunction'}, {'end': 105, 'start': 97, 'tag': 'Finding'}, {'end': 42, 'start': 30, 'tag': 'Finding'}, {'end': 154, 'start': 137, 'tag': 'DiseaseOrSyndrome'}, {'end': 132, 'start': 125, 'tag': 'PathologicFunction'}, {'end': 132, 'start': 125, 'tag': 'DiseaseOrSyndrome'}, {'end': 143, 'start': 137, 'tag': 'BiologicFunction'}, {'end': 124, 'start': 109, 'tag': 'BodyPartOrganOrOrganComponent'}]"
369,"Concordant atrophy, memory impairment, and abnormal CSF amyloid and tau was associated with the highest risk for conversion (HR 15.1).","[{'end': 71, 'start': 68, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 55, 'start': 52, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 63, 'start': 56, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 63, 'start': 56, 'tag': 'BiologicallyActiveSubstance'}, {'end': 71, 'start': 68, 'tag': 'BiologicallyActiveSubstance'}, {'end': 37, 'start': 20, 'tag': 'DiseaseOrSyndrome'}, {'end': 18, 'start': 11, 'tag': 'PathologicFunction'}, {'end': 18, 'start': 11, 'tag': 'DiseaseOrSyndrome'}, {'end': 63, 'start': 52, 'tag': 'ClinicalAttribute'}, {'end': 123, 'start': 104, 'tag': 'Finding'}, {'end': 71, 'start': 68, 'tag': 'ClinicalAttribute'}, {'end': 55, 'start': 52, 'tag': 'ClinicalAttribute'}]"
370,"The presence of medial temporal atrophy was associated with the shortest dementia-free survival time, both alone and in combination with memory impairment, abnormal CSF amyloid and tau, or both.","[{'end': 12, 'start': 4, 'tag': 'Finding'}, {'end': 164, 'start': 156, 'tag': 'Finding'}, {'end': 184, 'start': 181, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 168, 'start': 165, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 176, 'start': 169, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 176, 'start': 169, 'tag': 'BiologicallyActiveSubstance'}, {'end': 184, 'start': 181, 'tag': 'BiologicallyActiveSubstance'}, {'end': 81, 'start': 73, 'tag': 'DiseaseOrSyndrome'}, {'end': 95, 'start': 87, 'tag': 'CellFunction'}, {'end': 154, 'start': 137, 'tag': 'DiseaseOrSyndrome'}, {'end': 39, 'start': 32, 'tag': 'PathologicFunction'}, {'end': 39, 'start': 32, 'tag': 'DiseaseOrSyndrome'}, {'end': 100, 'start': 96, 'tag': 'TemporalConcept'}, {'end': 31, 'start': 16, 'tag': 'BodyPartOrganOrOrganComponent'}]"
371,"Conclusion: These results suggest that baseline biomarker-assisted predictions of decline to dementia are stable over the long term, and that combinations of complementary biomarkers can improve the accuracy of these predictions.","[{'end': 131, 'start': 122, 'tag': 'TemporalConcept'}, {'end': 182, 'start': 172, 'tag': 'ClinicalAttribute'}, {'end': 57, 'start': 48, 'tag': 'ClinicalAttribute'}, {'end': 101, 'start': 93, 'tag': 'DiseaseOrSyndrome'}, {'end': 207, 'start': 199, 'tag': 'Finding'}]"
372,PurposeThis study aimed to investigate the influence of 24-h ambulatory blood pressure (BP) on cognitive function and neuropathological biomarkers in patients with Alzheimer's disease (AD) at the stages of mild cognitive impairment (MCI) and dementia.,"[{'end': 86, 'start': 61, 'tag': 'Finding'}, {'end': 90, 'start': 88, 'tag': 'BiologicFunction'}, {'end': 202, 'start': 196, 'tag': 'TemporalConcept'}, {'end': 86, 'start': 72, 'tag': 'BiologicFunction'}, {'end': 183, 'start': 164, 'tag': 'DiseaseOrSyndrome'}, {'end': 187, 'start': 185, 'tag': 'DiseaseOrSyndrome'}, {'end': 158, 'start': 150, 'tag': 'PatientOrDisabledGroup'}, {'end': 250, 'start': 242, 'tag': 'DiseaseOrSyndrome'}, {'end': 146, 'start': 118, 'tag': 'ClinicalAttribute'}, {'end': 17, 'start': 12, 'tag': 'ResearchActivity'}, {'end': 236, 'start': 233, 'tag': 'DiseaseOrSyndrome'}, {'end': 231, 'start': 206, 'tag': 'DiseaseOrSyndrome'}, {'end': 113, 'start': 95, 'tag': 'BiologicFunction'}, {'end': 60, 'start': 56, 'tag': 'TemporalConcept'}]"
373,MethodsThe patients with AD were divided into the MCI (AD-MCI) group and the dementia (AD-D) group.,"[{'end': 27, 'start': 25, 'tag': 'DiseaseOrSyndrome'}, {'end': 57, 'start': 55, 'tag': 'DiseaseOrSyndrome'}, {'end': 89, 'start': 87, 'tag': 'DiseaseOrSyndrome'}, {'end': 19, 'start': 11, 'tag': 'PatientOrDisabledGroup'}, {'end': 85, 'start': 77, 'tag': 'DiseaseOrSyndrome'}, {'end': 53, 'start': 50, 'tag': 'DiseaseOrSyndrome'}, {'end': 61, 'start': 58, 'tag': 'DiseaseOrSyndrome'}, {'end': 68, 'start': 63, 'tag': 'PopulationGroup'}, {'end': 98, 'start': 93, 'tag': 'PopulationGroup'}]"
374,"Notably, 24-h BP variables, including BP level, coefficient of variation (CV) of BP, and pulse pressure, were collected and compared between the two groups.","[{'end': 16, 'start': 14, 'tag': 'BiologicFunction'}, {'end': 40, 'start': 38, 'tag': 'BiologicFunction'}, {'end': 83, 'start': 81, 'tag': 'BiologicFunction'}, {'end': 103, 'start': 89, 'tag': 'BiologicFunction'}, {'end': 155, 'start': 149, 'tag': 'PopulationGroup'}, {'end': 72, 'start': 48, 'tag': 'ResearchActivity'}, {'end': 13, 'start': 9, 'tag': 'TemporalConcept'}]"
375,The correlations between 24-h BP variables and the scores of cognitive domains were analyzed.,"[{'end': 32, 'start': 30, 'tag': 'BiologicFunction'}, {'end': 57, 'start': 51, 'tag': 'Finding'}, {'end': 16, 'start': 4, 'tag': 'ResearchActivity'}, {'end': 92, 'start': 84, 'tag': 'ResearchActivity'}, {'end': 29, 'start': 25, 'tag': 'TemporalConcept'}, {'end': 78, 'start': 61, 'tag': 'Finding'}]"
376,The independent influencing factors of cognitive domains of patients with AD were investigated.,"[{'end': 76, 'start': 74, 'tag': 'DiseaseOrSyndrome'}, {'end': 68, 'start': 60, 'tag': 'PatientOrDisabledGroup'}, {'end': 56, 'start': 39, 'tag': 'Finding'}, {'end': 35, 'start': 4, 'tag': 'Finding'}]"
377,"The levels of neuropathological biomarkers of AD, including beta amyloid (A beta)(1-42), phosphorylated tau (P-tau), and total tau (T-tau), in cerebrospinal fluid (CSF) were measured and compared between the two groups, and the correlations between 24-h BP variables and the levels of neuropathological biomarkers of AD were analyzed.","[{'end': 72, 'start': 60, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 256, 'start': 254, 'tag': 'BiologicFunction'}, {'end': 137, 'start': 132, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 137, 'start': 132, 'tag': 'BiologicallyActiveSubstance'}, {'end': 114, 'start': 109, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 114, 'start': 109, 'tag': 'BiologicallyActiveSubstance'}, {'end': 167, 'start': 164, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 48, 'start': 46, 'tag': 'DiseaseOrSyndrome'}, {'end': 319, 'start': 317, 'tag': 'DiseaseOrSyndrome'}, {'end': 162, 'start': 143, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 130, 'start': 121, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 130, 'start': 121, 'tag': 'BiologicallyActiveSubstance'}, {'end': 107, 'start': 89, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 107, 'start': 89, 'tag': 'BiologicallyActiveSubstance'}, {'end': 42, 'start': 14, 'tag': 'ClinicalAttribute'}, {'end': 313, 'start': 285, 'tag': 'ClinicalAttribute'}, {'end': 218, 'start': 212, 'tag': 'PopulationGroup'}, {'end': 80, 'start': 74, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 240, 'start': 228, 'tag': 'ResearchActivity'}, {'end': 253, 'start': 249, 'tag': 'TemporalConcept'}]"
378,ResultsDaytime CV of systolic BP (SBP) was significantly increased in the AD-D group compared to that in the AD-MCI group.,"[{'end': 32, 'start': 21, 'tag': 'ClinicalAttribute'}, {'end': 37, 'start': 34, 'tag': 'ClinicalAttribute'}, {'end': 76, 'start': 74, 'tag': 'DiseaseOrSyndrome'}, {'end': 111, 'start': 109, 'tag': 'DiseaseOrSyndrome'}, {'end': 66, 'start': 43, 'tag': 'Finding'}, {'end': 115, 'start': 112, 'tag': 'DiseaseOrSyndrome'}, {'end': 84, 'start': 79, 'tag': 'PopulationGroup'}, {'end': 121, 'start': 116, 'tag': 'PopulationGroup'}, {'end': 14, 'start': 7, 'tag': 'TemporalConcept'}]"
379,The 24-h and daytime CV of SBP and ambulatory pulse pressure were significantly and negatively correlated with memory score.,"[{'end': 20, 'start': 13, 'tag': 'TemporalConcept'}, {'end': 30, 'start': 27, 'tag': 'ClinicalAttribute'}, {'end': 123, 'start': 118, 'tag': 'Finding'}, {'end': 117, 'start': 111, 'tag': 'BiologicFunction'}, {'end': 60, 'start': 35, 'tag': 'BiologicFunction'}, {'end': 8, 'start': 4, 'tag': 'TemporalConcept'}]"
380,"The average 24-h and average daytime SBP level and CV of SBP, daytime CV of diastolic BP (DBP), and 24-h, daytime, and night-time ambulatory pulse pressure were significantly and negatively correlated with language score.","[{'end': 40, 'start': 37, 'tag': 'ClinicalAttribute'}, {'end': 60, 'start': 57, 'tag': 'ClinicalAttribute'}, {'end': 93, 'start': 90, 'tag': 'ClinicalAttribute'}, {'end': 113, 'start': 106, 'tag': 'TemporalConcept'}, {'end': 220, 'start': 215, 'tag': 'Finding'}, {'end': 129, 'start': 125, 'tag': 'TemporalConcept'}, {'end': 16, 'start': 12, 'tag': 'TemporalConcept'}, {'end': 104, 'start': 100, 'tag': 'TemporalConcept'}, {'end': 36, 'start': 29, 'tag': 'TemporalConcept'}, {'end': 65, 'start': 64, 'tag': 'TemporalConcept'}, {'end': 88, 'start': 76, 'tag': 'ClinicalAttribute'}, {'end': 155, 'start': 130, 'tag': 'BiologicFunction'}, {'end': 214, 'start': 206, 'tag': 'BiologicFunction'}]"
381,"The average 24-h SBP level, daytime CV of SBP, and 24-h, daytime, and night-time ambulatory pulse pressure were significantly and negatively correlated with attention score.","[{'end': 20, 'start': 17, 'tag': 'ClinicalAttribute'}, {'end': 45, 'start': 42, 'tag': 'ClinicalAttribute'}, {'end': 64, 'start': 57, 'tag': 'TemporalConcept'}, {'end': 166, 'start': 157, 'tag': 'BiologicFunction'}, {'end': 172, 'start': 167, 'tag': 'Finding'}, {'end': 80, 'start': 76, 'tag': 'TemporalConcept'}, {'end': 106, 'start': 81, 'tag': 'BiologicFunction'}, {'end': 16, 'start': 12, 'tag': 'TemporalConcept'}, {'end': 55, 'start': 51, 'tag': 'TemporalConcept'}, {'end': 35, 'start': 28, 'tag': 'TemporalConcept'}, {'end': 75, 'start': 70, 'tag': 'TemporalConcept'}]"
382,Further analysis indicated that daytime CV of SBP as well as age and course of disease were the independent influencing factors of language.,"[{'end': 39, 'start': 32, 'tag': 'TemporalConcept'}, {'end': 49, 'start': 46, 'tag': 'ClinicalAttribute'}, {'end': 64, 'start': 61, 'tag': 'OrganismAttribute'}, {'end': 16, 'start': 8, 'tag': 'ResearchActivity'}, {'end': 75, 'start': 69, 'tag': 'TemporalConcept'}, {'end': 127, 'start': 96, 'tag': 'Finding'}, {'end': 139, 'start': 131, 'tag': 'BiologicFunction'}]"
383,Age was also the independent influencing factor of memory and attention of patients with AD.,"[{'end': 71, 'start': 62, 'tag': 'BiologicFunction'}, {'end': 3, 'start': 0, 'tag': 'OrganismAttribute'}, {'end': 91, 'start': 89, 'tag': 'DiseaseOrSyndrome'}, {'end': 83, 'start': 75, 'tag': 'PatientOrDisabledGroup'}, {'end': 57, 'start': 51, 'tag': 'BiologicFunction'}, {'end': 47, 'start': 17, 'tag': 'Finding'}]"
384,"T-tau level in CSF in the AD-D group was significantly higher than that in the AD-MCI group, but the levels of A beta(1-42), P-tau, and T-tau in CSF were not correlated with 24-h ambulatory BP variables.","[{'end': 5, 'start': 0, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 141, 'start': 136, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 5, 'start': 0, 'tag': 'BiologicallyActiveSubstance'}, {'end': 141, 'start': 136, 'tag': 'BiologicallyActiveSubstance'}, {'end': 85, 'start': 79, 'tag': 'DiseaseOrSyndrome'}, {'end': 130, 'start': 125, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 130, 'start': 125, 'tag': 'BiologicallyActiveSubstance'}, {'end': 18, 'start': 15, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 148, 'start': 145, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 28, 'start': 26, 'tag': 'DiseaseOrSyndrome'}, {'end': 81, 'start': 79, 'tag': 'DiseaseOrSyndrome'}, {'end': 85, 'start': 82, 'tag': 'DiseaseOrSyndrome'}, {'end': 36, 'start': 31, 'tag': 'PopulationGroup'}, {'end': 91, 'start': 86, 'tag': 'PopulationGroup'}, {'end': 123, 'start': 111, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 192, 'start': 179, 'tag': 'BiologicFunction'}, {'end': 178, 'start': 174, 'tag': 'TemporalConcept'}, {'end': 123, 'start': 111, 'tag': 'BiologicallyActiveSubstance'}]"
385,ConclusionDaytime CV of SBP was the independent influencing factor of language in patients with AD.,"[{'end': 27, 'start': 24, 'tag': 'ClinicalAttribute'}, {'end': 98, 'start': 96, 'tag': 'DiseaseOrSyndrome'}, {'end': 90, 'start': 82, 'tag': 'PatientOrDisabledGroup'}, {'end': 17, 'start': 10, 'tag': 'TemporalConcept'}, {'end': 66, 'start': 36, 'tag': 'Finding'}, {'end': 78, 'start': 70, 'tag': 'BiologicFunction'}]"
386,"The AD-D patients had significantly severe neurodegeneration than AD-MCI patients, which was, however, not through the influence of 24-h ambulatory BP variables on neuropathological biomarkers of AD.","[{'end': 68, 'start': 66, 'tag': 'DiseaseOrSyndrome'}, {'end': 6, 'start': 4, 'tag': 'DiseaseOrSyndrome'}, {'end': 198, 'start': 196, 'tag': 'DiseaseOrSyndrome'}, {'end': 17, 'start': 9, 'tag': 'PatientOrDisabledGroup'}, {'end': 81, 'start': 73, 'tag': 'PatientOrDisabledGroup'}, {'end': 192, 'start': 164, 'tag': 'ClinicalAttribute'}, {'end': 60, 'start': 43, 'tag': 'CellOrMolecularDysfunction'}, {'end': 42, 'start': 36, 'tag': 'Finding'}, {'end': 150, 'start': 137, 'tag': 'BiologicFunction'}, {'end': 136, 'start': 132, 'tag': 'TemporalConcept'}, {'end': 72, 'start': 69, 'tag': 'DiseaseOrSyndrome'}]"
387,"The aim of our study was to establish empirically to what extent reduced glucose uptake in the precuneus, posterior cingulate and/or temporo-parietal cortex (PCTP), which is thought to indicate brain amyloidosis in patients with dementia or MCI due to Alzheimer's Disease (AD), permits to distinguish amyloid-positive from amyloid-negative patients with non-classical AD phenotypes at the single-case level.","[{'end': 87, 'start': 73, 'tag': 'CellFunction'}, {'end': 125, 'start': 106, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 211, 'start': 194, 'tag': 'DiseaseOrSyndrome'}, {'end': 400, 'start': 389, 'tag': 'ResearchActivity'}, {'end': 80, 'start': 73, 'tag': 'Chemical'}, {'end': 80, 'start': 73, 'tag': 'PharmacologicSubstance'}, {'end': 80, 'start': 73, 'tag': 'BiologicallyActiveSubstance'}, {'end': 381, 'start': 371, 'tag': 'OrganismAttribute'}, {'end': 87, 'start': 73, 'tag': 'BiologicFunction'}, {'end': 308, 'start': 301, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 330, 'start': 323, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 308, 'start': 301, 'tag': 'BiologicallyActiveSubstance'}, {'end': 330, 'start': 323, 'tag': 'BiologicallyActiveSubstance'}, {'end': 275, 'start': 273, 'tag': 'DiseaseOrSyndrome'}, {'end': 370, 'start': 368, 'tag': 'DiseaseOrSyndrome'}, {'end': 271, 'start': 252, 'tag': 'DiseaseOrSyndrome'}, {'end': 237, 'start': 229, 'tag': 'DiseaseOrSyndrome'}, {'end': 223, 'start': 215, 'tag': 'PatientOrDisabledGroup'}, {'end': 348, 'start': 340, 'tag': 'PatientOrDisabledGroup'}, {'end': 20, 'start': 15, 'tag': 'ResearchActivity'}, {'end': 244, 'start': 241, 'tag': 'DiseaseOrSyndrome'}, {'end': 400, 'start': 396, 'tag': 'ManufacturedObject'}, {'end': 104, 'start': 95, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 156, 'start': 133, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 162, 'start': 158, 'tag': 'BodyPartOrganOrOrganComponent'}]"
388,We enrolled 127 neurodegenerative patients with cognitive impairment and a positive (n.,"[{'end': 68, 'start': 48, 'tag': 'DiseaseOrSyndrome'}, {'end': 42, 'start': 16, 'tag': 'PatientOrDisabledGroup'}]"
389,63) or negative (n.,[]
390,64) amyloid marker (cerebrospinal fluid or amy-PET).,"[{'end': 11, 'start': 4, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 11, 'start': 4, 'tag': 'BiologicallyActiveSubstance'}, {'end': 39, 'start': 20, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 50, 'start': 43, 'tag': 'HealthCareActivity'}, {'end': 18, 'start': 12, 'tag': 'ClinicalAttribute'}]"
391,"Three rating methods of FDG-PET scan were applied: purely qualitative visual interpretation of uptake images (VIUI), and visual reading assisted by a semi-automated and semi-quantitative tool: INLAB, provided by the Italian National Research Council, or Cortex ID Suite, marketed by GE Healthcare.","[{'end': 31, 'start': 24, 'tag': 'HealthCareActivity'}, {'end': 296, 'start': 283, 'tag': 'HealthCareActivity'}, {'end': 36, 'start': 32, 'tag': 'HealthCareActivity'}, {'end': 249, 'start': 216, 'tag': 'HealthCareRelatedOrganization'}, {'end': 108, 'start': 70, 'tag': 'HealthCareActivity'}, {'end': 114, 'start': 110, 'tag': 'HealthCareActivity'}, {'end': 191, 'start': 150, 'tag': 'ResearchActivity'}, {'end': 198, 'start': 193, 'tag': 'ResearchActivity'}, {'end': 269, 'start': 254, 'tag': 'ResearchActivity'}]"
392,"Fourteen scans (11.0%) patients remained unclassified by VIUI or INLAB procedures, therefore, validity values were computed on the remaining 113 cases.","[{'end': 14, 'start': 9, 'tag': 'HealthCareActivity'}, {'end': 102, 'start': 94, 'tag': 'Finding'}, {'end': 31, 'start': 23, 'tag': 'PatientOrDisabledGroup'}, {'end': 61, 'start': 57, 'tag': 'ResearchActivity'}, {'end': 70, 'start': 65, 'tag': 'ResearchActivity'}]"
393,"The three rating approaches showed good total accuracy (77-78%), good to optimal sensitivity (81-93%), but poorer specificity (62-75%).","[{'end': 92, 'start': 81, 'tag': 'Finding'}, {'end': 125, 'start': 114, 'tag': 'Finding'}, {'end': 54, 'start': 46, 'tag': 'Finding'}]"
394,"VIUI showed the highest sensitivity and the lowest specificity, and also the highest proportion of unclassified cases.","[{'end': 35, 'start': 24, 'tag': 'Finding'}, {'end': 62, 'start': 51, 'tag': 'Finding'}]"
395,"Cases with asymmetric temporo-parietal hypometabolism and a progressive aphasia or corticobasal clinical profile, in particular, tended to be rated as AD-like, even if biomarkers indicated non-amyloid pathology.","[{'end': 79, 'start': 60, 'tag': 'DiseaseOrSyndrome'}, {'end': 210, 'start': 189, 'tag': 'PathologicFunction'}, {'end': 112, 'start': 96, 'tag': 'ClinicalAttribute'}, {'end': 200, 'start': 193, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 200, 'start': 193, 'tag': 'BiologicallyActiveSubstance'}, {'end': 153, 'start': 151, 'tag': 'DiseaseOrSyndrome'}, {'end': 178, 'start': 168, 'tag': 'ClinicalAttribute'}, {'end': 95, 'start': 83, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 53, 'start': 11, 'tag': 'Finding'}]"
396,"Our findings provide formal support to the value of PCTP hypometabolism for single-level diagnosis of amyloid pathophysiology in atypical AD, but also highlight the risk of qualitative assessment to misclassify patients with non-AD PPA or CBS underpinned by asymmetric temporo-parietal hypometabolism.","[{'end': 71, 'start': 52, 'tag': 'Finding'}, {'end': 242, 'start': 239, 'tag': 'GeneOrGenome'}, {'end': 109, 'start': 102, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 109, 'start': 102, 'tag': 'BiologicallyActiveSubstance'}, {'end': 140, 'start': 138, 'tag': 'DiseaseOrSyndrome'}, {'end': 231, 'start': 229, 'tag': 'DiseaseOrSyndrome'}, {'end': 98, 'start': 89, 'tag': 'HealthCareActivity'}, {'end': 137, 'start': 129, 'tag': 'Finding'}, {'end': 219, 'start': 211, 'tag': 'PatientOrDisabledGroup'}, {'end': 125, 'start': 110, 'tag': 'PathologicFunction'}, {'end': 125, 'start': 110, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 195, 'start': 185, 'tag': 'HealthCareActivity'}, {'end': 195, 'start': 185, 'tag': 'ResearchActivity'}, {'end': 300, 'start': 258, 'tag': 'Finding'}]"
397,"Background: Vascular risk factors promote cerebral small vessel disease and neuropathological changes, particularly in white matter where large-caliber axons are located.","[{'end': 71, 'start': 42, 'tag': 'DiseaseOrSyndrome'}, {'end': 157, 'start': 138, 'tag': 'CellComponent'}, {'end': 33, 'start': 21, 'tag': 'Finding'}, {'end': 131, 'start': 119, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 101, 'start': 76, 'tag': 'Finding'}, {'end': 20, 'start': 12, 'tag': 'BodyPartOrganOrOrganComponent'}]"
398,How Alzheimer's disease pathology influences the brain's vulnerability in this regard is not well understood.,"[{'end': 70, 'start': 57, 'tag': 'ClinicalAttribute'}, {'end': 33, 'start': 16, 'tag': 'PathologicFunction'}, {'end': 23, 'start': 4, 'tag': 'DiseaseOrSyndrome'}, {'end': 54, 'start': 49, 'tag': 'BodyPartOrganOrOrganComponent'}]"
399,"Objective: Systemic vascular risk was assessed in relation to cerebrospinal fluid concentrations of neurofilament light, a biomarker of large-caliber axonal injury, evaluating for interactions by clinical and protein markers of Alzheimer's disease.","[{'end': 119, 'start': 100, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 119, 'start': 100, 'tag': 'BiologicallyActiveSubstance'}, {'end': 96, 'start': 82, 'tag': 'BiologicFunction'}, {'end': 163, 'start': 157, 'tag': 'InjuryOrPoisoning'}, {'end': 28, 'start': 20, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 192, 'start': 180, 'tag': 'Finding'}, {'end': 247, 'start': 228, 'tag': 'DiseaseOrSyndrome'}, {'end': 132, 'start': 123, 'tag': 'ClinicalAttribute'}, {'end': 81, 'start': 62, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 224, 'start': 217, 'tag': 'ClinicalAttribute'}, {'end': 156, 'start': 136, 'tag': 'CellComponent'}, {'end': 33, 'start': 29, 'tag': 'Finding'}]"
400,"Methods: Among Alzheimer's Disease Neuroimaging Initiative participants with normal cognition (n = 117), mild cognitive impairment (n = 190), and Alzheimer's disease (n = 95), linear regression related vascular risk (as measured by the modified Framingham Stroke Risk Profile) to neurofilament light, adjusting for age, sex, education, and cognitive diagnosis.","[{'end': 299, 'start': 280, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 299, 'start': 280, 'tag': 'BiologicallyActiveSubstance'}, {'end': 83, 'start': 77, 'tag': 'Finding'}, {'end': 58, 'start': 15, 'tag': 'ResearchActivity'}, {'end': 58, 'start': 15, 'tag': 'HealthCareRelatedOrganization'}, {'end': 210, 'start': 202, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 323, 'start': 320, 'tag': 'OrganismAttribute'}, {'end': 93, 'start': 77, 'tag': 'Finding'}, {'end': 193, 'start': 176, 'tag': 'ResearchActivity'}, {'end': 165, 'start': 146, 'tag': 'DiseaseOrSyndrome'}, {'end': 71, 'start': 59, 'tag': 'PopulationGroup'}, {'end': 130, 'start': 110, 'tag': 'DiseaseOrSyndrome'}, {'end': 34, 'start': 15, 'tag': 'DiseaseOrSyndrome'}, {'end': 359, 'start': 340, 'tag': 'HealthCareActivity'}, {'end': 318, 'start': 315, 'tag': 'OrganismAttribute'}, {'end': 93, 'start': 84, 'tag': 'BiologicFunction'}, {'end': 130, 'start': 105, 'tag': 'DiseaseOrSyndrome'}, {'end': 334, 'start': 325, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 109, 'start': 105, 'tag': 'Finding'}, {'end': 215, 'start': 211, 'tag': 'Finding'}, {'end': 275, 'start': 236, 'tag': 'HealthCareActivity'}]"
401,"Interactions were assessed by cognitive diagnosis, and by cerebrospinal fluid markers of A beta(42), hyperphosphorylated tau, and total tau.","[{'end': 124, 'start': 101, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 124, 'start': 101, 'tag': 'BiologicallyActiveSubstance'}, {'end': 77, 'start': 58, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 139, 'start': 130, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 139, 'start': 130, 'tag': 'BiologicallyActiveSubstance'}, {'end': 49, 'start': 30, 'tag': 'HealthCareActivity'}, {'end': 99, 'start': 89, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 85, 'start': 78, 'tag': 'ClinicalAttribute'}, {'end': 99, 'start': 89, 'tag': 'BiologicallyActiveSubstance'}, {'end': 12, 'start': 0, 'tag': 'Finding'}]"
402,Results: Vascular risk and neurofilament light were not related in the main effect model (p = 0.08).,"[{'end': 46, 'start': 27, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 46, 'start': 27, 'tag': 'BiologicallyActiveSubstance'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 88, 'start': 71, 'tag': 'ResearchActivity'}, {'end': 17, 'start': 9, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 22, 'start': 18, 'tag': 'Finding'}]"
403,"However, interactions emerged for total tau (p = 0.01) and hyperphosphorylated tau (p = 0.002) reflecting vascular risk becoming more associated with cerebrospinal fluid neurofilament light in the context of greater concentrations of tau biomarkers.","[{'end': 189, 'start': 170, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 189, 'start': 170, 'tag': 'BiologicallyActiveSubstance'}, {'end': 230, 'start': 216, 'tag': 'BiologicFunction'}, {'end': 114, 'start': 106, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 82, 'start': 59, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 82, 'start': 59, 'tag': 'BiologicallyActiveSubstance'}, {'end': 21, 'start': 9, 'tag': 'Finding'}, {'end': 237, 'start': 234, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 237, 'start': 234, 'tag': 'BiologicallyActiveSubstance'}, {'end': 169, 'start': 150, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 43, 'start': 34, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 43, 'start': 34, 'tag': 'BiologicallyActiveSubstance'}, {'end': 248, 'start': 238, 'tag': 'ClinicalAttribute'}, {'end': 119, 'start': 115, 'tag': 'Finding'}]"
404,"An interaction also emerged for the Alzheimer's disease biomarker profiles (p = 0.046) where in comparison to the referent 'normal' biomarker group, individuals with abnormal levels of both A beta(42) and total tau showed stronger associations between vascular risk and neurofilament light.","[{'end': 289, 'start': 270, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 289, 'start': 270, 'tag': 'BiologicallyActiveSubstance'}, {'end': 130, 'start': 124, 'tag': 'Finding'}, {'end': 260, 'start': 252, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 174, 'start': 166, 'tag': 'Finding'}, {'end': 106, 'start': 96, 'tag': 'ResearchActivity'}, {'end': 181, 'start': 166, 'tag': 'Finding'}, {'end': 55, 'start': 36, 'tag': 'DiseaseOrSyndrome'}, {'end': 65, 'start': 56, 'tag': 'ClinicalAttribute'}, {'end': 141, 'start': 132, 'tag': 'ClinicalAttribute'}, {'end': 214, 'start': 205, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 214, 'start': 205, 'tag': 'BiologicallyActiveSubstance'}, {'end': 160, 'start': 149, 'tag': 'PopulationGroup'}, {'end': 147, 'start': 142, 'tag': 'PopulationGroup'}, {'end': 200, 'start': 190, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 74, 'start': 66, 'tag': 'ResearchActivity'}, {'end': 200, 'start': 190, 'tag': 'BiologicallyActiveSubstance'}, {'end': 265, 'start': 261, 'tag': 'Finding'}]"
405,Conclusion: Older adults may be more vulnerable to axonal injury in response to higher vascular risk burdens in the context of concomitant Alzheimer's disease pathology.,"[{'end': 138, 'start': 127, 'tag': 'TemporalConcept'}, {'end': 64, 'start': 58, 'tag': 'InjuryOrPoisoning'}, {'end': 95, 'start': 87, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 24, 'start': 12, 'tag': 'PopulationGroup'}, {'end': 168, 'start': 151, 'tag': 'PathologicFunction'}, {'end': 158, 'start': 139, 'tag': 'DiseaseOrSyndrome'}, {'end': 57, 'start': 51, 'tag': 'CellComponent'}, {'end': 100, 'start': 96, 'tag': 'Finding'}]"
406,"The core Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers; amyloid-beta (Ass), total tau (t-tau), and phosphorylated tau (p-tau181), are strong indicators of the presence of AD pathology, but do not correlate well with disease progression, and can be difficult to implement in longitudinal studies where repeat biofluid sampling is required.","[{'end': 310, 'start': 290, 'tag': 'ResearchActivity'}, {'end': 28, 'start': 9, 'tag': 'DiseaseOrSyndrome'}, {'end': 84, 'start': 72, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 58, 'start': 55, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 199, 'start': 190, 'tag': 'PathologicFunction'}, {'end': 199, 'start': 190, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 32, 'start': 30, 'tag': 'DiseaseOrSyndrome'}, {'end': 189, 'start': 187, 'tag': 'DiseaseOrSyndrome'}, {'end': 53, 'start': 34, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 251, 'start': 240, 'tag': 'PathologicFunction'}, {'end': 251, 'start': 240, 'tag': 'TemporalConcept'}, {'end': 143, 'start': 135, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 143, 'start': 135, 'tag': 'BiologicallyActiveSubstance'}, {'end': 70, 'start': 60, 'tag': 'ClinicalAttribute'}, {'end': 101, 'start': 92, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 101, 'start': 92, 'tag': 'BiologicallyActiveSubstance'}, {'end': 133, 'start': 115, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 133, 'start': 115, 'tag': 'BiologicallyActiveSubstance'}, {'end': 108, 'start': 103, 'tag': 'BiologicallyActiveSubstance'}, {'end': 108, 'start': 103, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 183, 'start': 175, 'tag': 'Finding'}, {'end': 251, 'start': 232, 'tag': 'PathologicFunction'}, {'end': 341, 'start': 333, 'tag': 'HealthCareActivity'}, {'end': 332, 'start': 324, 'tag': 'BodyPartOrganOrOrganComponent'}]"
407,"As a result, blood-based biomarkers are increasingly being sought as alternatives.","[{'end': 35, 'start': 25, 'tag': 'ClinicalAttribute'}, {'end': 11, 'start': 5, 'tag': 'Finding'}, {'end': 18, 'start': 13, 'tag': 'BodyPartOrganOrOrganComponent'}]"
408,"In this study, we aimed to evaluate a promising blood biomarker discovery technology, Olink Proximity Extension Assays for technical reproducibility characteristics in order to highlight the advantages and disadvantages of using this technology in biomarker discovery in AD.","[{'end': 73, 'start': 64, 'tag': 'ResearchActivity'}, {'end': 267, 'start': 258, 'tag': 'ResearchActivity'}, {'end': 273, 'start': 271, 'tag': 'DiseaseOrSyndrome'}, {'end': 63, 'start': 54, 'tag': 'ClinicalAttribute'}, {'end': 257, 'start': 248, 'tag': 'ClinicalAttribute'}, {'end': 13, 'start': 8, 'tag': 'ResearchActivity'}, {'end': 53, 'start': 48, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 118, 'start': 86, 'tag': 'ResearchActivity'}]"
409,We evaluated the performance of five Olink Proteomic multiplex proximity extension assays (PEA) in plasma samples.,"[{'end': 105, 'start': 99, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 28, 'start': 17, 'tag': 'Finding'}, {'end': 89, 'start': 37, 'tag': 'ResearchActivity'}]"
410,Three technical control samples included on each plate allowed calculation of technical variability.,"[{'end': 54, 'start': 49, 'tag': 'ManufacturedObject'}, {'end': 99, 'start': 88, 'tag': 'Finding'}, {'end': 23, 'start': 16, 'tag': 'PopulationGroup'}]"
411,Biotemporal stability was measured in three sequential annual samples from 54 individuals with and without AD.,"[{'end': 61, 'start': 55, 'tag': 'TemporalConcept'}, {'end': 109, 'start': 107, 'tag': 'DiseaseOrSyndrome'}, {'end': 89, 'start': 78, 'tag': 'PopulationGroup'}]"
412,"Coefficients of variation (CVs), analysis of variance (ANOVA), and variance component analyses were used to quantify technical and individual variation over time.","[{'end': 30, 'start': 27, 'tag': 'ResearchActivity'}, {'end': 60, 'start': 55, 'tag': 'ResearchActivity'}, {'end': 53, 'start': 33, 'tag': 'ResearchActivity'}, {'end': 161, 'start': 157, 'tag': 'TemporalConcept'}, {'end': 94, 'start': 67, 'tag': 'ResearchActivity'}, {'end': 141, 'start': 131, 'tag': 'PopulationGroup'}, {'end': 141, 'start': 131, 'tag': 'OrganismAttribute'}, {'end': 25, 'start': 0, 'tag': 'ResearchActivity'}]"
413,"We show that overall, Olink assays are technically robust, with the largest experimental variation stemming from biological differences between individuals for most analytes.","[{'end': 173, 'start': 165, 'tag': 'Substance'}, {'end': 155, 'start': 144, 'tag': 'PopulationGroup'}, {'end': 135, 'start': 124, 'tag': 'Finding'}, {'end': 34, 'start': 22, 'tag': 'ResearchActivity'}, {'end': 98, 'start': 76, 'tag': 'ResearchActivity'}]"
414,"As a powerful illustration of one of the potential pitfalls of using a multi-plexed technology for discovery, we performed power calculations using the baseline samples to demonstrate the size of study required to overcome the need for multiple test correction with this technology.","[{'end': 108, 'start': 71, 'tag': 'ResearchActivity'}, {'end': 201, 'start': 196, 'tag': 'ResearchActivity'}, {'end': 260, 'start': 245, 'tag': 'ResearchActivity'}, {'end': 192, 'start': 188, 'tag': 'OrganismAttribute'}]"
415,"We show that the power of moderate effect size proteins was strongly reduced, and as a result investigators should strongly consider pooling resources to perform larger studies using this multiplexed technique where possible.","[{'end': 93, 'start': 87, 'tag': 'Finding'}, {'end': 55, 'start': 47, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 176, 'start': 169, 'tag': 'ResearchActivity'}, {'end': 209, 'start': 188, 'tag': 'ResearchActivity'}, {'end': 46, 'start': 35, 'tag': 'ResearchActivity'}]"
416,Intraindividual variability (IIV) across neuropsychological measures within a single testing session is a promising marker predictive of cognitive decline and development of Alzheimer's disease (AD).,"[{'end': 100, 'start': 85, 'tag': 'HealthCareActivity'}, {'end': 193, 'start': 174, 'tag': 'DiseaseOrSyndrome'}, {'end': 197, 'start': 195, 'tag': 'DiseaseOrSyndrome'}, {'end': 170, 'start': 159, 'tag': 'BiologicFunction'}, {'end': 170, 'start': 159, 'tag': 'CellFunction'}, {'end': 154, 'start': 137, 'tag': 'DiseaseOrSyndrome'}, {'end': 122, 'start': 116, 'tag': 'ClinicalAttribute'}, {'end': 68, 'start': 41, 'tag': 'HealthCareActivity'}, {'end': 27, 'start': 0, 'tag': 'ClinicalAttribute'}, {'end': 32, 'start': 29, 'tag': 'ClinicalAttribute'}]"
417,"We have previously shown that greater IIV is cross-sectionally associated with reduced cerebral blood flow (CBF), but not with cortical thickness or brain volume, in older adults without dementia who were amyloid beta (A beta) positive.","[{'end': 111, 'start': 108, 'tag': 'BiologicFunction'}, {'end': 217, 'start': 205, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 212, 'start': 205, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 212, 'start': 205, 'tag': 'BiologicallyActiveSubstance'}, {'end': 195, 'start': 187, 'tag': 'DiseaseOrSyndrome'}, {'end': 178, 'start': 172, 'tag': 'PopulationGroup'}, {'end': 171, 'start': 166, 'tag': 'TemporalConcept'}, {'end': 106, 'start': 87, 'tag': 'BiologicFunction'}, {'end': 101, 'start': 96, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 225, 'start': 219, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 178, 'start': 166, 'tag': 'PopulationGroup'}, {'end': 135, 'start': 127, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 145, 'start': 127, 'tag': 'ClinicalAttribute'}, {'end': 161, 'start': 149, 'tag': 'ClinicalAttribute'}, {'end': 41, 'start': 38, 'tag': 'ClinicalAttribute'}]"
418,"However, there is little known about the association between change in IIV and CBF over time.","[{'end': 82, 'start': 79, 'tag': 'BiologicFunction'}, {'end': 92, 'start': 88, 'tag': 'TemporalConcept'}, {'end': 74, 'start': 71, 'tag': 'ClinicalAttribute'}]"
419,"Therefore, we examined 12-month longitudinal change in IIV and interactions of IIV and AD biomarker status on changes in regional CBF.","[{'end': 133, 'start': 130, 'tag': 'BiologicFunction'}, {'end': 75, 'start': 63, 'tag': 'Finding'}, {'end': 89, 'start': 87, 'tag': 'DiseaseOrSyndrome'}, {'end': 99, 'start': 90, 'tag': 'ClinicalAttribute'}, {'end': 106, 'start': 100, 'tag': 'Finding'}, {'end': 51, 'start': 32, 'tag': 'ResearchActivity'}, {'end': 58, 'start': 55, 'tag': 'ClinicalAttribute'}, {'end': 82, 'start': 79, 'tag': 'ClinicalAttribute'}]"
420,Fifty-three non-demented Alzheimer's Disease Neuroimaging Initiative (ADNI) participants underwent lumbar puncture to obtain cerebrospinal fluid (CSF) at baseline and neuropsychological testing and magnetic resonance imaging (MRI) exams at baseline and 12-month follow-up evaluation.,"[{'end': 193, 'start': 167, 'tag': 'HealthCareActivity'}, {'end': 149, 'start': 146, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 88, 'start': 76, 'tag': 'PopulationGroup'}, {'end': 114, 'start': 99, 'tag': 'HealthCareActivity'}, {'end': 224, 'start': 217, 'tag': 'HealthCareActivity'}, {'end': 144, 'start': 125, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 229, 'start': 226, 'tag': 'HealthCareActivity'}, {'end': 271, 'start': 262, 'tag': 'HealthCareActivity'}, {'end': 271, 'start': 262, 'tag': 'TemporalConcept'}, {'end': 144, 'start': 139, 'tag': 'Substance'}, {'end': 44, 'start': 25, 'tag': 'DiseaseOrSyndrome'}, {'end': 68, 'start': 25, 'tag': 'ResearchActivity'}, {'end': 282, 'start': 272, 'tag': 'HealthCareActivity'}, {'end': 282, 'start': 272, 'tag': 'ResearchActivity'}, {'end': 24, 'start': 16, 'tag': 'DiseaseOrSyndrome'}, {'end': 224, 'start': 198, 'tag': 'HealthCareActivity'}, {'end': 224, 'start': 198, 'tag': 'ManufacturedObject'}, {'end': 68, 'start': 25, 'tag': 'HealthCareRelatedOrganization'}, {'end': 74, 'start': 70, 'tag': 'HealthCareRelatedOrganization'}, {'end': 74, 'start': 70, 'tag': 'ResearchActivity'}]"
421,IIV was calculated as the intraindividual standard deviation across 6 demographically-corrected neuropsychological measures.,"[{'end': 41, 'start': 26, 'tag': 'PopulationGroup'}, {'end': 60, 'start': 42, 'tag': 'ResearchActivity'}, {'end': 3, 'start': 0, 'tag': 'ClinicalAttribute'}, {'end': 123, 'start': 96, 'tag': 'HealthCareActivity'}]"
422,Pulsed arterial spin labeling (ASL) MRI was acquired to quantify CBF and FreeSurfer-derived a priori CBF regions of interest (ROIs) were examined.,"[{'end': 68, 'start': 65, 'tag': 'BiologicFunction'}, {'end': 104, 'start': 101, 'tag': 'BiologicFunction'}, {'end': 39, 'start': 0, 'tag': 'HealthCareActivity'}, {'end': 130, 'start': 126, 'tag': 'ResearchActivity'}, {'end': 124, 'start': 105, 'tag': 'ResearchActivity'}]"
423,AD biomarker positivity was determined using a published CSF p-tau/A beta ratio cut-score.,"[{'end': 23, 'start': 13, 'tag': 'ResearchActivity'}, {'end': 66, 'start': 63, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 60, 'start': 57, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 66, 'start': 63, 'tag': 'BiologicallyActiveSubstance'}, {'end': 2, 'start': 0, 'tag': 'DiseaseOrSyndrome'}, {'end': 12, 'start': 3, 'tag': 'ClinicalAttribute'}, {'end': 73, 'start': 67, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 66, 'start': 61, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 66, 'start': 61, 'tag': 'BiologicallyActiveSubstance'}, {'end': 79, 'start': 57, 'tag': 'ClinicalAttribute'}, {'end': 89, 'start': 80, 'tag': 'ResearchActivity'}]"
424,"Change scores were calculated for IIV, CBF, and mean neuropsychological performance from baseline to 12 months.","[{'end': 42, 'start': 39, 'tag': 'BiologicFunction'}, {'end': 83, 'start': 72, 'tag': 'Finding'}, {'end': 110, 'start': 104, 'tag': 'TemporalConcept'}, {'end': 6, 'start': 0, 'tag': 'Finding'}, {'end': 37, 'start': 34, 'tag': 'ClinicalAttribute'}]"
425,"Hierarchical linear regression models showed that after adjusting for age and gender, there was a significant interaction between IIV change and biomarker-positivity (p-tau/A beta+) for change in entorhinal and hippocampal CBF but not for the other ROIs.","[{'end': 226, 'start': 223, 'tag': 'BiologicFunction'}, {'end': 84, 'start': 78, 'tag': 'OrganismAttribute'}, {'end': 172, 'start': 169, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 172, 'start': 169, 'tag': 'BiologicallyActiveSubstance'}, {'end': 73, 'start': 70, 'tag': 'OrganismAttribute'}, {'end': 154, 'start': 145, 'tag': 'ClinicalAttribute'}, {'end': 179, 'start': 173, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 253, 'start': 249, 'tag': 'ResearchActivity'}, {'end': 222, 'start': 211, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 222, 'start': 211, 'tag': 'Cell'}, {'end': 172, 'start': 167, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 172, 'start': 167, 'tag': 'BiologicallyActiveSubstance'}, {'end': 37, 'start': 13, 'tag': 'ResearchActivity'}, {'end': 30, 'start': 13, 'tag': 'ResearchActivity'}, {'end': 133, 'start': 130, 'tag': 'ClinicalAttribute'}, {'end': 121, 'start': 98, 'tag': 'Finding'}, {'end': 165, 'start': 155, 'tag': 'ResearchActivity'}, {'end': 206, 'start': 196, 'tag': 'BodyPartOrganOrOrganComponent'}]"
426,"Specifically, increases in IIV were associated with reductions in entorhinal and hippocampal CBF among individuals who were biomarker-positive (n = 21).","[{'end': 62, 'start': 52, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 62, 'start': 52, 'tag': 'HealthCareActivity'}, {'end': 96, 'start': 93, 'tag': 'BiologicFunction'}, {'end': 133, 'start': 124, 'tag': 'ClinicalAttribute'}, {'end': 114, 'start': 103, 'tag': 'PopulationGroup'}, {'end': 92, 'start': 81, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 92, 'start': 81, 'tag': 'Cell'}, {'end': 30, 'start': 27, 'tag': 'ClinicalAttribute'}, {'end': 76, 'start': 66, 'tag': 'BodyPartOrganOrOrganComponent'}]"
427,"In contrast, there were no significant associations between change in IIV and CBF among those who were biomarker-negative (n = 32).","[{'end': 81, 'start': 78, 'tag': 'BiologicFunction'}, {'end': 112, 'start': 103, 'tag': 'ClinicalAttribute'}, {'end': 51, 'start': 24, 'tag': 'Finding'}, {'end': 73, 'start': 70, 'tag': 'ClinicalAttribute'}]"
428,Findings remained similar when analyses were performed adjusting for change in mean level of neuropsychological performance.,"[{'end': 111, 'start': 93, 'tag': 'HealthCareActivity'}, {'end': 123, 'start': 112, 'tag': 'Finding'}, {'end': 39, 'start': 31, 'tag': 'ResearchActivity'}]"
429,"Changes in IIV may be sensitive to changes in regional hypoperfusion in AD-vulnerable regions among AD biomarker-positive individuals, above and beyond demographics and mean neuropsychological performance.","[{'end': 192, 'start': 174, 'tag': 'HealthCareActivity'}, {'end': 7, 'start': 0, 'tag': 'Finding'}, {'end': 204, 'start': 193, 'tag': 'Finding'}, {'end': 74, 'start': 72, 'tag': 'DiseaseOrSyndrome'}, {'end': 102, 'start': 100, 'tag': 'DiseaseOrSyndrome'}, {'end': 112, 'start': 103, 'tag': 'ClinicalAttribute'}, {'end': 133, 'start': 122, 'tag': 'PopulationGroup'}, {'end': 31, 'start': 22, 'tag': 'PathologicFunction'}, {'end': 14, 'start': 11, 'tag': 'ClinicalAttribute'}, {'end': 68, 'start': 55, 'tag': 'PathologicFunction'}]"
430,These findings provide further evidence supporting IIV as a potential marker of cerebrovascular brain changes in individuals at risk for dementia.,"[{'end': 95, 'start': 80, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 145, 'start': 137, 'tag': 'DiseaseOrSyndrome'}, {'end': 124, 'start': 113, 'tag': 'PopulationGroup'}, {'end': 109, 'start': 96, 'tag': 'Finding'}, {'end': 76, 'start': 70, 'tag': 'ClinicalAttribute'}, {'end': 39, 'start': 31, 'tag': 'Finding'}, {'end': 54, 'start': 51, 'tag': 'ClinicalAttribute'}]"
431,This randomized clinical trial evaluates the short-term effects of atabecestat in preclinical Alzheimer disease.,"[{'end': 30, 'start': 5, 'tag': 'ResearchActivity'}, {'end': 55, 'start': 45, 'tag': 'TemporalConcept'}, {'end': 78, 'start': 67, 'tag': 'Chemical'}, {'end': 111, 'start': 82, 'tag': 'DiseaseOrSyndrome'}, {'end': 78, 'start': 67, 'tag': 'PharmacologicSubstance'}, {'end': 63, 'start': 56, 'tag': 'Finding'}]"
432,"Question What are the short-term effects of atabecestat in preclinical Alzheimer disease (AD), and are adverse effects reversible after stopping treatment? Findings In this truncated randomized clinical trial of 557 participants with preclinical AD, atabecestat treatment was associated with statistically significant greater, dose-related cognitive worsening and neuropsychiatric adverse events (AEs) vs placebo.","[{'end': 32, 'start': 22, 'tag': 'TemporalConcept'}, {'end': 55, 'start': 44, 'tag': 'Chemical'}, {'end': 118, 'start': 103, 'tag': 'PathologicFunction'}, {'end': 144, 'start': 136, 'tag': 'PharmacologicSubstance'}, {'end': 208, 'start': 183, 'tag': 'ResearchActivity'}, {'end': 261, 'start': 250, 'tag': 'Chemical'}, {'end': 400, 'start': 397, 'tag': 'PathologicFunction'}, {'end': 359, 'start': 340, 'tag': 'Finding'}, {'end': 92, 'start': 90, 'tag': 'DiseaseOrSyndrome'}, {'end': 228, 'start': 216, 'tag': 'PopulationGroup'}, {'end': 248, 'start': 234, 'tag': 'DiseaseOrSyndrome'}, {'end': 412, 'start': 405, 'tag': 'HealthCareActivity'}, {'end': 40, 'start': 33, 'tag': 'Finding'}, {'end': 88, 'start': 59, 'tag': 'DiseaseOrSyndrome'}, {'end': 154, 'start': 145, 'tag': 'HealthCareActivity'}, {'end': 271, 'start': 262, 'tag': 'HealthCareActivity'}, {'end': 154, 'start': 145, 'tag': 'ResearchActivity'}, {'end': 271, 'start': 262, 'tag': 'ResearchActivity'}, {'end': 55, 'start': 44, 'tag': 'PharmacologicSubstance'}, {'end': 261, 'start': 250, 'tag': 'PharmacologicSubstance'}, {'end': 395, 'start': 364, 'tag': 'PathologicFunction'}]"
433,"Baseline to last off-treatment cognitive assessment suggested return to baseline cognitive status, and frequency of neuropsychiatric AEs returned to placebo levels after stopping atabecestat.","[{'end': 178, 'start': 170, 'tag': 'PharmacologicSubstance'}, {'end': 190, 'start': 179, 'tag': 'Chemical'}, {'end': 51, 'start': 31, 'tag': 'HealthCareActivity'}, {'end': 97, 'start': 72, 'tag': 'Finding'}, {'end': 112, 'start': 103, 'tag': 'TemporalConcept'}, {'end': 156, 'start': 149, 'tag': 'HealthCareActivity'}, {'end': 30, 'start': 21, 'tag': 'HealthCareActivity'}, {'end': 30, 'start': 21, 'tag': 'ResearchActivity'}, {'end': 190, 'start': 179, 'tag': 'PharmacologicSubstance'}, {'end': 136, 'start': 116, 'tag': 'PathologicFunction'}]"
434,"Meaning This study's findings confirm dose-related worsening of cognition and neuropsychiatric AEs in atabecestat-treated participants, with recovery after up to 6 months off treatment.","[{'end': 60, 'start': 38, 'tag': 'Finding'}, {'end': 149, 'start': 141, 'tag': 'BiologicFunction'}, {'end': 149, 'start': 141, 'tag': 'HealthCareActivity'}, {'end': 149, 'start': 141, 'tag': 'TemporalConcept'}, {'end': 134, 'start': 122, 'tag': 'PopulationGroup'}, {'end': 18, 'start': 13, 'tag': 'ResearchActivity'}, {'end': 73, 'start': 64, 'tag': 'BiologicFunction'}, {'end': 170, 'start': 164, 'tag': 'TemporalConcept'}, {'end': 184, 'start': 171, 'tag': 'HealthCareActivity'}, {'end': 98, 'start': 78, 'tag': 'PathologicFunction'}, {'end': 113, 'start': 102, 'tag': 'PharmacologicSubstance'}, {'end': 113, 'start': 102, 'tag': 'Chemical'}]"
435,"Importance Atabecestat, a nonselective oral beta-secretase inhibitor, was evaluated in the EARLY trial for slowing cognitive decline in participants with preclinical Alzheimer disease.","[{'end': 22, 'start': 11, 'tag': 'Chemical'}, {'end': 68, 'start': 59, 'tag': 'BiologicallyActiveSubstance'}, {'end': 68, 'start': 59, 'tag': 'PharmacologicSubstance'}, {'end': 68, 'start': 59, 'tag': 'Chemical'}, {'end': 148, 'start': 136, 'tag': 'PopulationGroup'}, {'end': 132, 'start': 115, 'tag': 'DiseaseOrSyndrome'}, {'end': 102, 'start': 91, 'tag': 'ResearchActivity'}, {'end': 184, 'start': 154, 'tag': 'DiseaseOrSyndrome'}, {'end': 22, 'start': 11, 'tag': 'PharmacologicSubstance'}, {'end': 58, 'start': 44, 'tag': 'BiologicallyActiveSubstance'}, {'end': 58, 'start': 44, 'tag': 'AminoAcidPeptideOrProtein'}]"
436,Preliminary analyses suggested dose-related cognitive worsening and neuropsychiatric adverse events (AEs).,"[{'end': 104, 'start': 101, 'tag': 'PathologicFunction'}, {'end': 63, 'start': 44, 'tag': 'Finding'}, {'end': 20, 'start': 12, 'tag': 'ResearchActivity'}, {'end': 99, 'start': 68, 'tag': 'PathologicFunction'}]"
437,"Objective To report efficacy, safety, and biomarker findings in the EARLY trial, both on and off atabecestat treatment, with focus on potential recovery of effects on cognition and behavior.","[{'end': 108, 'start': 97, 'tag': 'Chemical'}, {'end': 152, 'start': 144, 'tag': 'BiologicFunction'}, {'end': 152, 'start': 144, 'tag': 'HealthCareActivity'}, {'end': 152, 'start': 144, 'tag': 'TemporalConcept'}, {'end': 189, 'start': 181, 'tag': 'BiologicFunction'}, {'end': 189, 'start': 181, 'tag': 'IndividualBehavior'}, {'end': 189, 'start': 181, 'tag': 'ResearchActivity'}, {'end': 51, 'start': 42, 'tag': 'ClinicalAttribute'}, {'end': 36, 'start': 30, 'tag': 'HealthCareActivity'}, {'end': 79, 'start': 68, 'tag': 'ResearchActivity'}, {'end': 176, 'start': 167, 'tag': 'BiologicFunction'}, {'end': 19, 'start': 13, 'tag': 'HealthCareActivity'}, {'end': 19, 'start': 13, 'tag': 'ResearchActivity'}, {'end': 118, 'start': 109, 'tag': 'HealthCareActivity'}, {'end': 118, 'start': 109, 'tag': 'ResearchActivity'}, {'end': 108, 'start': 97, 'tag': 'PharmacologicSubstance'}, {'end': 28, 'start': 20, 'tag': 'Finding'}]"
438,"Design, Setting, and Participants Randomized, double-blind, placebo-controlled, phase 2b/3 study conducted from November 2015 to December 2018 after being stopped prematurely.","[{'end': 15, 'start': 8, 'tag': 'BiologicFunction'}, {'end': 44, 'start': 34, 'tag': 'ResearchActivity'}, {'end': 44, 'start': 34, 'tag': 'Finding'}, {'end': 85, 'start': 80, 'tag': 'TemporalConcept'}, {'end': 33, 'start': 21, 'tag': 'PopulationGroup'}, {'end': 96, 'start': 91, 'tag': 'ResearchActivity'}, {'end': 58, 'start': 46, 'tag': 'ResearchActivity'}, {'end': 78, 'start': 60, 'tag': 'ResearchActivity'}, {'end': 67, 'start': 60, 'tag': 'HealthCareActivity'}, {'end': 125, 'start': 112, 'tag': 'TemporalConcept'}, {'end': 142, 'start': 129, 'tag': 'TemporalConcept'}, {'end': 174, 'start': 163, 'tag': 'TemporalConcept'}]"
439,The study was conducted at 143 centers across 14 countries.,"[{'end': 9, 'start': 4, 'tag': 'ResearchActivity'}]"
440,"Participants were permitted to be followed off-treatment by the original protocol, collecting safety and efficacy data.","[{'end': 81, 'start': 73, 'tag': 'HealthCareActivity'}, {'end': 100, 'start': 94, 'tag': 'HealthCareActivity'}, {'end': 12, 'start': 0, 'tag': 'PopulationGroup'}, {'end': 118, 'start': 114, 'tag': 'ResearchActivity'}, {'end': 56, 'start': 47, 'tag': 'HealthCareActivity'}, {'end': 56, 'start': 47, 'tag': 'ResearchActivity'}, {'end': 113, 'start': 105, 'tag': 'Finding'}]"
441,"From 4464 screened participants, 557 amyloid-positive, cognitively normal (Clinical Dementia Rating of 0; aged 60-85 years) participants (approximately 34% of originally planned 1650) were randomized before the trial sponsor stopped enrollment.","[{'end': 18, 'start': 10, 'tag': 'HealthCareActivity'}, {'end': 18, 'start': 10, 'tag': 'ResearchActivity'}, {'end': 110, 'start': 106, 'tag': 'TemporalConcept'}, {'end': 206, 'start': 200, 'tag': 'TemporalConcept'}, {'end': 44, 'start': 37, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 44, 'start': 37, 'tag': 'BiologicallyActiveSubstance'}, {'end': 31, 'start': 19, 'tag': 'PopulationGroup'}, {'end': 136, 'start': 124, 'tag': 'PopulationGroup'}, {'end': 122, 'start': 117, 'tag': 'TemporalConcept'}, {'end': 73, 'start': 55, 'tag': 'Finding'}, {'end': 216, 'start': 211, 'tag': 'ResearchActivity'}, {'end': 243, 'start': 233, 'tag': 'HealthCareActivity'}, {'end': 99, 'start': 75, 'tag': 'HealthCareActivity'}]"
442,"Interventions Participants were randomized (1:1:1) to atabecestat, 5 mg (n = 189), 25 mg (n = 183), or placebo (n = 185).","[{'end': 13, 'start': 0, 'tag': 'HealthCareActivity'}, {'end': 65, 'start': 54, 'tag': 'Chemical'}, {'end': 26, 'start': 14, 'tag': 'PopulationGroup'}, {'end': 110, 'start': 103, 'tag': 'HealthCareActivity'}, {'end': 65, 'start': 54, 'tag': 'PharmacologicSubstance'}]"
443,Main Outcomes and Measures Primary outcome: change from baseline in Preclinical Alzheimer Cognitive Composite score.,"[{'end': 13, 'start': 5, 'tag': 'HealthCareActivity'}, {'end': 115, 'start': 110, 'tag': 'Finding'}, {'end': 109, 'start': 68, 'tag': 'HealthCareActivity'}]"
444,Secondary outcomes: change from baseline in the Cognitive Function Index and the Repeatable Battery for the Assessment of Neuropsychological Status total scale score.,"[{'end': 72, 'start': 48, 'tag': 'HealthCareActivity'}, {'end': 18, 'start': 10, 'tag': 'Finding'}, {'end': 165, 'start': 160, 'tag': 'Finding'}, {'end': 159, 'start': 81, 'tag': 'HealthCareActivity'}]"
445,Safety was monitored throughout the study.,"[{'end': 6, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 41, 'start': 36, 'tag': 'ResearchActivity'}]"
446,"Results Of 557 participants, 341 were women (61.2%); mean (SD) age was 70.4 (5.56) years.","[{'end': 43, 'start': 38, 'tag': 'PopulationGroup'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 27, 'start': 15, 'tag': 'PopulationGroup'}, {'end': 66, 'start': 63, 'tag': 'OrganismAttribute'}, {'end': 88, 'start': 83, 'tag': 'TemporalConcept'}, {'end': 61, 'start': 59, 'tag': 'ResearchActivity'}]"
447,"In May 2018, study medication was stopped early owing to hepatic-related AEs; participants were followed up off-treatment for 6 months.","[{'end': 76, 'start': 57, 'tag': 'PathologicFunction'}, {'end': 90, 'start': 78, 'tag': 'PopulationGroup'}, {'end': 18, 'start': 13, 'tag': 'ResearchActivity'}, {'end': 47, 'start': 42, 'tag': 'TemporalConcept'}, {'end': 134, 'start': 128, 'tag': 'TemporalConcept'}, {'end': 121, 'start': 112, 'tag': 'HealthCareActivity'}, {'end': 121, 'start': 112, 'tag': 'ResearchActivity'}, {'end': 11, 'start': 3, 'tag': 'TemporalConcept'}]"
448,"Atabecestat, 25 mg, showed significant cognitive worsening vs placebo for Preclinical Alzheimer Cognitive Composite at month 6 (least-square mean difference, -1.09; 95% CI, -1.66 to -0.53; P < .001) and month 12 (least-square mean, -1.62; 95% CI, -2.49 to -0.76; P < .001), and at month 3 for Repeatable Battery for the Assessment of Neuropsychological Status (least-square mean, -3.70; 95% CI, -5.76 to -1.63; P < .001).","[{'end': 11, 'start': 0, 'tag': 'Chemical'}, {'end': 124, 'start': 119, 'tag': 'TemporalConcept'}, {'end': 208, 'start': 203, 'tag': 'TemporalConcept'}, {'end': 286, 'start': 281, 'tag': 'TemporalConcept'}, {'end': 58, 'start': 39, 'tag': 'Finding'}, {'end': 171, 'start': 169, 'tag': 'ResearchActivity'}, {'end': 245, 'start': 243, 'tag': 'ResearchActivity'}, {'end': 393, 'start': 391, 'tag': 'ResearchActivity'}, {'end': 69, 'start': 62, 'tag': 'HealthCareActivity'}, {'end': 11, 'start': 0, 'tag': 'PharmacologicSubstance'}, {'end': 115, 'start': 74, 'tag': 'HealthCareActivity'}, {'end': 359, 'start': 293, 'tag': 'HealthCareActivity'}]"
449,Cognitive Function Index participant report showed nonsignificant worsening at month 12.,"[{'end': 24, 'start': 0, 'tag': 'HealthCareActivity'}, {'end': 84, 'start': 79, 'tag': 'TemporalConcept'}, {'end': 75, 'start': 51, 'tag': 'Finding'}, {'end': 36, 'start': 25, 'tag': 'PopulationGroup'}, {'end': 43, 'start': 37, 'tag': 'HealthCareActivity'}, {'end': 43, 'start': 37, 'tag': 'ResearchActivity'}]"
450,Systemic and neuropsychiatric-related treatment-emergent AEs were greater in atabecestat groups vs placebo.,"[{'end': 60, 'start': 57, 'tag': 'PathologicFunction'}, {'end': 88, 'start': 77, 'tag': 'Chemical'}, {'end': 95, 'start': 89, 'tag': 'PopulationGroup'}, {'end': 106, 'start': 99, 'tag': 'HealthCareActivity'}, {'end': 47, 'start': 38, 'tag': 'HealthCareActivity'}, {'end': 47, 'start': 38, 'tag': 'ResearchActivity'}, {'end': 88, 'start': 77, 'tag': 'PharmacologicSubstance'}]"
451,"After stopping treatment, follow-up cognitive testing and AE assessment provided evidence of reversibility of drug-induced cognitive worsening and AEs in atabecestat groups.","[{'end': 60, 'start': 58, 'tag': 'PathologicFunction'}, {'end': 106, 'start': 93, 'tag': 'TemporalConcept'}, {'end': 150, 'start': 147, 'tag': 'PathologicFunction'}, {'end': 165, 'start': 154, 'tag': 'Chemical'}, {'end': 142, 'start': 123, 'tag': 'Finding'}, {'end': 114, 'start': 110, 'tag': 'PharmacologicSubstance'}, {'end': 172, 'start': 166, 'tag': 'PopulationGroup'}, {'end': 53, 'start': 36, 'tag': 'HealthCareActivity'}, {'end': 35, 'start': 26, 'tag': 'HealthCareActivity'}, {'end': 35, 'start': 26, 'tag': 'TemporalConcept'}, {'end': 89, 'start': 81, 'tag': 'Finding'}, {'end': 71, 'start': 61, 'tag': 'HealthCareActivity'}, {'end': 71, 'start': 61, 'tag': 'ResearchActivity'}, {'end': 24, 'start': 15, 'tag': 'HealthCareActivity'}, {'end': 24, 'start': 15, 'tag': 'ResearchActivity'}, {'end': 165, 'start': 154, 'tag': 'PharmacologicSubstance'}]"
452,"Conclusions and Relevance Atabecestat treatment was associated with dose-related cognitive worsening as early as 3 months and presence of neuropsychiatric treatment-emergent AEs, with evidence of reversibility after 6 months off treatment.","[{'end': 37, 'start': 26, 'tag': 'Chemical'}, {'end': 209, 'start': 196, 'tag': 'TemporalConcept'}, {'end': 100, 'start': 81, 'tag': 'Finding'}, {'end': 192, 'start': 184, 'tag': 'Finding'}, {'end': 109, 'start': 104, 'tag': 'TemporalConcept'}, {'end': 121, 'start': 115, 'tag': 'TemporalConcept'}, {'end': 224, 'start': 218, 'tag': 'TemporalConcept'}, {'end': 134, 'start': 126, 'tag': 'Finding'}, {'end': 47, 'start': 38, 'tag': 'HealthCareActivity'}, {'end': 164, 'start': 138, 'tag': 'HealthCareActivity'}, {'end': 238, 'start': 225, 'tag': 'HealthCareActivity'}, {'end': 47, 'start': 38, 'tag': 'ResearchActivity'}, {'end': 37, 'start': 26, 'tag': 'PharmacologicSubstance'}, {'end': 177, 'start': 174, 'tag': 'PathologicFunction'}]"
453,Background: We investigated a sample of cognitively healthy subjects with normal Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarker levels to identify the earliest variables related to longitudinal memory changes.,"[{'end': 36, 'start': 30, 'tag': 'Substance'}, {'end': 36, 'start': 30, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 100, 'start': 81, 'tag': 'DiseaseOrSyndrome'}, {'end': 130, 'start': 127, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 104, 'start': 102, 'tag': 'DiseaseOrSyndrome'}, {'end': 141, 'start': 132, 'tag': 'ClinicalAttribute'}, {'end': 80, 'start': 74, 'tag': 'Finding'}, {'end': 125, 'start': 106, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 173, 'start': 165, 'tag': 'TemporalConcept'}, {'end': 68, 'start': 60, 'tag': 'PopulationGroup'}, {'end': 59, 'start': 40, 'tag': 'OrganismAttribute'}, {'end': 214, 'start': 208, 'tag': 'BiologicFunction'}, {'end': 222, 'start': 195, 'tag': 'Finding'}]"
454,"Objective: Employing a new highly demanding learning and memory test (the Ancient Farming Equipment Test; AFE-T), we aimed to investigate whether a biomarker related to neurodegeneration (i.e., CSF tau) was associated with longitudinal memory decline.","[{'end': 63, 'start': 44, 'tag': 'BiologicFunction'}, {'end': 250, 'start': 223, 'tag': 'Finding'}, {'end': 201, 'start': 198, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 186, 'start': 169, 'tag': 'CellOrMolecularDysfunction'}, {'end': 197, 'start': 194, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 201, 'start': 198, 'tag': 'BiologicallyActiveSubstance'}, {'end': 157, 'start': 148, 'tag': 'ClinicalAttribute'}, {'end': 52, 'start': 44, 'tag': 'BiologicFunction'}, {'end': 63, 'start': 57, 'tag': 'BiologicFunction'}, {'end': 242, 'start': 236, 'tag': 'BiologicFunction'}, {'end': 68, 'start': 44, 'tag': 'HealthCareActivity'}, {'end': 104, 'start': 74, 'tag': 'HealthCareActivity'}, {'end': 111, 'start': 106, 'tag': 'HealthCareActivity'}]"
455,"Methods: Thirty-two cognitively and biologically normal (CBN) subjects underwent MRI, neuropsychological assessment, and the AFE-T at baseline and 18 months later.","[{'end': 55, 'start': 49, 'tag': 'Finding'}, {'end': 84, 'start': 81, 'tag': 'HealthCareActivity'}, {'end': 70, 'start': 62, 'tag': 'PopulationGroup'}, {'end': 115, 'start': 86, 'tag': 'HealthCareActivity'}, {'end': 115, 'start': 105, 'tag': 'HealthCareActivity'}, {'end': 115, 'start': 105, 'tag': 'ResearchActivity'}, {'end': 156, 'start': 150, 'tag': 'TemporalConcept'}, {'end': 130, 'start': 125, 'tag': 'HealthCareActivity'}, {'end': 162, 'start': 157, 'tag': 'TemporalConcept'}]"
456,"To explore the relationship between cognitive performance and relevant factors, a linear model was set up.","[{'end': 57, 'start': 46, 'tag': 'Finding'}, {'end': 94, 'start': 82, 'tag': 'ResearchActivity'}, {'end': 27, 'start': 15, 'tag': 'Finding'}]"
457,"For a secondary analysis that further explore the effect of tau, the subjects were divided into CBN-Tau(down arrow) (tau < 228.64 pg/ml; n= 16) and CBN-Tau(up arrow) (tau (>)228.64 pg/ml; n= 16).","[{'end': 63, 'start': 60, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 120, 'start': 117, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 170, 'start': 167, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 63, 'start': 60, 'tag': 'BiologicallyActiveSubstance'}, {'end': 120, 'start': 117, 'tag': 'BiologicallyActiveSubstance'}, {'end': 170, 'start': 167, 'tag': 'BiologicallyActiveSubstance'}, {'end': 77, 'start': 69, 'tag': 'PopulationGroup'}, {'end': 24, 'start': 16, 'tag': 'ResearchActivity'}, {'end': 103, 'start': 100, 'tag': 'BiologicallyActiveSubstance'}, {'end': 155, 'start': 152, 'tag': 'BiologicallyActiveSubstance'}, {'end': 103, 'start': 100, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 155, 'start': 152, 'tag': 'AminoAcidPeptideOrProtein'}]"
458,We also performed voxel-based morphometry (VBM) to identify regions of grey matter volume that would predict both baseline and longitudinal cognitive performance.,"[{'end': 82, 'start': 71, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 161, 'start': 127, 'tag': 'Finding'}, {'end': 89, 'start': 71, 'tag': 'ClinicalAttribute'}, {'end': 41, 'start': 18, 'tag': 'HealthCareActivity'}, {'end': 46, 'start': 43, 'tag': 'HealthCareActivity'}]"
459,"Results: Our main finding was an association between CSF tau and longitudinal memory decline measured with AFE-T (B = -0.17, p < 0.05; r= -0.414; p <0.01), and further analyses showed different evolvement between subgroups, with an accelerated decline in individuals with higher tau (F(1,31) = 8.37; p < 0.01).","[{'end': 25, 'start': 18, 'tag': 'Finding'}, {'end': 60, 'start': 57, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 282, 'start': 279, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 56, 'start': 53, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 60, 'start': 57, 'tag': 'BiologicallyActiveSubstance'}, {'end': 282, 'start': 279, 'tag': 'BiologicallyActiveSubstance'}, {'end': 266, 'start': 255, 'tag': 'PopulationGroup'}, {'end': 176, 'start': 168, 'tag': 'ResearchActivity'}, {'end': 92, 'start': 65, 'tag': 'Finding'}, {'end': 112, 'start': 107, 'tag': 'HealthCareActivity'}]"
460,"VBM results suggested that AFE-T performance is related to grey matter volume in a medial temporal, middle frontal, and posterior cerebellar network at baseline, and that there are strategic brain areas driving the longitudinal cognitive changes.","[{'end': 70, 'start': 59, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 98, 'start': 90, 'tag': 'TemporalConcept'}, {'end': 148, 'start': 141, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 98, 'start': 90, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 245, 'start': 215, 'tag': 'Finding'}, {'end': 44, 'start': 33, 'tag': 'Finding'}, {'end': 196, 'start': 191, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 210, 'start': 203, 'tag': 'IndividualBehavior'}, {'end': 3, 'start': 0, 'tag': 'HealthCareActivity'}, {'end': 32, 'start': 27, 'tag': 'HealthCareActivity'}, {'end': 77, 'start': 59, 'tag': 'ClinicalAttribute'}, {'end': 148, 'start': 141, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 114, 'start': 100, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 148, 'start': 120, 'tag': 'BodyPartOrganOrOrganComponent'}]"
461,"Conclusions: The present findings provide evidence for structural and biological markers linked to cognitive aging by highlighting the role of tau, a marker of neurodegeneration, which can be related with the earliest memory changes in healthy subjects.","[{'end': 252, 'start': 236, 'tag': 'PopulationGroup'}, {'end': 146, 'start': 143, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 177, 'start': 160, 'tag': 'CellOrMolecularDysfunction'}, {'end': 146, 'start': 143, 'tag': 'BiologicallyActiveSubstance'}, {'end': 217, 'start': 209, 'tag': 'TemporalConcept'}, {'end': 252, 'start': 244, 'tag': 'PopulationGroup'}, {'end': 114, 'start': 99, 'tag': 'BiologicFunction'}, {'end': 114, 'start': 109, 'tag': 'CellFunction'}, {'end': 156, 'start': 150, 'tag': 'ClinicalAttribute'}, {'end': 50, 'start': 42, 'tag': 'Finding'}, {'end': 243, 'start': 236, 'tag': 'OrganismAttribute'}, {'end': 224, 'start': 218, 'tag': 'BiologicFunction'}, {'end': 88, 'start': 70, 'tag': 'ClinicalAttribute'}, {'end': 232, 'start': 218, 'tag': 'Finding'}]"
462,The parahippocampal gyrus-orbitofrontal cortex (PHG-OFC) circuit in humans is homologous to the postrhinal cortex (POR)-ventral lateral orbitofrontal cortex (vlOFC) circuit in rodents.,"[{'end': 25, 'start': 4, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 183, 'start': 176, 'tag': 'Eukaryote'}, {'end': 74, 'start': 68, 'tag': 'Eukaryote'}, {'end': 46, 'start': 26, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 64, 'start': 47, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 113, 'start': 96, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 156, 'start': 120, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 172, 'start': 157, 'tag': 'BodyPartOrganOrOrganComponent'}]"
463,Both are associated with visuospatial malfunctions in Alzheimer's disease (AD).,"[{'end': 73, 'start': 54, 'tag': 'DiseaseOrSyndrome'}, {'end': 77, 'start': 75, 'tag': 'DiseaseOrSyndrome'}, {'end': 50, 'start': 25, 'tag': 'PathologicFunction'}]"
464,"However, the underlying mechanisms remain to be elucidated.",[]
465,"In this study, we explored the relationship between an impaired POR-vlOFC circuit and visuospatial memory deficits through retrograde tracing and in vivo local field potential recordings in 5XFAD mice, and investigated alterations of the PHG-OFC circuit by multi-domain magnetic resonance imaging (MRI) in patients on the AD spectrum.","[{'end': 200, 'start': 190, 'tag': 'ExperimentalModelOfDisease'}, {'end': 333, 'start': 322, 'tag': 'DiseaseOrSyndrome'}, {'end': 301, 'start': 298, 'tag': 'HealthCareActivity'}, {'end': 43, 'start': 31, 'tag': 'Finding'}, {'end': 314, 'start': 306, 'tag': 'PatientOrDisabledGroup'}, {'end': 13, 'start': 8, 'tag': 'ResearchActivity'}, {'end': 186, 'start': 146, 'tag': 'ResearchActivity'}, {'end': 296, 'start': 257, 'tag': 'HealthCareActivity'}, {'end': 81, 'start': 64, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 114, 'start': 86, 'tag': 'PathologicFunction'}, {'end': 141, 'start': 123, 'tag': 'ResearchActivity'}, {'end': 253, 'start': 238, 'tag': 'BodyPartOrganOrOrganComponent'}]"
466,We demonstrated that an impaired glutamatergic POR-vlOFC circuit resulted in deficient visuospatial memory in 5XFAD mice.,"[{'end': 120, 'start': 110, 'tag': 'ExperimentalModelOfDisease'}, {'end': 64, 'start': 24, 'tag': 'PathologicFunction'}, {'end': 106, 'start': 77, 'tag': 'PathologicFunction'}]"
467,"Moreover, MRI measurements of the PHG-OFC circuit had an accuracy of 77.33% for the classification of amnestic mild cognitive impairment converters versus non-converters.","[{'end': 13, 'start': 10, 'tag': 'HealthCareActivity'}, {'end': 26, 'start': 14, 'tag': 'HealthCareActivity'}, {'end': 65, 'start': 57, 'tag': 'Finding'}, {'end': 136, 'start': 102, 'tag': 'DiseaseOrSyndrome'}, {'end': 49, 'start': 34, 'tag': 'BodyPartOrganOrOrganComponent'}]"
468,"Thus, the PHG-OFC circuit explains the neuroanatomical basis of visuospatial memory deficits in AD, thereby providing a potential predictor for AD progression and a promising interventional approach for AD.","[{'end': 54, 'start': 39, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 98, 'start': 96, 'tag': 'DiseaseOrSyndrome'}, {'end': 146, 'start': 144, 'tag': 'DiseaseOrSyndrome'}, {'end': 205, 'start': 203, 'tag': 'DiseaseOrSyndrome'}, {'end': 158, 'start': 147, 'tag': 'PathologicFunction'}, {'end': 158, 'start': 147, 'tag': 'TemporalConcept'}, {'end': 25, 'start': 10, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 92, 'start': 64, 'tag': 'PathologicFunction'}, {'end': 198, 'start': 175, 'tag': 'HealthCareActivity'}]"
469,BACKGROUND AND PURPOSE: Cell loss within the nucleus basalis of Meynert is an early event in Alzheimer disease.,"[{'end': 71, 'start': 45, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 110, 'start': 93, 'tag': 'DiseaseOrSyndrome'}, {'end': 83, 'start': 78, 'tag': 'TemporalConcept'}, {'end': 33, 'start': 24, 'tag': 'CellOrMolecularDysfunction'}]"
470,The thickness of the nucleus basalis of Meynert (NBM) can be measured on structural MR imaging.,"[{'end': 47, 'start': 21, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 52, 'start': 49, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 94, 'start': 73, 'tag': 'HealthCareActivity'}]"
471,We investigated NBM thickness in relation to cognitive state and biochemical markers.,"[{'end': 19, 'start': 16, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 84, 'start': 65, 'tag': 'ClinicalAttribute'}, {'end': 29, 'start': 16, 'tag': 'ClinicalAttribute'}]"
472,MATERIALS AND METHODS: Mean bilateral nucleus basalis of Meynert thickness was measured on coronal T1-weighted MR imaging scans from the Alzheimer?s Disease Neuroimaging Initiative dataset.,"[{'end': 127, 'start': 91, 'tag': 'HealthCareActivity'}, {'end': 188, 'start': 137, 'tag': 'ResearchActivity'}, {'end': 64, 'start': 38, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 74, 'start': 38, 'tag': 'ClinicalAttribute'}, {'end': 180, 'start': 137, 'tag': 'HealthCareRelatedOrganization'}]"
473,"Three hundred and fifteen scans (80 controls, 79 cases of early mild cognitive impairment, 77 cases of late mild cognitive impairment and 79 cases of Alzheimer disease) were assessed.","[{'end': 167, 'start': 150, 'tag': 'DiseaseOrSyndrome'}, {'end': 44, 'start': 36, 'tag': 'PopulationGroup'}, {'end': 31, 'start': 26, 'tag': 'HealthCareActivity'}, {'end': 63, 'start': 58, 'tag': 'TemporalConcept'}, {'end': 89, 'start': 64, 'tag': 'DiseaseOrSyndrome'}, {'end': 133, 'start': 108, 'tag': 'DiseaseOrSyndrome'}]"
474,"Alzheimer?s Disease Assessment Scale-Cognitive scores, CSF tau, and amyloid quantification were extracted.","[{'end': 62, 'start': 55, 'tag': 'ClinicalAttribute'}, {'end': 53, 'start': 47, 'tag': 'Finding'}, {'end': 62, 'start': 59, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 58, 'start': 55, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 62, 'start': 59, 'tag': 'BiologicallyActiveSubstance'}, {'end': 75, 'start': 68, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 75, 'start': 68, 'tag': 'BiologicallyActiveSubstance'}, {'end': 46, 'start': 0, 'tag': 'HealthCareActivity'}]"
475,"Group differences in NBM thickness, their correlates and measurement reliability were assessed.","[{'end': 24, 'start': 21, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 68, 'start': 57, 'tag': 'ResearchActivity'}, {'end': 68, 'start': 57, 'tag': 'HealthCareActivity'}, {'end': 17, 'start': 6, 'tag': 'Finding'}, {'end': 34, 'start': 21, 'tag': 'ClinicalAttribute'}]"
476,"RESULTS: Mean NBM thickness ? SD progressively declined from 2.9 ? 0.3, 2.5 ? 0.3, and 2.3 ? 0.3 to 1.8 ? 0.4 mm in healthy controls, patients with early mild cognitive impairment, late mild cognitive impairment and Alzheimer disease respectively (P?<?.001).","[{'end': 17, 'start': 14, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 233, 'start': 216, 'tag': 'DiseaseOrSyndrome'}, {'end': 142, 'start': 134, 'tag': 'PatientOrDisabledGroup'}, {'end': 123, 'start': 116, 'tag': 'OrganismAttribute'}, {'end': 132, 'start': 124, 'tag': 'PopulationGroup'}, {'end': 153, 'start': 148, 'tag': 'TemporalConcept'}, {'end': 32, 'start': 30, 'tag': 'ResearchActivity'}, {'end': 179, 'start': 154, 'tag': 'DiseaseOrSyndrome'}, {'end': 211, 'start': 186, 'tag': 'DiseaseOrSyndrome'}, {'end': 27, 'start': 14, 'tag': 'ClinicalAttribute'}]"
477,"NBM thickness was negatively correlated with Alzheimer?s Disease Assessment Scale-Cognitive scores (r = ?0.53, P?<?.001) and weakly positively correlated with CSF amyloid (r?=?0.250, P?<?.001) respectively.","[{'end': 3, 'start': 0, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 170, 'start': 159, 'tag': 'ClinicalAttribute'}, {'end': 98, 'start': 92, 'tag': 'Finding'}, {'end': 162, 'start': 159, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 170, 'start': 163, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 170, 'start': 163, 'tag': 'BiologicallyActiveSubstance'}, {'end': 13, 'start': 0, 'tag': 'ClinicalAttribute'}, {'end': 91, 'start': 45, 'tag': 'HealthCareActivity'}]"
478,No association with CSF tau was found.,"[{'end': 27, 'start': 20, 'tag': 'ClinicalAttribute'}, {'end': 27, 'start': 24, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 23, 'start': 20, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 27, 'start': 24, 'tag': 'BiologicallyActiveSubstance'}]"
479,"NBM thickness showed excellent diagnostic accuracy to differentiate Alzheimer disease (area under the curve, 0.986) and late mild cognitive impairment from controls (area under the curve, 0.936) with excellent sensitivity, but lower specificity 66.7%.","[{'end': 3, 'start': 0, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 67, 'start': 54, 'tag': 'CellFunction'}, {'end': 50, 'start': 31, 'tag': 'Finding'}, {'end': 85, 'start': 68, 'tag': 'DiseaseOrSyndrome'}, {'end': 164, 'start': 156, 'tag': 'PopulationGroup'}, {'end': 107, 'start': 87, 'tag': 'ResearchActivity'}, {'end': 186, 'start': 166, 'tag': 'ResearchActivity'}, {'end': 221, 'start': 210, 'tag': 'Finding'}, {'end': 244, 'start': 233, 'tag': 'Finding'}, {'end': 150, 'start': 125, 'tag': 'DiseaseOrSyndrome'}, {'end': 13, 'start': 0, 'tag': 'ClinicalAttribute'}, {'end': 124, 'start': 120, 'tag': 'TemporalConcept'}]"
480,Intra- and interrater reliability for measurements was 0.66 and 0.47 (P?<?.001).,"[{'end': 50, 'start': 38, 'tag': 'HealthCareActivity'}]"
481,"CONCLUSIONS: There is progressive NBM thinning across the aging-dementia spectrum, which correlates with cognitive decline and CSF markers of amyloid-? pathology.","[{'end': 37, 'start': 34, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 81, 'start': 73, 'tag': 'ResearchActivity'}, {'end': 63, 'start': 58, 'tag': 'BiologicFunction'}, {'end': 63, 'start': 58, 'tag': 'CellFunction'}, {'end': 130, 'start': 127, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 33, 'start': 22, 'tag': 'TemporalConcept'}, {'end': 149, 'start': 142, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 149, 'start': 142, 'tag': 'BiologicallyActiveSubstance'}, {'end': 72, 'start': 64, 'tag': 'DiseaseOrSyndrome'}, {'end': 161, 'start': 152, 'tag': 'PathologicFunction'}, {'end': 161, 'start': 152, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 122, 'start': 105, 'tag': 'DiseaseOrSyndrome'}, {'end': 138, 'start': 131, 'tag': 'ClinicalAttribute'}, {'end': 46, 'start': 34, 'tag': 'Finding'}]"
482,"We show high diagnostic accuracy but limited reliability, representing an area for future improvement.","[{'end': 32, 'start': 13, 'tag': 'Finding'}, {'end': 89, 'start': 83, 'tag': 'TemporalConcept'}, {'end': 12, 'start': 8, 'tag': 'Finding'}]"
483,"NBM thickness is a promising, readily available MR imaging biomarker of Alzheimer disease warranting diagnostic-accuracy testing in clinical practice.","[{'end': 3, 'start': 0, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 50, 'start': 48, 'tag': 'HealthCareActivity'}, {'end': 13, 'start': 0, 'tag': 'ClinicalAttribute'}, {'end': 149, 'start': 132, 'tag': 'HealthCareActivity'}, {'end': 89, 'start': 72, 'tag': 'DiseaseOrSyndrome'}, {'end': 68, 'start': 51, 'tag': 'ClinicalAttribute'}, {'end': 128, 'start': 121, 'tag': 'HealthCareActivity'}, {'end': 120, 'start': 112, 'tag': 'Finding'}, {'end': 111, 'start': 101, 'tag': 'HealthCareActivity'}]"
484,IMPORTANCE Alzheimer disease (AD) is the leading cause of death in individuals with Down syndrome (DS).,"[{'end': 10, 'start': 0, 'tag': 'Finding'}, {'end': 63, 'start': 58, 'tag': 'BiologicFunction'}, {'end': 63, 'start': 58, 'tag': 'PathologicFunction'}, {'end': 63, 'start': 58, 'tag': 'CellFunction'}, {'end': 32, 'start': 30, 'tag': 'DiseaseOrSyndrome'}, {'end': 28, 'start': 11, 'tag': 'DiseaseOrSyndrome'}, {'end': 78, 'start': 67, 'tag': 'PopulationGroup'}, {'end': 97, 'start': 84, 'tag': 'DiseaseOrSyndrome'}, {'end': 101, 'start': 99, 'tag': 'DiseaseOrSyndrome'}]"
485,"Previous studies have suggested that the APOE epsilon 4 allele plays a role in the risk and age at onset of dementia in DS; however, data on in vivo biomarkers remain scarce.","[{'end': 62, 'start': 56, 'tag': 'GeneOrGenome'}, {'end': 148, 'start': 141, 'tag': 'ResearchActivity'}, {'end': 159, 'start': 149, 'tag': 'ClinicalAttribute'}, {'end': 104, 'start': 99, 'tag': 'TemporalConcept'}, {'end': 95, 'start': 92, 'tag': 'OrganismAttribute'}, {'end': 16, 'start': 9, 'tag': 'ResearchActivity'}, {'end': 116, 'start': 108, 'tag': 'DiseaseOrSyndrome'}, {'end': 55, 'start': 41, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 137, 'start': 133, 'tag': 'ResearchActivity'}, {'end': 45, 'start': 41, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 45, 'start': 41, 'tag': 'BiologicallyActiveSubstance'}, {'end': 122, 'start': 120, 'tag': 'DiseaseOrSyndrome'}, {'end': 8, 'start': 0, 'tag': 'TemporalConcept'}]"
486,OBJECTIVE To investigate the association of the APOE epsilon 4 allele with dinical and multimodal biomarkers of AD in adults with DS.,"[{'end': 69, 'start': 63, 'tag': 'GeneOrGenome'}, {'end': 108, 'start': 98, 'tag': 'ClinicalAttribute'}, {'end': 114, 'start': 112, 'tag': 'DiseaseOrSyndrome'}, {'end': 124, 'start': 118, 'tag': 'PopulationGroup'}, {'end': 62, 'start': 48, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 52, 'start': 48, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 52, 'start': 48, 'tag': 'BiologicallyActiveSubstance'}, {'end': 132, 'start': 130, 'tag': 'DiseaseOrSyndrome'}]"
487,"DESIGN, SETTING, AND PARTICIPANTS This dual-center cohort study recruited adults with DS in Barcelona, Spain, and in Cambridge, UK, between June 1, 2009, and February 28, 2020.","[{'end': 15, 'start': 8, 'tag': 'BiologicFunction'}, {'end': 57, 'start': 51, 'tag': 'PopulationGroup'}, {'end': 80, 'start': 74, 'tag': 'PopulationGroup'}, {'end': 63, 'start': 58, 'tag': 'ResearchActivity'}, {'end': 88, 'start': 86, 'tag': 'DiseaseOrSyndrome'}]"
488,Included individuals had been genotyped for APOE and had at least 1 clinical or AD biomarker measurement; 2 individuals were excluded because of the absence of trisomy 21.,"[{'end': 170, 'start': 160, 'tag': 'DiseaseOrSyndrome'}, {'end': 170, 'start': 160, 'tag': 'CellOrMolecularDysfunction'}, {'end': 104, 'start': 93, 'tag': 'ResearchActivity'}, {'end': 104, 'start': 93, 'tag': 'HealthCareActivity'}, {'end': 82, 'start': 80, 'tag': 'DiseaseOrSyndrome'}, {'end': 92, 'start': 83, 'tag': 'ClinicalAttribute'}, {'end': 20, 'start': 9, 'tag': 'PopulationGroup'}, {'end': 119, 'start': 108, 'tag': 'PopulationGroup'}, {'end': 48, 'start': 44, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 48, 'start': 44, 'tag': 'BiologicallyActiveSubstance'}]"
489,Participants were either APOE epsilon 4 allele carriers or noncarriers.,"[{'end': 55, 'start': 47, 'tag': 'PopulationGroup'}, {'end': 12, 'start': 0, 'tag': 'PopulationGroup'}, {'end': 39, 'start': 25, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 70, 'start': 59, 'tag': 'PopulationGroup'}]"
490,MAIN OUTCOMES AND MEASURES Participants underwent a neurological and neuropsychological assessment.,"[{'end': 39, 'start': 27, 'tag': 'PopulationGroup'}, {'end': 98, 'start': 69, 'tag': 'HealthCareActivity'}]"
491,"A subset of participants had biomarker measurements: A beta 1-42, A beta 1-40, phosphorylated tau 181 (pTau181) and neurofilament light chain (NfL) in cerebrospinal fluid (CSF), pTau181, and NfL in plasma; amyloid positron emission tomography (PET); fluorine 18-labeled-fluorodeoxyglucose PET; and/or magnetic resonance imaging.","[{'end': 288, 'start': 250, 'tag': 'Chemical'}, {'end': 204, 'start': 198, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 175, 'start': 172, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 146, 'start': 143, 'tag': 'BiologicallyActiveSubstance'}, {'end': 194, 'start': 191, 'tag': 'BiologicallyActiveSubstance'}, {'end': 146, 'start': 143, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 194, 'start': 191, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 141, 'start': 116, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 141, 'start': 116, 'tag': 'BiologicallyActiveSubstance'}, {'end': 213, 'start': 206, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 213, 'start': 206, 'tag': 'BiologicallyActiveSubstance'}, {'end': 38, 'start': 29, 'tag': 'ClinicalAttribute'}, {'end': 24, 'start': 12, 'tag': 'PopulationGroup'}, {'end': 327, 'start': 320, 'tag': 'HealthCareActivity'}, {'end': 170, 'start': 151, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 247, 'start': 244, 'tag': 'HealthCareActivity'}, {'end': 292, 'start': 289, 'tag': 'HealthCareActivity'}, {'end': 101, 'start': 79, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 101, 'start': 79, 'tag': 'BiologicallyActiveSubstance'}, {'end': 64, 'start': 53, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 77, 'start': 66, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 64, 'start': 53, 'tag': 'BiologicallyActiveSubstance'}, {'end': 77, 'start': 66, 'tag': 'BiologicallyActiveSubstance'}, {'end': 242, 'start': 214, 'tag': 'HealthCareActivity'}, {'end': 327, 'start': 301, 'tag': 'HealthCareActivity'}, {'end': 51, 'start': 39, 'tag': 'HealthCareActivity'}, {'end': 110, 'start': 103, 'tag': 'BiologicallyActiveSubstance'}, {'end': 110, 'start': 103, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 185, 'start': 178, 'tag': 'BiologicallyActiveSubstance'}, {'end': 185, 'start': 178, 'tag': 'AminoAcidPeptideOrProtein'}]"
492,"Age at symptom onset was compared between APOE epsilon 4 allele carriers and noncarriers, and within-group local regression models were used to compare the association of biomarkers with age.","[{'end': 3, 'start': 0, 'tag': 'OrganismAttribute'}, {'end': 72, 'start': 64, 'tag': 'PopulationGroup'}, {'end': 181, 'start': 171, 'tag': 'ClinicalAttribute'}, {'end': 20, 'start': 7, 'tag': 'TemporalConcept'}, {'end': 14, 'start': 7, 'tag': 'SignOrSymptom'}, {'end': 190, 'start': 187, 'tag': 'OrganismAttribute'}, {'end': 130, 'start': 124, 'tag': 'ResearchActivity'}, {'end': 56, 'start': 42, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 106, 'start': 101, 'tag': 'PopulationGroup'}, {'end': 46, 'start': 42, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 46, 'start': 42, 'tag': 'BiologicallyActiveSubstance'}, {'end': 63, 'start': 57, 'tag': 'GeneOrGenome'}, {'end': 88, 'start': 77, 'tag': 'PopulationGroup'}]"
493,Voxelwise analyses were performed to assess topographical differences in gray matter metabolism and volume.,"[{'end': 69, 'start': 58, 'tag': 'Finding'}, {'end': 84, 'start': 73, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 18, 'start': 10, 'tag': 'ResearchActivity'}]"
494,"RESULTS Of the 464 adults with DS included in the study, 97 (20.9%) were APOE epsilon 4 allele carriers and 367 (79.1%) were noncarriers.","[{'end': 103, 'start': 95, 'tag': 'PopulationGroup'}, {'end': 25, 'start': 19, 'tag': 'PopulationGroup'}, {'end': 87, 'start': 73, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 55, 'start': 50, 'tag': 'ResearchActivity'}, {'end': 77, 'start': 73, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 77, 'start': 73, 'tag': 'BiologicallyActiveSubstance'}, {'end': 33, 'start': 31, 'tag': 'DiseaseOrSyndrome'}]"
495,"No differences between the 2 groups were found by age (median [interquartile range], 45.9 [36.4-50.2] years vs 43.7 [34.9-50.2] years; P = .56) or sex (51 male carriers [52.6%] vs 199 male noncarriers [54.2%]).","[{'end': 159, 'start': 155, 'tag': 'OrganismAttribute'}, {'end': 188, 'start': 184, 'tag': 'OrganismAttribute'}, {'end': 61, 'start': 55, 'tag': 'ResearchActivity'}, {'end': 14, 'start': 3, 'tag': 'Finding'}, {'end': 168, 'start': 160, 'tag': 'PopulationGroup'}, {'end': 107, 'start': 102, 'tag': 'TemporalConcept'}, {'end': 133, 'start': 128, 'tag': 'TemporalConcept'}, {'end': 53, 'start': 50, 'tag': 'OrganismAttribute'}, {'end': 150, 'start': 147, 'tag': 'OrganismAttribute'}, {'end': 35, 'start': 29, 'tag': 'PopulationGroup'}, {'end': 200, 'start': 189, 'tag': 'PopulationGroup'}]"
496,"APOE epsilon 4 allele carriers compared with noncarriers presented with AD symptoms at a younger age (mean [SD] age, 50.7 [4.4] years vs 52.7 [5.8] years; P = .02) and showed earlier cognitive decline.","[{'end': 30, 'start': 22, 'tag': 'PopulationGroup'}, {'end': 133, 'start': 128, 'tag': 'TemporalConcept'}, {'end': 153, 'start': 148, 'tag': 'TemporalConcept'}, {'end': 100, 'start': 97, 'tag': 'OrganismAttribute'}, {'end': 115, 'start': 112, 'tag': 'OrganismAttribute'}, {'end': 83, 'start': 75, 'tag': 'SignOrSymptom'}, {'end': 74, 'start': 72, 'tag': 'DiseaseOrSyndrome'}, {'end': 14, 'start': 0, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 200, 'start': 183, 'tag': 'DiseaseOrSyndrome'}, {'end': 4, 'start': 0, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 4, 'start': 0, 'tag': 'BiologicallyActiveSubstance'}, {'end': 182, 'start': 175, 'tag': 'TemporalConcept'}, {'end': 56, 'start': 45, 'tag': 'PopulationGroup'}, {'end': 96, 'start': 89, 'tag': 'TemporalConcept'}]"
497,Locally estimated scatterplot smoothing curves further showed between-group differences in biomarker trajectories with age as reflected by nonoverlapping Cls.,"[{'end': 87, 'start': 70, 'tag': 'Finding'}, {'end': 87, 'start': 76, 'tag': 'Finding'}, {'end': 122, 'start': 119, 'tag': 'OrganismAttribute'}, {'end': 100, 'start': 91, 'tag': 'ClinicalAttribute'}, {'end': 75, 'start': 70, 'tag': 'PopulationGroup'}, {'end': 46, 'start': 18, 'tag': 'ResearchActivity'}]"
498,"Specifically, carriers showed lower levels of the CSF A beta 1-42 to A beta 1-40 ratio until age 40 years, earlier increases in amyloid PET and plasma pTau181, and earlier loss of cortical metabolism and hippocampal volume.","[{'end': 22, 'start': 14, 'tag': 'PopulationGroup'}, {'end': 105, 'start': 100, 'tag': 'TemporalConcept'}, {'end': 150, 'start': 144, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 135, 'start': 128, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 135, 'start': 128, 'tag': 'BiologicallyActiveSubstance'}, {'end': 96, 'start': 93, 'tag': 'OrganismAttribute'}, {'end': 139, 'start': 136, 'tag': 'HealthCareActivity'}, {'end': 80, 'start': 69, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 80, 'start': 69, 'tag': 'BiologicallyActiveSubstance'}, {'end': 222, 'start': 204, 'tag': 'ClinicalAttribute'}, {'end': 188, 'start': 180, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 114, 'start': 107, 'tag': 'TemporalConcept'}, {'end': 171, 'start': 164, 'tag': 'TemporalConcept'}, {'end': 158, 'start': 144, 'tag': 'ClinicalAttribute'}, {'end': 199, 'start': 172, 'tag': 'PathologicFunction'}, {'end': 65, 'start': 50, 'tag': 'ClinicalAttribute'}]"
499,No differences were found in NfL biomarkers or CSF total tau and pTau181.,"[{'end': 14, 'start': 3, 'tag': 'Finding'}, {'end': 43, 'start': 33, 'tag': 'ClinicalAttribute'}, {'end': 50, 'start': 47, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 32, 'start': 29, 'tag': 'BiologicallyActiveSubstance'}, {'end': 32, 'start': 29, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 60, 'start': 51, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 60, 'start': 51, 'tag': 'BiologicallyActiveSubstance'}, {'end': 72, 'start': 65, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 72, 'start': 65, 'tag': 'BiologicallyActiveSubstance'}, {'end': 60, 'start': 47, 'tag': 'ClinicalAttribute'}]"
500,Voxelwise analyses showed lower metabolism in subcortical and parieto-occipital structures and lower medial temporal volume in APOE epsilon 4 allele carriers.,"[{'end': 42, 'start': 32, 'tag': 'BiologicFunction'}, {'end': 42, 'start': 32, 'tag': 'CellFunction'}, {'end': 90, 'start': 62, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 148, 'start': 142, 'tag': 'GeneOrGenome'}, {'end': 157, 'start': 149, 'tag': 'PopulationGroup'}, {'end': 141, 'start': 127, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 131, 'start': 127, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 131, 'start': 127, 'tag': 'BiologicallyActiveSubstance'}, {'end': 57, 'start': 46, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 18, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 123, 'start': 101, 'tag': 'ClinicalAttribute'}]"
501,"CONCLUSIONS AND RELEVANCE In this study, the APOE epsilon 4 allele was associated with earlier clinical and biomarker changes of AD in DS.","[{'end': 66, 'start': 60, 'tag': 'GeneOrGenome'}, {'end': 131, 'start': 129, 'tag': 'DiseaseOrSyndrome'}, {'end': 117, 'start': 108, 'tag': 'ClinicalAttribute'}, {'end': 59, 'start': 45, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 39, 'start': 34, 'tag': 'ResearchActivity'}, {'end': 49, 'start': 45, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 49, 'start': 45, 'tag': 'BiologicallyActiveSubstance'}, {'end': 137, 'start': 135, 'tag': 'DiseaseOrSyndrome'}, {'end': 94, 'start': 87, 'tag': 'TemporalConcept'}]"
502,"These results provide insights into the mechanisms by which APOE increases the risk of AD, emphasizing the importance of APOE genotype for future clinical trials in DS.","[{'end': 145, 'start': 139, 'tag': 'TemporalConcept'}, {'end': 89, 'start': 87, 'tag': 'DiseaseOrSyndrome'}, {'end': 64, 'start': 60, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 125, 'start': 121, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 64, 'start': 60, 'tag': 'BiologicallyActiveSubstance'}, {'end': 125, 'start': 121, 'tag': 'BiologicallyActiveSubstance'}, {'end': 134, 'start': 126, 'tag': 'OrganismAttribute'}, {'end': 167, 'start': 165, 'tag': 'DiseaseOrSyndrome'}, {'end': 161, 'start': 146, 'tag': 'ResearchActivity'}]"
503,"Background CSF and PET biomarkers of amyloid 13 and tau accurately detect Alzheimer's disease pathology, but the invasiveness, high cost, and poor availability of these detection methods restrict their widespread use as clinical diagnostic tools.","[{'end': 73, 'start': 67, 'tag': 'Finding'}, {'end': 73, 'start': 67, 'tag': 'TemporalConcept'}, {'end': 125, 'start': 113, 'tag': 'PathologicFunction'}, {'end': 103, 'start': 86, 'tag': 'PathologicFunction'}, {'end': 55, 'start': 52, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 93, 'start': 74, 'tag': 'DiseaseOrSyndrome'}, {'end': 14, 'start': 11, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 55, 'start': 52, 'tag': 'BiologicallyActiveSubstance'}, {'end': 44, 'start': 37, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 44, 'start': 37, 'tag': 'BiologicallyActiveSubstance'}, {'end': 33, 'start': 23, 'tag': 'ClinicalAttribute'}, {'end': 22, 'start': 19, 'tag': 'HealthCareActivity'}, {'end': 186, 'start': 169, 'tag': 'HealthCareActivity'}, {'end': 245, 'start': 220, 'tag': 'HealthCareActivity'}, {'end': 136, 'start': 127, 'tag': 'Finding'}, {'end': 186, 'start': 169, 'tag': 'ResearchActivity'}]"
504,CSF tau phosphorylated at threonine 181 (p-tau181) is a highly specific biomarker for Alzheimer's disease pathology.,"[{'end': 39, 'start': 0, 'tag': 'ClinicalAttribute'}, {'end': 115, 'start': 98, 'tag': 'PathologicFunction'}, {'end': 105, 'start': 86, 'tag': 'DiseaseOrSyndrome'}, {'end': 81, 'start': 72, 'tag': 'ClinicalAttribute'}, {'end': 49, 'start': 41, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 49, 'start': 41, 'tag': 'BiologicallyActiveSubstance'}]"
505,We aimed to assess whether blood p-tau181 could be used as a biomarker for Alzheimer's disease and for prediction of cognitive decline and hippocampal atrophy.,"[{'end': 158, 'start': 139, 'tag': 'DiseaseOrSyndrome'}, {'end': 94, 'start': 75, 'tag': 'DiseaseOrSyndrome'}, {'end': 70, 'start': 61, 'tag': 'ClinicalAttribute'}, {'end': 41, 'start': 33, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 41, 'start': 33, 'tag': 'BiologicallyActiveSubstance'}, {'end': 32, 'start': 27, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 134, 'start': 117, 'tag': 'DiseaseOrSyndrome'}, {'end': 113, 'start': 103, 'tag': 'Finding'}, {'end': 41, 'start': 27, 'tag': 'ClinicalAttribute'}]"
506,Methods We developed and validated an ultrasensitive blood immunoassay for p-tau181.,"[{'end': 70, 'start': 59, 'tag': 'ResearchActivity'}, {'end': 83, 'start': 75, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 83, 'start': 75, 'tag': 'BiologicallyActiveSubstance'}, {'end': 58, 'start': 53, 'tag': 'BodyPartOrganOrOrganComponent'}]"
507,Assay performance was evaluated in four clinic-based prospective cohorts.,"[{'end': 64, 'start': 53, 'tag': 'BiologicFunction'}, {'end': 5, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 72, 'start': 65, 'tag': 'PopulationGroup'}, {'end': 17, 'start': 6, 'tag': 'Finding'}]"
508,The discovery cohort comprised patients with Alzheimer's disease and age-matched controls.,"[{'end': 64, 'start': 45, 'tag': 'DiseaseOrSyndrome'}, {'end': 89, 'start': 81, 'tag': 'PopulationGroup'}, {'end': 39, 'start': 31, 'tag': 'PatientOrDisabledGroup'}, {'end': 13, 'start': 4, 'tag': 'ResearchActivity'}, {'end': 72, 'start': 69, 'tag': 'OrganismAttribute'}, {'end': 20, 'start': 14, 'tag': 'PopulationGroup'}]"
509,"Two validation cohorts (TRIAD and BioFINDER-2) included cognitively unimpaired older adults (mean age 63-69 years), participants with mild cognitive impairment (MCI), Alzheimer's disease, and frontotemporal dementia.","[{'end': 78, 'start': 56, 'tag': 'Finding'}, {'end': 14, 'start': 4, 'tag': 'ResearchActivity'}, {'end': 91, 'start': 79, 'tag': 'PopulationGroup'}, {'end': 215, 'start': 192, 'tag': 'DiseaseOrSyndrome'}, {'end': 186, 'start': 167, 'tag': 'DiseaseOrSyndrome'}, {'end': 22, 'start': 15, 'tag': 'PopulationGroup'}, {'end': 128, 'start': 116, 'tag': 'PopulationGroup'}, {'end': 215, 'start': 207, 'tag': 'DiseaseOrSyndrome'}, {'end': 164, 'start': 161, 'tag': 'DiseaseOrSyndrome'}, {'end': 101, 'start': 98, 'tag': 'OrganismAttribute'}, {'end': 113, 'start': 108, 'tag': 'TemporalConcept'}, {'end': 159, 'start': 134, 'tag': 'DiseaseOrSyndrome'}, {'end': 29, 'start': 24, 'tag': 'ResearchActivity'}, {'end': 45, 'start': 34, 'tag': 'ResearchActivity'}]"
510,"In addition, TRIAD included healthy young adults (mean age 23 years) and BioFINDER-2 included patients with other neurodegenerative disorders.","[{'end': 48, 'start': 36, 'tag': 'PopulationGroup'}, {'end': 141, 'start': 114, 'tag': 'DiseaseOrSyndrome'}, {'end': 102, 'start': 94, 'tag': 'PatientOrDisabledGroup'}, {'end': 35, 'start': 28, 'tag': 'OrganismAttribute'}, {'end': 58, 'start': 55, 'tag': 'OrganismAttribute'}, {'end': 67, 'start': 62, 'tag': 'TemporalConcept'}, {'end': 18, 'start': 13, 'tag': 'ResearchActivity'}, {'end': 84, 'start': 73, 'tag': 'ResearchActivity'}]"
511,"The primary care cohort, which recruited participants in Montreal, Canada, comprised control participants from the community without a diagnosis of a neurological condition and patients referred from primary care physicians of the Canadian National Health Service for specialist care.","[{'end': 16, 'start': 4, 'tag': 'HealthCareActivity'}, {'end': 212, 'start': 200, 'tag': 'HealthCareActivity'}, {'end': 223, 'start': 213, 'tag': 'HealthCareActivity'}, {'end': 283, 'start': 279, 'tag': 'HealthCareActivity'}, {'end': 124, 'start': 115, 'tag': 'HealthCareRelatedOrganization'}, {'end': 185, 'start': 177, 'tag': 'PatientOrDisabledGroup'}, {'end': 53, 'start': 41, 'tag': 'PopulationGroup'}, {'end': 105, 'start': 93, 'tag': 'PopulationGroup'}, {'end': 144, 'start': 135, 'tag': 'HealthCareActivity'}, {'end': 92, 'start': 85, 'tag': 'PopulationGroup'}, {'end': 172, 'start': 150, 'tag': 'DiseaseOrSyndrome'}, {'end': 23, 'start': 17, 'tag': 'PopulationGroup'}, {'end': 263, 'start': 231, 'tag': 'HealthCareRelatedOrganization'}]"
512,"Concentrations of plasma p-tau181 were compared with established CSF and PET biomarkers and longitudinal measurements using Spearman correlation, area under the curve (AUC), and linear regression analyses.","[{'end': 14, 'start': 0, 'tag': 'BiologicFunction'}, {'end': 204, 'start': 178, 'tag': 'ResearchActivity'}, {'end': 68, 'start': 65, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 166, 'start': 146, 'tag': 'ResearchActivity'}, {'end': 87, 'start': 77, 'tag': 'ClinicalAttribute'}, {'end': 24, 'start': 18, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 33, 'start': 25, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 33, 'start': 25, 'tag': 'BiologicallyActiveSubstance'}, {'end': 117, 'start': 105, 'tag': 'HealthCareActivity'}, {'end': 76, 'start': 73, 'tag': 'HealthCareActivity'}, {'end': 104, 'start': 92, 'tag': 'ResearchActivity'}, {'end': 171, 'start': 168, 'tag': 'ResearchActivity'}, {'end': 144, 'start': 124, 'tag': 'ResearchActivity'}, {'end': 33, 'start': 18, 'tag': 'ClinicalAttribute'}]"
513,"Findings We studied 37 individuals in the discovery cohort, 226 in the first validation cohort (TRIAD), 763 in the second validation cohort (BioFINDER-2), and 105 in the primary care cohort (n=1131 individuals).","[{'end': 182, 'start': 178, 'tag': 'HealthCareActivity'}, {'end': 87, 'start': 77, 'tag': 'ResearchActivity'}, {'end': 132, 'start': 122, 'tag': 'ResearchActivity'}, {'end': 76, 'start': 71, 'tag': 'TemporalConcept'}, {'end': 34, 'start': 23, 'tag': 'PopulationGroup'}, {'end': 209, 'start': 198, 'tag': 'PopulationGroup'}, {'end': 51, 'start': 42, 'tag': 'ResearchActivity'}, {'end': 58, 'start': 52, 'tag': 'PopulationGroup'}, {'end': 94, 'start': 88, 'tag': 'PopulationGroup'}, {'end': 139, 'start': 133, 'tag': 'PopulationGroup'}, {'end': 189, 'start': 183, 'tag': 'PopulationGroup'}, {'end': 101, 'start': 96, 'tag': 'ResearchActivity'}, {'end': 152, 'start': 141, 'tag': 'ResearchActivity'}]"
514,"In all cohorts, plasma p-tau181 showed gradual increases along the Alzheimer's disease continuum, from the lowest concentrations in amyloid 13-negative young adults and cognitively unimpaired older adults, through higher concentrations in the amyloid 13-positive cognitively unimpaired older adults and MCI groups, to the highest concentrations in the amyloid 13-positive MCI and Alzheimer's disease groups (p<0.001, Alzheimer's disease vs all other groups).","[{'end': 96, 'start': 87, 'tag': 'HealthCareActivity'}, {'end': 164, 'start': 152, 'tag': 'PopulationGroup'}, {'end': 128, 'start': 114, 'tag': 'BiologicFunction'}, {'end': 235, 'start': 221, 'tag': 'BiologicFunction'}, {'end': 344, 'start': 330, 'tag': 'BiologicFunction'}, {'end': 191, 'start': 169, 'tag': 'Finding'}, {'end': 285, 'start': 263, 'tag': 'Finding'}, {'end': 204, 'start': 192, 'tag': 'PopulationGroup'}, {'end': 298, 'start': 286, 'tag': 'PopulationGroup'}, {'end': 86, 'start': 67, 'tag': 'DiseaseOrSyndrome'}, {'end': 399, 'start': 380, 'tag': 'DiseaseOrSyndrome'}, {'end': 436, 'start': 417, 'tag': 'DiseaseOrSyndrome'}, {'end': 14, 'start': 7, 'tag': 'PopulationGroup'}, {'end': 139, 'start': 132, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 253, 'start': 243, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 362, 'start': 352, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 139, 'start': 132, 'tag': 'BiologicallyActiveSubstance'}, {'end': 253, 'start': 243, 'tag': 'BiologicallyActiveSubstance'}, {'end': 362, 'start': 352, 'tag': 'BiologicallyActiveSubstance'}, {'end': 306, 'start': 303, 'tag': 'DiseaseOrSyndrome'}, {'end': 375, 'start': 372, 'tag': 'DiseaseOrSyndrome'}, {'end': 22, 'start': 16, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 31, 'start': 23, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 31, 'start': 23, 'tag': 'BiologicallyActiveSubstance'}, {'end': 313, 'start': 307, 'tag': 'PopulationGroup'}, {'end': 406, 'start': 400, 'tag': 'PopulationGroup'}, {'end': 456, 'start': 450, 'tag': 'PopulationGroup'}, {'end': 31, 'start': 16, 'tag': 'ClinicalAttribute'}]"
515,"Plasma p-tau181 distinguished Alzheimer's disease dementia from amyloid 13-negative young adults (AUC=99.40%) and cognitively unimpaired older adults (AUC=90.21-98.24% across cohorts), as well as other neurodegenerative disorders, including frontotemporal dementia (AUC=82.76-100% across cohorts), vascular dementia (AUC=92.13%), progressive supranuclear palsy or corticobasal syndrome (AUC=88.47%), and Parkinson's disease or multiple systems atrophy (AUC=81.90%).","[{'end': 96, 'start': 84, 'tag': 'PopulationGroup'}, {'end': 451, 'start': 427, 'tag': 'PathologicFunction'}, {'end': 306, 'start': 298, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 136, 'start': 114, 'tag': 'Finding'}, {'end': 315, 'start': 298, 'tag': 'DiseaseOrSyndrome'}, {'end': 6, 'start': 0, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 229, 'start': 202, 'tag': 'DiseaseOrSyndrome'}, {'end': 149, 'start': 137, 'tag': 'PopulationGroup'}, {'end': 264, 'start': 241, 'tag': 'DiseaseOrSyndrome'}, {'end': 385, 'start': 364, 'tag': 'DiseaseOrSyndrome'}, {'end': 360, 'start': 330, 'tag': 'DiseaseOrSyndrome'}, {'end': 360, 'start': 342, 'tag': 'DiseaseOrSyndrome'}, {'end': 49, 'start': 30, 'tag': 'DiseaseOrSyndrome'}, {'end': 341, 'start': 330, 'tag': 'TemporalConcept'}, {'end': 423, 'start': 404, 'tag': 'DiseaseOrSyndrome'}, {'end': 182, 'start': 175, 'tag': 'PopulationGroup'}, {'end': 295, 'start': 288, 'tag': 'PopulationGroup'}, {'end': 74, 'start': 64, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 74, 'start': 64, 'tag': 'BiologicallyActiveSubstance'}, {'end': 58, 'start': 50, 'tag': 'DiseaseOrSyndrome'}, {'end': 264, 'start': 256, 'tag': 'DiseaseOrSyndrome'}, {'end': 315, 'start': 307, 'tag': 'DiseaseOrSyndrome'}, {'end': 376, 'start': 364, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 15, 'start': 7, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 15, 'start': 7, 'tag': 'BiologicallyActiveSubstance'}, {'end': 101, 'start': 98, 'tag': 'ResearchActivity'}, {'end': 154, 'start': 151, 'tag': 'ResearchActivity'}, {'end': 269, 'start': 266, 'tag': 'ResearchActivity'}, {'end': 320, 'start': 317, 'tag': 'ResearchActivity'}, {'end': 390, 'start': 387, 'tag': 'ResearchActivity'}, {'end': 456, 'start': 453, 'tag': 'ResearchActivity'}, {'end': 15, 'start': 0, 'tag': 'ClinicalAttribute'}]"
516,"Plasma p-tau181 was associated with PET-measured cerebral tau (AUC=83.08-93.11% across cohorts) and amyloid 13 (AUC=76.14-88.09% across cohorts) pathologies, and 1-year cognitive decline (p=0.0015) and hippocampal atrophy (p=0.015).","[{'end': 110, 'start': 100, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 221, 'start': 202, 'tag': 'DiseaseOrSyndrome'}, {'end': 6, 'start': 0, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 48, 'start': 40, 'tag': 'HealthCareActivity'}, {'end': 156, 'start': 145, 'tag': 'PathologicFunction'}, {'end': 168, 'start': 164, 'tag': 'TemporalConcept'}, {'end': 61, 'start': 58, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 61, 'start': 58, 'tag': 'BiologicallyActiveSubstance'}, {'end': 94, 'start': 87, 'tag': 'PopulationGroup'}, {'end': 143, 'start': 136, 'tag': 'PopulationGroup'}, {'end': 110, 'start': 100, 'tag': 'BiologicallyActiveSubstance'}, {'end': 15, 'start': 7, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 15, 'start': 7, 'tag': 'BiologicallyActiveSubstance'}, {'end': 186, 'start': 169, 'tag': 'DiseaseOrSyndrome'}, {'end': 39, 'start': 36, 'tag': 'HealthCareActivity'}, {'end': 66, 'start': 63, 'tag': 'ResearchActivity'}, {'end': 115, 'start': 112, 'tag': 'ResearchActivity'}, {'end': 15, 'start': 0, 'tag': 'ClinicalAttribute'}]"
517,"In the primary care cohort, plasma p-tau181 discriminated Alzheimer's disease from young adults (AUC=100%) and cognitively unimpaired older adults (AUC=84.44%), but not from MCI (AUC=55.00%).","[{'end': 19, 'start': 7, 'tag': 'HealthCareActivity'}, {'end': 95, 'start': 83, 'tag': 'PopulationGroup'}, {'end': 133, 'start': 111, 'tag': 'Finding'}, {'end': 146, 'start': 134, 'tag': 'PopulationGroup'}, {'end': 77, 'start': 58, 'tag': 'DiseaseOrSyndrome'}, {'end': 177, 'start': 174, 'tag': 'DiseaseOrSyndrome'}, {'end': 34, 'start': 28, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 43, 'start': 35, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 43, 'start': 35, 'tag': 'BiologicallyActiveSubstance'}, {'end': 26, 'start': 20, 'tag': 'PopulationGroup'}, {'end': 100, 'start': 97, 'tag': 'ResearchActivity'}, {'end': 151, 'start': 148, 'tag': 'ResearchActivity'}, {'end': 182, 'start': 179, 'tag': 'ResearchActivity'}, {'end': 43, 'start': 28, 'tag': 'ClinicalAttribute'}]"
518,"Interpretation Blood p-tau181 can predict tau and amyloid 13 pathologies, differentiate Alzheimer's disease from other neurodegenerative disorders, and identify Alzheimer's disease across the clinical continuum.Blood p-tau181 could be used as a simple, accessible, and scalable test for screening and diagnosis of Alzheimer's disease.","[{'end': 60, 'start': 50, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 146, 'start': 119, 'tag': 'DiseaseOrSyndrome'}, {'end': 20, 'start': 15, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 216, 'start': 211, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 45, 'start': 42, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 107, 'start': 88, 'tag': 'DiseaseOrSyndrome'}, {'end': 180, 'start': 161, 'tag': 'DiseaseOrSyndrome'}, {'end': 333, 'start': 314, 'tag': 'DiseaseOrSyndrome'}, {'end': 45, 'start': 42, 'tag': 'BiologicallyActiveSubstance'}, {'end': 296, 'start': 287, 'tag': 'HealthCareActivity'}, {'end': 296, 'start': 287, 'tag': 'ResearchActivity'}, {'end': 60, 'start': 50, 'tag': 'BiologicallyActiveSubstance'}, {'end': 310, 'start': 301, 'tag': 'HealthCareActivity'}, {'end': 29, 'start': 21, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 225, 'start': 217, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 29, 'start': 21, 'tag': 'BiologicallyActiveSubstance'}, {'end': 225, 'start': 217, 'tag': 'BiologicallyActiveSubstance'}, {'end': 282, 'start': 278, 'tag': 'ResearchActivity'}, {'end': 282, 'start': 278, 'tag': 'HealthCareActivity'}, {'end': 29, 'start': 15, 'tag': 'ClinicalAttribute'}, {'end': 72, 'start': 61, 'tag': 'PathologicFunction'}, {'end': 225, 'start': 211, 'tag': 'ClinicalAttribute'}]"
519,Copyright (C) 2020 Elsevier Ltd.,[]
520,All rights reserved.,[]
521,Background We evaluated A beta misfolding in combination with A beta(42/40) ratio as a prognostic tool for future clinical progression to mild cognitive impairment (MCI) or dementia due to Alzheimer's disease (AD) in individuals with subjective cognitive decline (SCD).,"[{'end': 41, 'start': 31, 'tag': 'CellOrMolecularDysfunction'}, {'end': 134, 'start': 114, 'tag': 'TemporalConcept'}, {'end': 262, 'start': 234, 'tag': 'DiseaseOrSyndrome'}, {'end': 267, 'start': 264, 'tag': 'DiseaseOrSyndrome'}, {'end': 208, 'start': 189, 'tag': 'DiseaseOrSyndrome'}, {'end': 212, 'start': 210, 'tag': 'DiseaseOrSyndrome'}, {'end': 228, 'start': 217, 'tag': 'PopulationGroup'}, {'end': 181, 'start': 173, 'tag': 'DiseaseOrSyndrome'}, {'end': 168, 'start': 165, 'tag': 'DiseaseOrSyndrome'}, {'end': 134, 'start': 123, 'tag': 'PathologicFunction'}, {'end': 134, 'start': 123, 'tag': 'TemporalConcept'}, {'end': 113, 'start': 107, 'tag': 'TemporalConcept'}, {'end': 163, 'start': 138, 'tag': 'DiseaseOrSyndrome'}, {'end': 30, 'start': 24, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 102, 'start': 87, 'tag': 'HealthCareActivity'}, {'end': 81, 'start': 62, 'tag': 'ClinicalAttribute'}]"
522,"Methods Baseline plasma samples (n = 203) from SCD subjects in the SCIENCe project and Amsterdam Dementia Cohort (age 61 +/- 9 years; 57% male, mean follow-up time 2.7 years) were analyzed using immuno-infrared-sensor technology.","[{'end': 82, 'start': 67, 'tag': 'ResearchActivity'}, {'end': 50, 'start': 47, 'tag': 'DiseaseOrSyndrome'}, {'end': 142, 'start': 138, 'tag': 'OrganismAttribute'}, {'end': 105, 'start': 97, 'tag': 'DiseaseOrSyndrome'}, {'end': 23, 'start': 17, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 163, 'start': 159, 'tag': 'TemporalConcept'}, {'end': 117, 'start': 114, 'tag': 'OrganismAttribute'}, {'end': 158, 'start': 149, 'tag': 'HealthCareActivity'}, {'end': 158, 'start': 149, 'tag': 'TemporalConcept'}, {'end': 132, 'start': 127, 'tag': 'TemporalConcept'}, {'end': 173, 'start': 168, 'tag': 'TemporalConcept'}, {'end': 59, 'start': 51, 'tag': 'PopulationGroup'}, {'end': 188, 'start': 180, 'tag': 'ResearchActivity'}, {'end': 112, 'start': 87, 'tag': 'ResearchActivity'}, {'end': 228, 'start': 195, 'tag': 'ResearchActivity'}]"
523,"Within 6 years of follow-up, 22 (11%) individuals progressed to MCI or dementia due to AD.","[{'end': 89, 'start': 87, 'tag': 'DiseaseOrSyndrome'}, {'end': 49, 'start': 38, 'tag': 'PopulationGroup'}, {'end': 79, 'start': 71, 'tag': 'DiseaseOrSyndrome'}, {'end': 67, 'start': 64, 'tag': 'DiseaseOrSyndrome'}, {'end': 27, 'start': 18, 'tag': 'HealthCareActivity'}, {'end': 27, 'start': 18, 'tag': 'TemporalConcept'}, {'end': 14, 'start': 9, 'tag': 'TemporalConcept'}]"
524,Sensor readout values > 1646 cm(- 1) reflected normal A beta folding; readouts at <= 1646 cm(- 1) reflected low and at < 1644 cm(- 1) high misfolding.,"[{'end': 6, 'start': 0, 'tag': 'ManufacturedObject'}, {'end': 149, 'start': 139, 'tag': 'CellOrMolecularDysfunction'}, {'end': 53, 'start': 47, 'tag': 'Finding'}, {'end': 111, 'start': 108, 'tag': 'Finding'}, {'end': 60, 'start': 54, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 138, 'start': 134, 'tag': 'Finding'}, {'end': 68, 'start': 61, 'tag': 'CellFunction'}, {'end': 21, 'start': 7, 'tag': 'ResearchActivity'}]"
525,We used Cox proportional hazard models to quantify A beta misfolding as a prognostic biomarker for progression to MCI and dementia due to AD.,"[{'end': 68, 'start': 58, 'tag': 'CellOrMolecularDysfunction'}, {'end': 94, 'start': 74, 'tag': 'ClinicalAttribute'}, {'end': 140, 'start': 138, 'tag': 'DiseaseOrSyndrome'}, {'end': 130, 'start': 122, 'tag': 'DiseaseOrSyndrome'}, {'end': 117, 'start': 114, 'tag': 'DiseaseOrSyndrome'}, {'end': 110, 'start': 99, 'tag': 'PathologicFunction'}, {'end': 110, 'start': 99, 'tag': 'TemporalConcept'}, {'end': 38, 'start': 8, 'tag': 'ResearchActivity'}, {'end': 57, 'start': 51, 'tag': 'AminoAcidPeptideOrProtein'}]"
526,The accuracy of the predicted development of MCI/AD was determined by time-dependent receiver operating characteristic (t-ROC) curve analyses that take individual follow-up and conversion times into account.,"[{'end': 51, 'start': 49, 'tag': 'DiseaseOrSyndrome'}, {'end': 41, 'start': 30, 'tag': 'BiologicFunction'}, {'end': 41, 'start': 30, 'tag': 'CellFunction'}, {'end': 48, 'start': 45, 'tag': 'DiseaseOrSyndrome'}, {'end': 12, 'start': 4, 'tag': 'Finding'}, {'end': 162, 'start': 152, 'tag': 'PopulationGroup'}, {'end': 162, 'start': 152, 'tag': 'OrganismAttribute'}, {'end': 172, 'start': 163, 'tag': 'HealthCareActivity'}, {'end': 172, 'start': 163, 'tag': 'TemporalConcept'}, {'end': 141, 'start': 70, 'tag': 'ResearchActivity'}, {'end': 187, 'start': 177, 'tag': 'Finding'}]"
527,"Statistical models were adjusted for age, sex, and APOE epsilon 4 status.","[{'end': 45, 'start': 42, 'tag': 'OrganismAttribute'}, {'end': 40, 'start': 37, 'tag': 'OrganismAttribute'}, {'end': 18, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 55, 'start': 51, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 55, 'start': 51, 'tag': 'BiologicallyActiveSubstance'}, {'end': 72, 'start': 66, 'tag': 'Finding'}, {'end': 65, 'start': 51, 'tag': 'GeneOrGenome'}]"
528,"Additionally, plasma A beta(42/40) data measured by SIMOA were statistically analyzed and compared.","[{'end': 57, 'start': 52, 'tag': 'ResearchActivity'}, {'end': 39, 'start': 35, 'tag': 'ResearchActivity'}, {'end': 20, 'start': 14, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 34, 'start': 21, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 85, 'start': 77, 'tag': 'ResearchActivity'}, {'end': 34, 'start': 14, 'tag': 'ClinicalAttribute'}, {'end': 34, 'start': 21, 'tag': 'BiologicallyActiveSubstance'}]"
529,Results All 22 patients who converted to MCI or AD-dementia within 6 years exhibited A beta misfolding at baseline.,"[{'end': 102, 'start': 92, 'tag': 'CellOrMolecularDysfunction'}, {'end': 50, 'start': 48, 'tag': 'DiseaseOrSyndrome'}, {'end': 23, 'start': 15, 'tag': 'PatientOrDisabledGroup'}, {'end': 59, 'start': 51, 'tag': 'DiseaseOrSyndrome'}, {'end': 44, 'start': 41, 'tag': 'DiseaseOrSyndrome'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 74, 'start': 69, 'tag': 'TemporalConcept'}, {'end': 91, 'start': 85, 'tag': 'AminoAcidPeptideOrProtein'}]"
530,Cox analyses revealed a hazard ratio (HR) of 19 (95% confidence interval [CI] 2.2-157.8) for future conversion of SCD subjects with high misfolding and of 11 (95% CI 1.0-110.1) for those with low misfolding.,"[{'end': 147, 'start': 137, 'tag': 'CellOrMolecularDysfunction'}, {'end': 206, 'start': 196, 'tag': 'CellOrMolecularDysfunction'}, {'end': 117, 'start': 114, 'tag': 'DiseaseOrSyndrome'}, {'end': 72, 'start': 53, 'tag': 'ResearchActivity'}, {'end': 195, 'start': 192, 'tag': 'Finding'}, {'end': 76, 'start': 74, 'tag': 'ResearchActivity'}, {'end': 165, 'start': 163, 'tag': 'ResearchActivity'}, {'end': 12, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 99, 'start': 93, 'tag': 'TemporalConcept'}, {'end': 126, 'start': 118, 'tag': 'PopulationGroup'}, {'end': 110, 'start': 100, 'tag': 'Finding'}, {'end': 136, 'start': 132, 'tag': 'Finding'}, {'end': 36, 'start': 24, 'tag': 'ResearchActivity'}]"
531,"T-ROC curve analyses yielded an area under the curve (AUC) of 0.94 (95% CI 0.86-1.00; 6-year follow-up) for A beta misfolding in an age, sex, and APOE epsilon 4 model.","[{'end': 125, 'start': 115, 'tag': 'CellOrMolecularDysfunction'}, {'end': 140, 'start': 137, 'tag': 'OrganismAttribute'}, {'end': 92, 'start': 88, 'tag': 'TemporalConcept'}, {'end': 52, 'start': 32, 'tag': 'ResearchActivity'}, {'end': 74, 'start': 72, 'tag': 'ResearchActivity'}, {'end': 135, 'start': 132, 'tag': 'OrganismAttribute'}, {'end': 102, 'start': 93, 'tag': 'HealthCareActivity'}, {'end': 102, 'start': 93, 'tag': 'TemporalConcept'}, {'end': 20, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 166, 'start': 161, 'tag': 'ResearchActivity'}, {'end': 150, 'start': 146, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 150, 'start': 146, 'tag': 'BiologicallyActiveSubstance'}, {'end': 114, 'start': 108, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 57, 'start': 54, 'tag': 'ResearchActivity'}, {'end': 160, 'start': 146, 'tag': 'GeneOrGenome'}]"
532,"A similar model with plasma A beta(42/40) ratio yielded an AUC of 0.92 (95% CI, 0.82-1.00).","[{'end': 27, 'start': 21, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 78, 'start': 76, 'tag': 'ResearchActivity'}, {'end': 15, 'start': 10, 'tag': 'ResearchActivity'}, {'end': 47, 'start': 21, 'tag': 'ClinicalAttribute'}, {'end': 62, 'start': 59, 'tag': 'ResearchActivity'}]"
533,"The AUC increased to 0.99 (95% CI, 0.99-1.00) after inclusion of both A beta misfolding and the A beta(42/40) ratio.","[{'end': 87, 'start': 77, 'tag': 'CellOrMolecularDysfunction'}, {'end': 61, 'start': 52, 'tag': 'CellComponent'}, {'end': 33, 'start': 31, 'tag': 'ResearchActivity'}, {'end': 76, 'start': 70, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 115, 'start': 96, 'tag': 'ClinicalAttribute'}, {'end': 7, 'start': 4, 'tag': 'ResearchActivity'}]"
534,Conclusions A panel of structure- and concentration-based plasma amyloid biomarkers may predict conversion to clinical MCI and dementia due to AD in cognitively unimpaired subjects.,"[{'end': 171, 'start': 149, 'tag': 'Finding'}, {'end': 51, 'start': 38, 'tag': 'BiologicFunction'}, {'end': 145, 'start': 143, 'tag': 'DiseaseOrSyndrome'}, {'end': 72, 'start': 65, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 72, 'start': 65, 'tag': 'BiologicallyActiveSubstance'}, {'end': 135, 'start': 127, 'tag': 'DiseaseOrSyndrome'}, {'end': 83, 'start': 73, 'tag': 'ClinicalAttribute'}, {'end': 122, 'start': 110, 'tag': 'DiseaseOrSyndrome'}, {'end': 64, 'start': 58, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 180, 'start': 172, 'tag': 'PopulationGroup'}, {'end': 106, 'start': 96, 'tag': 'Finding'}]"
535,These plasma biomarkers provide a noninvasive and cost-effective alternative for screening early AD pathological changes.,"[{'end': 45, 'start': 34, 'tag': 'Finding'}, {'end': 99, 'start': 97, 'tag': 'DiseaseOrSyndrome'}, {'end': 90, 'start': 81, 'tag': 'HealthCareActivity'}, {'end': 90, 'start': 81, 'tag': 'ResearchActivity'}, {'end': 23, 'start': 13, 'tag': 'ClinicalAttribute'}, {'end': 12, 'start': 6, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 96, 'start': 91, 'tag': 'TemporalConcept'}, {'end': 76, 'start': 50, 'tag': 'Finding'}]"
536,Follow-up studies and external validation in larger cohorts are in progress for further validation of our findings.,"[{'end': 75, 'start': 67, 'tag': 'TemporalConcept'}, {'end': 9, 'start': 0, 'tag': 'HealthCareActivity'}, {'end': 9, 'start': 0, 'tag': 'TemporalConcept'}, {'end': 41, 'start': 31, 'tag': 'ResearchActivity'}, {'end': 98, 'start': 88, 'tag': 'ResearchActivity'}, {'end': 59, 'start': 52, 'tag': 'PopulationGroup'}, {'end': 17, 'start': 10, 'tag': 'ResearchActivity'}]"
537,Disclosure of personal disease-related information to asymptomatic adults has been debated over the last century in medicine and research.,"[{'end': 10, 'start': 0, 'tag': 'IndividualBehavior'}, {'end': 22, 'start': 14, 'tag': 'OrganismAttribute'}, {'end': 66, 'start': 54, 'tag': 'Finding'}, {'end': 124, 'start': 116, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 137, 'start': 129, 'tag': 'ResearchActivity'}, {'end': 73, 'start': 67, 'tag': 'PopulationGroup'}, {'end': 112, 'start': 100, 'tag': 'TemporalConcept'}, {'end': 124, 'start': 116, 'tag': 'PharmacologicSubstance'}, {'end': 50, 'start': 23, 'tag': 'Finding'}]"
538,"Recently, Alzheimer's disease (AD) has been conceptualized as a continuum that begins with a preclinical stage in which biomarkers are present in the absence of cognitive impairment.","[{'end': 8, 'start': 0, 'tag': 'TemporalConcept'}, {'end': 29, 'start': 10, 'tag': 'DiseaseOrSyndrome'}, {'end': 130, 'start': 120, 'tag': 'ClinicalAttribute'}, {'end': 33, 'start': 31, 'tag': 'DiseaseOrSyndrome'}, {'end': 110, 'start': 93, 'tag': 'TemporalConcept'}, {'end': 181, 'start': 161, 'tag': 'DiseaseOrSyndrome'}]"
539,"Studies have begun assessing the safety, psychological, and behavioral effects of disclosing both AD-related genetic and biomarker information to cognitively unimpaired older adults.","[{'end': 78, 'start': 71, 'tag': 'PathologicFunction'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 39, 'start': 33, 'tag': 'HealthCareActivity'}, {'end': 100, 'start': 98, 'tag': 'DiseaseOrSyndrome'}, {'end': 130, 'start': 121, 'tag': 'ClinicalAttribute'}, {'end': 181, 'start': 169, 'tag': 'PopulationGroup'}, {'end': 168, 'start': 146, 'tag': 'Finding'}]"
540,"Yet, debate continues over the appropriate circumstances and methods for returning such information.",[]
541,This article outlines concerns with and rationale for AD biomarker disclosure and summarizes findings from prior studies.,"[{'end': 77, 'start': 67, 'tag': 'IndividualBehavior'}, {'end': 12, 'start': 5, 'tag': 'ResearchActivity'}, {'end': 120, 'start': 113, 'tag': 'ResearchActivity'}, {'end': 56, 'start': 54, 'tag': 'DiseaseOrSyndrome'}, {'end': 66, 'start': 57, 'tag': 'ClinicalAttribute'}]"
542,"Overall, this article aims to describe and respond to key questions concerning disclosure of amyloid positron emission tomography scan results to asymptomatic adults in a research setting.","[{'end': 89, 'start': 79, 'tag': 'IndividualBehavior'}, {'end': 134, 'start': 101, 'tag': 'HealthCareActivity'}, {'end': 158, 'start': 146, 'tag': 'Finding'}, {'end': 21, 'start': 14, 'tag': 'ResearchActivity'}, {'end': 179, 'start': 171, 'tag': 'ResearchActivity'}, {'end': 165, 'start': 159, 'tag': 'PopulationGroup'}, {'end': 100, 'start': 93, 'tag': 'AminoAcidPeptideOrProtein'}]"
543,"Moving forward, such conditions are important to consider as interventions target the preclinical phase of AD and normalize disclosing biomarker information to cognitively unimpaired persons.","[{'end': 123, 'start': 114, 'tag': 'ResearchActivity'}, {'end': 190, 'start': 183, 'tag': 'PopulationGroup'}, {'end': 74, 'start': 61, 'tag': 'HealthCareActivity'}, {'end': 74, 'start': 61, 'tag': 'ResearchActivity'}, {'end': 103, 'start': 86, 'tag': 'TemporalConcept'}, {'end': 109, 'start': 107, 'tag': 'DiseaseOrSyndrome'}, {'end': 144, 'start': 135, 'tag': 'ClinicalAttribute'}, {'end': 182, 'start': 160, 'tag': 'Finding'}]"
544,"The progressive, chronic nature of Alzheimer's disease (AD), a form of dementia, defaces the adulthood of elderly individuals.","[{'end': 102, 'start': 93, 'tag': 'TemporalConcept'}, {'end': 24, 'start': 17, 'tag': 'TemporalConcept'}, {'end': 54, 'start': 35, 'tag': 'DiseaseOrSyndrome'}, {'end': 58, 'start': 56, 'tag': 'DiseaseOrSyndrome'}, {'end': 125, 'start': 114, 'tag': 'PopulationGroup'}, {'end': 79, 'start': 71, 'tag': 'DiseaseOrSyndrome'}, {'end': 15, 'start': 4, 'tag': 'TemporalConcept'}, {'end': 113, 'start': 106, 'tag': 'PopulationGroup'}]"
545,"The pathogenesis of the condition is primarily unascertained, turning the treatment efficacy more arduous.","[{'end': 33, 'start': 24, 'tag': 'DiseaseOrSyndrome'}, {'end': 16, 'start': 4, 'tag': 'PathologicFunction'}, {'end': 83, 'start': 74, 'tag': 'HealthCareActivity'}, {'end': 83, 'start': 74, 'tag': 'ResearchActivity'}]"
546,"Therefore, understanding the genetic etiology of AD is essential to identifying targeted therapeutics.","[{'end': 45, 'start': 37, 'tag': 'Finding'}, {'end': 101, 'start': 89, 'tag': 'HealthCareActivity'}, {'end': 51, 'start': 49, 'tag': 'DiseaseOrSyndrome'}, {'end': 24, 'start': 11, 'tag': 'BiologicFunction'}]"
547,This study aimed to use machine-learning techniques of expressed genes in patients with AD to identify potential biomarkers that can be used for future therapy.,"[{'end': 70, 'start': 65, 'tag': 'GeneOrGenome'}, {'end': 159, 'start': 152, 'tag': 'HealthCareActivity'}, {'end': 64, 'start': 55, 'tag': 'CellFunction'}, {'end': 90, 'start': 88, 'tag': 'DiseaseOrSyndrome'}, {'end': 123, 'start': 103, 'tag': 'ClinicalAttribute'}, {'end': 82, 'start': 74, 'tag': 'PatientOrDisabledGroup'}, {'end': 51, 'start': 24, 'tag': 'MachineActivity'}, {'end': 10, 'start': 5, 'tag': 'ResearchActivity'}, {'end': 151, 'start': 145, 'tag': 'TemporalConcept'}]"
548,The dataset is accessed from the Gene Expression Omnibus (GEO) database (Accession Number: GSE36980).,"[{'end': 71, 'start': 33, 'tag': 'ResearchActivity'}, {'end': 11, 'start': 4, 'tag': 'ResearchActivity'}, {'end': 99, 'start': 91, 'tag': 'ResearchActivity'}]"
549,"The subgroups (AD blood samples from frontal, hippocampal, and temporal regions) are individually investigated against non-AD models.","[{'end': 17, 'start': 15, 'tag': 'DiseaseOrSyndrome'}, {'end': 125, 'start': 123, 'tag': 'DiseaseOrSyndrome'}, {'end': 71, 'start': 63, 'tag': 'TemporalConcept'}, {'end': 79, 'start': 72, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 57, 'start': 46, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 132, 'start': 126, 'tag': 'ResearchActivity'}, {'end': 31, 'start': 18, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 79, 'start': 63, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 110, 'start': 98, 'tag': 'HealthCareActivity'}, {'end': 79, 'start': 72, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 44, 'start': 37, 'tag': 'BodyPartOrganOrOrganComponent'}]"
550,Prioritized gene cluster analyses are conducted with the STRING database.,"[{'end': 72, 'start': 57, 'tag': 'ResearchActivity'}, {'end': 33, 'start': 0, 'tag': 'ResearchActivity'}]"
551,The candidate gene biomarkers were trained with various supervised machine-learning (ML) classification algorithms.,"[{'end': 29, 'start': 19, 'tag': 'ClinicalAttribute'}, {'end': 114, 'start': 56, 'tag': 'MachineActivity'}]"
552,The interpretation of the model prediction is perpetrated with explainable artificial intelligence (AI) techniques.,"[{'end': 31, 'start': 26, 'tag': 'ResearchActivity'}, {'end': 42, 'start': 32, 'tag': 'Finding'}, {'end': 114, 'start': 63, 'tag': 'MachineActivity'}]"
553,"This experiment revealed 34, 60, and 28 genes as target biomarkers of AD mapped from the frontal, hippocampal, and temporal regions.","[{'end': 45, 'start': 40, 'tag': 'GeneOrGenome'}, {'end': 79, 'start': 73, 'tag': 'ResearchActivity'}, {'end': 15, 'start': 5, 'tag': 'ResearchActivity'}, {'end': 72, 'start': 70, 'tag': 'DiseaseOrSyndrome'}, {'end': 66, 'start': 56, 'tag': 'ClinicalAttribute'}, {'end': 123, 'start': 115, 'tag': 'TemporalConcept'}, {'end': 131, 'start': 124, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 109, 'start': 98, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 131, 'start': 115, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 131, 'start': 124, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 96, 'start': 89, 'tag': 'BodyPartOrganOrOrganComponent'}]"
554,It is identified ORAI2 as a shared biomarker in all three areas strongly associated with AD's progression.,"[{'end': 22, 'start': 17, 'tag': 'GeneOrGenome'}, {'end': 22, 'start': 17, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 91, 'start': 89, 'tag': 'DiseaseOrSyndrome'}, {'end': 44, 'start': 35, 'tag': 'ClinicalAttribute'}, {'end': 105, 'start': 94, 'tag': 'PathologicFunction'}, {'end': 105, 'start': 94, 'tag': 'TemporalConcept'}, {'end': 22, 'start': 17, 'tag': 'BiologicallyActiveSubstance'}]"
555,The pathway analysis showed that STIM1 and TRPC3 are strongly associated with ORAI2.,"[{'end': 38, 'start': 33, 'tag': 'GeneOrGenome'}, {'end': 38, 'start': 33, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 48, 'start': 43, 'tag': 'GeneOrGenome'}, {'end': 83, 'start': 78, 'tag': 'GeneOrGenome'}, {'end': 83, 'start': 78, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 20, 'start': 12, 'tag': 'ResearchActivity'}, {'end': 11, 'start': 4, 'tag': 'CellFunction'}, {'end': 83, 'start': 78, 'tag': 'BiologicallyActiveSubstance'}, {'end': 38, 'start': 33, 'tag': 'BiologicallyActiveSubstance'}, {'end': 48, 'start': 43, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 48, 'start': 43, 'tag': 'BiologicallyActiveSubstance'}]"
556,"We found three hub genes, TPI1, STIM1, and TRPC3, in the network of the ORAI2 gene that might be involved in the molecular pathogenesis of AD.","[{'end': 30, 'start': 26, 'tag': 'GeneOrGenome'}, {'end': 37, 'start': 32, 'tag': 'GeneOrGenome'}, {'end': 37, 'start': 32, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 48, 'start': 43, 'tag': 'GeneOrGenome'}, {'end': 64, 'start': 57, 'tag': 'PopulationGroup'}, {'end': 64, 'start': 57, 'tag': 'CellFunction'}, {'end': 82, 'start': 72, 'tag': 'GeneOrGenome'}, {'end': 135, 'start': 113, 'tag': 'PathologicFunction'}, {'end': 141, 'start': 139, 'tag': 'DiseaseOrSyndrome'}, {'end': 37, 'start': 32, 'tag': 'BiologicallyActiveSubstance'}, {'end': 48, 'start': 43, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 48, 'start': 43, 'tag': 'BiologicallyActiveSubstance'}]"
557,Naive Bayes classified the samples of different groups by fivefold cross-validation with 100% accuracy.,"[{'end': 83, 'start': 67, 'tag': 'ResearchActivity'}, {'end': 54, 'start': 48, 'tag': 'PopulationGroup'}, {'end': 102, 'start': 94, 'tag': 'Finding'}]"
558,AI and ML are promising tools in identifying disease-associated genes that will advance the field of targeted therapeutics against genetic diseases.,"[{'end': 147, 'start': 131, 'tag': 'DiseaseOrSyndrome'}, {'end': 69, 'start': 45, 'tag': 'GeneOrGenome'}, {'end': 122, 'start': 110, 'tag': 'HealthCareActivity'}, {'end': 2, 'start': 0, 'tag': 'MachineActivity'}, {'end': 9, 'start': 7, 'tag': 'MachineActivity'}]"
559,"Background We investigated the potential associations between cerebro-spinal fluid (CSF) levels of phosphorylated tau (P-tau) and total tau (T-tau) with short-term response to cholinesterase inhibitor (ChEI) treatment, longitudinal outcome and progression rates in Alzheimer's disease (AD).","[{'end': 200, 'start': 176, 'tag': 'Chemical'}, {'end': 200, 'start': 176, 'tag': 'PharmacologicSubstance'}, {'end': 206, 'start': 202, 'tag': 'Chemical'}, {'end': 206, 'start': 202, 'tag': 'PharmacologicSubstance'}, {'end': 82, 'start': 62, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 146, 'start': 141, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 146, 'start': 141, 'tag': 'BiologicallyActiveSubstance'}, {'end': 124, 'start': 119, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 124, 'start': 119, 'tag': 'BiologicallyActiveSubstance'}, {'end': 284, 'start': 265, 'tag': 'DiseaseOrSyndrome'}, {'end': 87, 'start': 84, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 288, 'start': 286, 'tag': 'DiseaseOrSyndrome'}, {'end': 139, 'start': 130, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 139, 'start': 130, 'tag': 'BiologicallyActiveSubstance'}, {'end': 117, 'start': 99, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 117, 'start': 99, 'tag': 'BiologicallyActiveSubstance'}, {'end': 217, 'start': 208, 'tag': 'HealthCareActivity'}, {'end': 217, 'start': 208, 'tag': 'ResearchActivity'}, {'end': 255, 'start': 244, 'tag': 'PathologicFunction'}, {'end': 255, 'start': 244, 'tag': 'TemporalConcept'}, {'end': 163, 'start': 153, 'tag': 'TemporalConcept'}, {'end': 172, 'start': 164, 'tag': 'OrganismAttribute'}, {'end': 231, 'start': 219, 'tag': 'ResearchActivity'}, {'end': 239, 'start': 232, 'tag': 'Finding'}]"
560,"Methods This prospective, observational study included 129 participants clinically diagnosed with mild-to-moderate AD, who underwent a lumbar puncture.","[{'end': 24, 'start': 13, 'tag': 'BiologicFunction'}, {'end': 45, 'start': 26, 'tag': 'ResearchActivity'}, {'end': 114, 'start': 106, 'tag': 'Finding'}, {'end': 150, 'start': 135, 'tag': 'HealthCareActivity'}, {'end': 117, 'start': 115, 'tag': 'DiseaseOrSyndrome'}, {'end': 92, 'start': 83, 'tag': 'HealthCareActivity'}, {'end': 71, 'start': 59, 'tag': 'PopulationGroup'}, {'end': 102, 'start': 98, 'tag': 'Finding'}]"
561,"The CSF biomarkers amyloid-beta(1-42) (A beta(42)), P-tau and T-tau were analysed with xMAP technology.","[{'end': 67, 'start': 62, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 67, 'start': 62, 'tag': 'BiologicallyActiveSubstance'}, {'end': 57, 'start': 52, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 57, 'start': 52, 'tag': 'BiologicallyActiveSubstance'}, {'end': 7, 'start': 4, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 37, 'start': 19, 'tag': 'BiologicallyActiveSubstance'}, {'end': 18, 'start': 8, 'tag': 'ClinicalAttribute'}, {'end': 37, 'start': 19, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 45, 'start': 39, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 102, 'start': 87, 'tag': 'ResearchActivity'}]"
562,"Cognitive, global, instrumental and basic activities of daily living (ADL) capacities at the start of ChEI therapy and semi-annually over 3 years were evaluated.","[{'end': 68, 'start': 42, 'tag': 'Finding'}, {'end': 31, 'start': 19, 'tag': 'Finding'}, {'end': 85, 'start': 75, 'tag': 'ClinicalAttribute'}, {'end': 132, 'start': 119, 'tag': 'TemporalConcept'}, {'end': 132, 'start': 124, 'tag': 'TemporalConcept'}, {'end': 68, 'start': 42, 'tag': 'BiologicFunction'}, {'end': 145, 'start': 140, 'tag': 'TemporalConcept'}, {'end': 114, 'start': 107, 'tag': 'HealthCareActivity'}, {'end': 61, 'start': 56, 'tag': 'TemporalConcept'}, {'end': 106, 'start': 102, 'tag': 'PharmacologicSubstance'}, {'end': 106, 'start': 102, 'tag': 'Chemical'}, {'end': 73, 'start': 70, 'tag': 'BiologicFunction'}]"
563,Results All patients had abnormal A beta(42) (A+).,"[{'end': 33, 'start': 25, 'tag': 'Finding'}, {'end': 20, 'start': 12, 'tag': 'PatientOrDisabledGroup'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 40, 'start': 34, 'tag': 'AminoAcidPeptideOrProtein'}]"
564,"Fifty-eight individuals (45%) exhibited normal P-tau and T-tau (A+ T- (N)-), 12 (9%) abnormal P-tau/normal T-tau (A+ T+ (N)-), 17 (13%) normal P-tau/abnormal T-tau (A+ T- (N)+) and 42 (33%) abnormal P-tau and T-tau (A+ T+ (N)+).","[{'end': 62, 'start': 57, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 112, 'start': 107, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 163, 'start': 158, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 214, 'start': 209, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 62, 'start': 57, 'tag': 'BiologicallyActiveSubstance'}, {'end': 112, 'start': 107, 'tag': 'BiologicallyActiveSubstance'}, {'end': 163, 'start': 158, 'tag': 'BiologicallyActiveSubstance'}, {'end': 214, 'start': 209, 'tag': 'BiologicallyActiveSubstance'}, {'end': 46, 'start': 40, 'tag': 'Finding'}, {'end': 142, 'start': 136, 'tag': 'Finding'}, {'end': 93, 'start': 85, 'tag': 'Finding'}, {'end': 157, 'start': 149, 'tag': 'Finding'}, {'end': 198, 'start': 190, 'tag': 'Finding'}, {'end': 52, 'start': 47, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 99, 'start': 94, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 148, 'start': 143, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 204, 'start': 199, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 52, 'start': 47, 'tag': 'BiologicallyActiveSubstance'}, {'end': 99, 'start': 94, 'tag': 'BiologicallyActiveSubstance'}, {'end': 148, 'start': 143, 'tag': 'BiologicallyActiveSubstance'}, {'end': 204, 'start': 199, 'tag': 'BiologicallyActiveSubstance'}, {'end': 23, 'start': 12, 'tag': 'PopulationGroup'}, {'end': 106, 'start': 100, 'tag': 'Finding'}]"
565,The participants with A+ T+ (N)+ were younger than A+ T- (N)+ at the estimated onset of AD and the initiation of ChEIs.,"[{'end': 109, 'start': 99, 'tag': 'TemporalConcept'}, {'end': 90, 'start': 88, 'tag': 'DiseaseOrSyndrome'}, {'end': 16, 'start': 4, 'tag': 'PopulationGroup'}, {'end': 84, 'start': 79, 'tag': 'TemporalConcept'}, {'end': 45, 'start': 38, 'tag': 'TemporalConcept'}, {'end': 118, 'start': 113, 'tag': 'Chemical'}, {'end': 118, 'start': 113, 'tag': 'PharmacologicSubstance'}]"
566,The proportion of 6-month responders to ChEI and deterioration/year after start of treatment did not differ between the AT(N) profiles in any scales.,"[{'end': 44, 'start': 40, 'tag': 'Chemical'}, {'end': 44, 'start': 40, 'tag': 'PharmacologicSubstance'}, {'end': 148, 'start': 142, 'tag': 'ManufacturedObject'}, {'end': 148, 'start': 142, 'tag': 'ResearchActivity'}, {'end': 134, 'start': 120, 'tag': 'ResearchActivity'}, {'end': 67, 'start': 63, 'tag': 'TemporalConcept'}, {'end': 92, 'start': 83, 'tag': 'HealthCareActivity'}, {'end': 92, 'start': 83, 'tag': 'ResearchActivity'}, {'end': 25, 'start': 20, 'tag': 'TemporalConcept'}, {'end': 134, 'start': 126, 'tag': 'ResearchActivity'}, {'end': 62, 'start': 49, 'tag': 'Finding'}, {'end': 79, 'start': 74, 'tag': 'TemporalConcept'}]"
567,"A higher percentage of globally improved/unchanged patients was exhibited in the A+ T- (N)- group after 12, 30 and 36 months of ChEI therapy but not at other assessments.","[{'end': 169, 'start': 158, 'tag': 'HealthCareActivity'}, {'end': 40, 'start': 32, 'tag': 'Finding'}, {'end': 50, 'start': 41, 'tag': 'Finding'}, {'end': 59, 'start': 51, 'tag': 'PatientOrDisabledGroup'}, {'end': 124, 'start': 118, 'tag': 'TemporalConcept'}, {'end': 140, 'start': 133, 'tag': 'HealthCareActivity'}, {'end': 97, 'start': 92, 'tag': 'PopulationGroup'}, {'end': 132, 'start': 128, 'tag': 'Chemical'}, {'end': 132, 'start': 128, 'tag': 'PharmacologicSubstance'}]"
568,"In apolipoprotein E (APOE) epsilon 4-carriers, linear relationships were found between greater cognitive decline/year and higher tau; Mini-Mental State Examination score - T-tau (r(s) = - 0.257, p = 0.014) and Alzheimer's Disease Assessment Scale-cognitive subscale - P-tau (r(s) = - 0.242, p = 0.022).","[{'end': 19, 'start': 3, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 19, 'start': 3, 'tag': 'BiologicallyActiveSubstance'}, {'end': 265, 'start': 210, 'tag': 'HealthCareActivity'}, {'end': 177, 'start': 172, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 177, 'start': 172, 'tag': 'BiologicallyActiveSubstance'}, {'end': 117, 'start': 113, 'tag': 'TemporalConcept'}, {'end': 273, 'start': 268, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 273, 'start': 268, 'tag': 'BiologicallyActiveSubstance'}, {'end': 132, 'start': 129, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 132, 'start': 129, 'tag': 'BiologicallyActiveSubstance'}, {'end': 163, 'start': 134, 'tag': 'HealthCareActivity'}, {'end': 169, 'start': 164, 'tag': 'Finding'}, {'end': 67, 'start': 54, 'tag': 'Finding'}, {'end': 229, 'start': 210, 'tag': 'DiseaseOrSyndrome'}, {'end': 112, 'start': 95, 'tag': 'DiseaseOrSyndrome'}, {'end': 25, 'start': 21, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 25, 'start': 21, 'tag': 'BiologicallyActiveSubstance'}, {'end': 45, 'start': 37, 'tag': 'PopulationGroup'}, {'end': 36, 'start': 27, 'tag': 'GeneOrGenome'}, {'end': 19, 'start': 3, 'tag': 'GeneOrGenome'}]"
569,"A correlation between faster progression in instrumental ADL (IADL) and higher T-tau was also detected (r(s) = - 0.232, p = 0.028).","[{'end': 84, 'start': 79, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 84, 'start': 79, 'tag': 'BiologicallyActiveSubstance'}, {'end': 40, 'start': 29, 'tag': 'PathologicFunction'}, {'end': 40, 'start': 29, 'tag': 'TemporalConcept'}, {'end': 60, 'start': 44, 'tag': 'Finding'}, {'end': 66, 'start': 62, 'tag': 'Finding'}]"
570,These associations were not demonstrated in non-epsilon 4-carriers.,"[{'end': 66, 'start': 58, 'tag': 'PopulationGroup'}]"
571,"Conclusions Younger age and faster global deterioration were observed in AD patients with pathologic tau and neurodegeneration, whereas more rapid cognitive and IADL decline were related to higher P-tau or T-tau in APOE epsilon 4-carriers only.","[{'end': 104, 'start': 90, 'tag': 'CellOrMolecularDysfunction'}, {'end': 211, 'start': 206, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 211, 'start': 206, 'tag': 'BiologicallyActiveSubstance'}, {'end': 202, 'start': 197, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 202, 'start': 197, 'tag': 'BiologicallyActiveSubstance'}, {'end': 75, 'start': 73, 'tag': 'DiseaseOrSyndrome'}, {'end': 84, 'start': 76, 'tag': 'PatientOrDisabledGroup'}, {'end': 23, 'start': 20, 'tag': 'OrganismAttribute'}, {'end': 238, 'start': 230, 'tag': 'PopulationGroup'}, {'end': 126, 'start': 109, 'tag': 'CellOrMolecularDysfunction'}, {'end': 229, 'start': 215, 'tag': 'GeneOrGenome'}, {'end': 19, 'start': 12, 'tag': 'TemporalConcept'}, {'end': 55, 'start': 42, 'tag': 'Finding'}, {'end': 165, 'start': 161, 'tag': 'Finding'}, {'end': 173, 'start': 166, 'tag': 'Finding'}]"
572,The results might indicate an association between more pronounced tau pathology/neuronal injury and the APOE epsilon 4-allele leading to a worse prognosis.,"[{'end': 95, 'start': 89, 'tag': 'InjuryOrPoisoning'}, {'end': 144, 'start': 139, 'tag': 'Finding'}, {'end': 154, 'start': 145, 'tag': 'HealthCareActivity'}, {'end': 88, 'start': 80, 'tag': 'Cell'}, {'end': 79, 'start': 66, 'tag': 'PathologicFunction'}, {'end': 125, 'start': 104, 'tag': 'GeneOrGenome'}]"
573,"Our findings showed that the AT(N) biomarker profiles have limited utility to predict AD progression rates and, thus, measure change and interpreting outcomes from clinical trials of future therapies.","[{'end': 199, 'start': 190, 'tag': 'HealthCareActivity'}, {'end': 179, 'start': 164, 'tag': 'ResearchActivity'}, {'end': 88, 'start': 86, 'tag': 'DiseaseOrSyndrome'}, {'end': 44, 'start': 35, 'tag': 'ClinicalAttribute'}, {'end': 100, 'start': 89, 'tag': 'PathologicFunction'}, {'end': 100, 'start': 89, 'tag': 'TemporalConcept'}, {'end': 158, 'start': 150, 'tag': 'Finding'}, {'end': 189, 'start': 183, 'tag': 'TemporalConcept'}, {'end': 53, 'start': 45, 'tag': 'ResearchActivity'}]"
574,BackgroundIt is possible to calculate the number of years to the expected clinical onset (YECO) of autosomal-dominant Alzheimer's disease (adAD).,"[{'end': 88, 'start': 74, 'tag': 'TemporalConcept'}, {'end': 137, 'start': 99, 'tag': 'DiseaseOrSyndrome'}, {'end': 57, 'start': 52, 'tag': 'TemporalConcept'}, {'end': 143, 'start': 139, 'tag': 'DiseaseOrSyndrome'}, {'end': 88, 'start': 52, 'tag': 'ClinicalAttribute'}, {'end': 94, 'start': 90, 'tag': 'ClinicalAttribute'}]"
575,A similar time scale is lacking for sporadic Alzheimer's disease (sAD).,"[{'end': 69, 'start': 66, 'tag': 'DiseaseOrSyndrome'}, {'end': 44, 'start': 36, 'tag': 'TemporalConcept'}, {'end': 64, 'start': 36, 'tag': 'DiseaseOrSyndrome'}, {'end': 64, 'start': 45, 'tag': 'DiseaseOrSyndrome'}, {'end': 14, 'start': 10, 'tag': 'TemporalConcept'}]"
576,"The purpose was to design and validate a time scale in YECO for patients with sAD in relation to CSF and PET biomarkers.MethodsPatients diagnosed with Alzheimer's disease (AD, n = 48) or mild cognitive impairment (MCI, n = 46) participated in the study.","[{'end': 81, 'start': 78, 'tag': 'DiseaseOrSyndrome'}, {'end': 170, 'start': 151, 'tag': 'DiseaseOrSyndrome'}, {'end': 100, 'start': 97, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 174, 'start': 172, 'tag': 'DiseaseOrSyndrome'}, {'end': 108, 'start': 105, 'tag': 'HealthCareActivity'}, {'end': 119, 'start': 109, 'tag': 'ClinicalAttribute'}, {'end': 72, 'start': 64, 'tag': 'PatientOrDisabledGroup'}, {'end': 252, 'start': 247, 'tag': 'ResearchActivity'}, {'end': 212, 'start': 187, 'tag': 'DiseaseOrSyndrome'}, {'end': 217, 'start': 214, 'tag': 'DiseaseOrSyndrome'}, {'end': 145, 'start': 136, 'tag': 'HealthCareActivity'}, {'end': 45, 'start': 41, 'tag': 'TemporalConcept'}, {'end': 25, 'start': 19, 'tag': 'ResearchActivity'}, {'end': 25, 'start': 19, 'tag': 'HealthCareActivity'}, {'end': 135, 'start': 127, 'tag': 'PatientOrDisabledGroup'}, {'end': 59, 'start': 55, 'tag': 'ClinicalAttribute'}]"
577,"They underwent a standardized clinical examination at the Memory clinic, Karolinska University Hospital, Stockholm, Sweden, which included present and previous medical history, laboratory screening, cognitive assessment, CSF biomarkers (A beta(42), total-tau, and p-tau), and an MRI of the brain.","[{'end': 175, 'start': 160, 'tag': 'Finding'}, {'end': 197, 'start': 177, 'tag': 'ResearchActivity'}, {'end': 94, 'start': 84, 'tag': 'HealthCareRelatedOrganization'}, {'end': 219, 'start': 199, 'tag': 'HealthCareActivity'}, {'end': 224, 'start': 221, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 247, 'start': 237, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 282, 'start': 279, 'tag': 'HealthCareActivity'}, {'end': 235, 'start': 225, 'tag': 'ClinicalAttribute'}, {'end': 295, 'start': 290, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 269, 'start': 264, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 269, 'start': 264, 'tag': 'BiologicallyActiveSubstance'}, {'end': 258, 'start': 249, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 258, 'start': 249, 'tag': 'BiologicallyActiveSubstance'}, {'end': 50, 'start': 30, 'tag': 'HealthCareActivity'}, {'end': 103, 'start': 58, 'tag': 'HealthCareRelatedOrganization'}, {'end': 247, 'start': 237, 'tag': 'BiologicallyActiveSubstance'}]"
578,"They were also assessed with two PET tracers, C-11-Pittsburgh compound B and F-18-fluorodeoxyglucose.","[{'end': 36, 'start': 33, 'tag': 'HealthCareActivity'}, {'end': 44, 'start': 37, 'tag': 'Chemical'}, {'end': 72, 'start': 46, 'tag': 'Chemical'}, {'end': 100, 'start': 77, 'tag': 'Chemical'}]"
579,"Assuming concordance of cognitive decline in sAD and adAD, YECO for these patients was calculated using equations for the relationship between cognitive performance, YECO, and years of education in adAD (Almkvist et al.","[{'end': 48, 'start': 45, 'tag': 'DiseaseOrSyndrome'}, {'end': 41, 'start': 24, 'tag': 'DiseaseOrSyndrome'}, {'end': 134, 'start': 122, 'tag': 'Finding'}, {'end': 82, 'start': 74, 'tag': 'PatientOrDisabledGroup'}, {'end': 181, 'start': 176, 'tag': 'TemporalConcept'}, {'end': 164, 'start': 143, 'tag': 'Finding'}, {'end': 194, 'start': 185, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 57, 'start': 53, 'tag': 'DiseaseOrSyndrome'}, {'end': 202, 'start': 198, 'tag': 'DiseaseOrSyndrome'}, {'end': 170, 'start': 166, 'tag': 'ClinicalAttribute'}, {'end': 63, 'start': 59, 'tag': 'ClinicalAttribute'}]"
580,"J Int Neuropsychol Soc 23:195-203, 2017).ResultsThe mean current point of disease progression was 3.2 years after the estimated clinical onset in patients with sAD and 3.4 years prior to the estimated clinical onset in patients with MCI, as indicated by the median YECO from five cognitive tests.","[{'end': 295, 'start': 280, 'tag': 'HealthCareActivity'}, {'end': 295, 'start': 280, 'tag': 'ResearchActivity'}, {'end': 142, 'start': 128, 'tag': 'TemporalConcept'}, {'end': 215, 'start': 201, 'tag': 'TemporalConcept'}, {'end': 163, 'start': 160, 'tag': 'DiseaseOrSyndrome'}, {'end': 93, 'start': 82, 'tag': 'PathologicFunction'}, {'end': 93, 'start': 82, 'tag': 'TemporalConcept'}, {'end': 154, 'start': 146, 'tag': 'PatientOrDisabledGroup'}, {'end': 227, 'start': 219, 'tag': 'PatientOrDisabledGroup'}, {'end': 107, 'start': 102, 'tag': 'TemporalConcept'}, {'end': 177, 'start': 172, 'tag': 'TemporalConcept'}, {'end': 64, 'start': 57, 'tag': 'TemporalConcept'}, {'end': 236, 'start': 233, 'tag': 'DiseaseOrSyndrome'}, {'end': 93, 'start': 74, 'tag': 'PathologicFunction'}, {'end': 295, 'start': 290, 'tag': 'ResearchActivity'}, {'end': 295, 'start': 290, 'tag': 'HealthCareActivity'}, {'end': 264, 'start': 258, 'tag': 'ResearchActivity'}, {'end': 269, 'start': 265, 'tag': 'ClinicalAttribute'}]"
581,"The associations between YECO and biomarkers were significant, while those between chronological age and biomarkers were nonsignificant.","[{'end': 96, 'start': 83, 'tag': 'OrganismAttribute'}, {'end': 100, 'start': 97, 'tag': 'OrganismAttribute'}, {'end': 44, 'start': 34, 'tag': 'ClinicalAttribute'}, {'end': 115, 'start': 105, 'tag': 'ClinicalAttribute'}, {'end': 29, 'start': 25, 'tag': 'ClinicalAttribute'}]"
582,The estimated disease onset (chronological age minus YECO) followed a bimodal distribution with frequency maxima before (early-onset) and after (late-onset) 65 years of age.,"[{'end': 46, 'start': 29, 'tag': 'OrganismAttribute'}, {'end': 90, 'start': 78, 'tag': 'BiologicFunction'}, {'end': 90, 'start': 78, 'tag': 'HealthCareRelatedOrganization'}, {'end': 119, 'start': 113, 'tag': 'TemporalConcept'}, {'end': 105, 'start': 96, 'tag': 'TemporalConcept'}, {'end': 172, 'start': 169, 'tag': 'OrganismAttribute'}, {'end': 165, 'start': 160, 'tag': 'TemporalConcept'}, {'end': 132, 'start': 127, 'tag': 'TemporalConcept'}, {'end': 126, 'start': 121, 'tag': 'TemporalConcept'}, {'end': 27, 'start': 14, 'tag': 'TemporalConcept'}, {'end': 155, 'start': 145, 'tag': 'TemporalConcept'}, {'end': 57, 'start': 53, 'tag': 'ClinicalAttribute'}]"
583,"The early- and late-onset subgroups differed significantly in biomarkers and cognition, but after control for YECO, this difference disappeared for all except the APOE e4 gene (more frequent in early- than in late-onset).ConclusionsA novel time scale in years of disease progression based on cognition was designed and validated in patients with AD using CSF and PET biomarkers.","[{'end': 190, 'start': 182, 'tag': 'TemporalConcept'}, {'end': 358, 'start': 355, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 348, 'start': 346, 'tag': 'DiseaseOrSyndrome'}, {'end': 366, 'start': 363, 'tag': 'HealthCareActivity'}, {'end': 282, 'start': 271, 'tag': 'PathologicFunction'}, {'end': 282, 'start': 271, 'tag': 'TemporalConcept'}, {'end': 72, 'start': 62, 'tag': 'ClinicalAttribute'}, {'end': 377, 'start': 367, 'tag': 'ClinicalAttribute'}, {'end': 340, 'start': 332, 'tag': 'PatientOrDisabledGroup'}, {'end': 259, 'start': 254, 'tag': 'TemporalConcept'}, {'end': 9, 'start': 4, 'tag': 'TemporalConcept'}, {'end': 199, 'start': 194, 'tag': 'TemporalConcept'}, {'end': 86, 'start': 77, 'tag': 'BiologicFunction'}, {'end': 301, 'start': 292, 'tag': 'BiologicFunction'}, {'end': 244, 'start': 240, 'tag': 'TemporalConcept'}, {'end': 167, 'start': 163, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 167, 'start': 163, 'tag': 'BiologicallyActiveSubstance'}, {'end': 282, 'start': 263, 'tag': 'PathologicFunction'}, {'end': 105, 'start': 98, 'tag': 'PopulationGroup'}, {'end': 25, 'start': 15, 'tag': 'TemporalConcept'}, {'end': 219, 'start': 209, 'tag': 'TemporalConcept'}, {'end': 114, 'start': 110, 'tag': 'ClinicalAttribute'}, {'end': 175, 'start': 163, 'tag': 'GeneOrGenome'}]"
584,Two early- and late-disease onset subgroups were identified differing with respect to APOE e4.,"[{'end': 9, 'start': 4, 'tag': 'TemporalConcept'}, {'end': 93, 'start': 86, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 93, 'start': 86, 'tag': 'BiologicallyActiveSubstance'}, {'end': 33, 'start': 20, 'tag': 'TemporalConcept'}]"
585,"Background: Alzheimer's disease (AD) begins with an asymptomatic preclinical phase, in which abnormal biomarkers indicate risk for developing cognitive impairment.","[{'end': 64, 'start': 52, 'tag': 'Finding'}, {'end': 31, 'start': 12, 'tag': 'DiseaseOrSyndrome'}, {'end': 112, 'start': 102, 'tag': 'ClinicalAttribute'}, {'end': 82, 'start': 65, 'tag': 'TemporalConcept'}, {'end': 35, 'start': 33, 'tag': 'DiseaseOrSyndrome'}, {'end': 162, 'start': 142, 'tag': 'DiseaseOrSyndrome'}, {'end': 141, 'start': 122, 'tag': 'Finding'}]"
586,Research is increasingly focused on validating biomarkers to improve reliable diagnosis and timely clinical treatment of AD.,"[{'end': 117, 'start': 99, 'tag': 'HealthCareActivity'}, {'end': 57, 'start': 47, 'tag': 'ClinicalAttribute'}, {'end': 123, 'start': 121, 'tag': 'DiseaseOrSyndrome'}, {'end': 87, 'start': 78, 'tag': 'HealthCareActivity'}, {'end': 8, 'start': 0, 'tag': 'ResearchActivity'}]"
587,"Most preclinical biomarker research lacks adequate representation of Black/African American and other racially and ethnically minoritized individuals, limiting the applicability of data to these groups.","[{'end': 35, 'start': 5, 'tag': 'ResearchActivity'}, {'end': 26, 'start': 5, 'tag': 'ClinicalAttribute'}, {'end': 149, 'start': 138, 'tag': 'PopulationGroup'}, {'end': 185, 'start': 181, 'tag': 'ResearchActivity'}, {'end': 91, 'start': 75, 'tag': 'PopulationGroup'}, {'end': 201, 'start': 195, 'tag': 'PopulationGroup'}, {'end': 74, 'start': 69, 'tag': 'PopulationGroup'}]"
588,This may exacerbate existing disparities by hindering diagnosis and treatment among racially and ethnically minoritized individuals.,"[{'end': 131, 'start': 120, 'tag': 'PopulationGroup'}, {'end': 63, 'start': 54, 'tag': 'HealthCareActivity'}, {'end': 77, 'start': 68, 'tag': 'HealthCareActivity'}, {'end': 77, 'start': 68, 'tag': 'ResearchActivity'}]"
589,Objective: Understand the factors influencing willingness of Blacks/African Americans to participate in AD biomarker research and identify opportunities to improve enrollment.,"[{'end': 174, 'start': 164, 'tag': 'HealthCareActivity'}, {'end': 125, 'start': 117, 'tag': 'ResearchActivity'}, {'end': 106, 'start': 104, 'tag': 'DiseaseOrSyndrome'}, {'end': 116, 'start': 107, 'tag': 'ClinicalAttribute'}, {'end': 85, 'start': 68, 'tag': 'PopulationGroup'}, {'end': 57, 'start': 46, 'tag': 'BiologicFunction'}, {'end': 67, 'start': 61, 'tag': 'PopulationGroup'}]"
590,Methods: We enrolled Blacks/African Americans (N = 145) between 46-85 years of age who had previously participated in AD research.,"[{'end': 75, 'start': 70, 'tag': 'TemporalConcept'}, {'end': 82, 'start': 79, 'tag': 'OrganismAttribute'}, {'end': 129, 'start': 121, 'tag': 'ResearchActivity'}, {'end': 120, 'start': 118, 'tag': 'DiseaseOrSyndrome'}, {'end': 45, 'start': 28, 'tag': 'PopulationGroup'}, {'end': 27, 'start': 21, 'tag': 'PopulationGroup'}]"
591,Participants gave open-ended responses to a vignette describing a hypothetical biomarker research study.,"[{'end': 103, 'start': 89, 'tag': 'ResearchActivity'}, {'end': 88, 'start': 79, 'tag': 'ClinicalAttribute'}, {'end': 12, 'start': 0, 'tag': 'PopulationGroup'}]"
592,"Using qualitative content analysis, we identified themes that motivated and discouraged enrollment in AD biomarker research.","[{'end': 98, 'start': 88, 'tag': 'HealthCareActivity'}, {'end': 123, 'start': 115, 'tag': 'ResearchActivity'}, {'end': 104, 'start': 102, 'tag': 'DiseaseOrSyndrome'}, {'end': 114, 'start': 105, 'tag': 'ClinicalAttribute'}, {'end': 34, 'start': 6, 'tag': 'ResearchActivity'}]"
593,Results: Participant responses were categorized into several themes.,"[{'end': 20, 'start': 9, 'tag': 'PopulationGroup'}, {'end': 30, 'start': 21, 'tag': 'Finding'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}]"
594,Themes motivating participation included a desire to know their biomarker results and to support research.,"[{'end': 105, 'start': 97, 'tag': 'ResearchActivity'}, {'end': 73, 'start': 64, 'tag': 'ClinicalAttribute'}, {'end': 49, 'start': 43, 'tag': 'BiologicFunction'}, {'end': 31, 'start': 0, 'tag': 'Finding'}]"
595,"Major themes discouraging participation included concerns about potential negative psychological outcomes to learning one's increased risk for AD, doubt about the usefulness of testing, and worry about the potential physical harms of testing.","[{'end': 195, 'start': 190, 'tag': 'Finding'}, {'end': 184, 'start': 177, 'tag': 'HealthCareActivity'}, {'end': 241, 'start': 234, 'tag': 'HealthCareActivity'}, {'end': 145, 'start': 143, 'tag': 'DiseaseOrSyndrome'}, {'end': 117, 'start': 109, 'tag': 'BiologicFunction'}, {'end': 105, 'start': 83, 'tag': 'Finding'}, {'end': 39, 'start': 6, 'tag': 'Finding'}, {'end': 173, 'start': 163, 'tag': 'Finding'}, {'end': 145, 'start': 118, 'tag': 'Finding'}, {'end': 230, 'start': 216, 'tag': 'Finding'}]"
596,"Conclusion: Understanding themes motivating and discouraging AD preclinical biomarker research participation may inform research material development, approach to community engagement, and/or trial design to increase enrollment of Blacks/African Americans.","[{'end': 197, 'start': 192, 'tag': 'ResearchActivity'}, {'end': 227, 'start': 217, 'tag': 'HealthCareActivity'}, {'end': 204, 'start': 198, 'tag': 'ResearchActivity'}, {'end': 204, 'start': 198, 'tag': 'HealthCareActivity'}, {'end': 172, 'start': 163, 'tag': 'HealthCareRelatedOrganization'}, {'end': 128, 'start': 120, 'tag': 'ResearchActivity'}, {'end': 63, 'start': 61, 'tag': 'DiseaseOrSyndrome'}, {'end': 85, 'start': 76, 'tag': 'ClinicalAttribute'}, {'end': 149, 'start': 138, 'tag': 'BiologicFunction'}, {'end': 149, 'start': 138, 'tag': 'CellFunction'}, {'end': 255, 'start': 238, 'tag': 'PopulationGroup'}, {'end': 183, 'start': 173, 'tag': 'Finding'}, {'end': 108, 'start': 86, 'tag': 'ResearchActivity'}, {'end': 25, 'start': 12, 'tag': 'BiologicFunction'}, {'end': 237, 'start': 231, 'tag': 'PopulationGroup'}]"
597,Background: Cognitively normal (CN) older adults participating in Alzheimer's disease (AD) research increasingly ask for their research results-including genetic and neuroimaging findings-to understand their risk of developing AD dementia.,"[{'end': 30, 'start': 12, 'tag': 'Finding'}, {'end': 34, 'start': 32, 'tag': 'Finding'}, {'end': 178, 'start': 166, 'tag': 'HealthCareActivity'}, {'end': 48, 'start': 36, 'tag': 'PopulationGroup'}, {'end': 85, 'start': 66, 'tag': 'DiseaseOrSyndrome'}, {'end': 89, 'start': 87, 'tag': 'DiseaseOrSyndrome'}, {'end': 229, 'start': 227, 'tag': 'DiseaseOrSyndrome'}, {'end': 99, 'start': 91, 'tag': 'ResearchActivity'}, {'end': 143, 'start': 127, 'tag': 'ResearchActivity'}, {'end': 238, 'start': 230, 'tag': 'DiseaseOrSyndrome'}, {'end': 212, 'start': 208, 'tag': 'Finding'}]"
598,"AD research results are typically not returned for multiple reasons, including possible psychosocial harms of knowing one is at risk of a highly feared and untreatable disease.","[{'end': 106, 'start': 88, 'tag': 'Finding'}, {'end': 2, 'start': 0, 'tag': 'DiseaseOrSyndrome'}, {'end': 19, 'start': 3, 'tag': 'ResearchActivity'}]"
599,Objective: We developed materials that convey information about 5-year absolute risk of developing AD dementia based on research results.,"[{'end': 33, 'start': 24, 'tag': 'Substance'}, {'end': 70, 'start': 66, 'tag': 'TemporalConcept'}, {'end': 101, 'start': 99, 'tag': 'DiseaseOrSyndrome'}, {'end': 136, 'start': 120, 'tag': 'ResearchActivity'}, {'end': 110, 'start': 102, 'tag': 'DiseaseOrSyndrome'}]"
600,Methods: 20 CN older adults who received a research brain MRI result were interviewed regarding their wishes for research results to inform material development (Pilot 1).,"[{'end': 14, 'start': 12, 'tag': 'Finding'}, {'end': 27, 'start': 15, 'tag': 'PopulationGroup'}, {'end': 51, 'start': 43, 'tag': 'ResearchActivity'}, {'end': 129, 'start': 113, 'tag': 'ResearchActivity'}, {'end': 160, 'start': 149, 'tag': 'BiologicFunction'}, {'end': 160, 'start': 149, 'tag': 'CellFunction'}, {'end': 68, 'start': 62, 'tag': 'Finding'}, {'end': 61, 'start': 58, 'tag': 'HealthCareActivity'}, {'end': 57, 'start': 52, 'tag': 'BodyPartOrganOrOrganComponent'}]"
601,"Following material development, 17 CN older adults evaluated the materials for clarity and acceptability (Pilot 2).","[{'end': 18, 'start': 10, 'tag': 'Substance'}, {'end': 74, 'start': 65, 'tag': 'Substance'}, {'end': 86, 'start': 79, 'tag': 'ResearchActivity'}, {'end': 37, 'start': 35, 'tag': 'Finding'}, {'end': 50, 'start': 38, 'tag': 'PopulationGroup'}, {'end': 30, 'start': 19, 'tag': 'BiologicFunction'}, {'end': 30, 'start': 19, 'tag': 'CellFunction'}, {'end': 104, 'start': 91, 'tag': 'Finding'}]"
602,All participants were community-dwelling older adults participating in longitudinal studies of aging at a single site.,"[{'end': 31, 'start': 22, 'tag': 'HealthCareRelatedOrganization'}, {'end': 100, 'start': 95, 'tag': 'BiologicFunction'}, {'end': 100, 'start': 95, 'tag': 'CellFunction'}, {'end': 53, 'start': 41, 'tag': 'PopulationGroup'}, {'end': 16, 'start': 4, 'tag': 'PopulationGroup'}, {'end': 91, 'start': 71, 'tag': 'ResearchActivity'}]"
603,"Results: Participants want information on their risk of developing AD dementia to better understand their own health, satisfy curiosity, inform family, and future planning.","[{'end': 135, 'start': 126, 'tag': 'IndividualBehavior'}, {'end': 150, 'start': 144, 'tag': 'PopulationGroup'}, {'end': 171, 'start': 163, 'tag': 'BiologicFunction'}, {'end': 69, 'start': 67, 'tag': 'DiseaseOrSyndrome'}, {'end': 78, 'start': 70, 'tag': 'DiseaseOrSyndrome'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 21, 'start': 9, 'tag': 'PopulationGroup'}, {'end': 162, 'start': 156, 'tag': 'TemporalConcept'}, {'end': 116, 'start': 110, 'tag': 'HealthCareActivity'}, {'end': 52, 'start': 48, 'tag': 'Finding'}]"
604,"Some articulated concerns, but the majority wanted to know their risk despite the limitations of information.","[{'end': 69, 'start': 65, 'tag': 'Finding'}]"
605,"Participants found the educational materials and results report clear and acceptable, and the majority would want to know their research results after reviewing them.","[{'end': 144, 'start': 128, 'tag': 'ResearchActivity'}, {'end': 12, 'start': 0, 'tag': 'PopulationGroup'}, {'end': 63, 'start': 57, 'tag': 'HealthCareActivity'}, {'end': 63, 'start': 57, 'tag': 'ResearchActivity'}]"
606,Conclusion: These materials will be used in a clinical study examining the psychosocial and cognitive effects of offering research results to a cohort of CN older adults.,"[{'end': 27, 'start': 18, 'tag': 'Substance'}, {'end': 60, 'start': 46, 'tag': 'ResearchActivity'}, {'end': 156, 'start': 154, 'tag': 'Finding'}, {'end': 169, 'start': 157, 'tag': 'PopulationGroup'}, {'end': 138, 'start': 122, 'tag': 'ResearchActivity'}, {'end': 109, 'start': 75, 'tag': 'Finding'}, {'end': 150, 'start': 144, 'tag': 'PopulationGroup'}]"
607,"Future AD research may incorporate the return of complex risk information to CN older adults, and materials are needed to communicate this information.","[{'end': 107, 'start': 98, 'tag': 'Substance'}, {'end': 79, 'start': 77, 'tag': 'Finding'}, {'end': 92, 'start': 80, 'tag': 'PopulationGroup'}, {'end': 9, 'start': 7, 'tag': 'DiseaseOrSyndrome'}, {'end': 18, 'start': 10, 'tag': 'ResearchActivity'}, {'end': 61, 'start': 57, 'tag': 'Finding'}]"
608,There is an urgent need to establish blood biomarkers for Alzheimer's disease (AD).,"[{'end': 77, 'start': 58, 'tag': 'DiseaseOrSyndrome'}, {'end': 53, 'start': 43, 'tag': 'ClinicalAttribute'}, {'end': 81, 'start': 79, 'tag': 'DiseaseOrSyndrome'}, {'end': 42, 'start': 37, 'tag': 'BodyPartOrganOrOrganComponent'}]"
609,"Although it has been speculated that brain-derived neurotrophic factor (BDNF) is associated with AD, whether it can be used as a blood biomarker has yet to be determined.","[{'end': 70, 'start': 37, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 70, 'start': 37, 'tag': 'BiologicallyActiveSubstance'}, {'end': 76, 'start': 72, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 76, 'start': 72, 'tag': 'BiologicallyActiveSubstance'}, {'end': 99, 'start': 97, 'tag': 'DiseaseOrSyndrome'}, {'end': 144, 'start': 135, 'tag': 'ClinicalAttribute'}, {'end': 134, 'start': 129, 'tag': 'BodyPartOrganOrOrganComponent'}]"
610,"We used serum, cerebrospinal fluid (CSF), and medial temporal lobe atrophy from patients with AD to evaluate the association of BDNF with AD and assess its severity.","[{'end': 132, 'start': 128, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 132, 'start': 128, 'tag': 'BiologicallyActiveSubstance'}, {'end': 88, 'start': 80, 'tag': 'PatientOrDisabledGroup'}, {'end': 39, 'start': 36, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 96, 'start': 94, 'tag': 'DiseaseOrSyndrome'}, {'end': 140, 'start': 138, 'tag': 'DiseaseOrSyndrome'}, {'end': 34, 'start': 15, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 164, 'start': 156, 'tag': 'ClinicalAttribute'}, {'end': 164, 'start': 156, 'tag': 'Finding'}, {'end': 13, 'start': 8, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 74, 'start': 67, 'tag': 'PathologicFunction'}, {'end': 66, 'start': 46, 'tag': 'BodyPartOrganOrOrganComponent'}]"
611,"For the blood analysis, 66 participants [21 normal controls (NCs) with normal cognitive function, 22 patients with mild cognitive impairment (MCI) due to AD, and 23 patients with AD] were included.","[{'end': 22, 'start': 8, 'tag': 'ResearchActivity'}, {'end': 96, 'start': 78, 'tag': 'BiologicFunction'}, {'end': 109, 'start': 101, 'tag': 'PatientOrDisabledGroup'}, {'end': 173, 'start': 165, 'tag': 'PatientOrDisabledGroup'}, {'end': 156, 'start': 154, 'tag': 'DiseaseOrSyndrome'}, {'end': 181, 'start': 179, 'tag': 'DiseaseOrSyndrome'}, {'end': 39, 'start': 27, 'tag': 'PopulationGroup'}, {'end': 77, 'start': 71, 'tag': 'Finding'}, {'end': 59, 'start': 44, 'tag': 'PopulationGroup'}, {'end': 145, 'start': 142, 'tag': 'DiseaseOrSyndrome'}, {'end': 140, 'start': 120, 'tag': 'DiseaseOrSyndrome'}, {'end': 140, 'start': 115, 'tag': 'DiseaseOrSyndrome'}, {'end': 119, 'start': 115, 'tag': 'Finding'}]"
612,"For the CSF analysis, 30 participants were included.","[{'end': 11, 'start': 8, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 37, 'start': 25, 'tag': 'PopulationGroup'}, {'end': 20, 'start': 12, 'tag': 'ResearchActivity'}]"
613,"Magnetic resonance imaging, including a voxel-based specific regional analysis system for AD, and a Mini Mental State Examination were performed.","[{'end': 26, 'start': 0, 'tag': 'HealthCareActivity'}, {'end': 129, 'start': 100, 'tag': 'HealthCareActivity'}, {'end': 92, 'start': 90, 'tag': 'DiseaseOrSyndrome'}, {'end': 85, 'start': 40, 'tag': 'ResearchActivity'}]"
614,"Serum levels of BDNF and CSF levels of amyloid-beta(42), total tau, and phosphorylated tau were measured using ELISA.","[{'end': 20, 'start': 16, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 20, 'start': 16, 'tag': 'BiologicallyActiveSubstance'}, {'end': 116, 'start': 111, 'tag': 'ResearchActivity'}, {'end': 5, 'start': 0, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 55, 'start': 39, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 28, 'start': 25, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 90, 'start': 72, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 90, 'start': 72, 'tag': 'BiologicallyActiveSubstance'}, {'end': 55, 'start': 39, 'tag': 'BiologicallyActiveSubstance'}, {'end': 66, 'start': 57, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 66, 'start': 57, 'tag': 'BiologicallyActiveSubstance'}, {'end': 20, 'start': 0, 'tag': 'ClinicalAttribute'}, {'end': 55, 'start': 25, 'tag': 'ClinicalAttribute'}]"
615,Serum BDNF levels were significantly lower in the MCI due to AD group than in the NC group (p = 0.037).,"[{'end': 10, 'start': 6, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 10, 'start': 6, 'tag': 'BiologicallyActiveSubstance'}, {'end': 5, 'start': 0, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 63, 'start': 61, 'tag': 'DiseaseOrSyndrome'}, {'end': 69, 'start': 64, 'tag': 'PopulationGroup'}, {'end': 90, 'start': 85, 'tag': 'PopulationGroup'}, {'end': 53, 'start': 50, 'tag': 'DiseaseOrSyndrome'}, {'end': 84, 'start': 82, 'tag': 'PopulationGroup'}, {'end': 17, 'start': 0, 'tag': 'ClinicalAttribute'}]"
616,"Although there was no significant difference in the AD group, there was a downward trend compared to the NC group.","[{'end': 44, 'start': 19, 'tag': 'Finding'}, {'end': 54, 'start': 52, 'tag': 'DiseaseOrSyndrome'}, {'end': 60, 'start': 55, 'tag': 'PopulationGroup'}, {'end': 113, 'start': 108, 'tag': 'PopulationGroup'}, {'end': 107, 'start': 105, 'tag': 'PopulationGroup'}]"
617,"Serum BDNF levels were positively correlated with CSF A beta(42) levels (r = 0.49, p = 0.005).","[{'end': 10, 'start': 6, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 10, 'start': 6, 'tag': 'BiologicallyActiveSubstance'}, {'end': 5, 'start': 0, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 53, 'start': 50, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 64, 'start': 54, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 17, 'start': 0, 'tag': 'ClinicalAttribute'}, {'end': 64, 'start': 54, 'tag': 'BiologicallyActiveSubstance'}, {'end': 71, 'start': 50, 'tag': 'ClinicalAttribute'}]"
618,There was a significant correlation between serum BDNF levels and medial temporal lobe atrophy.,"[{'end': 54, 'start': 50, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 54, 'start': 50, 'tag': 'BiologicallyActiveSubstance'}, {'end': 49, 'start': 44, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 94, 'start': 87, 'tag': 'PathologicFunction'}, {'end': 94, 'start': 87, 'tag': 'DiseaseOrSyndrome'}, {'end': 61, 'start': 44, 'tag': 'ClinicalAttribute'}, {'end': 86, 'start': 66, 'tag': 'BodyPartOrganOrOrganComponent'}]"
619,Decreased serum BDNF can potentially be used as a biomarker for early AD detection.,"[{'end': 20, 'start': 0, 'tag': 'Finding'}, {'end': 20, 'start': 16, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 20, 'start': 16, 'tag': 'BiologicallyActiveSubstance'}, {'end': 72, 'start': 70, 'tag': 'DiseaseOrSyndrome'}, {'end': 59, 'start': 50, 'tag': 'ClinicalAttribute'}, {'end': 15, 'start': 10, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 82, 'start': 64, 'tag': 'HealthCareActivity'}]"
620,"Early detection of AD with a less invasive blood test is very beneficial, as it allows for intervention before dementia progresses.","[{'end': 53, 'start': 43, 'tag': 'ResearchActivity'}, {'end': 110, 'start': 104, 'tag': 'TemporalConcept'}, {'end': 119, 'start': 111, 'tag': 'DiseaseOrSyndrome'}, {'end': 21, 'start': 0, 'tag': 'HealthCareActivity'}]"
621,"Background: This study evaluated whether the apolipoprotein epsilon 4 (APOE4) allele, a genetic marker associated with increased risk of developing late-onset Alzheimer's disease (AD), was associated with differences in evoked pain responsiveness in cognitively healthy subjects.","[{'end': 231, 'start': 227, 'tag': 'SignOrSymptom'}, {'end': 178, 'start': 159, 'tag': 'DiseaseOrSyndrome'}, {'end': 182, 'start': 180, 'tag': 'DiseaseOrSyndrome'}, {'end': 216, 'start': 205, 'tag': 'Finding'}, {'end': 22, 'start': 17, 'tag': 'ResearchActivity'}, {'end': 278, 'start': 270, 'tag': 'PopulationGroup'}, {'end': 102, 'start': 88, 'tag': 'ClinicalAttribute'}, {'end': 158, 'start': 148, 'tag': 'TemporalConcept'}, {'end': 84, 'start': 78, 'tag': 'GeneOrGenome'}, {'end': 76, 'start': 71, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 76, 'start': 71, 'tag': 'BiologicallyActiveSubstance'}, {'end': 269, 'start': 250, 'tag': 'OrganismAttribute'}, {'end': 69, 'start': 45, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 69, 'start': 45, 'tag': 'BiologicallyActiveSubstance'}, {'end': 133, 'start': 119, 'tag': 'Finding'}, {'end': 246, 'start': 227, 'tag': 'BiologicFunction'}]"
622,Objective: The aim was to determine whether individuals at increased risk of late-onset AD based on APOE allele genotype differ phenotypically in their response to experimentally-induced painful stimuli compared to those who do not have at least one copy of the epsilon 4 allele.,"[{'end': 194, 'start': 187, 'tag': 'SignOrSymptom'}, {'end': 90, 'start': 88, 'tag': 'DiseaseOrSyndrome'}, {'end': 55, 'start': 44, 'tag': 'PopulationGroup'}, {'end': 104, 'start': 100, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 104, 'start': 100, 'tag': 'BiologicallyActiveSubstance'}, {'end': 87, 'start': 77, 'tag': 'TemporalConcept'}, {'end': 111, 'start': 105, 'tag': 'GeneOrGenome'}, {'end': 278, 'start': 262, 'tag': 'GeneOrGenome'}, {'end': 120, 'start': 112, 'tag': 'OrganismAttribute'}, {'end': 202, 'start': 164, 'tag': 'ResearchActivity'}, {'end': 160, 'start': 152, 'tag': 'OrganismAttribute'}]"
623,Methods: Forty-nine cognitively healthy subjects aged 30-89 years old with the APOE4 allele (n = 12) and without (n = 37) were assessed for group differences in pain thresholds and affective (unpleasantness) responses to experimentally-induced thermal pain stimuli.,"[{'end': 176, 'start': 166, 'tag': 'Finding'}, {'end': 165, 'start': 161, 'tag': 'SignOrSymptom'}, {'end': 256, 'start': 252, 'tag': 'SignOrSymptom'}, {'end': 53, 'start': 49, 'tag': 'TemporalConcept'}, {'end': 157, 'start': 146, 'tag': 'Finding'}, {'end': 145, 'start': 140, 'tag': 'PopulationGroup'}, {'end': 65, 'start': 60, 'tag': 'TemporalConcept'}, {'end': 48, 'start': 40, 'tag': 'PopulationGroup'}, {'end': 91, 'start': 85, 'tag': 'GeneOrGenome'}, {'end': 190, 'start': 181, 'tag': 'Finding'}, {'end': 84, 'start': 79, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 84, 'start': 79, 'tag': 'BiologicallyActiveSubstance'}, {'end': 39, 'start': 20, 'tag': 'OrganismAttribute'}, {'end': 206, 'start': 192, 'tag': 'Finding'}, {'end': 264, 'start': 221, 'tag': 'ResearchActivity'}, {'end': 217, 'start': 208, 'tag': 'OrganismAttribute'}]"
624,Results: Statistically significant main effects of APOE4 status were observed for both the temperature at which three different pain intensity percepts were reached (p = 0.040) and the level of unpleasantness associated with each (p = 0.014).,"[{'end': 102, 'start': 91, 'tag': 'OrganismAttribute'}, {'end': 102, 'start': 91, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 132, 'start': 128, 'tag': 'SignOrSymptom'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 63, 'start': 57, 'tag': 'Finding'}, {'end': 56, 'start': 51, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 56, 'start': 51, 'tag': 'BiologicallyActiveSubstance'}, {'end': 47, 'start': 9, 'tag': 'Finding'}, {'end': 208, 'start': 194, 'tag': 'Finding'}]"
625,APOE4 positive participants displayed lower overall pain sensitivity than those who were APOE4 negative and also greater overall levels of pain unpleasantness regardless of intensity level.,"[{'end': 56, 'start': 52, 'tag': 'SignOrSymptom'}, {'end': 143, 'start': 139, 'tag': 'SignOrSymptom'}, {'end': 27, 'start': 15, 'tag': 'PopulationGroup'}, {'end': 68, 'start': 57, 'tag': 'Finding'}, {'end': 5, 'start': 0, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 94, 'start': 89, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 5, 'start': 0, 'tag': 'BiologicallyActiveSubstance'}, {'end': 94, 'start': 89, 'tag': 'BiologicallyActiveSubstance'}, {'end': 158, 'start': 144, 'tag': 'Finding'}]"
626,Conclusion: Cognitively healthy APOE4 carriers at increased risk of late-onset AD demonstrated reduced thermal pain sensitivity but greater unpleasantness to thermal pain stimuli relative to individuals at lower risk of late-onset AD.,"[{'end': 115, 'start': 111, 'tag': 'SignOrSymptom'}, {'end': 170, 'start': 166, 'tag': 'SignOrSymptom'}, {'end': 81, 'start': 79, 'tag': 'DiseaseOrSyndrome'}, {'end': 233, 'start': 231, 'tag': 'DiseaseOrSyndrome'}, {'end': 202, 'start': 191, 'tag': 'PopulationGroup'}, {'end': 31, 'start': 12, 'tag': 'OrganismAttribute'}, {'end': 127, 'start': 116, 'tag': 'Finding'}, {'end': 46, 'start': 38, 'tag': 'PopulationGroup'}, {'end': 78, 'start': 68, 'tag': 'TemporalConcept'}, {'end': 230, 'start': 220, 'tag': 'TemporalConcept'}, {'end': 37, 'start': 32, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 37, 'start': 32, 'tag': 'BiologicallyActiveSubstance'}, {'end': 154, 'start': 140, 'tag': 'Finding'}]"
627,These results suggest that altered evoked pain perception could potentially be used as a phenotypic biomarker of late-onset AD risk prior to disease onset.,"[{'end': 99, 'start': 89, 'tag': 'OrganismAttribute'}, {'end': 57, 'start': 47, 'tag': 'BiologicFunction'}, {'end': 46, 'start': 42, 'tag': 'SignOrSymptom'}, {'end': 126, 'start': 124, 'tag': 'DiseaseOrSyndrome'}, {'end': 109, 'start': 100, 'tag': 'ClinicalAttribute'}, {'end': 154, 'start': 141, 'tag': 'TemporalConcept'}, {'end': 123, 'start': 113, 'tag': 'TemporalConcept'}, {'end': 57, 'start': 27, 'tag': 'ClinicalAttribute'}]"
628,Additional studies of this issue may be warranted.,"[{'end': 18, 'start': 11, 'tag': 'ResearchActivity'}]"
629,Background A reduced amyloid-beta (A beta)42/40 peptide ratio in blood plasma represents a peripheral biomarker of the cerebral amyloid pathology observed in Alzheimer's disease brains.,"[{'end': 77, 'start': 65, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 145, 'start': 119, 'tag': 'PathologicFunction'}, {'end': 177, 'start': 158, 'tag': 'DiseaseOrSyndrome'}, {'end': 111, 'start': 102, 'tag': 'ClinicalAttribute'}, {'end': 77, 'start': 71, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 33, 'start': 21, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 61, 'start': 34, 'tag': 'ClinicalAttribute'}, {'end': 101, 'start': 91, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 184, 'start': 178, 'tag': 'BodyPartOrganOrOrganComponent'}]"
630,"The magnitude of the measurable effect in plasma is smaller than in cerebrospinal fluid, presumably due to dilution by A beta peptides originating from peripheral sources.","[{'end': 115, 'start': 107, 'tag': 'ResearchActivity'}, {'end': 115, 'start': 107, 'tag': 'Chemical'}, {'end': 170, 'start': 163, 'tag': 'Finding'}, {'end': 87, 'start': 68, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 48, 'start': 42, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 134, 'start': 119, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 162, 'start': 152, 'tag': 'BodyPartOrganOrOrganComponent'}]"
631,We hypothesized that the observable effect in plasma can be accentuated to some extent by specifically measuring A beta 1-42 and A beta 1-40 instead of A beta X-42 and A beta X-40.Methods We assessed the plasma A beta X-42/X-40 and A beta 1-42/1-40 ratios in an idealized clinical sample by semi-automated A beta immunoprecipitation followed by closely related sandwich immunoassays.,"[{'end': 124, 'start': 113, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 140, 'start': 129, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 124, 'start': 113, 'tag': 'BiologicallyActiveSubstance'}, {'end': 140, 'start': 129, 'tag': 'BiologicallyActiveSubstance'}, {'end': 52, 'start': 46, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 210, 'start': 204, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 163, 'start': 152, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 179, 'start': 168, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 312, 'start': 306, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 287, 'start': 281, 'tag': 'Substance'}, {'end': 287, 'start': 281, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 332, 'start': 313, 'tag': 'ResearchActivity'}, {'end': 227, 'start': 204, 'tag': 'ClinicalAttribute'}, {'end': 255, 'start': 232, 'tag': 'ClinicalAttribute'}, {'end': 382, 'start': 361, 'tag': 'ResearchActivity'}]"
632,"The amyloid-positive and amyloid-negative groups (dichotomized according to A beta 42/40 in cerebrospinal fluid) were compared regarding the median difference, mean difference, standardized effect size (Cohen's d) and receiver operating characteristic curves.","[{'end': 111, 'start': 92, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 11, 'start': 4, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 32, 'start': 25, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 11, 'start': 4, 'tag': 'BiologicallyActiveSubstance'}, {'end': 32, 'start': 25, 'tag': 'BiologicallyActiveSubstance'}, {'end': 201, 'start': 190, 'tag': 'ResearchActivity'}, {'end': 48, 'start': 42, 'tag': 'PopulationGroup'}, {'end': 158, 'start': 141, 'tag': 'ResearchActivity'}, {'end': 111, 'start': 76, 'tag': 'ClinicalAttribute'}, {'end': 175, 'start': 160, 'tag': 'ResearchActivity'}, {'end': 258, 'start': 218, 'tag': 'ResearchActivity'}, {'end': 212, 'start': 203, 'tag': 'ResearchActivity'}]"
633,"For statistical evaluation, we applied bootstrapping.Results The median A beta 1-42/1-40 ratio was 20.86% lower in amyloid-positive subjects than in the amyloid-negative group, while the median A beta X-42/X-40 ratio was only 15.56% lower.","[{'end': 238, 'start': 233, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 122, 'start': 115, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 160, 'start': 153, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 122, 'start': 115, 'tag': 'BiologicallyActiveSubstance'}, {'end': 160, 'start': 153, 'tag': 'BiologicallyActiveSubstance'}, {'end': 60, 'start': 53, 'tag': 'ResearchActivity'}, {'end': 71, 'start': 65, 'tag': 'ResearchActivity'}, {'end': 193, 'start': 187, 'tag': 'ResearchActivity'}, {'end': 175, 'start': 170, 'tag': 'PopulationGroup'}, {'end': 140, 'start': 132, 'tag': 'PopulationGroup'}, {'end': 26, 'start': 4, 'tag': 'ResearchActivity'}, {'end': 52, 'start': 39, 'tag': 'ResearchActivity'}, {'end': 94, 'start': 72, 'tag': 'ClinicalAttribute'}, {'end': 216, 'start': 194, 'tag': 'ClinicalAttribute'}]"
634,The relative mean difference between amyloid-positive and amyloid-negative subjects was -18.34% for plasma A beta 1-42/1-40 compared to -15.50% for A beta X-42/X-40.,"[{'end': 44, 'start': 37, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 65, 'start': 58, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 44, 'start': 37, 'tag': 'BiologicallyActiveSubstance'}, {'end': 65, 'start': 58, 'tag': 'BiologicallyActiveSubstance'}, {'end': 83, 'start': 75, 'tag': 'PopulationGroup'}, {'end': 154, 'start': 148, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 28, 'start': 4, 'tag': 'ResearchActivity'}, {'end': 123, 'start': 100, 'tag': 'ClinicalAttribute'}, {'end': 164, 'start': 148, 'tag': 'ClinicalAttribute'}]"
635,Cohen's d was 1.73 for A beta 1-42/1-40 and 1.48 for plasma A beta X-42/X-40.,"[{'end': 59, 'start': 53, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 9, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 39, 'start': 23, 'tag': 'ClinicalAttribute'}, {'end': 76, 'start': 53, 'tag': 'ClinicalAttribute'}]"
636,Unadjusted p-values < 0.05 were obtained after .632 bootstrapping for all three parameters.,"[{'end': 65, 'start': 52, 'tag': 'ResearchActivity'}]"
637,Receiver operating characteristic analysis indicated very similar areas under the curves for plasma A beta 1-42/1-40 and A beta X-42/X-40.Conclusions Our findings support the hypothesis that the relatively small difference in the plasma A beta 42/40 ratio between subjects with and without evidence of brain amyloidosis can be accentuated by specifically measuring A beta 1-42/1-40 instead of A beta X-42/X-40.,"[{'end': 319, 'start': 308, 'tag': 'DiseaseOrSyndrome'}, {'end': 319, 'start': 302, 'tag': 'DiseaseOrSyndrome'}, {'end': 236, 'start': 230, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 298, 'start': 290, 'tag': 'Finding'}, {'end': 42, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 272, 'start': 264, 'tag': 'PopulationGroup'}, {'end': 399, 'start': 393, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 116, 'start': 93, 'tag': 'ClinicalAttribute'}, {'end': 137, 'start': 121, 'tag': 'ClinicalAttribute'}, {'end': 255, 'start': 230, 'tag': 'ClinicalAttribute'}, {'end': 381, 'start': 365, 'tag': 'ClinicalAttribute'}, {'end': 409, 'start': 393, 'tag': 'ClinicalAttribute'}]"
638,A simplified theoretical model explaining this observation is presented.,"[{'end': 58, 'start': 47, 'tag': 'ResearchActivity'}, {'end': 58, 'start': 47, 'tag': 'HealthCareActivity'}, {'end': 58, 'start': 47, 'tag': 'Finding'}, {'end': 30, 'start': 13, 'tag': 'ResearchActivity'}]"
639,Background The Amyloid/Tau/Neurodegeneration (ATN) framework has been proposed as a means of evidencing the biological state of Alzheimer's disease (AD).,"[{'end': 44, 'start': 27, 'tag': 'CellOrMolecularDysfunction'}, {'end': 147, 'start': 128, 'tag': 'DiseaseOrSyndrome'}, {'end': 151, 'start': 149, 'tag': 'DiseaseOrSyndrome'}, {'end': 26, 'start': 23, 'tag': 'BiologicallyActiveSubstance'}, {'end': 26, 'start': 23, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 60, 'start': 15, 'tag': 'HealthCareActivity'}]"
640,Predicting ATN status in pre-dementia individuals therefore provides an important opportunity for targeted recruitment into AD interventional studies.,"[{'end': 149, 'start': 127, 'tag': 'ResearchActivity'}, {'end': 126, 'start': 124, 'tag': 'DiseaseOrSyndrome'}, {'end': 37, 'start': 29, 'tag': 'DiseaseOrSyndrome'}, {'end': 21, 'start': 15, 'tag': 'Finding'}, {'end': 49, 'start': 38, 'tag': 'PopulationGroup'}, {'end': 14, 'start': 11, 'tag': 'HealthCareActivity'}]"
641,We investigated the extent to which ATN-defined biomarker status can be predicted by known AD risk factors as well as vascular-related composite risk scores.,"[{'end': 106, 'start': 94, 'tag': 'Finding'}, {'end': 93, 'start': 91, 'tag': 'DiseaseOrSyndrome'}, {'end': 64, 'start': 36, 'tag': 'ClinicalAttribute'}, {'end': 126, 'start': 118, 'tag': 'BodyPartOrganOrOrganComponent'}]"
642,Methods One thousand ten cognitively healthy older adults were allocated to one of five ATN-defined biomarker categories.,"[{'end': 120, 'start': 88, 'tag': 'ClinicalAttribute'}, {'end': 57, 'start': 45, 'tag': 'PopulationGroup'}, {'end': 44, 'start': 25, 'tag': 'OrganismAttribute'}]"
643,"Multinomial logistic regression tested risk factors including age, sex, education, APOE4, family history of dementia, cognitive function, vascular risk indices (high systolic blood pressure, body mass index (BMI), high cholesterol, physical inactivity, ever smoked, blood pressure medication, diabetes, prior cardiovascular disease, atrial fibrillation and white matter lesion (WML) volume), and three vascular-related composite scores, to predict five ATN subgroups; ROC curve models estimated their added value in predicting pathology.","[{'end': 136, 'start': 118, 'tag': 'BiologicFunction'}, {'end': 211, 'start': 208, 'tag': 'ClinicalAttribute'}, {'end': 230, 'start': 214, 'tag': 'Finding'}, {'end': 251, 'start': 232, 'tag': 'Finding'}, {'end': 331, 'start': 309, 'tag': 'DiseaseOrSyndrome'}, {'end': 352, 'start': 333, 'tag': 'DiseaseOrSyndrome'}, {'end': 376, 'start': 357, 'tag': 'Finding'}, {'end': 435, 'start': 429, 'tag': 'Finding'}, {'end': 51, 'start': 39, 'tag': 'Finding'}, {'end': 230, 'start': 219, 'tag': 'Chemical'}, {'end': 230, 'start': 219, 'tag': 'BiologicallyActiveSubstance'}, {'end': 104, 'start': 90, 'tag': 'Finding'}, {'end': 206, 'start': 191, 'tag': 'ClinicalAttribute'}, {'end': 301, 'start': 293, 'tag': 'DiseaseOrSyndrome'}, {'end': 536, 'start': 527, 'tag': 'PathologicFunction'}, {'end': 536, 'start': 527, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 65, 'start': 62, 'tag': 'OrganismAttribute'}, {'end': 116, 'start': 108, 'tag': 'DiseaseOrSyndrome'}, {'end': 484, 'start': 468, 'tag': 'ResearchActivity'}, {'end': 146, 'start': 138, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 410, 'start': 402, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 88, 'start': 83, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 88, 'start': 83, 'tag': 'BiologicallyActiveSubstance'}, {'end': 81, 'start': 72, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 70, 'start': 67, 'tag': 'OrganismAttribute'}, {'end': 195, 'start': 191, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 31, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 189, 'start': 166, 'tag': 'ClinicalAttribute'}, {'end': 189, 'start': 161, 'tag': 'Finding'}, {'end': 291, 'start': 266, 'tag': 'PharmacologicSubstance'}, {'end': 389, 'start': 377, 'tag': 'ClinicalAttribute'}, {'end': 456, 'start': 453, 'tag': 'HealthCareActivity'}]"
644,"Results Age, APOE4, family history, BMI, MMSE and white matter lesions (WML) volume differed between ATN biomarker groups.","[{'end': 39, 'start': 36, 'tag': 'ClinicalAttribute'}, {'end': 70, 'start': 50, 'tag': 'Finding'}, {'end': 34, 'start': 20, 'tag': 'Finding'}, {'end': 11, 'start': 8, 'tag': 'OrganismAttribute'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 114, 'start': 101, 'tag': 'ClinicalAttribute'}, {'end': 34, 'start': 27, 'tag': 'Finding'}, {'end': 18, 'start': 13, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 18, 'start': 13, 'tag': 'BiologicallyActiveSubstance'}, {'end': 121, 'start': 115, 'tag': 'PopulationGroup'}, {'end': 45, 'start': 41, 'tag': 'HealthCareActivity'}, {'end': 83, 'start': 77, 'tag': 'ClinicalAttribute'}, {'end': 70, 'start': 50, 'tag': 'ClinicalAttribute'}]"
645,"Prediction of Alzheimer's disease pathology (versus normal AD biomarkers) improved by 7% after adding family history, BMI, MMSE and WML to a ROC curve that included age, sex and APOE4.","[{'end': 121, 'start': 118, 'tag': 'ClinicalAttribute'}, {'end': 135, 'start': 132, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 144, 'start': 141, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 116, 'start': 102, 'tag': 'Finding'}, {'end': 33, 'start': 14, 'tag': 'DiseaseOrSyndrome'}, {'end': 72, 'start': 62, 'tag': 'ClinicalAttribute'}, {'end': 43, 'start': 26, 'tag': 'PathologicFunction'}, {'end': 168, 'start': 165, 'tag': 'OrganismAttribute'}, {'end': 61, 'start': 59, 'tag': 'DiseaseOrSyndrome'}, {'end': 58, 'start': 52, 'tag': 'Finding'}, {'end': 183, 'start': 178, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 183, 'start': 178, 'tag': 'BiologicallyActiveSubstance'}, {'end': 173, 'start': 170, 'tag': 'OrganismAttribute'}, {'end': 127, 'start': 123, 'tag': 'HealthCareActivity'}]"
646,Risk composite scores did not add value.,"[{'end': 21, 'start': 15, 'tag': 'Finding'}]"
647,Conclusions ATN-defined Alzheimer's disease biomarker status prediction among cognitively healthy individuals is possible through a combination of constitutional and cardiovascular risk factors but established dementia composite risk scores do not appear to add value in this context.,"[{'end': 193, 'start': 166, 'tag': 'Finding'}, {'end': 193, 'start': 181, 'tag': 'Finding'}, {'end': 109, 'start': 90, 'tag': 'PopulationGroup'}, {'end': 43, 'start': 24, 'tag': 'DiseaseOrSyndrome'}, {'end': 53, 'start': 44, 'tag': 'ClinicalAttribute'}, {'end': 218, 'start': 210, 'tag': 'DiseaseOrSyndrome'}, {'end': 60, 'start': 54, 'tag': 'Finding'}, {'end': 109, 'start': 98, 'tag': 'PopulationGroup'}, {'end': 97, 'start': 90, 'tag': 'OrganismAttribute'}, {'end': 240, 'start': 219, 'tag': 'Finding'}, {'end': 15, 'start': 12, 'tag': 'HealthCareActivity'}]"
648,"Background: Currently, brain tissue atrophy serves as an in vivo MRI biomarker of neurodegeneration in Alzheimer's disease (AD).","[{'end': 21, 'start': 12, 'tag': 'TemporalConcept'}, {'end': 122, 'start': 103, 'tag': 'DiseaseOrSyndrome'}, {'end': 126, 'start': 124, 'tag': 'DiseaseOrSyndrome'}, {'end': 78, 'start': 69, 'tag': 'ClinicalAttribute'}, {'end': 68, 'start': 65, 'tag': 'HealthCareActivity'}, {'end': 99, 'start': 82, 'tag': 'CellOrMolecularDysfunction'}, {'end': 43, 'start': 36, 'tag': 'PathologicFunction'}, {'end': 43, 'start': 36, 'tag': 'DiseaseOrSyndrome'}, {'end': 64, 'start': 57, 'tag': 'ResearchActivity'}, {'end': 35, 'start': 23, 'tag': 'BodyPartOrganOrOrganComponent'}]"
649,"However, postmortem histopathological studies show that neuronal loss in AD exceeds volumetric loss of tissue and that loss of memory in AD begins when neurons and synapses are lost.","[{'end': 37, 'start': 20, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 75, 'start': 73, 'tag': 'DiseaseOrSyndrome'}, {'end': 139, 'start': 137, 'tag': 'DiseaseOrSyndrome'}, {'end': 69, 'start': 56, 'tag': 'CellOrMolecularDysfunction'}, {'end': 19, 'start': 9, 'tag': 'TemporalConcept'}, {'end': 45, 'start': 38, 'tag': 'ResearchActivity'}, {'end': 172, 'start': 164, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 109, 'start': 103, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 159, 'start': 152, 'tag': 'Cell'}, {'end': 94, 'start': 84, 'tag': 'HealthCareActivity'}, {'end': 133, 'start': 119, 'tag': 'SignOrSymptom'}]"
650,"Therefore, in vivo detection of neuronal loss prior to detectable atrophy in MRI is essential for early AD diagnosis.","[{'end': 28, 'start': 19, 'tag': 'HealthCareActivity'}, {'end': 106, 'start': 104, 'tag': 'DiseaseOrSyndrome'}, {'end': 80, 'start': 77, 'tag': 'HealthCareActivity'}, {'end': 116, 'start': 107, 'tag': 'HealthCareActivity'}, {'end': 73, 'start': 66, 'tag': 'PathologicFunction'}, {'end': 73, 'start': 66, 'tag': 'DiseaseOrSyndrome'}, {'end': 45, 'start': 32, 'tag': 'CellOrMolecularDysfunction'}, {'end': 103, 'start': 98, 'tag': 'TemporalConcept'}, {'end': 18, 'start': 11, 'tag': 'ResearchActivity'}]"
651,Objective: To apply a recently developed quantitative Gradient Recalled Echo (qGRE) MRI technique for in vivo evaluation of neuronal loss in human hippocampus.,"[{'end': 97, 'start': 41, 'tag': 'HealthCareActivity'}, {'end': 137, 'start': 124, 'tag': 'CellOrMolecularDysfunction'}, {'end': 109, 'start': 102, 'tag': 'ResearchActivity'}, {'end': 146, 'start': 141, 'tag': 'Eukaryote'}, {'end': 30, 'start': 22, 'tag': 'TemporalConcept'}, {'end': 120, 'start': 110, 'tag': 'HealthCareActivity'}, {'end': 120, 'start': 110, 'tag': 'ResearchActivity'}, {'end': 158, 'start': 147, 'tag': 'BodyPartOrganOrOrganComponent'}]"
652,"Methods: Seventy participants were recruited from the Knight Alzheimer Disease Research Center, representing three groups: Healthy controls [Clinical Dementia Rating (R) (CDR (R)) = 0, amyloid beta (A beta)-negative, n = 34]; Preclinical AD (CDR = 0, A beta-positive, n = 19); and mild AD (CDR = 0.5 or 1, A beta-positive, n = 17).","[{'end': 240, 'start': 226, 'tag': 'DiseaseOrSyndrome'}, {'end': 174, 'start': 171, 'tag': 'HealthCareActivity'}, {'end': 245, 'start': 242, 'tag': 'HealthCareActivity'}, {'end': 293, 'start': 290, 'tag': 'HealthCareActivity'}, {'end': 192, 'start': 185, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 192, 'start': 185, 'tag': 'BiologicallyActiveSubstance'}, {'end': 288, 'start': 286, 'tag': 'DiseaseOrSyndrome'}, {'end': 29, 'start': 17, 'tag': 'PopulationGroup'}, {'end': 121, 'start': 115, 'tag': 'PopulationGroup'}, {'end': 205, 'start': 199, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 257, 'start': 251, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 312, 'start': 306, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 139, 'start': 123, 'tag': 'PopulationGroup'}, {'end': 285, 'start': 281, 'tag': 'Finding'}, {'end': 197, 'start': 185, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 165, 'start': 141, 'tag': 'HealthCareActivity'}, {'end': 94, 'start': 54, 'tag': 'HealthCareRelatedOrganization'}]"
653,"Results: In hippocampal tissue, qGRE identified two types of regions: one, practically devoid of neurons, we designate as Dark Matter, and the other, with relatively preserved neurons, Viable Tissue.","[{'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 30, 'start': 12, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 104, 'start': 97, 'tag': 'Cell'}, {'end': 183, 'start': 176, 'tag': 'Cell'}, {'end': 36, 'start': 32, 'tag': 'HealthCareActivity'}, {'end': 198, 'start': 185, 'tag': 'BodyPartOrganOrOrganComponent'}]"
654,"Data showed a greater loss of neurons than defined by atrophy in the mild AD group compared with the healthy control group; neuronal loss ranged between 31% and 43%, while volume loss ranged only between 10% and 19%.","[{'end': 137, 'start': 124, 'tag': 'CellOrMolecularDysfunction'}, {'end': 37, 'start': 22, 'tag': 'CellOrMolecularDysfunction'}, {'end': 122, 'start': 109, 'tag': 'PopulationGroup'}, {'end': 76, 'start': 74, 'tag': 'DiseaseOrSyndrome'}, {'end': 82, 'start': 77, 'tag': 'PopulationGroup'}, {'end': 61, 'start': 54, 'tag': 'PathologicFunction'}, {'end': 61, 'start': 54, 'tag': 'DiseaseOrSyndrome'}, {'end': 108, 'start': 101, 'tag': 'OrganismAttribute'}, {'end': 73, 'start': 69, 'tag': 'Finding'}, {'end': 4, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 183, 'start': 172, 'tag': 'ClinicalAttribute'}]"
655,The concept of Dark Matter was confirmed with histopathological study of one participant who underwent in vivo qGRE 14 months prior to expiration.,"[{'end': 69, 'start': 46, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 145, 'start': 135, 'tag': 'BiologicFunction'}, {'end': 145, 'start': 135, 'tag': 'TemporalConcept'}, {'end': 88, 'start': 77, 'tag': 'PopulationGroup'}, {'end': 110, 'start': 103, 'tag': 'ResearchActivity'}, {'end': 125, 'start': 119, 'tag': 'TemporalConcept'}, {'end': 115, 'start': 111, 'tag': 'HealthCareActivity'}]"
656,"Conclusion: In vivo qGRE method identifies neuronal loss that is associated with impaired AD-related cognition but is not recognized by MRI measurements of tissue atrophy, therefore providing new biomarkers for early AD detection.","[{'end': 19, 'start': 12, 'tag': 'ResearchActivity'}, {'end': 56, 'start': 43, 'tag': 'CellOrMolecularDysfunction'}, {'end': 229, 'start': 220, 'tag': 'HealthCareActivity'}, {'end': 92, 'start': 90, 'tag': 'DiseaseOrSyndrome'}, {'end': 219, 'start': 217, 'tag': 'DiseaseOrSyndrome'}, {'end': 139, 'start': 136, 'tag': 'HealthCareActivity'}, {'end': 206, 'start': 196, 'tag': 'ClinicalAttribute'}, {'end': 170, 'start': 163, 'tag': 'PathologicFunction'}, {'end': 170, 'start': 163, 'tag': 'DiseaseOrSyndrome'}, {'end': 152, 'start': 140, 'tag': 'HealthCareActivity'}, {'end': 216, 'start': 211, 'tag': 'TemporalConcept'}, {'end': 162, 'start': 156, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 110, 'start': 101, 'tag': 'BiologicFunction'}, {'end': 31, 'start': 20, 'tag': 'HealthCareActivity'}]"
657,Background: Down syndrome (DS) is associated with increased risk for Alzheimer's disease (AD).,"[{'end': 88, 'start': 69, 'tag': 'DiseaseOrSyndrome'}, {'end': 92, 'start': 90, 'tag': 'DiseaseOrSyndrome'}, {'end': 25, 'start': 12, 'tag': 'DiseaseOrSyndrome'}, {'end': 29, 'start': 27, 'tag': 'DiseaseOrSyndrome'}]"
658,"In neurotypical individuals, clinical AD is preceded by reduced resting state functional connectivity in the default mode network (DMN), but it is unknown whether changes in DMN connectivity predict clinical onset of AD in DS.","[{'end': 101, 'start': 64, 'tag': 'HealthCareActivity'}, {'end': 213, 'start': 199, 'tag': 'TemporalConcept'}, {'end': 129, 'start': 109, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 40, 'start': 38, 'tag': 'DiseaseOrSyndrome'}, {'end': 219, 'start': 217, 'tag': 'DiseaseOrSyndrome'}, {'end': 27, 'start': 16, 'tag': 'PopulationGroup'}, {'end': 225, 'start': 223, 'tag': 'DiseaseOrSyndrome'}, {'end': 134, 'start': 131, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 177, 'start': 174, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 190, 'start': 178, 'tag': 'BiologicFunction'}]"
659,"Objective: Does lower DMN functional connectivity predict clinical onset of AD and cognitive decline in people with DS? Methods: Resting state functional MRI (rsfMRI), longitudinal neuropsychological, and clinical assessment data were collected on 15 nondemented people with DS (mean age = 51.66 years, SD = 5.34 years, range = 42-59 years) over four years, during which 4 transitioned to dementia.","[{'end': 72, 'start': 58, 'tag': 'TemporalConcept'}, {'end': 110, 'start': 104, 'tag': 'PopulationGroup'}, {'end': 269, 'start': 263, 'tag': 'PopulationGroup'}, {'end': 78, 'start': 76, 'tag': 'DiseaseOrSyndrome'}, {'end': 100, 'start': 83, 'tag': 'DiseaseOrSyndrome'}, {'end': 287, 'start': 284, 'tag': 'OrganismAttribute'}, {'end': 397, 'start': 389, 'tag': 'DiseaseOrSyndrome'}, {'end': 157, 'start': 129, 'tag': 'HealthCareActivity'}, {'end': 301, 'start': 296, 'tag': 'TemporalConcept'}, {'end': 318, 'start': 313, 'tag': 'TemporalConcept'}, {'end': 339, 'start': 334, 'tag': 'TemporalConcept'}, {'end': 356, 'start': 351, 'tag': 'TemporalConcept'}, {'end': 229, 'start': 225, 'tag': 'ResearchActivity'}, {'end': 180, 'start': 168, 'tag': 'ResearchActivity'}, {'end': 224, 'start': 214, 'tag': 'HealthCareActivity'}, {'end': 224, 'start': 214, 'tag': 'ResearchActivity'}, {'end': 305, 'start': 303, 'tag': 'ResearchActivity'}, {'end': 49, 'start': 26, 'tag': 'BiologicFunction'}, {'end': 199, 'start': 181, 'tag': 'HealthCareActivity'}, {'end': 118, 'start': 116, 'tag': 'DiseaseOrSyndrome'}, {'end': 277, 'start': 275, 'tag': 'DiseaseOrSyndrome'}, {'end': 25, 'start': 22, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 165, 'start': 159, 'tag': 'HealthCareActivity'}]"
660,Amyloid-beta (A beta) PET data were acquired on 13 of the 15 participants.,"[{'end': 73, 'start': 61, 'tag': 'PopulationGroup'}, {'end': 25, 'start': 22, 'tag': 'HealthCareActivity'}, {'end': 20, 'start': 14, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 30, 'start': 26, 'tag': 'ResearchActivity'}, {'end': 12, 'start': 0, 'tag': 'AminoAcidPeptideOrProtein'}]"
661,"Resting state fMRI, neuropsychological, and clinical assessment data were also acquired on an independent, slightly younger unimpaired sample of 14 nondemented people with DS (mean age = 44.63 years, SD = 7.99 years, range = 38-61 years).","[{'end': 166, 'start': 160, 'tag': 'PopulationGroup'}, {'end': 184, 'start': 181, 'tag': 'OrganismAttribute'}, {'end': 141, 'start': 135, 'tag': 'Substance'}, {'end': 141, 'start': 135, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 198, 'start': 193, 'tag': 'TemporalConcept'}, {'end': 215, 'start': 210, 'tag': 'TemporalConcept'}, {'end': 236, 'start': 231, 'tag': 'TemporalConcept'}, {'end': 68, 'start': 64, 'tag': 'ResearchActivity'}, {'end': 63, 'start': 53, 'tag': 'HealthCareActivity'}, {'end': 63, 'start': 53, 'tag': 'ResearchActivity'}, {'end': 202, 'start': 200, 'tag': 'ResearchActivity'}, {'end': 38, 'start': 20, 'tag': 'HealthCareActivity'}, {'end': 174, 'start': 172, 'tag': 'DiseaseOrSyndrome'}, {'end': 123, 'start': 116, 'tag': 'TemporalConcept'}, {'end': 18, 'start': 0, 'tag': 'HealthCareActivity'}]"
662,Results: Lower functional connectivity between long-range but not short-range DMN regions predicts AD diagnosis and cognitive decline in people with DS.,"[{'end': 143, 'start': 137, 'tag': 'PopulationGroup'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 101, 'start': 99, 'tag': 'DiseaseOrSyndrome'}, {'end': 133, 'start': 116, 'tag': 'DiseaseOrSyndrome'}, {'end': 111, 'start': 102, 'tag': 'HealthCareActivity'}, {'end': 38, 'start': 15, 'tag': 'BiologicFunction'}, {'end': 151, 'start': 149, 'tag': 'DiseaseOrSyndrome'}, {'end': 89, 'start': 78, 'tag': 'BodyPartOrganOrOrganComponent'}]"
663,A beta accumulation in the inferior parietal cortex is associated with lower regional DMN functional connectivity.,"[{'end': 19, 'start': 7, 'tag': 'Finding'}, {'end': 6, 'start': 0, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 113, 'start': 90, 'tag': 'BiologicFunction'}, {'end': 89, 'start': 86, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 51, 'start': 27, 'tag': 'BodyPartOrganOrOrganComponent'}]"
664,Conclusion: Reduction of long-range DMN connectivity is a potential biomarker for AD in people with DS that precedes and predicts clinical conversion.,"[{'end': 21, 'start': 12, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 21, 'start': 12, 'tag': 'Finding'}, {'end': 94, 'start': 88, 'tag': 'PopulationGroup'}, {'end': 84, 'start': 82, 'tag': 'DiseaseOrSyndrome'}, {'end': 77, 'start': 68, 'tag': 'ClinicalAttribute'}, {'end': 77, 'start': 58, 'tag': 'ClinicalAttribute'}, {'end': 149, 'start': 139, 'tag': 'Finding'}, {'end': 102, 'start': 100, 'tag': 'DiseaseOrSyndrome'}, {'end': 39, 'start': 36, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 52, 'start': 25, 'tag': 'BiologicFunction'}]"
665,Background Ongoing research seeks to identify blood-based biomarkers able to predict onset and progression of Alzheimer's disease (AD).,"[{'end': 129, 'start': 110, 'tag': 'DiseaseOrSyndrome'}, {'end': 133, 'start': 131, 'tag': 'DiseaseOrSyndrome'}, {'end': 106, 'start': 95, 'tag': 'PathologicFunction'}, {'end': 106, 'start': 95, 'tag': 'TemporalConcept'}, {'end': 68, 'start': 58, 'tag': 'ClinicalAttribute'}, {'end': 27, 'start': 19, 'tag': 'ResearchActivity'}, {'end': 90, 'start': 85, 'tag': 'TemporalConcept'}, {'end': 51, 'start': 46, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 18, 'start': 11, 'tag': 'TemporalConcept'}]"
666,"Objective The unfolded conformational variant of p53 (U-p53(AZ)), previously observed in AD individuals, was evaluated in plasma samples from individuals participating in the Australian Imaging, Biomarkers and Lifestyle (AIBL) cohort for diagnostic and prognostic assessment, validated on a neuropsychological-based diagnosis, over the course of six years.","[{'end': 128, 'start': 122, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 91, 'start': 89, 'tag': 'DiseaseOrSyndrome'}, {'end': 103, 'start': 92, 'tag': 'PopulationGroup'}, {'end': 153, 'start': 142, 'tag': 'PopulationGroup'}, {'end': 325, 'start': 316, 'tag': 'HealthCareActivity'}, {'end': 355, 'start': 350, 'tag': 'TemporalConcept'}, {'end': 233, 'start': 227, 'tag': 'PopulationGroup'}, {'end': 342, 'start': 336, 'tag': 'TemporalConcept'}, {'end': 248, 'start': 238, 'tag': 'HealthCareActivity'}, {'end': 274, 'start': 264, 'tag': 'HealthCareActivity'}, {'end': 274, 'start': 264, 'tag': 'ResearchActivity'}, {'end': 309, 'start': 291, 'tag': 'HealthCareActivity'}, {'end': 219, 'start': 175, 'tag': 'ResearchActivity'}, {'end': 225, 'start': 221, 'tag': 'ResearchActivity'}, {'end': 52, 'start': 14, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 63, 'start': 54, 'tag': 'AminoAcidPeptideOrProtein'}]"
667,Design Retrospective Longitudinal Prognostic biomarker study.,"[{'end': 54, 'start': 45, 'tag': 'ClinicalAttribute'}, {'end': 60, 'start': 0, 'tag': 'ResearchActivity'}]"
668,Setting Single-center study based on the AIBL cohort.,"[{'end': 27, 'start': 8, 'tag': 'ResearchActivity'}, {'end': 52, 'start': 46, 'tag': 'PopulationGroup'}, {'end': 45, 'start': 41, 'tag': 'ResearchActivity'}]"
669,"Participants 482 participants of the AIBL cohort, aged 60-85 years, without uncontrolled diabetes, vascular disease, severe depression or psychiatric illnesses.","[{'end': 115, 'start': 99, 'tag': 'DiseaseOrSyndrome'}, {'end': 159, 'start': 138, 'tag': 'DiseaseOrSyndrome'}, {'end': 123, 'start': 117, 'tag': 'Finding'}, {'end': 134, 'start': 124, 'tag': 'DiseaseOrSyndrome'}, {'end': 54, 'start': 50, 'tag': 'TemporalConcept'}, {'end': 29, 'start': 17, 'tag': 'PopulationGroup'}, {'end': 12, 'start': 0, 'tag': 'PopulationGroup'}, {'end': 66, 'start': 61, 'tag': 'TemporalConcept'}, {'end': 48, 'start': 42, 'tag': 'PopulationGroup'}, {'end': 97, 'start': 89, 'tag': 'DiseaseOrSyndrome'}, {'end': 41, 'start': 37, 'tag': 'ResearchActivity'}]"
670,"Measurements The AlzoSure (R) Predict test, consisting of immunoprecipitation (IP) followed by liquid chromatography (LC) tandem mass spectrometry (MS/MS), was performed to quantify the AZ 284 (R) peptide as readout of U-p53(AZ) and compared with an independent neuropsychological diagnosis.","[{'end': 12, 'start': 0, 'tag': 'HealthCareActivity'}, {'end': 81, 'start': 79, 'tag': 'ResearchActivity'}, {'end': 120, 'start': 118, 'tag': 'ResearchActivity'}, {'end': 153, 'start': 148, 'tag': 'ResearchActivity'}, {'end': 290, 'start': 262, 'tag': 'HealthCareActivity'}, {'end': 204, 'start': 186, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 116, 'start': 95, 'tag': 'ResearchActivity'}, {'end': 146, 'start': 122, 'tag': 'ResearchActivity'}, {'end': 77, 'start': 58, 'tag': 'ResearchActivity'}, {'end': 42, 'start': 17, 'tag': 'HealthCareActivity'}, {'end': 228, 'start': 219, 'tag': 'AminoAcidPeptideOrProtein'}]"
671,The amyloid load via amyloid beta-positron emission tomography (A beta-PET) and supporting clinical information were included where possible.,"[{'end': 11, 'start': 4, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 11, 'start': 4, 'tag': 'BiologicallyActiveSubstance'}, {'end': 74, 'start': 71, 'tag': 'HealthCareActivity'}, {'end': 70, 'start': 64, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 62, 'start': 34, 'tag': 'HealthCareActivity'}, {'end': 33, 'start': 21, 'tag': 'AminoAcidPeptideOrProtein'}]"
672,"Results U-p53(AZ) diagnostic and prognostic performance was assessed in both time-independent and time-dependent (36, 72 and 90 months following initial sampling) analyses.","[{'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 152, 'start': 145, 'tag': 'TemporalConcept'}, {'end': 134, 'start': 128, 'tag': 'TemporalConcept'}, {'end': 28, 'start': 18, 'tag': 'HealthCareActivity'}, {'end': 81, 'start': 77, 'tag': 'TemporalConcept'}, {'end': 102, 'start': 98, 'tag': 'TemporalConcept'}, {'end': 55, 'start': 44, 'tag': 'Finding'}, {'end': 171, 'start': 163, 'tag': 'ResearchActivity'}, {'end': 161, 'start': 153, 'tag': 'HealthCareActivity'}, {'end': 17, 'start': 8, 'tag': 'AminoAcidPeptideOrProtein'}]"
673,"Prognostic performance of A beta-PET and survival analyses with different risk factors (gender, A beta-PET and APOE epsilon 4 allele status) were also performed.","[{'end': 58, 'start': 41, 'tag': 'ResearchActivity'}, {'end': 139, 'start': 133, 'tag': 'Finding'}, {'end': 36, 'start': 33, 'tag': 'HealthCareActivity'}, {'end': 106, 'start': 103, 'tag': 'HealthCareActivity'}, {'end': 32, 'start': 26, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 102, 'start': 96, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 22, 'start': 11, 'tag': 'Finding'}, {'end': 115, 'start': 111, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 115, 'start': 111, 'tag': 'BiologicallyActiveSubstance'}, {'end': 94, 'start': 88, 'tag': 'OrganismAttribute'}, {'end': 86, 'start': 74, 'tag': 'Finding'}, {'end': 58, 'start': 50, 'tag': 'ResearchActivity'}, {'end': 49, 'start': 41, 'tag': 'CellFunction'}, {'end': 132, 'start': 126, 'tag': 'GeneOrGenome'}, {'end': 125, 'start': 111, 'tag': 'AminoAcidPeptideOrProtein'}]"
674,"U-p53(AZ) differentiated neuropsychologically graded AD from non-AD samples, and its detection at intermediate/high levels precisely identified present and future symptomatic AD.","[{'end': 94, 'start': 85, 'tag': 'HealthCareActivity'}, {'end': 55, 'start': 53, 'tag': 'DiseaseOrSyndrome'}, {'end': 67, 'start': 65, 'tag': 'DiseaseOrSyndrome'}, {'end': 177, 'start': 175, 'tag': 'DiseaseOrSyndrome'}, {'end': 162, 'start': 156, 'tag': 'TemporalConcept'}, {'end': 174, 'start': 163, 'tag': 'SignOrSymptom'}, {'end': 9, 'start': 0, 'tag': 'AminoAcidPeptideOrProtein'}]"
675,"In both time-independent and time-dependent prognostic analyses U-p53(AZ) achieved area under the curve (AUC) >98%, significantly higher than A beta-PET AUCs (between 84% and 93%, P respectively <0.0001 and <0.001).","[{'end': 152, 'start': 149, 'tag': 'HealthCareActivity'}, {'end': 148, 'start': 142, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 103, 'start': 83, 'tag': 'ResearchActivity'}, {'end': 12, 'start': 8, 'tag': 'TemporalConcept'}, {'end': 33, 'start': 29, 'tag': 'TemporalConcept'}, {'end': 108, 'start': 105, 'tag': 'ResearchActivity'}, {'end': 63, 'start': 44, 'tag': 'HealthCareActivity'}, {'end': 73, 'start': 64, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 157, 'start': 153, 'tag': 'ResearchActivity'}]"
676,"As single factor, U-p53(AZ) could clearly determine the risk of AD neuropsychological diagnosis over time (low versus intermediate/high U-p53(AZ) hazard ratio=2.99).","[{'end': 95, 'start': 67, 'tag': 'HealthCareActivity'}, {'end': 66, 'start': 64, 'tag': 'DiseaseOrSyndrome'}, {'end': 105, 'start': 101, 'tag': 'TemporalConcept'}, {'end': 27, 'start': 18, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 145, 'start': 136, 'tag': 'AminoAcidPeptideOrProtein'}]"
677,Proportional hazards regression analysis identified U-p53(AZ) levels as a major independent predictor of AD onset.,"[{'end': 107, 'start': 105, 'tag': 'DiseaseOrSyndrome'}, {'end': 113, 'start': 108, 'tag': 'TemporalConcept'}, {'end': 40, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 61, 'start': 52, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 101, 'start': 74, 'tag': 'Finding'}]"
678,Conclusions These findings support use of U-p53(AZ) as blood-based biomarker predicting whether individuals would reach neuropsychologically-defined AD within six years prior to AD diagnosis.,"[{'end': 151, 'start': 149, 'tag': 'DiseaseOrSyndrome'}, {'end': 180, 'start': 178, 'tag': 'DiseaseOrSyndrome'}, {'end': 76, 'start': 67, 'tag': 'ClinicalAttribute'}, {'end': 107, 'start': 96, 'tag': 'PopulationGroup'}, {'end': 190, 'start': 181, 'tag': 'HealthCareActivity'}, {'end': 168, 'start': 163, 'tag': 'TemporalConcept'}, {'end': 60, 'start': 55, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 51, 'start': 42, 'tag': 'AminoAcidPeptideOrProtein'}]"
679,Integration of U-p53(AZ) in screening processes could support refined participant stratification for interventional studies.,"[{'end': 11, 'start': 0, 'tag': 'CellFunction'}, {'end': 11, 'start': 0, 'tag': 'MachineActivity'}, {'end': 96, 'start': 82, 'tag': 'ResearchActivity'}, {'end': 81, 'start': 70, 'tag': 'PopulationGroup'}, {'end': 123, 'start': 101, 'tag': 'ResearchActivity'}, {'end': 24, 'start': 15, 'tag': 'AminoAcidPeptideOrProtein'}]"
680,Background and purpose Careful counseling through the diagnostic process and adequate postdiagnostic support in patients with mild cognitive impairment (MCI) is important.,"[{'end': 41, 'start': 31, 'tag': 'HealthCareActivity'}, {'end': 120, 'start': 112, 'tag': 'PatientOrDisabledGroup'}, {'end': 156, 'start': 153, 'tag': 'DiseaseOrSyndrome'}, {'end': 151, 'start': 131, 'tag': 'DiseaseOrSyndrome'}, {'end': 151, 'start': 126, 'tag': 'DiseaseOrSyndrome'}, {'end': 72, 'start': 54, 'tag': 'HealthCareActivity'}, {'end': 108, 'start': 86, 'tag': 'HealthCareActivity'}]"
681,Previous studies have indicated heterogeneity in practice and the need for guidance for clinicians.,"[{'end': 45, 'start': 32, 'tag': 'Finding'}, {'end': 57, 'start': 49, 'tag': 'BiologicFunction'}, {'end': 83, 'start': 75, 'tag': 'ClinicalAttribute'}, {'end': 16, 'start': 9, 'tag': 'ResearchActivity'}, {'end': 8, 'start': 0, 'tag': 'TemporalConcept'}, {'end': 98, 'start': 88, 'tag': 'HealthCareActivity'}]"
682,Methods A joint European Academy of Neurology/European Alzheimer's Disease Consortium panel of dementia specialists was appointed.,"[{'end': 103, 'start': 95, 'tag': 'DiseaseOrSyndrome'}, {'end': 24, 'start': 16, 'tag': 'PopulationGroup'}, {'end': 54, 'start': 46, 'tag': 'PopulationGroup'}, {'end': 74, 'start': 55, 'tag': 'DiseaseOrSyndrome'}, {'end': 45, 'start': 16, 'tag': 'HealthCareRelatedOrganization'}, {'end': 85, 'start': 46, 'tag': 'HealthCareRelatedOrganization'}]"
683,"Through online meetings and emails, positions were developed regarding disclosing a syndrome diagnosis of MCI, pre- and postbiomarker sampling counseling, and postdiagnostic support.","[{'end': 92, 'start': 84, 'tag': 'DiseaseOrSyndrome'}, {'end': 23, 'start': 15, 'tag': 'ResearchActivity'}, {'end': 102, 'start': 93, 'tag': 'HealthCareActivity'}, {'end': 109, 'start': 106, 'tag': 'DiseaseOrSyndrome'}, {'end': 153, 'start': 111, 'tag': 'HealthCareActivity'}, {'end': 181, 'start': 159, 'tag': 'HealthCareActivity'}]"
684,"Results Prior to diagnostic evaluation, motives and wishes of the patient should be sought.","[{'end': 38, 'start': 17, 'tag': 'HealthCareActivity'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 38, 'start': 28, 'tag': 'HealthCareActivity'}, {'end': 38, 'start': 28, 'tag': 'ResearchActivity'}, {'end': 73, 'start': 66, 'tag': 'PatientOrDisabledGroup'}]"
685,Diagnostic disclosure should be carried out by a dementia specialist taking the ethical principles of the right to know versus the wish not to know into account.,"[{'end': 57, 'start': 49, 'tag': 'DiseaseOrSyndrome'}, {'end': 119, 'start': 106, 'tag': 'Finding'}, {'end': 147, 'start': 131, 'tag': 'Finding'}]"
686,Disclosure should be accompanied by written information and a follow-up plan.,"[{'end': 10, 'start': 0, 'tag': 'IndividualBehavior'}, {'end': 76, 'start': 62, 'tag': 'HealthCareActivity'}, {'end': 71, 'start': 62, 'tag': 'TemporalConcept'}]"
687,It should be made clear that MCI is not dementia.,"[{'end': 48, 'start': 40, 'tag': 'DiseaseOrSyndrome'}, {'end': 32, 'start': 29, 'tag': 'DiseaseOrSyndrome'}]"
688,Prebiomarker counseling should always be carried out if biomarker sampling is considered and postbiomarker counseling if sampling is carried out.,"[{'end': 129, 'start': 121, 'tag': 'HealthCareActivity'}, {'end': 65, 'start': 56, 'tag': 'ClinicalAttribute'}, {'end': 23, 'start': 0, 'tag': 'HealthCareActivity'}, {'end': 117, 'start': 93, 'tag': 'HealthCareActivity'}, {'end': 74, 'start': 56, 'tag': 'HealthCareActivity'}]"
689,"A dementia specialist knowledgeable about biomarkers should inform about pros and cons, including alternatives, to enable an autonomous and informed decision.","[{'end': 157, 'start': 125, 'tag': 'BiologicFunction'}, {'end': 52, 'start': 42, 'tag': 'ClinicalAttribute'}, {'end': 10, 'start': 2, 'tag': 'DiseaseOrSyndrome'}]"
690,Postbiomarker counseling will depend in part on the results of biomarkers.,"[{'end': 73, 'start': 63, 'tag': 'ClinicalAttribute'}, {'end': 24, 'start': 0, 'tag': 'HealthCareActivity'}]"
691,Follow-up should be considered for all patients with MCI and include brain-healthy advice and possibly treatment for specific underlying causes.,"[{'end': 89, 'start': 83, 'tag': 'HealthCareActivity'}, {'end': 9, 'start': 0, 'tag': 'HealthCareActivity'}, {'end': 9, 'start': 0, 'tag': 'TemporalConcept'}, {'end': 47, 'start': 39, 'tag': 'PatientOrDisabledGroup'}, {'end': 74, 'start': 69, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 56, 'start': 53, 'tag': 'DiseaseOrSyndrome'}, {'end': 112, 'start': 103, 'tag': 'HealthCareActivity'}, {'end': 112, 'start': 103, 'tag': 'ResearchActivity'}, {'end': 82, 'start': 75, 'tag': 'OrganismAttribute'}]"
692,Advice on advance directives may be relevant.,"[{'end': 6, 'start': 0, 'tag': 'HealthCareActivity'}]"
693,Conclusions Guidance to clinicians on various aspects of the diagnostic process in patients with MCI is presented here as position statements.,"[{'end': 91, 'start': 83, 'tag': 'PatientOrDisabledGroup'}, {'end': 100, 'start': 97, 'tag': 'DiseaseOrSyndrome'}, {'end': 79, 'start': 61, 'tag': 'HealthCareActivity'}, {'end': 34, 'start': 24, 'tag': 'HealthCareActivity'}]"
694,Further studies are needed to enable more evidence-based and standardized recommendations in the future.,"[{'end': 56, 'start': 42, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 103, 'start': 97, 'tag': 'TemporalConcept'}, {'end': 15, 'start': 8, 'tag': 'ResearchActivity'}, {'end': 50, 'start': 42, 'tag': 'Finding'}]"
695,Background Cerebrospinal fluid biomarker profiles characterized by decreased amyloid-beta peptide levels and increased total and phosphorylated tau levels at threonine 181 (pT181) are currently used to discriminate between Alzheimer's disease and other neurodegenerative diseases.,"[{'end': 76, 'start': 67, 'tag': 'Finding'}, {'end': 97, 'start': 77, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 30, 'start': 11, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 279, 'start': 253, 'tag': 'DiseaseOrSyndrome'}, {'end': 154, 'start': 129, 'tag': 'ClinicalAttribute'}, {'end': 193, 'start': 184, 'tag': 'TemporalConcept'}, {'end': 242, 'start': 223, 'tag': 'DiseaseOrSyndrome'}, {'end': 40, 'start': 31, 'tag': 'ClinicalAttribute'}, {'end': 49, 'start': 41, 'tag': 'ResearchActivity'}, {'end': 171, 'start': 158, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 178, 'start': 173, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 178, 'start': 173, 'tag': 'BiologicallyActiveSubstance'}, {'end': 104, 'start': 77, 'tag': 'ClinicalAttribute'}]"
696,"However, these changes are not entirely specific to Alzheimer's disease, and it is noteworthy that other phosphorylated isoforms of tau, possibly more specific for the disease process, have been described in the brain parenchyma of patients.","[{'end': 135, 'start': 120, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 228, 'start': 212, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 119, 'start': 105, 'tag': 'CellFunction'}, {'end': 135, 'start': 132, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 71, 'start': 52, 'tag': 'DiseaseOrSyndrome'}, {'end': 135, 'start': 132, 'tag': 'BiologicallyActiveSubstance'}, {'end': 240, 'start': 232, 'tag': 'PatientOrDisabledGroup'}]"
697,The precise detection of these isoforms in biological fluids remains however a challenge.,"[{'end': 39, 'start': 31, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 39, 'start': 31, 'tag': 'NucleicAcidNucleosideOrNucleotide'}, {'end': 88, 'start': 79, 'tag': 'HealthCareActivity'}, {'end': 21, 'start': 12, 'tag': 'HealthCareActivity'}, {'end': 60, 'start': 43, 'tag': 'Substance'}]"
698,"Methods In the present study, we used the latest quantitative mass spectrometry approach, which achieves a sensitive detection in cerebrospinal fluid biomarker of two phosphorylated tau isoforms, pT181 and pT217, and first analyzed a cohort of probable Alzheimer's disease patients and patients with other neurological disorders, including tauopathies, and a set of cognitively normal controls.","[{'end': 351, 'start': 340, 'tag': 'DiseaseOrSyndrome'}, {'end': 328, 'start': 306, 'tag': 'DiseaseOrSyndrome'}, {'end': 48, 'start': 42, 'tag': 'TemporalConcept'}, {'end': 79, 'start': 49, 'tag': 'ResearchActivity'}, {'end': 384, 'start': 378, 'tag': 'Finding'}, {'end': 79, 'start': 62, 'tag': 'ResearchActivity'}, {'end': 116, 'start': 107, 'tag': 'PathologicFunction'}, {'end': 222, 'start': 217, 'tag': 'TemporalConcept'}, {'end': 393, 'start': 378, 'tag': 'PopulationGroup'}, {'end': 272, 'start': 253, 'tag': 'DiseaseOrSyndrome'}, {'end': 159, 'start': 150, 'tag': 'ClinicalAttribute'}, {'end': 149, 'start': 130, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 281, 'start': 273, 'tag': 'PatientOrDisabledGroup'}, {'end': 294, 'start': 286, 'tag': 'PatientOrDisabledGroup'}, {'end': 194, 'start': 167, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 194, 'start': 167, 'tag': 'BiologicallyActiveSubstance'}, {'end': 28, 'start': 23, 'tag': 'ResearchActivity'}, {'end': 384, 'start': 366, 'tag': 'Finding'}, {'end': 126, 'start': 117, 'tag': 'HealthCareActivity'}, {'end': 240, 'start': 234, 'tag': 'PopulationGroup'}, {'end': 231, 'start': 223, 'tag': 'ResearchActivity'}, {'end': 201, 'start': 196, 'tag': 'BiologicallyActiveSubstance'}, {'end': 201, 'start': 196, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 211, 'start': 206, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 211, 'start': 206, 'tag': 'BiologicallyActiveSubstance'}]"
699,We then checked the validity of our results on a second cohort comprising cognitively normal individuals and patients with mild cognitive impairments and AD stratified in terms of their amyloid status based on PiB-PET imaging methods.,"[{'end': 149, 'start': 123, 'tag': 'DiseaseOrSyndrome'}, {'end': 149, 'start': 128, 'tag': 'DiseaseOrSyndrome'}, {'end': 225, 'start': 214, 'tag': 'HealthCareActivity'}, {'end': 213, 'start': 210, 'tag': 'Chemical'}, {'end': 92, 'start': 86, 'tag': 'Finding'}, {'end': 225, 'start': 218, 'tag': 'HealthCareActivity'}, {'end': 156, 'start': 154, 'tag': 'DiseaseOrSyndrome'}, {'end': 117, 'start': 109, 'tag': 'PatientOrDisabledGroup'}, {'end': 104, 'start': 93, 'tag': 'PopulationGroup'}, {'end': 28, 'start': 20, 'tag': 'Finding'}, {'end': 193, 'start': 186, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 193, 'start': 186, 'tag': 'BiologicallyActiveSubstance'}, {'end': 92, 'start': 74, 'tag': 'Finding'}, {'end': 217, 'start': 214, 'tag': 'HealthCareActivity'}, {'end': 200, 'start': 194, 'tag': 'Finding'}, {'end': 127, 'start': 123, 'tag': 'Finding'}, {'end': 62, 'start': 56, 'tag': 'PopulationGroup'}]"
700,"Results In the first cohort, pT217 but not pT181 differentiated between Alzheimer's disease patients and those with other neurodegenerative diseases and control subjects much more specificity and sensitivity than pT181.","[{'end': 148, 'start': 122, 'tag': 'DiseaseOrSyndrome'}, {'end': 20, 'start': 15, 'tag': 'TemporalConcept'}, {'end': 169, 'start': 153, 'tag': 'PopulationGroup'}, {'end': 91, 'start': 72, 'tag': 'DiseaseOrSyndrome'}, {'end': 100, 'start': 92, 'tag': 'PatientOrDisabledGroup'}, {'end': 207, 'start': 196, 'tag': 'Finding'}, {'end': 191, 'start': 180, 'tag': 'Finding'}, {'end': 160, 'start': 153, 'tag': 'PopulationGroup'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 169, 'start': 161, 'tag': 'PopulationGroup'}, {'end': 27, 'start': 21, 'tag': 'PopulationGroup'}, {'end': 218, 'start': 213, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 218, 'start': 213, 'tag': 'BiologicallyActiveSubstance'}, {'end': 34, 'start': 29, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 34, 'start': 29, 'tag': 'BiologicallyActiveSubstance'}, {'end': 48, 'start': 43, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 48, 'start': 43, 'tag': 'BiologicallyActiveSubstance'}]"
701,"T217 phosphorylation was increased by 6.0-fold in patients with Alzheimer's disease whereas T181 phosphorylation was only increased by 1.3-fold, when compared with control subjects.","[{'end': 20, 'start': 5, 'tag': 'CellFunction'}, {'end': 112, 'start': 97, 'tag': 'CellFunction'}, {'end': 180, 'start': 164, 'tag': 'PopulationGroup'}, {'end': 83, 'start': 64, 'tag': 'DiseaseOrSyndrome'}, {'end': 58, 'start': 50, 'tag': 'PatientOrDisabledGroup'}, {'end': 171, 'start': 164, 'tag': 'PopulationGroup'}, {'end': 180, 'start': 172, 'tag': 'PopulationGroup'}, {'end': 96, 'start': 92, 'tag': 'AminoAcidPeptideOrProtein'}]"
702,"These results were confirmed in the case of a second cohort, in which the pT217 cerebrospinal fluid levels marked out amyloid-positive patients with a sensitivity and a specificity of more than 90% (AUC 0.961; CI 0.874 to 0.995).","[{'end': 99, 'start': 80, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 143, 'start': 135, 'tag': 'PatientOrDisabledGroup'}, {'end': 125, 'start': 118, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 125, 'start': 118, 'tag': 'BiologicallyActiveSubstance'}, {'end': 162, 'start': 151, 'tag': 'Finding'}, {'end': 180, 'start': 169, 'tag': 'Finding'}, {'end': 40, 'start': 36, 'tag': 'ManufacturedObject'}, {'end': 212, 'start': 210, 'tag': 'ResearchActivity'}, {'end': 59, 'start': 53, 'tag': 'PopulationGroup'}, {'end': 202, 'start': 199, 'tag': 'ResearchActivity'}, {'end': 79, 'start': 74, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 79, 'start': 74, 'tag': 'BiologicallyActiveSubstance'}, {'end': 106, 'start': 74, 'tag': 'ClinicalAttribute'}]"
703,The pT217 concentrations were also highly correlated with the PiB-PET values (correlation coefficient 0.72; P < 0.001).,"[{'end': 24, 'start': 10, 'tag': 'BiologicFunction'}, {'end': 65, 'start': 62, 'tag': 'Chemical'}, {'end': 69, 'start': 66, 'tag': 'HealthCareActivity'}, {'end': 9, 'start': 4, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 9, 'start': 4, 'tag': 'BiologicallyActiveSubstance'}]"
704,"Conclusions Increased cerebrospinal fluid pT217 levels, more than those of pT181, are highly specific biomarkers for detecting both the preclinical and advanced forms of Alzheimer's disease.","[{'end': 189, 'start': 170, 'tag': 'DiseaseOrSyndrome'}, {'end': 41, 'start': 22, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 112, 'start': 102, 'tag': 'ClinicalAttribute'}, {'end': 80, 'start': 75, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 80, 'start': 75, 'tag': 'BiologicallyActiveSubstance'}, {'end': 54, 'start': 22, 'tag': 'ClinicalAttribute'}]"
705,"This finding should greatly improve the diagnosis of Alzheimer's disease, along with the correlations found to exist between pT217 levels and PiB-PET data.","[{'end': 35, 'start': 28, 'tag': 'Finding'}, {'end': 145, 'start': 142, 'tag': 'Chemical'}, {'end': 12, 'start': 5, 'tag': 'Finding'}, {'end': 72, 'start': 53, 'tag': 'DiseaseOrSyndrome'}, {'end': 154, 'start': 150, 'tag': 'ResearchActivity'}, {'end': 49, 'start': 40, 'tag': 'HealthCareActivity'}, {'end': 149, 'start': 146, 'tag': 'HealthCareActivity'}, {'end': 101, 'start': 89, 'tag': 'ResearchActivity'}, {'end': 130, 'start': 125, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 130, 'start': 125, 'tag': 'BiologicallyActiveSubstance'}]"
706,It also suggests that pT217 is a promising potential target for therapeutic applications and that a link exists between amyloid and tau pathology.,"[{'end': 88, 'start': 64, 'tag': 'HealthCareActivity'}, {'end': 135, 'start': 132, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 135, 'start': 132, 'tag': 'BiologicallyActiveSubstance'}, {'end': 145, 'start': 132, 'tag': 'PathologicFunction'}, {'end': 127, 'start': 120, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 127, 'start': 120, 'tag': 'BiologicallyActiveSubstance'}, {'end': 27, 'start': 22, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 27, 'start': 22, 'tag': 'BiologicallyActiveSubstance'}]"
707,Introduction: Previous studies showed associations of brain volume differences and biomarker evidence for Alzheimer's disease (AD) in subjective cognitive decline (SCD).,"[{'end': 78, 'start': 67, 'tag': 'Finding'}, {'end': 125, 'start': 106, 'tag': 'DiseaseOrSyndrome'}, {'end': 30, 'start': 23, 'tag': 'ResearchActivity'}, {'end': 129, 'start': 127, 'tag': 'DiseaseOrSyndrome'}, {'end': 92, 'start': 83, 'tag': 'ClinicalAttribute'}, {'end': 162, 'start': 134, 'tag': 'DiseaseOrSyndrome'}, {'end': 22, 'start': 14, 'tag': 'TemporalConcept'}, {'end': 101, 'start': 93, 'tag': 'Finding'}, {'end': 66, 'start': 54, 'tag': 'ClinicalAttribute'}, {'end': 167, 'start': 164, 'tag': 'DiseaseOrSyndrome'}]"
708,The consistency of this finding across SCD studies has not been investigated.,"[{'end': 31, 'start': 24, 'tag': 'Finding'}, {'end': 50, 'start': 43, 'tag': 'ResearchActivity'}, {'end': 42, 'start': 39, 'tag': 'DiseaseOrSyndrome'}]"
709,"Methods: We studied gray matter volume differences between SCD subjects with and without cerebrospinal fluid biomarker evidence for AD across three European memory clinic samples (German Center for Neurodegenerative Diseases Longitudinal Cognitive Impairment and Dementia study, Amsterdam, Barcelona).","[{'end': 50, 'start': 39, 'tag': 'Finding'}, {'end': 134, 'start': 132, 'tag': 'DiseaseOrSyndrome'}, {'end': 118, 'start': 109, 'tag': 'ClinicalAttribute'}, {'end': 277, 'start': 180, 'tag': 'ResearchActivity'}, {'end': 108, 'start': 89, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 71, 'start': 63, 'tag': 'PopulationGroup'}, {'end': 156, 'start': 148, 'tag': 'PopulationGroup'}, {'end': 108, 'start': 103, 'tag': 'Substance'}, {'end': 31, 'start': 20, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 127, 'start': 119, 'tag': 'Finding'}, {'end': 163, 'start': 157, 'tag': 'BiologicFunction'}, {'end': 38, 'start': 20, 'tag': 'ClinicalAttribute'}, {'end': 62, 'start': 59, 'tag': 'DiseaseOrSyndrome'}]"
710,Analysis of covariance models with samples and cerebrospinal fluid biomarkers as between-subject factors were calculated.,"[{'end': 8, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 77, 'start': 67, 'tag': 'ClinicalAttribute'}, {'end': 29, 'start': 12, 'tag': 'ResearchActivity'}, {'end': 66, 'start': 47, 'tag': 'BodyPartOrganOrOrganComponent'}]"
711,"Results: A significant main effect for AD biomarker (A beta(422)- > A beta(42)+) in the left medial temporal lobe (MTL) was found, with the absence of main effects for sample or interaction effects between AD biomarker and sample.","[{'end': 163, 'start': 156, 'tag': 'PathologicFunction'}, {'end': 174, 'start': 168, 'tag': 'Substance'}, {'end': 174, 'start': 168, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 229, 'start': 223, 'tag': 'Substance'}, {'end': 229, 'start': 223, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 41, 'start': 39, 'tag': 'DiseaseOrSyndrome'}, {'end': 208, 'start': 206, 'tag': 'DiseaseOrSyndrome'}, {'end': 51, 'start': 42, 'tag': 'ClinicalAttribute'}, {'end': 218, 'start': 209, 'tag': 'ClinicalAttribute'}, {'end': 64, 'start': 53, 'tag': 'BiologicallyActiveSubstance'}, {'end': 78, 'start': 68, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 118, 'start': 115, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 78, 'start': 68, 'tag': 'BiologicallyActiveSubstance'}, {'end': 113, 'start': 88, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 197, 'start': 178, 'tag': 'Finding'}]"
712,This indicates consistent lower left MTL volume across three samples in SCD subjects with abnormal A beta(42) levels.,"[{'end': 109, 'start': 90, 'tag': 'CellOrMolecularDysfunction'}, {'end': 84, 'start': 76, 'tag': 'PopulationGroup'}, {'end': 40, 'start': 37, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 47, 'start': 37, 'tag': 'ClinicalAttribute'}, {'end': 75, 'start': 72, 'tag': 'DiseaseOrSyndrome'}]"
713,"Discussion: Our results support the model that in the presence of AD pathology, SCD corresponds to the late preclinical stage (stage 2 of AD) with smaller MTL volumes.","[{'end': 62, 'start': 54, 'tag': 'Finding'}, {'end': 78, 'start': 69, 'tag': 'PathologicFunction'}, {'end': 78, 'start': 69, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 68, 'start': 66, 'tag': 'DiseaseOrSyndrome'}, {'end': 140, 'start': 138, 'tag': 'DiseaseOrSyndrome'}, {'end': 41, 'start': 36, 'tag': 'ResearchActivity'}, {'end': 125, 'start': 108, 'tag': 'TemporalConcept'}, {'end': 125, 'start': 120, 'tag': 'TemporalConcept'}, {'end': 132, 'start': 127, 'tag': 'TemporalConcept'}, {'end': 125, 'start': 120, 'tag': 'ClinicalAttribute'}, {'end': 132, 'start': 127, 'tag': 'ClinicalAttribute'}, {'end': 158, 'start': 155, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 83, 'start': 80, 'tag': 'DiseaseOrSyndrome'}, {'end': 166, 'start': 155, 'tag': 'ClinicalAttribute'}]"
714,(C) 2018 the Alzheimer's Association.,"[{'end': 36, 'start': 13, 'tag': 'HealthCareRelatedOrganization'}]"
715,Published by Elsevier Inc.,[]
716,All rights reserved.,[]
717,"Background Intranasally administered insulin has shown promise in both rodent and human studies in Alzheimer's disease; however, both effects and mechanisms require elucidation.","[{'end': 44, 'start': 37, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 44, 'start': 37, 'tag': 'BiologicallyActiveSubstance'}, {'end': 44, 'start': 37, 'tag': 'PharmacologicSubstance'}, {'end': 77, 'start': 71, 'tag': 'Eukaryote'}, {'end': 118, 'start': 99, 'tag': 'DiseaseOrSyndrome'}, {'end': 95, 'start': 88, 'tag': 'ResearchActivity'}, {'end': 87, 'start': 82, 'tag': 'Eukaryote'}, {'end': 141, 'start': 134, 'tag': 'PathologicFunction'}, {'end': 44, 'start': 11, 'tag': 'HealthCareActivity'}]"
718,Objective We assessed the effects of intranasally administered insulin on white matter health and its association with cognition and cerebral spinal fluid biomarker profiles in adults with mild cognitive impairment or Alzheimer's disease in secondary analyses from a prior phase 2 clinical trial (NCT01767909).,"[{'end': 70, 'start': 63, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 70, 'start': 63, 'tag': 'BiologicallyActiveSubstance'}, {'end': 70, 'start': 63, 'tag': 'PharmacologicSubstance'}, {'end': 154, 'start': 133, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 295, 'start': 273, 'tag': 'ResearchActivity'}, {'end': 93, 'start': 87, 'tag': 'HealthCareActivity'}, {'end': 237, 'start': 218, 'tag': 'DiseaseOrSyndrome'}, {'end': 164, 'start': 155, 'tag': 'ClinicalAttribute'}, {'end': 86, 'start': 74, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 183, 'start': 177, 'tag': 'PopulationGroup'}, {'end': 214, 'start': 189, 'tag': 'DiseaseOrSyndrome'}, {'end': 173, 'start': 165, 'tag': 'ResearchActivity'}, {'end': 128, 'start': 119, 'tag': 'BiologicFunction'}, {'end': 33, 'start': 26, 'tag': 'PathologicFunction'}, {'end': 259, 'start': 251, 'tag': 'ResearchActivity'}, {'end': 70, 'start': 37, 'tag': 'HealthCareActivity'}]"
719,Design A randomized (1:1) double-blind clinical trial.,"[{'end': 53, 'start': 9, 'tag': 'ResearchActivity'}]"
720,Setting Twelve sites across the United States.,"[{'end': 45, 'start': 32, 'tag': 'PopulationGroup'}]"
721,Participants Adults with mild cognitive impairment or Alzheimer's disease.,"[{'end': 19, 'start': 13, 'tag': 'PopulationGroup'}, {'end': 73, 'start': 54, 'tag': 'DiseaseOrSyndrome'}, {'end': 12, 'start': 0, 'tag': 'PopulationGroup'}, {'end': 50, 'start': 25, 'tag': 'DiseaseOrSyndrome'}]"
722,Intervention Participants received either twice daily placebo or insulin (20 IU Humulin R U-100 b.i.d.) intranasally for 12 months.,"[{'end': 72, 'start': 65, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 72, 'start': 65, 'tag': 'BiologicallyActiveSubstance'}, {'end': 72, 'start': 65, 'tag': 'PharmacologicSubstance'}, {'end': 130, 'start': 121, 'tag': 'TemporalConcept'}, {'end': 25, 'start': 13, 'tag': 'PopulationGroup'}, {'end': 61, 'start': 54, 'tag': 'HealthCareActivity'}, {'end': 53, 'start': 48, 'tag': 'TemporalConcept'}, {'end': 102, 'start': 74, 'tag': 'PharmacologicSubstance'}]"
723,"Seventy-eight participants were screened, of whom 49 (32 men) were enrolled.","[{'end': 60, 'start': 57, 'tag': 'PopulationGroup'}, {'end': 40, 'start': 32, 'tag': 'HealthCareActivity'}, {'end': 40, 'start': 32, 'tag': 'ResearchActivity'}, {'end': 26, 'start': 14, 'tag': 'PopulationGroup'}]"
724,"Measurements Changes from baseline in global and regional white matter hyperintensity volume and gray matter volume were analyzed and related to changes in cerebral spinal fluid biomarkers, Alzheimer's Disease Assessment Scale-Cognition, Clinical Disease Rating-Sum of Boxes, Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale, and a memory composite.","[{'end': 12, 'start': 0, 'tag': 'HealthCareActivity'}, {'end': 177, 'start': 156, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 70, 'start': 58, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 188, 'start': 178, 'tag': 'ClinicalAttribute'}, {'end': 20, 'start': 13, 'tag': 'Finding'}, {'end': 360, 'start': 354, 'tag': 'BiologicFunction'}, {'end': 129, 'start': 121, 'tag': 'ResearchActivity'}, {'end': 115, 'start': 97, 'tag': 'ClinicalAttribute'}, {'end': 92, 'start': 58, 'tag': 'ClinicalAttribute'}, {'end': 236, 'start': 190, 'tag': 'HealthCareActivity'}, {'end': 274, 'start': 238, 'tag': 'HealthCareActivity'}, {'end': 346, 'start': 276, 'tag': 'HealthCareActivity'}]"
725,"Results The insulin-treated group demonstrated significantly reduced changes in white matter hyperintensity volume in deep and frontal regions after 12 months, with a similar trend for global volume.","[{'end': 142, 'start': 118, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 92, 'start': 80, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 33, 'start': 28, 'tag': 'PopulationGroup'}, {'end': 158, 'start': 152, 'tag': 'TemporalConcept'}, {'end': 19, 'start': 12, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 19, 'start': 12, 'tag': 'BiologicallyActiveSubstance'}, {'end': 19, 'start': 12, 'tag': 'PharmacologicSubstance'}, {'end': 114, 'start': 80, 'tag': 'ClinicalAttribute'}]"
726,"White matter hyperintensity volume progression correlated with worsened Alzheimer's disease cerebral spinal fluid biomarker profile and cognitive function; however, patterns of correlations differed by treatment group.","[{'end': 71, 'start': 63, 'tag': 'Finding'}, {'end': 217, 'start': 202, 'tag': 'PopulationGroup'}, {'end': 154, 'start': 136, 'tag': 'BiologicFunction'}, {'end': 91, 'start': 72, 'tag': 'DiseaseOrSyndrome'}, {'end': 123, 'start': 114, 'tag': 'ClinicalAttribute'}, {'end': 46, 'start': 35, 'tag': 'PathologicFunction'}, {'end': 46, 'start': 35, 'tag': 'TemporalConcept'}, {'end': 217, 'start': 212, 'tag': 'PopulationGroup'}, {'end': 189, 'start': 177, 'tag': 'ResearchActivity'}, {'end': 211, 'start': 202, 'tag': 'HealthCareActivity'}, {'end': 211, 'start': 202, 'tag': 'ResearchActivity'}, {'end': 173, 'start': 165, 'tag': 'ResearchActivity'}, {'end': 113, 'start': 92, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 34, 'start': 0, 'tag': 'ClinicalAttribute'}]"
727,Conclusion Intranasal insulin treatment for 12 months reduced white matter hyperintensity volume progression and supports insulin's potential as a therapeutic option for Alzheimer's disease.,"[{'end': 189, 'start': 170, 'tag': 'DiseaseOrSyndrome'}, {'end': 108, 'start': 97, 'tag': 'PathologicFunction'}, {'end': 108, 'start': 97, 'tag': 'TemporalConcept'}, {'end': 53, 'start': 47, 'tag': 'TemporalConcept'}, {'end': 39, 'start': 11, 'tag': 'HealthCareActivity'}, {'end': 96, 'start': 62, 'tag': 'ClinicalAttribute'}, {'end': 165, 'start': 147, 'tag': 'HealthCareActivity'}]"
728,BackgroundEarly diagnosis and effective intervention are the keys to delaying the progression of Alzheimer's Disease (AD).,"[{'end': 120, 'start': 118, 'tag': 'DiseaseOrSyndrome'}, {'end': 93, 'start': 82, 'tag': 'PathologicFunction'}, {'end': 93, 'start': 82, 'tag': 'TemporalConcept'}, {'end': 116, 'start': 97, 'tag': 'DiseaseOrSyndrome'}, {'end': 25, 'start': 10, 'tag': 'HealthCareActivity'}]"
729,"Therefore, we aimed to identify new biomarkers for the early diagnosis of AD through bioinformatic analysis and elucidate the possible underlying mechanisms.","[{'end': 70, 'start': 55, 'tag': 'HealthCareActivity'}, {'end': 76, 'start': 74, 'tag': 'DiseaseOrSyndrome'}, {'end': 46, 'start': 36, 'tag': 'ClinicalAttribute'}, {'end': 107, 'start': 85, 'tag': 'ResearchActivity'}]"
730,"Methods and ResultsGSE1297, GSE63063, and GSE110226 datasets from the GEO database were used to screen the highly differentially expressed genes.","[{'end': 102, 'start': 96, 'tag': 'HealthCareActivity'}, {'end': 102, 'start': 96, 'tag': 'ResearchActivity'}, {'end': 82, 'start': 70, 'tag': 'ResearchActivity'}, {'end': 138, 'start': 114, 'tag': 'Finding'}, {'end': 26, 'start': 19, 'tag': 'ResearchActivity'}, {'end': 36, 'start': 28, 'tag': 'ResearchActivity'}, {'end': 51, 'start': 42, 'tag': 'ResearchActivity'}, {'end': 144, 'start': 139, 'tag': 'GeneOrGenome'}, {'end': 60, 'start': 52, 'tag': 'ResearchActivity'}]"
731,"We identified a potential biomarker, Platelet activating factor receptor (PTAFR), significantly upregulated in the brain tissue, peripheral blood, and cerebrospinal fluid of AD patients.","[{'end': 72, 'start': 37, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 72, 'start': 37, 'tag': 'BiologicallyActiveSubstance'}, {'end': 79, 'start': 74, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 79, 'start': 74, 'tag': 'GeneOrGenome'}, {'end': 79, 'start': 74, 'tag': 'BiologicallyActiveSubstance'}, {'end': 13, 'start': 3, 'tag': 'Finding'}, {'end': 176, 'start': 174, 'tag': 'DiseaseOrSyndrome'}, {'end': 170, 'start': 151, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 35, 'start': 16, 'tag': 'ClinicalAttribute'}, {'end': 185, 'start': 177, 'tag': 'PatientOrDisabledGroup'}, {'end': 127, 'start': 115, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 145, 'start': 129, 'tag': 'BodyPartOrganOrOrganComponent'}]"
732,"Furthermore, PTAFR levels in the plasma and brain tissues of APP/PS1 mice were significantly elevated.","[{'end': 18, 'start': 13, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 18, 'start': 13, 'tag': 'GeneOrGenome'}, {'end': 18, 'start': 13, 'tag': 'BiologicallyActiveSubstance'}, {'end': 39, 'start': 33, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 57, 'start': 44, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 73, 'start': 61, 'tag': 'ExperimentalModelOfDisease'}, {'end': 39, 'start': 13, 'tag': 'ClinicalAttribute'}]"
733,"Simultaneously, PTAFR could mediate the inflammatory responses to exaggerate the microenvironment, particularly mediated by the microglia through the IL10-STAT3 pathway.","[{'end': 21, 'start': 16, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 21, 'start': 16, 'tag': 'GeneOrGenome'}, {'end': 21, 'start': 16, 'tag': 'BiologicallyActiveSubstance'}, {'end': 97, 'start': 81, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 97, 'start': 81, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 160, 'start': 155, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 160, 'start': 155, 'tag': 'GeneOrGenome'}, {'end': 160, 'start': 155, 'tag': 'BiologicallyActiveSubstance'}, {'end': 62, 'start': 40, 'tag': 'PathologicFunction'}, {'end': 137, 'start': 128, 'tag': 'Cell'}, {'end': 168, 'start': 161, 'tag': 'CellFunction'}, {'end': 154, 'start': 150, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 154, 'start': 150, 'tag': 'BiologicallyActiveSubstance'}]"
734,"In addition, PTAFR was a putative target of anti-AD compounds, including EGCG, donepezil, curcumin, memantine, and Huperzine A.","[{'end': 18, 'start': 13, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 18, 'start': 13, 'tag': 'GeneOrGenome'}, {'end': 18, 'start': 13, 'tag': 'BiologicallyActiveSubstance'}, {'end': 77, 'start': 73, 'tag': 'Chemical'}, {'end': 109, 'start': 100, 'tag': 'Chemical'}, {'end': 98, 'start': 90, 'tag': 'Chemical'}, {'end': 98, 'start': 90, 'tag': 'PharmacologicSubstance'}, {'end': 88, 'start': 79, 'tag': 'Chemical'}, {'end': 88, 'start': 79, 'tag': 'PharmacologicSubstance'}, {'end': 51, 'start': 49, 'tag': 'DiseaseOrSyndrome'}, {'end': 109, 'start': 100, 'tag': 'PharmacologicSubstance'}, {'end': 126, 'start': 115, 'tag': 'PharmacologicSubstance'}, {'end': 126, 'start': 115, 'tag': 'Chemical'}, {'end': 61, 'start': 44, 'tag': 'PharmacologicSubstance'}]"
735,ConclusionPTAFR was a potential biomarker for early AD diagnosis and treatment which correlated with the microglia-mediated microenvironment.,"[{'end': 140, 'start': 124, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 140, 'start': 124, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 54, 'start': 52, 'tag': 'DiseaseOrSyndrome'}, {'end': 41, 'start': 22, 'tag': 'ClinicalAttribute'}, {'end': 64, 'start': 55, 'tag': 'HealthCareActivity'}, {'end': 114, 'start': 105, 'tag': 'Cell'}, {'end': 51, 'start': 46, 'tag': 'TemporalConcept'}, {'end': 78, 'start': 69, 'tag': 'HealthCareActivity'}, {'end': 78, 'start': 69, 'tag': 'ResearchActivity'}, {'end': 15, 'start': 10, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 15, 'start': 10, 'tag': 'BiologicallyActiveSubstance'}, {'end': 15, 'start': 10, 'tag': 'GeneOrGenome'}]"
736,It is an important putative target for the development of a novel strategy for clinical treatment and drug discovery for AD.,"[{'end': 116, 'start': 102, 'tag': 'ResearchActivity'}, {'end': 123, 'start': 121, 'tag': 'DiseaseOrSyndrome'}, {'end': 54, 'start': 43, 'tag': 'BiologicFunction'}, {'end': 54, 'start': 43, 'tag': 'CellFunction'}, {'end': 97, 'start': 79, 'tag': 'HealthCareActivity'}]"
737,Introduction: A critical and as-yet unmet need in Alzheimer's disease (AD) is the discovery of peripheral small molecule biomarkers.,"[{'end': 24, 'start': 16, 'tag': 'Finding'}, {'end': 46, 'start': 36, 'tag': 'Finding'}, {'end': 91, 'start': 82, 'tag': 'ResearchActivity'}, {'end': 69, 'start': 50, 'tag': 'DiseaseOrSyndrome'}, {'end': 73, 'start': 71, 'tag': 'DiseaseOrSyndrome'}, {'end': 131, 'start': 121, 'tag': 'ClinicalAttribute'}, {'end': 120, 'start': 106, 'tag': 'Chemical'}, {'end': 105, 'start': 95, 'tag': 'BodyPartOrganOrOrganComponent'}]"
738,"Given that brain pathology precedes clinical symptom onset, we set out to test whether metabolites in blood associated with pathology as indexed by cerebrospinal fluid (CSF) AD biomarkers.","[{'end': 26, 'start': 11, 'tag': 'PathologicFunction'}, {'end': 172, 'start': 169, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 133, 'start': 124, 'tag': 'PathologicFunction'}, {'end': 133, 'start': 124, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 176, 'start': 174, 'tag': 'DiseaseOrSyndrome'}, {'end': 167, 'start': 148, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 98, 'start': 87, 'tag': 'BiologicallyActiveSubstance'}, {'end': 187, 'start': 177, 'tag': 'ClinicalAttribute'}, {'end': 107, 'start': 102, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 78, 'start': 74, 'tag': 'ResearchActivity'}, {'end': 78, 'start': 74, 'tag': 'HealthCareActivity'}, {'end': 58, 'start': 45, 'tag': 'TemporalConcept'}, {'end': 52, 'start': 45, 'tag': 'SignOrSymptom'}]"
739,"Methods: This study analyzed 593 plasma samples selected from the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery study, of individuals who were cognitively healthy (n = 242), had mild cognitive impairment (n = 236), or had AD-type dementia (n = 115).","[{'end': 39, 'start': 33, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 272, 'start': 270, 'tag': 'DiseaseOrSyndrome'}, {'end': 181, 'start': 170, 'tag': 'PopulationGroup'}, {'end': 128, 'start': 109, 'tag': 'DiseaseOrSyndrome'}, {'end': 286, 'start': 270, 'tag': 'DiseaseOrSyndrome'}, {'end': 149, 'start': 140, 'tag': 'ClinicalAttribute'}, {'end': 19, 'start': 14, 'tag': 'ResearchActivity'}, {'end': 165, 'start': 109, 'tag': 'ResearchActivity'}, {'end': 251, 'start': 226, 'tag': 'DiseaseOrSyndrome'}, {'end': 28, 'start': 20, 'tag': 'ResearchActivity'}, {'end': 210, 'start': 191, 'tag': 'OrganismAttribute'}, {'end': 74, 'start': 66, 'tag': 'PopulationGroup'}, {'end': 104, 'start': 66, 'tag': 'HealthCareRelatedOrganization'}]"
740,"Logistic regressions were carried out between plasma metabolites (n = 883) and CSF markers, magnetic resonance imaging, cognition, and clinical diagnosis.","[{'end': 20, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 52, 'start': 46, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 82, 'start': 79, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 64, 'start': 53, 'tag': 'BiologicallyActiveSubstance'}, {'end': 153, 'start': 135, 'tag': 'HealthCareActivity'}, {'end': 129, 'start': 120, 'tag': 'BiologicFunction'}, {'end': 118, 'start': 92, 'tag': 'HealthCareActivity'}, {'end': 90, 'start': 83, 'tag': 'ClinicalAttribute'}]"
741,"Results: Eight metabolites were associated with amyloid b and one with t-tau in CSF, these were primary fatty acid amides (PFAMs), lipokines, and amino acids.","[{'end': 57, 'start': 48, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 157, 'start': 146, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 83, 'start': 80, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 26, 'start': 15, 'tag': 'BiologicallyActiveSubstance'}, {'end': 76, 'start': 71, 'tag': 'BiologicallyActiveSubstance'}, {'end': 76, 'start': 71, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 121, 'start': 96, 'tag': 'Chemical'}, {'end': 140, 'start': 131, 'tag': 'BiologicallyActiveSubstance'}, {'end': 128, 'start': 123, 'tag': 'Chemical'}]"
742,"From these, PFAMs, glutamate, and aspartate also associated with hippocampal volume and memory.","[{'end': 28, 'start': 19, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 43, 'start': 34, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 94, 'start': 88, 'tag': 'BiologicFunction'}, {'end': 76, 'start': 65, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 76, 'start': 65, 'tag': 'Cell'}, {'end': 83, 'start': 65, 'tag': 'ClinicalAttribute'}, {'end': 17, 'start': 12, 'tag': 'Chemical'}, {'end': 28, 'start': 19, 'tag': 'BiologicallyActiveSubstance'}, {'end': 43, 'start': 34, 'tag': 'BiologicallyActiveSubstance'}]"
743,Discussion: PFAMs have been found increased and associated with amyloid b burden in CSF and clinical measures.,"[{'end': 109, 'start': 92, 'tag': 'ClinicalAttribute'}, {'end': 80, 'start': 74, 'tag': 'ResearchActivity'}, {'end': 87, 'start': 84, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 73, 'start': 64, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 17, 'start': 12, 'tag': 'Chemical'}]"
744,Crown Copyright (C) 2019 Published by Elsevier Inc.,[]
745,on behalf of the Alzheimer's Association.,"[{'end': 40, 'start': 17, 'tag': 'HealthCareRelatedOrganization'}]"
746,This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-ncnd/4.0/).,"[{'end': 30, 'start': 23, 'tag': 'ResearchActivity'}, {'end': 49, 'start': 47, 'tag': 'PopulationGroup'}]"
747,"Phospho-tau 217, phospho-tau 231 and phospho-tau 181 in cerebrospinal fluid and plasma are promising biomarkers for the diagnosis of Alzheimer's disease.","[{'end': 15, 'start': 0, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 32, 'start': 17, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 152, 'start': 133, 'tag': 'DiseaseOrSyndrome'}, {'end': 86, 'start': 80, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 15, 'start': 0, 'tag': 'BiologicallyActiveSubstance'}, {'end': 32, 'start': 17, 'tag': 'BiologicallyActiveSubstance'}, {'end': 75, 'start': 56, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 129, 'start': 120, 'tag': 'HealthCareActivity'}, {'end': 111, 'start': 101, 'tag': 'ClinicalAttribute'}, {'end': 52, 'start': 37, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 52, 'start': 37, 'tag': 'BiologicallyActiveSubstance'}]"
748,All these p-tau proteins are detected in neurofibrillary tangles in brains obtained post-mortem from Alzheimer's disease patients.,"[{'end': 64, 'start': 41, 'tag': 'CellComponent'}, {'end': 24, 'start': 10, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 24, 'start': 10, 'tag': 'BiologicallyActiveSubstance'}, {'end': 120, 'start': 101, 'tag': 'DiseaseOrSyndrome'}, {'end': 88, 'start': 84, 'tag': 'TemporalConcept'}, {'end': 129, 'start': 121, 'tag': 'PatientOrDisabledGroup'}, {'end': 95, 'start': 84, 'tag': 'TemporalConcept'}, {'end': 74, 'start': 68, 'tag': 'BodyPartOrganOrOrganComponent'}]"
749,"However, increases in p-tau levels in cerebrospinal fluid and plasma during the preclinical stage of Alzheimer's disease correlate with amyloid-beta burden and precede neurofibrillary tangles in brains, suggesting that these p-tau proteins are indicative of amyloid-beta-mediated brain pathology.","[{'end': 183, 'start': 168, 'tag': 'CellComponent'}, {'end': 239, 'start': 225, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 239, 'start': 225, 'tag': 'BiologicallyActiveSubstance'}, {'end': 34, 'start': 24, 'tag': 'ClinicalAttribute'}, {'end': 155, 'start': 149, 'tag': 'ResearchActivity'}, {'end': 120, 'start': 101, 'tag': 'DiseaseOrSyndrome'}, {'end': 68, 'start': 62, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 148, 'start': 136, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 270, 'start': 258, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 295, 'start': 286, 'tag': 'PathologicFunction'}, {'end': 295, 'start': 286, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 143, 'start': 136, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 265, 'start': 258, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 143, 'start': 136, 'tag': 'BiologicallyActiveSubstance'}, {'end': 265, 'start': 258, 'tag': 'BiologicallyActiveSubstance'}, {'end': 57, 'start': 38, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 285, 'start': 280, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 97, 'start': 92, 'tag': 'TemporalConcept'}, {'end': 97, 'start': 92, 'tag': 'ClinicalAttribute'}, {'end': 201, 'start': 195, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 97, 'start': 80, 'tag': 'TemporalConcept'}, {'end': 191, 'start': 168, 'tag': 'CellOrMolecularDysfunction'}]"
750,"In addition, phospho-tau 217 has greater sensitivity than phospho-tau 181, though it is unclear whether each of these p-tau variants contributes to the same or a different type of neuropathology prior to neurofibrillary tangle formation.","[{'end': 219, 'start': 204, 'tag': 'CellComponent'}, {'end': 28, 'start': 13, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 123, 'start': 120, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 123, 'start': 120, 'tag': 'BiologicallyActiveSubstance'}, {'end': 194, 'start': 180, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 194, 'start': 180, 'tag': 'PathologicFunction'}, {'end': 73, 'start': 58, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 28, 'start': 13, 'tag': 'BiologicallyActiveSubstance'}, {'end': 73, 'start': 58, 'tag': 'BiologicallyActiveSubstance'}, {'end': 52, 'start': 41, 'tag': 'Finding'}, {'end': 123, 'start': 118, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 123, 'start': 118, 'tag': 'BiologicallyActiveSubstance'}, {'end': 236, 'start': 204, 'tag': 'CellOrMolecularDysfunction'}]"
751,"In this study, we evaluated the intracerebral localization of p-tau in App knock-in mice with amyloid-beta plaques without neurofibrillary tangle pathology (App(NLGF)), in App knock-in mice with increased amyloid-beta levels without amyloid-beta plaques (App(NL)) and in wild-type mice.","[{'end': 58, 'start': 46, 'tag': 'BiologicFunction'}, {'end': 58, 'start': 46, 'tag': 'ResearchActivity'}, {'end': 58, 'start': 46, 'tag': 'CellFunction'}, {'end': 74, 'start': 71, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 74, 'start': 71, 'tag': 'GeneOrGenome'}, {'end': 88, 'start': 75, 'tag': 'ResearchActivity'}, {'end': 175, 'start': 172, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 175, 'start': 172, 'tag': 'GeneOrGenome'}, {'end': 189, 'start': 176, 'tag': 'ResearchActivity'}, {'end': 280, 'start': 271, 'tag': 'ResearchActivity'}, {'end': 83, 'start': 75, 'tag': 'ResearchActivity'}, {'end': 184, 'start': 176, 'tag': 'ResearchActivity'}, {'end': 285, 'start': 271, 'tag': 'Eukaryote'}, {'end': 138, 'start': 123, 'tag': 'CellComponent'}, {'end': 217, 'start': 205, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 155, 'start': 146, 'tag': 'PathologicFunction'}, {'end': 155, 'start': 146, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 212, 'start': 205, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 212, 'start': 205, 'tag': 'BiologicallyActiveSubstance'}, {'end': 13, 'start': 8, 'tag': 'ResearchActivity'}, {'end': 88, 'start': 84, 'tag': 'Eukaryote'}, {'end': 189, 'start': 185, 'tag': 'Eukaryote'}, {'end': 285, 'start': 281, 'tag': 'Eukaryote'}, {'end': 67, 'start': 62, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 67, 'start': 62, 'tag': 'BiologicallyActiveSubstance'}, {'end': 45, 'start': 32, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 166, 'start': 157, 'tag': 'ExperimentalModelOfDisease'}, {'end': 262, 'start': 255, 'tag': 'ExperimentalModelOfDisease'}, {'end': 253, 'start': 233, 'tag': 'AnatomicalAbnormality'}, {'end': 114, 'start': 94, 'tag': 'AnatomicalAbnormality'}]"
752,"Immunohistochemical analysis showed that phospho-tau 217 and phospho-tau 231 were detected only in App(NLGF) mice as punctate structures around amyloid-beta plaques, overlapping with the tau pathology marker, AT8 epitope phospho-tau 202/205/208.","[{'end': 220, 'start': 213, 'tag': 'BiologicallyActiveSubstance'}, {'end': 190, 'start': 187, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 151, 'start': 144, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 190, 'start': 187, 'tag': 'BiologicallyActiveSubstance'}, {'end': 113, 'start': 99, 'tag': 'ExperimentalModelOfDisease'}, {'end': 28, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 56, 'start': 41, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 76, 'start': 61, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 244, 'start': 221, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 56, 'start': 41, 'tag': 'BiologicallyActiveSubstance'}, {'end': 76, 'start': 61, 'tag': 'BiologicallyActiveSubstance'}, {'end': 244, 'start': 221, 'tag': 'BiologicallyActiveSubstance'}, {'end': 207, 'start': 201, 'tag': 'ClinicalAttribute'}, {'end': 212, 'start': 209, 'tag': 'BiologicallyActiveSubstance'}, {'end': 200, 'start': 187, 'tag': 'PathologicFunction'}, {'end': 164, 'start': 144, 'tag': 'AnatomicalAbnormality'}]"
753,"Moreover, phospho-tau 217 and phospho-tau 202/205/208 colocalized with the postsynaptic marker PSD95 and with a major tau kinase active, GSK3 beta.","[{'end': 100, 'start': 95, 'tag': 'GeneOrGenome'}, {'end': 100, 'start': 95, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 146, 'start': 137, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 87, 'start': 75, 'tag': 'CellComponent'}, {'end': 25, 'start': 10, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 53, 'start': 30, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 121, 'start': 118, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 25, 'start': 10, 'tag': 'BiologicallyActiveSubstance'}, {'end': 121, 'start': 118, 'tag': 'BiologicallyActiveSubstance'}, {'end': 53, 'start': 30, 'tag': 'BiologicallyActiveSubstance'}, {'end': 94, 'start': 88, 'tag': 'ClinicalAttribute'}, {'end': 146, 'start': 137, 'tag': 'BiologicallyActiveSubstance'}]"
754,"In contrast and similar to total tau, phospho-tau 181 signals were readily detectable as fibre structures in wild-type and App(NL) mice and colocalized with an axonal marker neurofilament light chain.","[{'end': 85, 'start': 75, 'tag': 'ClinicalAttribute'}, {'end': 118, 'start': 109, 'tag': 'ResearchActivity'}, {'end': 135, 'start': 123, 'tag': 'ExperimentalModelOfDisease'}, {'end': 36, 'start': 27, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 36, 'start': 27, 'tag': 'BiologicallyActiveSubstance'}, {'end': 53, 'start': 38, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 53, 'start': 38, 'tag': 'BiologicallyActiveSubstance'}, {'end': 173, 'start': 167, 'tag': 'ClinicalAttribute'}, {'end': 61, 'start': 54, 'tag': 'CellFunction'}, {'end': 166, 'start': 160, 'tag': 'CellComponent'}, {'end': 199, 'start': 174, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 199, 'start': 174, 'tag': 'BiologicallyActiveSubstance'}]"
755,"In App(NLGF) mice, these phospho-tau 181-positive structures were disrupted around amyloid-beta plaques and only partially overlapped with phospho-tau 217.","[{'end': 75, 'start': 66, 'tag': 'PathologicFunction'}, {'end': 40, 'start': 25, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 95, 'start': 83, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 90, 'start': 83, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 90, 'start': 83, 'tag': 'BiologicallyActiveSubstance'}, {'end': 17, 'start': 3, 'tag': 'ExperimentalModelOfDisease'}, {'end': 154, 'start': 139, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 40, 'start': 25, 'tag': 'BiologicallyActiveSubstance'}, {'end': 154, 'start': 139, 'tag': 'BiologicallyActiveSubstance'}, {'end': 103, 'start': 83, 'tag': 'AnatomicalAbnormality'}]"
756,"These results indicate that phospho-tau 217, phospho-tau 231 and a part of phospho-tau 181 signals are markers of postsynaptic pathology around amyloid-beta plaques, with phospho-tau 181 also being a marker of axonal abnormality caused by amyloid-beta burden in brains.","[{'end': 126, 'start': 114, 'tag': 'CellComponent'}, {'end': 258, 'start': 252, 'tag': 'ResearchActivity'}, {'end': 251, 'start': 239, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 136, 'start': 127, 'tag': 'PathologicFunction'}, {'end': 136, 'start': 127, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 246, 'start': 239, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 246, 'start': 239, 'tag': 'BiologicallyActiveSubstance'}, {'end': 43, 'start': 28, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 60, 'start': 45, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 90, 'start': 75, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 186, 'start': 171, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 43, 'start': 28, 'tag': 'BiologicallyActiveSubstance'}, {'end': 60, 'start': 45, 'tag': 'BiologicallyActiveSubstance'}, {'end': 90, 'start': 75, 'tag': 'BiologicallyActiveSubstance'}, {'end': 186, 'start': 171, 'tag': 'BiologicallyActiveSubstance'}, {'end': 228, 'start': 217, 'tag': 'Finding'}, {'end': 268, 'start': 262, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 206, 'start': 200, 'tag': 'ClinicalAttribute'}, {'end': 98, 'start': 91, 'tag': 'CellFunction'}, {'end': 216, 'start': 210, 'tag': 'CellComponent'}, {'end': 110, 'start': 103, 'tag': 'ClinicalAttribute'}, {'end': 164, 'start': 144, 'tag': 'AnatomicalAbnormality'}]"
757,Background Diet may be a modifiable factor for reducing the risk of Alzheimer's disease (AD).,"[{'end': 15, 'start': 11, 'tag': 'HealthCareActivity'}, {'end': 55, 'start': 47, 'tag': 'Finding'}, {'end': 87, 'start': 68, 'tag': 'DiseaseOrSyndrome'}, {'end': 91, 'start': 89, 'tag': 'DiseaseOrSyndrome'}]"
758,"Western-style dietary patterns are considered to increase the risk, whereas Mediterranean-style dietary patterns are considered to reduce the risk.","[{'end': 112, 'start': 76, 'tag': 'Finding'}, {'end': 30, 'start': 0, 'tag': 'Finding'}]"
759,"An association between diet and AD-related biomarkers have been suggested, but studies are limited.","[{'end': 27, 'start': 23, 'tag': 'HealthCareActivity'}, {'end': 53, 'start': 43, 'tag': 'ClinicalAttribute'}, {'end': 86, 'start': 79, 'tag': 'ResearchActivity'}, {'end': 34, 'start': 32, 'tag': 'DiseaseOrSyndrome'}]"
760,Aim To investigate potential relations between dietary patterns and cerebrospinal fluid (CSF) biomarkers for AD among dementia-free older adults.,"[{'end': 63, 'start': 47, 'tag': 'Finding'}, {'end': 104, 'start': 94, 'tag': 'ClinicalAttribute'}, {'end': 92, 'start': 89, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 111, 'start': 109, 'tag': 'DiseaseOrSyndrome'}, {'end': 126, 'start': 118, 'tag': 'DiseaseOrSyndrome'}, {'end': 144, 'start': 138, 'tag': 'PopulationGroup'}, {'end': 137, 'start': 132, 'tag': 'TemporalConcept'}, {'end': 87, 'start': 68, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 87, 'start': 82, 'tag': 'Substance'}, {'end': 144, 'start': 132, 'tag': 'PopulationGroup'}]"
761,"Methods Data were derived from the population-based Gothenburg H70 Birth Cohort Studies, Sweden.","[{'end': 87, 'start': 35, 'tag': 'ResearchActivity'}, {'end': 12, 'start': 8, 'tag': 'ResearchActivity'}, {'end': 45, 'start': 35, 'tag': 'PopulationGroup'}]"
762,"A total of 269 dementia-free 70-year-olds with dietary and cerebrospinal fluid (CSF) amyloid beta (A beta 42 and A beta 40), total tau (t-tau), and phosphorylated tau (p-tau) data were investigated.","[{'end': 141, 'start': 136, 'tag': 'ResearchActivity'}, {'end': 197, 'start': 185, 'tag': 'HealthCareActivity'}, {'end': 97, 'start': 85, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 134, 'start': 131, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 141, 'start': 138, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 166, 'start': 163, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 173, 'start': 170, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 83, 'start': 80, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 92, 'start': 85, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 92, 'start': 85, 'tag': 'BiologicallyActiveSubstance'}, {'end': 134, 'start': 131, 'tag': 'BiologicallyActiveSubstance'}, {'end': 141, 'start': 138, 'tag': 'BiologicallyActiveSubstance'}, {'end': 166, 'start': 163, 'tag': 'BiologicallyActiveSubstance'}, {'end': 173, 'start': 170, 'tag': 'BiologicallyActiveSubstance'}, {'end': 23, 'start': 15, 'tag': 'DiseaseOrSyndrome'}, {'end': 36, 'start': 32, 'tag': 'TemporalConcept'}, {'end': 78, 'start': 59, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 179, 'start': 175, 'tag': 'ResearchActivity'}, {'end': 166, 'start': 148, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 166, 'start': 148, 'tag': 'BiologicallyActiveSubstance'}, {'end': 78, 'start': 73, 'tag': 'Substance'}, {'end': 105, 'start': 99, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 119, 'start': 113, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 134, 'start': 125, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 134, 'start': 125, 'tag': 'BiologicallyActiveSubstance'}, {'end': 173, 'start': 168, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 173, 'start': 168, 'tag': 'BiologicallyActiveSubstance'}, {'end': 122, 'start': 113, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 108, 'start': 99, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 122, 'start': 113, 'tag': 'BiologicallyActiveSubstance'}, {'end': 108, 'start': 99, 'tag': 'BiologicallyActiveSubstance'}]"
763,"Dietary intake was determined by the diet history method, and four dietary patterns were derived by principal component analysis.","[{'end': 14, 'start': 0, 'tag': 'Finding'}, {'end': 83, 'start': 67, 'tag': 'ResearchActivity'}, {'end': 83, 'start': 75, 'tag': 'ResearchActivity'}, {'end': 56, 'start': 50, 'tag': 'ResearchActivity'}, {'end': 56, 'start': 50, 'tag': 'HealthCareActivity'}, {'end': 49, 'start': 42, 'tag': 'Finding'}, {'end': 128, 'start': 120, 'tag': 'ResearchActivity'}]"
764,"A Western dietary pattern, a Mediterranean/prudent dietary pattern, a high-protein and alcohol pattern, and a high-total and saturated fat pattern.","[{'end': 102, 'start': 70, 'tag': 'Finding'}, {'end': 25, 'start': 2, 'tag': 'Finding'}, {'end': 66, 'start': 29, 'tag': 'Finding'}, {'end': 146, 'start': 110, 'tag': 'Finding'}]"
765,"Logistic regression models, with CSF biomarker pathology (yes/no) as dependent variables, and linear regression models with continuous CSF biomarker levels as dependent variables were performed.","[{'end': 78, 'start': 69, 'tag': 'Finding'}, {'end': 178, 'start': 159, 'tag': 'ResearchActivity'}, {'end': 134, 'start': 124, 'tag': 'TemporalConcept'}, {'end': 36, 'start': 33, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 138, 'start': 135, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 56, 'start': 47, 'tag': 'PathologicFunction'}, {'end': 56, 'start': 47, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 46, 'start': 37, 'tag': 'ClinicalAttribute'}, {'end': 148, 'start': 139, 'tag': 'ClinicalAttribute'}, {'end': 26, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 118, 'start': 94, 'tag': 'ResearchActivity'}, {'end': 88, 'start': 69, 'tag': 'ResearchActivity'}]"
766,"The analyses were adjusted for sex, energy intake, body mass index (BMI), educational level, and physical activity level.","[{'end': 71, 'start': 68, 'tag': 'ClinicalAttribute'}, {'end': 91, 'start': 74, 'tag': 'Finding'}, {'end': 114, 'start': 97, 'tag': 'BiologicFunction'}, {'end': 66, 'start': 51, 'tag': 'ClinicalAttribute'}, {'end': 34, 'start': 31, 'tag': 'OrganismAttribute'}, {'end': 55, 'start': 51, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 12, 'start': 4, 'tag': 'ResearchActivity'}, {'end': 49, 'start': 36, 'tag': 'ClinicalAttribute'}, {'end': 120, 'start': 97, 'tag': 'ClinicalAttribute'}]"
767,Results The odds ratio for having total tau pathology (odds ratio [OR] 1.43; 95% confidence interval [CI] 1.02 to 2.01) and preclinical AD (A beta 42 and tau pathology; OR 1.79; 95% CI 1.03 to 3.10) was higher among those with a higher adherence to a Western dietary pattern.,"[{'end': 53, 'start': 40, 'tag': 'PathologicFunction'}, {'end': 167, 'start': 154, 'tag': 'PathologicFunction'}, {'end': 100, 'start': 81, 'tag': 'ResearchActivity'}, {'end': 43, 'start': 40, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 157, 'start': 154, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 43, 'start': 40, 'tag': 'BiologicallyActiveSubstance'}, {'end': 157, 'start': 154, 'tag': 'BiologicallyActiveSubstance'}, {'end': 138, 'start': 124, 'tag': 'DiseaseOrSyndrome'}, {'end': 146, 'start': 140, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 43, 'start': 34, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 43, 'start': 34, 'tag': 'BiologicallyActiveSubstance'}, {'end': 149, 'start': 140, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 149, 'start': 140, 'tag': 'BiologicallyActiveSubstance'}, {'end': 65, 'start': 55, 'tag': 'ResearchActivity'}, {'end': 274, 'start': 251, 'tag': 'Finding'}]"
768,There were no other associations between the dietary patterns and CSF biomarkers that remained significant in both unadjusted and adjusted models.,"[{'end': 61, 'start': 45, 'tag': 'Finding'}, {'end': 80, 'start': 70, 'tag': 'ClinicalAttribute'}, {'end': 69, 'start': 66, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 145, 'start': 139, 'tag': 'ResearchActivity'}]"
769,Discussion Our findings suggest that higher adherence to a Western dietary pattern may be associated with pathological levels of AD biomarkers in the preclinical phase of AD.,"[{'end': 142, 'start': 132, 'tag': 'ClinicalAttribute'}, {'end': 167, 'start': 162, 'tag': 'TemporalConcept'}, {'end': 131, 'start': 129, 'tag': 'DiseaseOrSyndrome'}, {'end': 173, 'start': 171, 'tag': 'DiseaseOrSyndrome'}, {'end': 82, 'start': 59, 'tag': 'Finding'}]"
770,These findings can be added to the increasing amount of evidence linking diet with AD and may be useful for future intervention studies investigating dietary intake in relation to AD.,"[{'end': 77, 'start': 73, 'tag': 'HealthCareActivity'}, {'end': 45, 'start': 35, 'tag': 'Finding'}, {'end': 164, 'start': 150, 'tag': 'Finding'}, {'end': 114, 'start': 108, 'tag': 'TemporalConcept'}, {'end': 85, 'start': 83, 'tag': 'DiseaseOrSyndrome'}, {'end': 182, 'start': 180, 'tag': 'DiseaseOrSyndrome'}, {'end': 135, 'start': 115, 'tag': 'ResearchActivity'}, {'end': 64, 'start': 56, 'tag': 'Finding'}]"
771,It is an open issue whether blood biomarkers serve to diagnose Alzheimer's disease (AD) or monitor its progression over time from prodromal stages.,"[{'end': 62, 'start': 54, 'tag': 'HealthCareActivity'}, {'end': 146, 'start': 130, 'tag': 'SignOrSymptom'}, {'end': 82, 'start': 63, 'tag': 'DiseaseOrSyndrome'}, {'end': 44, 'start': 34, 'tag': 'ClinicalAttribute'}, {'end': 86, 'start': 84, 'tag': 'DiseaseOrSyndrome'}, {'end': 33, 'start': 28, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 98, 'start': 91, 'tag': 'HealthCareActivity'}, {'end': 98, 'start': 91, 'tag': 'ManufacturedObject'}, {'end': 146, 'start': 140, 'tag': 'TemporalConcept'}, {'end': 114, 'start': 103, 'tag': 'PathologicFunction'}, {'end': 114, 'start': 103, 'tag': 'TemporalConcept'}, {'end': 124, 'start': 120, 'tag': 'TemporalConcept'}]"
772,"Here, we addressed this question starting from data of the European FP7 IMI-PharmaCog/E-ADNI longitudinal study in amnesic mild cognitive impairment (aMCI) patients including biological, clinical, neuropsychological (e.g., ADAS-Cog13), neuroimaging, and electroencephalographic measures.","[{'end': 215, 'start': 197, 'tag': 'HealthCareActivity'}, {'end': 111, 'start': 93, 'tag': 'ResearchActivity'}, {'end': 164, 'start': 156, 'tag': 'PatientOrDisabledGroup'}, {'end': 111, 'start': 59, 'tag': 'ResearchActivity'}, {'end': 51, 'start': 47, 'tag': 'ResearchActivity'}, {'end': 248, 'start': 236, 'tag': 'HealthCareActivity'}, {'end': 148, 'start': 128, 'tag': 'DiseaseOrSyndrome'}, {'end': 148, 'start': 115, 'tag': 'DiseaseOrSyndrome'}, {'end': 67, 'start': 59, 'tag': 'PopulationGroup'}, {'end': 154, 'start': 150, 'tag': 'DiseaseOrSyndrome'}, {'end': 286, 'start': 254, 'tag': 'HealthCareActivity'}, {'end': 233, 'start': 223, 'tag': 'HealthCareActivity'}]"
773,"PharmaCog/E-ADNI patients were classified as positive (i.e., prodromal AD; n = 76) or negative (n = 52) based on a diagnostic cut-off of A beta(42)/P-tau in cerebrospinal fluid as well as APOE epsilon 4 genotype.","[{'end': 25, 'start': 17, 'tag': 'PatientOrDisabledGroup'}, {'end': 73, 'start': 61, 'tag': 'DiseaseOrSyndrome'}, {'end': 202, 'start': 188, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 176, 'start': 157, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 192, 'start': 188, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 192, 'start': 188, 'tag': 'BiologicallyActiveSubstance'}, {'end': 211, 'start': 203, 'tag': 'OrganismAttribute'}, {'end': 176, 'start': 171, 'tag': 'Substance'}, {'end': 133, 'start': 115, 'tag': 'HealthCareActivity'}, {'end': 147, 'start': 137, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 153, 'start': 148, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 153, 'start': 148, 'tag': 'BiologicallyActiveSubstance'}, {'end': 16, 'start': 0, 'tag': 'HealthCareActivity'}, {'end': 147, 'start': 137, 'tag': 'BiologicallyActiveSubstance'}]"
774,"Blood was sampled at baseline and at two followups (12 and 18 months), when plasma amyloid peptide 42 and 40 (A beta(42), A beta(40)) and apolipoprotein J (clusterin, CLU) were assessed.","[{'end': 50, 'start': 41, 'tag': 'HealthCareActivity'}, {'end': 154, 'start': 138, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 154, 'start': 138, 'tag': 'GeneOrGenome'}, {'end': 154, 'start': 138, 'tag': 'BiologicallyActiveSubstance'}, {'end': 165, 'start': 156, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 165, 'start': 156, 'tag': 'GeneOrGenome'}, {'end': 165, 'start': 156, 'tag': 'BiologicallyActiveSubstance'}, {'end': 170, 'start': 167, 'tag': 'GeneOrGenome'}, {'end': 82, 'start': 76, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 101, 'start': 83, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 101, 'start': 83, 'tag': 'BiologicallyActiveSubstance'}, {'end': 5, 'start': 0, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 120, 'start': 110, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 132, 'start': 122, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 68, 'start': 62, 'tag': 'TemporalConcept'}, {'end': 108, 'start': 106, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 98, 'start': 83, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 108, 'start': 106, 'tag': 'BiologicallyActiveSubstance'}, {'end': 98, 'start': 83, 'tag': 'BiologicallyActiveSubstance'}, {'end': 120, 'start': 110, 'tag': 'BiologicallyActiveSubstance'}, {'end': 132, 'start': 122, 'tag': 'BiologicallyActiveSubstance'}]"
775,Linear Mixed Models found no significant differences in plasma molecules between the positive (i.,"[{'end': 52, 'start': 41, 'tag': 'Finding'}, {'end': 62, 'start': 56, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 72, 'start': 63, 'tag': 'Substance'}, {'end': 19, 'start': 0, 'tag': 'ResearchActivity'}]"
776,"e., prodromal AD) and negative groups at baseline.","[{'end': 16, 'start': 4, 'tag': 'DiseaseOrSyndrome'}, {'end': 37, 'start': 31, 'tag': 'PopulationGroup'}]"
777,"In contrast, plasma A beta(42) showed a greater reduction over time in the prodromal AD than the negative aMCI group (p = 0.048), while CLU and A beta(40) increased, but similarly in the two groups.","[{'end': 139, 'start': 136, 'tag': 'GeneOrGenome'}, {'end': 19, 'start': 13, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 87, 'start': 75, 'tag': 'DiseaseOrSyndrome'}, {'end': 116, 'start': 111, 'tag': 'PopulationGroup'}, {'end': 57, 'start': 48, 'tag': 'Finding'}, {'end': 57, 'start': 48, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 197, 'start': 191, 'tag': 'PopulationGroup'}, {'end': 30, 'start': 20, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 154, 'start': 144, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 110, 'start': 106, 'tag': 'DiseaseOrSyndrome'}, {'end': 67, 'start': 63, 'tag': 'TemporalConcept'}, {'end': 30, 'start': 20, 'tag': 'BiologicallyActiveSubstance'}, {'end': 154, 'start': 144, 'tag': 'BiologicallyActiveSubstance'}]"
778,"Furthermore, plasma A beta(42) correlated with the ADAS-Cog13 score both in aMCI patients as a whole and the prodromal AD group alone.","[{'end': 67, 'start': 62, 'tag': 'Finding'}, {'end': 19, 'start': 13, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 89, 'start': 81, 'tag': 'PatientOrDisabledGroup'}, {'end': 121, 'start': 109, 'tag': 'DiseaseOrSyndrome'}, {'end': 127, 'start': 122, 'tag': 'PopulationGroup'}, {'end': 30, 'start': 20, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 80, 'start': 76, 'tag': 'DiseaseOrSyndrome'}, {'end': 30, 'start': 20, 'tag': 'BiologicallyActiveSubstance'}, {'end': 61, 'start': 51, 'tag': 'HealthCareActivity'}]"
779,"Finally, CLU correlated with the ADAS-Cog13 only in the whole aMCI group, and no association with ADAS-Cog13 was found for A beta(40).","[{'end': 12, 'start': 9, 'tag': 'GeneOrGenome'}, {'end': 72, 'start': 67, 'tag': 'PopulationGroup'}, {'end': 133, 'start': 123, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 66, 'start': 62, 'tag': 'DiseaseOrSyndrome'}, {'end': 43, 'start': 33, 'tag': 'HealthCareActivity'}, {'end': 108, 'start': 98, 'tag': 'HealthCareActivity'}, {'end': 133, 'start': 123, 'tag': 'BiologicallyActiveSubstance'}]"
780,"In conclusion, plasma A beta(42) showed disease progression-related features in aMCI patients with prodromal AD.","[{'end': 21, 'start': 15, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 93, 'start': 85, 'tag': 'PatientOrDisabledGroup'}, {'end': 111, 'start': 99, 'tag': 'DiseaseOrSyndrome'}, {'end': 59, 'start': 48, 'tag': 'PathologicFunction'}, {'end': 59, 'start': 48, 'tag': 'TemporalConcept'}, {'end': 59, 'start': 40, 'tag': 'PathologicFunction'}, {'end': 32, 'start': 22, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 84, 'start': 80, 'tag': 'DiseaseOrSyndrome'}, {'end': 32, 'start': 22, 'tag': 'BiologicallyActiveSubstance'}]"
781,"IntroductionWhile the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) was ongoing, external data suggested higher doses were needed to achieve targeted effects; therefore, doses of gantenerumab were increased 5-fold, and solanezumab was increased 4-fold.","[{'end': 206, 'start': 194, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 245, 'start': 234, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 94, 'start': 87, 'tag': 'TemporalConcept'}, {'end': 52, 'start': 22, 'tag': 'DiseaseOrSyndrome'}, {'end': 60, 'start': 22, 'tag': 'HealthCareRelatedOrganization'}, {'end': 78, 'start': 74, 'tag': 'HealthCareRelatedOrganization'}, {'end': 109, 'start': 105, 'tag': 'ResearchActivity'}, {'end': 72, 'start': 22, 'tag': 'ResearchActivity'}, {'end': 81, 'start': 74, 'tag': 'ResearchActivity'}, {'end': 206, 'start': 194, 'tag': 'BiologicallyActiveSubstance'}, {'end': 206, 'start': 194, 'tag': 'PharmacologicSubstance'}, {'end': 245, 'start': 234, 'tag': 'BiologicallyActiveSubstance'}, {'end': 245, 'start': 234, 'tag': 'PharmacologicSubstance'}]"
782,We evaluated to what extent mid-trial dose increases produced a dose-dependent treatment effect.,"[{'end': 37, 'start': 32, 'tag': 'ResearchActivity'}, {'end': 88, 'start': 79, 'tag': 'HealthCareActivity'}, {'end': 88, 'start': 79, 'tag': 'ResearchActivity'}, {'end': 95, 'start': 64, 'tag': 'Finding'}]"
783,"MethodsUsing generalized linear mixed effects (LME) models, we estimated the annual low- and high-dose treatment effects in clinical, cognitive, and biomarker outcomes.","[{'end': 83, 'start': 77, 'tag': 'TemporalConcept'}, {'end': 120, 'start': 103, 'tag': 'Finding'}, {'end': 158, 'start': 149, 'tag': 'ClinicalAttribute'}, {'end': 167, 'start': 159, 'tag': 'Finding'}, {'end': 58, 'start': 13, 'tag': 'ResearchActivity'}, {'end': 112, 'start': 103, 'tag': 'HealthCareActivity'}, {'end': 112, 'start': 103, 'tag': 'ResearchActivity'}]"
784,"ResultsBoth gantenerumab and solanezumab demonstrated dose-dependent treatment effects (significant for gantenerumab, non-significant for solanezumab) in their respective target amyloid biomarkers (Pittsburgh compound B positron emission tomography standardized uptake value ratio and cerebrospinal fluid amyloid beta 42), with gantenerumab demonstrating additional treatment effects in some downstream biomarkers.","[{'end': 24, 'start': 12, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 40, 'start': 29, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 116, 'start': 104, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 149, 'start': 138, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 340, 'start': 328, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 86, 'start': 54, 'tag': 'Finding'}, {'end': 383, 'start': 366, 'tag': 'Finding'}, {'end': 268, 'start': 262, 'tag': 'BiologicFunction'}, {'end': 268, 'start': 262, 'tag': 'CellFunction'}, {'end': 185, 'start': 178, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 320, 'start': 305, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 185, 'start': 178, 'tag': 'BiologicallyActiveSubstance'}, {'end': 320, 'start': 305, 'tag': 'BiologicallyActiveSubstance'}, {'end': 304, 'start': 285, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 248, 'start': 198, 'tag': 'HealthCareActivity'}, {'end': 248, 'start': 220, 'tag': 'ManufacturedObject'}, {'end': 196, 'start': 186, 'tag': 'ClinicalAttribute'}, {'end': 413, 'start': 403, 'tag': 'ClinicalAttribute'}, {'end': 78, 'start': 69, 'tag': 'HealthCareActivity'}, {'end': 375, 'start': 366, 'tag': 'HealthCareActivity'}, {'end': 78, 'start': 69, 'tag': 'ResearchActivity'}, {'end': 375, 'start': 366, 'tag': 'ResearchActivity'}, {'end': 24, 'start': 12, 'tag': 'PharmacologicSubstance'}, {'end': 24, 'start': 12, 'tag': 'BiologicallyActiveSubstance'}, {'end': 40, 'start': 29, 'tag': 'BiologicallyActiveSubstance'}, {'end': 40, 'start': 29, 'tag': 'PharmacologicSubstance'}, {'end': 116, 'start': 104, 'tag': 'PharmacologicSubstance'}, {'end': 116, 'start': 104, 'tag': 'BiologicallyActiveSubstance'}, {'end': 149, 'start': 138, 'tag': 'BiologicallyActiveSubstance'}, {'end': 149, 'start': 138, 'tag': 'PharmacologicSubstance'}, {'end': 340, 'start': 328, 'tag': 'BiologicallyActiveSubstance'}, {'end': 340, 'start': 328, 'tag': 'PharmacologicSubstance'}]"
785,No dose-dependent treatment effects were observed in clinical or cognitive outcomes.,"[{'end': 83, 'start': 53, 'tag': 'ClinicalAttribute'}, {'end': 27, 'start': 18, 'tag': 'HealthCareActivity'}, {'end': 27, 'start': 18, 'tag': 'ResearchActivity'}, {'end': 35, 'start': 3, 'tag': 'Finding'}]"
786,"ConclusionsMid-trial dose escalation can be implemented as a remedy for an insufficient initial dose and can be more cost effective and less burdensome to participants than starting a new trial with higher doses, especially in rare diseases.","[{'end': 240, 'start': 227, 'tag': 'DiseaseOrSyndrome'}, {'end': 231, 'start': 227, 'tag': 'TemporalConcept'}, {'end': 167, 'start': 155, 'tag': 'PopulationGroup'}, {'end': 20, 'start': 15, 'tag': 'ResearchActivity'}, {'end': 193, 'start': 188, 'tag': 'ResearchActivity'}, {'end': 95, 'start': 88, 'tag': 'TemporalConcept'}]"
787,"HighlightsWe evaluated the dose-dependent treatment effect of two different amyloid-specific immunotherapies.Dose-dependent treatment effects were observed in some biomarkers.No dose-dependent treatment effects were observed in clinical/cognitive outcomes, potentially due to the fact that the modified study may not have been powered to detect such treatment effects in symptomatic subjects at a mild stage of disease exposed to high (or maximal) doses of medication for prolonged durations.","[{'end': 434, 'start': 430, 'tag': 'Finding'}, {'end': 446, 'start': 439, 'tag': 'Finding'}, {'end': 467, 'start': 457, 'tag': 'PharmacologicSubstance'}, {'end': 467, 'start': 457, 'tag': 'HealthCareActivity'}, {'end': 481, 'start': 472, 'tag': 'TemporalConcept'}, {'end': 141, 'start': 124, 'tag': 'Finding'}, {'end': 210, 'start': 193, 'tag': 'Finding'}, {'end': 367, 'start': 350, 'tag': 'Finding'}, {'end': 491, 'start': 482, 'tag': 'TemporalConcept'}, {'end': 83, 'start': 76, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 83, 'start': 76, 'tag': 'BiologicallyActiveSubstance'}, {'end': 255, 'start': 228, 'tag': 'ClinicalAttribute'}, {'end': 174, 'start': 164, 'tag': 'ClinicalAttribute'}, {'end': 308, 'start': 303, 'tag': 'ResearchActivity'}, {'end': 391, 'start': 383, 'tag': 'PopulationGroup'}, {'end': 407, 'start': 402, 'tag': 'TemporalConcept'}, {'end': 407, 'start': 402, 'tag': 'ClinicalAttribute'}, {'end': 401, 'start': 397, 'tag': 'Finding'}, {'end': 382, 'start': 371, 'tag': 'SignOrSymptom'}, {'end': 51, 'start': 42, 'tag': 'HealthCareActivity'}, {'end': 133, 'start': 124, 'tag': 'HealthCareActivity'}, {'end': 202, 'start': 193, 'tag': 'HealthCareActivity'}, {'end': 359, 'start': 350, 'tag': 'HealthCareActivity'}, {'end': 51, 'start': 42, 'tag': 'ResearchActivity'}, {'end': 133, 'start': 124, 'tag': 'ResearchActivity'}, {'end': 202, 'start': 193, 'tag': 'ResearchActivity'}, {'end': 359, 'start': 350, 'tag': 'ResearchActivity'}, {'end': 58, 'start': 27, 'tag': 'Finding'}, {'end': 210, 'start': 178, 'tag': 'Finding'}, {'end': 108, 'start': 93, 'tag': 'HealthCareActivity'}, {'end': 141, 'start': 109, 'tag': 'AminoAcidPeptideOrProtein'}]"
788,Accurate diagnosis of the initial phase of Alzheimer's disease (AD) is essential and crucial.,"[{'end': 33, 'start': 26, 'tag': 'TemporalConcept'}, {'end': 62, 'start': 43, 'tag': 'DiseaseOrSyndrome'}, {'end': 39, 'start': 34, 'tag': 'TemporalConcept'}, {'end': 66, 'start': 64, 'tag': 'DiseaseOrSyndrome'}, {'end': 18, 'start': 9, 'tag': 'HealthCareActivity'}]"
789,The objective of this research was to employ efficient biomarkers for the diagnostic analysis and classification of AD based on combining structural MRI (sMRI) and resting-state functional MRI (rs-fMRI).,"[{'end': 65, 'start': 55, 'tag': 'ClinicalAttribute'}, {'end': 30, 'start': 22, 'tag': 'ResearchActivity'}, {'end': 118, 'start': 116, 'tag': 'DiseaseOrSyndrome'}, {'end': 152, 'start': 138, 'tag': 'HealthCareActivity'}, {'end': 192, 'start': 164, 'tag': 'HealthCareActivity'}, {'end': 84, 'start': 74, 'tag': 'HealthCareActivity'}, {'end': 93, 'start': 85, 'tag': 'ResearchActivity'}, {'end': 158, 'start': 154, 'tag': 'HealthCareActivity'}, {'end': 201, 'start': 194, 'tag': 'HealthCareActivity'}]"
790,"So far, several anatomical MRI imaging markers for AD diagnosis have been identified.","[{'end': 53, 'start': 51, 'tag': 'DiseaseOrSyndrome'}, {'end': 38, 'start': 27, 'tag': 'HealthCareActivity'}, {'end': 63, 'start': 54, 'tag': 'HealthCareActivity'}, {'end': 46, 'start': 16, 'tag': 'ClinicalAttribute'}]"
791,"The use of cortical and subcortical volumes, the hippocampus, and amygdala volume, as well as genetic patterns, has proven to be beneficial in distinguishing patients with AD from the healthy population.","[{'end': 110, 'start': 102, 'tag': 'ResearchActivity'}, {'end': 166, 'start': 158, 'tag': 'PatientOrDisabledGroup'}, {'end': 174, 'start': 172, 'tag': 'DiseaseOrSyndrome'}, {'end': 202, 'start': 192, 'tag': 'PopulationGroup'}, {'end': 74, 'start': 66, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 60, 'start': 49, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 81, 'start': 66, 'tag': 'ClinicalAttribute'}, {'end': 35, 'start': 24, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 19, 'start': 11, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 191, 'start': 184, 'tag': 'OrganismAttribute'}, {'end': 43, 'start': 24, 'tag': 'ClinicalAttribute'}, {'end': 43, 'start': 36, 'tag': 'ClinicalAttribute'}, {'end': 19, 'start': 11, 'tag': 'ClinicalAttribute'}]"
792,The fMRI time series data have the potential for specific numerical information as well as dynamic temporal information.,"[{'end': 8, 'start': 4, 'tag': 'HealthCareActivity'}, {'end': 25, 'start': 9, 'tag': 'ResearchActivity'}, {'end': 13, 'start': 9, 'tag': 'TemporalConcept'}]"
793,"Voxel and graphical analyses have gained popularity for analyzing neurodegenerative diseases, such as Alzheimer's and its prodromal phase, mild cognitive impairment (MCI).","[{'end': 137, 'start': 122, 'tag': 'TemporalConcept'}, {'end': 92, 'start': 66, 'tag': 'DiseaseOrSyndrome'}, {'end': 113, 'start': 102, 'tag': 'DiseaseOrSyndrome'}, {'end': 169, 'start': 166, 'tag': 'DiseaseOrSyndrome'}, {'end': 164, 'start': 139, 'tag': 'DiseaseOrSyndrome'}, {'end': 28, 'start': 0, 'tag': 'ResearchActivity'}]"
794,"So far, these approaches have been utilized separately for the diagnosis of AD.","[{'end': 78, 'start': 76, 'tag': 'DiseaseOrSyndrome'}, {'end': 72, 'start': 63, 'tag': 'HealthCareActivity'}]"
795,"In recent studies, the classification of cases of MCI into those that are not converted for a certain period as stable MCI (MCIs) and those that converted to AD as MCIc has been less commonly reported with inconsistent results.","[{'end': 9, 'start': 3, 'tag': 'TemporalConcept'}, {'end': 17, 'start': 10, 'tag': 'ResearchActivity'}, {'end': 160, 'start': 158, 'tag': 'DiseaseOrSyndrome'}, {'end': 108, 'start': 102, 'tag': 'TemporalConcept'}, {'end': 53, 'start': 50, 'tag': 'DiseaseOrSyndrome'}, {'end': 122, 'start': 119, 'tag': 'DiseaseOrSyndrome'}, {'end': 46, 'start': 23, 'tag': 'ResearchActivity'}]"
796,"In this study, we verified and validated the potency of a proposed diagnostic framework to identify AD and differentiate MCIs from MCIc by utilizing the efficient biomarkers obtained from sMRI, along with functional brain networks of the frequency range .01-.027 at the resting state and the voxel-based features.","[{'end': 283, 'start': 270, 'tag': 'Finding'}, {'end': 173, 'start': 163, 'tag': 'ClinicalAttribute'}, {'end': 102, 'start': 100, 'tag': 'DiseaseOrSyndrome'}, {'end': 13, 'start': 8, 'tag': 'ResearchActivity'}, {'end': 221, 'start': 216, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 87, 'start': 58, 'tag': 'HealthCareActivity'}, {'end': 247, 'start': 238, 'tag': 'TemporalConcept'}, {'end': 192, 'start': 188, 'tag': 'HealthCareActivity'}]"
797,"The latter mainly included default mode networks (amplitude of low-frequency fluctuation [ALFF], fractional ALFF [ALFF], and regional homogeneity [ReHo]), degree centrality (DC), and salience networks (SN).","[{'end': 66, 'start': 63, 'tag': 'Finding'}, {'end': 76, 'start': 67, 'tag': 'TemporalConcept'}, {'end': 88, 'start': 50, 'tag': 'ResearchActivity'}, {'end': 145, 'start': 125, 'tag': 'ResearchActivity'}, {'end': 172, 'start': 155, 'tag': 'ResearchActivity'}, {'end': 200, 'start': 183, 'tag': 'ResearchActivity'}, {'end': 112, 'start': 97, 'tag': 'ResearchActivity'}]"
798,Pearson's correlation coefficient for measuring fMRI functional networks has proven to be an efficient means for disease diagnosis.,"[{'end': 52, 'start': 48, 'tag': 'HealthCareActivity'}, {'end': 130, 'start': 113, 'tag': 'HealthCareActivity'}, {'end': 33, 'start': 0, 'tag': 'ResearchActivity'}]"
799,"We applied the graph theory to calculate nodal features (nodal degree [ND], nodal path length [NL], and between centrality [BC]) as a graphical feature and analyzed the connectivity link between different brain regions.","[{'end': 93, 'start': 76, 'tag': 'ResearchActivity'}, {'end': 218, 'start': 205, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 27, 'start': 15, 'tag': 'ResearchActivity'}, {'end': 69, 'start': 57, 'tag': 'ResearchActivity'}, {'end': 122, 'start': 112, 'tag': 'ResearchActivity'}]"
800,We extracted three-dimensional (3D) patterns to calculate regional coherence and then implement a univariate statistical t-test to access a 3D mask that preserves voxels showing significant changes.,"[{'end': 44, 'start': 13, 'tag': 'ResearchActivity'}, {'end': 127, 'start': 98, 'tag': 'ResearchActivity'}, {'end': 147, 'start': 140, 'tag': 'ResearchActivity'}]"
801,"Similarly, from sMRI, we calculated the hippocampal subfield and amygdala nuclei volume using Freesurfer (version 6).","[{'end': 80, 'start': 65, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 60, 'start': 40, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 20, 'start': 16, 'tag': 'HealthCareActivity'}, {'end': 87, 'start': 65, 'tag': 'ClinicalAttribute'}, {'end': 104, 'start': 94, 'tag': 'ResearchActivity'}]"
802,"Finally, we implemented and compared the different feature selection algorithms to integrate the structural features, brain networks, and voxel features to optimize the diagnostic identifications of AD using support vector machine (SVM) classifiers.","[{'end': 201, 'start': 199, 'tag': 'DiseaseOrSyndrome'}, {'end': 132, 'start': 118, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 230, 'start': 208, 'tag': 'MachineActivity'}, {'end': 235, 'start': 232, 'tag': 'MachineActivity'}, {'end': 194, 'start': 169, 'tag': 'HealthCareActivity'}, {'end': 79, 'start': 51, 'tag': 'MachineActivity'}]"
803,We also compared the performance of SVM with Random Forest (RF) classifiers.,"[{'end': 32, 'start': 21, 'tag': 'Finding'}, {'end': 39, 'start': 36, 'tag': 'MachineActivity'}, {'end': 58, 'start': 45, 'tag': 'MachineActivity'}, {'end': 62, 'start': 60, 'tag': 'MachineActivity'}]"
804,"The obtained results demonstrated the potency of our framework, wherein a combination of the hippocampal subfield, the amygdala volume, and brain networks with multiple measures of rs-fMRI could significantly enhance the accuracy of other approaches in diagnosing AD.","[{'end': 263, 'start': 253, 'tag': 'HealthCareActivity'}, {'end': 266, 'start': 264, 'tag': 'DiseaseOrSyndrome'}, {'end': 154, 'start': 140, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 229, 'start': 221, 'tag': 'Finding'}, {'end': 127, 'start': 119, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 134, 'start': 119, 'tag': 'ClinicalAttribute'}, {'end': 113, 'start': 93, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 188, 'start': 181, 'tag': 'HealthCareActivity'}]"
805,The accuracy obtained by the proposed method was reported for binary classification.,"[{'end': 44, 'start': 38, 'tag': 'ResearchActivity'}, {'end': 44, 'start': 38, 'tag': 'HealthCareActivity'}, {'end': 12, 'start': 4, 'tag': 'Finding'}, {'end': 83, 'start': 62, 'tag': 'ResearchActivity'}]"
806,"More importantly, the classification results of the less commonly reported MCIs vs.","[{'end': 44, 'start': 22, 'tag': 'ResearchActivity'}]"
807,MCIc improved significantly.,[]
808,"However, this research involved only the AD Neuroimaging Initiative (ADNI) cohort to focus on the diagnosis of AD advancement by integrating sMRI and fMRI.","[{'end': 154, 'start': 150, 'tag': 'HealthCareActivity'}, {'end': 81, 'start': 75, 'tag': 'PopulationGroup'}, {'end': 22, 'start': 14, 'tag': 'ResearchActivity'}, {'end': 113, 'start': 111, 'tag': 'DiseaseOrSyndrome'}, {'end': 107, 'start': 98, 'tag': 'HealthCareActivity'}, {'end': 67, 'start': 41, 'tag': 'ResearchActivity'}, {'end': 73, 'start': 69, 'tag': 'ResearchActivity'}, {'end': 145, 'start': 141, 'tag': 'HealthCareActivity'}]"
809,"Hence, the study's primary disadvantage is its small sample size.","[{'end': 64, 'start': 60, 'tag': 'OrganismAttribute'}, {'end': 16, 'start': 11, 'tag': 'ResearchActivity'}]"
810,"In this case, the dataset we utilized did not fully reflect the whole population.","[{'end': 12, 'start': 8, 'tag': 'ManufacturedObject'}, {'end': 80, 'start': 70, 'tag': 'PopulationGroup'}]"
811,"As a result, we cannot guarantee that our findings will be applicable to other populations.","[{'end': 90, 'start': 79, 'tag': 'PopulationGroup'}, {'end': 11, 'start': 5, 'tag': 'Finding'}]"
812,Adeno-associated viruses (AAV): AAVs are non-pathogenic viruses that can efficiently infect both dividing and non-dividing cells.,"[{'end': 128, 'start': 110, 'tag': 'Cell'}, {'end': 55, 'start': 45, 'tag': 'PathologicFunction'}, {'end': 24, 'start': 17, 'tag': 'Virus'}, {'end': 63, 'start': 56, 'tag': 'Virus'}, {'end': 29, 'start': 26, 'tag': 'Virus'}, {'end': 36, 'start': 32, 'tag': 'Virus'}, {'end': 24, 'start': 0, 'tag': 'Virus'}, {'end': 91, 'start': 85, 'tag': 'PathologicFunction'}, {'end': 105, 'start': 97, 'tag': 'Cell'}, {'end': 128, 'start': 123, 'tag': 'Cell'}]"
813,,[]
814,AAVs are particularly useful for delivering therapeutic genes or small interfering RNAs (siRNAs) to targeted brain regions.,"[{'end': 87, 'start': 65, 'tag': 'NucleicAcidNucleosideOrNucleotide'}, {'end': 122, 'start': 109, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 61, 'start': 56, 'tag': 'GeneOrGenome'}, {'end': 4, 'start': 0, 'tag': 'Virus'}, {'end': 87, 'start': 65, 'tag': 'BiologicallyActiveSubstance'}, {'end': 95, 'start': 89, 'tag': 'BiologicallyActiveSubstance'}, {'end': 95, 'start': 89, 'tag': 'NucleicAcidNucleosideOrNucleotide'}]"
815,The potential impacts of SARS-CoV-2 on neurodegenerative diseases have also been considered.,"[{'end': 65, 'start': 39, 'tag': 'DiseaseOrSyndrome'}, {'end': 35, 'start': 25, 'tag': 'Virus'}]"
816,,[]
817,SARS-CoV-2 infectivity is predicated upon the virus exploiting angiotensin-converting enzyme 2 (ACE2) to gain entry into host cells.,"[{'end': 131, 'start': 126, 'tag': 'Cell'}, {'end': 125, 'start': 121, 'tag': 'Organism'}, {'end': 10, 'start': 0, 'tag': 'Virus'}, {'end': 94, 'start': 63, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 94, 'start': 63, 'tag': 'BiologicallyActiveSubstance'}, {'end': 100, 'start': 96, 'tag': 'BiologicallyActiveSubstance'}, {'end': 100, 'start': 96, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 22, 'start': 11, 'tag': 'Finding'}, {'end': 51, 'start': 46, 'tag': 'Virus'}]"
818,Other factors beyond the RAS also likely contribute to effects of SARS-CoV-2 on the CNS and AD risk.,"[{'end': 87, 'start': 84, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 94, 'start': 92, 'tag': 'DiseaseOrSyndrome'}, {'end': 99, 'start': 95, 'tag': 'Finding'}, {'end': 76, 'start': 66, 'tag': 'Virus'}]"
819,,[]
820,"Lastly, it is possible that amyloid fibrils might, as is the case with other viruses, entrap SARS-CoV-2 particles and thereby lead to polarization of microglia toward a pro-inflammatory phenotype","[{'end': 159, 'start': 150, 'tag': 'Cell'}, {'end': 185, 'start': 169, 'tag': 'PathologicFunction'}, {'end': 43, 'start': 28, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 43, 'start': 28, 'tag': 'BiologicallyActiveSubstance'}, {'end': 65, 'start': 61, 'tag': 'ManufacturedObject'}, {'end': 195, 'start': 186, 'tag': 'OrganismAttribute'}, {'end': 6, 'start': 0, 'tag': 'TemporalConcept'}, {'end': 103, 'start': 93, 'tag': 'Virus'}, {'end': 84, 'start': 77, 'tag': 'Virus'}, {'end': 159, 'start': 134, 'tag': 'CellFunction'}, {'end': 113, 'start': 93, 'tag': 'CellComponent'}]"
821,"We tested the hypothesis that MS is caused by Epstein-Barr virus (EBV) in a cohort comprising more than 10 million young adults on active duty in the US military, 955 of whom were diagnosed with MS during their period of service.","[{'end': 32, 'start': 30, 'tag': 'DiseaseOrSyndrome'}, {'end': 197, 'start': 195, 'tag': 'DiseaseOrSyndrome'}, {'end': 82, 'start': 76, 'tag': 'PopulationGroup'}, {'end': 120, 'start': 115, 'tag': 'TemporalConcept'}, {'end': 217, 'start': 211, 'tag': 'TemporalConcept'}, {'end': 127, 'start': 121, 'tag': 'PopulationGroup'}, {'end': 64, 'start': 46, 'tag': 'Virus'}, {'end': 69, 'start': 66, 'tag': 'Virus'}]"
822,,[]
823,"Serum levels of neurofilament light chain, a biomarker of neuroaxonal degeneration, increased only after EBV seroconversion.","[{'end': 54, 'start': 45, 'tag': 'ClinicalAttribute'}, {'end': 5, 'start': 0, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 41, 'start': 16, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 41, 'start': 16, 'tag': 'BiologicallyActiveSubstance'}, {'end': 108, 'start': 105, 'tag': 'Virus'}, {'end': 82, 'start': 58, 'tag': 'CellOrMolecularDysfunction'}, {'end': 41, 'start': 0, 'tag': 'ClinicalAttribute'}, {'end': 123, 'start': 109, 'tag': 'Finding'}]"
824,Epstein-Barr virus (EBV) is a common herpesvirus that has been implicated in the development of multiple sclerosis (MS).,"[{'end': 118, 'start': 116, 'tag': 'DiseaseOrSyndrome'}, {'end': 114, 'start': 96, 'tag': 'DiseaseOrSyndrome'}, {'end': 18, 'start': 0, 'tag': 'Virus'}, {'end': 23, 'start': 20, 'tag': 'Virus'}, {'end': 48, 'start': 37, 'tag': 'Virus'}, {'end': 92, 'start': 81, 'tag': 'CellFunction'}, {'end': 92, 'start': 81, 'tag': 'BiologicFunction'}]"
825,"Many individuals with MS have been found to have evidence of previous EBV infection, suggesting a potential association between the two.","[{'end': 57, 'start': 49, 'tag': 'Finding'}, {'end': 24, 'start': 22, 'tag': 'DiseaseOrSyndrome'}, {'end': 83, 'start': 74, 'tag': 'PathologicFunction'}, {'end': 16, 'start': 5, 'tag': 'PopulationGroup'}, {'end': 73, 'start': 70, 'tag': 'Virus'}]"
826,"While the exact role of EBV in MS remains unclear, research suggests that the virus may trigger an abnormal immune response in genetically susceptible individuals, leading to the autoimmune attack on the central nervous system seen in MS.","[{'end': 226, 'start': 204, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 33, 'start': 31, 'tag': 'DiseaseOrSyndrome'}, {'end': 237, 'start': 235, 'tag': 'DiseaseOrSyndrome'}, {'end': 59, 'start': 51, 'tag': 'ResearchActivity'}, {'end': 123, 'start': 108, 'tag': 'BiologicFunction'}, {'end': 162, 'start': 151, 'tag': 'PopulationGroup'}, {'end': 107, 'start': 99, 'tag': 'Finding'}, {'end': 27, 'start': 24, 'tag': 'Virus'}, {'end': 83, 'start': 78, 'tag': 'Virus'}, {'end': 196, 'start': 179, 'tag': 'PathologicFunction'}]"
827,"Studies have shown that individuals who were infected with EBV at a young age may have a higher risk of developing MS later in life, indicating a potential link between early viral exposure and disease susceptibility.","[{'end': 117, 'start': 115, 'tag': 'DiseaseOrSyndrome'}, {'end': 100, 'start': 96, 'tag': 'Finding'}, {'end': 123, 'start': 118, 'tag': 'TemporalConcept'}, {'end': 131, 'start': 127, 'tag': 'TemporalConcept'}, {'end': 35, 'start': 24, 'tag': 'PopulationGroup'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 174, 'start': 169, 'tag': 'TemporalConcept'}, {'end': 62, 'start': 59, 'tag': 'Virus'}, {'end': 77, 'start': 68, 'tag': 'OrganismAttribute'}, {'end': 189, 'start': 175, 'tag': 'Finding'}, {'end': 216, 'start': 194, 'tag': 'ClinicalAttribute'}]"
828,"EBV has been found to activate certain immune cells called B cells, which can then cross the blood-brain barrier and contribute to the inflammation and demyelination observed in MS.","[{'end': 180, 'start': 178, 'tag': 'DiseaseOrSyndrome'}, {'end': 147, 'start': 135, 'tag': 'PathologicFunction'}, {'end': 112, 'start': 93, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 165, 'start': 152, 'tag': 'PathologicFunction'}, {'end': 3, 'start': 0, 'tag': 'Virus'}, {'end': 51, 'start': 39, 'tag': 'Cell'}, {'end': 66, 'start': 59, 'tag': 'Cell'}]"
829,"Lentiviruses: Lentiviruses, such as the human immunodeficiency virus (HIV), have been modified to remove their ability to cause disease and are used as gene delivery vehicles in research.","[{'end': 174, 'start': 152, 'tag': 'ResearchActivity'}, {'end': 186, 'start': 178, 'tag': 'ResearchActivity'}, {'end': 118, 'start': 111, 'tag': 'OrganismAttribute'}, {'end': 73, 'start': 70, 'tag': 'Virus'}, {'end': 12, 'start': 0, 'tag': 'Virus'}, {'end': 26, 'start': 14, 'tag': 'Virus'}, {'end': 68, 'start': 40, 'tag': 'Virus'}]"
830,,[]
831,Ongoing research is focused on understanding the specific mechanisms by which EBV may contribute to MS development and exploring potential therapeutic strategies that target the virus to manage or prevent the progression of the disease.,"[{'end': 44, 'start': 31, 'tag': 'BiologicFunction'}, {'end': 102, 'start': 100, 'tag': 'DiseaseOrSyndrome'}, {'end': 16, 'start': 8, 'tag': 'ResearchActivity'}, {'end': 161, 'start': 129, 'tag': 'HealthCareActivity'}, {'end': 235, 'start': 209, 'tag': 'PathologicFunction'}, {'end': 7, 'start': 0, 'tag': 'TemporalConcept'}, {'end': 81, 'start': 78, 'tag': 'Virus'}, {'end': 114, 'start': 103, 'tag': 'BiologicFunction'}, {'end': 114, 'start': 103, 'tag': 'CellFunction'}, {'end': 183, 'start': 178, 'tag': 'Virus'}]"
832,"Porphyromonas gingivalis, the keystone pathogen in chronic periodontitis, was identified in the brain of Alzheimer's disease patients.","[{'end': 101, 'start': 96, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 124, 'start': 105, 'tag': 'DiseaseOrSyndrome'}, {'end': 133, 'start': 125, 'tag': 'PatientOrDisabledGroup'}, {'end': 58, 'start': 51, 'tag': 'TemporalConcept'}, {'end': 47, 'start': 39, 'tag': 'Organism'}, {'end': 24, 'start': 0, 'tag': 'Bacterium'}, {'end': 72, 'start': 59, 'tag': 'DiseaseOrSyndrome'}]"
833,Oral P.,"[{'end': 4, 'start': 0, 'tag': 'BodyPartOrganOrOrganComponent'}]"
834,"gingivalis infection in mice resulted in brain colonization and increased production of A1-42, a component of amyloid plaques.","[{'end': 46, 'start': 41, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 28, 'start': 24, 'tag': 'Eukaryote'}, {'end': 126, 'start': 111, 'tag': 'AnatomicalAbnormality'}, {'end': 20, 'start': 11, 'tag': 'PathologicFunction'}, {'end': 59, 'start': 47, 'tag': 'Finding'}, {'end': 94, 'start': 88, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 94, 'start': 88, 'tag': 'BiologicallyActiveSubstance'}]"
835,These data suggest that gingipain inhibitors could be valuable for treating P.,"[{'end': 10, 'start': 6, 'tag': 'ResearchActivity'}, {'end': 33, 'start': 24, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 33, 'start': 24, 'tag': 'BiologicallyActiveSubstance'}, {'end': 44, 'start': 34, 'tag': 'BiologicallyActiveSubstance'}]"
836,gingivalis brain colonization and neurodegeneration in Alzheimer's disease.,"[{'end': 16, 'start': 11, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 51, 'start': 34, 'tag': 'CellOrMolecularDysfunction'}, {'end': 74, 'start': 55, 'tag': 'DiseaseOrSyndrome'}, {'end': 29, 'start': 17, 'tag': 'Finding'}]"
837,Chlamydia pneumoniae is a Gram-negative intracellular pathogen antibodies against which are detectable in as many as 80% of individuals between 60 to 70 years of age,"[{'end': 165, 'start': 162, 'tag': 'OrganismAttribute'}, {'end': 158, 'start': 153, 'tag': 'TemporalConcept'}, {'end': 73, 'start': 63, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 73, 'start': 63, 'tag': 'BiologicallyActiveSubstance'}, {'end': 62, 'start': 54, 'tag': 'Bacterium'}, {'end': 39, 'start': 26, 'tag': 'Bacterium'}, {'end': 53, 'start': 40, 'tag': 'CellComponent'}, {'end': 135, 'start': 124, 'tag': 'PopulationGroup'}, {'end': 102, 'start': 92, 'tag': 'ClinicalAttribute'}, {'end': 20, 'start': 0, 'tag': 'Bacterium'}]"
838,The presence of C.,"[{'end': 12, 'start': 4, 'tag': 'Finding'}]"
839,pneumonia in the CSF and brain of AD patients has been highlighted by many authors,"[{'end': 30, 'start': 25, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 36, 'start': 34, 'tag': 'DiseaseOrSyndrome'}, {'end': 45, 'start': 37, 'tag': 'PatientOrDisabledGroup'}, {'end': 20, 'start': 17, 'tag': 'BodyPartOrganOrOrganComponent'}]"
840,Balin et al.,[]
841,[168] identified C.,[]
842,pneumonia in 17 of 19 post-mortem frozen brain fragments from AD patients,"[{'end': 56, 'start': 34, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 64, 'start': 62, 'tag': 'DiseaseOrSyndrome'}, {'end': 73, 'start': 65, 'tag': 'PatientOrDisabledGroup'}, {'end': 33, 'start': 22, 'tag': 'TemporalConcept'}]"
843,"Helicobacter pylori is a curved, Gram-negative bacterium that may lead to stomach ulcers and gastric cancers and is estimated to be present in more than 50% of the population worldwide.","[{'end': 174, 'start': 164, 'tag': 'PopulationGroup'}, {'end': 19, 'start': 0, 'tag': 'Bacterium'}, {'end': 100, 'start': 93, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 56, 'start': 33, 'tag': 'Bacterium'}, {'end': 81, 'start': 74, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 88, 'start': 74, 'tag': 'DiseaseOrSyndrome'}, {'end': 108, 'start': 93, 'tag': 'DiseaseOrSyndrome'}]"
844,Kontouras et al.,[]
845,"[188] showed that among 27 AD patients, 100% presented with high levels of anti H.","[{'end': 29, 'start': 27, 'tag': 'DiseaseOrSyndrome'}, {'end': 38, 'start': 30, 'tag': 'PatientOrDisabledGroup'}, {'end': 71, 'start': 60, 'tag': 'Finding'}]"
846,pylori IgG antibodies in the serum and CSF,"[{'end': 42, 'start': 39, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 21, 'start': 11, 'tag': 'BiologicallyActiveSubstance'}, {'end': 34, 'start': 29, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 10, 'start': 7, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 10, 'start': 7, 'tag': 'BiologicallyActiveSubstance'}]"
847,"Spirochetes are gram-negative, helical bacteria, with neurotropism for the trigeminal ganglion and nerve","[{'end': 47, 'start': 39, 'tag': 'Bacterium'}, {'end': 47, 'start': 39, 'tag': 'Bacterium'}, {'end': 11, 'start': 0, 'tag': 'Bacterium'}, {'end': 11, 'start': 0, 'tag': 'Bacterium'}, {'end': 47, 'start': 39, 'tag': 'Bacterium'}, {'end': 29, 'start': 16, 'tag': 'Bacterium'}, {'end': 29, 'start': 16, 'tag': 'Bacterium'}, {'end': 47, 'start': 31, 'tag': 'Bacterium'}, {'end': 66, 'start': 54, 'tag': 'PathologicFunction'}, {'end': 104, 'start': 99, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 85, 'start': 75, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 94, 'start': 75, 'tag': 'BodyPartOrganOrOrganComponent'}]"
848,"Lentiviral vectors can carry larger genetic payloads compared to AAVs, making them suitable for delivering bigger genes or multiple genes simultaneously.","[{'end': 152, 'start': 138, 'tag': 'TemporalConcept'}, {'end': 119, 'start': 114, 'tag': 'GeneOrGenome'}, {'end': 137, 'start': 132, 'tag': 'GeneOrGenome'}, {'end': 69, 'start': 65, 'tag': 'Virus'}, {'end': 10, 'start': 0, 'tag': 'Virus'}, {'end': 52, 'start': 36, 'tag': 'GeneOrGenome'}, {'end': 18, 'start': 11, 'tag': 'NucleicAcidNucleosideOrNucleotide'}]"
849,"Recently, spirochetal invasion of the olfactory tracts and bulbs of patients with early evidence of AD neurodegeneration was demonstrated ","[{'end': 96, 'start': 88, 'tag': 'Finding'}, {'end': 8, 'start': 0, 'tag': 'TemporalConcept'}, {'end': 76, 'start': 68, 'tag': 'PatientOrDisabledGroup'}, {'end': 87, 'start': 82, 'tag': 'TemporalConcept'}, {'end': 102, 'start': 100, 'tag': 'DiseaseOrSyndrome'}, {'end': 21, 'start': 10, 'tag': 'Bacterium'}, {'end': 54, 'start': 38, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 64, 'start': 59, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 47, 'start': 38, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 120, 'start': 103, 'tag': 'CellOrMolecularDysfunction'}, {'end': 30, 'start': 22, 'tag': 'Finding'}]"
850,"The presence of spirochetes has been reported in the CSF, blood, and brain of AD patients, with neural invasion being 8-fold more frequent among those with AD as compared to controls","[{'end': 74, 'start': 69, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 80, 'start': 78, 'tag': 'DiseaseOrSyndrome'}, {'end': 158, 'start': 156, 'tag': 'DiseaseOrSyndrome'}, {'end': 63, 'start': 58, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 89, 'start': 81, 'tag': 'PatientOrDisabledGroup'}, {'end': 182, 'start': 174, 'tag': 'PopulationGroup'}, {'end': 56, 'start': 53, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 12, 'start': 4, 'tag': 'Finding'}, {'end': 138, 'start': 130, 'tag': 'TemporalConcept'}, {'end': 27, 'start': 16, 'tag': 'Bacterium'}, {'end': 111, 'start': 96, 'tag': 'PathologicFunction'}]"
851,Air Pollution: Several studies have found a correlation between long-term exposure to air pollution and an elevated risk of neurodegenerative diseases.,"[{'end': 150, 'start': 124, 'tag': 'DiseaseOrSyndrome'}, {'end': 30, 'start': 23, 'tag': 'ResearchActivity'}, {'end': 120, 'start': 107, 'tag': 'Finding'}, {'end': 99, 'start': 86, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 73, 'start': 64, 'tag': 'TemporalConcept'}, {'end': 99, 'start': 74, 'tag': 'Finding'}, {'end': 30, 'start': 23, 'tag': 'HealthCareActivity'}, {'end': 55, 'start': 44, 'tag': 'ResearchActivity'}, {'end': 13, 'start': 0, 'tag': 'EnvironmentalEffectOfHumans'}]"
852, ,[]
853,Both air pollution and dementia are current and growing global issues.,"[{'end': 31, 'start': 23, 'tag': 'DiseaseOrSyndrome'}, {'end': 43, 'start': 36, 'tag': 'TemporalConcept'}, {'end': 18, 'start': 5, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 69, 'start': 56, 'tag': 'Finding'}]"
854,,[]
855,"Air pollution components, such as particulate matter (PM), nitrogen dioxide (NO2), ozone (O3), and volatile organic compounds (VOCs), can enter the bloodstream and travel to the brain.","[{'end': 183, 'start': 178, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 159, 'start': 148, 'tag': 'BiologicFunction'}, {'end': 125, 'start': 99, 'tag': 'Chemical'}, {'end': 13, 'start': 0, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 52, 'start': 34, 'tag': 'Substance'}, {'end': 56, 'start': 54, 'tag': 'Substance'}, {'end': 75, 'start': 59, 'tag': 'InjuryOrPoisoning'}, {'end': 80, 'start': 77, 'tag': 'InjuryOrPoisoning'}, {'end': 88, 'start': 83, 'tag': 'Chemical'}, {'end': 92, 'start': 90, 'tag': 'Chemical'}, {'end': 131, 'start': 127, 'tag': 'Chemical'}, {'end': 75, 'start': 59, 'tag': 'Chemical'}, {'end': 80, 'start': 77, 'tag': 'Chemical'}]"
856,"The highest deaths were attributed to smoking globally, followed by air pollution and occupational risks.","[{'end': 81, 'start': 68, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 18, 'start': 12, 'tag': 'BiologicFunction'}, {'end': 18, 'start': 12, 'tag': 'Finding'}, {'end': 104, 'start': 86, 'tag': 'Finding'}, {'end': 45, 'start': 38, 'tag': 'IndividualBehavior'}]"
857,"Alzheimer's Disease: Several studies have shown that exposure to tobacco smoke, either directly through smoking or indirectly through secondhand smoke, is associated with an increased risk of Alzheimer's disease.","[{'end': 36, 'start': 29, 'tag': 'ResearchActivity'}, {'end': 211, 'start': 192, 'tag': 'DiseaseOrSyndrome'}, {'end': 19, 'start': 0, 'tag': 'DiseaseOrSyndrome'}, {'end': 188, 'start': 174, 'tag': 'Finding'}, {'end': 61, 'start': 53, 'tag': 'Finding'}, {'end': 36, 'start': 29, 'tag': 'HealthCareActivity'}, {'end': 78, 'start': 65, 'tag': 'Substance'}, {'end': 150, 'start': 134, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 111, 'start': 104, 'tag': 'IndividualBehavior'}]"
858,,[]
859,There is evidence to suggest that tobacco smoke exposure may also be a risk factor for Parkinson's disease.,"[{'end': 106, 'start': 87, 'tag': 'DiseaseOrSyndrome'}, {'end': 17, 'start': 9, 'tag': 'Finding'}, {'end': 82, 'start': 71, 'tag': 'Finding'}, {'end': 47, 'start': 34, 'tag': 'Substance'}, {'end': 56, 'start': 34, 'tag': 'Finding'}]"
860,tobacco smoke exposure and neurodegenerative diseases is likely influenced by genetic factors and other lifestyle choices.,"[{'end': 53, 'start': 27, 'tag': 'DiseaseOrSyndrome'}, {'end': 121, 'start': 104, 'tag': 'Finding'}, {'end': 13, 'start': 0, 'tag': 'Substance'}, {'end': 22, 'start': 0, 'tag': 'Finding'}, {'end': 93, 'start': 78, 'tag': 'Finding'}]"
861,Exposure to tobacco smoke pollution has been linked to an increased risk of neurodegenerative diseases.,"[{'end': 102, 'start': 76, 'tag': 'DiseaseOrSyndrome'}, {'end': 72, 'start': 58, 'tag': 'Finding'}, {'end': 35, 'start': 12, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 25, 'start': 0, 'tag': 'Finding'}]"
862,Herpes simplex viruses (HSV): HSVs are neurotropic viruses that have been engineered for use in research.,"[{'end': 104, 'start': 96, 'tag': 'ResearchActivity'}, {'end': 22, 'start': 15, 'tag': 'Virus'}, {'end': 58, 'start': 51, 'tag': 'Virus'}, {'end': 22, 'start': 0, 'tag': 'Virus'}, {'end': 6, 'start': 0, 'tag': 'Virus'}, {'end': 27, 'start': 24, 'tag': 'Virus'}, {'end': 34, 'start': 30, 'tag': 'Virus'}, {'end': 58, 'start': 39, 'tag': 'Virus'}]"
863,They are particularly useful for tracing neural circuits and understanding connectivity in the brain.,"[{'end': 100, 'start': 95, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 74, 'start': 61, 'tag': 'BiologicFunction'}, {'end': 56, 'start': 41, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 87, 'start': 75, 'tag': 'BiologicFunction'}]"
864,,[]
865,Water pollution has also been associated with an increased risk of neurodegenerative diseases.,"[{'end': 93, 'start': 67, 'tag': 'DiseaseOrSyndrome'}, {'end': 63, 'start': 49, 'tag': 'Finding'}, {'end': 15, 'start': 0, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 15, 'start': 6, 'tag': 'EnvironmentalEffectOfHumans'}]"
866,"Contamination of water sources with various pollutants can have harmful effects on human health, including potential impacts on the brain and nervous system.","[{'end': 137, 'start': 132, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 88, 'start': 83, 'tag': 'Eukaryote'}, {'end': 95, 'start': 89, 'tag': 'HealthCareActivity'}, {'end': 156, 'start': 142, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 79, 'start': 64, 'tag': 'Finding'}, {'end': 22, 'start': 17, 'tag': 'Chemical'}, {'end': 22, 'start': 0, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 13, 'start': 0, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 54, 'start': 44, 'tag': 'InjuryOrPoisoning'}, {'end': 30, 'start': 0, 'tag': 'EnvironmentalEffectOfHumans'}]"
867,,[]
868,Here are some key points about the relationship between water pollution and neurodegenerative diseases:,"[{'end': 102, 'start': 76, 'tag': 'DiseaseOrSyndrome'}, {'end': 47, 'start': 35, 'tag': 'Finding'}, {'end': 61, 'start': 56, 'tag': 'Chemical'}, {'end': 71, 'start': 56, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 71, 'start': 62, 'tag': 'EnvironmentalEffectOfHumans'}]"
869,"Water pollution from industrial activities and improper waste disposal can lead to the release of heavy metals like lead, mercury, and arsenic into water sources.","[{'end': 153, 'start': 148, 'tag': 'Chemical'}, {'end': 15, 'start': 0, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 15, 'start': 6, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 70, 'start': 56, 'tag': 'HealthCareActivity'}, {'end': 110, 'start': 98, 'tag': 'Chemical'}, {'end': 129, 'start': 122, 'tag': 'Chemical'}, {'end': 161, 'start': 143, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 129, 'start': 122, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 142, 'start': 135, 'tag': 'Chemical'}, {'end': 161, 'start': 135, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 120, 'start': 116, 'tag': 'Chemical'}, {'end': 120, 'start': 116, 'tag': 'InjuryOrPoisoning'}]"
870,,[]
871,Reducing water pollution and promoting clean water sources are essential for safeguarding public health and potentially mitigating the risk of neurodegenerative disorders.,"[{'end': 170, 'start': 143, 'tag': 'DiseaseOrSyndrome'}, {'end': 103, 'start': 97, 'tag': 'HealthCareActivity'}, {'end': 139, 'start': 135, 'tag': 'Finding'}, {'end': 58, 'start': 51, 'tag': 'Finding'}, {'end': 50, 'start': 45, 'tag': 'Chemical'}, {'end': 103, 'start': 90, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 103, 'start': 90, 'tag': 'HealthCareActivity'}, {'end': 24, 'start': 9, 'tag': 'EnvironmentalEffectOfHumans'}]"
872,,[]
873,Environmental pollution-induced inflammation in the brain is thought to play a role in the development of neurodegenerative diseases.,"[{'end': 132, 'start': 106, 'tag': 'DiseaseOrSyndrome'}, {'end': 57, 'start': 52, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 102, 'start': 91, 'tag': 'BiologicFunction'}, {'end': 102, 'start': 91, 'tag': 'CellFunction'}, {'end': 44, 'start': 32, 'tag': 'PathologicFunction'}, {'end': 23, 'start': 0, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 23, 'start': 14, 'tag': 'EnvironmentalEffectOfHumans'}]"
874,Chronic inflammation can damage neurons and contribute to the progression of conditions like Alzheimer's and Parkinson's.,"[{'end': 120, 'start': 109, 'tag': 'DiseaseOrSyndrome'}, {'end': 39, 'start': 32, 'tag': 'Cell'}, {'end': 104, 'start': 93, 'tag': 'DiseaseOrSyndrome'}, {'end': 31, 'start': 25, 'tag': 'InjuryOrPoisoning'}, {'end': 20, 'start': 0, 'tag': 'PathologicFunction'}]"
875,"Fueled by aging populations and continued environmental pollution, the global burden of Parkinson's disease (PD) is increasing.","[{'end': 107, 'start': 88, 'tag': 'DiseaseOrSyndrome'}, {'end': 111, 'start': 109, 'tag': 'DiseaseOrSyndrome'}, {'end': 15, 'start': 10, 'tag': 'BiologicFunction'}, {'end': 15, 'start': 10, 'tag': 'CellFunction'}, {'end': 84, 'start': 78, 'tag': 'ResearchActivity'}, {'end': 27, 'start': 16, 'tag': 'PopulationGroup'}, {'end': 65, 'start': 42, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 65, 'start': 56, 'tag': 'EnvironmentalEffectOfHumans'}]"
876,,[]
877,Ginkgo biloba: Ginkgo biloba is one of the oldest living tree species and is known for its use in traditional medicine.,"[{'end': 69, 'start': 57, 'tag': 'OrganismAttribute'}, {'end': 56, 'start': 50, 'tag': 'Finding'}, {'end': 13, 'start': 0, 'tag': 'Organism'}, {'end': 28, 'start': 15, 'tag': 'Organism'}, {'end': 118, 'start': 110, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 118, 'start': 110, 'tag': 'PharmacologicSubstance'}, {'end': 118, 'start': 98, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 49, 'start': 43, 'tag': 'TemporalConcept'}]"
878,,[]
879,Some studies have suggested that Ginkgo biloba extract may help improve cognitive function and memory in individuals with Alzheimer's disease.,"[{'end': 12, 'start': 5, 'tag': 'ResearchActivity'}, {'end': 141, 'start': 122, 'tag': 'DiseaseOrSyndrome'}, {'end': 116, 'start': 105, 'tag': 'PopulationGroup'}, {'end': 101, 'start': 95, 'tag': 'BiologicFunction'}, {'end': 90, 'start': 72, 'tag': 'BiologicFunction'}, {'end': 54, 'start': 47, 'tag': 'Substance'}, {'end': 46, 'start': 33, 'tag': 'Organism'}, {'end': 12, 'start': 5, 'tag': 'HealthCareActivity'}]"
880,"The bakers yeast Saccharomyces cerevisiae has been used for thousands of years for industrial applications, including baking bread.","[{'end': 79, 'start': 74, 'tag': 'TemporalConcept'}, {'end': 17, 'start': 12, 'tag': 'Organism'}, {'end': 42, 'start': 18, 'tag': 'Organism'}]"
881,,[]
882,HSV vectors can also be used to deliver therapeutic genes to specific neurons affected by neurodegenerative diseases.,"[{'end': 116, 'start': 90, 'tag': 'DiseaseOrSyndrome'}, {'end': 77, 'start': 70, 'tag': 'Cell'}, {'end': 11, 'start': 4, 'tag': 'NucleicAcidNucleosideOrNucleotide'}, {'end': 57, 'start': 52, 'tag': 'GeneOrGenome'}, {'end': 3, 'start': 0, 'tag': 'Virus'}]"
883,The identification of yeast proteins with prion behavior led to the use of S.,"[{'end': 36, 'start': 28, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 47, 'start': 42, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 27, 'start': 22, 'tag': 'Organism'}]"
884,cerevisiae (herewith referred to as yeast) as a living test tube with which to investigate the molecular underpinnings of neurodegenerative diseases associated with protein misfolding and aggregation.,"[{'end': 148, 'start': 122, 'tag': 'DiseaseOrSyndrome'}, {'end': 183, 'start': 165, 'tag': 'CellOrMolecularDysfunction'}, {'end': 199, 'start': 188, 'tag': 'CellFunction'}, {'end': 172, 'start': 165, 'tag': 'CellFunction'}, {'end': 54, 'start': 48, 'tag': 'Finding'}, {'end': 41, 'start': 36, 'tag': 'Organism'}, {'end': 59, 'start': 55, 'tag': 'ResearchActivity'}, {'end': 59, 'start': 55, 'tag': 'HealthCareActivity'}]"
885,,[]
886,"Yeast alone will not be the solution, but together with more complex models, it has already proven to be an invaluable tool/model organism in which to investigate the basic biology and pathobiology of -synuclein ","[{'end': 180, 'start': 173, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 129, 'start': 124, 'tag': 'ResearchActivity'}, {'end': 75, 'start': 69, 'tag': 'ResearchActivity'}, {'end': 180, 'start': 173, 'tag': 'BiologicFunction'}, {'end': 212, 'start': 201, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 212, 'start': 201, 'tag': 'BiologicallyActiveSubstance'}, {'end': 197, 'start': 185, 'tag': 'PathologicFunction'}, {'end': 138, 'start': 130, 'tag': 'Organism'}, {'end': 5, 'start': 0, 'tag': 'Organism'}]"
887,"Despite initial skepticism, these basic studies in yeast have provided tremendous insight into the biology and pathobiology of -synuclein and other PD-associated genes","[{'end': 47, 'start': 40, 'tag': 'ResearchActivity'}, {'end': 106, 'start': 99, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 151, 'start': 149, 'tag': 'DiseaseOrSyndrome'}, {'end': 106, 'start': 99, 'tag': 'BiologicFunction'}, {'end': 15, 'start': 8, 'tag': 'TemporalConcept'}, {'end': 168, 'start': 163, 'tag': 'GeneOrGenome'}, {'end': 138, 'start': 127, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 138, 'start': 127, 'tag': 'BiologicallyActiveSubstance'}, {'end': 47, 'start': 40, 'tag': 'HealthCareActivity'}, {'end': 123, 'start': 111, 'tag': 'PathologicFunction'}, {'end': 56, 'start': 51, 'tag': 'Organism'}, {'end': 26, 'start': 16, 'tag': 'BiologicFunction'}]"
888,"Interestingly, some genera, such as Ramularia, appeared unique to HD patients","[{'end': 77, 'start': 66, 'tag': 'PatientOrDisabledGroup'}, {'end': 45, 'start': 36, 'tag': 'Organism'}]"
889,Our observations suggest that microbial colonization may be a risk factor for HD and might explain why the onset of the disease appears after several decades of life.,"[{'end': 80, 'start': 78, 'tag': 'DiseaseOrSyndrome'}, {'end': 112, 'start': 107, 'tag': 'TemporalConcept'}, {'end': 157, 'start': 150, 'tag': 'TemporalConcept'}, {'end': 73, 'start': 62, 'tag': 'Finding'}, {'end': 165, 'start': 161, 'tag': 'TemporalConcept'}, {'end': 16, 'start': 4, 'tag': 'Finding'}, {'end': 52, 'start': 40, 'tag': 'Finding'}, {'end': 39, 'start': 30, 'tag': 'Organism'}]"
890,"Patients who fail to lower the elevated homocysteine levels, through high protein-restricted diet or by B6 and folic acid supplements, are at higher risk for cardiovascular diseases, neurodegenerative diseases, neural tube defects, and other severe clinical complications.","[{'end': 209, 'start': 183, 'tag': 'DiseaseOrSyndrome'}, {'end': 153, 'start': 149, 'tag': 'Finding'}, {'end': 73, 'start': 69, 'tag': 'Finding'}, {'end': 248, 'start': 242, 'tag': 'Finding'}, {'end': 271, 'start': 258, 'tag': 'PathologicFunction'}, {'end': 81, 'start': 74, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 8, 'start': 0, 'tag': 'PatientOrDisabledGroup'}, {'end': 97, 'start': 93, 'tag': 'HealthCareActivity'}, {'end': 222, 'start': 211, 'tag': 'EmbryonicStructure'}, {'end': 181, 'start': 158, 'tag': 'DiseaseOrSyndrome'}, {'end': 52, 'start': 40, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 52, 'start': 40, 'tag': 'BiologicallyActiveSubstance'}, {'end': 106, 'start': 104, 'tag': 'BiologicallyActiveSubstance'}, {'end': 121, 'start': 111, 'tag': 'BiologicallyActiveSubstance'}, {'end': 121, 'start': 111, 'tag': 'Chemical'}, {'end': 133, 'start': 111, 'tag': 'PharmacologicSubstance'}, {'end': 133, 'start': 122, 'tag': 'PharmacologicSubstance'}, {'end': 106, 'start': 104, 'tag': 'PharmacologicSubstance'}, {'end': 230, 'start': 211, 'tag': 'AnatomicalAbnormality'}, {'end': 106, 'start': 104, 'tag': 'PharmacologicSubstance'}, {'end': 121, 'start': 111, 'tag': 'PharmacologicSubstance'}]"
891,,[]
892,"CDH2 is involved in a wide range of processes including maintenance of neuroepithelial integrity, neural tube closure (neurulation), confinement of radial glia progenitor cells","[{'end': 176, 'start': 171, 'tag': 'Cell'}, {'end': 159, 'start': 148, 'tag': 'EmbryonicStructure'}, {'end': 67, 'start': 56, 'tag': 'BiologicFunction'}, {'end': 176, 'start': 160, 'tag': 'Cell'}, {'end': 96, 'start': 87, 'tag': 'IndividualBehavior'}, {'end': 109, 'start': 98, 'tag': 'EmbryonicStructure'}, {'end': 4, 'start': 0, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 4, 'start': 0, 'tag': 'BiologicallyActiveSubstance'}, {'end': 4, 'start': 0, 'tag': 'GeneOrGenome'}, {'end': 86, 'start': 71, 'tag': 'EmbryonicStructure'}, {'end': 130, 'start': 119, 'tag': 'BiologicFunction'}, {'end': 117, 'start': 98, 'tag': 'BiologicFunction'}]"
893,"The human cortex comprises diverse cell types that emerge from an initially uniform neuroepithelium that gives rise to radial glia, the neural stem cells of the cortex.","[{'end': 45, 'start': 35, 'tag': 'Cell'}, {'end': 9, 'start': 4, 'tag': 'Eukaryote'}, {'end': 16, 'start': 10, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 167, 'start': 161, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 130, 'start': 126, 'tag': 'Cell'}, {'end': 153, 'start': 136, 'tag': 'Cell'}, {'end': 130, 'start': 119, 'tag': 'EmbryonicStructure'}, {'end': 99, 'start': 84, 'tag': 'EmbryonicStructure'}, {'end': 75, 'start': 66, 'tag': 'TemporalConcept'}]"
894,T,[]
895,"Radial glial cells (RGC) are at the center of brain development in vertebrates, acting as progenitors for neurons and macroglia (oligodendrocytes and astrocytes) ","[{'end': 113, 'start': 106, 'tag': 'Cell'}, {'end': 18, 'start': 7, 'tag': 'Cell'}, {'end': 145, 'start': 129, 'tag': 'Cell'}, {'end': 160, 'start': 150, 'tag': 'Cell'}, {'end': 63, 'start': 46, 'tag': 'BiologicFunction'}, {'end': 101, 'start': 90, 'tag': 'Cell'}, {'end': 18, 'start': 0, 'tag': 'EmbryonicStructure'}, {'end': 23, 'start': 20, 'tag': 'EmbryonicStructure'}, {'end': 12, 'start': 0, 'tag': 'EmbryonicStructure'}, {'end': 127, 'start': 118, 'tag': 'Cell'}, {'end': 78, 'start': 67, 'tag': 'Eukaryote'}]"
896,"Mouse cortical radial glial cells (RGCs) are primary neural stem cells that give rise to cortical oligodendrocytes, astrocytes, and olfactory bulb (OB) GABAergic interneurons in late embryogenesis.","[{'end': 174, 'start': 152, 'tag': 'Cell'}, {'end': 33, 'start': 22, 'tag': 'Cell'}, {'end': 114, 'start': 98, 'tag': 'Cell'}, {'end': 126, 'start': 116, 'tag': 'Cell'}, {'end': 14, 'start': 6, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 97, 'start': 89, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 182, 'start': 178, 'tag': 'TemporalConcept'}, {'end': 27, 'start': 22, 'tag': 'Cell'}, {'end': 70, 'start': 53, 'tag': 'Cell'}, {'end': 174, 'start': 162, 'tag': 'Cell'}, {'end': 146, 'start': 132, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 27, 'start': 15, 'tag': 'EmbryonicStructure'}, {'end': 39, 'start': 35, 'tag': 'EmbryonicStructure'}, {'end': 38, 'start': 35, 'tag': 'EmbryonicStructure'}, {'end': 27, 'start': 15, 'tag': 'EmbryonicStructure'}, {'end': 150, 'start': 148, 'tag': 'BodyPartOrganOrOrganComponent'}]"
897,Herpes Simplex Virus (HSV) is a member of the Herpesviridae family and one of the most widespread viruses in the human population.,"[{'end': 118, 'start': 113, 'tag': 'Eukaryote'}, {'end': 129, 'start': 119, 'tag': 'PopulationGroup'}, {'end': 105, 'start': 98, 'tag': 'Virus'}, {'end': 20, 'start': 0, 'tag': 'Virus'}, {'end': 25, 'start': 22, 'tag': 'Virus'}, {'end': 66, 'start': 46, 'tag': 'Virus'}, {'end': 59, 'start': 46, 'tag': 'Virus'}]"
898,The neural crest is a migratory stem cell population that contributes to various tissues and organs during vertebrate embryonic development,"[{'end': 88, 'start': 81, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 99, 'start': 93, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 52, 'start': 37, 'tag': 'Cell'}, {'end': 139, 'start': 118, 'tag': 'BiologicFunction'}, {'end': 16, 'start': 4, 'tag': 'EmbryonicStructure'}, {'end': 139, 'start': 107, 'tag': 'BiologicFunction'}]"
899,"By using single-cell transcriptomics to generate a gene expression atlas of the entire neural crest lineage, we show that early SCPs and late migratory crest cells have similar transcriptional profiles","[{'end': 163, 'start': 158, 'tag': 'Cell'}, {'end': 201, 'start': 193, 'tag': 'ResearchActivity'}, {'end': 141, 'start': 137, 'tag': 'TemporalConcept'}, {'end': 66, 'start': 51, 'tag': 'CellFunction'}, {'end': 36, 'start': 21, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 127, 'start': 122, 'tag': 'TemporalConcept'}, {'end': 192, 'start': 177, 'tag': 'CellFunction'}, {'end': 99, 'start': 87, 'tag': 'EmbryonicStructure'}, {'end': 132, 'start': 128, 'tag': 'Cell'}, {'end': 72, 'start': 67, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 20, 'start': 9, 'tag': 'ResearchActivity'}, {'end': 20, 'start': 9, 'tag': 'Cell'}]"
900,Neural crest stem cells (NCSCs) are a transient population of cells that arise during early vertebrate development,"[{'end': 67, 'start': 62, 'tag': 'Cell'}, {'end': 23, 'start': 13, 'tag': 'Cell'}, {'end': 23, 'start': 13, 'tag': 'ResearchActivity'}, {'end': 47, 'start': 38, 'tag': 'TemporalConcept'}, {'end': 58, 'start': 48, 'tag': 'PopulationGroup'}, {'end': 12, 'start': 0, 'tag': 'EmbryonicStructure'}, {'end': 114, 'start': 86, 'tag': 'OrganismAttribute'}]"
901,Understanding how disparate epidemiologically-validated exposures may produce similar developmental brain abnormalities may unlock convergent early disease-related pathways/processes.,"[{'end': 172, 'start': 164, 'tag': 'CellFunction'}, {'end': 147, 'start': 142, 'tag': 'TemporalConcept'}, {'end': 13, 'start': 0, 'tag': 'BiologicFunction'}, {'end': 105, 'start': 86, 'tag': 'EmbryonicStructure'}, {'end': 119, 'start': 86, 'tag': 'PathologicFunction'}]"
902,"HSV may result in an asymptomatic latent infection, where the virus lies dormant within neurons until the lytic cycle is triggered by an adverse reaction to a drug or immunodeficiency secondary to physiological aging or myriad pathophysiological processes","[{'end': 95, 'start': 88, 'tag': 'Cell'}, {'end': 216, 'start': 211, 'tag': 'BiologicFunction'}, {'end': 216, 'start': 211, 'tag': 'CellFunction'}, {'end': 163, 'start': 159, 'tag': 'PharmacologicSubstance'}, {'end': 255, 'start': 227, 'tag': 'BiologicFunction'}, {'end': 245, 'start': 227, 'tag': 'PathologicFunction'}, {'end': 50, 'start': 34, 'tag': 'PathologicFunction'}, {'end': 255, 'start': 227, 'tag': 'PathologicFunction'}, {'end': 14, 'start': 8, 'tag': 'Finding'}, {'end': 33, 'start': 21, 'tag': 'Finding'}, {'end': 3, 'start': 0, 'tag': 'Virus'}]"
903,Three mechanisms of HSV-associated A accumulation have been examined.,"[{'end': 51, 'start': 39, 'tag': 'Finding'}, {'end': 23, 'start': 20, 'tag': 'Virus'}]"
904,Adenoviruses: Adenoviruses are commonly used in gene therapy research but are less commonly employed in neurodegenerative disorder research compared to AAVs and lentiviruses.,"[{'end': 130, 'start': 104, 'tag': 'DiseaseOrSyndrome'}, {'end': 60, 'start': 53, 'tag': 'HealthCareActivity'}, {'end': 69, 'start': 61, 'tag': 'ResearchActivity'}, {'end': 139, 'start': 131, 'tag': 'ResearchActivity'}, {'end': 52, 'start': 48, 'tag': 'GeneOrGenome'}, {'end': 156, 'start': 152, 'tag': 'Virus'}, {'end': 155, 'start': 152, 'tag': 'Virus'}, {'end': 173, 'start': 161, 'tag': 'Virus'}, {'end': 12, 'start': 0, 'tag': 'Virus'}, {'end': 26, 'start': 14, 'tag': 'Virus'}]"
905,They are more suitable for transient gene expression due to their immunogenicity.,"[{'end': 36, 'start': 27, 'tag': 'TemporalConcept'}, {'end': 52, 'start': 37, 'tag': 'CellFunction'}, {'end': 80, 'start': 66, 'tag': 'ResearchActivity'}]"
906,Lentivirus-based gene therapy shows promise in halting the progression of neurodegenerative disorders by delivering therapeutic genes to affected neurons.,"[{'end': 101, 'start': 74, 'tag': 'DiseaseOrSyndrome'}, {'end': 153, 'start': 146, 'tag': 'Cell'}, {'end': 29, 'start': 17, 'tag': 'HealthCareActivity'}, {'end': 21, 'start': 17, 'tag': 'GeneOrGenome'}, {'end': 133, 'start': 116, 'tag': 'GeneOrGenome'}, {'end': 10, 'start': 0, 'tag': 'Virus'}, {'end': 70, 'start': 59, 'tag': 'TemporalConcept'}, {'end': 70, 'start': 59, 'tag': 'PathologicFunction'}]"
907,Lentivirus-mediated RNA interference emerges as a potential therapeutic strategy to target specific genes involved in neurodegeneration.,"[{'end': 135, 'start': 118, 'tag': 'CellOrMolecularDysfunction'}, {'end': 23, 'start': 20, 'tag': 'NucleicAcidNucleosideOrNucleotide'}, {'end': 80, 'start': 60, 'tag': 'HealthCareActivity'}, {'end': 105, 'start': 100, 'tag': 'GeneOrGenome'}, {'end': 10, 'start': 0, 'tag': 'Virus'}, {'end': 36, 'start': 20, 'tag': 'CellFunction'}]"
908,Herpes Simplex Virus-based oncolytic therapy exhibits potential in selectively targeting and eliminating neurodegenerative disease-associated glial cells.,"[{'end': 44, 'start': 27, 'tag': 'HealthCareActivity'}, {'end': 130, 'start': 105, 'tag': 'DiseaseOrSyndrome'}, {'end': 153, 'start': 142, 'tag': 'Cell'}, {'end': 20, 'start': 0, 'tag': 'Virus'}, {'end': 6, 'start': 0, 'tag': 'Virus'}]"
909,"Air pollution, particularly the presence of fine particulate matter, has been associated with an increased risk of neurodegenerative diseases, highlighting its potential impact on brain health.","[{'end': 141, 'start': 115, 'tag': 'DiseaseOrSyndrome'}, {'end': 185, 'start': 180, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 192, 'start': 186, 'tag': 'HealthCareActivity'}, {'end': 40, 'start': 32, 'tag': 'Finding'}, {'end': 111, 'start': 97, 'tag': 'Finding'}, {'end': 13, 'start': 0, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 67, 'start': 44, 'tag': 'Substance'}]"
910,Investigating the role of air pollution in promoting neuroinflammation and oxidative stress in the brain is essential for understanding its contribution to neurodegeneration.,"[{'end': 104, 'start': 99, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 173, 'start': 156, 'tag': 'CellOrMolecularDysfunction'}, {'end': 135, 'start': 122, 'tag': 'BiologicFunction'}, {'end': 70, 'start': 53, 'tag': 'PathologicFunction'}, {'end': 91, 'start': 75, 'tag': 'CellOrMolecularDysfunction'}, {'end': 39, 'start': 26, 'tag': 'EnvironmentalEffectOfHumans'}]"
911,"Chronic exposure to air pollution may lead to the accumulation of toxic substances in the brain, potentially exacerbating neurodegenerative disease progression.","[{'end': 95, 'start': 90, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 147, 'start': 122, 'tag': 'DiseaseOrSyndrome'}, {'end': 62, 'start': 50, 'tag': 'Finding'}, {'end': 71, 'start': 66, 'tag': 'InjuryOrPoisoning'}, {'end': 33, 'start': 20, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 16, 'start': 8, 'tag': 'InjuryOrPoisoning'}, {'end': 82, 'start': 66, 'tag': 'InjuryOrPoisoning'}, {'end': 7, 'start': 0, 'tag': 'TemporalConcept'}, {'end': 159, 'start': 140, 'tag': 'PathologicFunction'}]"
912,"Air pollution-induced impairment of respiratory and cardiovascular systems may influence brain health, contributing to the development of neurodegenerative conditions.","[{'end': 94, 'start': 89, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 101, 'start': 95, 'tag': 'HealthCareActivity'}, {'end': 166, 'start': 138, 'tag': 'DiseaseOrSyndrome'}, {'end': 134, 'start': 123, 'tag': 'BiologicFunction'}, {'end': 134, 'start': 123, 'tag': 'CellFunction'}, {'end': 32, 'start': 22, 'tag': 'Finding'}, {'end': 74, 'start': 52, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 74, 'start': 67, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 47, 'start': 36, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 13, 'start': 0, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 13, 'start': 4, 'tag': 'EnvironmentalEffectOfHumans'}]"
913,The potential of air pollution to transport neurotoxic agents across the blood-brain barrier warrants investigation in the context of neurodegeneration.,"[{'end': 151, 'start': 134, 'tag': 'CellOrMolecularDysfunction'}, {'end': 115, 'start': 102, 'tag': 'ResearchActivity'}, {'end': 43, 'start': 34, 'tag': 'CellFunction'}, {'end': 43, 'start': 34, 'tag': 'ManufacturedObject'}, {'end': 92, 'start': 73, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 30, 'start': 17, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 61, 'start': 44, 'tag': 'InjuryOrPoisoning'}, {'end': 30, 'start': 21, 'tag': 'EnvironmentalEffectOfHumans'}]"
914,"Implementing effective strategies to mitigate air pollution is crucial for reducing its impact on public health, including its potential role in neurodegenerative diseases.","[{'end': 171, 'start': 145, 'tag': 'DiseaseOrSyndrome'}, {'end': 59, 'start': 46, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 83, 'start': 75, 'tag': 'Finding'}, {'end': 111, 'start': 98, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 111, 'start': 98, 'tag': 'HealthCareActivity'}, {'end': 59, 'start': 50, 'tag': 'EnvironmentalEffectOfHumans'}]"
915,"Air pollution exposure may interact with genetic factors, increasing susceptibility to neurodegenerative diseases in vulnerable populations.","[{'end': 113, 'start': 87, 'tag': 'DiseaseOrSyndrome'}, {'end': 139, 'start': 128, 'tag': 'PopulationGroup'}, {'end': 13, 'start': 0, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 13, 'start': 4, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 56, 'start': 41, 'tag': 'Finding'}, {'end': 83, 'start': 69, 'tag': 'Finding'}, {'end': 22, 'start': 0, 'tag': 'InjuryOrPoisoning'}]"
916,Studies examining the relationship between long-term exposure to air pollution and cognitive decline provide insights into its role in neurodegeneration.,"[{'end': 152, 'start': 135, 'tag': 'CellOrMolecularDysfunction'}, {'end': 100, 'start': 83, 'tag': 'DiseaseOrSyndrome'}, {'end': 78, 'start': 65, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 34, 'start': 22, 'tag': 'Finding'}, {'end': 52, 'start': 43, 'tag': 'TemporalConcept'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 78, 'start': 53, 'tag': 'InjuryOrPoisoning'}, {'end': 78, 'start': 69, 'tag': 'EnvironmentalEffectOfHumans'}]"
917,Investigating the impact of air pollution on the gut microbiota-brain axis may shed light on its potential influence on neurodegenerative disease pathogenesis.,"[{'end': 145, 'start': 120, 'tag': 'DiseaseOrSyndrome'}, {'end': 158, 'start': 146, 'tag': 'PathologicFunction'}, {'end': 63, 'start': 49, 'tag': 'Organism'}, {'end': 41, 'start': 28, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 73, 'start': 49, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 89, 'start': 84, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 41, 'start': 32, 'tag': 'EnvironmentalEffectOfHumans'}]"
918,The association between air pollution and amyloid-beta deposition in the brain has implications for understanding its role in Alzheimer's disease and related disorders.,"[{'end': 78, 'start': 73, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 145, 'start': 126, 'tag': 'DiseaseOrSyndrome'}, {'end': 54, 'start': 42, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 113, 'start': 100, 'tag': 'BiologicFunction'}, {'end': 37, 'start': 24, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 167, 'start': 158, 'tag': 'DiseaseOrSyndrome'}, {'end': 54, 'start': 42, 'tag': 'BiologicallyActiveSubstance'}, {'end': 65, 'start': 42, 'tag': 'PathologicFunction'}]"
919,Understanding the intricate interactions between Herpes Simplex Virus and the immune system is crucial for developing targeted immunotherapies for neurodegenerative disorders.,"[{'end': 174, 'start': 147, 'tag': 'DiseaseOrSyndrome'}, {'end': 91, 'start': 78, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 40, 'start': 28, 'tag': 'Finding'}, {'end': 13, 'start': 0, 'tag': 'BiologicFunction'}, {'end': 142, 'start': 127, 'tag': 'HealthCareActivity'}, {'end': 69, 'start': 49, 'tag': 'Virus'}, {'end': 55, 'start': 49, 'tag': 'Virus'}]"
920,"Tobacco smoke pollution contains harmful chemicals that can cross the blood-brain barrier, potentially contributing to neurodegeneration and cognitive decline.","[{'end': 136, 'start': 119, 'tag': 'CellOrMolecularDysfunction'}, {'end': 158, 'start': 141, 'tag': 'DiseaseOrSyndrome'}, {'end': 89, 'start': 70, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 7, 'start': 0, 'tag': 'Chemical'}, {'end': 23, 'start': 8, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 23, 'start': 0, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 13, 'start': 0, 'tag': 'Substance'}, {'end': 50, 'start': 33, 'tag': 'InjuryOrPoisoning'}, {'end': 7, 'start': 0, 'tag': 'InjuryOrPoisoning'}, {'end': 50, 'start': 33, 'tag': 'Chemical'}]"
921,Understanding the impact of tobacco smoke pollution on the epigenetic regulation of genes associated with neurodegenerative diseases is an area of active research.,"[{'end': 132, 'start': 106, 'tag': 'DiseaseOrSyndrome'}, {'end': 162, 'start': 154, 'tag': 'ResearchActivity'}, {'end': 80, 'start': 59, 'tag': 'CellFunction'}, {'end': 89, 'start': 84, 'tag': 'GeneOrGenome'}, {'end': 13, 'start': 0, 'tag': 'BiologicFunction'}, {'end': 41, 'start': 28, 'tag': 'Substance'}, {'end': 51, 'start': 28, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 51, 'start': 42, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 51, 'start': 36, 'tag': 'EnvironmentalEffectOfHumans'}]"
922,"Secondhand smoke exposure, a form of tobacco smoke pollution, has been linked to an increased risk of neurodegenerative conditions in non-smokers.","[{'end': 130, 'start': 102, 'tag': 'DiseaseOrSyndrome'}, {'end': 98, 'start': 84, 'tag': 'Finding'}, {'end': 25, 'start': 0, 'tag': 'InjuryOrPoisoning'}, {'end': 16, 'start': 0, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 60, 'start': 37, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 60, 'start': 45, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 60, 'start': 51, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 50, 'start': 37, 'tag': 'Substance'}, {'end': 145, 'start': 134, 'tag': 'PopulationGroup'}]"
923,Tobacco smoke pollution-induced activation of microglia may contribute to neuroinflammatory processes relevant to neurodegeneration.,"[{'end': 131, 'start': 114, 'tag': 'CellOrMolecularDysfunction'}, {'end': 55, 'start': 46, 'tag': 'Cell'}, {'end': 101, 'start': 74, 'tag': 'PathologicFunction'}, {'end': 23, 'start': 0, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 13, 'start': 0, 'tag': 'Substance'}, {'end': 23, 'start': 8, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 23, 'start': 14, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 42, 'start': 32, 'tag': 'CellFunction'}]"
924,"Tobacco smoke pollution-derived free radicals and oxidative stress may damage neuronal cells, accelerating neurodegenerative disease progression.","[{'end': 144, 'start': 125, 'tag': 'PathologicFunction'}, {'end': 132, 'start': 107, 'tag': 'DiseaseOrSyndrome'}, {'end': 66, 'start': 50, 'tag': 'CellOrMolecularDysfunction'}, {'end': 92, 'start': 78, 'tag': 'Cell'}, {'end': 45, 'start': 32, 'tag': 'Chemical'}, {'end': 77, 'start': 71, 'tag': 'InjuryOrPoisoning'}, {'end': 45, 'start': 32, 'tag': 'BiologicallyActiveSubstance'}, {'end': 23, 'start': 0, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 13, 'start': 0, 'tag': 'Substance'}, {'end': 23, 'start': 8, 'tag': 'EnvironmentalEffectOfHumans'}]"
925,Investigating the potential of tobacco smoke pollution in promoting tau protein hyperphosphorylation provides insights into its impact on Alzheimer's disease pathology.,"[{'end': 157, 'start': 138, 'tag': 'DiseaseOrSyndrome'}, {'end': 100, 'start': 68, 'tag': 'CellOrMolecularDysfunction'}, {'end': 44, 'start': 31, 'tag': 'Substance'}, {'end': 54, 'start': 39, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 167, 'start': 158, 'tag': 'PathologicFunction'}]"
926,The influence of tobacco smoke pollution on blood-brain barrier integrity is a focus of research to understand its impact on brain health.,"[{'end': 130, 'start': 125, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 137, 'start': 131, 'tag': 'HealthCareActivity'}, {'end': 96, 'start': 88, 'tag': 'ResearchActivity'}, {'end': 63, 'start': 44, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 73, 'start': 64, 'tag': 'IndividualBehavior'}, {'end': 40, 'start': 25, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 30, 'start': 17, 'tag': 'Substance'}, {'end': 40, 'start': 17, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 73, 'start': 64, 'tag': 'Finding'}]"
927,"Tobacco smoke pollution may interact with specific genetic variants, influencing individual susceptibility to neurodegenerative diseases.","[{'end': 136, 'start': 110, 'tag': 'DiseaseOrSyndrome'}, {'end': 23, 'start': 0, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 13, 'start': 0, 'tag': 'Substance'}, {'end': 23, 'start': 8, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 106, 'start': 81, 'tag': 'Finding'}, {'end': 67, 'start': 51, 'tag': 'GeneOrGenome'}]"
928,Longitudinal studies assessing the impact of reducing tobacco smoke pollution on neurodegenerative disease risk and progression are essential for public health policy.,"[{'end': 20, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 106, 'start': 81, 'tag': 'DiseaseOrSyndrome'}, {'end': 111, 'start': 107, 'tag': 'Finding'}, {'end': 53, 'start': 45, 'tag': 'Finding'}, {'end': 166, 'start': 146, 'tag': 'HealthCareActivity'}, {'end': 77, 'start': 54, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 127, 'start': 116, 'tag': 'PathologicFunction'}, {'end': 127, 'start': 116, 'tag': 'TemporalConcept'}]"
929,Public health campaigns targeting tobacco smoke pollution may have broader implications for reducing the burden of neurodegenerative disorders in the population.,"[{'end': 142, 'start': 115, 'tag': 'DiseaseOrSyndrome'}, {'end': 23, 'start': 0, 'tag': 'HealthCareActivity'}, {'end': 111, 'start': 105, 'tag': 'ResearchActivity'}, {'end': 160, 'start': 150, 'tag': 'PopulationGroup'}, {'end': 57, 'start': 35, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 47, 'start': 34, 'tag': 'Substance'}, {'end': 57, 'start': 42, 'tag': 'EnvironmentalEffectOfHumans'}]"
930,Herpes Simplex Virus-based gene delivery systems provide an efficient means of introducing therapeutic genes to neural tissues affected by neurodegenerative processes.,"[{'end': 40, 'start': 32, 'tag': 'BiologicFunction'}, {'end': 126, 'start': 112, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 166, 'start': 139, 'tag': 'DiseaseOrSyndrome'}, {'end': 31, 'start': 27, 'tag': 'GeneOrGenome'}, {'end': 108, 'start': 91, 'tag': 'GeneOrGenome'}, {'end': 20, 'start': 0, 'tag': 'Virus'}, {'end': 6, 'start': 0, 'tag': 'Virus'}, {'end': 48, 'start': 27, 'tag': 'ResearchActivity'}]"
931,"Water pollution, particularly the presence of heavy metals and toxins, is a growing concern for its potential role in neurodegenerative disease development.","[{'end': 143, 'start': 118, 'tag': 'DiseaseOrSyndrome'}, {'end': 42, 'start': 34, 'tag': 'Finding'}, {'end': 155, 'start': 136, 'tag': 'PathologicFunction'}, {'end': 58, 'start': 46, 'tag': 'Chemical'}, {'end': 15, 'start': 0, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 15, 'start': 6, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 69, 'start': 63, 'tag': 'InjuryOrPoisoning'}, {'end': 69, 'start': 63, 'tag': 'BiologicallyActiveSubstance'}]"
932,Investigating the impact of water pollution on aquatic organisms may provide insights into the neurotoxic effects of contaminant exposure.,"[{'end': 64, 'start': 47, 'tag': 'Organism'}, {'end': 113, 'start': 95, 'tag': 'InjuryOrPoisoning'}, {'end': 33, 'start': 28, 'tag': 'Chemical'}, {'end': 137, 'start': 117, 'tag': 'InjuryOrPoisoning'}, {'end': 43, 'start': 28, 'tag': 'EnvironmentalEffectOfHumans'}]"
933,"Chronic exposure to water pollution may lead to the accumulation of neurotoxic substances in the food chain, posing risks to human brain health.","[{'end': 136, 'start': 131, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 130, 'start': 125, 'tag': 'Eukaryote'}, {'end': 143, 'start': 137, 'tag': 'HealthCareActivity'}, {'end': 64, 'start': 52, 'tag': 'Finding'}, {'end': 25, 'start': 20, 'tag': 'Chemical'}, {'end': 35, 'start': 8, 'tag': 'InjuryOrPoisoning'}, {'end': 89, 'start': 79, 'tag': 'Substance'}, {'end': 35, 'start': 20, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 89, 'start': 68, 'tag': 'InjuryOrPoisoning'}, {'end': 7, 'start': 0, 'tag': 'TemporalConcept'}, {'end': 107, 'start': 97, 'tag': 'NaturalPhenomenonOrProcess'}]"
934,Water pollution-induced alterations in neurodevelopment and brain function in early life may have long-term implications for neurodegenerative disease susceptibility.,"[{'end': 150, 'start': 125, 'tag': 'DiseaseOrSyndrome'}, {'end': 88, 'start': 84, 'tag': 'TemporalConcept'}, {'end': 55, 'start': 39, 'tag': 'BiologicFunction'}, {'end': 74, 'start': 60, 'tag': 'BiologicFunction'}, {'end': 107, 'start': 98, 'tag': 'TemporalConcept'}, {'end': 35, 'start': 24, 'tag': 'Finding'}, {'end': 83, 'start': 78, 'tag': 'TemporalConcept'}, {'end': 15, 'start': 0, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 120, 'start': 108, 'tag': 'Finding'}, {'end': 165, 'start': 151, 'tag': 'Finding'}]"
935,"The potential of water pollution to act as a vehicle for pathogenic microorganisms, affecting brain health, warrants investigation in the context of neurodegeneration.","[{'end': 99, 'start': 94, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 166, 'start': 149, 'tag': 'CellOrMolecularDysfunction'}, {'end': 130, 'start': 117, 'tag': 'ResearchActivity'}, {'end': 106, 'start': 100, 'tag': 'HealthCareActivity'}, {'end': 67, 'start': 57, 'tag': 'PathologicFunction'}, {'end': 82, 'start': 68, 'tag': 'Organism'}, {'end': 22, 'start': 17, 'tag': 'Chemical'}, {'end': 32, 'start': 17, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 52, 'start': 45, 'tag': 'ManufacturedObject'}, {'end': 52, 'start': 45, 'tag': 'Substance'}]"
936,Implementing effective water treatment and purification methods is crucial for reducing the risk of neurodegenerative diseases associated with contaminated water sources.,"[{'end': 126, 'start': 100, 'tag': 'DiseaseOrSyndrome'}, {'end': 96, 'start': 92, 'tag': 'Finding'}, {'end': 169, 'start': 162, 'tag': 'Finding'}, {'end': 28, 'start': 23, 'tag': 'Chemical'}, {'end': 161, 'start': 156, 'tag': 'Chemical'}, {'end': 169, 'start': 143, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 161, 'start': 143, 'tag': 'EnvironmentalEffectOfHumans'}]"
937,"Water pollution may contribute to the spread of harmful algal blooms, releasing neurotoxins that impact the central nervous system.","[{'end': 130, 'start': 108, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 15, 'start': 0, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 5, 'start': 0, 'tag': 'Chemical'}, {'end': 91, 'start': 80, 'tag': 'InjuryOrPoisoning'}, {'end': 68, 'start': 48, 'tag': 'NaturalPhenomenonOrProcess'}]"
938,The role of water pollution in promoting neuroinflammation and glial activation requires further exploration in neurodegenerative disease models.,"[{'end': 137, 'start': 112, 'tag': 'DiseaseOrSyndrome'}, {'end': 58, 'start': 41, 'tag': 'PathologicFunction'}, {'end': 17, 'start': 12, 'tag': 'Chemical'}, {'end': 79, 'start': 63, 'tag': 'CellFunction'}, {'end': 27, 'start': 12, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 144, 'start': 112, 'tag': 'ExperimentalModelOfDisease'}]"
939,Studying the impact of water pollution on wildlife and ecosystems provides insights into its potential influence on neurodegeneration in the human population.,"[{'end': 133, 'start': 116, 'tag': 'CellOrMolecularDysfunction'}, {'end': 146, 'start': 141, 'tag': 'Eukaryote'}, {'end': 157, 'start': 147, 'tag': 'PopulationGroup'}, {'end': 28, 'start': 23, 'tag': 'Chemical'}, {'end': 38, 'start': 23, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 65, 'start': 55, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 50, 'start': 42, 'tag': 'NaturalPhenomenonOrProcess'}]"
940,Integrating water quality monitoring into public health initiatives is essential for assessing the potential impact of water pollution on neurodegenerative disease prevalence.,"[{'end': 163, 'start': 138, 'tag': 'DiseaseOrSyndrome'}, {'end': 36, 'start': 26, 'tag': 'HealthCareActivity'}, {'end': 17, 'start': 12, 'tag': 'Chemical'}, {'end': 124, 'start': 119, 'tag': 'Chemical'}, {'end': 67, 'start': 42, 'tag': 'HealthCareActivity'}, {'end': 134, 'start': 119, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 25, 'start': 12, 'tag': 'Finding'}, {'end': 17, 'start': 12, 'tag': 'PharmacologicSubstance'}, {'end': 124, 'start': 119, 'tag': 'PharmacologicSubstance'}]"
941,Investigating the role of Herpes Simplex Virus latency-associated transcripts may offer insights into the link between viral reactivation and neurodegenerative disease exacerbation.,"[{'end': 167, 'start': 142, 'tag': 'DiseaseOrSyndrome'}, {'end': 180, 'start': 168, 'tag': 'Finding'}, {'end': 54, 'start': 47, 'tag': 'TemporalConcept'}, {'end': 77, 'start': 66, 'tag': 'NucleicAcidNucleosideOrNucleotide'}, {'end': 46, 'start': 26, 'tag': 'Virus'}, {'end': 32, 'start': 26, 'tag': 'Virus'}, {'end': 137, 'start': 119, 'tag': 'BiologicFunction'}]"
942,"Environmental pollution, arising from multiple sources, may contribute to the complex etiology of neurodegenerative diseases.","[{'end': 124, 'start': 98, 'tag': 'DiseaseOrSyndrome'}, {'end': 54, 'start': 47, 'tag': 'Finding'}, {'end': 94, 'start': 86, 'tag': 'Finding'}, {'end': 23, 'start': 0, 'tag': 'EnvironmentalEffectOfHumans'}]"
943,Investigating the cumulative impact of various environmental pollutants on brain health is critical for understanding their combined effects on neurodegeneration.,"[{'end': 80, 'start': 75, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 161, 'start': 144, 'tag': 'CellOrMolecularDysfunction'}, {'end': 117, 'start': 104, 'tag': 'BiologicFunction'}, {'end': 87, 'start': 81, 'tag': 'HealthCareActivity'}, {'end': 99, 'start': 91, 'tag': 'Finding'}, {'end': 71, 'start': 47, 'tag': 'InjuryOrPoisoning'}]"
944,"Chronic exposure to environmental pollution may synergistically interact with genetic and lifestyle factors, influencing neurodegenerative disease risk.","[{'end': 146, 'start': 121, 'tag': 'DiseaseOrSyndrome'}, {'end': 151, 'start': 147, 'tag': 'Finding'}, {'end': 16, 'start': 8, 'tag': 'InjuryOrPoisoning'}, {'end': 99, 'start': 90, 'tag': 'IndividualBehavior'}, {'end': 43, 'start': 20, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 7, 'start': 0, 'tag': 'TemporalConcept'}, {'end': 85, 'start': 78, 'tag': 'Finding'}, {'end': 107, 'start': 100, 'tag': 'Finding'}]"
945,Environmental pollution-induced disruption of circadian rhythms may have implications for neurodegenerative disease pathogenesis.,"[{'end': 115, 'start': 90, 'tag': 'DiseaseOrSyndrome'}, {'end': 128, 'start': 116, 'tag': 'PathologicFunction'}, {'end': 63, 'start': 46, 'tag': 'BiologicFunction'}, {'end': 23, 'start': 0, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 63, 'start': 32, 'tag': 'PathologicFunction'}]"
946,The impact of environmental pollution on mitochondrial function and dynamics is a focus of research in neurodegeneration.,"[{'end': 120, 'start': 103, 'tag': 'CellOrMolecularDysfunction'}, {'end': 99, 'start': 91, 'tag': 'ResearchActivity'}, {'end': 76, 'start': 68, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 63, 'start': 41, 'tag': 'CellFunction'}, {'end': 37, 'start': 14, 'tag': 'EnvironmentalEffectOfHumans'}]"
947,Understanding the contribution of environmental pollution to the dysregulation of protein homeostasis in the brain is crucial for targeted therapeutic strategies.,"[{'end': 114, 'start': 109, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 161, 'start': 139, 'tag': 'HealthCareActivity'}, {'end': 101, 'start': 82, 'tag': 'CellFunction'}, {'end': 13, 'start': 0, 'tag': 'BiologicFunction'}, {'end': 57, 'start': 34, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 101, 'start': 65, 'tag': 'CellOrMolecularDysfunction'}]"
948,The potential of environmental pollutants to alter neurotransmitter signaling and synaptic plasticity may impact cognitive function in neurodegenerative conditions.,"[{'end': 101, 'start': 82, 'tag': 'CellFunction'}, {'end': 101, 'start': 82, 'tag': 'BiologicFunction'}, {'end': 163, 'start': 135, 'tag': 'DiseaseOrSyndrome'}, {'end': 131, 'start': 113, 'tag': 'BiologicFunction'}, {'end': 77, 'start': 68, 'tag': 'CellFunction'}, {'end': 67, 'start': 51, 'tag': 'BiologicallyActiveSubstance'}, {'end': 41, 'start': 17, 'tag': 'InjuryOrPoisoning'}]"
949,Investigating the impact of environmental pollution on brain epigenetic modifications provides insights into its role in modifying gene expression relevant to neurodegeneration.,"[{'end': 60, 'start': 55, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 176, 'start': 159, 'tag': 'CellOrMolecularDysfunction'}, {'end': 146, 'start': 131, 'tag': 'CellFunction'}, {'end': 85, 'start': 61, 'tag': 'CellFunction'}, {'end': 51, 'start': 28, 'tag': 'InjuryOrPoisoning'}]"
950,"Environmental pollution mitigation strategies, such as green urban planning, may have potential neuroprotective effects in reducing neurodegenerative disease risks.","[{'end': 157, 'start': 132, 'tag': 'DiseaseOrSyndrome'}, {'end': 119, 'start': 96, 'tag': 'Finding'}, {'end': 45, 'start': 35, 'tag': 'ResearchActivity'}, {'end': 45, 'start': 35, 'tag': 'BiologicFunction'}, {'end': 131, 'start': 123, 'tag': 'Finding'}, {'end': 75, 'start': 67, 'tag': 'BiologicFunction'}, {'end': 23, 'start': 0, 'tag': 'EnvironmentalEffectOfHumans'}]"
951,Comprehensive risk assessments of environmental pollution exposure are necessary to inform public health policies aimed at reducing the burden of neurodegenerative disorders.,"[{'end': 173, 'start': 146, 'tag': 'DiseaseOrSyndrome'}, {'end': 142, 'start': 136, 'tag': 'ResearchActivity'}, {'end': 18, 'start': 14, 'tag': 'Finding'}, {'end': 131, 'start': 123, 'tag': 'Finding'}, {'end': 113, 'start': 91, 'tag': 'HealthCareActivity'}, {'end': 66, 'start': 34, 'tag': 'InjuryOrPoisoning'}, {'end': 57, 'start': 34, 'tag': 'EnvironmentalEffectOfHumans'}]"
952,"Herpes Simplex Virus vectors engineered for anterograde transport enable precise targeting of affected brain regions, offering potential therapeutic benefits in neurodegenerative diseases.","[{'end': 187, 'start': 161, 'tag': 'DiseaseOrSyndrome'}, {'end': 65, 'start': 44, 'tag': 'CellFunction'}, {'end': 28, 'start': 21, 'tag': 'NucleicAcidNucleosideOrNucleotide'}, {'end': 116, 'start': 103, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 20, 'start': 0, 'tag': 'Virus'}, {'end': 6, 'start': 0, 'tag': 'Virus'}, {'end': 157, 'start': 127, 'tag': 'Finding'}]"
953,"Ginkgo biloba, a traditional herbal medicine, has been studied for its potential neuroprotective effects and its ability to mitigate cognitive decline in neurodegenerative diseases.","[{'end': 180, 'start': 154, 'tag': 'DiseaseOrSyndrome'}, {'end': 104, 'start': 81, 'tag': 'Finding'}, {'end': 150, 'start': 133, 'tag': 'DiseaseOrSyndrome'}, {'end': 120, 'start': 113, 'tag': 'OrganismAttribute'}, {'end': 13, 'start': 0, 'tag': 'Organism'}, {'end': 44, 'start': 29, 'tag': 'PharmacologicSubstance'}, {'end': 44, 'start': 17, 'tag': 'BiomedicalOccupationOrDiscipline'}]"
954,The antioxidant and anti-inflammatory properties of Ginkgo biloba extract make it a promising candidate for therapeutic intervention in neurodegeneration.,"[{'end': 153, 'start': 136, 'tag': 'CellOrMolecularDysfunction'}, {'end': 37, 'start': 20, 'tag': 'BiologicFunction'}, {'end': 37, 'start': 20, 'tag': 'PharmacologicSubstance'}, {'end': 15, 'start': 4, 'tag': 'PharmacologicSubstance'}, {'end': 15, 'start': 4, 'tag': 'CellFunction'}, {'end': 132, 'start': 108, 'tag': 'HealthCareActivity'}, {'end': 37, 'start': 25, 'tag': 'PathologicFunction'}, {'end': 73, 'start': 66, 'tag': 'Substance'}, {'end': 65, 'start': 52, 'tag': 'Organism'}]"
955,Ginkgo biloba supplementation has shown promising results in enhancing memory and cognitive function in individuals with mild cognitive impairment associated with neurodegenerative conditions.,"[{'end': 146, 'start': 121, 'tag': 'DiseaseOrSyndrome'}, {'end': 191, 'start': 163, 'tag': 'DiseaseOrSyndrome'}, {'end': 115, 'start': 104, 'tag': 'PopulationGroup'}, {'end': 77, 'start': 71, 'tag': 'BiologicFunction'}, {'end': 77, 'start': 71, 'tag': 'Finding'}, {'end': 100, 'start': 82, 'tag': 'BiologicFunction'}, {'end': 13, 'start': 0, 'tag': 'Organism'}, {'end': 29, 'start': 0, 'tag': 'HealthCareActivity'}]"
956,Investigating the mechanisms of Ginkgo biloba's action in improving cerebral blood flow and neuroplasticity provides insights into its potential benefits for brain health.,"[{'end': 163, 'start': 158, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 170, 'start': 164, 'tag': 'HealthCareActivity'}, {'end': 107, 'start': 92, 'tag': 'BiologicFunction'}, {'end': 45, 'start': 32, 'tag': 'Organism'}, {'end': 87, 'start': 68, 'tag': 'BiologicFunction'}, {'end': 153, 'start': 135, 'tag': 'Finding'}]"
957,"Ginkgo biloba-derived flavonoids and terpenoids exhibit potential in targeting multiple pathways involved in neurodegeneration, offering a multi-target therapeutic approach.","[{'end': 126, 'start': 109, 'tag': 'CellOrMolecularDysfunction'}, {'end': 96, 'start': 88, 'tag': 'CellFunction'}, {'end': 172, 'start': 152, 'tag': 'HealthCareActivity'}, {'end': 13, 'start': 0, 'tag': 'Organism'}, {'end': 32, 'start': 22, 'tag': 'Chemical'}, {'end': 47, 'start': 37, 'tag': 'Chemical'}, {'end': 47, 'start': 37, 'tag': 'BiologicallyActiveSubstance'}]"
958,The potential of Ginkgo biloba to modulate amyloid-beta metabolism and tau protein phosphorylation is of interest in Alzheimer's disease research.,"[{'end': 136, 'start': 117, 'tag': 'DiseaseOrSyndrome'}, {'end': 55, 'start': 43, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 145, 'start': 137, 'tag': 'ResearchActivity'}, {'end': 66, 'start': 56, 'tag': 'CellFunction'}, {'end': 66, 'start': 56, 'tag': 'BiologicFunction'}, {'end': 82, 'start': 71, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 98, 'start': 83, 'tag': 'CellFunction'}, {'end': 82, 'start': 71, 'tag': 'BiologicallyActiveSubstance'}, {'end': 30, 'start': 17, 'tag': 'Organism'}, {'end': 55, 'start': 43, 'tag': 'BiologicallyActiveSubstance'}]"
959,The safety and efficacy of Ginkgo biloba as an adjuvant therapy in neurodegenerative diseases are subjects of ongoing clinical trials.,"[{'end': 93, 'start': 67, 'tag': 'DiseaseOrSyndrome'}, {'end': 133, 'start': 118, 'tag': 'ResearchActivity'}, {'end': 63, 'start': 47, 'tag': 'HealthCareActivity'}, {'end': 10, 'start': 4, 'tag': 'HealthCareActivity'}, {'end': 106, 'start': 98, 'tag': 'PopulationGroup'}, {'end': 23, 'start': 15, 'tag': 'Finding'}, {'end': 117, 'start': 110, 'tag': 'TemporalConcept'}, {'end': 40, 'start': 27, 'tag': 'Organism'}]"
960,Ginkgo biloba's ability to scavenge free radicals and inhibit lipid peroxidation may confer neuroprotective effects in various neurodegenerative conditions.,"[{'end': 115, 'start': 92, 'tag': 'Finding'}, {'end': 155, 'start': 127, 'tag': 'DiseaseOrSyndrome'}, {'end': 23, 'start': 16, 'tag': 'OrganismAttribute'}, {'end': 115, 'start': 108, 'tag': 'Finding'}, {'end': 49, 'start': 36, 'tag': 'Chemical'}, {'end': 49, 'start': 36, 'tag': 'BiologicallyActiveSubstance'}, {'end': 13, 'start': 0, 'tag': 'Organism'}, {'end': 80, 'start': 62, 'tag': 'CellFunction'}]"
961,Understanding the interactions between Ginkgo biloba and specific neurodegeneration-related genes sheds light on its molecular mechanisms of action.,"[{'end': 83, 'start': 66, 'tag': 'CellOrMolecularDysfunction'}, {'end': 137, 'start': 117, 'tag': 'CellFunction'}, {'end': 30, 'start': 18, 'tag': 'Finding'}, {'end': 97, 'start': 92, 'tag': 'GeneOrGenome'}, {'end': 109, 'start': 104, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 52, 'start': 39, 'tag': 'Organism'}, {'end': 13, 'start': 0, 'tag': 'BiologicFunction'}]"
962,Comprehensive meta-analyses of Ginkgo biloba clinical trials are valuable in evaluating its overall efficacy in mitigating neurodegenerative disease progression.,"[{'end': 60, 'start': 45, 'tag': 'ResearchActivity'}, {'end': 160, 'start': 141, 'tag': 'PathologicFunction'}, {'end': 148, 'start': 123, 'tag': 'DiseaseOrSyndrome'}, {'end': 27, 'start': 14, 'tag': 'ResearchActivity'}, {'end': 108, 'start': 100, 'tag': 'Finding'}, {'end': 44, 'start': 31, 'tag': 'Organism'}]"
963,The use of modified Herpes Simplex Virus for neural circuit tracing provides valuable information about the connectivity changes occurring in neurodegeneration.,"[{'end': 159, 'start': 142, 'tag': 'CellOrMolecularDysfunction'}, {'end': 120, 'start': 108, 'tag': 'BiologicFunction'}, {'end': 40, 'start': 20, 'tag': 'Virus'}, {'end': 26, 'start': 20, 'tag': 'Virus'}, {'end': 59, 'start': 45, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 128, 'start': 121, 'tag': 'Finding'}]"
964,"Saccharomyces cerevisiae, a model organism in biology, plays a pivotal role in studying cellular processes relevant to neurodegenerative disease pathogenesis.","[{'end': 144, 'start': 119, 'tag': 'DiseaseOrSyndrome'}, {'end': 157, 'start': 145, 'tag': 'PathologicFunction'}, {'end': 53, 'start': 46, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 53, 'start': 46, 'tag': 'BiologicFunction'}, {'end': 106, 'start': 88, 'tag': 'CellFunction'}, {'end': 42, 'start': 28, 'tag': 'ResearchActivity'}, {'end': 24, 'start': 0, 'tag': 'Organism'}]"
965,The potential of Saccharomyces cerevisiae as a biotechnological platform for the production of therapeutic proteins for neurodegenerative diseases is under investigation.,"[{'end': 146, 'start': 120, 'tag': 'DiseaseOrSyndrome'}, {'end': 169, 'start': 156, 'tag': 'ResearchActivity'}, {'end': 115, 'start': 107, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 41, 'start': 17, 'tag': 'Organism'}, {'end': 72, 'start': 47, 'tag': 'ResearchActivity'}]"
966,The use of Saccharomyces cerevisiae-derived nanoparticles for targeted drug delivery in the brain holds promise for neurodegenerative disease treatment.,"[{'end': 97, 'start': 92, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 141, 'start': 116, 'tag': 'DiseaseOrSyndrome'}, {'end': 84, 'start': 71, 'tag': 'HealthCareActivity'}, {'end': 84, 'start': 71, 'tag': 'ManufacturedObject'}, {'end': 151, 'start': 134, 'tag': 'HealthCareActivity'}, {'end': 35, 'start': 11, 'tag': 'Organism'}, {'end': 57, 'start': 44, 'tag': 'Chemical'}]"
967,Understanding the genetic and molecular factors that influence protein misfolding and aggregation in Saccharomyces cerevisiae provides insights into neurodegeneration mechanisms.,"[{'end': 166, 'start': 149, 'tag': 'CellOrMolecularDysfunction'}, {'end': 81, 'start': 63, 'tag': 'CellOrMolecularDysfunction'}, {'end': 13, 'start': 0, 'tag': 'BiologicFunction'}, {'end': 125, 'start': 101, 'tag': 'Organism'}, {'end': 47, 'start': 18, 'tag': 'Finding'}]"
968,Saccharomyces cerevisiae-based screening platforms have facilitated the identification of potential drug candidates for neurodegenerative diseases.,"[{'end': 146, 'start': 120, 'tag': 'DiseaseOrSyndrome'}, {'end': 104, 'start': 100, 'tag': 'PharmacologicSubstance'}, {'end': 24, 'start': 0, 'tag': 'Organism'}, {'end': 50, 'start': 31, 'tag': 'ResearchActivity'}]"
969,Saccharomyces cerevisiae's role in studying the interplay between mitochondrial dysfunction and neurodegeneration is critical for understanding disease pathogenesis.,"[{'end': 113, 'start': 96, 'tag': 'CellOrMolecularDysfunction'}, {'end': 164, 'start': 144, 'tag': 'PathologicFunction'}, {'end': 143, 'start': 130, 'tag': 'BiologicFunction'}, {'end': 57, 'start': 48, 'tag': 'Finding'}, {'end': 91, 'start': 66, 'tag': 'CellOrMolecularDysfunction'}, {'end': 125, 'start': 117, 'tag': 'Finding'}, {'end': 24, 'start': 0, 'tag': 'Organism'}]"
970,The potential of Saccharomyces cerevisiae as a probiotic agent in modulating gut-brain axis communication may have implications for neurodegenerative diseases.,"[{'end': 158, 'start': 132, 'tag': 'DiseaseOrSyndrome'}, {'end': 91, 'start': 77, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 56, 'start': 47, 'tag': 'Bacterium'}, {'end': 41, 'start': 17, 'tag': 'Organism'}, {'end': 62, 'start': 57, 'tag': 'PharmacologicSubstance'}]"
971,Harnessing the power of Saccharomyces cerevisiae genetics enables the development of tailored therapies for individuals with specific neurodegeneration-related genetic variants.,"[{'end': 57, 'start': 49, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 103, 'start': 94, 'tag': 'HealthCareActivity'}, {'end': 151, 'start': 134, 'tag': 'CellOrMolecularDysfunction'}, {'end': 119, 'start': 108, 'tag': 'PopulationGroup'}, {'end': 48, 'start': 24, 'tag': 'Organism'}, {'end': 57, 'start': 49, 'tag': 'BiologicFunction'}, {'end': 176, 'start': 160, 'tag': 'GeneOrGenome'}]"
972,The application of Saccharomyces cerevisiae in understanding prion-like protein propagation provides insights into the pathology of neurodegenerative conditions.,"[{'end': 128, 'start': 119, 'tag': 'PathologicFunction'}, {'end': 128, 'start': 119, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 60, 'start': 47, 'tag': 'BiologicFunction'}, {'end': 160, 'start': 132, 'tag': 'DiseaseOrSyndrome'}, {'end': 91, 'start': 80, 'tag': 'Finding'}, {'end': 66, 'start': 61, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 79, 'start': 72, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 43, 'start': 19, 'tag': 'Organism'}]"
973,Saccharomyces cerevisiae-based systems biology approaches contribute to unraveling the complex molecular networks involved in neurodegenerative disease development.,"[{'end': 151, 'start': 126, 'tag': 'DiseaseOrSyndrome'}, {'end': 46, 'start': 31, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 113, 'start': 95, 'tag': 'CellFunction'}, {'end': 24, 'start': 0, 'tag': 'Organism'}, {'end': 57, 'start': 31, 'tag': 'ResearchActivity'}]"
974,"Herpes Simplex Virus-induced autophagy modulation presents a double-edged sword, influencing disease progression in neurodegenerative conditions.","[{'end': 112, 'start': 93, 'tag': 'PathologicFunction'}, {'end': 144, 'start': 116, 'tag': 'DiseaseOrSyndrome'}, {'end': 38, 'start': 29, 'tag': 'CellFunction'}, {'end': 20, 'start': 0, 'tag': 'Virus'}, {'end': 6, 'start': 0, 'tag': 'Virus'}, {'end': 79, 'start': 61, 'tag': 'Finding'}]"
975,"Yeast, including Saccharomyces cerevisiae, has been utilized as a valuable model organism in unraveling the molecular basis of neurodegenerative diseases.","[{'end': 153, 'start': 127, 'tag': 'DiseaseOrSyndrome'}, {'end': 89, 'start': 75, 'tag': 'ResearchActivity'}, {'end': 41, 'start': 17, 'tag': 'Organism'}, {'end': 5, 'start': 0, 'tag': 'Organism'}]"
976,The potential of yeast-based cell culture models to assess neurotoxicity and screen for potential therapeutic compounds is a valuable asset in neurodegeneration research.,"[{'end': 160, 'start': 143, 'tag': 'CellOrMolecularDysfunction'}, {'end': 169, 'start': 161, 'tag': 'ResearchActivity'}, {'end': 33, 'start': 29, 'tag': 'Cell'}, {'end': 72, 'start': 59, 'tag': 'InjuryOrPoisoning'}, {'end': 22, 'start': 17, 'tag': 'Organism'}, {'end': 48, 'start': 29, 'tag': 'ResearchActivity'}, {'end': 119, 'start': 98, 'tag': 'PharmacologicSubstance'}]"
977,Yeast-derived proteins and peptides show promise as potential neuroprotective agents in mitigating oxidative stress and neuroinflammation in neurodegenerative conditions.,"[{'end': 77, 'start': 62, 'tag': 'CellFunction'}, {'end': 22, 'start': 14, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 137, 'start': 120, 'tag': 'PathologicFunction'}, {'end': 169, 'start': 141, 'tag': 'DiseaseOrSyndrome'}, {'end': 115, 'start': 99, 'tag': 'CellOrMolecularDysfunction'}, {'end': 84, 'start': 62, 'tag': 'PharmacologicSubstance'}, {'end': 35, 'start': 27, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 84, 'start': 78, 'tag': 'Chemical'}, {'end': 5, 'start': 0, 'tag': 'Organism'}]"
978,Yeast-based high-throughput screening has facilitated the discovery of novel small molecules with therapeutic potential for neurodegenerative diseases.,"[{'end': 150, 'start': 124, 'tag': 'DiseaseOrSyndrome'}, {'end': 119, 'start': 98, 'tag': 'Finding'}, {'end': 67, 'start': 58, 'tag': 'ResearchActivity'}, {'end': 37, 'start': 12, 'tag': 'ResearchActivity'}, {'end': 92, 'start': 77, 'tag': 'Chemical'}, {'end': 5, 'start': 0, 'tag': 'Organism'}]"
979,Understanding the cellular response of yeast to protein misfolding and aggregation provides valuable insights into protein quality control mechanisms relevant to neurodegeneration.,"[{'end': 179, 'start': 162, 'tag': 'CellOrMolecularDysfunction'}, {'end': 66, 'start': 48, 'tag': 'CellOrMolecularDysfunction'}, {'end': 122, 'start': 115, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 44, 'start': 39, 'tag': 'Organism'}, {'end': 35, 'start': 18, 'tag': 'CellFunction'}, {'end': 13, 'start': 0, 'tag': 'BiologicFunction'}, {'end': 149, 'start': 115, 'tag': 'CellFunction'}]"
980,The use of yeast-based synthetic biology platforms enables the design and optimization of customized therapeutic approaches for neurodegenerative disorders.,"[{'end': 155, 'start': 128, 'tag': 'DiseaseOrSyndrome'}, {'end': 69, 'start': 63, 'tag': 'ResearchActivity'}, {'end': 69, 'start': 63, 'tag': 'HealthCareActivity'}, {'end': 123, 'start': 101, 'tag': 'HealthCareActivity'}, {'end': 16, 'start': 11, 'tag': 'Organism'}, {'end': 50, 'start': 23, 'tag': 'ResearchActivity'}]"
981,Yeast-based assays have contributed to the identification of potential modifiers of disease-associated genes relevant to neurodegeneration.,"[{'end': 138, 'start': 121, 'tag': 'CellOrMolecularDysfunction'}, {'end': 18, 'start': 12, 'tag': 'ResearchActivity'}, {'end': 108, 'start': 84, 'tag': 'GeneOrGenome'}, {'end': 5, 'start': 0, 'tag': 'Organism'}]"
982,Yeast-based genetic interactions analysis sheds light on the functional relationships between genes involved in neurodegenerative disease pathways.,"[{'end': 41, 'start': 12, 'tag': 'ResearchActivity'}, {'end': 137, 'start': 112, 'tag': 'DiseaseOrSyndrome'}, {'end': 146, 'start': 138, 'tag': 'CellFunction'}, {'end': 85, 'start': 72, 'tag': 'Finding'}, {'end': 99, 'start': 94, 'tag': 'GeneOrGenome'}, {'end': 53, 'start': 48, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 5, 'start': 0, 'tag': 'Organism'}]"
983,The potential of yeast-based bioinformatics tools in analyzing neurodegenerative disease-related omics data holds promise for identifying disease biomarkers and therapeutic targets.,"[{'end': 156, 'start': 146, 'tag': 'ClinicalAttribute'}, {'end': 88, 'start': 63, 'tag': 'DiseaseOrSyndrome'}, {'end': 180, 'start': 161, 'tag': 'ResearchActivity'}, {'end': 22, 'start': 17, 'tag': 'Organism'}, {'end': 107, 'start': 97, 'tag': 'ResearchActivity'}, {'end': 43, 'start': 29, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 49, 'start': 29, 'tag': 'ResearchActivity'}]"
984,Yeast-based systems biology approaches have provided a holistic understanding of the complex regulatory networks involved in neurodegeneration.,"[{'end': 142, 'start': 125, 'tag': 'CellOrMolecularDysfunction'}, {'end': 27, 'start': 12, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 77, 'start': 64, 'tag': 'BiologicFunction'}, {'end': 27, 'start': 20, 'tag': 'BiologicFunction'}, {'end': 112, 'start': 93, 'tag': 'CellFunction'}, {'end': 5, 'start': 0, 'tag': 'Organism'}, {'end': 38, 'start': 12, 'tag': 'ResearchActivity'}]"
985,"Herpes Simplex Virus amplicon vectors show promise as non-integrating tools for stable, long-term expression of therapeutic genes in neurodegenerative diseases.","[{'end': 159, 'start': 133, 'tag': 'DiseaseOrSyndrome'}, {'end': 108, 'start': 98, 'tag': 'CellFunction'}, {'end': 37, 'start': 30, 'tag': 'NucleicAcidNucleosideOrNucleotide'}, {'end': 97, 'start': 88, 'tag': 'TemporalConcept'}, {'end': 129, 'start': 112, 'tag': 'GeneOrGenome'}, {'end': 6, 'start': 0, 'tag': 'Virus'}, {'end': 20, 'start': 0, 'tag': 'Virus'}, {'end': 75, 'start': 54, 'tag': 'ResearchActivity'}]"
986,"Ramularia infection has been linked to neurological symptoms and cognitive impairments, raising questions about its potential role in neurodegenerative processes.","[{'end': 19, 'start': 10, 'tag': 'PathologicFunction'}, {'end': 161, 'start': 134, 'tag': 'DiseaseOrSyndrome'}, {'end': 86, 'start': 65, 'tag': 'DiseaseOrSyndrome'}, {'end': 60, 'start': 39, 'tag': 'SignOrSymptom'}, {'end': 9, 'start': 0, 'tag': 'Organism'}]"
987,Investigating the mechanisms by which Ramularia toxins affect neuronal function provides insights into their potential neurotoxic effects.,"[{'end': 137, 'start': 119, 'tag': 'InjuryOrPoisoning'}, {'end': 79, 'start': 62, 'tag': 'CellFunction'}, {'end': 47, 'start': 38, 'tag': 'Organism'}, {'end': 54, 'start': 48, 'tag': 'InjuryOrPoisoning'}]"
988,The potential of Ramularia-derived secondary metabolites in promoting oxidative stress and inflammation in the brain is a focus of research in neurodegeneration.,"[{'end': 116, 'start': 111, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 160, 'start': 143, 'tag': 'CellOrMolecularDysfunction'}, {'end': 139, 'start': 131, 'tag': 'ResearchActivity'}, {'end': 103, 'start': 91, 'tag': 'PathologicFunction'}, {'end': 86, 'start': 70, 'tag': 'CellOrMolecularDysfunction'}, {'end': 56, 'start': 45, 'tag': 'BiologicallyActiveSubstance'}, {'end': 26, 'start': 17, 'tag': 'Organism'}]"
989,Ramularia-induced alterations in gut microbiota composition may impact brain health and neurodegenerative disease susceptibility.,"[{'end': 76, 'start': 71, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 113, 'start': 88, 'tag': 'DiseaseOrSyndrome'}, {'end': 83, 'start': 77, 'tag': 'HealthCareActivity'}, {'end': 47, 'start': 33, 'tag': 'Organism'}, {'end': 36, 'start': 33, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 29, 'start': 18, 'tag': 'Finding'}, {'end': 9, 'start': 0, 'tag': 'Organism'}, {'end': 128, 'start': 114, 'tag': 'Finding'}]"
990,Understanding the interactions between Ramularia and the immune system in the central nervous system is critical for elucidating its potential impact on neurodegeneration.,"[{'end': 170, 'start': 153, 'tag': 'CellOrMolecularDysfunction'}, {'end': 100, 'start': 78, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 70, 'start': 57, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 30, 'start': 18, 'tag': 'Finding'}, {'end': 13, 'start': 0, 'tag': 'BiologicFunction'}, {'end': 112, 'start': 104, 'tag': 'Finding'}, {'end': 48, 'start': 39, 'tag': 'Organism'}]"
991,The role of Ramularia-derived proteins in modulating neuronal signaling pathways warrants investigation in the context of neurodegenerative diseases.,"[{'end': 148, 'start': 122, 'tag': 'DiseaseOrSyndrome'}, {'end': 103, 'start': 90, 'tag': 'ResearchActivity'}, {'end': 61, 'start': 53, 'tag': 'Cell'}, {'end': 38, 'start': 30, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 80, 'start': 62, 'tag': 'CellFunction'}, {'end': 21, 'start': 12, 'tag': 'Organism'}]"
992,The potential of Ramularia infection in promoting the aggregation of disease-related proteins in the brain is of interest in neurodegeneration research.,"[{'end': 106, 'start': 101, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 142, 'start': 125, 'tag': 'CellOrMolecularDysfunction'}, {'end': 93, 'start': 85, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 151, 'start': 143, 'tag': 'ResearchActivity'}, {'end': 36, 'start': 27, 'tag': 'PathologicFunction'}, {'end': 26, 'start': 17, 'tag': 'Organism'}, {'end': 93, 'start': 54, 'tag': 'PathologicFunction'}]"
993,Ramularia-induced neuroinflammation may contribute to the chronic inflammatory environment observed in neurodegenerative conditions.,"[{'end': 35, 'start': 18, 'tag': 'PathologicFunction'}, {'end': 131, 'start': 103, 'tag': 'DiseaseOrSyndrome'}, {'end': 65, 'start': 58, 'tag': 'TemporalConcept'}, {'end': 90, 'start': 66, 'tag': 'Finding'}, {'end': 9, 'start': 0, 'tag': 'Organism'}]"
994,Assessing the potential of Ramularia as a zoonotic pathogen with implications for neurodegeneration requires further exploration.,"[{'end': 99, 'start': 82, 'tag': 'CellOrMolecularDysfunction'}, {'end': 59, 'start': 42, 'tag': 'Organism'}, {'end': 36, 'start': 27, 'tag': 'Organism'}]"
995,Epidemiological studies investigating the association between Ramularia exposure and neurodegenerative diseases are essential for understanding its clinical significance.,"[{'end': 111, 'start': 85, 'tag': 'DiseaseOrSyndrome'}, {'end': 23, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 143, 'start': 130, 'tag': 'BiologicFunction'}, {'end': 80, 'start': 62, 'tag': 'InjuryOrPoisoning'}, {'end': 169, 'start': 157, 'tag': 'Finding'}, {'end': 71, 'start': 62, 'tag': 'Organism'}]"
996,Exploring the potential of Herpes Simplex Virus glycoprotein-mediated neuronal targeting for delivering neuroprotective agents is a current focus in neurodegeneration research.,"[{'end': 166, 'start': 149, 'tag': 'CellOrMolecularDysfunction'}, {'end': 78, 'start': 70, 'tag': 'Cell'}, {'end': 175, 'start': 167, 'tag': 'ResearchActivity'}, {'end': 126, 'start': 104, 'tag': 'PharmacologicSubstance'}, {'end': 60, 'start': 48, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 60, 'start': 48, 'tag': 'BiologicallyActiveSubstance'}, {'end': 126, 'start': 120, 'tag': 'Chemical'}, {'end': 47, 'start': 27, 'tag': 'Virus'}, {'end': 33, 'start': 27, 'tag': 'Virus'}]"
997,"Microbial dysbiosis, involving alterations in the gut microbiota composition, has been associated with an increased risk of neurodegenerative diseases.","[{'end': 150, 'start': 124, 'tag': 'DiseaseOrSyndrome'}, {'end': 64, 'start': 50, 'tag': 'Organism'}, {'end': 53, 'start': 50, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 120, 'start': 106, 'tag': 'Finding'}, {'end': 42, 'start': 31, 'tag': 'Finding'}, {'end': 9, 'start': 0, 'tag': 'Organism'}, {'end': 19, 'start': 10, 'tag': 'PathologicFunction'}]"
998,The potential of microbial-derived metabolites in modulating host brain function is an emerging area of research in neurodegeneration.,"[{'end': 133, 'start': 116, 'tag': 'CellOrMolecularDysfunction'}, {'end': 65, 'start': 61, 'tag': 'Organism'}, {'end': 112, 'start': 104, 'tag': 'ResearchActivity'}, {'end': 80, 'start': 66, 'tag': 'BiologicFunction'}, {'end': 46, 'start': 35, 'tag': 'BiologicallyActiveSubstance'}, {'end': 26, 'start': 17, 'tag': 'Organism'}]"
999,Understanding the impact of microbial infections on the activation of host immune responses in the brain is crucial for understanding neurodegenerative disease pathogenesis.,"[{'end': 104, 'start': 99, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 159, 'start': 134, 'tag': 'DiseaseOrSyndrome'}, {'end': 172, 'start': 160, 'tag': 'PathologicFunction'}, {'end': 133, 'start': 120, 'tag': 'BiologicFunction'}, {'end': 74, 'start': 70, 'tag': 'Organism'}, {'end': 91, 'start': 75, 'tag': 'BiologicFunction'}, {'end': 13, 'start': 0, 'tag': 'BiologicFunction'}, {'end': 37, 'start': 28, 'tag': 'Organism'}, {'end': 48, 'start': 38, 'tag': 'PathologicFunction'}]"
1000,Microbial-derived extracellular vesicles may serve as vehicles for transmitting neurodegeneration-related proteins and nucleic acids in the brain.,"[{'end': 145, 'start': 140, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 97, 'start': 80, 'tag': 'CellOrMolecularDysfunction'}, {'end': 40, 'start': 18, 'tag': 'CellComponent'}, {'end': 114, 'start': 106, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 132, 'start': 119, 'tag': 'NucleicAcidNucleosideOrNucleotide'}, {'end': 9, 'start': 0, 'tag': 'Organism'}, {'end': 62, 'start': 54, 'tag': 'Substance'}, {'end': 62, 'start': 54, 'tag': 'ManufacturedObject'}]"
1001,Investigating the interactions between microbial pathogens and host genetic factors provides insights into individual susceptibility to neurodegenerative diseases.,"[{'end': 162, 'start': 136, 'tag': 'DiseaseOrSyndrome'}, {'end': 67, 'start': 63, 'tag': 'Organism'}, {'end': 30, 'start': 18, 'tag': 'Finding'}, {'end': 83, 'start': 68, 'tag': 'Finding'}, {'end': 48, 'start': 39, 'tag': 'Organism'}, {'end': 58, 'start': 39, 'tag': 'Organism'}, {'end': 132, 'start': 107, 'tag': 'Finding'}, {'end': 13, 'start': 0, 'tag': 'ResearchActivity'}]"
1002,"Microbial-mediated alterations in blood-brain barrier integrity may facilitate the entry of neurotoxic agents, contributing to neurodegeneration.","[{'end': 144, 'start': 127, 'tag': 'CellOrMolecularDysfunction'}, {'end': 53, 'start': 34, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 63, 'start': 54, 'tag': 'IndividualBehavior'}, {'end': 30, 'start': 19, 'tag': 'Finding'}, {'end': 9, 'start': 0, 'tag': 'Organism'}, {'end': 109, 'start': 92, 'tag': 'InjuryOrPoisoning'}, {'end': 63, 'start': 54, 'tag': 'Finding'}]"
1003,Microbial immune evasion strategies may influence the chronic inflammatory environment observed in neurodegenerative conditions.,"[{'end': 127, 'start': 99, 'tag': 'DiseaseOrSyndrome'}, {'end': 61, 'start': 54, 'tag': 'TemporalConcept'}, {'end': 35, 'start': 25, 'tag': 'ResearchActivity'}, {'end': 35, 'start': 25, 'tag': 'BiologicFunction'}, {'end': 86, 'start': 62, 'tag': 'Finding'}, {'end': 74, 'start': 62, 'tag': 'PathologicFunction'}, {'end': 9, 'start': 0, 'tag': 'Organism'}, {'end': 24, 'start': 10, 'tag': 'BiologicFunction'}]"
1004,The potential of microbial enzymes in modulating protein aggregation and neurotoxicity is a focus of research in neurodegeneration.,"[{'end': 130, 'start': 113, 'tag': 'CellOrMolecularDysfunction'}, {'end': 109, 'start': 101, 'tag': 'ResearchActivity'}, {'end': 86, 'start': 73, 'tag': 'InjuryOrPoisoning'}, {'end': 68, 'start': 49, 'tag': 'CellFunction'}, {'end': 68, 'start': 49, 'tag': 'CellOrMolecularDysfunction'}, {'end': 34, 'start': 27, 'tag': 'BiologicallyActiveSubstance'}, {'end': 26, 'start': 17, 'tag': 'Organism'}]"
1005,Comprehensive metagenomic studies examining the microbial composition in neurodegenerative diseases provide valuable insights into disease-associated changes.,"[{'end': 99, 'start': 73, 'tag': 'DiseaseOrSyndrome'}, {'end': 57, 'start': 48, 'tag': 'Organism'}, {'end': 33, 'start': 0, 'tag': 'ResearchActivity'}]"
1006,Targeting microbial dysbiosis through probiotic and prebiotic interventions presents an exciting avenue for potential neuroprotective strategies in neurodegenerative disorders.,"[{'end': 175, 'start': 148, 'tag': 'DiseaseOrSyndrome'}, {'end': 133, 'start': 118, 'tag': 'CellFunction'}, {'end': 144, 'start': 134, 'tag': 'ResearchActivity'}, {'end': 144, 'start': 134, 'tag': 'BiologicFunction'}, {'end': 75, 'start': 53, 'tag': 'HealthCareActivity'}, {'end': 19, 'start': 10, 'tag': 'Organism'}, {'end': 29, 'start': 20, 'tag': 'PathologicFunction'}, {'end': 47, 'start': 38, 'tag': 'Bacterium'}]"
1007,Herpes Simplex Virus-based vaccine strategies hold potential in mitigating neuroinflammatory responses associated with neurodegenerative disorders.,"[{'end': 146, 'start': 119, 'tag': 'DiseaseOrSyndrome'}, {'end': 92, 'start': 75, 'tag': 'PathologicFunction'}, {'end': 102, 'start': 93, 'tag': 'Finding'}, {'end': 20, 'start': 0, 'tag': 'Virus'}, {'end': 6, 'start': 0, 'tag': 'Virus'}, {'end': 45, 'start': 27, 'tag': 'HealthCareActivity'}]"
1008,The neural tube is a hollow structure that forms early in embryonic development and gives rise to the brain and spinal cord.,"[{'end': 107, 'start': 102, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 123, 'start': 112, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 54, 'start': 49, 'tag': 'TemporalConcept'}, {'end': 79, 'start': 58, 'tag': 'BiologicFunction'}, {'end': 15, 'start': 4, 'tag': 'EmbryonicStructure'}]"
1009,"Closure of the neural tube is a critical process that occurs during early neurulation, ensuring proper formation of the central nervous system.","[{'end': 142, 'start': 120, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 73, 'start': 68, 'tag': 'TemporalConcept'}, {'end': 26, 'start': 15, 'tag': 'EmbryonicStructure'}, {'end': 48, 'start': 32, 'tag': 'Finding'}, {'end': 26, 'start': 0, 'tag': 'BiologicFunction'}, {'end': 85, 'start': 74, 'tag': 'BiologicFunction'}]"
1010,"Defects in neural tube closure can lead to severe congenital malformations known as neural tube defects, such as spina bifida and anencephaly.","[{'end': 49, 'start': 43, 'tag': 'Finding'}, {'end': 22, 'start': 11, 'tag': 'EmbryonicStructure'}, {'end': 95, 'start': 84, 'tag': 'EmbryonicStructure'}, {'end': 74, 'start': 43, 'tag': 'AnatomicalAbnormality'}, {'end': 30, 'start': 0, 'tag': 'PathologicFunction'}, {'end': 103, 'start': 84, 'tag': 'AnatomicalAbnormality'}, {'end': 125, 'start': 113, 'tag': 'AnatomicalAbnormality'}, {'end': 141, 'start': 130, 'tag': 'AnatomicalAbnormality'}]"
1011,"The neural tube is comprised of neuroepithelial cells that differentiate into various neural progenitor cells, laying the foundation for the nervous system's complex organization.","[{'end': 53, 'start': 32, 'tag': 'Cell'}, {'end': 155, 'start': 141, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 72, 'start': 59, 'tag': 'CellFunction'}, {'end': 109, 'start': 86, 'tag': 'Cell'}, {'end': 15, 'start': 4, 'tag': 'EmbryonicStructure'}]"
1012,The development of the neural tube involves a series of highly coordinated molecular signaling pathways that guide the formation of distinct neural regions.,"[{'end': 103, 'start': 75, 'tag': 'CellFunction'}, {'end': 34, 'start': 23, 'tag': 'EmbryonicStructure'}, {'end': 155, 'start': 141, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 15, 'start': 4, 'tag': 'BiologicFunction'}]"
1013,"The anterior neural tube gives rise to the forebrain, midbrain, and hindbrain, while the posterior neural tube forms the spinal cord.","[{'end': 132, 'start': 121, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 24, 'start': 4, 'tag': 'EmbryonicStructure'}, {'end': 110, 'start': 89, 'tag': 'EmbryonicStructure'}, {'end': 52, 'start': 43, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 62, 'start': 54, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 77, 'start': 68, 'tag': 'BodyPartOrganOrOrganComponent'}]"
1014,The neural tube's ventricular zone contains neural stem cells that divide and generate new neurons and glial cells throughout development.,"[{'end': 98, 'start': 91, 'tag': 'Cell'}, {'end': 114, 'start': 103, 'tag': 'Cell'}, {'end': 61, 'start': 44, 'tag': 'Cell'}, {'end': 15, 'start': 4, 'tag': 'EmbryonicStructure'}, {'end': 34, 'start': 18, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 137, 'start': 126, 'tag': 'BiologicFunction'}]"
1015,In utero screening and folic acid supplementation have been instrumental in reducing the incidence of neural tube defects and improving early detection and management.,"[{'end': 113, 'start': 102, 'tag': 'EmbryonicStructure'}, {'end': 166, 'start': 156, 'tag': 'HealthCareActivity'}, {'end': 98, 'start': 89, 'tag': 'Finding'}, {'end': 151, 'start': 136, 'tag': 'HealthCareActivity'}, {'end': 49, 'start': 23, 'tag': 'HealthCareActivity'}, {'end': 33, 'start': 23, 'tag': 'BiologicallyActiveSubstance'}, {'end': 33, 'start': 23, 'tag': 'PharmacologicSubstance'}, {'end': 18, 'start': 0, 'tag': 'HealthCareActivity'}, {'end': 121, 'start': 102, 'tag': 'AnatomicalAbnormality'}]"
1016,"The neural tube's morphogenesis is influenced by gradients of signaling molecules secreted by surrounding tissues, directing regional patterning of the brain and spinal cord.","[{'end': 157, 'start': 152, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 113, 'start': 106, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 81, 'start': 62, 'tag': 'BiologicallyActiveSubstance'}, {'end': 81, 'start': 49, 'tag': 'CellFunction'}, {'end': 173, 'start': 162, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 15, 'start': 4, 'tag': 'EmbryonicStructure'}, {'end': 144, 'start': 125, 'tag': 'BiologicFunction'}, {'end': 31, 'start': 18, 'tag': 'BiologicFunction'}]"
1017,Understanding the cellular and molecular mechanisms underlying neural tube development is essential for advancing regenerative medicine approaches in treating neurodevelopmental disorders.,"[{'end': 135, 'start': 114, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 26, 'start': 18, 'tag': 'Cell'}, {'end': 51, 'start': 31, 'tag': 'CellFunction'}, {'end': 74, 'start': 63, 'tag': 'EmbryonicStructure'}, {'end': 187, 'start': 159, 'tag': 'DiseaseOrSyndrome'}, {'end': 13, 'start': 0, 'tag': 'BiologicFunction'}, {'end': 86, 'start': 75, 'tag': 'BiologicFunction'}, {'end': 146, 'start': 114, 'tag': 'HealthCareActivity'}]"
1018,Lentiviral vectors carrying neurotrophic factors have demonstrated neuroprotective effects in preclinical models of neurodegenerative diseases.,"[{'end': 142, 'start': 116, 'tag': 'DiseaseOrSyndrome'}, {'end': 90, 'start': 67, 'tag': 'Finding'}, {'end': 18, 'start': 11, 'tag': 'NucleicAcidNucleosideOrNucleotide'}, {'end': 112, 'start': 94, 'tag': 'ResearchActivity'}, {'end': 48, 'start': 28, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 48, 'start': 28, 'tag': 'BiologicallyActiveSubstance'}, {'end': 10, 'start': 0, 'tag': 'Virus'}]"
1019,"Adeno Associated Viruses emerge as an attractive tool for delivering genome-editing technologies to specific neural cell types, opening new possibilities for neurodegenerative disease treatment.","[{'end': 183, 'start': 158, 'tag': 'DiseaseOrSyndrome'}, {'end': 126, 'start': 109, 'tag': 'Cell'}, {'end': 24, 'start': 0, 'tag': 'Virus'}, {'end': 96, 'start': 69, 'tag': 'ResearchActivity'}, {'end': 193, 'start': 184, 'tag': 'HealthCareActivity'}, {'end': 193, 'start': 184, 'tag': 'ResearchActivity'}]"
1020,"Radial glial cells, also known as radial glia, serve as essential scaffolds during brain development, guiding migrating neurons to their appropriate destinations.","[{'end': 127, 'start': 120, 'tag': 'Cell'}, {'end': 18, 'start': 7, 'tag': 'Cell'}, {'end': 45, 'start': 34, 'tag': 'EmbryonicStructure'}, {'end': 12, 'start': 7, 'tag': 'Cell'}, {'end': 100, 'start': 83, 'tag': 'BiologicFunction'}, {'end': 18, 'start': 0, 'tag': 'EmbryonicStructure'}, {'end': 12, 'start': 0, 'tag': 'EmbryonicStructure'}]"
1021,"The unique bipolar morphology of radial glial cells enables them to extend processes from the ventricular zone to the pial surface, providing a radial framework for neuronal migration.","[{'end': 51, 'start': 40, 'tag': 'Cell'}, {'end': 173, 'start': 165, 'tag': 'Cell'}, {'end': 45, 'start': 40, 'tag': 'Cell'}, {'end': 29, 'start': 11, 'tag': 'Finding'}, {'end': 183, 'start': 174, 'tag': 'CellFunction'}, {'end': 45, 'start': 33, 'tag': 'EmbryonicStructure'}, {'end': 51, 'start': 33, 'tag': 'EmbryonicStructure'}, {'end': 110, 'start': 94, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 130, 'start': 118, 'tag': 'BodyPartOrganOrOrganComponent'}]"
1022,"Radial glia play a crucial role in neurogenesis, as they not only serve as neural stem cells but also provide a niche environment that supports neuronal differentiation and migration.","[{'end': 47, 'start': 35, 'tag': 'BiologicFunction'}, {'end': 92, 'start': 75, 'tag': 'Cell'}, {'end': 182, 'start': 173, 'tag': 'CellFunction'}, {'end': 168, 'start': 144, 'tag': 'CellFunction'}, {'end': 11, 'start': 0, 'tag': 'EmbryonicStructure'}]"
1023,"The transformation of radial glial cells into astrocytes represents a key transition in brain development, marking the transition from neurogenesis to gliogenesis.","[{'end': 40, 'start': 29, 'tag': 'Cell'}, {'end': 56, 'start': 46, 'tag': 'Cell'}, {'end': 147, 'start': 135, 'tag': 'BiologicFunction'}, {'end': 34, 'start': 29, 'tag': 'Cell'}, {'end': 105, 'start': 88, 'tag': 'BiologicFunction'}, {'end': 34, 'start': 22, 'tag': 'EmbryonicStructure'}, {'end': 40, 'start': 22, 'tag': 'EmbryonicStructure'}, {'end': 162, 'start': 151, 'tag': 'BiologicFunction'}]"
1024,"Abnormalities in radial glia function have been implicated in neurodevelopmental disorders, emphasizing their significance in proper brain formation and function.","[{'end': 138, 'start': 133, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 28, 'start': 24, 'tag': 'Cell'}, {'end': 13, 'start': 0, 'tag': 'Finding'}, {'end': 90, 'start': 62, 'tag': 'DiseaseOrSyndrome'}, {'end': 122, 'start': 110, 'tag': 'Finding'}, {'end': 28, 'start': 17, 'tag': 'EmbryonicStructure'}, {'end': 161, 'start': 133, 'tag': 'BiologicFunction'}]"
1025,"Radial glial cells are characterized by the expression of specific molecular markers, such as Pax6 and Nestin, which are essential for their identity as neural progenitors.","[{'end': 84, 'start': 67, 'tag': 'ClinicalAttribute'}, {'end': 54, 'start': 44, 'tag': 'CellFunction'}, {'end': 171, 'start': 153, 'tag': 'Cell'}, {'end': 18, 'start': 0, 'tag': 'EmbryonicStructure'}, {'end': 98, 'start': 94, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 109, 'start': 103, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 109, 'start': 103, 'tag': 'BiologicallyActiveSubstance'}, {'end': 98, 'start': 94, 'tag': 'BiologicallyActiveSubstance'}, {'end': 98, 'start': 94, 'tag': 'GeneOrGenome'}]"
1026,The migration of radial glial cells to their final positions in the developing brain is regulated by complex molecular cues and signaling pathways.,"[{'end': 146, 'start': 128, 'tag': 'CellFunction'}, {'end': 13, 'start': 4, 'tag': 'CellFunction'}, {'end': 84, 'start': 68, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 35, 'start': 17, 'tag': 'EmbryonicStructure'}]"
1027,"Radial glia-mediated neurogenesis continues throughout embryonic and postnatal development, contributing to the expansion of the cerebral cortex and other brain regions.","[{'end': 144, 'start': 129, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 33, 'start': 21, 'tag': 'BiologicFunction'}, {'end': 168, 'start': 155, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 78, 'start': 69, 'tag': 'TemporalConcept'}, {'end': 11, 'start': 0, 'tag': 'EmbryonicStructure'}, {'end': 90, 'start': 79, 'tag': 'BiologicFunction'}, {'end': 64, 'start': 55, 'tag': 'BiologicFunction'}, {'end': 90, 'start': 69, 'tag': 'BiologicFunction'}, {'end': 144, 'start': 112, 'tag': 'BiologicFunction'}]"
1028,Experimental studies using transgenic animal models have provided valuable insights into the functional roles of radial glia in brain development and repair.,"[{'end': 51, 'start': 27, 'tag': 'ResearchActivity'}, {'end': 145, 'start': 128, 'tag': 'BiologicFunction'}, {'end': 124, 'start': 113, 'tag': 'EmbryonicStructure'}, {'end': 156, 'start': 150, 'tag': 'BiologicFunction'}, {'end': 133, 'start': 128, 'tag': 'BiologicFunction'}]"
1029,Emerging evidence suggests that radial glial cells may also have a role in modulating synaptic connectivity and plasticity in the mature brain.,"[{'end': 142, 'start': 137, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 17, 'start': 0, 'tag': 'Finding'}, {'end': 107, 'start': 86, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 122, 'start': 112, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 122, 'start': 112, 'tag': 'CellFunction'}, {'end': 136, 'start': 130, 'tag': 'TemporalConcept'}, {'end': 50, 'start': 32, 'tag': 'EmbryonicStructure'}]"
1030,AAV-based gene therapy targeting abnormal protein aggregation demonstrates promising results in halting disease progression in several neurodegenerative conditions.,"[{'end': 22, 'start': 10, 'tag': 'HealthCareActivity'}, {'end': 123, 'start': 104, 'tag': 'PathologicFunction'}, {'end': 163, 'start': 135, 'tag': 'DiseaseOrSyndrome'}, {'end': 14, 'start': 10, 'tag': 'GeneOrGenome'}, {'end': 61, 'start': 42, 'tag': 'CellFunction'}, {'end': 61, 'start': 42, 'tag': 'CellOrMolecularDysfunction'}, {'end': 61, 'start': 33, 'tag': 'CellOrMolecularDysfunction'}, {'end': 3, 'start': 0, 'tag': 'Virus'}]"
1031,The neural crest is a transient population of cells that arises at the border of the neural plate during early vertebrate development.,"[{'end': 51, 'start': 46, 'tag': 'Cell'}, {'end': 31, 'start': 22, 'tag': 'TemporalConcept'}, {'end': 42, 'start': 32, 'tag': 'PopulationGroup'}, {'end': 110, 'start': 105, 'tag': 'TemporalConcept'}, {'end': 16, 'start': 4, 'tag': 'EmbryonicStructure'}, {'end': 97, 'start': 85, 'tag': 'EmbryonicStructure'}, {'end': 133, 'start': 111, 'tag': 'BiologicFunction'}]"
1032,"Neural crest cells have remarkable migratory abilities, giving rise to a diverse array of cell types, including neurons, glia, melanocytes, and various components of the craniofacial skeleton.","[{'end': 100, 'start': 90, 'tag': 'Cell'}, {'end': 119, 'start': 112, 'tag': 'Cell'}, {'end': 18, 'start': 13, 'tag': 'Cell'}, {'end': 125, 'start': 121, 'tag': 'Cell'}, {'end': 12, 'start': 0, 'tag': 'EmbryonicStructure'}, {'end': 138, 'start': 127, 'tag': 'Cell'}, {'end': 191, 'start': 170, 'tag': 'BodyPartOrganOrOrganComponent'}]"
1033,"The delamination and migration of neural crest cells is regulated by a complex interplay of cell adhesion molecules, signaling pathways, and extracellular matrix interactions.","[{'end': 52, 'start': 47, 'tag': 'Cell'}, {'end': 96, 'start': 92, 'tag': 'Cell'}, {'end': 135, 'start': 117, 'tag': 'CellFunction'}, {'end': 88, 'start': 79, 'tag': 'Finding'}, {'end': 30, 'start': 21, 'tag': 'CellFunction'}, {'end': 161, 'start': 141, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 46, 'start': 34, 'tag': 'EmbryonicStructure'}, {'end': 16, 'start': 4, 'tag': 'CellFunction'}, {'end': 115, 'start': 92, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 115, 'start': 92, 'tag': 'BiologicallyActiveSubstance'}, {'end': 174, 'start': 162, 'tag': 'Finding'}]"
1034,"Defects in neural crest cell migration and differentiation can lead to a wide range of congenital malformations, such as craniofacial abnormalities and neurocristopathies.","[{'end': 38, 'start': 24, 'tag': 'CellFunction'}, {'end': 23, 'start': 11, 'tag': 'EmbryonicStructure'}, {'end': 111, 'start': 87, 'tag': 'AnatomicalAbnormality'}, {'end': 146, 'start': 121, 'tag': 'AnatomicalAbnormality'}, {'end': 170, 'start': 152, 'tag': 'AnatomicalAbnormality'}]"
1035,"The neural crest is a highly plastic and multipotent cell population, providing a valuable model for studying stem cell biology and regenerative medicine.","[{'end': 153, 'start': 132, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 127, 'start': 120, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 52, 'start': 41, 'tag': 'Cell'}, {'end': 119, 'start': 110, 'tag': 'Cell'}, {'end': 127, 'start': 120, 'tag': 'BiologicFunction'}, {'end': 68, 'start': 53, 'tag': 'Cell'}, {'end': 36, 'start': 29, 'tag': 'Substance'}, {'end': 16, 'start': 4, 'tag': 'EmbryonicStructure'}]"
1036,"Neural crest cells contribute to the development of sensory ganglia, autonomic ganglia, and Schwann cells, playing crucial roles in the peripheral nervous system.","[{'end': 18, 'start': 13, 'tag': 'Cell'}, {'end': 48, 'start': 37, 'tag': 'BiologicFunction'}, {'end': 48, 'start': 37, 'tag': 'CellFunction'}, {'end': 161, 'start': 136, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 105, 'start': 92, 'tag': 'Cell'}, {'end': 12, 'start': 0, 'tag': 'EmbryonicStructure'}, {'end': 67, 'start': 52, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 86, 'start': 69, 'tag': 'BodyPartOrganOrOrganComponent'}]"
1037,Recent research has highlighted the importance of neural crest cells in influencing brain development and function beyond their conventional roles in peripheral tissues.,"[{'end': 168, 'start': 150, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 68, 'start': 63, 'tag': 'Cell'}, {'end': 101, 'start': 84, 'tag': 'BiologicFunction'}, {'end': 62, 'start': 50, 'tag': 'EmbryonicStructure'}, {'end': 15, 'start': 7, 'tag': 'ResearchActivity'}, {'end': 6, 'start': 0, 'tag': 'TemporalConcept'}]"
1038,Understanding the molecular mechanisms that govern neural crest cell fate decisions offers insights into potential therapeutic strategies for neural crest-related disorders.,"[{'end': 38, 'start': 18, 'tag': 'CellFunction'}, {'end': 73, 'start': 64, 'tag': 'Finding'}, {'end': 137, 'start': 105, 'tag': 'HealthCareActivity'}, {'end': 63, 'start': 51, 'tag': 'EmbryonicStructure'}, {'end': 154, 'start': 142, 'tag': 'EmbryonicStructure'}, {'end': 172, 'start': 163, 'tag': 'DiseaseOrSyndrome'}, {'end': 83, 'start': 74, 'tag': 'BiologicFunction'}, {'end': 13, 'start': 0, 'tag': 'BiologicFunction'}]"
1039,The neural crest's remarkable ability to generate a diverse range of cell types has captivated researchers studying embryonic development and stem cell biology for decades.,"[{'end': 79, 'start': 69, 'tag': 'Cell'}, {'end': 159, 'start': 152, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 171, 'start': 164, 'tag': 'TemporalConcept'}, {'end': 37, 'start': 30, 'tag': 'OrganismAttribute'}, {'end': 106, 'start': 95, 'tag': 'ResearchActivity'}, {'end': 151, 'start': 142, 'tag': 'Cell'}, {'end': 159, 'start': 152, 'tag': 'BiologicFunction'}, {'end': 137, 'start': 116, 'tag': 'BiologicFunction'}, {'end': 16, 'start': 4, 'tag': 'EmbryonicStructure'}]"
1040,Investigating the genetic regulatory networks that control neural crest specification and migration is fundamental to understanding the formation of complex structures in the developing embryo.,"[{'end': 131, 'start': 118, 'tag': 'BiologicFunction'}, {'end': 192, 'start': 175, 'tag': 'EmbryonicStructure'}, {'end': 99, 'start': 90, 'tag': 'CellFunction'}, {'end': 45, 'start': 18, 'tag': 'CellFunction'}, {'end': 71, 'start': 59, 'tag': 'EmbryonicStructure'}, {'end': 58, 'start': 51, 'tag': 'PopulationGroup'}, {'end': 13, 'start': 0, 'tag': 'ResearchActivity'}]"
1041,The ability of Adeno Associated Viruses to efficiently cross the blood-brain barrier highlights their potential for systemic gene delivery in neurodegenerative disorders.,"[{'end': 169, 'start': 142, 'tag': 'DiseaseOrSyndrome'}, {'end': 138, 'start': 130, 'tag': 'BiologicFunction'}, {'end': 11, 'start': 4, 'tag': 'OrganismAttribute'}, {'end': 84, 'start': 65, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 129, 'start': 125, 'tag': 'GeneOrGenome'}, {'end': 39, 'start': 15, 'tag': 'Virus'}]"
1042,"The developmental brain undergoes a highly orchestrated series of events, including neurogenesis, migration, differentiation, and synaptogenesis, to form a functional nervous system.","[{'end': 96, 'start': 84, 'tag': 'BiologicFunction'}, {'end': 124, 'start': 109, 'tag': 'CellFunction'}, {'end': 181, 'start': 167, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 107, 'start': 98, 'tag': 'CellFunction'}, {'end': 23, 'start': 4, 'tag': 'EmbryonicStructure'}, {'end': 144, 'start': 130, 'tag': 'BiologicFunction'}]"
1043,"During the developmental brain's early stages, neural progenitor cells divide and produce a vast array of neuronal subtypes, establishing the fundamental architecture of the brain.","[{'end': 179, 'start': 174, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 45, 'start': 33, 'tag': 'TemporalConcept'}, {'end': 70, 'start': 47, 'tag': 'Cell'}, {'end': 30, 'start': 11, 'tag': 'EmbryonicStructure'}, {'end': 123, 'start': 106, 'tag': 'Cell'}]"
1044,"The developmental brain is particularly sensitive to genetic and environmental influences, making it susceptible to disruption and potential neurodevelopmental disorders.","[{'end': 49, 'start': 40, 'tag': 'PathologicFunction'}, {'end': 126, 'start': 116, 'tag': 'InjuryOrPoisoning'}, {'end': 169, 'start': 141, 'tag': 'DiseaseOrSyndrome'}, {'end': 23, 'start': 4, 'tag': 'EmbryonicStructure'}, {'end': 89, 'start': 65, 'tag': 'Finding'}]"
1045,"Proper neuronal migration is crucial in shaping the developmental brain's cytoarchitecture, ensuring precise connectivity between different brain regions.","[{'end': 15, 'start': 7, 'tag': 'Cell'}, {'end': 25, 'start': 16, 'tag': 'CellFunction'}, {'end': 153, 'start': 140, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 121, 'start': 109, 'tag': 'BiologicFunction'}, {'end': 71, 'start': 52, 'tag': 'EmbryonicStructure'}]"
1046,The establishment of neural circuits and synapses during the developmental brain's critical periods contributes to sensory and cognitive development.,"[{'end': 80, 'start': 75, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 49, 'start': 41, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 99, 'start': 83, 'tag': 'TemporalConcept'}, {'end': 36, 'start': 21, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 80, 'start': 61, 'tag': 'EmbryonicStructure'}, {'end': 148, 'start': 115, 'tag': 'BiologicFunction'}]"
1047,"Abnormalities during the developmental brain's early stages have been implicated in neurodevelopmental disorders, such as autism spectrum disorder and intellectual disabilities.","[{'end': 59, 'start': 47, 'tag': 'TemporalConcept'}, {'end': 13, 'start': 0, 'tag': 'Finding'}, {'end': 44, 'start': 25, 'tag': 'EmbryonicStructure'}, {'end': 112, 'start': 84, 'tag': 'DiseaseOrSyndrome'}, {'end': 146, 'start': 122, 'tag': 'DiseaseOrSyndrome'}, {'end': 176, 'start': 151, 'tag': 'DiseaseOrSyndrome'}]"
1048,"The developmental brain's plasticity allows it to adapt and reorganize in response to experience, facilitating learning and memory processes.","[{'end': 96, 'start': 86, 'tag': 'BiologicFunction'}, {'end': 130, 'start': 111, 'tag': 'BiologicFunction'}, {'end': 36, 'start': 26, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 36, 'start': 26, 'tag': 'CellFunction'}, {'end': 23, 'start': 4, 'tag': 'EmbryonicStructure'}]"
1049,Investigating the molecular and cellular mechanisms underlying the developmental brain's formation is essential for understanding normal brain development and related pathologies.,"[{'end': 129, 'start': 116, 'tag': 'BiologicFunction'}, {'end': 136, 'start': 130, 'tag': 'Finding'}, {'end': 178, 'start': 167, 'tag': 'DiseaseOrSyndrome'}, {'end': 154, 'start': 137, 'tag': 'BiologicFunction'}, {'end': 51, 'start': 18, 'tag': 'CellFunction'}, {'end': 86, 'start': 67, 'tag': 'EmbryonicStructure'}]"
1050,The study of animal models and human brain development has led to significant advances in our understanding of the complexities of the developmental brain.,"[{'end': 9, 'start': 4, 'tag': 'ResearchActivity'}, {'end': 36, 'start': 31, 'tag': 'Eukaryote'}, {'end': 86, 'start': 78, 'tag': 'Finding'}, {'end': 107, 'start': 94, 'tag': 'BiologicFunction'}, {'end': 26, 'start': 13, 'tag': 'ResearchActivity'}, {'end': 54, 'start': 37, 'tag': 'BiologicFunction'}, {'end': 154, 'start': 135, 'tag': 'EmbryonicStructure'}]"
1051,The developmental brain's intricate regulatory networks provide a foundation for exploring potential therapeutic interventions to address neurodevelopmental disorders and promote healthy brain function.,"[{'end': 186, 'start': 179, 'tag': 'OrganismAttribute'}, {'end': 201, 'start': 187, 'tag': 'BiologicFunction'}, {'end': 55, 'start': 36, 'tag': 'CellFunction'}, {'end': 126, 'start': 101, 'tag': 'HealthCareActivity'}, {'end': 166, 'start': 138, 'tag': 'DiseaseOrSyndrome'}, {'end': 23, 'start': 4, 'tag': 'EmbryonicStructure'}]"
1052,"Comparative studies of various AAV serotypes shed light on their transduction efficiency and tropism in different brain regions, aiding targeted therapeutic development.","[{'end': 127, 'start': 114, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 88, 'start': 78, 'tag': 'Finding'}, {'end': 55, 'start': 50, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 168, 'start': 136, 'tag': 'ResearchActivity'}, {'end': 34, 'start': 31, 'tag': 'Virus'}, {'end': 19, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 100, 'start': 93, 'tag': 'BiologicFunction'}, {'end': 77, 'start': 65, 'tag': 'BiologicFunction'}]"
1053,Exploiting the inherent neurotropic properties of Adeno Associated Viruses enables their use as non-invasive agents for gene delivery in neurodegenerative diseases.,"[{'end': 163, 'start': 137, 'tag': 'DiseaseOrSyndrome'}, {'end': 133, 'start': 125, 'tag': 'BiologicFunction'}, {'end': 108, 'start': 96, 'tag': 'Finding'}, {'end': 124, 'start': 120, 'tag': 'GeneOrGenome'}, {'end': 115, 'start': 109, 'tag': 'Chemical'}, {'end': 74, 'start': 50, 'tag': 'Virus'}]"
1054,AAV-mediated RNA-based therapeutics offer a versatile platform for targeting diverse neurodegeneration-related pathways with high specificity.,"[{'end': 102, 'start': 85, 'tag': 'CellOrMolecularDysfunction'}, {'end': 141, 'start': 130, 'tag': 'Finding'}, {'end': 119, 'start': 111, 'tag': 'CellFunction'}, {'end': 16, 'start': 13, 'tag': 'NucleicAcidNucleosideOrNucleotide'}, {'end': 35, 'start': 23, 'tag': 'HealthCareActivity'}, {'end': 129, 'start': 125, 'tag': 'Finding'}, {'end': 3, 'start': 0, 'tag': 'Virus'}]"
1055,The immunogenicity profile of AAV vectors is a crucial consideration in designing safe and effective gene therapies for neurodegenerative disorders.,"[{'end': 147, 'start': 120, 'tag': 'DiseaseOrSyndrome'}, {'end': 41, 'start': 34, 'tag': 'NucleicAcidNucleosideOrNucleotide'}, {'end': 18, 'start': 4, 'tag': 'ResearchActivity'}, {'end': 26, 'start': 19, 'tag': 'ResearchActivity'}, {'end': 115, 'start': 101, 'tag': 'HealthCareActivity'}, {'end': 33, 'start': 30, 'tag': 'Virus'}]"
1056,Investigating the potential of AAV-encoded microRNAs in modulating disease-associated gene expression presents exciting opportunities for precision medicine in neurodegeneration.,"[{'end': 177, 'start': 160, 'tag': 'CellOrMolecularDysfunction'}, {'end': 52, 'start': 43, 'tag': 'NucleicAcidNucleosideOrNucleotide'}, {'end': 52, 'start': 43, 'tag': 'BiologicallyActiveSubstance'}, {'end': 101, 'start': 86, 'tag': 'CellFunction'}, {'end': 156, 'start': 138, 'tag': 'HealthCareActivity'}, {'end': 34, 'start': 31, 'tag': 'Virus'}]"
1057,AAV-delivered CRISPR/Cas9 systems provide a promising approach for targeted genome editing to correct genetic mutations underlying neurodegenerative diseases.,"[{'end': 157, 'start': 131, 'tag': 'DiseaseOrSyndrome'}, {'end': 33, 'start': 14, 'tag': 'ResearchActivity'}, {'end': 25, 'start': 14, 'tag': 'BiologicFunction'}, {'end': 90, 'start': 76, 'tag': 'ResearchActivity'}, {'end': 119, 'start': 102, 'tag': 'CellFunction'}, {'end': 3, 'start': 0, 'tag': 'Virus'}]"
1058,Strategies to overcome pre-existing immunity against AAV vectors are essential for successful gene therapy translation in neurodegenerative disorders.,"[{'end': 149, 'start': 122, 'tag': 'DiseaseOrSyndrome'}, {'end': 106, 'start': 94, 'tag': 'HealthCareActivity'}, {'end': 64, 'start': 57, 'tag': 'NucleicAcidNucleosideOrNucleotide'}, {'end': 118, 'start': 107, 'tag': 'CellFunction'}, {'end': 98, 'start': 94, 'tag': 'GeneOrGenome'}, {'end': 44, 'start': 36, 'tag': 'BiologicFunction'}, {'end': 56, 'start': 53, 'tag': 'Virus'}]"
1059,Assessing the safety and long-term efficacy of lentivirus-based therapies is crucial before translation to clinical trials for neurodegenerative conditions.,"[{'end': 122, 'start': 92, 'tag': 'ResearchActivity'}, {'end': 73, 'start': 64, 'tag': 'HealthCareActivity'}, {'end': 155, 'start': 127, 'tag': 'DiseaseOrSyndrome'}, {'end': 20, 'start': 14, 'tag': 'HealthCareActivity'}, {'end': 43, 'start': 35, 'tag': 'Finding'}, {'end': 34, 'start': 25, 'tag': 'TemporalConcept'}, {'end': 91, 'start': 85, 'tag': 'TemporalConcept'}, {'end': 57, 'start': 47, 'tag': 'Virus'}]"
1060,Adenovirus-based gene delivery approaches offer potential therapeutic benefits in neurodegenerative diseases by efficiently transducing neurons and glial cells.,"[{'end': 108, 'start': 82, 'tag': 'DiseaseOrSyndrome'}, {'end': 30, 'start': 22, 'tag': 'BiologicFunction'}, {'end': 159, 'start': 154, 'tag': 'Cell'}, {'end': 143, 'start': 136, 'tag': 'Cell'}, {'end': 159, 'start': 148, 'tag': 'Cell'}, {'end': 153, 'start': 148, 'tag': 'Cell'}, {'end': 21, 'start': 17, 'tag': 'GeneOrGenome'}, {'end': 10, 'start': 0, 'tag': 'Virus'}, {'end': 41, 'start': 17, 'tag': 'ResearchActivity'}, {'end': 78, 'start': 58, 'tag': 'Finding'}]"
1061,The role of Adenovirus-induced neuroinflammation in exacerbating neurodegeneration is a critical focus of current research efforts.,"[{'end': 82, 'start': 65, 'tag': 'CellOrMolecularDysfunction'}, {'end': 113, 'start': 106, 'tag': 'TemporalConcept'}, {'end': 48, 'start': 31, 'tag': 'PathologicFunction'}, {'end': 122, 'start': 114, 'tag': 'ResearchActivity'}, {'end': 102, 'start': 88, 'tag': 'Finding'}, {'end': 22, 'start': 12, 'tag': 'Virus'}]"
1062,"Adenovirus vectors engineered for conditional replication selectively target neurodegenerative disease cells while sparing healthy neurons, providing a promising strategy for oncolytic virotherapy.","[{'end': 138, 'start': 131, 'tag': 'Cell'}, {'end': 108, 'start': 103, 'tag': 'Cell'}, {'end': 102, 'start': 77, 'tag': 'DiseaseOrSyndrome'}, {'end': 130, 'start': 123, 'tag': 'OrganismAttribute'}, {'end': 18, 'start': 11, 'tag': 'NucleicAcidNucleosideOrNucleotide'}, {'end': 170, 'start': 152, 'tag': 'Finding'}, {'end': 10, 'start': 0, 'tag': 'Virus'}, {'end': 196, 'start': 175, 'tag': 'HealthCareActivity'}, {'end': 57, 'start': 46, 'tag': 'CellFunction'}, {'end': 57, 'start': 0, 'tag': 'ResearchActivity'}]"
1063,Understanding the molecular mechanisms of Adenovirus-mediated cell death can lead to novel therapeutic interventions in neurodegenerative disorders.,"[{'end': 147, 'start': 120, 'tag': 'DiseaseOrSyndrome'}, {'end': 72, 'start': 62, 'tag': 'CellFunction'}, {'end': 38, 'start': 18, 'tag': 'CellFunction'}, {'end': 116, 'start': 91, 'tag': 'HealthCareActivity'}, {'end': 52, 'start': 42, 'tag': 'Virus'}]"
1064,Exploring the potential of Adenovirus as a vector for CRISPR/Cas9-mediated genome editing presents exciting prospects for precision gene therapy in neurodegeneration.,"[{'end': 165, 'start': 148, 'tag': 'CellOrMolecularDysfunction'}, {'end': 144, 'start': 132, 'tag': 'HealthCareActivity'}, {'end': 131, 'start': 122, 'tag': 'TemporalConcept'}, {'end': 136, 'start': 132, 'tag': 'GeneOrGenome'}, {'end': 65, 'start': 54, 'tag': 'ResearchActivity'}, {'end': 65, 'start': 54, 'tag': 'BiologicFunction'}, {'end': 89, 'start': 75, 'tag': 'ResearchActivity'}, {'end': 37, 'start': 27, 'tag': 'Virus'}]"
1065,Adenovirus-mediated delivery of neurotrophic factors holds promise as a strategy to promote neuronal survival and function in neurodegenerative conditions.,"[{'end': 154, 'start': 126, 'tag': 'DiseaseOrSyndrome'}, {'end': 109, 'start': 92, 'tag': 'CellFunction'}, {'end': 10, 'start': 0, 'tag': 'Virus'}, {'end': 52, 'start': 32, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 52, 'start': 32, 'tag': 'BiologicallyActiveSubstance'}, {'end': 28, 'start': 20, 'tag': 'BiologicFunction'}]"
1066,The immune response to Adenovirus vectors may influence their long-term efficacy in neurodegenerative disease gene therapy.,"[{'end': 122, 'start': 110, 'tag': 'HealthCareActivity'}, {'end': 109, 'start': 84, 'tag': 'DiseaseOrSyndrome'}, {'end': 19, 'start': 4, 'tag': 'BiologicFunction'}, {'end': 41, 'start': 34, 'tag': 'NucleicAcidNucleosideOrNucleotide'}, {'end': 80, 'start': 72, 'tag': 'Finding'}, {'end': 71, 'start': 62, 'tag': 'TemporalConcept'}, {'end': 33, 'start': 23, 'tag': 'Virus'}]"
1067,Adenovirus-based vaccines targeting neurodegeneration-related proteins may induce protective immune responses against pathological aggregation.,"[{'end': 53, 'start': 36, 'tag': 'CellOrMolecularDysfunction'}, {'end': 70, 'start': 62, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 109, 'start': 93, 'tag': 'BiologicFunction'}, {'end': 10, 'start': 0, 'tag': 'Virus'}, {'end': 25, 'start': 17, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 25, 'start': 17, 'tag': 'PharmacologicSubstance'}, {'end': 25, 'start': 17, 'tag': 'BiologicallyActiveSubstance'}, {'end': 142, 'start': 118, 'tag': 'PathologicFunction'}]"
1068,Combining Adenovirus vectors with stem cell-based therapies enhances their regenerative potential in neurodegenerative disorders.,"[{'end': 128, 'start': 101, 'tag': 'DiseaseOrSyndrome'}, {'end': 59, 'start': 50, 'tag': 'HealthCareActivity'}, {'end': 28, 'start': 21, 'tag': 'NucleicAcidNucleosideOrNucleotide'}, {'end': 43, 'start': 34, 'tag': 'Cell'}, {'end': 20, 'start': 10, 'tag': 'Virus'}, {'end': 97, 'start': 75, 'tag': 'Finding'}]"
1069,Adenovirus-based exosome delivery systems show promise in promoting intercellular communication and therapeutics exchange in neurodegenerative diseases.,"[{'end': 151, 'start': 125, 'tag': 'DiseaseOrSyndrome'}, {'end': 33, 'start': 25, 'tag': 'BiologicFunction'}, {'end': 95, 'start': 68, 'tag': 'CellFunction'}, {'end': 112, 'start': 100, 'tag': 'HealthCareActivity'}, {'end': 24, 'start': 17, 'tag': 'CellComponent'}, {'end': 10, 'start': 0, 'tag': 'Virus'}, {'end': 41, 'start': 17, 'tag': 'ResearchActivity'}]"
1070,Lentivirus-induced overexpression of heat shock proteins exhibits neuroprotective effects against protein misfolding and aggregation in neurodegenerative disorders.,"[{'end': 163, 'start': 136, 'tag': 'DiseaseOrSyndrome'}, {'end': 89, 'start': 66, 'tag': 'Finding'}, {'end': 116, 'start': 98, 'tag': 'CellOrMolecularDysfunction'}, {'end': 33, 'start': 19, 'tag': 'Finding'}, {'end': 56, 'start': 37, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 56, 'start': 37, 'tag': 'BiologicallyActiveSubstance'}, {'end': 10, 'start': 0, 'tag': 'Virus'}]"
1071,SARS-CoV-2 infection elicits neuroinflammatory responses that may contribute to neurological complications observed in COVID-19 patients.,"[{'end': 136, 'start': 128, 'tag': 'PatientOrDisabledGroup'}, {'end': 20, 'start': 11, 'tag': 'PathologicFunction'}, {'end': 46, 'start': 29, 'tag': 'PathologicFunction'}, {'end': 106, 'start': 80, 'tag': 'PathologicFunction'}, {'end': 10, 'start': 0, 'tag': 'Virus'}, {'end': 127, 'start': 119, 'tag': 'DiseaseOrSyndrome'}]"
1072,Investigating the direct and indirect effects of SARS-CoV-2 on neuronal function is crucial for understanding its potential role in neurodegeneration.,"[{'end': 149, 'start': 132, 'tag': 'CellOrMolecularDysfunction'}, {'end': 109, 'start': 96, 'tag': 'BiologicFunction'}, {'end': 59, 'start': 49, 'tag': 'Virus'}, {'end': 80, 'start': 63, 'tag': 'CellFunction'}, {'end': 45, 'start': 38, 'tag': 'Finding'}]"
1073,Neurological manifestations of COVID-19 prompt the examination of SARS-CoV-2's neurotropism and neurovirulence mechanisms.,"[{'end': 27, 'start': 0, 'tag': 'SignOrSymptom'}, {'end': 76, 'start': 66, 'tag': 'Virus'}, {'end': 39, 'start': 31, 'tag': 'DiseaseOrSyndrome'}, {'end': 91, 'start': 79, 'tag': 'BiologicFunction'}, {'end': 110, 'start': 96, 'tag': 'BiologicFunction'}]"
1074,SARS-CoV-2-induced dysregulation of autophagy and lysosomal function may contribute to neurodegeneration in severe COVID-19 cases.,"[{'end': 104, 'start': 87, 'tag': 'CellOrMolecularDysfunction'}, {'end': 68, 'start': 50, 'tag': 'CellFunction'}, {'end': 45, 'start': 36, 'tag': 'CellFunction'}, {'end': 114, 'start': 108, 'tag': 'Finding'}, {'end': 10, 'start': 0, 'tag': 'Virus'}, {'end': 59, 'start': 50, 'tag': 'CellComponent'}, {'end': 123, 'start': 115, 'tag': 'DiseaseOrSyndrome'}]"
1075,The impact of SARS-CoV-2 infection on blood-brain barrier integrity has implications for viral entry and potential neurotoxicity.,"[{'end': 128, 'start': 115, 'tag': 'InjuryOrPoisoning'}, {'end': 34, 'start': 25, 'tag': 'PathologicFunction'}, {'end': 57, 'start': 38, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 67, 'start': 58, 'tag': 'IndividualBehavior'}, {'end': 24, 'start': 14, 'tag': 'Virus'}, {'end': 67, 'start': 58, 'tag': 'Finding'}, {'end': 100, 'start': 89, 'tag': 'CellFunction'}]"
1076,SARS-CoV-2 spike protein interactions with neuronal receptors warrant investigation as potential contributors to neurodegeneration.,"[{'end': 130, 'start': 113, 'tag': 'CellOrMolecularDysfunction'}, {'end': 83, 'start': 70, 'tag': 'ResearchActivity'}, {'end': 51, 'start': 43, 'tag': 'Cell'}, {'end': 37, 'start': 25, 'tag': 'Finding'}, {'end': 24, 'start': 11, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 10, 'start': 0, 'tag': 'Virus'}, {'end': 61, 'start': 52, 'tag': 'BiologicallyActiveSubstance'}, {'end': 24, 'start': 11, 'tag': 'BiologicallyActiveSubstance'}]"
1077,The role of SARS-CoV-2-induced cytokine storms in exacerbating neuroinflammation and neuronal damage requires further exploration.,"[{'end': 93, 'start': 85, 'tag': 'Cell'}, {'end': 80, 'start': 63, 'tag': 'PathologicFunction'}, {'end': 22, 'start': 12, 'tag': 'Virus'}, {'end': 100, 'start': 94, 'tag': 'InjuryOrPoisoning'}, {'end': 39, 'start': 31, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 39, 'start': 31, 'tag': 'BiologicallyActiveSubstance'}, {'end': 46, 'start': 31, 'tag': 'DiseaseOrSyndrome'}]"
1078,SARS-CoV-2 vaccines show promise in reducing the risk of COVID-19-associated neurological sequelae and potential neurodegenerative outcomes.,"[{'end': 53, 'start': 49, 'tag': 'Finding'}, {'end': 10, 'start': 0, 'tag': 'Virus'}, {'end': 65, 'start': 57, 'tag': 'DiseaseOrSyndrome'}, {'end': 19, 'start': 11, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 19, 'start': 11, 'tag': 'BiologicallyActiveSubstance'}, {'end': 19, 'start': 11, 'tag': 'PharmacologicSubstance'}, {'end': 98, 'start': 77, 'tag': 'PathologicFunction'}, {'end': 139, 'start': 113, 'tag': 'PathologicFunction'}]"
1079,Longitudinal studies assessing the cognitive and neurological outcomes in recovered COVID-19 patients are essential for understanding potential neurodegenerative risks.,"[{'end': 20, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 133, 'start': 120, 'tag': 'BiologicFunction'}, {'end': 101, 'start': 93, 'tag': 'PatientOrDisabledGroup'}, {'end': 70, 'start': 35, 'tag': 'Finding'}, {'end': 92, 'start': 84, 'tag': 'DiseaseOrSyndrome'}, {'end': 167, 'start': 144, 'tag': 'Finding'}]"
1080,Identifying potential SARS-CoV-2 antiviral therapies that also exhibit neuroprotective properties holds significant potential for treating neurodegenerative diseases.,"[{'end': 165, 'start': 139, 'tag': 'DiseaseOrSyndrome'}, {'end': 52, 'start': 33, 'tag': 'HealthCareActivity'}, {'end': 86, 'start': 71, 'tag': 'CellFunction'}, {'end': 32, 'start': 22, 'tag': 'Virus'}, {'end': 97, 'start': 71, 'tag': 'Finding'}]"
1081,Exploiting lentiviral-mediated gene editing techniques offers exciting possibilities for correcting genetic mutations associated with hereditary neurodegenerative conditions.,"[{'end': 173, 'start': 145, 'tag': 'DiseaseOrSyndrome'}, {'end': 54, 'start': 31, 'tag': 'ResearchActivity'}, {'end': 144, 'start': 134, 'tag': 'CellFunction'}, {'end': 117, 'start': 100, 'tag': 'CellFunction'}, {'end': 21, 'start': 11, 'tag': 'Virus'}]"
1082,Epstein-Barr Virus latency-associated gene products may modulate cellular pathways relevant to neurodegeneration in latent infection.,"[{'end': 112, 'start': 95, 'tag': 'CellOrMolecularDysfunction'}, {'end': 82, 'start': 65, 'tag': 'CellFunction'}, {'end': 132, 'start': 123, 'tag': 'PathologicFunction'}, {'end': 132, 'start': 116, 'tag': 'PathologicFunction'}, {'end': 26, 'start': 19, 'tag': 'TemporalConcept'}, {'end': 42, 'start': 38, 'tag': 'GeneOrGenome'}, {'end': 18, 'start': 0, 'tag': 'Virus'}]"
1083,Investigating the interactions between Epstein-Barr Virus and host genetic factors may reveal susceptibility loci for neurodegenerative diseases.,"[{'end': 144, 'start': 118, 'tag': 'DiseaseOrSyndrome'}, {'end': 66, 'start': 62, 'tag': 'Organism'}, {'end': 30, 'start': 18, 'tag': 'Finding'}, {'end': 113, 'start': 109, 'tag': 'Finding'}, {'end': 82, 'start': 67, 'tag': 'Finding'}, {'end': 57, 'start': 39, 'tag': 'Virus'}, {'end': 108, 'start': 94, 'tag': 'Finding'}]"
1084,The potential role of Epstein-Barr Virus in triggering neuroinflammatory responses requires examination to understand its contribution to neurodegeneration.,"[{'end': 155, 'start': 138, 'tag': 'CellOrMolecularDysfunction'}, {'end': 72, 'start': 55, 'tag': 'PathologicFunction'}, {'end': 40, 'start': 22, 'tag': 'Virus'}]"
1085,"Epstein-Barr Virus-encoded microRNAs may target key genes involved in neurodegeneration pathways, influencing disease progression.","[{'end': 87, 'start': 70, 'tag': 'CellOrMolecularDysfunction'}, {'end': 129, 'start': 110, 'tag': 'PathologicFunction'}, {'end': 36, 'start': 27, 'tag': 'NucleicAcidNucleosideOrNucleotide'}, {'end': 36, 'start': 27, 'tag': 'BiologicallyActiveSubstance'}, {'end': 96, 'start': 88, 'tag': 'CellFunction'}, {'end': 57, 'start': 52, 'tag': 'GeneOrGenome'}, {'end': 18, 'start': 0, 'tag': 'Virus'}]"
1086,The link between Epstein-Barr Virus infection and demyelinating disorders is an intriguing area of research in the field of neurodegeneration.,"[{'end': 141, 'start': 124, 'tag': 'CellOrMolecularDysfunction'}, {'end': 107, 'start': 99, 'tag': 'ResearchActivity'}, {'end': 45, 'start': 36, 'tag': 'PathologicFunction'}, {'end': 73, 'start': 50, 'tag': 'DiseaseOrSyndrome'}, {'end': 35, 'start': 17, 'tag': 'Virus'}]"
1087,Epstein-Barr Virus-induced alterations in autophagy and lysosomal function may impact protein homeostasis and contribute to neurodegenerative processes.,"[{'end': 74, 'start': 56, 'tag': 'CellFunction'}, {'end': 151, 'start': 124, 'tag': 'DiseaseOrSyndrome'}, {'end': 51, 'start': 42, 'tag': 'CellFunction'}, {'end': 105, 'start': 94, 'tag': 'BiologicFunction'}, {'end': 38, 'start': 27, 'tag': 'Finding'}, {'end': 65, 'start': 56, 'tag': 'CellComponent'}, {'end': 105, 'start': 86, 'tag': 'CellFunction'}, {'end': 18, 'start': 0, 'tag': 'Virus'}]"
1088,The role of Epstein-Barr Virus in promoting chronic inflammation and neurodegeneration necessitates mechanistic investigations.,"[{'end': 86, 'start': 69, 'tag': 'CellOrMolecularDysfunction'}, {'end': 64, 'start': 52, 'tag': 'PathologicFunction'}, {'end': 51, 'start': 44, 'tag': 'TemporalConcept'}, {'end': 64, 'start': 44, 'tag': 'PathologicFunction'}, {'end': 126, 'start': 112, 'tag': 'ResearchActivity'}, {'end': 30, 'start': 12, 'tag': 'Virus'}]"
1089,Investigating the potential of Epstein-Barr Virus vaccines to mitigate neuroinflammatory responses in neurodegenerative disorders presents a novel avenue for research.,"[{'end': 129, 'start': 102, 'tag': 'DiseaseOrSyndrome'}, {'end': 88, 'start': 71, 'tag': 'PathologicFunction'}, {'end': 49, 'start': 31, 'tag': 'Virus'}, {'end': 58, 'start': 50, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 58, 'start': 50, 'tag': 'BiologicallyActiveSubstance'}, {'end': 58, 'start': 50, 'tag': 'PharmacologicSubstance'}]"
1090,The role of Epstein-Barr Virus in mediating immune dysregulation may contribute to neurodegenerative disease pathogenesis.,"[{'end': 108, 'start': 83, 'tag': 'DiseaseOrSyndrome'}, {'end': 121, 'start': 109, 'tag': 'PathologicFunction'}, {'end': 30, 'start': 12, 'tag': 'Virus'}, {'end': 64, 'start': 44, 'tag': 'PathologicFunction'}]"
1091,Comprehensive epidemiological studies examining the association between Epstein-Barr Virus infection and specific neurodegenerative conditions are essential to establish causal relationships.,"[{'end': 142, 'start': 114, 'tag': 'DiseaseOrSyndrome'}, {'end': 100, 'start': 91, 'tag': 'PathologicFunction'}, {'end': 37, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 190, 'start': 170, 'tag': 'Finding'}, {'end': 90, 'start': 72, 'tag': 'Virus'}]"
1092,Lentiviral vector delivery of microRNA regulators holds potential for modulating disease-related pathways in various neurodegenerative diseases.,"[{'end': 143, 'start': 117, 'tag': 'DiseaseOrSyndrome'}, {'end': 26, 'start': 18, 'tag': 'BiologicFunction'}, {'end': 105, 'start': 97, 'tag': 'CellFunction'}, {'end': 38, 'start': 30, 'tag': 'NucleicAcidNucleosideOrNucleotide'}, {'end': 38, 'start': 30, 'tag': 'BiologicallyActiveSubstance'}, {'end': 10, 'start': 0, 'tag': 'Virus'}, {'end': 17, 'start': 11, 'tag': 'NucleicAcidNucleosideOrNucleotide'}]"
1093,P.,[]
1094,"gingivalis, a periodontal pathogen, has been implicated in chronic periodontitis and has also been associated with an increased risk of developing neurodegenerative diseases.","[{'end': 173, 'start': 147, 'tag': 'DiseaseOrSyndrome'}, {'end': 66, 'start': 59, 'tag': 'TemporalConcept'}, {'end': 34, 'start': 26, 'tag': 'Organism'}, {'end': 132, 'start': 118, 'tag': 'Finding'}, {'end': 80, 'start': 67, 'tag': 'DiseaseOrSyndrome'}, {'end': 25, 'start': 14, 'tag': 'BodyPartOrganOrOrganComponent'}]"
1095,The ability of P.,"[{'end': 11, 'start': 4, 'tag': 'OrganismAttribute'}]"
1096,gingivalis to invade and persist in the brain suggests its potential involvement in the neuroinflammatory processes observed in Alzheimer's disease.,"[{'end': 45, 'start': 40, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 147, 'start': 128, 'tag': 'DiseaseOrSyndrome'}, {'end': 80, 'start': 69, 'tag': 'Finding'}, {'end': 105, 'start': 88, 'tag': 'PathologicFunction'}]"
1097,Studies have revealed a potential link between P.,"[{'end': 7, 'start': 0, 'tag': 'ResearchActivity'}]"
1098,"gingivalis infection and the dysregulation of host immune responses, contributing to neurodegeneration.","[{'end': 102, 'start': 85, 'tag': 'CellOrMolecularDysfunction'}, {'end': 50, 'start': 46, 'tag': 'Organism'}, {'end': 20, 'start': 11, 'tag': 'PathologicFunction'}, {'end': 67, 'start': 51, 'tag': 'BiologicFunction'}]"
1099,P.,[]
1100,"gingivalis-derived virulence factors may promote the aggregation of amyloid-beta protein, a hallmark of Alzheimer's disease pathology.","[{'end': 123, 'start': 104, 'tag': 'DiseaseOrSyndrome'}, {'end': 80, 'start': 68, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 133, 'start': 116, 'tag': 'PathologicFunction'}, {'end': 36, 'start': 19, 'tag': 'BiologicallyActiveSubstance'}, {'end': 80, 'start': 68, 'tag': 'BiologicallyActiveSubstance'}, {'end': 88, 'start': 53, 'tag': 'CellOrMolecularDysfunction'}, {'end': 100, 'start': 92, 'tag': 'Finding'}]"
1101,Investigating the role of P.,[]
1102,gingivalis in disrupting the blood-brain barrier may shed light on how oral infections could impact the progression of neurodegenerative diseases.,"[{'end': 145, 'start': 119, 'tag': 'DiseaseOrSyndrome'}, {'end': 48, 'start': 29, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 75, 'start': 71, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 63, 'start': 58, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 86, 'start': 76, 'tag': 'PathologicFunction'}, {'end': 115, 'start': 104, 'tag': 'PathologicFunction'}, {'end': 115, 'start': 104, 'tag': 'TemporalConcept'}]"
1103,P.,[]
1104,gingivalis-induced production of pro-inflammatory cytokines may contribute to neuroinflammation and neuronal damage in neurodegenerative disorders.,"[{'end': 146, 'start': 119, 'tag': 'DiseaseOrSyndrome'}, {'end': 108, 'start': 100, 'tag': 'Cell'}, {'end': 95, 'start': 78, 'tag': 'PathologicFunction'}, {'end': 59, 'start': 33, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 59, 'start': 33, 'tag': 'BiologicallyActiveSubstance'}, {'end': 115, 'start': 109, 'tag': 'InjuryOrPoisoning'}]"
1105,Therapeutic strategies targeting P.,"[{'end': 22, 'start': 0, 'tag': 'HealthCareActivity'}]"
1106,gingivalis and its virulence factors show promise as potential interventions for preventing or slowing neurodegeneration.,"[{'end': 120, 'start': 103, 'tag': 'CellOrMolecularDysfunction'}, {'end': 36, 'start': 19, 'tag': 'BiologicallyActiveSubstance'}]"
1107,The potential involvement of P.,[]
1108,gingivalis in triggering tau protein hyperphosphorylation warrants further exploration in the context of neurodegenerative diseases.,"[{'end': 131, 'start': 105, 'tag': 'DiseaseOrSyndrome'}, {'end': 57, 'start': 25, 'tag': 'CellOrMolecularDysfunction'}]"
1109,P.,[]
1110,gingivalis-driven alterations in gut microbiota composition may have implications for brain health and the development of neurodegenerative conditions.,"[{'end': 91, 'start': 86, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 98, 'start': 92, 'tag': 'HealthCareActivity'}, {'end': 150, 'start': 122, 'tag': 'DiseaseOrSyndrome'}, {'end': 47, 'start': 33, 'tag': 'Organism'}, {'end': 36, 'start': 33, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 29, 'start': 18, 'tag': 'Finding'}, {'end': 118, 'start': 107, 'tag': 'BiologicFunction'}]"
1111,Understanding the interplay between P.,"[{'end': 27, 'start': 18, 'tag': 'Finding'}]"
1112,"gingivalis infection, genetic susceptibility, and environmental factors is critical for elucidating its role in neurodegenerative pathogenesis.","[{'end': 20, 'start': 11, 'tag': 'PathologicFunction'}, {'end': 71, 'start': 50, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 71, 'start': 50, 'tag': 'EnvironmentalEffectOfHumans'}, {'end': 44, 'start': 22, 'tag': 'Finding'}, {'end': 142, 'start': 112, 'tag': 'PathologicFunction'}]"
1113,Lentivirus-engineered exosomes carrying therapeutic cargo emerge as a novel approach for intercellular communication and neuroprotection in neurodegenerative disorders.,"[{'end': 167, 'start': 140, 'tag': 'DiseaseOrSyndrome'}, {'end': 57, 'start': 40, 'tag': 'PharmacologicSubstance'}, {'end': 116, 'start': 89, 'tag': 'CellFunction'}, {'end': 30, 'start': 22, 'tag': 'CellComponent'}, {'end': 136, 'start': 121, 'tag': 'CellFunction'}, {'end': 10, 'start': 0, 'tag': 'Virus'}]"
1114,Chlamydia pneumoniae infection has been proposed as a potential risk factor for the development or exacerbation of neurodegenerative diseases through chronic inflammation.,"[{'end': 141, 'start': 115, 'tag': 'DiseaseOrSyndrome'}, {'end': 75, 'start': 64, 'tag': 'Finding'}, {'end': 170, 'start': 158, 'tag': 'PathologicFunction'}, {'end': 157, 'start': 150, 'tag': 'TemporalConcept'}, {'end': 30, 'start': 21, 'tag': 'PathologicFunction'}, {'end': 111, 'start': 99, 'tag': 'Finding'}, {'end': 170, 'start': 150, 'tag': 'PathologicFunction'}, {'end': 20, 'start': 0, 'tag': 'Bacterium'}, {'end': 95, 'start': 84, 'tag': 'BiologicFunction'}]"
1115,The ability of Chlamydia pneumoniae to persist in the central nervous system may contribute to the chronic neuroinflammatory processes observed in neurodegeneration.,"[{'end': 164, 'start': 147, 'tag': 'CellOrMolecularDysfunction'}, {'end': 76, 'start': 54, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 106, 'start': 99, 'tag': 'TemporalConcept'}, {'end': 11, 'start': 4, 'tag': 'OrganismAttribute'}, {'end': 124, 'start': 107, 'tag': 'PathologicFunction'}, {'end': 35, 'start': 15, 'tag': 'Bacterium'}]"
1116,Chlamydia pneumoniae-induced oxidative stress and cellular damage are under investigation for their potential role in neurodegenerative pathogenesis.,"[{'end': 89, 'start': 76, 'tag': 'ResearchActivity'}, {'end': 148, 'start': 118, 'tag': 'PathologicFunction'}, {'end': 45, 'start': 29, 'tag': 'CellOrMolecularDysfunction'}, {'end': 58, 'start': 50, 'tag': 'Cell'}, {'end': 65, 'start': 59, 'tag': 'InjuryOrPoisoning'}, {'end': 20, 'start': 0, 'tag': 'Bacterium'}]"
1117,Therapeutic approaches targeting Chlamydia pneumoniae infection may offer novel strategies for mitigating neuroinflammation and slowing disease progression in neurodegenerative disorders.,"[{'end': 186, 'start': 159, 'tag': 'DiseaseOrSyndrome'}, {'end': 155, 'start': 136, 'tag': 'PathologicFunction'}, {'end': 123, 'start': 106, 'tag': 'PathologicFunction'}, {'end': 63, 'start': 54, 'tag': 'PathologicFunction'}, {'end': 53, 'start': 33, 'tag': 'Bacterium'}, {'end': 22, 'start': 0, 'tag': 'HealthCareActivity'}]"
1118,Investigating the potential of Chlamydia pneumoniae-mediated epigenetic modifications in neuronal cells may provide insights into its impact on gene expression related to neurodegeneration.,"[{'end': 188, 'start': 171, 'tag': 'CellOrMolecularDysfunction'}, {'end': 159, 'start': 144, 'tag': 'CellFunction'}, {'end': 103, 'start': 89, 'tag': 'Cell'}, {'end': 85, 'start': 61, 'tag': 'CellFunction'}, {'end': 51, 'start': 31, 'tag': 'Bacterium'}]"
1119,"Chlamydia pneumoniae-driven dysregulation of microglial activation may contribute to the chronic neuroinflammatory environment in the brain, promoting neurodegeneration.","[{'end': 139, 'start': 134, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 168, 'start': 151, 'tag': 'CellOrMolecularDysfunction'}, {'end': 66, 'start': 45, 'tag': 'CellFunction'}, {'end': 96, 'start': 89, 'tag': 'TemporalConcept'}, {'end': 114, 'start': 97, 'tag': 'PathologicFunction'}, {'end': 20, 'start': 0, 'tag': 'Bacterium'}, {'end': 41, 'start': 28, 'tag': 'Finding'}, {'end': 126, 'start': 115, 'tag': 'NaturalPhenomenonOrProcess'}]"
1120,The role of Chlamydia pneumoniae in altering amyloid processing and accumulation warrants examination in the context of Alzheimer's disease pathogenesis.,"[{'end': 139, 'start': 120, 'tag': 'DiseaseOrSyndrome'}, {'end': 152, 'start': 140, 'tag': 'PathologicFunction'}, {'end': 80, 'start': 68, 'tag': 'Finding'}, {'end': 52, 'start': 45, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 52, 'start': 45, 'tag': 'BiologicallyActiveSubstance'}, {'end': 32, 'start': 12, 'tag': 'Bacterium'}]"
1121,Understanding the cellular and molecular mechanisms by which Chlamydia pneumoniae infection influences neuronal dysfunction is crucial for developing targeted therapies in neurodegenerative diseases.,"[{'end': 198, 'start': 172, 'tag': 'DiseaseOrSyndrome'}, {'end': 168, 'start': 150, 'tag': 'HealthCareActivity'}, {'end': 123, 'start': 103, 'tag': 'CellOrMolecularDysfunction'}, {'end': 91, 'start': 82, 'tag': 'PathologicFunction'}, {'end': 51, 'start': 18, 'tag': 'CellFunction'}, {'end': 81, 'start': 61, 'tag': 'Bacterium'}]"
1122,Chlamydia pneumoniae-induced alterations in autophagy pathways are being explored for their potential impact on protein homeostasis in neurodegeneration.,"[{'end': 152, 'start': 135, 'tag': 'CellOrMolecularDysfunction'}, {'end': 53, 'start': 44, 'tag': 'CellFunction'}, {'end': 40, 'start': 29, 'tag': 'Finding'}, {'end': 131, 'start': 112, 'tag': 'CellFunction'}, {'end': 20, 'start': 0, 'tag': 'Bacterium'}]"
1123,Epidemiological studies investigating the association between Chlamydia pneumoniae infection and specific neurodegenerative conditions are essential for establishing potential causal relationships.,"[{'end': 134, 'start': 106, 'tag': 'DiseaseOrSyndrome'}, {'end': 92, 'start': 83, 'tag': 'PathologicFunction'}, {'end': 196, 'start': 176, 'tag': 'Finding'}, {'end': 82, 'start': 62, 'tag': 'Bacterium'}, {'end': 23, 'start': 0, 'tag': 'ResearchActivity'}]"
1124,Advancements in lentivirus manufacturing and delivery systems enhance the feasibility and safety of using lentiviral vectors for neurodegenerative disease treatment.,"[{'end': 154, 'start': 129, 'tag': 'DiseaseOrSyndrome'}, {'end': 96, 'start': 90, 'tag': 'HealthCareActivity'}, {'end': 124, 'start': 117, 'tag': 'NucleicAcidNucleosideOrNucleotide'}, {'end': 85, 'start': 74, 'tag': 'ResearchActivity'}, {'end': 26, 'start': 16, 'tag': 'Virus'}, {'end': 61, 'start': 27, 'tag': 'ResearchActivity'}, {'end': 116, 'start': 106, 'tag': 'Virus'}, {'end': 164, 'start': 155, 'tag': 'HealthCareActivity'}, {'end': 164, 'start': 155, 'tag': 'ResearchActivity'}]"
1125,"Helicobacter pylori infection has been linked to an increased risk of developing Parkinson's disease, prompting investigations into the gut-brain axis in neurodegeneration.","[{'end': 100, 'start': 81, 'tag': 'DiseaseOrSyndrome'}, {'end': 150, 'start': 136, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 171, 'start': 154, 'tag': 'CellOrMolecularDysfunction'}, {'end': 29, 'start': 20, 'tag': 'PathologicFunction'}, {'end': 19, 'start': 0, 'tag': 'Bacterium'}, {'end': 66, 'start': 52, 'tag': 'Finding'}, {'end': 126, 'start': 112, 'tag': 'ResearchActivity'}]"
1126,The potential of Helicobacter pylori to induce systemic inflammation may contribute to neuroinflammatory processes in various neurodegenerative disorders.,"[{'end': 153, 'start': 126, 'tag': 'DiseaseOrSyndrome'}, {'end': 68, 'start': 56, 'tag': 'PathologicFunction'}, {'end': 104, 'start': 87, 'tag': 'PathologicFunction'}, {'end': 36, 'start': 17, 'tag': 'Bacterium'}, {'end': 68, 'start': 47, 'tag': 'PathologicFunction'}]"
1127,Helicobacter pylori-driven alterations in gut microbiota composition may influence neurodegenerative disease susceptibility and progression.,"[{'end': 108, 'start': 83, 'tag': 'DiseaseOrSyndrome'}, {'end': 56, 'start': 42, 'tag': 'Organism'}, {'end': 19, 'start': 0, 'tag': 'Bacterium'}, {'end': 45, 'start': 42, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 123, 'start': 109, 'tag': 'Finding'}, {'end': 139, 'start': 128, 'tag': 'TemporalConcept'}, {'end': 139, 'start': 128, 'tag': 'PathologicFunction'}]"
1128,Investigating the role of Helicobacter pylori in promoting -synuclein aggregation in the gut and its subsequent propagation to the brain is a current focus in Parkinson's disease research.,"[{'end': 179, 'start': 160, 'tag': 'DiseaseOrSyndrome'}, {'end': 137, 'start': 132, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 150, 'start': 143, 'tag': 'TemporalConcept'}, {'end': 188, 'start': 180, 'tag': 'ResearchActivity'}, {'end': 124, 'start': 113, 'tag': 'Finding'}, {'end': 45, 'start': 26, 'tag': 'Bacterium'}, {'end': 93, 'start': 90, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 70, 'start': 59, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 70, 'start': 59, 'tag': 'BiologicallyActiveSubstance'}, {'end': 82, 'start': 71, 'tag': 'Finding'}]"
1129,"Helicobacter pylori-associated chronic gastritis may contribute to vitamin B12 deficiency, potentially impacting neurodegenerative disease risk.","[{'end': 138, 'start': 113, 'tag': 'DiseaseOrSyndrome'}, {'end': 38, 'start': 31, 'tag': 'TemporalConcept'}, {'end': 143, 'start': 139, 'tag': 'Finding'}, {'end': 19, 'start': 0, 'tag': 'Bacterium'}, {'end': 89, 'start': 67, 'tag': 'DiseaseOrSyndrome'}, {'end': 78, 'start': 67, 'tag': 'Chemical'}, {'end': 48, 'start': 31, 'tag': 'DiseaseOrSyndrome'}, {'end': 78, 'start': 67, 'tag': 'PharmacologicSubstance'}, {'end': 78, 'start': 67, 'tag': 'BiologicallyActiveSubstance'}]"
1130,Therapeutic strategies targeting Helicobacter pylori infection in the gut-brain axis hold promise as potential interventions for neuroprotection in Parkinson's disease and other neurodegenerative conditions.,"[{'end': 167, 'start': 148, 'tag': 'DiseaseOrSyndrome'}, {'end': 206, 'start': 178, 'tag': 'DiseaseOrSyndrome'}, {'end': 144, 'start': 129, 'tag': 'CellFunction'}, {'end': 62, 'start': 53, 'tag': 'PathologicFunction'}, {'end': 52, 'start': 33, 'tag': 'Bacterium'}, {'end': 84, 'start': 70, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 22, 'start': 0, 'tag': 'HealthCareActivity'}]"
1131,The potential involvement of Helicobacter pylori in triggering neuroinflammation through molecular mimicry mechanisms warrants investigation in the context of neurodegeneration.,"[{'end': 176, 'start': 159, 'tag': 'CellOrMolecularDysfunction'}, {'end': 25, 'start': 14, 'tag': 'Finding'}, {'end': 140, 'start': 127, 'tag': 'ResearchActivity'}, {'end': 80, 'start': 63, 'tag': 'PathologicFunction'}, {'end': 48, 'start': 29, 'tag': 'Bacterium'}, {'end': 117, 'start': 89, 'tag': 'CellFunction'}]"
1132,"Helicobacter pylori virulence factors may influence blood-brain barrier integrity, affecting the neuroinflammatory response in neurodegenerative diseases.","[{'end': 153, 'start': 127, 'tag': 'DiseaseOrSyndrome'}, {'end': 71, 'start': 52, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 123, 'start': 97, 'tag': 'PathologicFunction'}, {'end': 37, 'start': 20, 'tag': 'Chemical'}, {'end': 19, 'start': 0, 'tag': 'Bacterium'}, {'end': 37, 'start': 20, 'tag': 'BiologicallyActiveSubstance'}, {'end': 37, 'start': 20, 'tag': 'InjuryOrPoisoning'}, {'end': 81, 'start': 72, 'tag': 'IndividualBehavior'}]"
1133,The association between Helicobacter pylori infection and increased oxidative stress in neurodegenerative disorders requires further exploration to understand its impact on disease pathogenesis.,"[{'end': 115, 'start': 88, 'tag': 'DiseaseOrSyndrome'}, {'end': 193, 'start': 181, 'tag': 'PathologicFunction'}, {'end': 84, 'start': 68, 'tag': 'CellOrMolecularDysfunction'}, {'end': 53, 'start': 44, 'tag': 'PathologicFunction'}, {'end': 43, 'start': 24, 'tag': 'Bacterium'}]"
1134,Longitudinal studies assessing the impact of Helicobacter pylori eradication on neurodegenerative disease risk and progression are essential for understanding potential therapeutic implications.,"[{'end': 20, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 105, 'start': 80, 'tag': 'DiseaseOrSyndrome'}, {'end': 110, 'start': 106, 'tag': 'Finding'}, {'end': 64, 'start': 45, 'tag': 'Bacterium'}]"
1135,Lentivirus-mediated CRISPR activation (CRISPRa) emerges as a promising avenue for upregulating protective genes in neurodegenerative conditions.,"[{'end': 143, 'start': 115, 'tag': 'DiseaseOrSyndrome'}, {'end': 111, 'start': 95, 'tag': 'GeneOrGenome'}, {'end': 94, 'start': 82, 'tag': 'CellFunction'}, {'end': 37, 'start': 20, 'tag': 'ResearchActivity'}, {'end': 46, 'start': 39, 'tag': 'ResearchActivity'}, {'end': 10, 'start': 0, 'tag': 'Virus'}]"
1136,"Spirochetes, such as Borrelia burgdorferi, have been proposed as potential triggers of neuroinflammation in Lyme neuroborreliosis, raising questions about their role in other neurodegenerative diseases.","[{'end': 201, 'start': 175, 'tag': 'DiseaseOrSyndrome'}, {'end': 104, 'start': 87, 'tag': 'PathologicFunction'}, {'end': 11, 'start': 0, 'tag': 'Bacterium'}, {'end': 41, 'start': 21, 'tag': 'Bacterium'}, {'end': 129, 'start': 108, 'tag': 'DiseaseOrSyndrome'}]"
1137,Investigating the mechanisms by which spirochetes evade the immune system in the central nervous system is crucial for understanding their impact on neurodegeneration.,"[{'end': 166, 'start': 149, 'tag': 'CellOrMolecularDysfunction'}, {'end': 103, 'start': 81, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 132, 'start': 119, 'tag': 'BiologicFunction'}, {'end': 73, 'start': 60, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 49, 'start': 38, 'tag': 'Bacterium'}]"
1138,Spirochete-associated toxins and inflammatory mediators are under scrutiny for their potential contribution to neurodegenerative disease pathology.,"[{'end': 136, 'start': 111, 'tag': 'DiseaseOrSyndrome'}, {'end': 55, 'start': 46, 'tag': 'Finding'}, {'end': 45, 'start': 33, 'tag': 'PathologicFunction'}, {'end': 10, 'start': 0, 'tag': 'Bacterium'}, {'end': 28, 'start': 22, 'tag': 'InjuryOrPoisoning'}, {'end': 146, 'start': 137, 'tag': 'PathologicFunction'}]"
1139,Spirochetes may induce neurodegeneration through the production of reactive oxygen species and subsequent cellular damage.,"[{'end': 40, 'start': 23, 'tag': 'CellOrMolecularDysfunction'}, {'end': 114, 'start': 106, 'tag': 'Cell'}, {'end': 90, 'start': 67, 'tag': 'BiologicallyActiveSubstance'}, {'end': 90, 'start': 67, 'tag': 'Chemical'}, {'end': 121, 'start': 115, 'tag': 'InjuryOrPoisoning'}, {'end': 11, 'start': 0, 'tag': 'Bacterium'}]"
1140,Exploring the potential of spirochete-derived amyloid proteins in inducing protein misfolding and aggregation opens new avenues for understanding neurodegenerative processes.,"[{'end': 93, 'start': 75, 'tag': 'CellOrMolecularDysfunction'}, {'end': 173, 'start': 146, 'tag': 'DiseaseOrSyndrome'}, {'end': 62, 'start': 46, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 37, 'start': 27, 'tag': 'Bacterium'}, {'end': 145, 'start': 132, 'tag': 'BiologicFunction'}]"
1141,"Spirochetes may elicit dysregulation of host immune responses in the brain, promoting chronic neuroinflammatory states relevant to neurodegenerative diseases.","[{'end': 157, 'start': 131, 'tag': 'DiseaseOrSyndrome'}, {'end': 74, 'start': 69, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 118, 'start': 112, 'tag': 'TemporalConcept'}, {'end': 44, 'start': 40, 'tag': 'Organism'}, {'end': 93, 'start': 86, 'tag': 'TemporalConcept'}, {'end': 111, 'start': 94, 'tag': 'PathologicFunction'}, {'end': 61, 'start': 45, 'tag': 'BiologicFunction'}, {'end': 11, 'start': 0, 'tag': 'Bacterium'}, {'end': 36, 'start': 23, 'tag': 'Finding'}]"
1142,The potential of spirochetes to disrupt neuronal network connectivity and synaptic function is a focus of investigation in the context of neurodegeneration.,"[{'end': 155, 'start': 138, 'tag': 'CellOrMolecularDysfunction'}, {'end': 119, 'start': 106, 'tag': 'ResearchActivity'}, {'end': 91, 'start': 74, 'tag': 'CellFunction'}, {'end': 28, 'start': 17, 'tag': 'Bacterium'}, {'end': 69, 'start': 40, 'tag': 'BiologicFunction'}]"
1143,Spirochete-driven alterations in neurotransmitter metabolism and release may contribute to neurodegenerative disease symptoms and progression.,"[{'end': 116, 'start': 91, 'tag': 'DiseaseOrSyndrome'}, {'end': 29, 'start': 18, 'tag': 'Finding'}, {'end': 125, 'start': 109, 'tag': 'SignOrSymptom'}, {'end': 49, 'start': 33, 'tag': 'BiologicallyActiveSubstance'}, {'end': 10, 'start': 0, 'tag': 'Bacterium'}, {'end': 60, 'start': 33, 'tag': 'CellFunction'}, {'end': 72, 'start': 65, 'tag': 'CellFunction'}, {'end': 49, 'start': 33, 'tag': 'CellFunction'}, {'end': 141, 'start': 130, 'tag': 'PathologicFunction'}, {'end': 141, 'start': 130, 'tag': 'TemporalConcept'}]"
1144,Understanding the molecular mimicry mechanisms between spirochete antigens and host proteins may provide insights into their potential role in triggering autoimmunity in neurodegeneration.,"[{'end': 92, 'start': 84, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 83, 'start': 79, 'tag': 'Organism'}, {'end': 166, 'start': 154, 'tag': 'PathologicFunction'}, {'end': 65, 'start': 55, 'tag': 'Bacterium'}, {'end': 13, 'start': 0, 'tag': 'BiologicFunction'}, {'end': 46, 'start': 18, 'tag': 'CellFunction'}]"
1145,Epidemiological studies examining the association between spirochete infections and specific neurodegenerative conditions are essential for determining their clinical significance.,"[{'end': 121, 'start': 93, 'tag': 'DiseaseOrSyndrome'}, {'end': 179, 'start': 158, 'tag': 'Finding'}, {'end': 68, 'start': 58, 'tag': 'Bacterium'}, {'end': 23, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 79, 'start': 69, 'tag': 'PathologicFunction'}]"
1146,"Electromagnetic radiation is a form of energy that travels in waves and encompasses a wide range of frequencies, from extremely low frequencies to high-energy gamma rays.","[{'end': 45, 'start': 39, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 158, 'start': 152, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 67, 'start': 62, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 111, 'start': 100, 'tag': 'TemporalConcept'}, {'end': 25, 'start': 0, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 169, 'start': 159, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 169, 'start': 147, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 143, 'start': 128, 'tag': 'TemporalConcept'}]"
1147,"The impact of electromagnetic radiation on health depends on its frequency and intensity, with different types having varying levels of potential harm.","[{'end': 49, 'start': 43, 'tag': 'HealthCareActivity'}, {'end': 74, 'start': 65, 'tag': 'TemporalConcept'}, {'end': 39, 'start': 14, 'tag': 'NaturalPhenomenonOrProcess'}]"
1148,"UV radiation can cause premature aging of the skin, leading to wrinkles, age spots, and loss of skin elasticity.","[{'end': 76, 'start': 73, 'tag': 'OrganismAttribute'}, {'end': 50, 'start': 46, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 100, 'start': 96, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 12, 'start': 0, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 111, 'start': 88, 'tag': 'DiseaseOrSyndrome'}, {'end': 38, 'start': 33, 'tag': 'CellFunction'}, {'end': 38, 'start': 33, 'tag': 'BiologicFunction'}, {'end': 82, 'start': 77, 'tag': 'SignOrSymptom'}, {'end': 71, 'start': 63, 'tag': 'SignOrSymptom'}]"
1149,Machine learning algorithms are increasingly employed in Alzheimer's disease research to analyze large datasets and identify patterns in brain imaging scans.,"[{'end': 142, 'start': 137, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 76, 'start': 57, 'tag': 'DiseaseOrSyndrome'}, {'end': 85, 'start': 77, 'tag': 'ResearchActivity'}, {'end': 111, 'start': 103, 'tag': 'ResearchActivity'}, {'end': 150, 'start': 143, 'tag': 'HealthCareActivity'}, {'end': 133, 'start': 125, 'tag': 'ResearchActivity'}, {'end': 27, 'start': 0, 'tag': 'MachineActivity'}, {'end': 156, 'start': 151, 'tag': 'HealthCareActivity'}, {'end': 16, 'start': 0, 'tag': 'MachineActivity'}]"
1150,"Using machine learning in Alzheimer's research, researchers can detect subtle changes in brain structures that may serve as early biomarkers for the disease.","[{'end': 140, 'start': 130, 'tag': 'ClinicalAttribute'}, {'end': 46, 'start': 38, 'tag': 'ResearchActivity'}, {'end': 37, 'start': 26, 'tag': 'DiseaseOrSyndrome'}, {'end': 59, 'start': 48, 'tag': 'ResearchActivity'}, {'end': 129, 'start': 124, 'tag': 'TemporalConcept'}, {'end': 22, 'start': 6, 'tag': 'MachineActivity'}, {'end': 105, 'start': 89, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 85, 'start': 71, 'tag': 'Finding'}]"
1151,"Machine learning models are utilized to predict disease progression and assess an individual's risk of developing Alzheimer's based on various genetic, lifestyle, and demographic factors.","[{'end': 67, 'start': 48, 'tag': 'PathologicFunction'}, {'end': 125, 'start': 114, 'tag': 'DiseaseOrSyndrome'}, {'end': 99, 'start': 95, 'tag': 'Finding'}, {'end': 161, 'start': 152, 'tag': 'IndividualBehavior'}, {'end': 186, 'start': 167, 'tag': 'Finding'}, {'end': 23, 'start': 0, 'tag': 'MachineActivity'}, {'end': 16, 'start': 0, 'tag': 'MachineActivity'}, {'end': 186, 'start': 179, 'tag': 'Finding'}, {'end': 150, 'start': 143, 'tag': 'Finding'}]"
1152,"Advanced machine learning algorithms help in identifying specific genetic markers associated with Alzheimer's disease, providing a deeper understanding of its underlying genetic basis.","[{'end': 117, 'start': 98, 'tag': 'DiseaseOrSyndrome'}, {'end': 151, 'start': 131, 'tag': 'Finding'}, {'end': 81, 'start': 66, 'tag': 'ClinicalAttribute'}, {'end': 25, 'start': 9, 'tag': 'MachineActivity'}, {'end': 183, 'start': 170, 'tag': 'Finding'}, {'end': 36, 'start': 9, 'tag': 'MachineActivity'}]"
1153,"Machine learning-powered cognitive assessments can aid in early diagnosis and monitoring the cognitive decline in Alzheimer's patients, allowing for timely intervention.","[{'end': 73, 'start': 58, 'tag': 'HealthCareActivity'}, {'end': 134, 'start': 126, 'tag': 'PatientOrDisabledGroup'}, {'end': 110, 'start': 93, 'tag': 'DiseaseOrSyndrome'}, {'end': 125, 'start': 114, 'tag': 'DiseaseOrSyndrome'}, {'end': 88, 'start': 78, 'tag': 'HealthCareActivity'}, {'end': 16, 'start': 0, 'tag': 'MachineActivity'}, {'end': 46, 'start': 25, 'tag': 'HealthCareActivity'}, {'end': 168, 'start': 156, 'tag': 'HealthCareActivity'}]"
1154,"Data from wearable devices, such as smartwatches, are analyzed using machine learning to track changes in daily activities, sleep patterns, and mobility, providing valuable data for Alzheimer's research.","[{'end': 177, 'start': 173, 'tag': 'ResearchActivity'}, {'end': 202, 'start': 194, 'tag': 'ResearchActivity'}, {'end': 193, 'start': 182, 'tag': 'DiseaseOrSyndrome'}, {'end': 62, 'start': 54, 'tag': 'ResearchActivity'}, {'end': 4, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 138, 'start': 130, 'tag': 'ResearchActivity'}, {'end': 85, 'start': 69, 'tag': 'MachineActivity'}, {'end': 129, 'start': 124, 'tag': 'BiologicFunction'}, {'end': 26, 'start': 10, 'tag': 'ManufacturedObject'}, {'end': 48, 'start': 36, 'tag': 'ManufacturedObject'}, {'end': 102, 'start': 95, 'tag': 'Finding'}, {'end': 111, 'start': 106, 'tag': 'TemporalConcept'}, {'end': 122, 'start': 112, 'tag': 'Finding'}, {'end': 152, 'start': 144, 'tag': 'Finding'}]"
1155,Machine learning-driven drug discovery processes enable the identification of potential therapeutic targets and the development of more effective drugs for Alzheimer's treatment.,"[{'end': 151, 'start': 146, 'tag': 'PharmacologicSubstance'}, {'end': 107, 'start': 78, 'tag': 'ResearchActivity'}, {'end': 38, 'start': 24, 'tag': 'ResearchActivity'}, {'end': 16, 'start': 0, 'tag': 'MachineActivity'}, {'end': 177, 'start': 156, 'tag': 'HealthCareActivity'}]"
1156,Virtual reality combined with machine learning algorithms is used to simulate scenarios and assess memory and spatial navigation abilities in individuals at risk of Alzheimer's disease.,"[{'end': 184, 'start': 165, 'tag': 'DiseaseOrSyndrome'}, {'end': 105, 'start': 99, 'tag': 'Finding'}, {'end': 46, 'start': 30, 'tag': 'MachineActivity'}, {'end': 15, 'start': 0, 'tag': 'MachineActivity'}, {'end': 57, 'start': 30, 'tag': 'MachineActivity'}, {'end': 138, 'start': 110, 'tag': 'BiologicFunction'}, {'end': 153, 'start': 142, 'tag': 'PopulationGroup'}, {'end': 161, 'start': 157, 'tag': 'Finding'}]"
1157,"Machine learning-based predictive models are being developed to estimate the economic and societal impact of Alzheimer's disease, guiding healthcare planning and resource allocation for better patient care.","[{'end': 128, 'start': 109, 'tag': 'DiseaseOrSyndrome'}, {'end': 157, 'start': 138, 'tag': 'HealthCareActivity'}, {'end': 16, 'start': 8, 'tag': 'BiologicFunction'}, {'end': 205, 'start': 193, 'tag': 'HealthCareActivity'}, {'end': 16, 'start': 0, 'tag': 'MachineActivity'}, {'end': 40, 'start': 23, 'tag': 'MachineActivity'}, {'end': 181, 'start': 162, 'tag': 'HealthCareActivity'}]"
1158,"Machine learning models based on NLP are used to identify potential genetic markers and biomarkers associated with Huntington's disease, aiding in early diagnosis and personalized treatment approaches.","[{'end': 135, 'start': 115, 'tag': 'DiseaseOrSyndrome'}, {'end': 162, 'start': 147, 'tag': 'HealthCareActivity'}, {'end': 98, 'start': 88, 'tag': 'ClinicalAttribute'}, {'end': 83, 'start': 76, 'tag': 'ClinicalAttribute'}, {'end': 75, 'start': 68, 'tag': 'HealthCareActivity'}, {'end': 23, 'start': 0, 'tag': 'MachineActivity'}, {'end': 16, 'start': 0, 'tag': 'MachineActivity'}, {'end': 36, 'start': 33, 'tag': 'MachineActivity'}, {'end': 200, 'start': 167, 'tag': 'HealthCareActivity'}]"
1159,"Short-term exposure to high levels of UV radiation can cause sunburn, which can be painful and increase the risk of skin cancer later in life.","[{'end': 112, 'start': 108, 'tag': 'Finding'}, {'end': 133, 'start': 128, 'tag': 'TemporalConcept'}, {'end': 141, 'start': 137, 'tag': 'TemporalConcept'}, {'end': 127, 'start': 121, 'tag': 'DiseaseOrSyndrome'}, {'end': 120, 'start': 116, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 19, 'start': 11, 'tag': 'Finding'}, {'end': 90, 'start': 83, 'tag': 'SignOrSymptom'}, {'end': 50, 'start': 38, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 10, 'start': 0, 'tag': 'TemporalConcept'}, {'end': 68, 'start': 61, 'tag': 'InjuryOrPoisoning'}]"
1160,"Natural language processing (NLP) techniques are being applied to analyze text data, such as medical records and research papers, to extract valuable insights related to Alzheimer's disease.","[{'end': 83, 'start': 74, 'tag': 'ResearchActivity'}, {'end': 189, 'start': 170, 'tag': 'DiseaseOrSyndrome'}, {'end': 128, 'start': 113, 'tag': 'ResearchActivity'}, {'end': 140, 'start': 133, 'tag': 'Substance'}, {'end': 44, 'start': 34, 'tag': 'MachineActivity'}, {'end': 27, 'start': 0, 'tag': 'MachineActivity'}, {'end': 32, 'start': 29, 'tag': 'MachineActivity'}, {'end': 108, 'start': 93, 'tag': 'HealthCareActivity'}]"
1161,"Natural language processing (NLP) is playing a critical role in extracting valuable information from vast amounts of text data, such as medical records and research literature, related to Huntington's disease.","[{'end': 208, 'start': 188, 'tag': 'DiseaseOrSyndrome'}, {'end': 126, 'start': 117, 'tag': 'ResearchActivity'}, {'end': 175, 'start': 165, 'tag': 'ResearchActivity'}, {'end': 164, 'start': 156, 'tag': 'ResearchActivity'}, {'end': 60, 'start': 47, 'tag': 'Finding'}, {'end': 32, 'start': 29, 'tag': 'MachineActivity'}, {'end': 27, 'start': 0, 'tag': 'MachineActivity'}, {'end': 151, 'start': 136, 'tag': 'HealthCareActivity'}]"
1162,"NLP algorithms are being used to automatically analyze and categorize clinical notes and reports, enabling researchers to identify specific symptoms and disease progression patterns in patients with Huntington's disease.","[{'end': 219, 'start': 199, 'tag': 'DiseaseOrSyndrome'}, {'end': 148, 'start': 140, 'tag': 'SignOrSymptom'}, {'end': 172, 'start': 153, 'tag': 'PathologicFunction'}, {'end': 193, 'start': 185, 'tag': 'PatientOrDisabledGroup'}, {'end': 96, 'start': 89, 'tag': 'HealthCareActivity'}, {'end': 96, 'start': 89, 'tag': 'ResearchActivity'}, {'end': 118, 'start': 107, 'tag': 'ResearchActivity'}, {'end': 3, 'start': 0, 'tag': 'MachineActivity'}, {'end': 14, 'start': 0, 'tag': 'MachineActivity'}, {'end': 84, 'start': 70, 'tag': 'HealthCareActivity'}]"
1163,"By processing and analyzing patient-generated text data, NLP helps researchers gain insights into the daily challenges and experiences of individuals living with Huntington's disease.","[{'end': 182, 'start': 162, 'tag': 'DiseaseOrSyndrome'}, {'end': 55, 'start': 46, 'tag': 'ResearchActivity'}, {'end': 35, 'start': 28, 'tag': 'PatientOrDisabledGroup'}, {'end': 118, 'start': 108, 'tag': 'HealthCareActivity'}, {'end': 78, 'start': 67, 'tag': 'ResearchActivity'}, {'end': 149, 'start': 138, 'tag': 'PopulationGroup'}, {'end': 107, 'start': 102, 'tag': 'TemporalConcept'}, {'end': 60, 'start': 57, 'tag': 'MachineActivity'}, {'end': 134, 'start': 123, 'tag': 'BiologicFunction'}]"
1164,"NLP-powered sentiment analysis is used to gauge the emotional and psychological impact of Huntington's disease on patients and their caregivers, contributing to better understanding and support for the affected individuals.","[{'end': 110, 'start': 90, 'tag': 'DiseaseOrSyndrome'}, {'end': 30, 'start': 12, 'tag': 'MachineActivity'}, {'end': 181, 'start': 168, 'tag': 'BiologicFunction'}, {'end': 122, 'start': 114, 'tag': 'PatientOrDisabledGroup'}, {'end': 222, 'start': 211, 'tag': 'PopulationGroup'}, {'end': 143, 'start': 133, 'tag': 'HealthCareActivity'}, {'end': 86, 'start': 66, 'tag': 'Finding'}, {'end': 3, 'start': 0, 'tag': 'MachineActivity'}]"
1165,"NLP-based chatbots and virtual assistants provide a user-friendly platform for individuals affected by Huntington's disease to access relevant information, support resources, and connect with others in the community.","[{'end': 123, 'start': 103, 'tag': 'DiseaseOrSyndrome'}, {'end': 215, 'start': 206, 'tag': 'HealthCareRelatedOrganization'}, {'end': 90, 'start': 79, 'tag': 'PopulationGroup'}, {'end': 3, 'start': 0, 'tag': 'MachineActivity'}, {'end': 18, 'start': 10, 'tag': 'MachineActivity'}, {'end': 41, 'start': 23, 'tag': 'MachineActivity'}, {'end': 74, 'start': 52, 'tag': 'MachineActivity'}]"
1166,"NLP is applied to analyze patient-reported outcomes and responses from surveys, allowing researchers to assess the effectiveness of different interventions and treatments in managing Huntington's disease symptoms.","[{'end': 203, 'start': 183, 'tag': 'DiseaseOrSyndrome'}, {'end': 33, 'start': 26, 'tag': 'PatientOrDisabledGroup'}, {'end': 100, 'start': 89, 'tag': 'ResearchActivity'}, {'end': 128, 'start': 115, 'tag': 'Finding'}, {'end': 3, 'start': 0, 'tag': 'MachineActivity'}, {'end': 212, 'start': 204, 'tag': 'SignOrSymptom'}, {'end': 170, 'start': 160, 'tag': 'HealthCareActivity'}, {'end': 170, 'start': 160, 'tag': 'ResearchActivity'}, {'end': 51, 'start': 43, 'tag': 'Finding'}, {'end': 78, 'start': 71, 'tag': 'HealthCareActivity'}]"
1167,"Integrating NLP with neuroimaging data helps researchers extract meaningful information from brain scans, aiding in the identification of brain regions affected by Huntington's disease and tracking disease progression.","[{'end': 184, 'start': 164, 'tag': 'DiseaseOrSyndrome'}, {'end': 98, 'start': 93, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 38, 'start': 34, 'tag': 'ResearchActivity'}, {'end': 217, 'start': 198, 'tag': 'PathologicFunction'}, {'end': 56, 'start': 45, 'tag': 'ResearchActivity'}, {'end': 151, 'start': 138, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 64, 'start': 57, 'tag': 'Substance'}, {'end': 33, 'start': 21, 'tag': 'HealthCareActivity'}, {'end': 104, 'start': 99, 'tag': 'HealthCareActivity'}, {'end': 15, 'start': 12, 'tag': 'MachineActivity'}]"
1168,"Natural language processing algorithms are utilized to review and summarize large volumes of research articles and clinical trials, enabling researchers to stay up-to-date with the latest advancements in Huntington's disease research.","[{'end': 224, 'start': 204, 'tag': 'DiseaseOrSyndrome'}, {'end': 61, 'start': 55, 'tag': 'ResearchActivity'}, {'end': 61, 'start': 55, 'tag': 'HealthCareActivity'}, {'end': 130, 'start': 115, 'tag': 'ResearchActivity'}, {'end': 110, 'start': 93, 'tag': 'ResearchActivity'}, {'end': 233, 'start': 225, 'tag': 'ResearchActivity'}, {'end': 152, 'start': 141, 'tag': 'ResearchActivity'}, {'end': 171, 'start': 167, 'tag': 'TemporalConcept'}, {'end': 187, 'start': 181, 'tag': 'TemporalConcept'}, {'end': 27, 'start': 0, 'tag': 'MachineActivity'}, {'end': 38, 'start': 0, 'tag': 'MachineActivity'}, {'end': 75, 'start': 66, 'tag': 'MachineActivity'}, {'end': 200, 'start': 188, 'tag': 'Finding'}]"
1169,"The application of NLP in Huntington's disease research is accelerating the discovery of new insights, facilitating interdisciplinary collaboration, and ultimately contributing to the development of more effective treatments and therapies for this devastating neurodegenerative disorder.","[{'end': 46, 'start': 26, 'tag': 'DiseaseOrSyndrome'}, {'end': 286, 'start': 260, 'tag': 'DiseaseOrSyndrome'}, {'end': 85, 'start': 76, 'tag': 'ResearchActivity'}, {'end': 55, 'start': 47, 'tag': 'ResearchActivity'}, {'end': 22, 'start': 19, 'tag': 'MachineActivity'}, {'end': 224, 'start': 214, 'tag': 'HealthCareActivity'}, {'end': 224, 'start': 214, 'tag': 'ResearchActivity'}, {'end': 238, 'start': 229, 'tag': 'HealthCareActivity'}, {'end': 147, 'start': 116, 'tag': 'HealthCareActivity'}, {'end': 195, 'start': 184, 'tag': 'BiologicFunction'}]"
1170,"UV radiation can also affect the eyes, leading to conditions like cataracts and photokeratitis (a painful eye condition similar to sunburn).","[{'end': 60, 'start': 50, 'tag': 'DiseaseOrSyndrome'}, {'end': 119, 'start': 110, 'tag': 'DiseaseOrSyndrome'}, {'end': 105, 'start': 98, 'tag': 'SignOrSymptom'}, {'end': 12, 'start': 0, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 37, 'start': 33, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 109, 'start': 106, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 75, 'start': 66, 'tag': 'DiseaseOrSyndrome'}, {'end': 94, 'start': 80, 'tag': 'DiseaseOrSyndrome'}, {'end': 138, 'start': 131, 'tag': 'InjuryOrPoisoning'}]"
1171,Automated Speech Recognition (ASR) technology is being explored as a potential tool for early detection and monitoring of neurodegenerative disorders through changes in speech patterns.,"[{'end': 149, 'start': 122, 'tag': 'DiseaseOrSyndrome'}, {'end': 118, 'start': 108, 'tag': 'HealthCareActivity'}, {'end': 103, 'start': 88, 'tag': 'HealthCareActivity'}, {'end': 28, 'start': 0, 'tag': 'MachineActivity'}, {'end': 33, 'start': 30, 'tag': 'MachineActivity'}, {'end': 165, 'start': 158, 'tag': 'Finding'}, {'end': 184, 'start': 169, 'tag': 'ClinicalAttribute'}, {'end': 175, 'start': 169, 'tag': 'BiologicFunction'}]"
1172,ASR algorithms can analyze speech samples from individuals with neurodegenerative disorders to detect subtle speech abnormalities that may indicate disease progression.,"[{'end': 91, 'start': 64, 'tag': 'DiseaseOrSyndrome'}, {'end': 167, 'start': 148, 'tag': 'PathologicFunction'}, {'end': 58, 'start': 47, 'tag': 'PopulationGroup'}, {'end': 3, 'start': 0, 'tag': 'MachineActivity'}, {'end': 14, 'start': 0, 'tag': 'MachineActivity'}, {'end': 33, 'start': 27, 'tag': 'BiologicFunction'}, {'end': 129, 'start': 109, 'tag': 'SignOrSymptom'}, {'end': 41, 'start': 34, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 41, 'start': 34, 'tag': 'Substance'}]"
1173,Speech-based biomarkers identified through ASR have shown promise in distinguishing between individuals with different types of neurodegenerative disorders.,"[{'end': 155, 'start': 128, 'tag': 'DiseaseOrSyndrome'}, {'end': 23, 'start': 13, 'tag': 'ClinicalAttribute'}, {'end': 103, 'start': 92, 'tag': 'PopulationGroup'}, {'end': 46, 'start': 43, 'tag': 'MachineActivity'}, {'end': 6, 'start': 0, 'tag': 'BiologicFunction'}]"
1174,ASR-powered voice assistants and virtual communication tools can facilitate remote monitoring and support for individuals with neurodegenerative disorders who may experience communication difficulties.,"[{'end': 154, 'start': 127, 'tag': 'DiseaseOrSyndrome'}, {'end': 173, 'start': 163, 'tag': 'BiologicFunction'}, {'end': 93, 'start': 83, 'tag': 'HealthCareActivity'}, {'end': 121, 'start': 110, 'tag': 'PopulationGroup'}, {'end': 54, 'start': 41, 'tag': 'HealthCareActivity'}, {'end': 54, 'start': 41, 'tag': 'CellFunction'}, {'end': 3, 'start': 0, 'tag': 'MachineActivity'}, {'end': 60, 'start': 33, 'tag': 'MachineActivity'}, {'end': 28, 'start': 12, 'tag': 'MachineActivity'}, {'end': 200, 'start': 174, 'tag': 'SignOrSymptom'}]"
1175,ASR is used to transcribe and analyze speech samples in research studies focused on understanding the impact of neurodegenerative disorders on language and communication abilities.,"[{'end': 139, 'start': 112, 'tag': 'DiseaseOrSyndrome'}, {'end': 97, 'start': 84, 'tag': 'BiologicFunction'}, {'end': 52, 'start': 45, 'tag': 'Substance'}, {'end': 169, 'start': 156, 'tag': 'HealthCareActivity'}, {'end': 169, 'start': 156, 'tag': 'CellFunction'}, {'end': 72, 'start': 56, 'tag': 'ResearchActivity'}, {'end': 3, 'start': 0, 'tag': 'MachineActivity'}, {'end': 44, 'start': 38, 'tag': 'BiologicFunction'}]"
1176,ASR systems are being integrated into wearable devices to provide real-time monitoring of speech changes in individuals at risk of developing neurodegenerative disorders.,"[{'end': 169, 'start': 142, 'tag': 'DiseaseOrSyndrome'}, {'end': 75, 'start': 71, 'tag': 'TemporalConcept'}, {'end': 127, 'start': 123, 'tag': 'Finding'}, {'end': 86, 'start': 76, 'tag': 'HealthCareActivity'}, {'end': 119, 'start': 108, 'tag': 'PopulationGroup'}, {'end': 11, 'start': 0, 'tag': 'MachineActivity'}, {'end': 54, 'start': 38, 'tag': 'ManufacturedObject'}, {'end': 96, 'start': 90, 'tag': 'BiologicFunction'}, {'end': 104, 'start': 97, 'tag': 'Finding'}]"
1177,ASR-powered speech therapies are being developed to assist individuals with neurodegenerative disorders in maintaining and improving their communication skills.,"[{'end': 103, 'start': 76, 'tag': 'DiseaseOrSyndrome'}, {'end': 28, 'start': 12, 'tag': 'HealthCareActivity'}, {'end': 70, 'start': 59, 'tag': 'PopulationGroup'}, {'end': 3, 'start': 0, 'tag': 'MachineActivity'}, {'end': 159, 'start': 139, 'tag': 'BiologicFunction'}]"
1178,The development of personalized ASR models allows for better adaptation to changes in speech patterns as neurodegenerative disorders progress.,"[{'end': 132, 'start': 105, 'tag': 'DiseaseOrSyndrome'}, {'end': 141, 'start': 133, 'tag': 'TemporalConcept'}, {'end': 71, 'start': 61, 'tag': 'BiologicFunction'}, {'end': 42, 'start': 32, 'tag': 'MachineActivity'}, {'end': 82, 'start': 75, 'tag': 'Finding'}, {'end': 101, 'start': 86, 'tag': 'BiologicFunction'}]"
1179,"By analyzing large datasets of speech samples, ASR can contribute to the discovery of novel speech biomarkers and improve diagnostic accuracy for neurodegenerative disorders.","[{'end': 173, 'start': 146, 'tag': 'DiseaseOrSyndrome'}, {'end': 109, 'start': 99, 'tag': 'ClinicalAttribute'}, {'end': 82, 'start': 73, 'tag': 'ResearchActivity'}, {'end': 27, 'start': 19, 'tag': 'ResearchActivity'}, {'end': 141, 'start': 122, 'tag': 'Finding'}, {'end': 50, 'start': 47, 'tag': 'MachineActivity'}, {'end': 37, 'start': 31, 'tag': 'BiologicFunction'}, {'end': 45, 'start': 38, 'tag': 'Substance'}, {'end': 45, 'start': 38, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 98, 'start': 92, 'tag': 'BiologicFunction'}]"
1180,ASR technology has the potential to revolutionize the field of neurodegenerative disorder research and care by enabling early intervention and more personalized treatment approaches based on speech analysis.,"[{'end': 89, 'start': 63, 'tag': 'DiseaseOrSyndrome'}, {'end': 206, 'start': 198, 'tag': 'ResearchActivity'}, {'end': 98, 'start': 90, 'tag': 'ResearchActivity'}, {'end': 138, 'start': 120, 'tag': 'HealthCareActivity'}, {'end': 107, 'start': 103, 'tag': 'HealthCareActivity'}, {'end': 14, 'start': 0, 'tag': 'MachineActivity'}, {'end': 181, 'start': 148, 'tag': 'HealthCareActivity'}, {'end': 197, 'start': 191, 'tag': 'BiologicFunction'}]"
1181,"People with fair skin, light-colored eyes, and a history of sunburns are at a higher risk of UV radiation-related health issues.","[{'end': 120, 'start': 114, 'tag': 'HealthCareActivity'}, {'end': 89, 'start': 85, 'tag': 'Finding'}, {'end': 21, 'start': 17, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 28, 'start': 23, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 56, 'start': 49, 'tag': 'Finding'}, {'end': 6, 'start': 0, 'tag': 'PopulationGroup'}, {'end': 105, 'start': 93, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 41, 'start': 37, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 68, 'start': 60, 'tag': 'InjuryOrPoisoning'}]"
1182,"Protective measures, such as wearing hats, sunglasses, and sunscreen, can help reduce the harmful effects of UV radiation on the skin and eyes.","[{'end': 105, 'start': 90, 'tag': 'PathologicFunction'}, {'end': 133, 'start': 129, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 121, 'start': 109, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 142, 'start': 138, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 53, 'start': 43, 'tag': 'ManufacturedObject'}, {'end': 68, 'start': 59, 'tag': 'Substance'}, {'end': 41, 'start': 37, 'tag': 'ManufacturedObject'}, {'end': 19, 'start': 0, 'tag': 'HealthCareActivity'}]"
1183,"It is essential to seek shade and limit sun exposure, especially during peak UV hours between 10 am and 4 pm, to minimize the risk of UV-related health problems.","[{'end': 130, 'start': 126, 'tag': 'Finding'}, {'end': 79, 'start': 77, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 136, 'start': 134, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 52, 'start': 40, 'tag': 'Finding'}, {'end': 160, 'start': 145, 'tag': 'Finding'}]"
1184,Regular skin self-examinations and annual check-ups with a dermatologist can aid in early detection and treatment of skin cancer caused by UV radiation.,"[{'end': 128, 'start': 122, 'tag': 'DiseaseOrSyndrome'}, {'end': 12, 'start': 8, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 121, 'start': 117, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 41, 'start': 35, 'tag': 'TemporalConcept'}, {'end': 99, 'start': 84, 'tag': 'HealthCareActivity'}, {'end': 151, 'start': 139, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 30, 'start': 13, 'tag': 'HealthCareActivity'}, {'end': 51, 'start': 42, 'tag': 'HealthCareActivity'}, {'end': 113, 'start': 104, 'tag': 'HealthCareActivity'}, {'end': 113, 'start': 104, 'tag': 'ResearchActivity'}, {'end': 72, 'start': 59, 'tag': 'HealthCareActivity'}]"
1185,Ultraviolet (UV) radiation is a type of electromagnetic radiation emitted by the sun and artificial sources like tanning beds and UV lamps.,"[{'end': 107, 'start': 100, 'tag': 'Finding'}, {'end': 132, 'start': 130, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 15, 'start': 13, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 26, 'start': 17, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 11, 'start': 0, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 65, 'start': 40, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 138, 'start': 130, 'tag': 'ManufacturedObject'}, {'end': 125, 'start': 113, 'tag': 'ManufacturedObject'}, {'end': 84, 'start': 81, 'tag': 'NaturalPhenomenonOrProcess'}]"
1186,"UV radiation is classified into three types: UVA, UVB, and UVC, with UVA being the least energetic and UVC being the most harmful, though it is mostly absorbed by the ozone layer.","[{'end': 12, 'start': 0, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 48, 'start': 45, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 53, 'start': 50, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 62, 'start': 59, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 106, 'start': 103, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 72, 'start': 69, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 178, 'start': 167, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 172, 'start': 167, 'tag': 'Chemical'}]"
1187,"Prolonged exposure to UV radiation can damage the DNA in skin cells, leading to an increased risk of skin cancer, including melanoma, basal cell carcinoma, and squamous cell carcinoma.","[{'end': 67, 'start': 62, 'tag': 'Cell'}, {'end': 144, 'start': 134, 'tag': 'Cell'}, {'end': 173, 'start': 160, 'tag': 'Cell'}, {'end': 97, 'start': 83, 'tag': 'Finding'}, {'end': 112, 'start': 106, 'tag': 'DiseaseOrSyndrome'}, {'end': 53, 'start': 50, 'tag': 'NucleicAcidNucleosideOrNucleotide'}, {'end': 61, 'start': 57, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 105, 'start': 101, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 45, 'start': 39, 'tag': 'InjuryOrPoisoning'}, {'end': 18, 'start': 10, 'tag': 'Finding'}, {'end': 34, 'start': 22, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 9, 'start': 0, 'tag': 'TemporalConcept'}, {'end': 132, 'start': 124, 'tag': 'DiseaseOrSyndrome'}, {'end': 154, 'start': 134, 'tag': 'DiseaseOrSyndrome'}, {'end': 183, 'start': 160, 'tag': 'DiseaseOrSyndrome'}]"
1188,"Non-ionizing electromagnetic radiation, such as radio waves and microwaves, is generally considered safe and does not have enough energy to break chemical bonds or cause ionization in biological tissues.","[{'end': 202, 'start': 184, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 136, 'start': 130, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 59, 'start': 48, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 38, 'start': 0, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 38, 'start': 13, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 38, 'start': 4, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 180, 'start': 170, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 74, 'start': 64, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 160, 'start': 146, 'tag': 'CellFunction'}]"
1189,Emerging research is uncovering the significant role of host-bacteria interactions in the pathogenesis of neurodegenerative disorders.,"[{'end': 133, 'start': 106, 'tag': 'DiseaseOrSyndrome'}, {'end': 102, 'start': 90, 'tag': 'PathologicFunction'}, {'end': 60, 'start': 56, 'tag': 'Organism'}, {'end': 17, 'start': 9, 'tag': 'ResearchActivity'}, {'end': 69, 'start': 61, 'tag': 'Bacterium'}, {'end': 82, 'start': 70, 'tag': 'Finding'}, {'end': 82, 'start': 56, 'tag': 'NaturalPhenomenonOrProcess'}]"
1190,"Dysregulation of the gut microbiota has been implicated in various neurodegenerative diseases, highlighting the importance of understanding host-bacteria interactions in the context of brain health.","[{'end': 93, 'start': 67, 'tag': 'DiseaseOrSyndrome'}, {'end': 190, 'start': 185, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 139, 'start': 126, 'tag': 'BiologicFunction'}, {'end': 197, 'start': 191, 'tag': 'HealthCareActivity'}, {'end': 144, 'start': 140, 'tag': 'Organism'}, {'end': 35, 'start': 21, 'tag': 'Organism'}, {'end': 153, 'start': 145, 'tag': 'Bacterium'}, {'end': 24, 'start': 21, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 166, 'start': 154, 'tag': 'Finding'}, {'end': 166, 'start': 140, 'tag': 'NaturalPhenomenonOrProcess'}]"
1191,"The gut-brain axis, which involves bidirectional communication between the gut microbiota and the central nervous system, is a key pathway through which host-bacteria interactions may influence neurodegenerative disorders.","[{'end': 221, 'start': 194, 'tag': 'DiseaseOrSyndrome'}, {'end': 18, 'start': 4, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 120, 'start': 98, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 138, 'start': 131, 'tag': 'CellFunction'}, {'end': 157, 'start': 153, 'tag': 'Organism'}, {'end': 89, 'start': 75, 'tag': 'Organism'}, {'end': 166, 'start': 158, 'tag': 'Bacterium'}, {'end': 179, 'start': 167, 'tag': 'Finding'}, {'end': 179, 'start': 153, 'tag': 'NaturalPhenomenonOrProcess'}]"
1192,"Altered host-bacteria interactions in the gut have been associated with increased neuroinflammation, a common feature in neurodegenerative diseases.","[{'end': 147, 'start': 121, 'tag': 'DiseaseOrSyndrome'}, {'end': 12, 'start': 8, 'tag': 'Organism'}, {'end': 99, 'start': 82, 'tag': 'PathologicFunction'}, {'end': 21, 'start': 13, 'tag': 'Bacterium'}, {'end': 45, 'start': 42, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 34, 'start': 22, 'tag': 'Finding'}, {'end': 34, 'start': 8, 'tag': 'NaturalPhenomenonOrProcess'}]"
1193,Manipulating the gut microbiota through probiotics or prebiotics has shown potential in modulating host-bacteria interactions and exerting neuroprotective effects in animal models of neurodegenerative disorders.,"[{'end': 210, 'start': 183, 'tag': 'DiseaseOrSyndrome'}, {'end': 210, 'start': 166, 'tag': 'ExperimentalModelOfDisease'}, {'end': 103, 'start': 99, 'tag': 'Organism'}, {'end': 162, 'start': 139, 'tag': 'Finding'}, {'end': 31, 'start': 17, 'tag': 'Organism'}, {'end': 112, 'start': 104, 'tag': 'Bacterium'}, {'end': 125, 'start': 113, 'tag': 'Finding'}, {'end': 179, 'start': 166, 'tag': 'ResearchActivity'}, {'end': 125, 'start': 99, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 50, 'start': 40, 'tag': 'Bacterium'}, {'end': 64, 'start': 54, 'tag': 'Chemical'}, {'end': 172, 'start': 166, 'tag': 'Eukaryote'}]"
1194,"The role of host-bacteria interactions in the aggregation of misfolded proteins, such as amyloid-beta and alpha-synuclein, is an active area of investigation in neurodegenerative disease research.","[{'end': 101, 'start': 89, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 157, 'start': 144, 'tag': 'ResearchActivity'}, {'end': 186, 'start': 161, 'tag': 'DiseaseOrSyndrome'}, {'end': 16, 'start': 12, 'tag': 'Organism'}, {'end': 195, 'start': 187, 'tag': 'ResearchActivity'}, {'end': 96, 'start': 89, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 96, 'start': 89, 'tag': 'BiologicallyActiveSubstance'}, {'end': 25, 'start': 17, 'tag': 'Bacterium'}, {'end': 38, 'start': 26, 'tag': 'Finding'}, {'end': 79, 'start': 61, 'tag': 'CellOrMolecularDysfunction'}, {'end': 121, 'start': 106, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 121, 'start': 106, 'tag': 'BiologicallyActiveSubstance'}, {'end': 101, 'start': 89, 'tag': 'BiologicallyActiveSubstance'}, {'end': 38, 'start': 12, 'tag': 'NaturalPhenomenonOrProcess'}]"
1195,"Understanding the impact of antibiotics and other medications on host-bacteria interactions is critical, as they may influence the progression of neurodegenerative disorders through the gut-brain axis.","[{'end': 173, 'start': 146, 'tag': 'DiseaseOrSyndrome'}, {'end': 200, 'start': 186, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 69, 'start': 65, 'tag': 'Organism'}, {'end': 78, 'start': 70, 'tag': 'Bacterium'}, {'end': 91, 'start': 79, 'tag': 'Finding'}, {'end': 61, 'start': 50, 'tag': 'PharmacologicSubstance'}, {'end': 103, 'start': 95, 'tag': 'Finding'}, {'end': 91, 'start': 65, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 39, 'start': 28, 'tag': 'PharmacologicSubstance'}, {'end': 142, 'start': 131, 'tag': 'TemporalConcept'}, {'end': 142, 'start': 131, 'tag': 'PathologicFunction'}]"
1196,Studies have shown that aging-related changes in the gut microbiota can influence host-bacteria interactions and may contribute to the development of age-related neurodegenerative diseases.,"[{'end': 86, 'start': 82, 'tag': 'Organism'}, {'end': 188, 'start': 150, 'tag': 'DiseaseOrSyndrome'}, {'end': 67, 'start': 53, 'tag': 'Organism'}, {'end': 95, 'start': 87, 'tag': 'Bacterium'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 108, 'start': 96, 'tag': 'Finding'}, {'end': 108, 'start': 82, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 29, 'start': 24, 'tag': 'BiologicFunction'}, {'end': 29, 'start': 24, 'tag': 'CellFunction'}, {'end': 45, 'start': 38, 'tag': 'Finding'}]"
1197,Analyzing the metagenomic profiles of gut bacteria in individuals with neurodegenerative disorders can provide insights into the specific microbial species involved in host-bacteria interactions linked to disease progression.,"[{'end': 98, 'start': 71, 'tag': 'DiseaseOrSyndrome'}, {'end': 224, 'start': 205, 'tag': 'PathologicFunction'}, {'end': 155, 'start': 148, 'tag': 'OrganismAttribute'}, {'end': 172, 'start': 168, 'tag': 'Organism'}, {'end': 34, 'start': 14, 'tag': 'ResearchActivity'}, {'end': 50, 'start': 42, 'tag': 'Bacterium'}, {'end': 181, 'start': 173, 'tag': 'Bacterium'}, {'end': 41, 'start': 38, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 65, 'start': 54, 'tag': 'PopulationGroup'}, {'end': 194, 'start': 182, 'tag': 'Finding'}, {'end': 194, 'start': 168, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 155, 'start': 138, 'tag': 'Organism'}]"
1198,"Harnessing knowledge about host-bacteria interactions in neurodegenerative disorders may open up new avenues for developing novel therapeutic strategies, including microbiota-targeted interventions, to manage or even prevent these debilitating conditions.","[{'end': 84, 'start': 57, 'tag': 'DiseaseOrSyndrome'}, {'end': 152, 'start': 130, 'tag': 'HealthCareActivity'}, {'end': 31, 'start': 27, 'tag': 'Organism'}, {'end': 20, 'start': 11, 'tag': 'Finding'}, {'end': 40, 'start': 32, 'tag': 'Bacterium'}, {'end': 53, 'start': 41, 'tag': 'Finding'}, {'end': 254, 'start': 231, 'tag': 'DiseaseOrSyndrome'}, {'end': 53, 'start': 27, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 174, 'start': 164, 'tag': 'Organism'}]"
1199,"However, long-term exposure to high levels of non-ionizing radiation, such as from prolonged use of cell phones or living near power lines, has raised concerns about potential health effects.","[{'end': 182, 'start': 176, 'tag': 'HealthCareActivity'}, {'end': 18, 'start': 9, 'tag': 'TemporalConcept'}, {'end': 190, 'start': 183, 'tag': 'Finding'}, {'end': 27, 'start': 19, 'tag': 'Finding'}, {'end': 92, 'start': 83, 'tag': 'TemporalConcept'}, {'end': 68, 'start': 46, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 68, 'start': 50, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 111, 'start': 100, 'tag': 'ManufacturedObject'}, {'end': 138, 'start': 127, 'tag': 'ManufacturedObject'}]"
1200,"Retinal defects, such as thinning of the retinal nerve fiber layer, have been observed in individuals with neurodegenerative disorders like Alzheimer's disease and Parkinson's disease.","[{'end': 183, 'start': 164, 'tag': 'DiseaseOrSyndrome'}, {'end': 134, 'start': 107, 'tag': 'DiseaseOrSyndrome'}, {'end': 159, 'start': 140, 'tag': 'DiseaseOrSyndrome'}, {'end': 101, 'start': 90, 'tag': 'PopulationGroup'}, {'end': 66, 'start': 41, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 7, 'start': 0, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 15, 'start': 0, 'tag': 'AnatomicalAbnormality'}, {'end': 66, 'start': 25, 'tag': 'Finding'}]"
1201,Optical coherence tomography (OCT) is a non-invasive imaging technique used to detect retinal defects that may serve as potential biomarkers for neurodegenerative diseases.,"[{'end': 171, 'start': 145, 'tag': 'DiseaseOrSyndrome'}, {'end': 140, 'start': 120, 'tag': 'ClinicalAttribute'}, {'end': 70, 'start': 61, 'tag': 'ResearchActivity'}, {'end': 33, 'start': 30, 'tag': 'HealthCareActivity'}, {'end': 93, 'start': 86, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 60, 'start': 40, 'tag': 'HealthCareActivity'}, {'end': 28, 'start': 0, 'tag': 'HealthCareActivity'}, {'end': 101, 'start': 86, 'tag': 'AnatomicalAbnormality'}]"
1202,"Studies have shown that abnormalities in the retinal vasculature, detected through angiography, are associated with certain neurodegenerative disorders, including multiple sclerosis.","[{'end': 151, 'start': 124, 'tag': 'DiseaseOrSyndrome'}, {'end': 181, 'start': 163, 'tag': 'DiseaseOrSyndrome'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 64, 'start': 53, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 52, 'start': 45, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 94, 'start': 83, 'tag': 'HealthCareActivity'}]"
1203,Fundus autofluorescence imaging is used to identify retinal abnormalities that have been linked to certain neurodegenerative diseases.,"[{'end': 133, 'start': 107, 'tag': 'DiseaseOrSyndrome'}, {'end': 31, 'start': 0, 'tag': 'HealthCareActivity'}, {'end': 59, 'start': 52, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 73, 'start': 53, 'tag': 'AnatomicalAbnormality'}]"
1204,"Retinal imaging techniques, combined with artificial intelligence algorithms, show promise in distinguishing between healthy individuals and those with neurodegenerative disorders based on subtle retinal defects.","[{'end': 179, 'start': 152, 'tag': 'DiseaseOrSyndrome'}, {'end': 26, 'start': 8, 'tag': 'HealthCareActivity'}, {'end': 136, 'start': 117, 'tag': 'PopulationGroup'}, {'end': 203, 'start': 196, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 7, 'start': 0, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 211, 'start': 196, 'tag': 'AnatomicalAbnormality'}, {'end': 65, 'start': 42, 'tag': 'MachineActivity'}, {'end': 76, 'start': 42, 'tag': 'MachineActivity'}]"
1205,"In some neurodegenerative disorders, examination of retinal abnormalities may be used as a complementary approach to cerebrospinal fluid analysis and neuroimaging for diagnostic purposes.","[{'end': 35, 'start': 8, 'tag': 'DiseaseOrSyndrome'}, {'end': 136, 'start': 117, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 145, 'start': 137, 'tag': 'ResearchActivity'}, {'end': 59, 'start': 52, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 162, 'start': 150, 'tag': 'HealthCareActivity'}, {'end': 177, 'start': 167, 'tag': 'HealthCareActivity'}, {'end': 73, 'start': 52, 'tag': 'AnatomicalAbnormality'}]"
1206,Continued research into the relationship between retinal defects and neurodegenerative disorders holds the potential to provide valuable insights into disease mechanisms and improve early detection and treatment strategies.,"[{'end': 96, 'start': 69, 'tag': 'DiseaseOrSyndrome'}, {'end': 222, 'start': 202, 'tag': 'HealthCareActivity'}, {'end': 18, 'start': 10, 'tag': 'ResearchActivity'}, {'end': 40, 'start': 28, 'tag': 'Finding'}, {'end': 169, 'start': 151, 'tag': 'PathologicFunction'}, {'end': 222, 'start': 202, 'tag': 'ResearchActivity'}, {'end': 56, 'start': 49, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 197, 'start': 182, 'tag': 'HealthCareActivity'}, {'end': 64, 'start': 49, 'tag': 'AnatomicalAbnormality'}]"
1207,Studies have shown that changes in the retina can occur before the onset of cognitive symptoms in individuals with neurodegenerative diseases like Alzheimer's disease.,"[{'end': 141, 'start': 115, 'tag': 'DiseaseOrSyndrome'}, {'end': 166, 'start': 147, 'tag': 'DiseaseOrSyndrome'}, {'end': 72, 'start': 67, 'tag': 'TemporalConcept'}, {'end': 94, 'start': 76, 'tag': 'SignOrSymptom'}, {'end': 109, 'start': 98, 'tag': 'PopulationGroup'}, {'end': 45, 'start': 39, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 62, 'start': 56, 'tag': 'TemporalConcept'}, {'end': 7, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 31, 'start': 24, 'tag': 'Finding'}]"
1208,"The use of advanced retinal imaging techniques, such as optical coherence tomography (OCT), allows for the detection of subtle retinal changes that may be indicative of underlying neurodegenerative processes.","[{'end': 207, 'start': 180, 'tag': 'DiseaseOrSyndrome'}, {'end': 46, 'start': 28, 'tag': 'HealthCareActivity'}, {'end': 84, 'start': 56, 'tag': 'HealthCareActivity'}, {'end': 89, 'start': 86, 'tag': 'HealthCareActivity'}, {'end': 27, 'start': 20, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 134, 'start': 127, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 142, 'start': 135, 'tag': 'Finding'}]"
1209,"Research into the association between retinal defects and neurodegenerative disorders is ongoing, offering promise for non-invasive methods of early diagnosis and disease monitoring.","[{'end': 85, 'start': 58, 'tag': 'DiseaseOrSyndrome'}, {'end': 158, 'start': 143, 'tag': 'HealthCareActivity'}, {'end': 181, 'start': 163, 'tag': 'HealthCareActivity'}, {'end': 131, 'start': 119, 'tag': 'Finding'}, {'end': 96, 'start': 89, 'tag': 'TemporalConcept'}, {'end': 131, 'start': 119, 'tag': 'ClinicalAttribute'}, {'end': 8, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 45, 'start': 38, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 53, 'start': 38, 'tag': 'AnatomicalAbnormality'}, {'end': 139, 'start': 119, 'tag': 'HealthCareActivity'}]"
1210,"Ionizing electromagnetic radiation, including X-rays and gamma rays, has higher energy levels and can cause ionization, which may damage cells and DNA if exposure is excessive or not properly controlled.","[{'end': 142, 'start': 137, 'tag': 'Cell'}, {'end': 150, 'start': 147, 'tag': 'NucleicAcidNucleosideOrNucleotide'}, {'end': 136, 'start': 130, 'tag': 'InjuryOrPoisoning'}, {'end': 86, 'start': 80, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 162, 'start': 154, 'tag': 'Finding'}, {'end': 34, 'start': 9, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 34, 'start': 0, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 52, 'start': 46, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 67, 'start': 57, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 118, 'start': 108, 'tag': 'NaturalPhenomenonOrProcess'}]"
1211,Amyloid plaques are abnormal protein deposits that accumulate in the brain and are commonly associated with neurodegenerative disorders such as Alzheimer's disease.,"[{'end': 135, 'start': 108, 'tag': 'DiseaseOrSyndrome'}, {'end': 74, 'start': 69, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 163, 'start': 144, 'tag': 'DiseaseOrSyndrome'}, {'end': 15, 'start': 0, 'tag': 'AnatomicalAbnormality'}, {'end': 45, 'start': 20, 'tag': 'CellOrMolecularDysfunction'}]"
1212,"Amyloid plaques are primarily composed of beta-amyloid protein fragments, which clump together to form insoluble deposits outside nerve cells.","[{'end': 141, 'start': 130, 'tag': 'Cell'}, {'end': 62, 'start': 42, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 62, 'start': 42, 'tag': 'BiologicallyActiveSubstance'}, {'end': 15, 'start': 0, 'tag': 'AnatomicalAbnormality'}, {'end': 121, 'start': 103, 'tag': 'Substance'}]"
1213,"The accumulation of amyloid plaques in the brain disrupts normal cellular function and communication, contributing to the progressive loss of cognitive abilities in individuals with Alzheimer's disease.","[{'end': 48, 'start': 43, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 201, 'start': 182, 'tag': 'DiseaseOrSyndrome'}, {'end': 16, 'start': 4, 'tag': 'Finding'}, {'end': 35, 'start': 20, 'tag': 'AnatomicalAbnormality'}, {'end': 64, 'start': 58, 'tag': 'Finding'}, {'end': 133, 'start': 122, 'tag': 'TemporalConcept'}, {'end': 176, 'start': 165, 'tag': 'PopulationGroup'}, {'end': 100, 'start': 87, 'tag': 'HealthCareActivity'}, {'end': 82, 'start': 65, 'tag': 'CellFunction'}, {'end': 100, 'start': 87, 'tag': 'CellFunction'}, {'end': 161, 'start': 134, 'tag': 'PathologicFunction'}]"
1214,"Research suggests that amyloid plaques play a crucial role in the early stages of Alzheimer's disease, and their presence can be detected using neuroimaging techniques like PET scans.","[{'end': 101, 'start': 82, 'tag': 'DiseaseOrSyndrome'}, {'end': 121, 'start': 113, 'tag': 'Finding'}, {'end': 38, 'start': 23, 'tag': 'AnatomicalAbnormality'}, {'end': 176, 'start': 173, 'tag': 'HealthCareActivity'}, {'end': 78, 'start': 66, 'tag': 'TemporalConcept'}, {'end': 38, 'start': 23, 'tag': 'PathologicFunction'}, {'end': 8, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 182, 'start': 177, 'tag': 'HealthCareActivity'}, {'end': 167, 'start': 144, 'tag': 'HealthCareActivity'}, {'end': 58, 'start': 46, 'tag': 'Finding'}]"
1215,"The build-up of amyloid plaques is believed to trigger a cascade of events, leading to neuroinflammation, the formation of neurofibrillary tangles, and the eventual death of brain cells.","[{'end': 185, 'start': 174, 'tag': 'Cell'}, {'end': 104, 'start': 87, 'tag': 'PathologicFunction'}, {'end': 146, 'start': 110, 'tag': 'CellOrMolecularDysfunction'}, {'end': 31, 'start': 16, 'tag': 'AnatomicalAbnormality'}, {'end': 31, 'start': 16, 'tag': 'PathologicFunction'}, {'end': 146, 'start': 123, 'tag': 'CellComponent'}, {'end': 185, 'start': 165, 'tag': 'CellOrMolecularDysfunction'}]"
1216,"Several experimental therapies aim to target and remove amyloid plaques from the brain as a potential treatment for Alzheimer's disease, although their effectiveness remains an active area of research.","[{'end': 86, 'start': 81, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 135, 'start': 116, 'tag': 'DiseaseOrSyndrome'}, {'end': 200, 'start': 192, 'tag': 'ResearchActivity'}, {'end': 71, 'start': 56, 'tag': 'AnatomicalAbnormality'}, {'end': 165, 'start': 152, 'tag': 'Finding'}, {'end': 30, 'start': 8, 'tag': 'HealthCareActivity'}, {'end': 111, 'start': 102, 'tag': 'HealthCareActivity'}, {'end': 111, 'start': 102, 'tag': 'ResearchActivity'}]"
1217,"Amyloid plaques have also been observed in other neurodegenerative disorders, such as cerebral amyloid angiopathy (CAA) and certain forms of frontotemporal dementia.","[{'end': 76, 'start': 49, 'tag': 'DiseaseOrSyndrome'}, {'end': 164, 'start': 141, 'tag': 'DiseaseOrSyndrome'}, {'end': 113, 'start': 86, 'tag': 'DiseaseOrSyndrome'}, {'end': 118, 'start': 115, 'tag': 'DiseaseOrSyndrome'}, {'end': 15, 'start': 0, 'tag': 'AnatomicalAbnormality'}]"
1218,"The presence and distribution of amyloid plaques in the brain can help pathologists differentiate between different types of neurodegenerative disorders, aiding in accurate diagnosis.","[{'end': 182, 'start': 173, 'tag': 'HealthCareActivity'}, {'end': 152, 'start': 125, 'tag': 'DiseaseOrSyndrome'}, {'end': 61, 'start': 56, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 12, 'start': 4, 'tag': 'Finding'}, {'end': 48, 'start': 33, 'tag': 'AnatomicalAbnormality'}, {'end': 83, 'start': 71, 'tag': 'HealthCareActivity'}]"
1219,Animal models that develop amyloid plaques have been instrumental in studying the underlying mechanisms of neurodegenerative diseases and testing potential therapeutic interventions.,"[{'end': 133, 'start': 107, 'tag': 'DiseaseOrSyndrome'}, {'end': 42, 'start': 27, 'tag': 'AnatomicalAbnormality'}, {'end': 145, 'start': 138, 'tag': 'HealthCareActivity'}, {'end': 181, 'start': 156, 'tag': 'HealthCareActivity'}, {'end': 13, 'start': 0, 'tag': 'ResearchActivity'}]"
1220,"While amyloid plaques are a hallmark feature of neurodegenerative disorders, the relationship between their presence and the progression of these diseases is complex and continues to be a subject of intensive research.","[{'end': 75, 'start': 48, 'tag': 'DiseaseOrSyndrome'}, {'end': 217, 'start': 209, 'tag': 'ResearchActivity'}, {'end': 116, 'start': 108, 'tag': 'Finding'}, {'end': 21, 'start': 6, 'tag': 'AnatomicalAbnormality'}, {'end': 93, 'start': 81, 'tag': 'Finding'}, {'end': 44, 'start': 28, 'tag': 'Finding'}, {'end': 154, 'start': 125, 'tag': 'PathologicFunction'}]"
1221,"Medical imaging procedures that use ionizing radiation, like X-rays and CT scans, are beneficial for diagnosis and treatment, but their use should be carefully balanced with the potential risks.","[{'end': 110, 'start': 101, 'tag': 'HealthCareActivity'}, {'end': 26, 'start': 0, 'tag': 'HealthCareActivity'}, {'end': 80, 'start': 75, 'tag': 'HealthCareActivity'}, {'end': 67, 'start': 61, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 54, 'start': 36, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 54, 'start': 45, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 80, 'start': 72, 'tag': 'HealthCareActivity'}, {'end': 124, 'start': 115, 'tag': 'ResearchActivity'}, {'end': 124, 'start': 115, 'tag': 'HealthCareActivity'}, {'end': 193, 'start': 178, 'tag': 'Finding'}]"
1222,Brain stem compression can occur in some neurodegenerative disorders due to the accumulation of abnormal protein deposits or other pathological changes.,"[{'end': 68, 'start': 41, 'tag': 'DiseaseOrSyndrome'}, {'end': 92, 'start': 80, 'tag': 'Finding'}, {'end': 22, 'start': 0, 'tag': 'AnatomicalAbnormality'}, {'end': 121, 'start': 96, 'tag': 'CellOrMolecularDysfunction'}, {'end': 151, 'start': 131, 'tag': 'PathologicFunction'}]"
1223,"In conditions like multiple system atrophy and progressive supranuclear palsy, brain stem compression can lead to significant neurological symptoms and impairments.","[{'end': 147, 'start': 126, 'tag': 'SignOrSymptom'}, {'end': 77, 'start': 47, 'tag': 'DiseaseOrSyndrome'}, {'end': 42, 'start': 19, 'tag': 'PathologicFunction'}, {'end': 13, 'start': 3, 'tag': 'DiseaseOrSyndrome'}, {'end': 101, 'start': 79, 'tag': 'AnatomicalAbnormality'}]"
1224,"Brain stem compression in neurodegenerative disorders may result in disturbances in vital functions, such as breathing, heart rate, and blood pressure regulation.","[{'end': 53, 'start': 26, 'tag': 'DiseaseOrSyndrome'}, {'end': 80, 'start': 68, 'tag': 'Finding'}, {'end': 130, 'start': 126, 'tag': 'TemporalConcept'}, {'end': 125, 'start': 120, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 64, 'start': 58, 'tag': 'Finding'}, {'end': 150, 'start': 136, 'tag': 'BiologicFunction'}, {'end': 22, 'start': 0, 'tag': 'AnatomicalAbnormality'}, {'end': 118, 'start': 109, 'tag': 'BiologicFunction'}, {'end': 161, 'start': 136, 'tag': 'BiologicFunction'}]"
1225,"Neuroimaging techniques, such as MRI, are valuable in diagnosing brain stem compression and assessing its severity in individuals with neurodegenerative diseases.","[{'end': 161, 'start': 135, 'tag': 'DiseaseOrSyndrome'}, {'end': 36, 'start': 33, 'tag': 'HealthCareActivity'}, {'end': 114, 'start': 106, 'tag': 'ClinicalAttribute'}, {'end': 114, 'start': 106, 'tag': 'Finding'}, {'end': 64, 'start': 54, 'tag': 'HealthCareActivity'}, {'end': 129, 'start': 118, 'tag': 'PopulationGroup'}, {'end': 23, 'start': 0, 'tag': 'MachineActivity'}, {'end': 87, 'start': 65, 'tag': 'AnatomicalAbnormality'}]"
1226,Identifying brain stem compression early in the course of neurodegenerative disorders is crucial for implementing appropriate management strategies and interventions.,"[{'end': 85, 'start': 58, 'tag': 'DiseaseOrSyndrome'}, {'end': 147, 'start': 126, 'tag': 'HealthCareActivity'}, {'end': 165, 'start': 152, 'tag': 'HealthCareActivity'}, {'end': 165, 'start': 152, 'tag': 'ResearchActivity'}, {'end': 34, 'start': 12, 'tag': 'AnatomicalAbnormality'}]"
1227,Surgical decompression may be considered in cases of severe brain stem compression to relieve pressure and improve neurological function.,"[{'end': 59, 'start': 53, 'tag': 'Finding'}, {'end': 82, 'start': 60, 'tag': 'AnatomicalAbnormality'}, {'end': 22, 'start': 0, 'tag': 'HealthCareActivity'}, {'end': 136, 'start': 115, 'tag': 'BiologicFunction'}]"
1228,Research is ongoing to understand the underlying mechanisms of brain stem compression in different neurodegenerative disorders and its contribution to disease progression.,"[{'end': 126, 'start': 99, 'tag': 'DiseaseOrSyndrome'}, {'end': 170, 'start': 151, 'tag': 'PathologicFunction'}, {'end': 19, 'start': 12, 'tag': 'TemporalConcept'}, {'end': 8, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 85, 'start': 63, 'tag': 'AnatomicalAbnormality'}]"
1229,"In some cases, brain stem compression may lead to additional complications, such as hydrocephalus or obstructive sleep apnea.","[{'end': 74, 'start': 61, 'tag': 'PathologicFunction'}, {'end': 118, 'start': 113, 'tag': 'BiologicFunction'}, {'end': 37, 'start': 15, 'tag': 'AnatomicalAbnormality'}, {'end': 124, 'start': 101, 'tag': 'DiseaseOrSyndrome'}, {'end': 97, 'start': 84, 'tag': 'DiseaseOrSyndrome'}]"
1230,The presence and extent of brain stem compression can influence treatment decisions and prognosis in individuals with neurodegenerative diseases.,"[{'end': 144, 'start': 118, 'tag': 'DiseaseOrSyndrome'}, {'end': 73, 'start': 64, 'tag': 'HealthCareActivity'}, {'end': 73, 'start': 64, 'tag': 'ResearchActivity'}, {'end': 12, 'start': 4, 'tag': 'Finding'}, {'end': 112, 'start': 101, 'tag': 'PopulationGroup'}, {'end': 97, 'start': 88, 'tag': 'HealthCareActivity'}, {'end': 83, 'start': 74, 'tag': 'BiologicFunction'}, {'end': 49, 'start': 27, 'tag': 'AnatomicalAbnormality'}]"
1231,Collaborative efforts between neurologists and neurosurgeons are essential for optimizing care and outcomes for patients with neurodegenerative disorders experiencing brain stem compression.,"[{'end': 153, 'start': 126, 'tag': 'DiseaseOrSyndrome'}, {'end': 120, 'start': 112, 'tag': 'PatientOrDisabledGroup'}, {'end': 107, 'start': 99, 'tag': 'Finding'}, {'end': 94, 'start': 90, 'tag': 'HealthCareActivity'}, {'end': 189, 'start': 167, 'tag': 'AnatomicalAbnormality'}, {'end': 42, 'start': 30, 'tag': 'HealthCareActivity'}, {'end': 60, 'start': 47, 'tag': 'HealthCareActivity'}]"
1232,"Research on the health effects of electromagnetic radiation is ongoing, and scientists continue to study the possible links between certain exposures and conditions like cancer and neurological disorders.","[{'end': 104, 'start': 99, 'tag': 'ResearchActivity'}, {'end': 203, 'start': 181, 'tag': 'DiseaseOrSyndrome'}, {'end': 176, 'start': 170, 'tag': 'DiseaseOrSyndrome'}, {'end': 70, 'start': 63, 'tag': 'TemporalConcept'}, {'end': 8, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 164, 'start': 154, 'tag': 'DiseaseOrSyndrome'}, {'end': 59, 'start': 34, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 86, 'start': 76, 'tag': 'ResearchActivity'}, {'end': 22, 'start': 16, 'tag': 'HealthCareActivity'}, {'end': 30, 'start': 23, 'tag': 'Finding'}]"
1233,"Emerging therapies aim to target specific molecules involved in the molecular pathways of neurodegenerative disorders, with the hope of developing more effective treatments for these devastating conditions.","[{'end': 117, 'start': 90, 'tag': 'DiseaseOrSyndrome'}, {'end': 18, 'start': 9, 'tag': 'HealthCareActivity'}, {'end': 51, 'start': 42, 'tag': 'Substance'}, {'end': 172, 'start': 162, 'tag': 'HealthCareActivity'}, {'end': 172, 'start': 162, 'tag': 'ResearchActivity'}, {'end': 86, 'start': 68, 'tag': 'CellFunction'}, {'end': 132, 'start': 128, 'tag': 'BiologicFunction'}, {'end': 205, 'start': 183, 'tag': 'DiseaseOrSyndrome'}]"
1234,"Excitotoxicity, a process involving the overactivation of neurotransmitter molecules like glutamate, plays a role in the pathogenesis of several neurodegenerative diseases.","[{'end': 171, 'start': 145, 'tag': 'DiseaseOrSyndrome'}, {'end': 84, 'start': 75, 'tag': 'Substance'}, {'end': 133, 'start': 121, 'tag': 'PathologicFunction'}, {'end': 99, 'start': 90, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 99, 'start': 90, 'tag': 'BiologicallyActiveSubstance'}, {'end': 74, 'start': 58, 'tag': 'BiologicallyActiveSubstance'}, {'end': 14, 'start': 0, 'tag': 'PathologicFunction'}]"
1235,"Molecular imaging techniques, such as positron emission tomography (PET), allow researchers to visualize specific molecules and their distribution in the brain of individuals with neurodegenerative disorders.","[{'end': 207, 'start': 180, 'tag': 'DiseaseOrSyndrome'}, {'end': 159, 'start': 154, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 66, 'start': 38, 'tag': 'HealthCareActivity'}, {'end': 123, 'start': 114, 'tag': 'Substance'}, {'end': 91, 'start': 80, 'tag': 'ResearchActivity'}, {'end': 174, 'start': 163, 'tag': 'PopulationGroup'}, {'end': 71, 'start': 68, 'tag': 'HealthCareActivity'}, {'end': 28, 'start': 0, 'tag': 'HealthCareActivity'}]"
1236,Various antioxidant molecules are being investigated for their potential neuroprotective effects in slowing down the progression of neurodegenerative diseases.,"[{'end': 158, 'start': 132, 'tag': 'DiseaseOrSyndrome'}, {'end': 96, 'start': 73, 'tag': 'Finding'}, {'end': 29, 'start': 8, 'tag': 'PharmacologicSubstance'}, {'end': 52, 'start': 40, 'tag': 'HealthCareActivity'}, {'end': 128, 'start': 117, 'tag': 'TemporalConcept'}, {'end': 128, 'start': 117, 'tag': 'PathologicFunction'}]"
1237,"Neuroinflammation, a common feature in neurodegenerative disorders, involves the release of inflammatory molecules that contribute to neuronal degeneration.","[{'end': 66, 'start': 39, 'tag': 'DiseaseOrSyndrome'}, {'end': 114, 'start': 105, 'tag': 'Substance'}, {'end': 17, 'start': 0, 'tag': 'PathologicFunction'}, {'end': 104, 'start': 92, 'tag': 'PathologicFunction'}, {'end': 155, 'start': 134, 'tag': 'CellOrMolecularDysfunction'}]"
1238,"Oligomeric forms of prion protein molecules are thought to be responsible for the development of prion diseases, a group of fatal neurodegenerative disorders.","[{'end': 157, 'start': 130, 'tag': 'DiseaseOrSyndrome'}, {'end': 43, 'start': 34, 'tag': 'Substance'}, {'end': 111, 'start': 97, 'tag': 'DiseaseOrSyndrome'}, {'end': 33, 'start': 0, 'tag': 'AminoAcidPeptideOrProtein'}]"
1239,"In Huntington's disease, the expansion of CAG repeat molecules in the huntingtin gene leads to the production of toxic proteins that cause neuronal damage.","[{'end': 85, 'start': 70, 'tag': 'GeneOrGenome'}, {'end': 23, 'start': 3, 'tag': 'DiseaseOrSyndrome'}, {'end': 62, 'start': 53, 'tag': 'Substance'}, {'end': 147, 'start': 139, 'tag': 'Cell'}, {'end': 127, 'start': 119, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 118, 'start': 113, 'tag': 'InjuryOrPoisoning'}, {'end': 154, 'start': 148, 'tag': 'InjuryOrPoisoning'}, {'end': 52, 'start': 42, 'tag': 'MolecularSequence'}]"
1240,"Alpha-synuclein molecules are implicated in the formation of Lewy bodies, characteristic of neurodegenerative disorders like Parkinson's disease and Lewy body dementia.","[{'end': 144, 'start': 125, 'tag': 'DiseaseOrSyndrome'}, {'end': 119, 'start': 92, 'tag': 'DiseaseOrSyndrome'}, {'end': 25, 'start': 16, 'tag': 'Substance'}, {'end': 72, 'start': 61, 'tag': 'CellComponent'}, {'end': 15, 'start': 0, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 15, 'start': 0, 'tag': 'BiologicallyActiveSubstance'}, {'end': 167, 'start': 149, 'tag': 'DiseaseOrSyndrome'}, {'end': 167, 'start': 159, 'tag': 'DiseaseOrSyndrome'}]"
1241,"Tau protein molecules, when abnormally phosphorylated, form neurofibrillary tangles that are associated with the progression of Alzheimer's disease.","[{'end': 53, 'start': 39, 'tag': 'CellFunction'}, {'end': 147, 'start': 128, 'tag': 'DiseaseOrSyndrome'}, {'end': 21, 'start': 12, 'tag': 'Substance'}, {'end': 83, 'start': 60, 'tag': 'CellOrMolecularDysfunction'}, {'end': 3, 'start': 0, 'tag': 'BiologicallyActiveSubstance'}, {'end': 3, 'start': 0, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 11, 'start': 4, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 83, 'start': 60, 'tag': 'CellComponent'}]"
1242,"The accumulation of beta-amyloid molecules in the brain is a hallmark feature of Alzheimer's disease, a common neurodegenerative disorder.","[{'end': 55, 'start': 50, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 100, 'start': 81, 'tag': 'DiseaseOrSyndrome'}, {'end': 137, 'start': 111, 'tag': 'DiseaseOrSyndrome'}, {'end': 42, 'start': 33, 'tag': 'Substance'}, {'end': 16, 'start': 4, 'tag': 'Finding'}, {'end': 32, 'start': 20, 'tag': 'AminoAcidPeptideOrProtein'}, {'end': 77, 'start': 61, 'tag': 'Finding'}]"
1243,The World Health Organization (WHO) and other health agencies have established guidelines and safety limits for exposure to electromagnetic radiation to protect public health.,"[{'end': 107, 'start': 94, 'tag': 'HealthCareActivity'}, {'end': 174, 'start': 161, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 174, 'start': 161, 'tag': 'HealthCareActivity'}, {'end': 149, 'start': 112, 'tag': 'InjuryOrPoisoning'}, {'end': 29, 'start': 0, 'tag': 'HealthCareRelatedOrganization'}, {'end': 34, 'start': 31, 'tag': 'HealthCareRelatedOrganization'}, {'end': 149, 'start': 124, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 61, 'start': 46, 'tag': 'HealthCareRelatedOrganization'}, {'end': 89, 'start': 79, 'tag': 'HealthCareActivity'}]"
1244,Post-mortem brain specimens from individuals with neurodegenerative disorders are invaluable for studying the pathological changes associated with these conditions.,"[{'end': 77, 'start': 50, 'tag': 'DiseaseOrSyndrome'}, {'end': 17, 'start': 12, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 44, 'start': 33, 'tag': 'PopulationGroup'}, {'end': 27, 'start': 18, 'tag': 'Substance'}, {'end': 163, 'start': 153, 'tag': 'DiseaseOrSyndrome'}, {'end': 11, 'start': 0, 'tag': 'TemporalConcept'}, {'end': 130, 'start': 110, 'tag': 'PathologicFunction'}]"
1245,"Researchers use cerebrospinal fluid (CSF) specimens to identify biomarkers indicative of neurodegenerative disorders, aiding in early diagnosis and disease monitoring.","[{'end': 116, 'start': 89, 'tag': 'DiseaseOrSyndrome'}, {'end': 143, 'start': 128, 'tag': 'HealthCareActivity'}, {'end': 74, 'start': 64, 'tag': 'ClinicalAttribute'}, {'end': 166, 'start': 148, 'tag': 'HealthCareActivity'}, {'end': 35, 'start': 16, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 40, 'start': 37, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 51, 'start': 42, 'tag': 'Substance'}, {'end': 11, 'start': 0, 'tag': 'ResearchActivity'}]"
1246,"Animal models are often used to study the effects of potential therapeutic interventions on neurodegenerative disorders, utilizing brain tissue specimens for analysis.","[{'end': 119, 'start': 92, 'tag': 'DiseaseOrSyndrome'}, {'end': 37, 'start': 32, 'tag': 'ResearchActivity'}, {'end': 166, 'start': 158, 'tag': 'ResearchActivity'}, {'end': 143, 'start': 131, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 153, 'start': 144, 'tag': 'Substance'}, {'end': 88, 'start': 63, 'tag': 'HealthCareActivity'}, {'end': 13, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 49, 'start': 42, 'tag': 'Finding'}]"
1247,Biopsy specimens of nerve tissue can provide critical insights into the cellular and molecular changes occurring in specific regions affected by neurodegenerative disorders.,"[{'end': 172, 'start': 145, 'tag': 'DiseaseOrSyndrome'}, {'end': 32, 'start': 20, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 16, 'start': 7, 'tag': 'Substance'}, {'end': 62, 'start': 45, 'tag': 'Finding'}, {'end': 102, 'start': 72, 'tag': 'Finding'}, {'end': 6, 'start': 0, 'tag': 'HealthCareActivity'}]"
1248,"The study of retinal specimens has shown promise in identifying molecular changes that may be associated with neurodegenerative disorders, such as Alzheimer's disease.","[{'end': 137, 'start': 110, 'tag': 'DiseaseOrSyndrome'}, {'end': 9, 'start': 4, 'tag': 'ResearchActivity'}, {'end': 166, 'start': 147, 'tag': 'DiseaseOrSyndrome'}, {'end': 30, 'start': 21, 'tag': 'Substance'}, {'end': 20, 'start': 13, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 81, 'start': 64, 'tag': 'Finding'}]"
1249,Genetic analysis of DNA specimens is crucial for identifying mutations and variations that contribute to the development of inherited neurodegenerative disorders.,"[{'end': 161, 'start': 124, 'tag': 'DiseaseOrSyndrome'}, {'end': 16, 'start': 0, 'tag': 'ResearchActivity'}, {'end': 70, 'start': 61, 'tag': 'CellFunction'}, {'end': 23, 'start': 20, 'tag': 'NucleicAcidNucleosideOrNucleotide'}, {'end': 33, 'start': 24, 'tag': 'Substance'}, {'end': 120, 'start': 109, 'tag': 'BiologicFunction'}, {'end': 120, 'start': 109, 'tag': 'CellFunction'}]"
1250,"In clinical trials, blood specimens are collected to assess the efficacy and safety of new treatments for neurodegenerative disorders.","[{'end': 133, 'start': 106, 'tag': 'DiseaseOrSyndrome'}, {'end': 18, 'start': 3, 'tag': 'ResearchActivity'}, {'end': 25, 'start': 20, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 83, 'start': 77, 'tag': 'HealthCareActivity'}, {'end': 72, 'start': 64, 'tag': 'Finding'}, {'end': 35, 'start': 26, 'tag': 'Substance'}, {'end': 101, 'start': 91, 'tag': 'ResearchActivity'}, {'end': 101, 'start': 91, 'tag': 'HealthCareActivity'}]"
1251,"Advanced imaging techniques, such as positron emission tomography (PET), help visualize molecular changes in brain specimens related to neurodegenerative disorders.","[{'end': 163, 'start': 136, 'tag': 'DiseaseOrSyndrome'}, {'end': 114, 'start': 109, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 65, 'start': 37, 'tag': 'HealthCareActivity'}, {'end': 70, 'start': 67, 'tag': 'HealthCareActivity'}, {'end': 27, 'start': 9, 'tag': 'HealthCareActivity'}, {'end': 124, 'start': 115, 'tag': 'Substance'}, {'end': 105, 'start': 88, 'tag': 'Finding'}]"
1252,"The study of prion protein in brain specimens has been instrumental in understanding prion diseases, a unique group of neurodegenerative disorders.","[{'end': 146, 'start': 119, 'tag': 'DiseaseOrSyndrome'}, {'end': 9, 'start': 4, 'tag': 'ResearchActivity'}, {'end': 35, 'start': 30, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 99, 'start': 85, 'tag': 'DiseaseOrSyndrome'}, {'end': 45, 'start': 36, 'tag': 'Substance'}, {'end': 26, 'start': 13, 'tag': 'AminoAcidPeptideOrProtein'}]"
1253,"Brain tissue specimens are stored in biobanks, allowing researchers worldwide to access crucial material for neurodegenerative disorder research and collaboration.","[{'end': 135, 'start': 109, 'tag': 'DiseaseOrSyndrome'}, {'end': 162, 'start': 136, 'tag': 'ResearchActivity'}, {'end': 12, 'start': 0, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 67, 'start': 56, 'tag': 'ResearchActivity'}, {'end': 104, 'start': 96, 'tag': 'Substance'}, {'end': 22, 'start': 13, 'tag': 'Substance'}, {'end': 45, 'start': 37, 'tag': 'HealthCareRelatedOrganization'}]"
1254,"Minimizing unnecessary exposure to electromagnetic radiation sources, such as by maintaining distance from high-power electrical devices, is a precautionary measure to reduce potential risks.","[{'end': 68, 'start': 61, 'tag': 'Finding'}, {'end': 60, 'start': 23, 'tag': 'InjuryOrPoisoning'}, {'end': 60, 'start': 35, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 136, 'start': 107, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 190, 'start': 175, 'tag': 'Finding'}, {'end': 164, 'start': 143, 'tag': 'HealthCareActivity'}]"
1255,"In the field of MS research, biofluid analysis plays a crucial role in understanding the disease's progression and identifying potential biomarkers.","[{'end': 46, 'start': 38, 'tag': 'ResearchActivity'}, {'end': 18, 'start': 16, 'tag': 'DiseaseOrSyndrome'}, {'end': 27, 'start': 19, 'tag': 'ResearchActivity'}, {'end': 37, 'start': 29, 'tag': 'Substance'}, {'end': 147, 'start': 127, 'tag': 'ClinicalAttribute'}, {'end': 110, 'start': 89, 'tag': 'PathologicFunction'}, {'end': 84, 'start': 71, 'tag': 'BiologicFunction'}]"
1256,"Cerebrospinal fluid (CSF) is an essential biofluid used in diagnosing MS, as it can reveal the presence of specific antibodies and other biomolecules associated with the disease.","[{'end': 72, 'start': 70, 'tag': 'DiseaseOrSyndrome'}, {'end': 19, 'start': 0, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 24, 'start': 21, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 50, 'start': 42, 'tag': 'Substance'}, {'end': 103, 'start': 95, 'tag': 'Finding'}, {'end': 126, 'start': 116, 'tag': 'BiologicallyActiveSubstance'}, {'end': 69, 'start': 59, 'tag': 'HealthCareActivity'}, {'end': 149, 'start': 137, 'tag': 'Substance'}]"
1257,"Blood serum is another biofluid studied extensively in MS research, offering insights into the immune system's activity and inflammatory markers.","[{'end': 57, 'start': 55, 'tag': 'DiseaseOrSyndrome'}, {'end': 144, 'start': 137, 'tag': 'ClinicalAttribute'}, {'end': 66, 'start': 58, 'tag': 'ResearchActivity'}, {'end': 31, 'start': 23, 'tag': 'Substance'}, {'end': 11, 'start': 6, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 5, 'start': 0, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 108, 'start': 95, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 136, 'start': 124, 'tag': 'PathologicFunction'}]"
1258,The discovery of novel biofluid-based biomarkers has shown promise in predicting disease activity and response to treatments in individuals with multiple sclerosis.,"[{'end': 48, 'start': 38, 'tag': 'ClinicalAttribute'}, {'end': 13, 'start': 4, 'tag': 'ResearchActivity'}, {'end': 31, 'start': 23, 'tag': 'Substance'}, {'end': 139, 'start': 128, 'tag': 'PopulationGroup'}, {'end': 163, 'start': 145, 'tag': 'DiseaseOrSyndrome'}, {'end': 97, 'start': 81, 'tag': 'HealthCareActivity'}]"
1259,Research studies often analyze biofluid samples collected from MS patients to uncover potential disease mechanisms and develop more targeted therapies.,"[{'end': 150, 'start': 132, 'tag': 'HealthCareActivity'}, {'end': 65, 'start': 63, 'tag': 'DiseaseOrSyndrome'}, {'end': 74, 'start': 66, 'tag': 'PatientOrDisabledGroup'}, {'end': 39, 'start': 31, 'tag': 'Substance'}, {'end': 114, 'start': 96, 'tag': 'ResearchActivity'}, {'end': 47, 'start': 31, 'tag': 'Substance'}, {'end': 16, 'start': 0, 'tag': 'ResearchActivity'}]"
1260,"Advances in biofluid analysis technologies, such as proteomics and metabolomics, have accelerated MS research, enabling a deeper understanding of the disease's complexity.","[{'end': 29, 'start': 21, 'tag': 'ResearchActivity'}, {'end': 142, 'start': 122, 'tag': 'Finding'}, {'end': 100, 'start': 98, 'tag': 'DiseaseOrSyndrome'}, {'end': 109, 'start': 101, 'tag': 'ResearchActivity'}, {'end': 20, 'start': 12, 'tag': 'Substance'}, {'end': 42, 'start': 30, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 62, 'start': 52, 'tag': 'BiomedicalOccupationOrDiscipline'}, {'end': 79, 'start': 67, 'tag': 'BiomedicalOccupationOrDiscipline'}]"
1261,"Biofluid-based biomarker research in MS is paving the way for personalized medicine, allowing clinicians to tailor treatments to individual patients based on their unique disease profiles.","[{'end': 39, 'start': 37, 'tag': 'DiseaseOrSyndrome'}, {'end': 148, 'start': 140, 'tag': 'PatientOrDisabledGroup'}, {'end': 24, 'start': 15, 'tag': 'ClinicalAttribute'}, {'end': 33, 'start': 25, 'tag': 'ResearchActivity'}, {'end': 187, 'start': 179, 'tag': 'ResearchActivity'}, {'end': 104, 'start': 94, 'tag': 'HealthCareActivity'}, {'end': 8, 'start': 0, 'tag': 'Substance'}, {'end': 83, 'start': 62, 'tag': 'HealthCareActivity'}, {'end': 125, 'start': 115, 'tag': 'HealthCareActivity'}, {'end': 125, 'start': 115, 'tag': 'ResearchActivity'}]"
1262,"One of the challenges in MS biofluid research is the variability in biomarker levels, necessitating large-scale studies and robust statistical analyses to identify reliable markers.","[{'end': 119, 'start': 100, 'tag': 'ResearchActivity'}, {'end': 21, 'start': 11, 'tag': 'HealthCareActivity'}, {'end': 27, 'start': 25, 'tag': 'DiseaseOrSyndrome'}, {'end': 77, 'start': 68, 'tag': 'ClinicalAttribute'}, {'end': 180, 'start': 173, 'tag': 'ClinicalAttribute'}, {'end': 45, 'start': 37, 'tag': 'ResearchActivity'}, {'end': 36, 'start': 28, 'tag': 'Substance'}, {'end': 151, 'start': 131, 'tag': 'ResearchActivity'}, {'end': 64, 'start': 53, 'tag': 'Finding'}]"
1263,"As technology continues to advance, biofluid analysis is expected to remain a cornerstone in MS research, offering hope for improved diagnostic accuracy and more effective therapeutic interventions.","[{'end': 53, 'start': 45, 'tag': 'ResearchActivity'}, {'end': 95, 'start': 93, 'tag': 'DiseaseOrSyndrome'}, {'end': 104, 'start': 96, 'tag': 'ResearchActivity'}, {'end': 44, 'start': 36, 'tag': 'Substance'}, {'end': 119, 'start': 115, 'tag': 'BiologicFunction'}, {'end': 197, 'start': 172, 'tag': 'HealthCareActivity'}, {'end': 152, 'start': 133, 'tag': 'Finding'}]"
1264,"Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system, leading to demyelination of nerve fibers.","[{'end': 95, 'start': 73, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 18, 'start': 0, 'tag': 'DiseaseOrSyndrome'}, {'end': 22, 'start': 20, 'tag': 'DiseaseOrSyndrome'}, {'end': 36, 'start': 29, 'tag': 'TemporalConcept'}, {'end': 121, 'start': 108, 'tag': 'PathologicFunction'}, {'end': 55, 'start': 37, 'tag': 'DiseaseOrSyndrome'}, {'end': 137, 'start': 125, 'tag': 'BodyPartOrganOrOrganComponent'}]"
1265,The study of biofluids is of high importance in diagnosis and prognosis of MS,"[{'end': 57, 'start': 48, 'tag': 'HealthCareActivity'}, {'end': 9, 'start': 4, 'tag': 'ResearchActivity'}, {'end': 77, 'start': 75, 'tag': 'DiseaseOrSyndrome'}, {'end': 22, 'start': 13, 'tag': 'Substance'}, {'end': 71, 'start': 62, 'tag': 'HealthCareActivity'}]"
1266,"Overall, while electromagnetic radiation is an essential part of modern life and technology, responsible use and adherence to safety guidelines can help mitigate potential health risks associated with its exposure.","[{'end': 178, 'start': 172, 'tag': 'HealthCareActivity'}, {'end': 143, 'start': 126, 'tag': 'HealthCareActivity'}, {'end': 76, 'start': 72, 'tag': 'TemporalConcept'}, {'end': 213, 'start': 205, 'tag': 'Finding'}, {'end': 40, 'start': 15, 'tag': 'NaturalPhenomenonOrProcess'}, {'end': 184, 'start': 179, 'tag': 'Finding'}]"
1267,Disease-modifying therapies for multiple sclerosis often come in the form of injectable suspensions that slow down the progression of the disease.,"[{'end': 27, 'start': 0, 'tag': 'HealthCareActivity'}, {'end': 50, 'start': 32, 'tag': 'DiseaseOrSyndrome'}, {'end': 145, 'start': 119, 'tag': 'PathologicFunction'}, {'end': 145, 'start': 119, 'tag': 'TemporalConcept'}, {'end': 99, 'start': 77, 'tag': 'Substance'}]"
1268,"In clinical trials, researchers study the safety and efficacy of new medications, including oral and intravenous suspensions, for managing multiple sclerosis symptoms.","[{'end': 166, 'start': 158, 'tag': 'SignOrSymptom'}, {'end': 37, 'start': 32, 'tag': 'ResearchActivity'}, {'end': 18, 'start': 3, 'tag': 'ResearchActivity'}, {'end': 48, 'start': 42, 'tag': 'HealthCareActivity'}, {'end': 31, 'start': 20, 'tag': 'ResearchActivity'}, {'end': 61, 'start': 53, 'tag': 'Finding'}, {'end': 157, 'start': 139, 'tag': 'DiseaseOrSyndrome'}, {'end': 96, 'start': 92, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 80, 'start': 69, 'tag': 'PharmacologicSubstance'}, {'end': 112, 'start': 101, 'tag': 'HealthCareActivity'}, {'end': 124, 'start': 113, 'tag': 'Substance'}]"
1269,"Magnetic resonance imaging (MRI) scans can reveal areas of demyelination and inflammation in the brain and spinal cord, leading to the use of contrast suspensions to enhance visualization.","[{'end': 102, 'start': 97, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 31, 'start': 28, 'tag': 'HealthCareActivity'}, {'end': 89, 'start': 77, 'tag': 'PathologicFunction'}, {'end': 72, 'start': 59, 'tag': 'PathologicFunction'}, {'end': 118, 'start': 107, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 38, 'start': 33, 'tag': 'HealthCareActivity'}, {'end': 26, 'start': 0, 'tag': 'HealthCareActivity'}, {'end': 162, 'start': 142, 'tag': 'Substance'}]"
1270,Disease relapses in multiple sclerosis may require short-term treatment with corticosteroid suspensions to reduce inflammation and speed up recovery.,"[{'end': 71, 'start': 62, 'tag': 'HealthCareActivity'}, {'end': 71, 'start': 62, 'tag': 'ResearchActivity'}, {'end': 126, 'start': 114, 'tag': 'PathologicFunction'}, {'end': 148, 'start': 140, 'tag': 'BiologicFunction'}, {'end': 148, 'start': 140, 'tag': 'HealthCareActivity'}, {'end': 148, 'start': 140, 'tag': 'TemporalConcept'}, {'end': 38, 'start': 20, 'tag': 'DiseaseOrSyndrome'}, {'end': 91, 'start': 77, 'tag': 'Chemical'}, {'end': 91, 'start': 77, 'tag': 'PharmacologicSubstance'}, {'end': 91, 'start': 77, 'tag': 'BiologicallyActiveSubstance'}, {'end': 61, 'start': 51, 'tag': 'TemporalConcept'}, {'end': 103, 'start': 92, 'tag': 'Substance'}, {'end': 16, 'start': 0, 'tag': 'Finding'}]"
1271,"The development of new biotechnological advances has led to the creation of longer-acting suspension therapies, reducing the frequency of administration for multiple sclerosis patients.","[{'end': 110, 'start': 101, 'tag': 'HealthCareActivity'}, {'end': 48, 'start': 23, 'tag': 'Finding'}, {'end': 184, 'start': 176, 'tag': 'PatientOrDisabledGroup'}, {'end': 134, 'start': 125, 'tag': 'TemporalConcept'}, {'end': 120, 'start': 112, 'tag': 'Finding'}, {'end': 175, 'start': 157, 'tag': 'DiseaseOrSyndrome'}, {'end': 100, 'start': 90, 'tag': 'Substance'}, {'end': 152, 'start': 138, 'tag': 'HealthCareActivity'}]"
1272,"Some multiple sclerosis patients experience adverse reactions to certain suspension medications, leading to adjustments in their treatment plan.","[{'end': 43, 'start': 33, 'tag': 'BiologicFunction'}, {'end': 32, 'start': 24, 'tag': 'PatientOrDisabledGroup'}, {'end': 23, 'start': 5, 'tag': 'DiseaseOrSyndrome'}, {'end': 95, 'start': 84, 'tag': 'PharmacologicSubstance'}, {'end': 83, 'start': 73, 'tag': 'Substance'}, {'end': 143, 'start': 129, 'tag': 'HealthCareActivity'}, {'end': 61, 'start': 44, 'tag': 'PathologicFunction'}]"
1273,Intrathecal suspensions of medications are administered through lumbar punctures for patients with aggressive forms of multiple sclerosis to deliver drugs directly to the cerebrospinal fluid.,"[{'end': 190, 'start': 171, 'tag': 'BodyPartOrganOrOrganComponent'}, {'end': 93, 'start': 85, 'tag': 'PatientOrDisabledGroup'}, {'end': 154, 'start': 149, 'tag': 'PharmacologicSubstance'}, {'end': 137, 'start': 119, 'tag': 'DiseaseOrSyndrome'}, {'end': 38, 'start': 27, 'tag': 'PharmacologicSubstance'}, {'end': 23, 'start': 12, 'tag': 'Substance'}, {'end': 80, 'start': 64, 'tag': 'HealthCareActivity'}, {'end': 11, 'start': 0, 'tag': 'BodyPartOrganOrOrganComponent'}]"
1274,Pharmaceutical companies are continually researching and innovating new suspension formulations to improve treatment outcomes and patient convenience for multiple sclerosis.,"[{'end': 137, 'start': 130, 'tag': 'PatientOrDisabledGroup'}, {'end': 172, 'start': 154, 'tag': 'DiseaseOrSyndrome'}, {'end': 82, 'start': 72, 'tag': 'Substance'}, {'end': 24, 'start': 0, 'tag': 'HealthCareRelatedOrganization'}, {'end': 125, 'start': 117, 'tag': 'Finding'}, {'end': 116, 'start': 107, 'tag': 'HealthCareActivity'}, {'end': 116, 'start': 107, 'tag': 'ResearchActivity'}]"
1275,Pharmacists play a vital role in preparing personalized suspensions based on individual patient needs and dosing requirements in multiple sclerosis management.,"[{'end': 95, 'start': 88, 'tag': 'PatientOrDisabledGroup'}, {'end': 147, 'start': 129, 'tag': 'DiseaseOrSyndrome'}, {'end': 158, 'start': 148, 'tag': 'HealthCareActivity'}, {'end': 67, 'start': 56, 'tag': 'Substance'}, {'end': 11, 'start': 0, 'tag': 'HealthCareActivity'}]"
1276,Proper storage and handling of medication suspensions are essential to maintain their efficacy and safety for multiple sclerosis patients undergoing treatment.,"[{'end': 137, 'start': 129, 'tag': 'PatientOrDisabledGroup'}, {'end': 105, 'start': 99, 'tag': 'HealthCareActivity'}, {'end': 94, 'start': 86, 'tag': 'Finding'}, {'end': 128, 'start': 110, 'tag': 'DiseaseOrSyndrome'}, {'end': 41, 'start': 31, 'tag': 'PharmacologicSubstance'}, {'end': 41, 'start': 31, 'tag': 'HealthCareActivity'}, {'end': 53, 'start': 42, 'tag': 'Substance'}, {'end': 158, 'start': 149, 'tag': 'HealthCareActivity'}, {'end': 158, 'start': 149, 'tag': 'ResearchActivity'}]"
